PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Berger, J; Swenson, JE; Persson, IL				Berger, J; Swenson, JE; Persson, IL			Recolonizing carnivores and naive prey: Conservation lessons from Pleistocene extinctions	SCIENCE			English	Article							BEHAVIOR; BEARS	The current extinction of many of Earth's Large terrestrial carnivores has Left some extant prey species Lacking knowledge about contemporary predators, a situation roughly parallel to that 10,000 to 50,000 years ago, when naive animals first encountered colonizing human hunters. Along present-day carnivore recolonization fronts, brown (also called grizzly) bears killed predator-naive adult moose at disproportionately high rates in Scandinavia, and moose mothers who Lost juveniles to recolonizing wolves in North America's Yellowstone region developed hypersensitivity to wolf howls. Although prey that had been unfamiliar with dangerous predators for as few as 50 to 130 years were highly vulnerable to initial encounters, behavioral adjustments to reduce predation transpired within a single generation. The fact that at Least one prey species quickly Learns to be wary of restored carnivores should negate fears about Localized prey extinction.	Univ Nevada, Program Ecol Evolut & Conservat Biol, Reno, NV 89512 USA; Wildlife Conservat Soc, Moose, WY 83012 USA; Agr Univ Norway, Dept Biol & Nat Conservat, N-1432 As, Norway; Norwegian Inst Nat Res, N-7485 Trondheim, Norway; Univ Oslo, Dept Zool, N-1040 Oslo, Norway	Nevada System of Higher Education (NSHE); University of Nevada Reno; Wildlife Conservation Society; Norwegian University of Life Sciences; Norwegian Institute Nature Research; University of Oslo	Berger, J (corresponding author), Univ Nevada, Program Ecol Evolut & Conservat Biol, Reno, NV 89512 USA.	berger@unr.edu	Swenson, Jon/AAE-2890-2019; Swenson, Jon/E-2883-2013					Berger J, 1999, P ROY SOC B-BIOL SCI, V266, P2261, DOI 10.1098/rspb.1999.0917; BERGER J, 1999, CONSERV BIOL, V13, P380; Boyd R., 1985, CULTURE EVOLUTIONARY; Byers JA, 1998, AM PRONGHORN SOCIAL; Cheney DL, 1991, MONKEYS SEE WORLD; Coulson Graeme, 1996, P158; Craighead J.J., 1995, GRIZZLY BEARS YELLOW; Guthrie R. D., 1990, CURR RES PLEISTOCENE, V7, P111; Haglund B., 1968, VILTREVY, V5, P213; Heinrich B., 1999, MIND RAVEN; Hunter LTB, 1998, BEHAVIOUR, V135, P195, DOI 10.1163/156853998793066320; Laland Kevin N., 1996, P129, DOI 10.1016/B978-012273965-1/50008-X; Martin P.S., 1984, P354; MARTIN PS, 1984, Q EXTINCTIONS; MECH LD, 1966, US NAT PARK SERV FAU, V7, P1; MOSIMANN JE, 1975, AM SCI, V63, P304; MURIE A, 1981, NATL PARK SERV MONOG, V14, P1; Reading Richard P., 1996, P296; SCHWARTZ C. C., 1992, ALCES S, V1, P177; Swenson JE, 1999, J WILDLIFE MANAGE, V63, P354, DOI 10.2307/3802519; Swenson JE, 1998, J ANIM ECOL, V67, P819, DOI 10.1046/j.1365-2656.1998.00248.x; Swenson JE, 1995, WILDLIFE BIOL, V1, P11, DOI 10.2981/wlb.1995.005; Testa J. Ward, 2000, Alces, V36, P155	23	298	304	4	177	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	2001	291	5506					1036	1039		10.1126/science.1056466	http://dx.doi.org/10.1126/science.1056466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161215				2022-12-28	WOS:000166860100043
J	Wiltshire, MCK; Pendry, JB; Young, IR; Larkman, DJ; Gilderdale, DJ; Hajnal, JV				Wiltshire, MCK; Pendry, JB; Young, IR; Larkman, DJ; Gilderdale, DJ; Hajnal, JV			Microstructured magnetic materials for RF flux guides in magnetic resonance imaging	SCIENCE			English	Article							LOW-FREQUENCY PLASMONS; BAND	Magnetic resonance imaging and spectroscopy systems use coils, either singly or as arrays, to intercept radio-frequency (RF) magnetic flux from regions of interest, often deep within the body. Here, we show that a new magnetic material offers novel possibilities for guiding RF flux to the receiver coil, permitting a clear image to be obtained where none might otherwise be detectable. The new material contains microstructure designed according to concepts taken from the field of photonic band gap materials. In the RF range, it has a magnetic permeability that can be produced to specification while exhibiting negligible direct-current magnetism, The latter property is vital to avoid perturbing the static and audio-frequency magnetic fields needed to obtain image and spectral data. The concept offers a new paradigm for the manipulation of RF flux in all nuclear magnetic resonance systems.	Marconi Caswell Ltd, Towcester NN12 8EQ, Northants, England; Univ London Imperial Coll Sci Technol & Med, London SW7 2BZ, England; Hammersmith Hosp, Imperial Coll Sch Med, Ctr Clin Sci, Robert Steiner Magnet Resonance Unit, London W12 0HS, England	Imperial College London; Imperial College London	Wiltshire, MCK (corresponding author), Marconi Caswell Ltd, Towcester NN12 8EQ, Northants, England.			Pendry, John/0000-0001-5145-5441				GHIRADELLA H, 1991, APPL OPTICS, V30, P3492, DOI 10.1364/AO.30.003492; HO KM, 1990, PHYS REV LETT, V65, P3152, DOI 10.1103/PhysRevLett.65.3152; HOULT DI, 1979, J MAGN RESON, V34, P425, DOI 10.1016/0022-2364(79)90019-2; HOULT DI, 1976, J MAGN RESON, V24, P71, DOI 10.1016/0022-2364(76)90233-X; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; Pendry JB, 1998, J PHYS-CONDENS MAT, V10, P4785, DOI 10.1088/0953-8984/10/22/007; Pendry JB, 1996, PHYS REV LETT, V76, P4773, DOI 10.1103/PhysRevLett.76.4773; Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002; Sievenpiper D, 1999, IEEE T MICROW THEORY, V47, P2059, DOI 10.1109/22.798001; Sievenpiper DF, 1996, PHYS REV LETT, V76, P2480, DOI 10.1103/PhysRevLett.76.2480; Smith DR, 2000, PHYS REV LETT, V84, P4184, DOI 10.1103/PhysRevLett.84.4184; STRATTON JA, 1941, ELECTROMAGNETIC THEO, P211; VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YABLONOVITCH E, 1991, PHYS REV LETT, V67, P2295, DOI 10.1103/PhysRevLett.67.2295	15	390	419	4	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 2	2001	291	5505					849	851		10.1126/science.291.5505.849	http://dx.doi.org/10.1126/science.291.5505.849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157159				2022-12-28	WOS:000166771700036
J	Richards, M; Hardy, R; Kuh, D; Wadsworth, MEJ				Richards, M; Hardy, R; Kuh, D; Wadsworth, MEJ			Birth weight and cognitive function in the British 1946 birth cohort: longitudinal population based study	BRITISH MEDICAL JOURNAL			English	Article							GROWTH-FACTORS; FOLLOW-UP; INSULIN; BRAIN; REGRESSION	Objective To examine the association between birth weight and cognitive function in the normal population. Design A longitudinal, population based, birth cohort study. Participants 3900 males and females born in 1946. Main outcome measures Cognitive function from childhood to middle life (measured at ages 8, 11, 15, 26, and 43 years). Results Birth weight was significantly and positively associated with cognitive ability at age 8 (with an estimated standard deviation score of 0.44 (95%, confidence interval 0.28 to 0.59)) between the lowest and highest birthweight categories after sex, father's social class, mother's education, and birth order were controlled for. This association was evident across the normal birthweight range (> 2.5 kg) and so was not accounted for exclusively by low birth weight The association was also observed at ages 11, 15, and 26, and weakly at age 43, although these associations were dependent on the association at age 8. Birth weight was also associated with education, with those of higher. birth weight more likely to have achieved higher qualifications, and this effect was accounted for partly by cognitive function at age 8. Conclusions Birth weight was associated with cognitive ability at age 8 in the general population, and in the normal birthweight range. The effect at this age largely explains associations between birth weight and cognitive function at subsequent ages. Similarly, the association between birth weight and education was accounted for partly by earlier cognitive scores.	UCL, Dept Epidemiol & Publ Hlth, Natl Survey Hlth & Dev, London WC1E 6BT, England	University of London; University College London	Richards, M (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Natl Survey Hlth & Dev, Mortimer St, London WC1E 6BT, England.	m.richards@ucl.ac.uk	Hardy, Rebecca/AFR-1989-2022; Kuh, Diana/L-6019-2014	Kuh, Diana/0000-0001-7386-2857; Hardy, Rebecca/0000-0001-9949-0799; Richards, Marcus/0000-0001-9191-2192				Barker DJP, 1998, MOTHERS BABIES HLTH; BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BRESLAU N, 1995, EPIDEMIOL REV, V17, P96, DOI 10.1093/oxfordjournals.epirev.a036191; COOKE RWI, 1977, EARLY HUM DEV, V1, P145, DOI 10.1016/0378-3782(77)90015-9; DEPABLO F, 1995, TRENDS NEUROSCI, V18, P143, DOI 10.1016/0166-2236(95)93892-2; Eckstein LW, 1997, DEV BRAIN RES, V103, P59, DOI 10.1016/S0165-3806(97)00117-X; Fall C. H. D., 1995, Archives of Disease in Childhood, V73, P287; Fawer CL, 1995, EARLY HUM DEV, V43, P151, DOI 10.1016/0378-3782(95)01673-2; Illsley R, 1984, LOW BIRTH WEIGHT MED; Kline J.S., 1989, CONCEPTION BIRTH EPI; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Martyn CN, 1996, BRIT MED J, V312, P1393; NELSON KB, 1970, DEV MED CHILD NEUROL, V12, P487; PAZ I, 1995, OBSTET GYNECOL, V85, P452; Pigeon DA, 1968, ALL OUR FUTURE; Pigeon DA, 1964, HOME SCH; Plewis I, 1996, BRIT J MATH STAT PSY, V49, P25, DOI 10.1111/j.2044-8317.1996.tb01073.x; RECORD RG, 1969, ANN HUM GENET, V33, P71, DOI 10.1111/j.1469-1809.1969.tb01631.x; Richards M, 1999, NEUROLOGY, V53, P308, DOI 10.1212/WNL.53.2.308; Singh SP, 1996, P SOC EXP BIOL MED, V212, P349; Sorensen HT, 1997, BRIT MED J, V315, P401, DOI 10.1136/bmj.315.7105.401; Stein Z., 1975, FAMINE HUM DEV DUTCH; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; Wickelgren I, 1998, SCIENCE, V280, P517, DOI 10.1126/science.280.5363.517	26	266	271	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					199	203		10.1136/bmj.322.7280.199	http://dx.doi.org/10.1136/bmj.322.7280.199			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159613	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000166733700024
J	Roos, K; Hakansson, EG; Holm, S				Roos, K; Hakansson, EG; Holm, S			Effect of recolonisation with "interfering" alpha streptococci on recurrences of acute and secretory otitis media in children: randomised placebo controlled trial	BRITISH MEDICAL JOURNAL			English	Article							NASOPHARYNGEAL BACTERIAL-FLORA; PRONE CHILDREN; PROPHYLAXIS; TONSILLITIS; PREVENTION; EFFUSION	Objective To study the effect of recolonisation with a streptococci with the ability to inhibit the growth of otopathogens ("interfering" activity) on the recurrence of acute otitis media in susceptible children and the effect on the frequency of secretory otitis media. Design Double blind, randomised, placebo controlled study: Setting Ear, nose, and throat clinic with three doctors. Participants 130 children prone to otitis media aged between 6 months and 6 years, 108 of whom were eligible and followed for 3 months. Main outcome measures Recurrence of otitis media during follow up and a normal tympanic membrane at the last valid visit. Interventions Children with no recurrences during the last month received phenoxymethylpenicillin (n = 22), and those with a recurrence within 1 month received amoxicillin clavulanic acid (n = 86), both twice daily for 10 days. These were followed by a streptococcal or placebo solution sprayed into the nose for a further 10 days. At day 60 the same spray was started for another 10 days. Results At 3 months 22 children (42%) given the streptococcal spray were healthy and had a normal tympanic membrane compared with 12 (22%) of those given placebo. This difference was shown separately for recurrences of both acute otitis media and secretor) otitis media. Conclusions Selected bacteria with the ability to inhibit the growth of common otopathogens can be used to protect against recurrent acute otitis media and secretory otitis media in children.	Lundby Hosp, Dept Ear Nose & Throat, S-41717 Gothenburg, Sweden; Umea Univ, Dept Clin Bacteriol, S-90187 Umea, Sweden; Umea Univ, Dept Clin Microbiol, S-90187 Umea, Sweden	Umea University; Umea University	Roos, K (corresponding author), Lundby Hosp, Dept Ear Nose & Throat, S-41717 Gothenburg, Sweden.							BERNSTEIN JM, 1993, ACTA OTO-LARYNGOL, V113, P88, DOI 10.3109/00016489309135772; Brook I, 1999, PEDIATR INFECT DIS J, V18, P835, DOI 10.1097/00006454-199909000-00021; CARLIN SA, 1987, J PEDIATR-US, V110, P20, DOI 10.1016/S0022-3476(87)80281-0; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; Fujimori I, 1996, EUR ARCH OTO-RHINO-L, V253, P260; GRAHN E, 1983, ZBL BAKT-INT J MED M, V254, P459; GRAHN E, 1983, ZBL BAKT-INT J MED M, V256, P72; INGVARSSON L, 1990, ANN OTOL RHINOL LA S, V149, P17; PRELLNER K, 1994, ACTA OTO-LARYNGOL, V114, P182, DOI 10.3109/00016489409126039; ROOS K, 1986, SCAND J INFECT DIS, V18, P313, DOI 10.3109/00365548609032342; Roos K, 1996, SCAND J INFECT DIS, V28, P459, DOI 10.3109/00365549609037940; ROOS K, 1993, SCAND J INFECT DIS, V25, P31, DOI 10.3109/00365549309169666; STENFORS LE, 1992, CLIN OTOLARYNGOL, V17, P195, DOI 10.1111/j.1365-2273.1992.tb01825.x; TOS M, 1989, ARCH OTOLARYNGOL, V115, P931	14	126	131	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					210	212		10.1136/bmj.322.7280.210	http://dx.doi.org/10.1136/bmj.322.7280.210			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159619	Green Published			2022-12-28	WOS:000166733700028
J	Tang, T; Noble-Jamieson, C				Tang, T; Noble-Jamieson, C			Lesson of the week - A painful hip as a presentation of Guillain-Barre syndrome in children	BRITISH MEDICAL JOURNAL			English	Review									Addenbrookes Hosp, Sch Clin Med, Cambridge CB2 2SP, England; W Suffolk Hosp, Bury St Edmunds IP33 2QZ, Suffolk, England	Addenbrooke's Hospital; University of Cambridge	Tang, T (corresponding author), Univ Cambridge Queens Coll, Cambridge CB3 9ET, England.							BEGHI E, 1985, ARCH NEUROL-CHICAGO, V42, P1053, DOI 10.1001/archneur.1985.04060100035016; Jones H R Jr, 1995, Curr Opin Pediatr, V7, P663; MANNERS PJ, 1992, ACTA PAEDIATR, V81, P1049, DOI 10.1111/j.1651-2227.1992.tb12174.x; Moulin DE, 1997, NEUROLOGY, V48, P328, DOI 10.1212/WNL.48.2.328; Nguyen DK, 1999, J PEDIATR-US, V134, P773, DOI 10.1016/S0022-3476(99)70297-0; RANTALA H, 1991, ARCH DIS CHILD, V66, P706, DOI 10.1136/adc.66.6.706; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; SAKAKIHARA Y, 1991, DEV MED CHILD NEUROL, V33, P611	8	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					149	150		10.1136/bmj.322.7279.149	http://dx.doi.org/10.1136/bmj.322.7279.149			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159574	Green Published			2022-12-28	WOS:000166615300028
J	Hatcher, MB; Fallowfield, L; A'Hern, R				Hatcher, MB; Fallowfield, L; A'Hern, R			The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; FAMILY-HISTORY; RISK PERCEPTION; WOMEN	Objectives To investigate the psychosocial impact of bilateral prophylactic mastectomy for women with increased risk of breast cancer and to identify, preoperatively, risk factors for postoperative distress. Design Prospective study using interviews and questionnaire assessments. Setting Participants' homes throughout the United Kingdom. Participants 143 women with increased risk of developing breast cancer who were offered bilateral prophylactic mastectomy and who accepted or declined the surgery; a further 11 were offered surgery but deferred making a decision. Main outcome measures Psychological and sexual morbidity. Results Psychological morbidity decreased significantly over time for the 79 women who chose to have surgery (accepters): 58% (41/71) preoperatively v 41% (29/71) 6 months postoperatively (difference in percentages 17%, 95% confidence interval 2% to 32%; P = 0.04) and 60% (39/65) preoperatively v 29% (19/65) 18 months postoperatively (31%, 15% to 47%; P < 0.001). Psychological morbidity in the 64 women who declined surgery (decliners) did not decrease significantly: 57% (31/54) at baseline v 43% (23/54) at 6 months (14%, 0% to 29%; P = 0.08) and 57% (29/52) at baseline v 41% (21/52) at 18 months (16%; - 2% to 33%; P = 0.11). Greater than normal proneness to anxiety was more common in the decliners than in the accepters: 78% (45/58) v 56% (41/73) (22%, 6% to 35%; P = 0.006). Accepters were more likely than decliners to believe it inevitable that they would develop breast cancer (32% (24/74) v 10% (6/58) (difference in percentages 22%, 9% to 35%;P = 0.003)), and decliners were more likely to believe that screening could help (92% (55/60) v 74% (55/74) (18%, 5% to 31%; P = 0.007)). Level of sexual discomfort and degree of sexual pleasure did not change significantly over time in either of the two groups. Conclusions Bilateral prophylactic mastectomy may provide psychological benefits in women with a high risk of developing breast cancer.	UCL Royal Free & Univ Coll Med Sch, Bland Sutton Inst, Canc Res Campaign, Psychosocial Oncol Grp, London W1P 7PL, England; Royal Marsden NHS Trust, London SW3 6JJ, England	University of London; University College London; UCL Medical School; Royal Marsden NHS Foundation Trust	Fallowfield, L (corresponding author), UCL Royal Free & Univ Coll Med Sch, Bland Sutton Inst, Canc Res Campaign, Psychosocial Oncol Grp, London W1P 7PL, England.	l.fallowfield@ucl.ac.uk		Fallowfield, Lesley/0000-0003-0577-4518				Al-Ghazal SK, 2000, EUR J SURG ONCOL, V26, P17, DOI 10.1053/ejso.1999.0733; Borgen PI, 1998, ANN SURG ONCOL, V5, P603, DOI 10.1007/BF02303829; EELES JWR, 1996, CLIN ONCOL, V8, P222; EVANS DGR, 1994, BRIT J CANCER, V70, P934, DOI 10.1038/bjc.1994.423; Fallowfield L, 1996, INT CONGR SER, V1120, P219; FALLOWFIELD LJ, 1994, BREAST, V3, P202; FOLKMAN S, 1985, J PERS SOC PSYCHOL, V48, P150, DOI 10.1037/0022-3514.48.1.150; Frost MH, 2000, JAMA-J AM MED ASSOC, V284, P319, DOI 10.1001/jama.284.3.319; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Hopwood P, 1998, PSYCHO-ONCOL, V7, P402, DOI 10.1002/(SICI)1099-1611(1998090)7:5<402::AID-PON317>3.3.CO;2-O; HOPWOOD P, IN PRESS EUR J CANC; LERMAN C, 1994, ARCH INTERN MED, V154, P609, DOI 10.1001/archinte.154.6.609; LYNCH HT, 1994, CANCER, V74, P1184, DOI 10.1002/1097-0142(19940801)74:3+<1184::AID-CNCR2820741530>3.0.CO;2-4; MACKE E, 1996, TROUBLED HELIX SOCIA, P31; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; Stead ML, 1999, BRIT J OBSTET GYNAEC, V106, P50, DOI 10.1111/j.1471-0528.1999.tb08084.x; Stefanek M E, 1995, J Natl Cancer Inst Monogr, P37; THIRLAWAY K, 1995, BREAST, V4, P203, DOI 10.1016/0960-9776(95)90078-0; Thirlaway K, 1996, BRIT J CANCER, V73, P1422, DOI 10.1038/bjc.1996.269; Thirlaway K, 1996, QUAL LIFE RES, V5, P81, DOI 10.1007/BF00435972; Watson M, 1999, BRIT J CANCER, V79, P868, DOI 10.1038/sj.bjc.6690139; ZATZ J, 1996, TROUBLED HELIX SOCIA, P27	23	121	122	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					76	79		10.1136/bmj.322.7278.76	http://dx.doi.org/10.1136/bmj.322.7278.76			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154619	Bronze, Green Accepted, Green Submitted, Green Published			2022-12-28	WOS:000166496100023
J	Dalal, S; Hanson, PI				Dalal, S; Hanson, PI			Membrane traffic: What drives the AAA motor?	CELL			English	Review							CRYSTAL-STRUCTURE; ATPASE; FUSION; PROTEIN; UBIQUITIN; COFACTOR; COMPLEX; NSF; P47; P97		Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Hanson, PI (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	phanson@cellbio.wustl.edu	Hanson, Phyllis/E-9420-2012					Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 1998, FEBS LETT, V437, P255, DOI 10.1016/S0014-5793(98)01232-0; Neuwald AF, 1999, GENOME RES, V9, P27; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rockel B, 1999, FEBS LETT, V451, P27, DOI 10.1016/S0014-5793(99)00431-7; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	18	38	39	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					5	8		10.1016/S0092-8674(01)00186-6	http://dx.doi.org/10.1016/S0092-8674(01)00186-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163235	Bronze			2022-12-28	WOS:000166882300002
J	Blunier, T; Brook, EJ				Blunier, T; Brook, EJ			Timing of millennial-scale climate change in Antarctica and Greenland during the last glacial period	SCIENCE			English	Article							ICE CORE; NORTH-ATLANTIC; ISOTOPE; RECORD; DEGLACIATION; TRANSITION; PROFILES; STATION; GISP2; CYCLE	A precise relative chronology for Greenland and West Antarctic paleotemperature is extended to 90,000 years ago, based on correlation of atmospheric methane records from the Greenland Ice Sheet Project 2 and Byrd ice cores. Over this period, the onset of seven major millennial-scale warmings in Antarctica preceded the onset of Greenland warmings by 1500 to 3000 years. In general, Antarctic temperatures increased gradually while Greenland temperatures were decreasing or constant, and the termination of Antarctic warming was apparently coincident with the onset of rapid warming in Greenland. This pattern provides further evidence for the operation of a "bipolar see-saw" in air temperatures and an oceanic teleconnection between the hemispheres on millennial time scales.	Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Washington State Univ, Dept Geol, Vancouver, WA 98686 USA; Washington State Univ, Environm Sci Program, Vancouver, WA 98686 USA	Princeton University; University of Bern; Washington State University; Washington State University	Blunier, T (corresponding author), Princeton Univ, Dept Geosci, Guyot Hall, Princeton, NJ 08544 USA.	blunier@princeton.edu	Brook, Edward/AAB-7807-2021; Blunier, Thomas/M-4609-2014	Blunier, Thomas/0000-0002-6065-7747				Alley RB, 1999, ANNU REV EARTH PL SC, V27, P149, DOI 10.1146/annurev.earth.27.1.149; Bender ML, 1999, GEOPH MONOG SERIES, V112, P149; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P119, DOI 10.1029/97PA03707; Brook EJ, 1999, GEOPH MONOG SERIES, V112, P165; Cane M, 1999, GEOPH MONOG SERIES, V112, P373; Dallenbach A, 2000, GEOPHYS RES LETT, V27, P1005, DOI 10.1029/1999GL010873; DALLENBACH A, 2000, THESIS U BERN BERN; DEQ G, 1983, CLIMATIC RECORD POLA, P180; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HARDER S, 2000, COMMUNICATION; Indermuhle A, 2000, GEOPHYS RES LETT, V27, P735, DOI 10.1029/1999GL010960; JOHNSEN SJ, 1972, NATURE, V235, P429, DOI 10.1038/235429a0; JOUZEL J, 1987, NATURE, V329, P403, DOI 10.1038/329403a0; JOUZEL J, 1995, CLIM DYNAM, V11, P151, DOI 10.1007/BF00223498; Krinner G, 1997, GEOPHYS RES LETT, V24, P2825, DOI 10.1029/97GL52891; Lang C, 1999, SCIENCE, V286, P934, DOI 10.1126/science.286.5441.934; MEESE DA, 1994, SCIENCE, V266, P1680, DOI 10.1126/science.266.5191.1680; Mulvaney R, 2000, GEOPHYS RES LETT, V27, P2673, DOI 10.1029/1999GL011254; Ninnemann US, 1999, GEOPH MONOG SERIES, V112, P99; Salamatin AN, 1998, J GEOPHYS RES-ATMOS, V103, P8963, DOI 10.1029/97JD02253; Schmittner A, 2000, GEOPHYS RES LETT, V27, P1163, DOI 10.1029/1999GL011048; Schwander J, 1997, J GEOPHYS RES-ATMOS, V102, P19483, DOI 10.1029/97JD01309; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; SHACKLETON NJ, 1987, QUATERNARY SCI REV, V6, P183, DOI 10.1016/0277-3791(87)90003-5; Stocker TF, 2000, QUATERNARY SCI REV, V19, P301, DOI 10.1016/S0277-3791(99)00067-0; Stocker TF, 2000, P NATL ACAD SCI USA, V97, P1362, DOI 10.1073/pnas.97.4.1362; Vidal L, 1999, CLIM DYNAM, V15, P909, DOI 10.1007/s003820050321; Watanabe O, 1999, ANN GLACIOL, V29, P176, DOI 10.3189/172756499781821553; Wunsch C, 2000, PALEOCEANOGRAPHY, V15, P417, DOI 10.1029/1999PA000468	33	798	841	2	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					109	112		10.1126/science.291.5501.109	http://dx.doi.org/10.1126/science.291.5501.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141558				2022-12-28	WOS:000166259100044
J	O'Connor, JB; Issa, K				O'Connor, JB; Issa, K			Rectal varices.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Duke Univ, Med Ctr, Durham, NC 27710 USA; Case Western Reserve Univ, Cleveland, OH 44109 USA	Duke University; Case Western Reserve University	O'Connor, JB (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					29	29		10.1056/NEJM200101043440105	http://dx.doi.org/10.1056/NEJM200101043440105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136957				2022-12-28	WOS:000166160400005
J	Smith, KC				Smith, KC			Genetic disease, genetic testing, and the clinician	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Clemson Univ, Clemson, SC 29634 USA	Clemson University	Smith, KC (corresponding author), Clemson Univ, Clemson, SC 29634 USA.							HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Smith KC, 1998, MT SINAI J MED, V65, P178; SMITH KC, IN PRESS EUR J MED P	3	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					91	91		10.1001/jama.285.1.91	http://dx.doi.org/10.1001/jama.285.1.91			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150119	hybrid, Green Submitted			2022-12-28	WOS:000166114500033
J	Sandock, LF				Sandock, LF			From rites of passage to last rights	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3100	3102		10.1001/jama.284.24.3100	http://dx.doi.org/10.1001/jama.284.24.3100			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	385FZ	11135750				2022-12-28	WOS:000165994100001
J	Odelberg, SJ; Kollhoff, A; Keating, MT				Odelberg, SJ; Kollhoff, A; Keating, MT			Dedifferentiation of mammalian myotubes induced by msx1	CELL			English	Article							MESENCHYMAL STEM-CELLS; TERMINAL DIFFERENTIATION; MYOGENIC DIFFERENTIATION; LIMB REGENERATION; GENE-EXPRESSION; C2C12 MYOBLASTS; MUSCLE-CELLS; FATTY-ACIDS; REVERSAL; CYCLE	The process of cellular differentiation culminating in terminally differentiated mammalian cells is thought to be irreversible. Here, we present evidence that terminally differentiated murine myotubes can be induced to dedifferentiate. Ectopic expression of msx1 in C2C12 myotubes reduced the nuclear muscle proteins MyoD, myogenin, MRF4, and p21 to undetectable levels in 20%-50% of the myotubes. Approximately 9% of the myotubes cleave to produce either smaller multinucleated myotubes or proliferating, mononucleated cells. Finally, clonal populations of the myotube-derived mononucleated cells can be induced to redifferentiate into cells expressing chondrogenic, adipogenic, myogenic, and osteogenic markers. These results suggest that terminally differentiated mammal lan myotubes can dedifferentiate when stimulated with the appropriate signals and that msx1 can contribute to the dedifferentiation process.	Univ Utah, Dept Internal Med, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Odelberg, SJ (corresponding author), Univ Utah, Dept Internal Med, Div Cardiol, Salt Lake City, UT 84112 USA.	odelberg@howard.genetics.utah.edu; mkeating@genetics.med.harvard.edu	Wilson, Matthew H/K-3193-2013					AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BECKER RO, 1974, NATURE, V248, P145, DOI 10.1038/248145a0; BODEMER CW, 1959, DEV BIOL, V1, P327, DOI 10.1016/0012-1606(59)90032-6; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHALKLEY DT, 1954, J MORPHOL, V94, P21, DOI 10.1002/jmor.1050940103; COMELISON DDW, 1997, DEV BIOL, V191, P270; DAVIS BM, 1990, EXP NEUROL, V108, P198, DOI 10.1016/0014-4886(90)90124-B; Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700; Endo T, 1998, J CELL SCI, V111, P1081; Endo T., 1989, CELLULAR MOL BIOL MU, P95; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; Grimaldi PA, 1997, PROSTAG LEUKOTR ESS, V57, P71, DOI 10.1016/S0952-3278(97)90495-6; HAY ED, 1961, DEV BIOL, V3, P26, DOI 10.1016/0012-1606(61)90009-4; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kumar A, 2000, DEV BIOL, V218, P125, DOI 10.1006/dbio.1999.9569; Lee TC, 1998, NUCLEIC ACIDS RES, V26, P3215, DOI 10.1093/nar/26.13.3215; LO DC, 1993, P NATL ACAD SCI USA, V90, P7230, DOI 10.1073/pnas.90.15.7230; LUJVIDIN S, 1990, DIFFERENTIATION, V43, P192; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Poss FD, 2000, DEV BIOL, V222, P347, DOI 10.1006/dbio.2000.9722; REGINELLI AD, 1995, DEVELOPMENT, V121, P1065; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; Rosania GR, 2000, NAT BIOTECHNOL, V18, P304, DOI 10.1038/73753; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SIMON HG, 1995, DEV DYNAM, V202, P1, DOI 10.1002/aja.1002020102; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; STEEN TP, 1968, J EXP ZOOL, V167, P49, DOI 10.1002/jez.1401670105; TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; Yoshida N, 1998, J CELL SCI, V111, P769	42	350	379	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1099	1109		10.1016/S0092-8674(00)00212-9	http://dx.doi.org/10.1016/S0092-8674(00)00212-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163185	Bronze			2022-12-28	WOS:000166040600012
J	Liu, ZH; Sun, CH; Olejniczak, ET; Meadows, RP; Betz, SF; Oost, T; Herrmann, J; Wu, JC; Fesik, SW				Liu, ZH; Sun, CH; Olejniczak, ET; Meadows, RP; Betz, SF; Oost, T; Herrmann, J; Wu, JC; Fesik, SW			Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain	NATURE			English	Article							APOPTOSIS PROTEIN XIAP; DISTANCE RESTRAINTS; NMR STRUCTURE; INHIBITOR; DROSOPHILA; HOMOLOGY; CASPASES; CANCER; GENE; IAP	The inhibitor-of-apoptosis proteins (IAPs)(1) regulate programmed cell death by inhibiting members of the caspase family of enzymes(2-5). Recently, a mammalian protein called Smac(6) (also named DIABLO(7)) was identified that binds to the IAPs and promotes caspase activation. Although undefined in the X-ray structure, the amino-terminal residues of Smac are critical for its function(8,9). To understand the structural basis for molecular recognition between Smac and the IAPs, we determined the solution structure of the BIR3 domain of X-linked IAP (XIAP) complexed with a functionally active nine-residue peptide derived from the N terminus of Smac. The peptide binds across the third beta -strand of the BIR3 domain in an extended conformation with only the first four residues contacting the protein. The complex is stabilized by four intermolecular hydrogen bonds, an electrostatic interaction involving the N terminus of the peptide, and several hydrophobic interactions. This structural information, along with the binding data from BIR3 and Smac peptide mutants reported here, should aid in the design of small molecules that may be used for the treatment of cancers that overexpress IAPs(10-12).	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA; Idun Pharmaceut Inc, Dept Biochem, La Jolla, CA 92037 USA	Abbott Laboratories	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA.							Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cutforth T, 1999, MECH DEVELOP, V82, P23, DOI 10.1016/S0925-4773(99)00006-4; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300	27	519	580	0	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					1004	1008		10.1038/35050006	http://dx.doi.org/10.1038/35050006			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140637				2022-12-28	WOS:000165951100058
J	Stewart, I; Cohen, J				Stewart, I; Cohen, J			Monolith - With apologies to Arthur C. Clarke.	NATURE			English	Editorial Material																			0	0	0	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					913	913		10.1038/35050175	http://dx.doi.org/10.1038/35050175			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140659	Bronze			2022-12-28	WOS:000165951100025
J	Loprinzi, CL; Kugler, JW; Sloan, JA; Mailliard, JA; LaVasseur, BI; Barton, DL; Novotny, PJ; Dakhil, SR; Rodger, K; Rummans, TA; Christensen, BJ				Loprinzi, CL; Kugler, JW; Sloan, JA; Mailliard, JA; LaVasseur, BI; Barton, DL; Novotny, PJ; Dakhil, SR; Rodger, K; Rummans, TA; Christensen, BJ			Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; ESTROGEN REPLACEMENT THERAPY; MAJOR DEPRESSION; PILOT EVALUATION; ANTIDEPRESSANTS; ATTITUDES; WOMEN	Background Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer. Methods Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually increased in the 75 mg and 150 mg groups. Patients completed daily hot-flash questionnaire diaries. The primary endpoint was average daily hot-flash activity (number of flashes and a score combining number and severity). Analyses were based on the women who provided data throughout the baseline and study weeks. Findings 191 patients had evaluable data for the whole study period (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg), After week 4 of treatment, median hot flash scores were reduced from baseline by 27% (95% CI 11-34), 37% (26-54), 61% (50-68), and 61% (48-75) in the four groups. Frequencies of some side-effects (mouth dryness, decreased appetite, nausea, and constipation) were significantly higher in the venlafaxine 75 mg and 150 mg groups than in the placebo group. Interpretation Venlafaxine is an effective non-hormonal treatment for hot flashes, though the efficacy must be balanced against the drug's side-effects. Confirmation of the results of this 4-week study awaits the completion of three ongoing randomised studies to assess the effects of other related antidepressants for the treatment of hot flashes.	Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA; Illinois Oncol Res Assoc, Community Clin Oncol Program, Peoria, IL USA; Missouri Valley Canc Consortium, Omaha, NE USA; Ann Arbor Reg CCOP, Ann Arbor, MI USA; Carle Canc Ctr CCOP, Urbana, IL USA; Wichita Community Clin Oncol, Wichita, KS USA; Ochsner CCOP, New Orleans, LA USA	Mayo Clinic; Ochsner Health System	Loprinzi, CL (corresponding author), Mayo Clin & Mayo Fdn, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL CANCER INSTITUTE [U10CA035113, U10CA037404, U10CA025224] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37404, CA-25224, CA-35113] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON NK, 1991, CANCER, V67, P844, DOI 10.1002/1097-0142(19910201)67:3+<844::AID-CNCR2820671416>3.0.CO;2-B; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; BAYLEY KB, 1995, MED CARE, V33, pAS226; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BERGMANS MGM, 1987, MATURITAS, V9, P227, DOI 10.1016/0378-5122(87)90005-3; Bruera E, 1991, J Palliat Care, V7, P6; CLARK A, 1986, J ROY SOC MED, V79, P165, DOI 10.1177/014107688607900311; COUZI RJ, 1995, J CLIN ONCOL, V13, P2737, DOI 10.1200/JCO.1995.13.11.2737; CUNNINGHAM LA, 1994, J CLIN PSYCHOPHARM, V14, P99; Finck G, 1998, J PAIN SYMPTOM MANAG, V16, P327, DOI 10.1016/S0885-3924(98)00090-6; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; Loprinzi C. L., 1999, Breast Cancer Research and Treatment, V57, P34; Loprinzi CL, 1998, J CLIN ONCOL, V16, P2377, DOI 10.1200/JCO.1998.16.7.2377; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; *MED EC DAT, 1995, PHYS DESK REF; NESHEIM BI, 1981, EUR J CLIN PHARMACOL, V20, P413, DOI 10.1007/BF00542092; Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004; PATRICK D, 1998, MED CARE S, V27; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; PRESKORN SH, 1995, J CLIN PSYCHIAT S, V6, P12; Quella SK, 1999, J UROLOGY, V162, P98, DOI 10.1097/00005392-199907000-00024; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; Sanchez C, 1999, CELL MOL NEUROBIOL, V19, P467, DOI 10.1023/A:1006986824213; SCHWEIZER E, 1994, J CLIN PSYCHIAT, V55, P104; Sloan JA, 1998, J CLIN ONCOL, V16, P3662, DOI 10.1200/JCO.1998.16.11.3662; Stearns V, 1997, BREAST CANC RES TREA, V46, P23; VASSILOPOULOUSELLIN R, 1992, AM J MED SCI, V304, P145, DOI 10.1097/00000441-199209000-00001; Westenberg HGM, 1999, J CLIN PSYCHIAT, V60, P4; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59	29	503	533	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2059	2063		10.1016/S0140-6736(00)03403-6	http://dx.doi.org/10.1016/S0140-6736(00)03403-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145492				2022-12-28	WOS:000165994300012
J	Hong, SY; Kalnay, E				Hong, SY; Kalnay, E			Role of sea surface temperature and soil-moisture feedback in the 1998 Oklahoma-Texas drought	NATURE			English	Article							UNITED-STATES; TROPICAL PACIFIC; PRECIPITATION; CLIMATE; SUMMER; MODEL; VARIABILITY; ANOMALIES; WAVE; ENSO	The drought that affected the US states of Oklahoma and Texas in the summer of 1998 was strong and persistent, with soil moisture reaching levels comparable to those of the 1930s 'dust bowl'(1,2). Although other effects of the record-strength 1997-98 El Nino were successfully predicted over much of the United States, the Oklahoma-Texas drought was not(3). Whereas the response of the tropical atmosphere to strong anomalies in sea surface temperature is quite predictable, the response of the extratropical atmosphere is more variable(4,5). Here we present results from mechanistic experiments to clarify the origin and maintenance of this extratropical climate extreme. In addition to global tmospheric models(6-11), we use a regional model(12,13) to isolate regional climate feedbacks. We conclude that during April and May 1998, sea surface temperature anomalies combined with a favourable atmospheric circulation to establish the drought. In June-August, the regional positive feedback associated with lower evaporation and precipitation contributed substantially to the maintenance of the drought. The drought ended in the autumn, when stronger large-scale weather systems were able to penetrate the region and overwhelm the soil-moisture feedback. Our results show the potential for numerical models including appropriate physical processes to make skilful predictions of regional climate.	Yonsei Univ, Dept Atmospher Sci, Seoul 134, South Korea; Natl Ctr Environm Predict, Camp Springs, MD 20746 USA; Univ Maryland, Dept Meteorol, College Pk, MD 20742 USA	Yonsei University; National Oceanic Atmospheric Admin (NOAA) - USA; University System of Maryland; University of Maryland College Park	Kalnay, E (corresponding author), Yonsei Univ, Dept Atmospher Sci, Seoul 134, South Korea.		Hong, Song-You/I-3824-2012; Kalnay, Eugenia/F-4393-2010	Kalnay, Eugenia/0000-0002-9984-9906				Anderson J, 1999, B AM METEOROL SOC, V80, P1349, DOI 10.1175/1520-0477(1999)080<1349:PDCONA>2.0.CO;2; ATLAS R, 1993, J CLIMATE, V6, P2034, DOI 10.1175/1520-0442(1993)006<2034:TEOSAS>2.0.CO;2; Barnston AG, 1999, B AM METEOROL SOC, V80, P1829, DOI 10.1175/1520-0477(1999)080<1829:NFOTEN>2.0.CO;2; Basara J.B., 1998, EOS T AM GEOPHYS UN, V79, P258; Bell GD, 1999, B AM METEOROL SOC, V80, pS1, DOI 10.1175/1520-0477-80.5s.S1; BONNER WD, 1970, MON WEATHER REV, V98, P735, DOI 10.1175/1520-0493(1970)098<0735:DVIBLW>2.3.CO;2; Caplan P, 1997, WEATHER FORECAST, V12, P581, DOI 10.1175/1520-0434(1997)012<0581:CTTNOM>2.0.CO;2; Chen P, 1998, J CLIMATE, V11, P2491, DOI 10.1175/1520-0442(1998)011<2491:RWPATR>2.0.CO;2; Juang HMH, 1997, B AM METEOROL SOC, V78, P2125, DOI 10.1175/1520-0477(1997)078<2125:TNRSMA>2.0.CO;2; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Koster RD, 2000, J HYDROMETEOROL, V1, P26, DOI 10.1175/1525-7541(2000)001<0026:VAPOPA>2.0.CO;2; Kumar A, 1998, J CLIMATE, V11, P3295, DOI 10.1175/1520-0442(1998)011<3295:ACOPNA>2.0.CO;2; MO KC, 1991, MON WEATHER REV, V119, P1512, DOI 10.1175/1520-0493(1991)119<1512:AGSOTU>2.0.CO;2; Montroy DL, 1998, J CLIMATE, V11, P1812, DOI 10.1175/1520-0442(1998)011<1812:ONOMTB>2.0.CO;2; MONTROY DL, 1997, J CLIMATE, V10, P531; ROADS J, IN PRESS J GEOPHYS R; Schubert SD, 1998, J CLIMATE, V11, P2530, DOI 10.1175/1520-0442(1998)011<2530:SVIWSM>2.0.CO;2; SHUKLA J, 1982, SCIENCE, V215, P1498, DOI 10.1126/science.215.4539.1498; Ting MF, 1997, J CLIMATE, V10, P1853, DOI 10.1175/1520-0442(1997)010<1853:SUSPVA>2.0.CO;2; TRENBERTH KE, 1988, SCIENCE, V242, P1640, DOI 10.1126/science.242.4886.1640; Wallace JM, 1998, J GEOPHYS RES-OCEANS, V103, P14241, DOI 10.1029/97JC02905; WOLFSON N, 1987, MON WEATHER REV, V115, P1345, DOI 10.1175/1520-0493(1987)115<1345:NERTTS>2.0.CO;2	22	103	106	0	32	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					842	844		10.1038/35048548	http://dx.doi.org/10.1038/35048548			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130719				2022-12-28	WOS:000165831300045
J	Shang, YF; Hu, X; DiRenzo, J; Lazar, MA; Brown, M				Shang, YF; Hu, X; DiRenzo, J; Lazar, MA; Brown, M			Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription	CELL			English	Article							RNA-POLYMERASE-II; NUCLEAR-RECEPTOR; ALPHA-AMANITIN; VITAMIN-D-3 RECEPTOR; COACTIVATOR COMPLEX; CHROMATIN STRUCTURE; N-COR; ACTIVATION; INHIBITOR; BINDING	Many cofactors bind the hormone-activated estrogen receptor (ER), yet the specific regulators of endogenous ER-mediated gene transcription are unknown. Using chromatin immunoprecipitation (ChIP), we find that ER and a number of coactivators rapidly associate with estrogen responsive promoters following estrogen treatment in a cyclic fashion that is not predicted by current models of hormone activation. Cycles of ER complex assembly are followed by transcription. In contrast, the anti-estrogen tamoxifen (TAM) recruits corepressors but not coactivators. Using a genetic approach, we show that recruitment of the p160 class of coactivators is sufficient for gene activation and for the growth stimulatory actions of estrogen in breast cancer supporting a model in which ER cofactors play unique roles in estrogen signaling.	Brigham & Womens Hosp, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Brown, M (corresponding author), Brigham & Womens Hosp, Dept Adult Oncol, 75 Francis St, Boston, MA 02115 USA.		Brown, Myles/AAX-5332-2021; Lazar, Mitchell A/AAF-3738-2019; Brown, Myles/B-6906-2008	Brown, Myles/0000-0002-8213-1658; 	NCI NIH HHS [CA57374] Funding Source: Medline; NIDDK NIH HHS [DK43806] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043806, R01DK043806] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bentley D, 1998, NATURE, V395, P21, DOI 10.1038/25616; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Castro-Rivera E, 1999, MOL CELL ENDOCRINOL, V150, P11, DOI 10.1016/S0303-7207(99)00041-6; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DUBIK D, 1992, ONCOGENE, V7, P1587; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317; Glass CK, 2000, GENE DEV, V14, P121; Guenther MG, 2000, GENE DEV, V14, P1048; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Polly P, 1996, J CELL BIOCHEM, V60, P322, DOI 10.1002/(SICI)1097-4644(19960301)60:3<322::AID-JCB4>3.0.CO;2-Y; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Smith WL, 1997, ACAD RADIOL, V4, P657, DOI 10.1016/S1076-6332(05)80273-9; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922	50	1403	1440	2	66	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					843	852		10.1016/S0092-8674(00)00188-4	http://dx.doi.org/10.1016/S0092-8674(00)00188-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136970	Bronze			2022-12-28	WOS:000165801300004
J	Narod, SA; Brunet, JS; Ghadirian, P; Robson, M; Heimdal, K; Neuhausen, SL; Stoppa-Lyonnet, D; Lerman, C; Pasini, B; de los Rios, P; Weber, B; Lynch, H				Narod, SA; Brunet, JS; Ghadirian, P; Robson, M; Heimdal, K; Neuhausen, SL; Stoppa-Lyonnet, D; Lerman, C; Pasini, B; de los Rios, P; Weber, B; Lynch, H		Hereditary Breast Canc Clin Study	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study	LANCET			English	Article							GENETIC-HETEROGENEITY; OVARIAN; PREVENTION; CARCINOMA; WOMEN	Background Women with a mutation in BRCA1 or BRCA2 have a high risk of developing breast cancer and of contralateral cancer after the initial diagnosis of breast cancer. Tamoxifen protects against contralateral breast cancer in the general population, but whether it protects against contralateral breast cancer in BRCA1 or BRCA2 mutation carriers is not known. Methods We compared 209 women with bilateral breast cancer and BRCA1 or BRCA2 mutation (bilateral-disease cases), with 384 women with unilateral disease and BRCA1 or BRCA2 mutation (controls) in a matched case-control study. Age and age at diagnosis of breast cancer (range 24-74 years) were much the same in bilateral-disease cases and controls, and both groups had been followed up for the same time for a second primary breast cancer. History of tamoxifen use for first breast cancer was obtained by interview, or by self-administered questionnaire. Findings The multivariate adds ratio for contralateral breast cancer associated with tamoxifen;use was 0.50 (95% CI 0.28-0.89). Tamoxifen protected against contralateral breast cancer for carriers of BRCA1 mutations (odds ratio 0.38, 95% CI 0.19-0.74) and for those with BRCA2 mutations (0.63, 0.20-1.50). In women who used tamoxifen for 2-4 years, the risk of contralateral breast cancer was reduced by 75%. A reduction in risk of contralateral cancer was also seen with oophorectomy (0.42, 0.22-0.83) and with chemotherapy (0.40, 0.26-0.60). Interpretation Tamoxifen use reduces the risk of contralateral breast cancer in women with pathogenic mutations in the BRCA1 or BRCA2 gene. The protective effect of tamoxifen seems independent of that of oophorectomy.	Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada; Ctr Hop Univ Montreal, Hotel Dieu, Epidemiol Res Unit, Montreal, PQ, Canada; Mem Sloan Kettering Canc Ctr, Dept Human Genet & Med, New York, NY 10021 USA; Norwegian Radium Hosp, Unit Med Genet, Oslo, Norway; Univ Utah, Dept Med Informat, Salt Lake City, UT 84112 USA; Inst Curie, Paris, France; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; Ist Nazl Tumori, I-20133 Milan, Italy; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE 68105 USA	University of Toronto; University Toronto Affiliates; Womens College Hospital; Laval University; Universite de Montreal; Memorial Sloan Kettering Cancer Center; University of Oslo; Utah System of Higher Education; University of Utah; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Georgetown University; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Pennsylvania; University of Pennsylvania; Creighton University	Narod, SA (corresponding author), Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, 790 Bay St,Room 750A, Toronto, ON M5G 1N8, Canada.	steven.narod@swchsc.on.ca	Narod, Steven A/AAA-6112-2022; Pasini, Barbara/AHI-2004-2022; Heimdal, Ketil Riddervold/H-3038-2019	Pasini, Barbara/0000-0002-4373-1212; Heimdal, Ketil Riddervold/0000-0002-8911-3508; Robson, Mark/0000-0002-3109-1692; Evans, Gareth/0000-0002-8482-5784	NCI NIH HHS [1R01 CA63582, CA57601, CA63678] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063678, R01CA057601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brunet JS, 1998, J NATL CANCER I, V90, P761, DOI 10.1093/jnci/90.10.761; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Chen Y, 1999, CANCER EPIDEM BIOMAR, V8, P855; Clarke M, 1998, LANCET, V351, P1451; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; EASTON DF, 1995, AM J HUM GENET, V56, P265; EISENGER F, 1999, CANCER, V85, P2291; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; Jernstrom H, 1999, LANCET, V354, P1846, DOI 10.1016/S0140-6736(99)04336-6; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Lakhani SR, 1997, LANCET, V349, P1505; Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W; Meakin JW, 1996, BREAST CANCER RES TR, V37, P11, DOI 10.1007/BF01806627; Moslehi R, 2000, AM J HUM GENET, V66, P1259, DOI 10.1086/302853; Narod SA, 1995, INT J CANCER, V64, P394, DOI 10.1002/ijc.2910640608; NAROD SA, 1995, AM J HUM GENET, V56, P254; O'Regan R, 1999, J AM COLL SURGEONS, V188, P678, DOI 10.1016/S1072-7515(99)00057-5; Powles T, 1998, LANCET, V352, P98; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Robson M, 1998, J CLIN ONCOL, V16, P1642, DOI 10.1200/JCO.1998.16.5.1642; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; Tonin PN, 1998, AM J HUM GENET, V63, P1341, DOI 10.1086/302099; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Veronesi U, 1998, LANCET, V352, P93	34	399	404	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	2000	356	9245					1876	1881		10.1016/S0140-6736(00)03258-X	http://dx.doi.org/10.1016/S0140-6736(00)03258-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130383				2022-12-28	WOS:000165665400010
J	Chen, BL; Eddaoudi, M; Hyde, ST; O'Keeffe, M; Yaghi, OM				Chen, BL; Eddaoudi, M; Hyde, ST; O'Keeffe, M; Yaghi, OM			Interwoven metal-organic framework on a periodic minimal surface with extra-large pores	SCIENCE			English	Article							DNA	Interpenetration (catenation) has Long been considered a major impediment in the achievement of stable and porous crystalline structures. A strategy for the design of highly porous and structurally stable networks makes use of metalorganic building blocks that can be assembled on a triply periodic P-minimal geometric surface to produce structures that are interpenetrating-more accurately considered as interwoven. We used 4,4',4"-benzene-1,3,5-triyl-tribenzoic acid (H3BTB), copper(II) nitrate, and N,N'-dimethylformamide (DMF) to prepare Cu-3(BTB)(2)(H2O)(3). (DMF)(9)(H2O)(2) (MOF-14), whose structure reveals a pair of interwoven metal-organic frameworks that are mutually reinforced. The structure contains remarkably large pores, 16.4 angstroms in diameter, in which voluminous amounts of gases and organic solvents can be reversibly sorbed.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Australian Natl Univ, Dept Appl Math, Canberra, ACT, Australia; Arizona State Univ, Dept Chem, Tempe, AZ 85287 USA	University of Michigan System; University of Michigan; Australian National University; Arizona State University; Arizona State University-Tempe	Yaghi, OM (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.		Hyde, Stephen/F-9248-2010; Yaghi, Omar M/C-6749-2013; Eddaoudi, Mohamed/D-2298-2009; Hyde, Stephen T/N-2928-2019; Chen, Banglin/F-5461-2010	Hyde, Stephen/0000-0003-2003-9992; Eddaoudi, Mohamed/0000-0003-1916-9837; Hyde, Stephen T/0000-0003-2003-9992; Chen, Banglin/0000-0001-8707-8115; Yaghi, Omar/0000-0002-5611-3325				Batten SR, 1998, ANGEW CHEM INT EDIT, V37, P1460, DOI 10.1002/(SICI)1521-3773(19980619)37:11<1460::AID-ANIE1460>3.0.CO;2-Z; Breck D. W., 1974, ZEOLITE MOL SIEVES; Chen BL, 2000, J AM CHEM SOC, V122, P11559, DOI 10.1021/ja003159k; Eddaoudi M, 2000, J AM CHEM SOC, V122, P1391, DOI 10.1021/ja9933386; Hyde S., 1997, LANGUAGE SHAPE; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; O'Keeffe M, 2000, J SOLID STATE CHEM, V152, P3, DOI 10.1006/jssc.2000.8723; OKEEFFE M, 1996, CRYSTAL STRUCTURES, V1; Raymo FM, 1999, CHEM REV, V99, P1643, DOI 10.1021/cr970081q; Reineke TM, 2000, J AM CHEM SOC, V122, P4843, DOI 10.1021/ja000363z; Sauvage, 1999, MOL CATENANES ROTAXA; Seeman NC, 1998, ANNU REV BIOPH BIOM, V27, P225, DOI 10.1146/annurev.biophys.27.1.225; Storhoff JJ, 1999, CHEM REV, V99, P1849, DOI 10.1021/cr970071p; WEBER E, 1988, J CHEM SOC PERK T 2, P1251, DOI 10.1039/p29880001251; Wikoff WR, 2000, SCIENCE, V289, P2129, DOI 10.1126/science.289.5487.2129	15	1147	1220	26	785	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	2001	291	5506					1021	1023		10.1126/science.1056598	http://dx.doi.org/10.1126/science.1056598			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161211				2022-12-28	WOS:000166860100039
J	Shepherd, A; Wingham, DJ; Mansley, JAD; Corr, HFJ				Shepherd, A; Wingham, DJ; Mansley, JAD; Corr, HFJ			Inland thinning of Pine Island Glacier, West Antarctica	SCIENCE			English	Article							ICE-SHEET	The Pine island Glacier (PIG) transports 69 cubic kilometers of ice each year from similar to 10% of the West Antarctic Ice Sheet (WAIS). It is possible that a retreat of the PIG may accelerate ice discharge from the WAIS interior. Satellite altimetry and interferometry show that the grounded PIG thinned by up to 1.6 meters per year between 1992 and 1999, affecting 150 kilometers of the inland glacier. The thinning cannot be explained by short-term variability in accumulation and must result from glacier dynamics.	UCL, Dept Space & Climate Phys, Ctr Polar Observat & Modelling, London WC1H 0AH, England; British Antarctic Survey, Cambridge CB3 0ET, England	University of London; University College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Shepherd, A (corresponding author), UCL, Dept Space & Climate Phys, Ctr Polar Observat & Modelling, 17 Gordon St, London WC1H 0AH, England.	aps@mssl.ucl.ac.uk	Corr, Hugh/C-5398-2011	Shepherd, Andrew/0000-0002-4914-1299				ALLEY RB, 1984, J GEOPHYS RES-OCEANS, V89, P6487, DOI 10.1029/JC089iC04p06487; BAMBER JL, 1994, INT J REMOTE SENS, V15, P925, DOI 10.1080/01431169408954125; BARCILON V, 1993, J GLACIOL, V39, P167, DOI 10.3189/S0022143000015811; BENTLEY CR, 1991, P INT C ROL POL REG, P481; Bintanja R, 1998, ANN GLACIOL, V27, P251; BUDD WF, 1996, ANN GLACIOL, V23, P21; Fowler AC, 1998, J GLACIOL, V44, P104, DOI 10.3189/S0022143000002409; GOLDSTEIN RM, 1993, SCIENCE, V262, P1525, DOI 10.1126/science.262.5139.1525; HINDMARSH RCA, 1996, ANN GLACIOL, V23, P105, DOI DOI 10.3198/1996A0G23-105-115); HUGHES TJ, 1981, J GLACIOL, V27, P518, DOI 10.3189/S002214300001159X; Joughin IR, 1998, IEEE T GEOSCI REMOTE, V36, P25, DOI 10.1109/36.655315; KELLOGG TB, 1987, J GEOPHYS RES-SOLID, V92, P8859, DOI 10.1029/JB092iB09p08859; KELLOGG TB, 1985, ANTARCT J US, V20, P79; Kwok R, 1996, IEEE T GEOSCI REMOTE, V34, P189, DOI 10.1109/36.481903; LINDSTROM D, 1984, ANTARCT J US, V19, P56; MERCER JH, 1978, NATURE, V271, P321, DOI 10.1038/271321a0; Oppenheimer M, 1998, NATURE, V393, P325, DOI 10.1038/30661; PARISH TR, 1987, NATURE, V328, P51, DOI 10.1038/328051a0; PAYNE AJ, 1995, J GEOPHYS RES-SOL EA, V100, P4249, DOI 10.1029/94JB02778; RIGNOT E, UNPUB; Rignot EJ, 1998, SCIENCE, V281, P549, DOI 10.1126/science.281.5376.549; Stenoien MD, 2000, J GEOPHYS RES-SOL EA, V105, P21761, DOI 10.1029/2000JB900151; Thomas R., 1979, J GLACIOL, V24, P167, DOI DOI 10.3189/S0022143000014726; VANDENBROEKE M, 1995, J GLACIOL, V41, P395, DOI 10.3189/S0022143000016269; VANDERVEEN CJ, 1985, QUATERNARY RES, V24, P257, DOI 10.1016/0033-5894(85)90049-3; VAUGHAN DG, 2001, ANTARCT RES SER, V77, P236; Weertman J., 1974, J GLACIOL, V13, P3, DOI [DOI 10.3189/S0022143000023327, 10.3189/S0022143000023327]; Wingham DJ, 1998, SCIENCE, V282, P456, DOI 10.1126/science.282.5388.456; ZEBKER HA, 1986, J GEOPHYS RES-SOLID, V91, P4993, DOI 10.1029/JB091iB05p04993; [No title captured]	30	160	164	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	2001	291	5505					862	864		10.1126/science.291.5505.862	http://dx.doi.org/10.1126/science.291.5505.862			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157163				2022-12-28	WOS:000166771700041
J	Bender, JB; Hedberg, CW; Boxrud, DJ; Besser, JM; Wicklund, JH; Smith, KE; Osterholm, MT				Bender, JB; Hedberg, CW; Boxrud, DJ; Besser, JM; Wicklund, JH; Smith, KE; Osterholm, MT			Use of molecular subtyping in surveillance for Salmonella enterica serotype typhimurium.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIELD GEL-ELECTROPHORESIS; RAW-MILK CHEESE; MULTIDRUG-RESISTANT; OUTBREAK; INFECTIONS; DT104; EPIDEMIOLOGY; STRAINS	Background: Because Salmonella enterica serotype typhimurium is the most common serotype isolated from persons with salmonellosis in the United States, it is difficult to detect unusual clusters or outbreaks. To determine whether molecular subtyping could be useful in public health surveillance for S. enterica serotype typhimurium, the Minnesota Department of Health initiated the routine use of pulsed-field gel electrophoresis (PFGE) of isolates. Methods: Beginning in 1994, all S. enterica serotype typhimurium isolates submitted by clinical laboratories to the Department of Health were subtyped by PFGE. A standard questionnaire was used to interview patients about possible sources of infection. Results: From 1994 through 1998, 998 cases of infection with S. enterica serotype typhimurium were reported to the Minnesota Department of Health (4.4 cases per 100,000 person-years). PFGE was performed on 958 of the isolates (96 percent), and 174 different patterns were identified. Sixteen outbreaks with a common source were identified, accounting for 154 cases. PFGE subtyping made it possible to confirm 10 outbreaks that involved small numbers of cases in institutional settings. Of six larger, community-based outbreaks, four would probably not have been recognized without PFGE subtyping. These four outbreaks accounted for 96 of the 154 culture-confirmed outbreak cases (62 percent). Fifty-six of 209 isolates tested for antimicrobial susceptibility (27 percent) were resistant to at least five antimicrobial agents. The multidrug-resistant isolates identified had unique PFGE patterns. Conclusions: Routine molecular subtyping of S. enterica serotype typhimurium by PFGE can improve the detection of outbreaks and aid in the identification of multidrug-resistant strains. Combining routine molecular subtyping with a method of rapid communication among public health authorities can improve surveillance for S. enterica serotype typhimurium infections. (N Engl J Med 2001;344:189-95.) Copyright (C) 2001 Massachusetts Medical Society.	Minnesota Dept Hlth, Acute Dis Epidemiol Sect, Minneapolis, MN USA; Minnesota Dept Hlth, Div Publ Hlth Labs, Minneapolis, MN USA	Minnesota Department of Health (MHD); Minnesota Department of Health (MHD)	Bender, JB (corresponding author), Univ Minnesota, 1988 Fitch Ave, St Paul, MN 55108 USA.			Bender, Jeffrey/0000-0003-4645-9936	PHS HHS [U50/CCU511190] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Andrews R, 1997, Commun Dis Intell, V21, P61; Bender JB, 1997, NEW ENGL J MED, V337, P388, DOI 10.1056/NEJM199708073370604; BENDER JB, 1999, 39 INT C ANT AG CHEM, P695; Besser TE, 1997, VET REC, V140, P75; Carraminana JJ, 1997, RES MICROBIOL, V148, P633, DOI 10.1016/S0923-2508(97)88087-4; *CDCP, 1996, SALM SURV ANN TAB SU; Centers for Disease Control and Prevention (CDC), 1996, STAND MOL SUBT ESCH; Cody SH, 1999, JAMA-J AM MED ASSOC, V281, P1805, DOI 10.1001/jama.281.19.1805; Corbett-Feeney G, 1998, J INFECTION, V36, P175, DOI 10.1016/S0163-4453(98)80009-1; Davies A, 1996, Commun Dis Rep CDR Rev, V6, pR159; Fey PD, 2000, NEW ENGL J MED, V342, P1242, DOI 10.1056/NEJM200004273421703; HUTWAGNER L, 1998, INT C EM DIS ATL MAR, P117; Hutwagner LC, 1997, EMERG INFECT DIS, V3, P395, DOI 10.3201/eid0303.970322; *MN DEP HLTH CTR H, 1998, MINN HLTH STAT 1996; Molbak K, 1999, NEW ENGL J MED, V341, P1420, DOI 10.1056/NEJM199911043411902; National Committee for Clinical Laboratory Standards, 1997, M2A6 NCCLS CLIN LAB, V6th; Ridley A, 1998, MICROB DRUG RESIST, V4, P113, DOI 10.1089/mdr.1998.4.113; Roels TH, 1997, EPIDEMIOL INFECT, V119, P127, DOI 10.1017/S0950268897007851; SMITH KE, 1999, CLIN INFECT DIS, V29, P1064; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Threlfall E J, 1996, Commun Dis Rep CDR Rev, V6, pR155; Vahaboglu H, 1996, J CLIN MICROBIOL, V34, P2942, DOI 10.1128/JCM.34.12.2942-2946.1996; Villar RG, 1999, JAMA-J AM MED ASSOC, V281, P1811, DOI 10.1001/jama.281.19.1811	23	78	82	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					189	195		10.1056/NEJM200101183440305	http://dx.doi.org/10.1056/NEJM200101183440305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	392GF	11172141				2022-12-28	WOS:000166402800005
J	Araya, R; Lewis, GH; Rojas, G; Mann, AH				Araya, R; Lewis, GH; Rojas, G; Mann, AH			"Patient knows best" - detection of common mental disorders in Santiago, Chile: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; RECOGNITION; DEPRESSION; ANXIETY		Univ Wales Coll Med, Div Psychol Med, Cardiff CF14 4XN, S Glam, Wales; Univ Chile, Fac Med, Unidad Psiquiatria & Epidemiol Psiquiatr, Santiago, Chile; Inst Psychiat, Sect Epidemiol & Gen Practice, London SE5 8AF, England	Cardiff University; Universidad de Chile; University of London; King's College London	Araya, R (corresponding author), Univ Wales Coll Med, Div Psychol Med, Cardiff CF14 4XN, S Glam, Wales.		Araya, Ricardo/S-3144-2019; mann, anthony/A-8911-2011; Rojas, Graciela/G-2971-2012; Lewis, Glyn/E-9944-2012	Araya, Ricardo/0000-0002-0420-5148; Lewis, Glyn/0000-0001-5205-8245; Collings, Sunny/0000-0002-5486-1194				Goldberg DP., 1992, COMMON MENTAL DISORD; Kessler D, 1999, BRIT MED J, V318, P436, DOI 10.1136/bmj.318.7181.436; KIRMAYER LJ, 1993, AM J PSYCHIAT, V150, P734; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; Ustun BT, 1995, MENTAL ILLNESS GEN H	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					79	80		10.1136/bmj.322.7278.79	http://dx.doi.org/10.1136/bmj.322.7278.79			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154620	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000166496100024
J	van Dijk, MR; Janse, CJ; Thompson, J; Waters, AP; Braks, JAM; Dodemont, HJ; Stunnenberg, HG; van Gemert, GJ; Sauerwein, RW; Eling, W				van Dijk, MR; Janse, CJ; Thompson, J; Waters, AP; Braks, JAM; Dodemont, HJ; Stunnenberg, HG; van Gemert, GJ; Sauerwein, RW; Eling, W			A central role for P48/45 in malaria parasite male gamete fertility	CELL			English	Article							TRANSMISSION-BLOCKING ACTIVITY; SEXUAL STAGE ANTIGENS; PLASMODIUM-FALCIPARUM; SURFACE-ANTIGENS; TARGET ANTIGEN; SIALIC-ACID; PFS 48/45; EXPRESSION; ANTIBODIES; BERGHEI	Fertilization and zygote development are obligate features of the malaria parasite life cycle and occur during parasite transmission to mosquitoes. The surface protein PFS48/45 is expressed by male and female gametes of Plasmodium falciparum and PFS48/45 antibodies prevent zygote development and transmission. Here, gene disruption was used to show that Pfs48/45 and the ortholog Pbs48/45 from a rodent malaria parasite P. berghei play a conserved and important role in fertilization. p48/45(-) parasites had a reduced capacity to produce oocysts in mosquitoes due to greatly reduced zygote formation. Unexpectedly, only male gamete fertility of p48/45(-) parasites was affected, failing to penetrate otherwise fertile female gametes. P48/45 is shown to be a surface protein of malaria parasites with a demonstrable role in fertilization.	Leiden Univ, Med Ctr, Parasitol Lab, NL-2300 RC Leiden, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Dept Mol Biol, NL-6525 ED Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen; Radboud University Nijmegen	Waters, AP (corresponding author), Leiden Univ, Med Ctr, Parasitol Lab, POB 9600, NL-2300 RC Leiden, Netherlands.	waters@lumc.nl	Waters, Andy P/C-9377-2009; Stunnenberg, Hendrik G./D-6875-2012; Sauerwein, Robert/C-8519-2013	Waters, Andy P/0000-0001-8900-2982; Stunnenberg, Hendrik G./0000-0002-0066-1576; Janse, Chris J/0000-0002-6410-6205				Al-Khedery B, 1999, MOL CELL, V3, P131, DOI 10.1016/S1097-2765(00)80304-4; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Birago C, 1996, MOL BIOCHEM PARASIT, V80, P193, DOI 10.1016/0166-6851(96)02680-1; BOUDIN C, 1993, AM J TROP MED HYG, V48, P700, DOI 10.4269/ajtmh.1993.48.700; Brooks SR, 2000, MOL BIOCHEM PARASIT, V106, P77, DOI 10.1016/S0166-6851(99)00201-7; CARTER R, 1990, PARASITE IMMUNOL, V12, P587, DOI 10.1111/j.1365-3024.1990.tb00990.x; CARTER R, 1995, MOL BIOCHEM PARASIT, V71, P203, DOI 10.1016/0166-6851(94)00054-Q; Carter R, 2000, NAT MED, V6, P241, DOI 10.1038/73062; Dessens JT, 1999, EMBO J, V18, P6221, DOI 10.1093/emboj/18.22.6221; DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753; Duffy PE, 1997, INFECT IMMUN, V65, P1109, DOI 10.1128/IAI.65.3.1109-1113.1997; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; GRAVES PM, 1992, AM J TROP MED HYG, V46, P711, DOI 10.4269/ajtmh.1992.46.711; Guinet F, 1996, J CELL BIOL, V135, P269, DOI 10.1083/jcb.135.1.269; GUPTA SK, 1985, J PROTOZOOL, V32, P91, DOI 10.1111/j.1550-7408.1985.tb03020.x; JANSE CJ, 1985, PARASITOLOGY, V91, P219, DOI 10.1017/S0031182000057322; JANSE CJ, 1985, PARASITOLOGY, V91, P19, DOI 10.1017/S0031182000056481; JANSE CJ, 1989, EXP PARASITOL, V68, P274, DOI 10.1016/0014-4894(89)90109-4; JANSE CJ, 1986, MOL BIOCHEM PARASIT, V20, P173, DOI 10.1016/0166-6851(86)90029-0; JANSE CJ, 1995, PARASITOL TODAY, V11, P138, DOI 10.1016/0169-4758(95)80133-2; Kaslow David C., 1996, P181; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; KAUSHAL DC, 1984, MOL BIOCHEM PARASIT, V11, P145, DOI 10.1016/0166-6851(84)90061-6; KOCKEN CHM, 1993, MOL BIOCHEM PARASIT, V61, P59, DOI 10.1016/0166-6851(93)90158-T; KUMAR N, 1987, PARASITE IMMUNOL, V9, P321, DOI 10.1111/j.1365-3024.1987.tb00511.x; Lobo CA, 1999, MOL CELL, V3, P793, DOI 10.1016/S1097-2765(01)80011-3; MAESSEN S, 1993, MOL BIOCHEM PARASIT, V60, P27, DOI 10.1016/0166-6851(93)90025-S; Menard R, 1997, METHODS, V13, P148, DOI 10.1006/meth.1997.0507; Menard R, 2000, MICROBES INFECT, V2, P633, DOI 10.1016/S1286-4579(00)00362-2; Milek RLB, 1998, PARASITE IMMUNOL, V20, P377, DOI 10.1046/j.1365-3024.1998.00171.x; MOELANS IIMD, 1995, MOL BIOCHEM PARASIT, V72, P179, DOI 10.1016/0166-6851(95)00072-9; Mulder B, 1999, EXP PARASITOL, V92, P81, DOI 10.1006/expr.1999.4398; Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509; Roeffen W, 1996, PARASITE IMMUNOL, V18, P103, DOI 10.1046/j.1365-3024.1996.d01-54.x; ROEFFEN W, 1995, AM J TROP MED HYG, V52, P60, DOI 10.4269/ajtmh.1995.52.60; Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y; TARGETT GAT, 1990, IMMUNOL LETT, V25, P77, DOI 10.1016/0165-2478(90)90095-8; Temple RC, 1999, DIABETES, V48, pA52; Templeton TJ, 1998, J EXP MED, V187, P1599, DOI 10.1084/jem.187.10.1599; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; VAIDYA AB, 1995, MOL BIOCHEM PARASIT, V69, P65, DOI 10.1016/0166-6851(94)00199-W; VERMEULEN AN, 1986, MOL BIOCHEM PARASIT, V20, P155, DOI 10.1016/0166-6851(86)90027-7; VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460; Wahlgren M, 1999, CELL, V96, P603, DOI 10.1016/S0092-8674(00)80569-3; Wengelnik K, 1999, EMBO J, V18, P5195, DOI 10.1093/emboj/18.19.5195; WILLIAMSON KC, 1993, MOL BIOCHEM PARASIT, V58, P355, DOI 10.1016/0166-6851(93)90058-6; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130	49	281	291	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					153	164		10.1016/S0092-8674(01)00199-4	http://dx.doi.org/10.1016/S0092-8674(01)00199-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163248	Bronze			2022-12-28	WOS:000166882300015
J	Cales, P; Masliah, C; Bernard, B; Garnier, P; Silvain, C; Szostak-Talbodec, N; Bronowicki, J; Ribard, D; Botta-Fridlund, D; Hillon, P; Besseghir, K; Lebrec, D				Cales, P; Masliah, C; Bernard, B; Garnier, P; Silvain, C; Szostak-Talbodec, N; Bronowicki, J; Ribard, D; Botta-Fridlund, D; Hillon, P; Besseghir, K; Lebrec, D		French Club Study Portal Hypertens	Early administration of vapreotide for variceal bleeding in patients with cirrhosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ESOPHAGEAL-VARICES; DOUBLE-BLIND; ENDOSCOPIC SCLEROTHERAPY; PORTAL-HYPERTENSION; SOMATOSTATIN; PREVENTION; OCTREOTIDE; MULTICENTER; HEMORRHAGE	Background: In patients with cirrhosis, pharmacologic or endoscopic treatment may control variceal bleeding. However, the effects of early administration of a somatostatin analogue followed by endoscopic treatment are unknown. Methods: We studied the effects of treatment with vapreotide, a somatostatin analogue, begun before endoscopic treatment in 227 patients with cirrhosis who were hospitalized for acute upper gastrointestinal bleeding. The patients were randomly assigned to receive vapreotide (a 50-mug intravenous bolus followed by an infusion at a rate of 50 mug per hour for five days) or placebo within a mean (+/-SD) of 2.3+/-1.5 hours after admission. The patients received endoscopic treatment a mean of 2.6+/-3.3 hours after the infusion was begun. After the exclusion of 31 patients whose bleeding was not caused by portal hypertension, there were 98 patients in each group. Results: At the time of endoscopy, active bleeding was evident in 28 of 91 patients in the vapreotide group (31 percent), as compared with 43 of 93 patients in the placebo group (46 percent, P = 0.03); in 12 patients endoscopy was either impossible or showed portal hypertensive gastropathy. During the five-day infusion, the primary objective - survival and control of bleeding - was achieved in 65 of 98 patients in the vapreotide group (66 percent) as compared with 49 of 98 patients in the placebo group (50 percent) (P = 0.02). The patients in the vapreotide group received significantly fewer blood transfusions (2.0+/-2.2 vs. 2.8+/-2.8 units, P = 0.04). Overall mortality rates at 42 days were not significantly different in the two groups. Conclusions: In patients with cirrhosis and variceal bleeding, the combination of vapreotide and endoscopic treatment is more effective than endoscopic treatment alone as a method of controlling acute bleeding. However, the use of combination therapy does not affect mortality rates at 42 days. (N Engl J Med 2001;344:23-8.) Copyright (C) 2001 Massachusetts Medical Society.	CHU Angers, Serv Hepatogastroenterol, F-49033 Angers 01, France; CHU Nantes, Serv Hepatogastroenterol, F-44035 Nantes 01, France; CHU Pitie Salpetriere, Serv Hepatogastroenterol, Paris, France; CHU La Reunion, Serv Hepatogastroenterol, La Reunion, France; CHU Poitiers, Serv Hepatogastroenterol, Poitiers, France; CHU Lille, Serv Hepatogastroenterol, F-59037 Lille, France; CHU Nancy, Serv Hepatogastroenterol, Nancy, France; CHU Nimes, Serv Hepatogastroenterol, Nimes, France; CHU Marseilles, Serv Hepatogastroenterol, Marseille, France; CHU Dijon, Serv Hepatogastroenterol, Dijon, France; Univ Angers, Lab Hemodynam Splanchn, Angers, France; Debiopharm, Lausanne, Switzerland; Hop Beaujon, INSERM, U481, Clichy, France; Hop Beaujon, Serv Hepatol, Clichy, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Reunion; CHU Poitiers; Universite de Poitiers; Universite de Lille - ISITE; CHU Lille; CHU de Nancy; Universite de Montpellier; CHU de Nimes; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Dijon Bourgogne; Universite d'Angers; Debiopharm; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Cales, P (corresponding author), CHU Angers, Serv Hepatogastroenterol, F-49033 Angers 01, France.	paul.cales@med.univ-angers.fr	CALES, Paul/AFN-9693-2022	CALES, Paul/0000-0003-4866-5274; Poynard, Thierry/0000-0002-2050-640X; MION, Francois/0000-0002-2908-1591; , Poynard/0000-0002-3726-7230; Durand, Francois/0000-0002-0357-1090				Armitage P., 2001, STAT METHODS MED RES; AVGERINOS A, 1995, J HEPATOL, V22, P247, DOI 10.1016/0168-8278(95)80436-6; Avgerinos A, 2000, J HEPATOL, V32, P171, DOI 10.1016/S0168-8278(00)80206-8; Avgerinos A, 1997, LANCET, V350, P1495, DOI 10.1016/S0140-6736(97)05099-X; Bernard B, 1999, HEPATOLOGY, V29, P1655, DOI 10.1002/hep.510290608; BESSON I, 1995, NEW ENGL J MED, V333, P555, DOI 10.1056/NEJM199508313330904; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; DAMICO G, 1986, DIGEST DIS SCI, V31, P468, DOI 10.1007/BF01320309; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; de Franchis R, 1996, P 2 BAV INT CONS WOR; Escorsell A, 2000, HEPATOLOGY, V32, P471, DOI 10.1053/jhep.2000.16601; Escorsell A, 1998, J HEPATOL, V29, P779, DOI 10.1016/S0168-8278(98)80259-6; FIACCADORI F, 1993, CURR THER RES CLIN E, V54, P519, DOI 10.1016/S0011-393X(05)80671-X; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; *INT OCTR VAR STUD, 1905, HEPATOLOGY S, V24, pA352; Lebrec D, 1998, J HEPATOL, V28, P896, DOI 10.1016/S0168-8278(98)80241-9; LEVACHER S, 1995, LANCET, V346, P865, DOI 10.1016/S0140-6736(95)92708-5; PATEL YC, 1994, ENDOCRINOLOGY, V135, P2814, DOI 10.1210/en.135.6.2814; Preneta E, 1998, HEPATOLOGY, V28, p453A; PRIMIGNANI M, 1995, HEPATOLOGY, V21, P1322, DOI 10.1016/0270-9139(95)90054-3; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Romaozinho JM, 1996, GASTROENTEROLOGY, V110, pA1306; Sung JJY, 1995, LANCET, V346, P1666, DOI 10.1016/S0140-6736(95)92840-5; VALENZUELA JE, 1989, HEPATOLOGY, V10, P958, DOI 10.1002/hep.1840100611; *WHO, 1998, WHO ADV REACT TERM	25	147	150	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					23	28		10.1056/NEJM200101043440104	http://dx.doi.org/10.1056/NEJM200101043440104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136956	Bronze			2022-12-28	WOS:000166160400004
J	Sellers, TA; Grabrick, DM; Hartmann, LC				Sellers, TA; Grabrick, DM; Hartmann, LC			Oral contraceptives and risk of breast cancer in women with a family history of breast cancer - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Mayo Clin & Mayo Clin Canc Ctr, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Clin Canc Ctr, Dept Med Oncol, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Sellers, TA (corresponding author), Mayo Clin & Mayo Clin Canc Ctr, Dept Hlth Sci Res, Rochester, MN 55905 USA.							Brunet JS, 1998, J NATL CANCER I, V90, P761, DOI 10.1093/jnci/90.10.761; COUCH FJ, 1999, 90 M AM ASS CANC RES; NISCHAN P, 1993, AM J EPIDEMIOL, V138, P697, DOI 10.1093/oxfordjournals.aje.a116907; Norell SE, 1998, INT J EPIDEMIOL, V27, P1033, DOI 10.1093/ije/27.6.1033	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					39	40						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150097				2022-12-28	WOS:000166114500012
J	Drescher, U				Drescher, U			Excitation at the synapse: Eph receptors team up with NMDA receptors	CELL			English	Review							TYROSINE PHOSPHORYLATION; ADHESION; LIGANDS; PROTEINS; CONTACT; DOMAINS		Kings Coll London, MRC, Ctr Dev Neurobiol, London SE1 1UL, England	University of London; King's College London	Drescher, U (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, 4th Floor,New Hunts House,Guys Campus, London SE1 1UL, England.	uwe.drescher@kcl.ac.uk	Drescher, Uwe/C-5438-2009	Drescher, Uwe/0000-0001-9725-7643				Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Bruses JL, 2000, CURR OPIN CELL BIOL, V12, P593, DOI 10.1016/S0955-0674(00)00137-X; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Ciossek T, 1999, MOL BRAIN RES, V74, P231, DOI 10.1016/S0169-328X(99)00285-5; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GOODMAN CS, 1994, CELL NEURON S, V10, P77; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Hopf C, 1998, J BIOL CHEM, V273, P6467, DOI 10.1074/jbc.273.11.6467; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Murase S, 1999, CURR OPIN CELL BIOL, V11, P549, DOI 10.1016/S0955-0674(99)00019-8; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	20	9	9	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1005	1008		10.1016/S0092-8674(00)00204-X	http://dx.doi.org/10.1016/S0092-8674(00)00204-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163177	Bronze			2022-12-28	WOS:000166040600004
J	Barlow, DH				Barlow, DH			Venlafaxine for hot flushes	LANCET			English	Editorial Material									Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	University of Oxford	Barlow, DH (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.		Barlow, David/F-8738-2011					ADASHI EY, 1994, HUM REPROD, V9, P1380, DOI 10.1093/oxfordjournals.humrep.a138715; BUNGAY GT, 1980, BRIT MED J, V281, P181, DOI 10.1136/bmj.281.6234.181; CLAYDEN JR, 1974, BRIT MED J, V1, P409, DOI 10.1136/bmj.1.5905.409; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; NESHEIM BI, 1981, EUR J CLIN PHARMACOL, V20, P413, DOI 10.1007/BF00542092; Pansini F., 1995, Clinical and Experimental Obstetrics and Gynecology, V22, P341; Stearns V, 2000, ANN ONCOL, V11, P17, DOI 10.1023/A:1008382706068	7	8	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2025	2026		10.1016/S0140-6736(00)03394-8	http://dx.doi.org/10.1016/S0140-6736(00)03394-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145483				2022-12-28	WOS:000165994300003
J	Dietz, WH				Dietz, WH			"Adiposity rebound": reality or epiphenomenon?	LANCET			English	Editorial Material							CHILDREN; AGE; ADULTHOOD; PATTERNS; OBESITY; GROWTH; BMI		Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Dietz, WH (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30341 USA.							BIRCH LL, 1984, CHILD DEV, V55, P431, DOI 10.2307/1129954; DIETZ WH, 1985, PEDIATRICS, V75, P807; DIETZ WH, 1994, AM J CLIN NUTR, V59, P995; Dorosty AR, 2000, PEDIATRICS, V105, P1115, DOI 10.1542/peds.105.5.1115; Fisher JO, 1999, AM J CLIN NUTR, V69, P1264; JOHNSON SL, 1994, PEDIATRICS, V94, P653; PROKOPEC M, 1993, ANN HUM BIOL, V20, P517, DOI 10.1080/03014469300002922; ROLLANDCACHERA MF, 1984, AM J CLIN NUTR, V39, P129, DOI 10.1093/ajcn/39.1.129; ROLLANDCACHERA MF, 1995, INT J OBESITY, V19, P573; ROLLANDCACHERA MF, 1987, ANN HUM BIOL, V14, P219, DOI 10.1080/03014468700008991; ROLLANDCACHWERA MF, 1988, OBESITY EUROPE 88; Scaglioni S, 2000, INT J OBESITY, V24, P777, DOI 10.1038/sj.ijo.0801225; SIERVOGEL RM, 1991, INT J OBESITY, V15, P479; Whitaker RC, 1998, PEDIATRICS, P101; Williams S, 1999, INT J OBESITY, V23, P348, DOI 10.1038/sj.ijo.0800824	15	54	56	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2027	2028		10.1016/S0140-6736(00)03396-1	http://dx.doi.org/10.1016/S0140-6736(00)03396-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145485				2022-12-28	WOS:000165994300005
J	Misteli, T; Gunjan, A; Hock, R; Bustin, M; Brown, DT				Misteli, T; Gunjan, A; Hock, R; Bustin, M; Brown, DT			Dynamic binding of histone H1 to chromatin in living cells	NATURE			English	Article							VARIANT OVEREXPRESSION; IN-VIVO; ACETYLATION; PHOSPHORYLATION; PROTEINS; EXCHANGE; CYCLE; BASAL	The linker histone H1 is believed to be involved in chromatin organization by stabilizing higher-order chromatin structure(1-3). Histone H1 is generally viewed as a repressor of transcription as it prevents the access of transcription factors and chromatin remodelling complexes to DNA(4-6). Determining the binding properties of histone H1 to chromatin in vivo is central to understanding how it exerts these functions. We have used photobleaching techniques to measure the dynamic binding of histone H1-GFP to unperturbed chromatin in living cells. Here we show that almost the entire population of H1-GFP is bound to chromatin at any one time; however, H1-GFP is exchanged continuously between chromatin regions. The residence time of H1-GFP on chromatin between exchange events is several minutes in both euchromatin and heterochromatin. In addition to the mobile fraction, we detected a kinetically distinct, less mobile fraction. After hyperacetylation of core histones, the residence time of H1-GFP is reduced, suggesting a higher rate of exchange upon chromatin remodelling. These results support a model in which linker histones bind dynamically to chromatin in a stop-and-go mode.	NCI, NIH, Bethesda, MD 20892 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Univ Wurzburg, Bioctr, D-97070 Wurzburg, Germany; NCI, NIH, Mol Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Mississippi; University of Mississippi Medical Center; University of Wurzburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Misteli, T (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.	mistelit@mail.nih.gov	Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242; Gunjan, Akash/0000-0001-8478-3978				BATES DL, 1981, EUR J BIOCHEM, V119, P469, DOI 10.1111/j.1432-1033.1981.tb05631.x; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gunjan A, 1999, NUCLEIC ACIDS RES, V27, P3355, DOI 10.1093/nar/27.16.3355; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; Krajewski WA, 1998, P NATL ACAD SCI USA, V95, P1540, DOI 10.1073/pnas.95.4.1540; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; LU MJ, 1995, MOL BIOL CELL, V6, P1077, DOI 10.1091/mbc.6.8.1077; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; THOMA F, 1977, CELL, V12, P101, DOI 10.1016/0092-8674(77)90188-X; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; URA K, 1994, J BIOL CHEM, V269, P27171; WU LH, 1986, J CELL BIOL, V103, P465, DOI 10.1083/jcb.103.2.465; Zlatanova J, 1998, BIOESSAYS, V20, P584, DOI 10.1002/(SICI)1521-1878(199807)20:7<584::AID-BIES10>3.0.CO;2-W	29	492	500	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					877	881		10.1038/35048610	http://dx.doi.org/10.1038/35048610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130729				2022-12-28	WOS:000165831300055
J	Gross, CP; Steiner, CA; Bass, EB; Powe, NR				Gross, CP; Steiner, CA; Bass, EB; Powe, NR			Relation between prepublication release of clinical trial results and the practice of Carotid Endarterectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INGELFINGER RULE; MYOCARDIAL-INFARCTION; UNITED-STATES; STENOSIS; ATHEROSCLEROSIS; APPROPRIATE; EMBARGOES	Context Little is known about how clinical practice is affected by disseminating results of clinical trials prior to publication in peer-reviewed journals. Objective To determine whether prepublication release of carotid endarteredomy (CEA) trial results via National Institutes of Health Clinical Alerts was associated with prompt changes in patient care that were consistent with the new medical evidence. Design, Setting, and Patients Longitudinal data series analysis using acute care hospital discharge data from the Healthcare Cost and Utilization Project for patients who had CEA performed in acute care hospitals in 7 states (New York, California, Pennsylvania, Florida, Colorado, Illinois, and Wisconsin). The trials were the North American Symptomatic Carotid Endarterectomy Trial (NASCET clinical alert released February 1991) and the Asymptomatic Carotid Atherosclerosis Study (ACAS clinical alert released September 1994). Main Outcome Measure Carotid endarterectomy rate during each month from 1989 (2 years before the NASCET clinical alert) to 1996 (2 years after the ACAS clinical alert), adjusted for age and sex. Because both trials were limited to patients 80 years or younger in hospitals with low mortality, we also stratified CEA rates by patient age and hospital mortality rate. Results From 1989 through 1996, 272 849 CEAs were performed in the acute care hospitals in these 7 states, with the annual number increasing from 22 300 to 51 495. After the NASCET clinical alert, the adjusted CEA rate increased 3.4% per month (95% confidence interval [Ct], 1.6%-5.3%) during the following 6 months and then increased 0.5% per month (95% CI, 0.2%-0.8%; P<.04) after journal publication of the NASCET study. After the ACAS clinical alert,the CEA rate increased 7.3% per month (95% CI, 6.0%-8.5%) during the following 7 months and then decreased by 0.44% per month (95% CI, -0.86% to -0.0002%; P<.04) after journal publication of the ACAS study. After the ACAS clinical alert, the CEA rate increased more in patients aged 80 years or older than in younger patients; whereas, after journal publication of ACAS, the CEA rate decreased more rapidly in the older population. The overall proportion of CEAs performed in low-mortality hospitals did not change substantially after release of the clinical alerts or after journal publication. Conclusion In this study, prepublication dissemination of CEA trial results with clinical alerts was associated with prompt and substantial changes in medical practice, but the observed changes suggest that the results were extrapolated to patients and settings not directly supported by the trials.	Yale Univ, Sch Med, Primary Care Ctr, Primary Care Sect, New Haven, CT 06520 USA; Johns Hopkins Med Inst, Div Gen Internal Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Dept Hlth & Management, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Epidemiol, Baltimore, MD 21205 USA; Agcy Healthcare Res & Qual, Ctr Org & Delivery Studies, Rockville, MD USA	Yale University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Agency for Healthcare Research & Quality	Gross, CP (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, Primary Care Sect, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.			Bass, Eric/0000-0001-9106-527X				*AG HLTH CAR POL R, 1996, HEALTHC COST UT PROJ; Altman LK, 1996, LANCET, V347, P1382, DOI 10.1016/S0140-6736(96)91016-8; Altman LK, 1996, LANCET, V347, P1459, DOI 10.1016/S0140-6736(96)91689-X; ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; Campion EW, 1999, NEW ENGL J MED, V341, P2085, DOI 10.1056/NEJM199912303412709; Chassin MR, 1998, NEW ENGL J MED, V339, P1468, DOI 10.1056/NEJM199811123392010; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; Chaturvedi S, 1999, ARCH NEUROL-CHICAGO, V56, P879, DOI 10.1001/archneur.56.7.879; Fineberg HV, 1985, ASSESSING MED TECHNO, P176; Frey JL, 1996, ANN NEUROL, V39, P405, DOI 10.1002/ana.410390322; GILLUM RF, 1995, STROKE, V26, P1724, DOI 10.1161/01.STR.26.9.1724; GORDIS L, 1996, EPIDEMIOLOGY, P176; Gould W. W., 1993, STATA TECH B, V3, P98; HEALY B, 1993, JAMA-J AM MED ASSOC, V269, P3096; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Huber TS, 1997, ARCH SURG-CHICAGO, V132, P1134; Johnson T, 1998, NEW ENGL J MED, V339, P87, DOI 10.1056/NEJM199807093390206; Kanouse D E, 1988, Int J Technol Assess Health Care, V4, P27; Kassirer JP, 1997, NEW ENGL J MED, V337, P1762, DOI 10.1056/NEJM199712113372409; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LUNDBERG GD, 1991, JAMA-J AM MED ASSOC, V265, P400, DOI 10.1001/jama.265.3.400; MCCRORY DC, 1993, STROKE, V24, P1285, DOI 10.1161/01.STR.24.9.1285; Miao LL, 1977, COSTS RISKS BENEFITS, P198; MOORE WS, 1991, STROKE, V22, P1353, DOI 10.1161/01.STR.22.11.1353; *NAT I NEUR DIS ST, 1991, BEN CAR END PAT HIGH; *NAT I NEUR DIS ST, 1994, CLIN ADV CAR END PAT; *NIH, 2000, NIH TECHN ASS STAT, V8; *NIH CONS DEV PROG, 2000, CLIN TRIAL RES EXPL; PALCA J, 1990, SCIENCE, V251, P374; PEAR R, 1999, NY TIMES        0608, pC1; PEAR R, 1999, NY TIMES        0608, P6; *PHS US DEP HHS, 1988, INT CLASS DIS; Sarasin FP, 1995, NEUROLOGY, V45, P2147, DOI 10.1212/WNL.45.12.2147; *STAT STAT SOFTW, 1999, REL 6 0 REF MAN, P8; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tu JV, 1998, NEW ENGL J MED, V339, P1441, DOI 10.1056/NEJM199811123392006; *US BUR CENS, 2000, POP US REG DIV STAT; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1995, LANCET, V345, P1254, DOI 10.1016/S0140-6736(95)90920-6; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; ZELLNER A, 1962, J AM STAT ASSOC, V57, P348, DOI 10.2307/2281644	45	54	54	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2886	2893		10.1001/jama.284.22.2886	http://dx.doi.org/10.1001/jama.284.22.2886			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11147985				2022-12-28	WOS:000165717000028
J	Pacold, ME; Suire, S; Perisic, O; Lara-Gonzalez, S; Davis, CT; Walker, EH; Hawkins, PT; Stephens, L; Eccleston, JF; Williams, RL				Pacold, ME; Suire, S; Perisic, O; Lara-Gonzalez, S; Davis, CT; Walker, EH; Hawkins, PT; Stephens, L; Eccleston, JF; Williams, RL			Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma	CELL			English	Article							H-RAS; 3-OH KINASE; PROTEIN; ACTIVATION; MECHANISM; SUBUNITS; SWITCH; BETA; TRANSFORMATION; HYDROLYSIS	Ras activation of phosphoinositide 3-kinase (PI3K) is important for survival of transformed cells. We find that PI3K gamma is strongly and directly activated by H-Ras G12V in vivo or by GTP gammaS-loaded H-Ras in vitro. We have determined a crystal structure of a PI3Ky/Ras.GMPPNP complex. A critical loop in the Ras binding domain positions Ras so that it uses its switch I and switch II regions to bind PI3K gamma. Mutagenesis shows that interactions with both regions are essential for binding PI3K gamma. Ras also forms a direct contact with the PI3K gamma catalytic domain. These unique Ras/PI3K gamma interactions are likely to be shared by PI3K alpha. The complex with Ras shows a change in the PI3K conformation that may represent an allosteric component of Ras activation.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Babraham Inst, Cambridge CB2 4AT, England; Natl Inst Med Res, London NW7 1AA, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; MRC National Institute for Medical Research	Williams, RL (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	rlw@mrc-lmb.cam.ac.uk		suire, sabine/0000-0002-2773-2215; stephens, len/0000-0002-2771-3487; Hawkins, Phillip/0000-0002-6979-0464; Williams, Roger/0000-0001-7754-4207; Lara-Gonzalez, Samuel/0000-0002-3313-0165; Perisic, Olga/0000-0002-3842-2896	Medical Research Council [MC_U105184308] Funding Source: Medline; MRC [MC_U105184308] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARNETT SF, 1995, BIOCHEMISTRY-US, V34, P14254, DOI 10.1021/bi00043a033; BENNETT JP, 1982, BIOCHEM J, V208, P801, DOI 10.1042/bj2080801; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Condliffe AM, 1998, FEBS LETT, V439, P147, DOI 10.1016/S0014-5793(98)01358-1; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; LESLIE AGW, 1992, JOINT CCP4 ESFEACMB, V6; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1995, ONCOGENE, V11, P447; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; Tanaka Y, 1999, J IMMUNOL, V163, P6209; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Zhou J, 1997, BIOCHEMISTRY-US, V36, P15733, DOI 10.1021/bi971438n	63	460	497	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 8	2000	103	6					931	943		10.1016/S0092-8674(00)00196-3	http://dx.doi.org/10.1016/S0092-8674(00)00196-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136978	Bronze			2022-12-28	WOS:000165801300012
J	Hogh, B; Clarke, PD; Camus, D; Nothdurft, HD; Overbosch, D; Gunther, M; Joubert, I; Kain, KC; Shaw, D; Roskell, NS; Chulay, JD				Hogh, B; Clarke, PD; Camus, D; Nothdurft, HD; Overbosch, D; Gunther, M; Joubert, I; Kain, KC; Shaw, D; Roskell, NS; Chulay, JD		Malarone Int Study Team	Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; SUB-SAHARAN AFRICA; ANTIMALARIAL PROPHYLAXIS; IMPORTED MALARIA; ADVERSE EVENTS; PLUS PROGUANIL; MEFLOQUINE; TRAVELERS; EFFICACY; SAFETY	Background Chloroquine plus proguanil is widely used for malaria chemoprophylaxis despite low effectiveness in areas where multidrug-resistant malaria occurs. Studies have shown that atovaquone and proguanil hydrochloride is safe and effective for prevention of falciparum malaria in lifelong residents of malaria-endemic countries, but little is known about non-immune travellers. Methods in a double-blind equivalence trial, 1083 participants travelling to a malaria-endemic area were randomly assigned to two treatment groups: atovaquone-proguanil plus placebos for chloroquine and proguanil, or chloroquine, proguanil, and placebo for atovaquone-proguanil. Follow-up was by telephone 7 and 60 days after travel and at a clinic at 28 days. Serum samples were tested for antibodies to a malaria circumsporozoite protein. Blood and serum samples of participants with a potential malaria diagnosis were tested in a reference laboratory. Findings 7 days after travel, at least one adverse event was reported by 311 (61%) of 511 participants who received atovaquone-proguanil and 329 (64%) of 511 who received chloroquine-proguanil. People receiving atovaquone-proguanil had a lower frequency of treatment-related gastrointestinal adverse events (59 [12%] vs 100 [20%], p=0.001), and of treatment-related adverse events of moderate or severe intensity (37 [7%] vs 56 [11%], p=0.05). There were fewer treatment-related adverse events that caused prophylaxis to be discontinued in the atovaquone-proguanil group than in the chloroquine-proguanil group (one [0.2%] vs ten [2%], p=0.015). Interpretation Overall the two preparations were similarly tolerated. However, significantly fewer adverse gastrointestinal events were observed in the atovaquone-proguanil group in than in the chloroquine-proguanil group.	Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Int Travel Vaccinat Ctr, Copenhagen, Denmark; Med Advisory Serv Travellers Abroad, London, England; Inst Pasteur, F-59019 Lille, France; Dept Infect Dis & Trop Med, Munich, Germany; Harbour Hosp, Rotterdam, Netherlands; Inst Trop Med, Rotterdam, Netherlands; Inst Trop Med, Berlin, Germany; Travelsafe Clin, Cape Town, South Africa; Toronto Gen Hosp, Toronto, ON, Canada; Glaxo Wellcome Inc, Greenford, Middx, England	GlaxoSmithKline; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Munich; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; GlaxoSmithKline	Hogh, B (corresponding author), Glaxo Wellcome Inc, Room 50-3505B,5 Moore Dr, Res Triangle Pk, NC 27709 USA.							BALLOU WR, 1987, LANCET, V1, P1277; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; Bwire R, 1998, TROP MED INT HEALTH, V3, P66, DOI 10.1046/j.1365-3156.1998.00165.x; Carme B, 1997, TROP MED INT HEALTH, V2, P953, DOI 10.1046/j.1365-3156.1997.d01-153.x; Duraisingh MT, 1997, PARASITOLOGY, V114, P205, DOI 10.1017/S0031182096008487; Durrheim DN, 1999, S AFR MED J, V89, P170; FAIRLEY NH, 1946, T ROY SOC TROP MED H, V40, P105, DOI 10.1016/0035-9203(46)90052-1; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Fleiss J, 1981, STAT METHODS RATES P, P38; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Lell B, 1998, LANCET, V351, P709, DOI 10.1016/S0140-6736(97)09222-2; Lobel HO, 1997, JAMA-J AM MED ASSOC, V278, P1767, DOI 10.1001/jama.278.21.1767; Looareesuwan S, 1999, T ROY SOC TROP MED H, V93, P637, DOI 10.1016/S0035-9203(99)90079-2; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P533, DOI 10.4269/ajtmh.1999.60.533; LUZZI GA, 1993, DRUG SAFETY, V8, P295, DOI 10.2165/00002018-199308040-00004; Muentener P, 1999, B WORLD HEALTH ORGAN, V77, P560; Nosten F, 1999, CNS DRUGS, V11, P1, DOI 10.2165/00023210-199911010-00001; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Shanks GD, 1999, J TRAVEL MED, V6, pS21; Shanks GD, 1998, CLIN INFECT DIS, V27, P494, DOI 10.1086/514710; Shapiro TA, 1999, AM J TROP MED HYG, V60, P831, DOI 10.4269/ajtmh.1999.60.831; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; Sukwa TY, 1999, AM J TROP MED HYG, V60, P521, DOI 10.4269/ajtmh.1999.60.521; SULZER AJ, 1969, AM J TROP MED HYG, V18, P199, DOI 10.4269/ajtmh.1969.18.199; WEBSTER HK, 1987, J CLIN MICROBIOL, V25, P1002, DOI 10.1128/JCM.25.6.1002-1008.1987; *WHO, 1997, INT TRAV HLTH, P67; Williams H A, 1999, MMWR CDC Surveill Summ, V48, P1	31	94	94	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	2000	356	9245					1888	1894		10.1016/S0140-6736(00)03260-8	http://dx.doi.org/10.1016/S0140-6736(00)03260-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130385				2022-12-28	WOS:000165665400012
J	Krige, JEJ; Beckingham, IJ				Krige, JEJ; Beckingham, IJ			ABC of diseases of liver, pancreas, and biliary system - Portal hypertension - 1: varices	BRITISH MEDICAL JOURNAL			English	Review									Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; Univ Cape Town, ZA-7700 Rondebosch, South Africa; Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England	University of Cape Town; University of Cape Town; University of Nottingham	Krige, JEJ (corresponding author), Groote Schuur Hosp, ZA-7925 Cape Town, South Africa.		Krige, Jake E/G-3496-2015	Krige, Jake E/0000-0002-7057-9156				KRIGE JEJ, 2000, SURG LIVER BILIARY T, P1885; Sarin SK, 1999, NEW ENGL J MED, V340, P988, DOI 10.1056/NEJM199904013401302; Sherlock Sheila, 1996, DIS LIVER BILIARY SY	3	11	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	2001	322	7282					348	351		10.1136/bmj.322.7282.348	http://dx.doi.org/10.1136/bmj.322.7282.348			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159662	Green Published			2022-12-28	WOS:000167050000032
J	Bodeker, G				Bodeker, G			Lessons on integration from the developing world's experience	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRADITIONAL MEDICINE; CHINESE MEDICINE; HEALTH		Univ Oxford Green Coll, Commonwealth Working Grp Tradit & Complementary H, Oxford OX2 6HG, England	University of Oxford	Bodeker, G (corresponding author), Univ Oxford Green Coll, Commonwealth Working Grp Tradit & Complementary H, Oxford OX2 6HG, England.	gerry.bodeker@green.ox.ac.uk						Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Bannerman R.H., 1983, TRADITIONAL MED HEAL; Bodeker G, 1999, J ALTERN COMPLEM MED, V5, P97; CHI CH, 1994, SOC SCI MED, V39, P307, DOI 10.1016/0277-9536(94)90127-9; Cho HJ, 2000, SOC SCI MED, V50, P123, DOI 10.1016/S0277-9536(99)00284-1; *DEP IND SYST MED, 2000, ANN REP 1999 2000; Easthope G, 1998, MED J AUSTRALIA, V169, P197, DOI 10.5694/j.1326-5377.1998.tb140221.x; Hesketh T, 1997, BRIT MED J, V315, P115, DOI 10.1136/bmj.315.7100.115; HESKETH T, 1994, BRIT MED J, V309, P1441, DOI 10.1136/bmj.309.6966.1441; Kumar S, 2000, LANCET, V355, P1252, DOI 10.1016/S0140-6736(05)74695-X; OSUIDE GE, 1999, INT C ETHN DRUG DISC; 2000, STRAITS TIMES   1114	12	69	70	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2001	322	7279					164	167		10.1136/bmj.322.7279.164	http://dx.doi.org/10.1136/bmj.322.7279.164			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159579	Green Published			2022-12-28	WOS:000166615300034
J	Nahin, RL; Straus, SE				Nahin, RL; Straus, SE			Research into complementary and alternative medicine: problems and potential	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; UNITED-STATES; ACUPUNCTURE; THERAPIES		NIH, Div Extramural Res Training & Review, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Nahin, RL (corresponding author), NIH, Div Extramural Res Training & Review, Natl Ctr Complementary & Alternat Med, 9000 Rockville Pike, Bethesda, MD 20892 USA.			Nahin, Richard/0000-0002-3682-4816				Astin JA, 2000, J GERONTOL A-BIOL, V55, pM4; Birch S, 1998, CLIN J PAIN, V14, P248, DOI 10.1097/00002508-199809000-00012; Brody H, 2000, J FAM PRACTICE, V49, P649; Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ellis PM, 2000, ANN ONCOL, V11, P939, DOI 10.1023/A:1008342222205; Eskinazi D, 2000, ALTERN THER HEALTH M, V6, P49; Hammerschlag R, 1998, J ALTERN COMPLEM MED, V4, P159, DOI 10.1089/acm.1998.4.159; Jenkins V, 2000, BRIT J CANCER, V82, P1783, DOI 10.1054/bjoc.2000.1142; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; *NAT CTR COMPL ALT, 2000, 5 YEAR STRAT PLAN; *NAT CTR COMPL ALT, 2000, LIST THES RES IN; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; Pelletier KR, 1997, AM J HEALTH PROMOT, V12, P112, DOI 10.4278/0890-1171-12.2.112; Richardson MA, 1998, ANN BEHAV MED, V20, P190, DOI 10.1007/BF02884960; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P375, DOI 10.1016/0272-7358(93)90010-J; VINCENT C, 1995, J ROY SOC MED, V88, P199; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604	22	119	123	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					161	164		10.1136/bmj.322.7279.161	http://dx.doi.org/10.1136/bmj.322.7279.161			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	396AZ	11159578	Green Published			2022-12-28	WOS:000166615300033
J	Chester, TL; Parcher, JF				Chester, TL; Parcher, JF			Blurring the boundaries	SCIENCE			English	Article							FLUID MOBILE PHASES; LIQUID-CHROMATOGRAPHY; GAS-CHROMATOGRAPHY		Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH 45253 USA; Univ Mississippi, Dept Chem, University, MS 38677 USA	Procter & Gamble; University of Mississippi	Chester, TL (corresponding author), Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH 45253 USA.							ANTON K, 1997, SUPERCRITICAL FLUID; Berger T.A., 1995, PACKED COLUMN SFC; Chester TL, 1997, ANAL CHEM, V69, pA165, DOI 10.1021/ac971559t; CUI Y, 1991, ANAL CHEM, V63, P1812, DOI 10.1021/ac00017a028; Giddings J.C., 1991, UNIFIED SEPARATION S; ISHII D, 1989, J CHROMATOGR SCI, V27, P71, DOI 10.1093/chromsci/27.2.71; ISHII D, 1988, J HIGH RES CHROMATOG, V11, P800, DOI 10.1002/jhrc.1240111110; MARTIRE DE, 1987, J PHYS CHEM-US, V91, P2433, DOI 10.1021/j100293a045; MARTIRE DE, 1988, J LIQ CHROMATOGR, V11, P1779, DOI 10.1080/01483918808069026; PARCHER JF, 2000, ACS S SERIES, V748; ROBINSON RE, 1991, J MICROCOLUMN, V5, P403; SANCHEZ IC, 1994, MODELS THERMODYNAMIC, P187; Shen YF, 1997, ANAL CHEM, V69, P2541, DOI 10.1021/ac970011j; STRUBINGER JR, 1991, ANAL CHEM, V63, P98, DOI 10.1021/ac00002a003; TONG DX, 1995, ANALYST, V120, P2461, DOI 10.1039/an9952002461; Wolf C, 1997, J CHROMATOGR A, V785, P173, DOI 10.1016/S0021-9673(97)00681-X	16	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					502	503		10.1126/science.1057979	http://dx.doi.org/10.1126/science.1057979			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161207				2022-12-28	WOS:000166487500047
J	Muramoto, O				Muramoto, O			Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Reg Eth Council, Kaiser Permanente Interstate Med Off E, Portland, OR 97227 USA		Muramoto, O (corresponding author), Reg Eth Council, Kaiser Permanente Interstate Med Off E, Portland, OR 97227 USA.	muramoto@aracnet.com						Bailey R, 1998, ARTIF CELL BLOOD SUB, V26, P571, DOI 10.3109/10731199809117476; Elder L, 2000, J MED ETHICS, V26, P375, DOI 10.1136/jme.26.5.375; GLEDHILL R, 2000, TIMES           0615; LITTLE J, 2000, BBC NEWS        0614; Mullon J, 2000, NEW ENGL J MED, V342, P1638, DOI 10.1056/NEJM200006013422204; Muramoto O, 2000, J MED ETHICS, V26, P381, DOI 10.1136/jme.26.5.381; Muramoto O, 1999, WESTERN J MED, V170, P297; Muramoto O, 1998, J MED ETHICS, V24, P223, DOI 10.1136/jme.24.4.223; Muramoto O, 1998, LANCET, V352, P824, DOI 10.1016/S0140-6736(05)60725-8; Muramoto O, 1999, J MED ETHICS, V25, P463, DOI 10.1136/jme.25.6.463; Ridley DT, 1999, J MED ETHICS, V25, P469, DOI 10.1136/jme.25.6.469; Sharp D, 2000, LANCET, V356, P8, DOI 10.1016/S0140-6736(00)02424-7; *WATCH TOW BIBL TR, 1981, WATCHTOWER      0915, P20; *WATCH TOW BIBL TR, 1987, WATCHTOWER      0901, P12; Watch Tower Bible & Tract Society, 2000, THE WATCHTOWER, P29; Wilcox P, 1999, LANCET, V353, P757, DOI 10.1016/S0140-6736(05)76132-8	16	59	61	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2001	322	7277					37	39		10.1136/bmj.322.7277.37	http://dx.doi.org/10.1136/bmj.322.7277.37			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141155	Green Published			2022-12-28	WOS:000166341400025
J	Briceno, C; Vivas, AK; Calvet, N; Hartmann, L; Pacheco, R; Herrera, D; Romero, L; Berlind, P; Sanchez, G; Snyder, JA; Andrews, P				Briceno, C; Vivas, AK; Calvet, N; Hartmann, L; Pacheco, R; Herrera, D; Romero, L; Berlind, P; Sanchez, G; Snyder, JA; Andrews, P			The CIDA-QUEST large-scale survey of Orion OB1: Evidence for rapid disk dissipation in a dispersed stellar population	SCIENCE			English	Article							EMISSION-LINE STARS; X-RAY; REGION; ASSOCIATION	We are conducting a large-scale, multiepoch, optical photometric survey [Centro de Investigaciones de Astronomia-Quasar Equatorial Survey Team (CIDA-QUEST)] covering about 120 square degrees to identify the young low-mass stars in the Orion OB1 association. We present results for an area of 34 square degrees. Using photometric variability as our main selection criterion, as well as follow-up spectroscopy, we confirmed 168 previously unidentified pre-main sequence stars that are about 0.6 to 0.9 times the mass of the sun (M-.), with ages of about 1 million to 3 million years (Ori OB1b) and about 3 million to 10 million years (Ori OB1a). The Low-mass stars are spatially coincident with the high-mass (at Least 3 M-.) members of the associations. Indicators of disk accretion such as H alpha emission and near-infrared emission from dusty disks fall sharply from Ori OB1b to Ori OB1a, indicating that the time scale for disk dissipation and possibly the onset of planet formation is a few million years.	Ctr Invest Astron, Merida 5101A, Venezuela; Yale Univ, Dept Astron, New Haven, CT 06511 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Los Andes, Dept Phys, Merida 5101, Venezuela; Yale Univ, Dept Phys, New Haven, CT 06520 USA	Yale University; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Los Andes Venezuela; Yale University	Briceno, C (corresponding author), Ctr Invest Astron, Apartado Postal 264, Merida 5101A, Venezuela.	briceno@cida.ve	Briceno, Cesar/AGQ-0172-2022; Briceno, Cesar/R-1368-2017	Briceno, Cesar/0000-0001-7124-4094; Briceno, Cesar/0000-0001-7124-4094				Alcala JM, 1996, ASTRON ASTROPHYS SUP, V119, P7, DOI 10.1051/aas:1996224; ALI B, 1995, ASTRON J, V109, P709, DOI 10.1086/117313; Baraffe I, 1998, ASTRON ASTROPHYS, V337, P403; BLAAUW A, 1964, ANNU REV ASTRON ASTR, V2, P213, DOI 10.1146/annurev.aa.02.090164.001241; BLAAUW A, 1991, NATO ADV SCI I C-MAT, V342, P125; Briceno C, 1997, ASTRON J, V113, P740, DOI 10.1086/118293; Briceno C, 1999, ASTRON J, V118, P1354, DOI 10.1086/300997; BROWN AGA, 1994, ASTRON ASTROPHYS, V289, P101; BROWN AGA, IN PRESS ASP C SERIE; Elmegreen BG, 2000, ASTROPHYS J, V530, P277, DOI 10.1086/308361; Fabricant D, 1998, PUBL ASTRON SOC PAC, V110, P79, DOI 10.1086/316111; FAZIO G, 1998, ASTROPHYS J LETT, V503, P79; Herbig G.H., 1978, PROBLEMS PHYSICS EVO, P171; HERBIG GH, 1988, LICK OBS B, V1111, P00001; Hillenbrand LA, 1997, ASTRON J, V113, P1733, DOI 10.1086/118389; Kastner JH, 1997, SCIENCE, V277, P67, DOI 10.1126/science.277.5322.67; KOGURE T, 1989, PUBL ASTRON SOC JPN, V41, P1195; LANDOLT AU, 1992, ASTRON J, V104, P340, DOI 10.1086/116242; Lunine J. I, 1993, PROTOSTARS PLANETS, P749; MADDALENA RJ, 1986, ASTROPHYS J, V303, P375, DOI 10.1086/164083; MCCAUGHREAN MJ, 1994, ASTRON J, V108, P1382, DOI 10.1086/117160; Meyer MR, 1997, ASTRON J, V114, P288, DOI 10.1086/118474; Muzerolle J, 1998, ASTROPHYS J, V492, P743, DOI 10.1086/305069; Muzerolle J, 2000, ASTROPHYS J, V535, pL47, DOI 10.1086/312691; Nakano M, 1995, PUBL ASTRON SOC JPN, V47, P889; Noyes RW, 1997, ASTROPHYS J, V483, pL111, DOI 10.1086/310754; ODELL CR, 1993, ASTROPHYS J, V410, P696, DOI 10.1086/172786; Pantin E, 2000, ASTRON ASTROPHYS, V361, pL9; PODOSEK FA, 1994, METEORITICS, V29, P6, DOI 10.1111/j.1945-5100.1994.tb00649.x; Queloz D, 2000, ASTRON ASTROPHYS, V354, P99; SHERRY W, 1999, B AM ASTRON SOC, V194, P6814; Snyder JA, 1998, P SOC PHOTO-OPT INS, V3355, P635, DOI 10.1117/12.316788; Stassun KG, 1999, ASTRON J, V117, P2941, DOI 10.1086/300881; Walter F. M., 1998, Astronomical Society of the Pacific Conference Series, V154, P1793; WARREN WH, 1978, ASTROPHYS J SUPPL S, V36, P497, DOI 10.1086/190510; WARREN WH, 1977, ASTROPHYS J SUPPL S, V34, P115, DOI 10.1086/190446; Wilner DJ, 2000, ASTROPHYS J, V534, pL101, DOI 10.1086/312642; WIRAMIHARDJA SD, 1993, PUBL ASTRON SOC JPN, V45, P643; WIRAMIHARDJA SD, 1991, PUBL ASTRON SOC JPN, V43, P27	40	103	103	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					93	96		10.1126/science.291.5501.93	http://dx.doi.org/10.1126/science.291.5501.93			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141553				2022-12-28	WOS:000166259100039
J	Hausser, M; Major, G; Stuart, GJ				Hausser, M; Major, G; Stuart, GJ			Differential shunting of EPSPs by action potentials	SCIENCE			English	Article							NEURONS	Neurons encode information and communicate via action potentials, which are generated following the summation of synaptic events. It is commonly assumed that action potentials reset the membrane potential completely, allowing another round of synaptic integration to begin. We show here that the conductances underlying the action potential act instead as a variable reset of synaptic integration. The strength of this reset is cell type-specific and depends on the kinetics, Location, and timing of the synaptic input. As a consequence, distal synapses. as well as inputs mediated by N-methyl-D-aspartate receptor activation, can contribute disproportionately to synaptic integration during action potential firing.	UCL, Dept Physiol, London WC1E 6BT, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Australian Natl Univ, John Curtin Sch Med Res, Div Neurosci, Canberra, ACT 0200, Australia	University of London; University College London; University of Oxford; Australian National University; John Curtin School of Medical Research	Stuart, GJ (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	m.hausser@ucl.ac.uk	Major, Guy/A-4335-2010; stuart, greg j/F-7328-2011; Hausser, Michael/AAW-6827-2020	Hausser, Michael/0000-0002-2673-8957; stuart, greg/0000-0001-9395-2219				[Anonymous], [No title captured]; ARMSTRONG DM, 1979, J PHYSIOL-LONDON, V289, P425, DOI 10.1113/jphysiol.1979.sp012745; Cole KS, 1939, J GEN PHYSIOL, V22, P649, DOI 10.1085/jgp.22.5.649; COOMBS JS, 1955, J PHYSIOL-LONDON, V130, P374, DOI 10.1113/jphysiol.1955.sp005413; CURTIS DR, 1959, J PHYSIOL-LONDON, V145, P529, DOI 10.1113/jphysiol.1959.sp006159; FATT P, 1957, J NEUROPHYSIOL, V20, P61, DOI 10.1152/jn.1957.20.1.61; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MAYER ML, 1984, NATURE, V309, P262; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; STORM JF, 1987, BRAIN RES, V435, P387, DOI 10.1016/0006-8993(87)91631-3; Stuart G, 1997, TRENDS NEUROSCI, V20, P125, DOI 10.1016/S0166-2236(96)10075-8; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Williams SR, 2000, J NEUROPHYSIOL, V83, P3177, DOI 10.1152/jn.2000.83.5.3177	15	81	82	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					138	141		10.1126/science.291.5501.138	http://dx.doi.org/10.1126/science.291.5501.138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141567				2022-12-28	WOS:000166259100053
J	Xiao, SY; Ellwood, S; Calis, O; Patrick, E; Li, TX; Coleman, M; Turner, JG				Xiao, SY; Ellwood, S; Calis, O; Patrick, E; Li, TX; Coleman, M; Turner, JG			Broad-spectrum mildew resistance in Arabidopsis thaliana mediated by RPW8	SCIENCE			English	Article							PLANT-DISEASE-RESISTANCE; POWDERY MILDEW; GENES; TOMATO; SEQUENCES	Plant disease resistance (R) genes control the recognition of specific pathogens and activate subsequent defense responses. We show that the Arabidopsis thaliana Locus RESISTANCE TO POWDERY MILDEW8 (RPW8) contains two naturally polymorphic, dominant R genes, RPW8.1 and RPW8.2, which individually control resistance to a broad range of powdery mildew pathogens. Although the predicted RPW8.1 and RPW8.2 proteins are different from the previously characterized R proteins, they induce Localized, salicylic acid-dependent defenses similar to those induced by R genes that control specific resistance. Apparently, broad-spectrum resistance mediated by RPW8 uses the same mechanisms as specific resistance.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Turner, JG (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.		Xiao, Shunyuan/K-2598-2013; Ellwood, Simon/K-2023-2013; CALIS, Ozer/C-5608-2016; Bruening, Stefan/B-8505-2011	Ellwood, Simon/0000-0002-2673-0816; CALIS, Ozer/0000-0002-7219-1219; 				Aarts N, 1998, P NATL ACAD SCI USA, V95, P10306, DOI 10.1073/pnas.95.17.10306; Adam L, 1999, MOL PLANT MICROBE IN, V12, P1031, DOI 10.1094/MPMI.1999.12.12.1031; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; Botella MA, 1997, PLANT J, V12, P1197, DOI 10.1046/j.1365-313X.1997.12051197.x; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; Hwang CF, 2000, PLANT CELL, V12, P1319, DOI 10.1105/tpc.12.8.1319; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Leister D, 1999, THEOR APPL GENET, V98, P509, DOI 10.1007/s001220051099; Luck JE, 2000, PLANT CELL, V12, P1367, DOI 10.1105/tpc.12.8.1367; Mylne J, 1998, PLANT MOL BIOL REP, V16, P257, DOI 10.1023/A:1007520410190; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Rommens CM, 2000, CURR OPIN BIOTECH, V11, P120, DOI 10.1016/S0958-1669(00)00083-5; Saenz GS, 1999, CAN J BOT, V77, P150, DOI 10.1139/cjb-77-1-150; SOMERVILLE SJ, COMMUNICATION; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Thomas CM, 1998, PHILOS T ROY SOC B, V353, P1413, DOI 10.1098/rstb.1998.0296; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; Whipps JM, 1998, PLANT PATHOL, V47, P36, DOI 10.1046/j.1365-3059.1998.00207.x; XIAO SQ, UNPUB; Xiao SY, 1997, PLANT J, V12, P757, DOI 10.1046/j.1365-313X.1997.12040757.x	24	334	385	5	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					118	120		10.1126/science.291.5501.118	http://dx.doi.org/10.1126/science.291.5501.118			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141561				2022-12-28	WOS:000166259100047
J	Kay, AB				Kay, AB			Advances in immunology - Allergy and allergic diseases - First of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FC-EPSILON-RI; MESSENGER-RNA EXPRESSION; T-CELL RESPONSES; COLONY-STIMULATING FACTOR; BRONCHOALVEOLAR LAVAGE; INTESTINAL MICROFLORA; GAMMA PRODUCTION; POLLEN ALLERGEN; GROWTH-FACTOR; HAY-FEVER		Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England	Imperial College London	Kay, AB (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England.							ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Adamko DJ, 1999, J EXP MED, V190, P1465, DOI 10.1084/jem.190.10.1465; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BELVISI MG, 1997, ALLERGY ALLERGIC DIS, V1, P447; Bjorksten, 2000, CLIN EXP ALLERGY, V30, P1047; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bonini S, 1999, INT ARCH ALLERGY IMM, V118, P159, DOI 10.1159/000024055; Braun A, 2000, CLIN EXP ALLERGY, V30, P178; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Burks W, 1998, ALLERGY, V53, P725, DOI 10.1111/j.1398-9995.1998.tb03967.x; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Caramori G, 1999, AM J RESP CRIT CARE, V159, pA908; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Corry DB, 1999, NATURE, V402, pB18; Denburg JA, 1998, ALLERGY, V53, P22, DOI 10.1111/j.1398-9995.1998.tb04935.x; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 1999, NEW ENGL J MED, V340, P663; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; DURHAM SR, 1992, J IMMUNOL, V148, P2390; EBNER C, 1995, J IMMUNOL, V154, P1932; Forsythe P, 2000, CLIN EXP ALLERGY, V30, P225; GUSTAVSSON S, 1994, J IMMUNOL, V152, P4793; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Holt PG, 1999, NATURE, V402, pB12; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KEMENY DM, 1989, CLIN EXP ALLERGY, V19, P545, DOI 10.1111/j.1365-2222.1989.tb02431.x; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Larche M, 1998, J IMMUNOL, V161, P6375; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Openshaw PJM, 2000, AM J RESP CRIT CARE, V162, pS40, DOI 10.1164/ajrccm.162.supplement_1.maic-11; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Prescott SL, 1998, J IMMUNOL, V160, P4730; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rogers PR, 1999, J IMMUNOL, V163, P1205; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Smith SJ, 2000, J ALLERGY CLIN IMMUN, V105, P309, DOI 10.1016/S0091-6749(00)90081-2; SQUIRE CM, 1994, J IMMUNOL, V152, P4388; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONPIRQUET C, 1963, CLIN ASPECTS IMMUNOL; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Ying S, 1999, J IMMUNOL, V163, P3976; Yoshimoto T, 1998, J IMMUNOL, V161, P1483	64	776	852	1	75	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					30	37		10.1056/NEJM200101043440106	http://dx.doi.org/10.1056/NEJM200101043440106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136958				2022-12-28	WOS:000166160400006
J	Hart, AW; Baeza, N; Apelqvist, A; Edlund, H				Hart, AW; Baeza, N; Apelqvist, A; Edlund, H			Attenuation of FGF signalling in mouse beta-cells leads to diabetes	NATURE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; FIBROBLAST GROWTH-FACTORS; INSULIN; GENE; PROINSULIN; ONSET; MUTATIONS; NIDDM; DIFFERENTIATION; CONVERSION	Fibroblast growth factor (FGF) signalling has been implicated in patterning, proliferation and cell differentiation in many organs, including the developing pancreas(1,2). Here we show that the FGF receptors (FGFRs) 1 and 2, together with the ligands FGF1, FGF2, FGF4, FGF5, FGF7 and FGF10, are expressed in adult mouse beta -cells, indicating that FGF signalling may have a role in differentiated beta -cells. When we perturbed signalling by expressing dominant-negative forms of the receptors, FGFR1c and FGFR2b, in the pancreas, we found that that mice with attenuated FGFR1c signalling, but not those with reduced FGFR2b signalling, develop diabetes with age and exhibit a decreased number of beta -cells, impaired expression of glucose transporter 2 and increased proinsulin content in beta -cells owing to impaired expression of prohormone convertases 1/3 and 2. These defects are all characteristic of patients with type-2 diabetes. Mutations in the homeobox gene Ipf1/Pdx1 are linked to diabetes in both mouse and human. We also show that Ipf1/Pdx1 is required for the expression of FGFR1 signalling components in beta -cells, indicating that Ipf1/Pdx1 acts upstream of FGFR1 signalling in beta -cells to maintain proper glucose sensing, insulin processing and glucose homeostasis.	Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; Umea Univ, ULMM, S-90187 Umea, Sweden	Umea University; Umea University	Edlund, H (corresponding author), Umea Univ, Dept Microbiol, S-90187 Umea, Sweden.			Hart, Alan/0000-0001-7463-2535; Edlund, Helena/0000-0002-3553-7348				Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; BLUME N, 1992, MOL ENDOCRINOL, V6, P299, DOI 10.1210/me.6.2.299; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; GITHENS S, 1988, J PEDIATR GASTR NUTR, V7, P486, DOI 10.1097/00005176-198807000-00004; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Haffner SM, 1997, DIABETOLOGIA, V40, P830, DOI 10.1007/s001250050756; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hellerstrom C, 1988, PATHOLOGY ENDOCRINE, P141; Itoh N, 1996, DEVELOPMENT, V122, P291; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KAHN SE, 1995, DIABETES, V44, P173, DOI 10.2337/diabetes.44.2.173; Kato S, 1999, CELL MOL BIOL, V45, P631; Larsson H, 1999, J CLIN ENDOCR METAB, V84, P2068, DOI 10.1210/jc.84.6.2068; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Nijpels G, 1996, DIABETOLOGIA, V39, P113; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Takumi I, 1998, MODERN PATHOL, V11, P232; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Thorens B, 2000, J BIOL CHEM, V275, P23751, DOI 10.1074/jbc.M002908200; van Assche F A, 1979, Contrib Gynecol Obstet, V5, P44; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3	30	184	201	0	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					864	868		10.1038/35048589	http://dx.doi.org/10.1038/35048589			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130726				2022-12-28	WOS:000165831300052
J	Bachoud-Levi, A; Remy, P; Nguyen, JP; Brugieres, P; Lefaucheur, JP; Bourdet, C; Baudic, S; Gaura, V; Maison, P; Haddad, B; Boisse, MF; Grandmougin, T; Jeny, R; Bartolomeo, P; Dalla Barba, G; Degos, JD; Lisovoski, F; Ergis, AM; Pailhous, E; Cesaro, P; Hantraye, P; Peschanski, M				Bachoud-Levi, A; Remy, P; Nguyen, JP; Brugieres, P; Lefaucheur, JP; Bourdet, C; Baudic, S; Gaura, V; Maison, P; Haddad, B; Boisse, MF; Grandmougin, T; Jeny, R; Bartolomeo, P; Dalla Barba, G; Degos, JD; Lisovoski, F; Ergis, AM; Pailhous, E; Cesaro, P; Hantraye, P; Peschanski, M			Motor and cognitive improvements in patients with Huntington's disease after neural transplantation	LANCET			English	Article							UNILATERAL NEOSTRIATAL LESIONS; STRIATAL GRAFTS; PRIMATE MODEL; RAT-BRAIN; IN-VIVO; ALLOGRAFTS; DISORDERS; RATIONALE; DEFICITS; RELEASE	Background Huntington's disease is a neurodegenerative disease of genetic origin that mainly affects the striatum. It has severe motor and cognitive consequences and, up to now, no treatment. Motor and cognitive functions can be restored in experimental animal models by means of intrastriatal transplantation of fetal striatal neuroblasts. We explored whether grafts of human fetal striatal tissue could survive and have detectable effects in five patients with mild to moderate Huntington's disease. Methods After 2 years of preoperative assessment, patients were grafted with human fetal neuroblasts into the right striatum then, after a year, the left striatum. Final results were assessed 1 year later on the basis of neurological, neuropsychological, neurophysiological, and psychiatric tests, The results obtained were compared with those of a cohort of 22 untreated patients at similar stages of the disease who were followed up in parallel. Repeated magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning with fluorine-18-labelled fluorodeoxyglucose was also done to assess metabolic activity. Findings The final PFT-scan assessment showed increased metabolic activity in various subnuclei of the striatum in three of five patients, contrasting with the progressive decline recorded in the two other patients in the series, as seen in patients with untreated Huntington's disease. Small areas of even higher metabolic activity, coregistering with spherical hyposignals on MRI were also present in the same three patients, suggesting that grafts were functional. Accordingly, motor and cognitive functions were improved or maintained within the normal range, and functional benefits were seen in daily-life activities in these three patients, but not in the other two. Interpretation Fetal neural allografts could be associated with functional, motor, and cognitive improvements in patients with Huntington's disease.	Fac Med, INSERM, U421, IM3, F-94010 Creteil, France; CHU Henri Mondor APHP, Creteil, France; CHU Henri Mondor APHP, Orsay, France; CEA, Serv Hosp Frederic Joliot, CNRS, URA 2210, F-91406 Orsay, France; Hop Albert Chenevier APHP, Psychiat Serv, Creteil, France; Ctr Hosp Intercommunal, Serv Gynecol Obstet, Creteil, France; Hop Esquirol, Serv Gynecol Obstet, St Maurice, France; INSERM, U324, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CEA; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Institut National de la Sante et de la Recherche Medicale (Inserm)	Peschanski, M (corresponding author), Fac Med, INSERM, U421, IM3, F-94010 Creteil, France.	peschanski@im3.inserm.fr	Haddad, Bassam/Q-7767-2018; Peschanski, Marc/N-5769-2017; Bachoud-Lévi, Anne-Catherine/GYU-8680-2022; Bartolomeo, Paolo/B-3046-2009; BARBA, Gianfranco DALLA/M-5269-2018	Bachoud-Lévi, Anne-Catherine/0000-0003-3000-2210; Bartolomeo, Paolo/0000-0002-2640-6426; Remy, Philippe/0000-0003-2150-2563; Baudic, Sophie/0000-0003-2024-5550				Bachoud-Levi AC, 2000, EXP NEUROL, V161, P194, DOI 10.1006/exnr.1999.7239; BAMFORD KA, 1995, NEUROLOGY, V45, P1867, DOI 10.1212/WNL.45.10.1867; Campodonico JR, 1996, J NEUROL NEUROSUR PS, V61, P621, DOI 10.1136/jnnp.61.6.621; CLARKE DJ, 1988, NEUROSCIENCE, V24, P791, DOI 10.1016/0306-4522(88)90067-X; DUNNETT SB, 1988, NEUROSCIENCE, V24, P813, DOI 10.1016/0306-4522(88)90069-3; Dunnett SB, 1999, NEUROPATH APPL NEURO, V25, P351; FREEMAN MA, 1995, BEHAV HEALTHC TOM, V4, P5; GENY C, 1994, J NEUROSCI, V14, P7553; Kendall AL, 1998, NAT MED, V4, P727, DOI 10.1038/nm0698-727; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Kopyov OV, 1998, EXP NEUROL, V149, P97, DOI 10.1006/exnr.1997.6685; Kremer B, 1999, NEUROLOGY, V53, P1000, DOI 10.1212/WNL.53.5.1000; Lindvall O, 1999, MOVEMENT DISORD, V14, P201, DOI 10.1002/1531-8257(199903)14:2<201::AID-MDS1001>3.3.CO;2-H; MANGIN JF, 1994, J CEREBR BLOOD F MET, V14, P749, DOI 10.1038/jcbfm.1994.96; Marder K, 2000, NEUROLOGY, V54, P452, DOI 10.1212/WNL.54.2.452; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P790, DOI 10.1002/1097-4679(199111)47:6<790::AID-JCLP2270470610>3.0.CO;2-C; Naimi S, 1996, EXP NEUROL, V137, P15, DOI 10.1006/exnr.1996.0002; Palfi S, 1998, EXP NEUROL, V150, P272, DOI 10.1006/exnr.1997.6754; Palfi S, 1998, NAT MED, V4, P963, DOI 10.1038/nm0898-963; PESCHANSKI M, 1995, NEUROSCIENCE, V68, P273, DOI 10.1016/0306-4522(95)00162-C; Peschanski M, 1999, Adv Neurol, V80, P651; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Quinn N, 1996, MOVEMENT DISORD, V11, P143; Shannon KM, 1996, CELL TRANSPLANT, V5, P339, DOI 10.1016/0963-6897(95)02052-7; SIRINATHSINGHJI DJS, 1988, NEUROSCIENCE, V24, P803, DOI 10.1016/0306-4522(88)90068-1; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x	26	336	341	0	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 9	2000	356	9246					1975	1979		10.1016/S0140-6736(00)03310-9	http://dx.doi.org/10.1016/S0140-6736(00)03310-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130527				2022-12-28	WOS:000165867600013
J	Bohn, LM; Gainetdinov, RR; Lin, FT; Lefkowitz, RJ; Caron, MG				Bohn, LM; Gainetdinov, RR; Lin, FT; Lefkowitz, RJ; Caron, MG			mu-Opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence	NATURE			English	Article							KNOCKOUT MICE; OPIATE DEPENDENCE; INDUCED ANALGESIA; ADENYLYL CYCLASE; CELL-MEMBRANES; BINDING; PROTEIN; ACTIVATION; WITHDRAWAL; ADDICTION	Morphine is a powerful pain reliever, but also a potent inducer of tolerance and dependence. The development of opiate tolerance occurs on continued use of the drug such that the amount of drug required to elicit pain relief must be increased to compensate for diminished responsiveness(1-3). In many systems, decreased responsiveness to agonists has been correlated with the desensitization of G-protein-coupled receptors. In vitro evidence indicates that this process involves phosphorylation of G-protein-coupled receptors and subsequent binding of regulatory proteins called beta -arrestins(4,5). Using a knockout mouse lacking beta -arrestin-2 (beta arr2(-/-)), we have assessed the contribution of desensitization of the mu -opioid receptor to the development of morphine antinociceptive tolerance and the subsequent onset of physical dependence. Here we show that in mice lacking beta -arrestin-2, desensitization of the mu -opioid receptor does not occur after chronic morphine treatment, and that these animals fail to develop antinociceptive tolerance. However, the deletion of beta -arrestin-2 does not prevent the chronic morphine-induced upregulation of adenylyl cyclase activity, a cellular marker of dependence, and the mutant mice still become physically dependent on the drug.	Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA.		Gainetdinov, Raul R/G-5875-2011; Bohn, Laura/A-4412-2008; Lefkowitz, Robert/AAW-2649-2021; Bohn, Laura M/A-7483-2014	Gainetdinov, Raul R/0000-0003-2951-6038; Bohn, Laura M/0000-0002-6474-8179	NIDA NIH HHS [F32 DA006023] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [F32DA006023] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; BRASE DA, 1977, J PHARMACOL EXP THER, V201, P368; Breivogel CS, 1997, J NEUROCHEM, V68, P1462; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; Cox B. M., 1999, OPIOIDS PAIN CONTROL, P109; Elliott J, 1997, BRIT J PHARMACOL, V121, P1422, DOI 10.1038/sj.bjp.0701253; Fairbanks CA, 1999, J PHARMACOL EXP THER, V288, P1107; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; Jolas T, 2000, NEUROSCIENCE, V95, P433; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; Noble F, 1996, BRIT J PHARMACOL, V117, P161, DOI 10.1111/j.1476-5381.1996.tb15169.x; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PUTTFARCKEN PS, 1988, MOL PHARMACOL, V33, P520; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; Sim LJ, 1996, J NEUROSCI, V16, P8057; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; WAY EL, 1969, J PHARMACOL EXP THER, V167, P1; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3	30	682	711	0	66	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					720	723		10.1038/35047086	http://dx.doi.org/10.1038/35047086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130073				2022-12-28	WOS:000165815200049
J	Schiff, ML; Siderovski, DP; Jordan, JD; Brothers, G; Snow, B; De Vries, L; Ortiz, DF; Diverse-Pierluissi, M				Schiff, ML; Siderovski, DP; Jordan, JD; Brothers, G; Snow, B; De Vries, L; Ortiz, DF; Diverse-Pierluissi, M			Tyrosine-kinase-dependent recruitment of RGS12 to the N-type calcium channel	NATURE			English	Article							HETEROTRIMERIC G-PROTEINS; DESENSITIZATION; RECEPTOR; SUBUNIT	gamma -Aminobutyric acid (GABA)(B) receptors couple to G(o) to inhibit N-type calcium channels in embryonic chick dorsal root ganglion neurons(1). The voltage-independent inhibition, mediated by means of a tyrosine-kinase pathway(2), is transient and lasts up to 100 seconds. Inhibition of endogenous RGS12, a member of the family of regulators of G-protein signalling, selectively alters the time course of voltage-independent inhibition. The RGS12 protein, in addition to the RGS domain, contains PDZ and PTB domains(3). Fusion proteins containing the PTB domain of RGS12 alter the rate of termination of the GABAB signal, whereas the PDZ or RGS domains of RGS12 have no observable effects. Using primary dorsal root ganglion neurons in culture, here we show an endogenous agonist-induced tyrosine-kinase-dependent complex of RGS12 and the calcium channel. These results indicate that RGS12 is a multifunctional protein capable of direct interactions through its PTB domain with the tyrosine-phosphorylated calcium channel. Recruitment of RGS proteins to G-protein effecters may represent an additional mechanism for signal termination in G-protein-coupled pathways.	CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27559 USA; Amgen Res Inst, Toronto, ON M5G 2C1, Canada; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; Tufts University	Diverse-Pierluissi, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol, Box 1215, New York, NY 10029 USA.		Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Jordan, Dedrick/0000-0002-0706-9583				AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; LUEBKE JI, 1994, PFLUG ARCH EUR J PHY, V428, P499, DOI 10.1007/BF00374571; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	13	111	114	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					723	727		10.1038/35047093	http://dx.doi.org/10.1038/35047093			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130074				2022-12-28	WOS:000165815200050
J	Wade, DT				Wade, DT			Ethical issues in diagnosis and management of patients in the permanent vegetative state	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTERESTS; INJURY; LIFE		Rivermead Rehabil Ctr, Oxford OX1 4XD, England		Wade, DT (corresponding author), Rivermead Rehabil Ctr, Oxford OX1 4XD, England.	derick.wade@dial.pipex.com		Wade, Derick/0000-0002-1188-8442				Andrews K, 1997, J ROY SOC MED, V90, P593, DOI 10.1177/014107689709001102; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Cotterill, 1998, ENCHANTED LOOMS CONS; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Fenwick AJ, 1998, J MED ETHICS, V24, P86, DOI 10.1136/jme.24.2.86; Fenwick AJ, 1999, J MED ETHICS, V25, P59, DOI 10.1136/jme.25.1.59; Gillon R, 1998, J MED ETHICS, V24, P75, DOI 10.1136/jme.24.2.75; HOMERWARD MD, 2000, CLIN REHABIL, V14, P220; McLean SAM, 1999, J CLIN PATHOL, V52, P490, DOI 10.1136/jcp.52.7.490; Roberts J, 1996, BRIT MED J, V312, P329; ROSENBERG JH, 1995, NEUROLOGY, V45, P1012; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; *ROYAL HOSP NEUR, 1996, INT WORK PART REP VE; Shiel A, 1998, BRAIN INJURY, V12, P809, DOI 10.1080/026990598122043; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841	18	21	22	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2001	322	7282					352	354		10.1136/bmj.322.7282.352	http://dx.doi.org/10.1136/bmj.322.7282.352			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159664	Green Published			2022-12-28	WOS:000167050000033
J	Abdulla, S; Armstrong, J; Schellenberg, A; Nathan, R; Mukasa, O; Marchant, T; Smith, T; Tanner, M; Lengeler, C				Abdulla, S; Armstrong, J; Schellenberg, A; Nathan, R; Mukasa, O; Marchant, T; Smith, T; Tanner, M; Lengeler, C			Impact on malaria morbidity of a programme supplying insecticide treated nets in children aged under 2 years in Tanzania: community cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERENNIAL TRANSMISSION; FALCIPARUM-MALARIA; INTENSE; ANEMIA; AREA; CHLOROQUINE; EFFICACY; INFANTS	Objective To assess the impact of a social marketing programme for distributing nets treated with insecticide on malarial parasitaemia and anaemia in very young children in an area of high malaria transmission. Design Community cross sectional study. Annual, cross sectional data were collected at the beginning of the social marketing campaign (1997) and the subsequent two years. Net ownership and other risk and confounding factors were assessed with a questionnaire. Blood samples were taken from the children to assess prevalence of parasitaemia and haemoglobin levels. Setting 18 villages in the Kilombero and Ulanga districts of southwestern Tanzania. participants A random sample of children aged under 2 years. Main outcome measures The presence of any parasitaemia in the peripheral blood sample and the presence of anaemia (classified as a haemoglobin level of <80 g/l). Results Ownership of nets increased rapidly (treated or not treated nets: from 58% to 83%; treated nets: from 10% to 61%). The mean haemoglobin level rose from 80 g/l to 89 g/l in the stud children in the successive surveys. Overall, the prevalence of anaemia in the stud population decreased from 49% to 26% in the two years studied. Treated nets had a protective efficacy of 62% (95% confidence interval 38% to 77%) on the prevalence of parasitaemia and of 63% (27% to 82%) on anaemia. Conclusions These results show that nets treated with insecticide have a substantial impact on morbidity when distributed in a public health setting.	Swiss Trop Inst, Basel, Switzerland; Ifakara Hlth Res & Dev Ctr, Ifakara, Tanzania	University of Basel; Swiss Tropical & Public Health Institute; Ifakara Health Institute	Lengeler, C (corresponding author), Swiss Trop Inst, POB 4002, Basel, Switzerland.	Christian.Lengeler@unibas.ch	Smith, Thomas/B-5569-2015	Smith, Thomas/0000-0002-3650-9381; Marchant, Tanya/0000-0002-4228-4334; Schellenberg, Joanna/0000-0002-0708-3676				BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Hatz C, 1998, TROP MED INT HEALTH, V3, P498, DOI 10.1046/j.1365-3156.1998.00250.x; Kitua AY, 1997, TROP MED INT HEALTH, V2, P325; Kitua AY, 1996, TROP MED INT HEALTH, V1, P475, DOI 10.1046/j.1365-3156.1996.d01-89.x; Langeler C, 1996, B WORLD HEALTH ORGAN, V74, P325; Lengeler C, 2000, COCHRANE DATABASE SY; *MAL CONS LOND SCH, 1999, 2 INT C INS TREAT NE; Marsh K, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P241; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; Schellenberg JRMA, 1999, T ROY SOC TROP MED H, V93, P225, DOI 10.1016/S0035-9203(99)90001-9; Smith T, 1999, T ROY SOC TROP MED H, V93, pS15, DOI 10.1016/S0035-9203(99)90322-X; *STAT CORP, 1999, STATA STAT SOFTW REL; Stoltzfus RJ, 1997, LANCET, V349, P1764, DOI 10.1016/S0140-6736(96)12355-2; Tanner M., 1991, DIS MORTALITY SUBSAH	15	110	113	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2001	322	7281					270	273		10.1136/bmj.322.7281.270	http://dx.doi.org/10.1136/bmj.322.7281.270			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157527	Green Submitted, Bronze, Green Accepted, Green Published			2022-12-28	WOS:000166917600027
J	Ascherio, A; Zhang, SM; Hernan, MA; Olek, MJ; Coplan, PM; Brodovicz, K; Walker, AM				Ascherio, A; Zhang, SM; Hernan, MA; Olek, MJ; Coplan, PM; Brodovicz, K; Walker, AM			Hepatitis B vaccination and the risk of multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NERVOUS-SYSTEM DEMYELINATION; MS	Background: Reports of multiple sclerosis developing after hepatitis B vaccination have led to the concern that this vaccine might be a cause of multiple sclerosis in previously healthy subjects. Methods: We conducted a nested case-control study in two large cohorts of nurses in the United States, those in the Nurses' Health Study (which has followed 121,700 women since 1976) and those in the Nurses' Health Study II (which has followed 116,671 women since 1989). For each woman with multiple sclerosis, we selected as controls five healthy women and one woman with breast cancer. Information about hepatitis B vaccination was obtained by means of a mailed questionnaire and was confirmed by means of vaccination certificates. The analyses included 192 women with multiple sclerosis and 645 matched controls (534 healthy controls and 111 with breast cancer) and were conducted with the use of conditional logistic regression. Results: The multivariate relative risk of multiple sclerosis associated with exposure to the hepatitis B vaccine at any time before the onset of the disease was 0.9 (95 percent confidence interval, 0.5 to 1.6). The relative risk associated with hepatitis B vaccination within two years before the onset of the disease was 0.7 (95 percent confidence interval, 0.3 to 1.8). The results were similar in analyses restricted to women with multiple sclerosis that began after the introduction of the recombinant hepatitis B vaccine. There was also no association between the number of doses of vaccine received and the risk of multiple sclerosis. Conclusions: These results indicate no association between hepatitis B vaccination and the development of multiple sclerosis. (N Engl J Med 2001;344:327-32.) Copyright (C) 2001 Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Multiple Sclerosis Unit, Boston, MA 02115 USA; Merck Res Labs, W Point, PA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Merck & Company	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.			Coplan, Paul/0000-0002-7078-7780; Olek, Michael/0000-0002-3840-2772	NATIONAL CANCER INSTITUTE [R01CA050385, R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035624] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356, CA50385] Funding Source: Medline; NINDS NIH HHS [NS35624] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brex PA, 1999, NEUROLOGY, V53, P1184, DOI 10.1212/WNL.53.6.1184; Fourrier A., 1999, PHARMACOEPIDEMIOL DR, V8, pS140; Hall M, 1999, UNIX REV-PERFORM COM, V17, P5; Hernan MA, 1999, NEUROLOGY, V53, P1711, DOI 10.1212/WNL.53.8.1711; Hernan MA, 1999, AM J EPIDEMIOL, V149, pS37; HERROELEN L, 1991, LANCET, V338, P1174, DOI 10.1016/0140-6736(91)92034-Y; KANE M, 1995, VACCINE, V13, pS47; KAPLANSKI G, 1995, J NEUROL NEUROSUR PS, V58, P758, DOI 10.1136/jnnp.58.6.758-a; Marshall E, 1998, SCIENCE, V281, P630, DOI 10.1126/science.281.5377.630; MCMAHON BJ, 1992, AM J MED, V92, P254, DOI 10.1016/0002-9343(92)90073-K; NADLER JP, 1993, CLIN INFECT DIS, V17, P928, DOI 10.1093/clinids/17.5.928-b; Niu MT, 1996, PEDIATR INFECT DIS J, V15, P771, DOI 10.1097/00006454-199609000-00007; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Sadovnick AD, 2000, LANCET, V355, P549, DOI 10.1016/S0140-6736(99)02991-8; SHAW FE, 1988, AM J EPIDEMIOL, V127, P337, DOI 10.1093/oxfordjournals.aje.a114808; Sturkenboom MC, 1999, PHARMACOEPIDEM DR S, V8, pS170; Tourbah A, 1999, NEUROLOGY, V53, P396, DOI 10.1212/WNL.53.2.396; Touze E, 2000, REV NEUROL, V156, P242; Zipp F, 1999, NAT MED, V5, P964, DOI 10.1038/12376	19	295	303	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					327	332		10.1056/NEJM200102013440502	http://dx.doi.org/10.1056/NEJM200102013440502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172163				2022-12-28	WOS:000166675800002
J	Harris, NS; Crawford, PB; Yangzom, Y; Pinzo, L; Gyaltsen, P; Hudes, M				Harris, NS; Crawford, PB; Yangzom, Y; Pinzo, L; Gyaltsen, P; Hudes, M			Nutritional and health status of Tibetan children living at high altitudes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL GROWTH REFERENCE; KASHIN-BECK-DISEASE; MALNUTRITION; CHINA; URBAN; POPULATIONS; MORTALITY; PNEUMONIA; REFORMS; ORIGIN	Background: Children living at high altitudes often have delayed growth, but whether growth retardation is related to altitude or to other factors is not known. Methods: A multicultural health care team assessed 2078 Tibetan children 0 to 84 months of age for anthropometric and clinical signs of malnutrition. The children lived in 11 counties, which contained more than 50 diverse urban and nonurban (nomadic, agricultural, or periurban) communities in the Tibet Autonomous Region of China. The height and weight of the children were compared with those of U.S. children. Height and weight were expressed as z scores (the number of standard deviations from the median of the age- and sex-specific reference group). Results: The mean z score for height fell from -0.5 to -1.6 in the first 12 months of life and generally ranged from -2.0 to -2.4 in older children. Overall, of 2078 children, 1067 (51 percent) had moderately or severely stunted growth, as defined by a z score of -2.0 or lower. Of the 1556 children 24 months of age or older, 871 (56 percent) had stunted growth, which was severe (z score, -3.0 or lower) in 380 (24 percent). Among the children in this age group, 787 of the 1313 nonurban children (60 percent) had stunting, as compared with 84 of the 243 urban children (35 percent). Stunting was associated with clinical conditions such as rickets, abdominal distention, hair depigmentation, and skin lesions and with a maternal history of hepatitis or goiter. Stunting was not associated with altitude, after adjustment for the type of community. Conclusions: In Tibetan children, severe stunting due to malnutrition occurs early in life, and morbidity is high. (N Engl J Med 2001;344:341-7.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA; Inst Publ Hlth, Tibet child Nutr & Collaborat Hlth Project, Santa Cruz, CA 95064 USA; First Peoples Hosp, Tibet Med Res Inst, Lhasa, Peoples R China; First Peoples Hosp, Dept Pediat & Med Res, Lhasa, Tibet, Peoples R China	University of California System; University of California Berkeley; Public Health Institute	Crawford, PB (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.							ALLEN LH, 1993, NUTR REV, V51, P255, DOI 10.1111/j.1753-4887.1993.tb03117.x; BEALL CM, 1981, ANN HUM BIOL, V8, P31, DOI 10.1080/03014468100004761; BEATON GH, 1989, EUR J CLIN NUTR, V43, P863; Burger Susan E., 1993, American Journal of Clinical Nutrition, V57, p295S, DOI 10.1093/ajcn/57.2.295S; Chang Y, 1996, Biomed Environ Sci, V9, P164; Chasseur C, 1997, LANCET, V350, P1074, DOI 10.1016/S0140-6736(05)70453-0; CHEN LC, 1980, AM J CLIN NUTR, V33, P1836, DOI 10.1093/ajcn/33.8.1836; *COMM EUR COMM, 1994, CHIN FEAS STUD INT R; Delange F, 1986, ERADICATION ENDEMIC, P373; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; DELONG GR, 1993, AM J CLIN NUTR, V57, P286; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P749, DOI 10.1093/ajcn/46.5.749; DORJE G, 1999, TIET HDB; Frisancho A R, 1983, Prog Clin Biol Res, V136, P383; GARN SM, 1973, ECOL FOOD NUTR, V2, P79; GOPLAN CC, 1983, SMALL HLTH POOR NOT, P1; Grantham-Mcgregor Sally M., 1993, American Journal of Clinical Nutrition, V57, p303S, DOI 10.1093/ajcn/57.2.303S; HAAS JD, 1982, AM J PHYS ANTHROPOL, V59, P251, DOI 10.1002/ajpa.1330590304; Haas JD, 1980, HUM BIOL, V52, P459; HABICHT JP, 1974, LANCET, V1, P611; HUO L, 1991, J RES CHILD HLTH, P1; Jelliffe D.B., 1966, ASSESSMENT NUTR STAT; KARIM MR, 1998, GEE SAS MACRO LONGIT; Kirk R.E., 1968, EXPT DESIGN PROCEDUR; KOLSTEREN P, 1990, NUTR HLTH WATER SANI; LEONARD WR, 1989, AM J PHYS ANTHROPOL, V80, P341, DOI 10.1002/ajpa.1330800308; MAJUMDER PP, 1986, AM J PHYS ANTHROPOL, V70, P377, DOI 10.1002/ajpa.1330700312; MARTORELL R, 1978, PROGR HUMAN NUTRITIO, V2, P142; Mathieu F, 1997, INT ORTHOP, V21, P151, DOI 10.1007/s002640050139; Moreno-Reyes R, 1998, NEW ENGL J MED, V339, P1112, DOI 10.1056/NEJM199810153391604; Muhe L, 1997, LANCET, V349, P1801, DOI 10.1016/S0140-6736(96)12098-5; *NAT CTR HLTH INF, MCH BAS STUD; National Family Health Survey, 1992, NAT FAM HLTH SURV; PAWSON IG, 1977, AM J PHYS ANTHROPOL, V47, P473, DOI 10.1002/ajpa.1330470320; PELLETIER DL, 1994, NUTR REV, V52, P409, DOI 10.1111/j.1753-4887.1994.tb01376.x; Seckler D., 1982, NEWER CONCEPTS NUTR, P127; Shen TF, 1996, NEW ENGL J MED, V335, P400, DOI 10.1056/NEJM199608083350606; SHI LY, 1993, B WORLD HEALTH ORGAN, V71, P723; SINGH S P, 1980, Zeitschrift fuer Morphologie und Anthropologie, V71, P187; TROWBRIDGE FL, 1987, AM J CLIN NUTR, V46, P411, DOI 10.1093/ajcn/46.3.411; TROWBRIDGE FL, 1981, AM J CLIN NUTR, V34, P2591, DOI 10.1093/ajcn/34.11.2591; VICTORA CG, 1990, AM J CLIN NUTR, V52, P391, DOI 10.1093/ajcn/52.2.391; VICTORA CG, 1992, J NUTR, V122, P1105, DOI 10.1093/jn/122.5.1105; ZHOUT AH, 1986, SURVEY STUDY NUTR GR	45	83	91	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					341	347		10.1056/NEJM200102013440504	http://dx.doi.org/10.1056/NEJM200102013440504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172165				2022-12-28	WOS:000166675800004
J	Verin, V; Popowski, Y; de Bruyne, B; Baumgart, D; Sauerwein, W; Lins, M; Kovacs, G; Thomas, M; Calman, F; Disco, C; Serruys, PW; Wijns, W				Verin, V; Popowski, Y; de Bruyne, B; Baumgart, D; Sauerwein, W; Lins, M; Kovacs, G; Thomas, M; Calman, F; Disco, C; Serruys, PW; Wijns, W		Dose-Finding Study Grp	Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVASCULAR ULTRASOUND; ARTERY DISEASE; INTRACORONARY BRACHYTHERAPY; REDUCE RESTENOSIS; IRRADIATION; MODEL; PLACEMENT; STENTS; INJURY; IMPLANTATION	Background: Beta radiation is effective in reducing vascular neointimal proliferation in animals after injury caused by balloon angioplasty. However, the lowest dose that can prevent restenosis after coronary angioplasty has yet to be determined. Methods: After successful balloon angioplasty of a previously untreated coronary stenosis, 181 patients were randomly assigned to receive 9, 12, 15, or 18 Gy of radiation delivered by a centered yttrium-90 source. Adjunctive stenting was required in 28 percent of the patients. The primary end point was the minimal luminal diameter six months after treatment, as a function of the delivered dose of radiation. Results: At the time of follow-up coronary angiography, the mean minimal luminal diameter was 1.67 mm in the 9-Gy group, 1.76 mm in the 12-Gy group, 1.83 mm in the 15-Gy group, and 1.97 mm in the 18-Gy group (P = 0.06 for the comparison of 9 Gy with 18 Gy), resulting in restenosis rates of 29 percent, 21 percent, 16 percent, and 15 percent, respectively (P = 0.14 for the comparison of 9 Gy with 18 Gy). At that time, 86 percent of the patients had had no serious cardiac events. In 130 patients treated with balloon angioplasty without a stent, restenosis rates were 28 percent, 17 percent, 16 percent, and 4 percent, respectively (P = 0.02 for the comparison of 9 Gy with 18 Gy). Among these patients, there was a dose-dependent enlargement of the lumen in 28 percent, 50 percent, 45 percent, and 74 percent of patients, respectively (P<0.001 for the comparison of 9 Gy with 18 Gy). The rate of repeated revascularization was 18 percent with 9 Gy and 6 percent with 18 Gy (P = 0.26). Conclusions: Intracoronary beta-radiation therapy produces a significant dose-dependent decrease in the rate of restenosis after angioplasty. An 18-Gy dose not only prevents the renarrowing of the lumen typically observed after successful balloon angioplasty, but actually induces luminal enlargement. (N Engl J Med 2001;344:243-9.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Hosp, Geneva, Switzerland; Onze Lieve Vrouw Hosp, Ctr Cardiovasc, Aalst, Belgium; Univ Hosp, Essen, Germany; Univ Hosp, Kiel, Germany; Kings Coll London Hosp, London, England; Erasmus Univ, Rotterdam, Netherlands	University of Geneva; Cardiovascular Center Aalst; University of Duisburg Essen; University of Kiel; Schleswig Holstein University Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; Erasmus University Rotterdam	Wijns, W (corresponding author), Onze Lieve Vrouw Hosp, Ctr Cardiovasc, B-9300 Aalst, Belgium.	wijns@olvz-aalst.be		Delafontaine, Patrice/0000-0003-3744-3617; Wijns, William/0000-0002-7267-4376				Bittl JA, 1997, NEW ENGL J MED, V336, P670; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; Condado JA, 1997, CIRCULATION, V96, P727; Costa MA, 1999, CIRCULATION, V100, P789, DOI 10.1161/01.CIR.100.8.789; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GILLETTE EL, 1989, INT J RADIAT ONCOL, V17, P1247, DOI 10.1016/0360-3016(89)90533-6; GORODETSKY R, 1988, RADIAT RES, V116, P135, DOI 10.2307/3577484; King SB, 1998, CIRCULATION, V97, P2025, DOI 10.1161/01.CIR.97.20.2025; KOVALIC JJ, 1989, INT J RADIAT ONCOL, V17, P77, DOI 10.1016/0360-3016(89)90373-8; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; Leon Martin B., 1999, Journal of the American College of Cardiology, V33, p19A; Mak KH, 1997, ANN NY ACAD SCI, V811, P255, DOI 10.1111/j.1749-6632.1997.tb52007.x; Meerkin D, 1999, CIRCULATION, V99, P1660, DOI 10.1161/01.CIR.99.13.1660; Popowski Y, 1996, INT J RADIAT ONCOL, V36, P923, DOI 10.1016/S0360-3016(96)00409-9; POPOWSKI Y, 1995, INT J RADIAT ONCOL, V33, P211, DOI 10.1016/0360-3016(95)00107-A; POPOWSKI Y, 1995, INT J RADIAT ONCOL, V33, P713, DOI 10.1016/0360-3016(95)00259-2; POPOWSKI Y, 1994, FREIBURG ONCOLOGY SE, V1, P163; Raizner AE, 2000, CIRCULATION, V102, P951, DOI 10.1161/01.CIR.102.9.951; Sabate M, 2000, J AM COLL CARDIOL, V36, P1536, DOI 10.1016/S0735-1097(00)00893-7; Sabate M, 1999, CIRCULATION, V100, P1182, DOI 10.1161/01.CIR.100.11.1182; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Serruys PW, 1997, CIRCULATION, V96, P709; STEWART JR, 1995, INT J RADIAT ONCOL, V31, P1205, DOI 10.1016/0360-3016(94)00656-6; TAGHIAN A, 1991, INT J RADIAT ONCOL, V21, P361, DOI 10.1016/0360-3016(91)90783-Z; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; Topol EJ, 1998, NEW ENGL J MED, V339, P1702, DOI 10.1056/NEJM199812033392311; VEGESNA V, 1993, RADIAT RES, V135, P431, DOI 10.2307/3578885; VERIN V, 1995, CIRCULATION, V92, P2284, DOI 10.1161/01.CIR.92.8.2284; Verin V, 1997, CIRCULATION, V95, P1138; Waksman R, 2000, CIRCULATION, V101, P2165, DOI 10.1161/01.CIR.101.18.2165; Waksman R, 2000, J AM COLL CARDIOL, V36, P65, DOI 10.1016/S0735-1097(00)00681-1; Waksman R, 1997, CIRCULATION, V96, P1944, DOI 10.1161/01.CIR.96.6.1944; WAKSMAN R, 1995, CIRCULATION, V92, P3025, DOI 10.1161/01.CIR.92.10.3025; WIEDERMANN JG, 1994, J AM COLL CARDIOL, V23, P1491, DOI 10.1016/0735-1097(94)90397-2; WILDER RB, 1992, INT J RADIAT ONCOL, V23, P533, DOI 10.1016/0360-3016(92)90008-6	38	186	193	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2001	344	4					243	249		10.1056/NEJM200101253440401	http://dx.doi.org/10.1056/NEJM200101253440401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	394WA	11172150	Green Published			2022-12-28	WOS:000166545200001
J	Mills, SY				Mills, SY			Regulation in complementary and alternative medicine	BRITISH MEDICAL JOURNAL			English	Article									Sch Educ, Dept Lifelong Learning, Complementary Hlth Studies Programme, Exeter EX1 2LU, Devon, England		Mills, SY (corresponding author), Sch Educ, Dept Lifelong Learning, Complementary Hlth Studies Programme, Exeter EX1 2LU, Devon, England.			Mills, Simon/0000-0001-7729-5300				DICKINSON D, 1995, COMPLEMENT THER MED, V3, P9; Ernst E., 1995, COMPLEMENT THER MED, V3, P6; *F INT MED, 1998, INT HEALTHC WAY NEXT; *HOUS LORDS SEL CO, 2000, COMPL ALT MED SESS 1; Mills S., 1997, PROFESSIONAL ORG COM; MILLS S, 2000, PROFESSIONAL ORG COM; Mills S. Y., 1996, COMPLEMENT THER MED, V4, P48; SHIFFIN K, 1993, COMPLEMENTARY THERAP, V1, P91; STONE J, 1996, COMPLEMENTARY MED LA; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207	10	31	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					158	160		10.1136/bmj.322.7279.158	http://dx.doi.org/10.1136/bmj.322.7279.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159577	Green Published			2022-12-28	WOS:000166615300032
J	Shah, JV; Cleveland, DW				Shah, JV; Cleveland, DW			Waiting for anaphase: Mad2 and the spindle assembly checkpoint	CELL			English	Review							CELL-CYCLE CHECKPOINT; PROTEIN MAD2; KINETOCHORES; LOCALIZATION; MITOSIS		Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Cleveland, DW (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Kitagawa R, 1999, NAT CELL BIOL, V1, P514, DOI 10.1038/70309; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rieder CL, 1997, P NATL ACAD SCI USA, V94, P5107, DOI 10.1073/pnas.94.10.5107; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yu HG, 1999, J CELL BIOL, V145, P425, DOI 10.1083/jcb.145.3.425	20	240	249	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 22	2000	103	7					997	1000		10.1016/S0092-8674(00)00202-6	http://dx.doi.org/10.1016/S0092-8674(00)00202-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163175	Bronze			2022-12-28	WOS:000166040600002
J	Hanaoka, K; Qian, F; Boletta, A; Bhumia, AK; Piontek, K; Tsiokas, L; Sukhatme, VP; Guggino, WB; Germino, GG				Hanaoka, K; Qian, F; Boletta, A; Bhumia, AK; Piontek, K; Tsiokas, L; Sukhatme, VP; Guggino, WB; Germino, GG			Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents	NATURE			English	Article							KIDNEY-DISEASE; GENE-PRODUCT; PKD1; CHANNEL; RECEPTOR; IDENTIFICATION; HETEROGENEITY; ENCODES	The human kidney is composed of roughly 1.2-million renal tubules that must maintain their tubular structure to function properly. In autosomal dominant polycystic kidney disease (ADPKD) cysts develop from renal tubules and enlarge independently, in a process that ultimately causes renal failure in 50% of affected individuals(1,2). Mutations in either PKD1 or PKD2 are associated with ADPKD but the function of these genes is unknown. PKD1 is thought to encode a membrane protein, polycystin-1, involved in cell-cell or cell-matrix interactions(3-5), whereas the PKD2 gene product, polycystin-2, is thought to be a channel protein(6). Here we show that polycystin-1 and -2 interact to produce new calcium-permeable non-selective cation currents. Neither polycystin-1 nor -2 alone is capable of producing currents. Moreover, disease-associated mutant forms of either polycystin protein that are incapable of heterodimerization do not result in new channel activity. We also show that polycystin-2 is localized in the cell in the absence of polycystin-1, but is translocated to the plasma membrane in its presence. Thus, polycystin-1 and -2 co-assemble at the plasma membrane to produce a new channel and to regulate renal tubular morphology and function.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Warren Med Res Inst, Oklahoma City, OK 73104 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA	Johns Hopkins University; Johns Hopkins University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Guggino, WB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 725 N Wolfe St, Baltimore, MD 21205 USA.	wguggino@jhmi.edu; ggermino@mail.jhmi.edu	Sukhatme, Vikas/W-2776-2019	Tsiokas, Leonidas/0000-0002-3659-1813; Germino, Gregory/0000-0002-3609-5588				BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; *EUR POL KIDN DIS, 1994, CELL, V78, P881; Fan JS, 1998, PFLUG ARCH EUR J PHY, V436, P1021, DOI 10.1007/PL00008086; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GRANTHAM JJ, 1993, J AM SOC NEPHROL, V3, P1843; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanaoka K, 1996, AM J PHYSIOL-CELL PH, V270, pC389, DOI 10.1152/ajpcell.1996.270.1.C389; Hanaoka K, 1999, J MEMBRANE BIOL, V172, P193, DOI 10.1007/s002329900596; Harris PC, 1999, HUM MOL GENET, V8, P1861, DOI 10.1093/hmg/8.10.1861; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Peral B, 1996, AM J HUM GENET, V58, P86; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Popp R, 1993, EXS, V66, P213; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Van Driessche W, 1993, EXS, V66, P225; Watnick T, 1999, SEMIN NEPHROL, V19, P327; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943	30	627	651	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					990	994		10.1038/35050128	http://dx.doi.org/10.1038/35050128			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140688				2022-12-28	WOS:000165951100054
J	Donnelly, CA				Donnelly, CA			Likely size of the French BSE epidemic - Epidemiological analysis helps in evaluating the potential risks of eating French beef.	NATURE			English	Article							TRANSMISSION DYNAMICS; CATTLE		Imperial Coll Sch Med, Dept Infect Dis Epidemiol, London W2 1PG, England	Imperial College London	Donnelly, CA (corresponding author), Imperial Coll Sch Med, Dept Infect Dis Epidemiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.			Donnelly, Christl/0000-0002-0195-2463				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Butler D, 1996, NATURE, V382, P5, DOI 10.1038/382005c0; Doherr MG, 1999, VET REC, V145, P155, DOI 10.1136/vr.145.6.155; Donnelly C A, 1999, J Epidemiol Biostat, V4, P277; Donnelly CA, 1997, NATURE, V389, P903, DOI 10.1038/39982; DONNELLY CA, 1999, STAT ASPECTS BSE VCJ; Ferguson NM, 1997, PHILOS T R SOC B, V352, P803, DOI 10.1098/rstb.1997.0063; Schreuder BEC, 1997, VET REC, V141, P187, DOI 10.1136/vr.141.8.187; *SPONG ENC ADV COM, 1999, SPONG ENC ADV COMM M	9	33	35	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					787	788		10.1038/35048666	http://dx.doi.org/10.1038/35048666			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130705				2022-12-28	WOS:000165831300030
J	Tromans, A				Tromans, A			Plant biology - Volatile defence	NATURE			English	Editorial Material																			0	1	1	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					785	785		10.1038/35048660	http://dx.doi.org/10.1038/35048660			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11147529	Bronze			2022-12-28	WOS:000165831300028
J	Russell, EV; Israeloff, NE				Russell, EV; Israeloff, NE			Direct observation of molecular cooperativity near the glass transition	NATURE			English	Article							RELAXATION; DYNAMICS; TEMPERATURE; LIQUIDS	The increasingly sluggish response of a supercooled liquid as it nears its glass transition(1) (for example, refrigerated honey) is prototypical of glassy dynamics found in proteins, neural networks and superconductors. The notion that molecules rearrange cooperatively has long been postulated(2) to explain diverging relaxation times and broadened (non-exponential) response functions near the glass transition. Recently, cooperativity was observed and analysed in colloid glasses(3) and in simulations of binary liquids well above the glass transition(4). But nanometre-scale studies of cooperativity at the molecular glass transition are lacking(5). Important issues to be resolved include the precise form of the cooperativity and its length scale(6), and whether the broadened response is intrinsic to individual cooperative regions, or arises only from heterogeneity(7-9) in an ensemble of such regions. Here we describe direct observations of molecular cooperativity near the glass transition in polyvinylacetate (PVAc), using nanometre-scale probing of dielectric fluctuations. Molecular dusters switched spontaneously among two to four distinct configurations, producing random telegraph noise. Our analysis of these noise signals and their power spectra reveals that individual dusters exhibit transient dynamical heterogeneity and non-exponential kinetics.	Northeastern Univ, Dept Phys, Boston, MA 02115 USA; Northeastern Univ, Ctr Interdisciplinary Res Complex Syst, Boston, MA 02115 USA	Northeastern University; Northeastern University	Israeloff, NE (corresponding author), Northeastern Univ, Dept Phys, Boston, MA 02115 USA.	Israeloff@neu.edu						ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442; ALBRECHT TR, 1991, J APPL PHYS, V69, P668, DOI 10.1063/1.347347; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; Arbe A, 1998, PHYS REV LETT, V81, P590, DOI 10.1103/PhysRevLett.81.590; Bennemann C, 1999, NATURE, V399, P246, DOI 10.1038/20406; Binder K, 1999, PHYS WORLD, V12, P54; Bohmer R, 1998, J NON-CRYST SOLIDS, V235, P1, DOI 10.1016/S0022-3093(98)00581-X; DIXON PK, 1990, PHYS REV LETT, V65, P1108, DOI 10.1103/PhysRevLett.65.1108; EDIGER MD, IN PRESS ANN REV PHY, V51; Forrest JA, 1996, PHYS REV LETT, V77, P2002, DOI 10.1103/PhysRevLett.77.2002; MARTIN Y, 1988, APPL PHYS LETT, V52, P1103, DOI 10.1063/1.99224; MCCRUM NG, 1991, ANELASTIC DIELECTRIC, P302; Russell EV, 1998, PHYS REV LETT, V81, P1461, DOI 10.1103/PhysRevLett.81.1461; Schiener B, 1996, SCIENCE, V274, P752, DOI 10.1126/science.274.5288.752; Tracht U, 1999, J CHEM PHYS, V111, P3720, DOI 10.1063/1.479652; Tracht U, 1998, PHYS REV LETT, V81, P2727, DOI 10.1103/PhysRevLett.81.2727; Walther LE, 1998, PHYS REV B, V57, P15112, DOI 10.1103/PhysRevB.57.R15112; Walther LE, 1998, APPL PHYS LETT, V72, P3223, DOI 10.1063/1.121556; WANG J, 1995, PHYS REV LETT, V74, P4317, DOI 10.1103/PhysRevLett.74.4317; Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627; Xia XY, 2000, P NATL ACAD SCI USA, V97, P2990, DOI 10.1073/pnas.97.7.2990	22	258	260	1	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					695	698						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130066				2022-12-28	WOS:000165815200042
J	Little, P; Gould, C; Williamson, I; Moore, M; Warner, G; Dunleavy, J				Little, P; Gould, C; Williamson, I; Moore, M; Warner, G; Dunleavy, J			Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; ACUTE MASTOIDITIS; ANTIBIOTIC USE; SORE THROAT; CHILDREN; QUESTIONNAIRE; DECISION; OTALGIA	Objective To compare immediate with delayed prescribing of antibiotics for acute otitis media. Design Open randomised controlled trial. Setting General practices in south west England. Participants 315 children aged between 6 months and and 10 years presenting with acute otitis media. Interventions Two treatment strategies, supported by standardised advice sheets-immediate antibiotics or delayed antibiotics (antibiotic prescription to be collected at parents' discretion after 72 hours if child stilt not improving). Main outcome measures Symptom resolution, absence from school or nursery, paracetamol consumption. Results On average, symptoms resolved after 3 days. Children prescribed antibiotics immediately had shorter illness (- 1.1 days (95% confidence interval - 0.54 to - 1.48)), fewer nights disturbed (- 0.72 (- 0.30 to - 1.13)), and slightly less paracetamol consumption (- 0.52 spoons/day (- 0.26 to - 0.79)). There was no difference in school absence or pain or distress scores since benefits of antibiotics occurred mainly after the first 24 hours-when distress was less severe. Parents of 36/150 of the children given delayed prescriptions used antibiotics, and 77% were very satisfied. Fewer children in the delayed group had diarrhoea (14/150 (9%) v 25/135 (19%), chi (2) = 5.2, P = 0.02). Fewer parents in the delayed group believed in the effectiveness of antibiotics and in the need to see the doctor with future episodes. Conclusion Immediate antibiotic prescription provided symptomatic benefit mainly after first 24 hours, when symptoms were already resolving. For children who are not very unwell systemically, a wait and see approach seems feasible and acceptable to parents and should substantially reduce the use of antibiotics for acute otitis media.	Univ Southampton, Community Clin Sci Primary Care Grp, Aldermoor Hlth Ctr, Southampton SO15 6ST, Hants, England; Nightingale Surg, Romsey SO51 7QN, Hants, England; Three Swans Surg, Salisbury, Wilts, England	University of Southampton	Little, P (corresponding author), Univ Southampton, Community Clin Sci Primary Care Grp, Aldermoor Hlth Ctr, Southampton SO15 6ST, Hants, England.	ps13@soton.ac.uk	Moore, Michael/C-3447-2011	Moore, Michael/0000-0002-5127-4509; Little, Paul/0000-0003-3664-1873				Antonelli PJ, 1999, OTOLARYNG HEAD NECK, V121, P190, DOI 10.1016/S0194-5998(99)70170-1; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; BAIN J, 1990, BMJ-BRIT MED J, V300, P1006, DOI 10.1136/bmj.300.6730.1006; Britten N, 1997, BRIT MED J, V315, P1506, DOI 10.1136/bmj.315.7121.1506; BROWN TCK, 1992, ANAESTHESIA CHILDREN, P129; BROWNING GG, 1990, BRIT MED J, V300, P1005, DOI 10.1136/bmj.300.6730.1005; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; BUTLER C, 1998, BMJ-BRIT MED J, V317, P632; CARTWRIGHT A, 1981, GEN PRACTICE REV 2ND; Cates C, 1999, BRIT MED J, V318, P715, DOI 10.1136/bmj.318.7185.715; Collison P J, 1998, S D J Med, V51, P379; Damoiseaux RAMJ, 2000, BRIT MED J, V320, P350, DOI 10.1136/bmj.320.7231.350; DelMar C, 1997, BRIT MED J, V314, P1526, DOI 10.1136/bmj.314.7093.1526; Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; GATES GA, 1989, ANN OTO RHINOL LARYN, V98, P2, DOI 10.1177/00034894890981S202; HOPPE JE, 1994, INFECTION, V22, P178, DOI 10.1007/BF01716698; Kudo F, 1998, Nihon Jibiinkoka Gakkai Kaiho, V101, P1075; Little P, 1997, BRIT MED J, V315, P350; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; Office of Population Censuses and Surveys, 1994, MORB STAT GEN PRACT; PITTS J, 1987, PRACTITIONER, V231, P1232; ROGERS M, 1992, PAED NURS, P4; RUUSKANEN O, 1994, PEDIATR INFECT DIS J, V13, pS23, DOI 10.1097/00006454-199401001-00006; SCHWARTZ RH, 1981, JAMA-J AM MED ASSOC, V245, P2057, DOI 10.1001/jama.245.20.2057; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; WILKIN D, 1992, MEASURES NEED OUTCOM	28	256	259	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2001	322	7282					336	342		10.1136/bmj.322.7282.336	http://dx.doi.org/10.1136/bmj.322.7282.336			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159657	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000167050000029
J	Weber, W; Riesen, S; Siegmann, HC				Weber, W; Riesen, S; Siegmann, HC			Magnetization precession by hot spin injection	SCIENCE			English	Article							MAGNETORESISTANCE; MULTILAYER; POLARIZATION; EXCITATIONS; INTERFACE; REVERSAL; MOTION	As electrons are injected at various energies into ferromagnetic material with their spin polarization vector perpendicular to the axis of the magnetization, we observe precessional motion of the spin polarization on the femtosecond time scale. Because of angular momentum conservation, the magnetization vector must process as well. We show that spin injection will generate the precessional magnetization reversal in nanosized ferromagnetic bits. At reasonable injected current densities this occurs on the picosecond time scale.	Stanford Univ, Stanford Linear Accelerator Ctr, Stanford, CA 94309 USA; Swiss Fed Inst Technol, Festkorperphys Lab, CH-8093 Zurich, Switzerland	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Swiss Federal Institutes of Technology Domain; ETH Zurich	Weber, W (corresponding author), Swiss Fed Inst Technol, Festkorperphys Lab, CH-8093 Zurich, Switzerland.	weber@solid.phys.ethz.ch						Acremann Y, 2000, SCIENCE, V290, P492, DOI 10.1126/science.290.5491.492; Aeschlimann M, 1997, PHYS REV LETT, V79, P5158, DOI 10.1103/PhysRevLett.79.5158; Back CH, 1999, SCIENCE, V285, P864, DOI 10.1126/science.285.5429.864; Bazaliy YB, 1998, PHYS REV B, V57, pR3213, DOI 10.1103/PhysRevB.57.R3213; BERGER L, 1995, IEEE T MAGN, V31, P3871, DOI 10.1109/20.489800; Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; CLONCZEWSKI JC, 1996, J MAGN MAGN MATER, V159, pL1; COLAVITA E, 1982, PHYS REV B, V25, P2490, DOI 10.1103/PhysRevB.25.2490; De Teresa JM, 1999, SCIENCE, V286, P507, DOI 10.1126/science.286.5439.507; Garcia N, 2000, PHYS REV LETT, V85, P3053, DOI 10.1103/PhysRevLett.85.3053; Heide C, 2000, EUROPHYS LETT, V50, P271, DOI 10.1209/epl/i2000-00265-7; HEIDE C, 2000, CONDMAT0005064; Katine JA, 2000, PHYS REV LETT, V84, P3149, DOI 10.1103/PhysRevLett.84.3149; Moodera JS, 1999, PHYS REV LETT, V83, P3029, DOI 10.1103/PhysRevLett.83.3029; Myers EB, 1999, SCIENCE, V285, P867, DOI 10.1126/science.285.5429.867; Oberli D, 1998, PHYS REV LETT, V81, P4228, DOI 10.1103/PhysRevLett.81.4228; PIPPARD WH, 2000, PHYS REV LETT, V84, P971; Rezende SM, 2000, PHYS REV LETT, V84, P4212, DOI 10.1103/PhysRevLett.84.4212; RIESEN S, 2001, THESIS ETH ZURICH; Sharma M, 1999, PHYS REV LETT, V82, P616, DOI 10.1103/PhysRevLett.82.616; SIEGMANN HC, 1995, J MAGN MAGN MATER, V151, pL8, DOI 10.1016/0304-8853(95)00602-8; Siegmann HC, 1996, PHYS ATOMS, P221; Sun JZ, 2000, PHYS REV B, V62, P570, DOI 10.1103/PhysRevB.62.570; Sun JZ, 1999, J MAGN MAGN MATER, V202, P157, DOI 10.1016/S0304-8853(99)00289-9; Tsoi M, 2000, NATURE, V406, P46, DOI 10.1038/35017512; Tsoi M, 1998, PHYS REV LETT, V80, P4281, DOI 10.1103/PhysRevLett.80.4281; Waintal X, 2000, PHYS REV B, V62, P12317, DOI 10.1103/PhysRevB.62.12317; Weber W, 1999, NEW J PHYS, V1, DOI 10.1088/1367-2630/1/1/309; Wegrowe JE, 1999, EUROPHYS LETT, V45, P626, DOI 10.1209/epl/i1999-00213-1	29	100	102	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	2001	291	5506					1015	1018		10.1126/science.1057430	http://dx.doi.org/10.1126/science.1057430			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161209				2022-12-28	WOS:000166860100037
J	Burch, JL; Mende, SB; Mitchell, DG; Moore, TE; Pollock, CJ; Reinisch, BW; Sandel, BR; Fuselier, SA; Gallagher, DL; Green, JL; Perez, JD; Reiff, PH				Burch, JL; Mende, SB; Mitchell, DG; Moore, TE; Pollock, CJ; Reinisch, BW; Sandel, BR; Fuselier, SA; Gallagher, DL; Green, JL; Perez, JD; Reiff, PH			Views of Earth's magnetosphere with the IMAGE satellite	SCIENCE			English	Article							RING CURRENT; MODEL	The IMAGE spacecraft uses photon and neutral atom imaging and radio sounding techniques to provide global images of Earth's inner magnetosphere and upper atmosphere. Auroral imaging at ultraviolet wavelengths shows that the proton aurora is displaced equatorward with respect to the electron aurora and that discrete auroral forms at higher Latitudes are caused almost completely by electrons. Energetic neutral atom imaging of ions injected into the inner magnetosphere during magnetospheric disturbances shows a strong energy-dependent drift that Leads to the formation of the ring current by ions in the several tens of kiloelectron volts energy range. Ultraviolet imaging of the plasmasphere has revealed two unexpected features-a premidnight trough region and a dayside shoulder region-and has confirmed the 30-year-old theory of the formation of a plasma tail extending from the duskside plasmasphere toward the magnetopause.	SW Res Inst, San Antonio, TX 78228 USA; Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Univ Massachusetts, Ctr Atmospher Res, Lowell, MA 01854 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Lockheed Martin Adv Technol Ctr, Palo Alto, CA 94304 USA; NASA, George C Marshall Space Flight Ctr, Huntsville, AL 35812 USA; Auburn Univ, Dept Phys, Auburn, AL 36849 USA; Rice Univ, Dept Phys & Astron, Houston, TX 77005 USA	Southwest Research Institute; University of California System; University of California Berkeley; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Massachusetts System; University of Massachusetts Lowell; University of Arizona; Lockheed Martin; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; Auburn University System; Auburn University; Rice University	Burch, JL (corresponding author), SW Res Inst, PO Drawer 28510, San Antonio, TX 78228 USA.		Moore, Thomas Earle/D-4675-2012; Mitchell, Donald G/H-4601-2016; Reiff, Patricia H/D-2564-2014	Moore, Thomas Earle/0000-0002-3150-1137; Mitchell, Donald G/0000-0003-1960-2119; Reiff, Patricia H/0000-0002-8043-5682				Akasofu S.-I., 1968, POLAR MAGNETOSPHERIC; ANGER CD, 1987, GEOPHYS RES LETT, V14, P387, DOI 10.1029/GL014i004p00387; BAKER DN, 1993, J GEOPHYS RES-SPACE, V98, P3815, DOI 10.1029/92JA02475; Burch JL, 2000, SPACE SCI REV, V91, P1, DOI 10.1023/A:1005245323115; CARPENTER DL, 1966, J GEOPHYS RES, V71, P693, DOI 10.1029/JZ071i003p00693; CHAPPELL CR, 1970, J GEOPHYS RES, V75, P3848, DOI 10.1029/JA075i019p03848; CHEN AJ, 1975, J GEOPHYS RES, V80, P968, DOI 10.1029/JA080i007p00968; FRANK LA, 1988, REV GEOPHYS, V26, P249, DOI 10.1029/RG026i002p00249; Galand M, 1999, J GEOPHYS RES-SPACE, V104, P27973, DOI 10.1029/1999JA900374; Germany GA, 1997, GEOPHYS RES LETT, V24, P995, DOI 10.1029/97GL00864; GREBOWSKY JM, 1970, J GEOPHYS RES, V75, P4329, DOI 10.1029/JA075i022p04329; HARDY DA, 1989, J GEOPHYS RES, V94, P370, DOI 10.1029/JA094iA01p00370; Henderson MG, 2000, ADV SPACE RES, V25, P2407, DOI 10.1016/S0273-1177(99)00530-X; Immel TJ, 2000, J ATMOS SOL-TERR PHY, V62, P47, DOI 10.1016/S1364-6826(99)00082-6; Jorgensen AM, 2000, J GEOPHYS RES-SPACE, V105, P18753, DOI 10.1029/1999JA000445; Meier RR, 1998, J GEOPHYS RES-SPACE, V103, P17505, DOI 10.1029/98JA01175; Mende SB, 2000, SPACE SCI REV, V91, P243, DOI 10.1023/A:1005271728567; Mende SB, 2000, SPACE SCI REV, V91, P287, DOI 10.1023/A:1005292301251; Mende SB, 2000, SPACE SCI REV, V91, P271, DOI 10.1023/A:1005227915363; Mitchell DG, 2000, SPACE SCI REV, V91, P67, DOI 10.1023/A:1005207308094; Moore TE, 2000, SPACE SCI REV, V91, P155, DOI 10.1023/A:1005211509003; MURPHREE JS, 1994, SPACE SCI REV, V70, P421, DOI 10.1007/BF00756880; Perez JD, 2000, SPACE SCI REV, V91, P421, DOI 10.1023/A:1005277307611; Pollock CJ, 2000, SPACE SCI REV, V91, P113, DOI 10.1023/A:1005259324933; RAIRDEN RL, 1986, J GEOPHYS RES, V91, P3613, DOI 10.1029/JA091iA12p13613; Reinisch BW, 2000, SPACE SCI REV, V91, P319, DOI 10.1023/A:1005252602159; ROELOF EC, 1985, J GEOPHYS RES-SPACE, V90, P991, DOI 10.1029/JA090iA11p10991; ROELOF EC, 1987, GEOPHYS RES LETT, V14, P652, DOI 10.1029/GL014i006p00652; Roelof EC, 2000, SPACE SCI REV, V91, P437, DOI 10.1023/A:1005281424449; Sandel BR, 2000, SPACE SCI REV, V91, P197, DOI 10.1023/A:1005263510820; TSURUTANI BT, 1997, GEOPHYSICAL MONOGRAP, V98; WILLIAMS DJ, 1987, REV GEOPHYS, V25, P570, DOI 10.1029/RG025i003p00570	32	131	132	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					619	624		10.1126/science.291.5504.619	http://dx.doi.org/10.1126/science.291.5504.619			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158668				2022-12-28	WOS:000166616000034
J	Clutton-Brock, TH; Brotherton, PNM; Russell, AF; O'Riain, MJ; Gaynor, D; Kansky, R; Griffin, A; Manser, M; Sharpe, L; McIlrath, GM; Small, T; Moss, A; Monfort, S				Clutton-Brock, TH; Brotherton, PNM; Russell, AF; O'Riain, MJ; Gaynor, D; Kansky, R; Griffin, A; Manser, M; Sharpe, L; McIlrath, GM; Small, T; Moss, A; Monfort, S			Cooperation, control, and concession in meerkat groups	SCIENCE			English	Article							SURICATA-SURICATTA; ANIMAL SOCIETIES	"Limited control" models of reproductive skew in cooperative societies suggest that the frequency of breeding by subordinates is determined by the outcome of power struggles with dominants. In contrast, "optimal skew" models suggest that dominants have full control of subordinate reproduction and allow subordinates to breed only when this serves to retain subordinates' assistance with rearing dominants' own Litters. The results of our 7-year field study of cooperative meerkats, Suricata suricatta, support the predictions of Limited control models and provide no indication that dominant females grant reproductive concessions to subordinates to retain their assistance with future breeding attempts.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Pretoria, Mammal Res Inst, ZA-0002 Pretoria, South Africa; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Smithsonian Inst, Conservat & Res Ctr, Front Royal, VA 22630 USA	University of Cambridge; University of Pretoria; University of Edinburgh; Smithsonian Institution	Clutton-Brock, TH (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.		Griffin, Ashleigh/C-6244-2014	Griffin, Ashleigh/0000-0001-7674-9825; O'Riain, M. Justin/0000-0001-5233-8327				BROTHERTON PNM, IN PRESS BEHAV ECOL; Clutton-Brock TH, 1998, P ROY SOC B-BIOL SCI, V265, P185, DOI 10.1098/rspb.1998.0281; Clutton-Brock TH, 1998, P ROY SOC B-BIOL SCI, V265, P2291, DOI 10.1098/rspb.1998.0573; Clutton-Brock TH, 1998, TRENDS ECOL EVOL, V13, P288, DOI 10.1016/S0169-5347(98)01402-5; Clutton-Brock TH, 1999, J ANIM ECOL, V68, P672, DOI 10.1046/j.1365-2656.1999.00317.x; CLUTTONBROCK TH, UNPUB; Doolan SP, 1999, ETHOLOGY, V105, P851, DOI 10.1046/j.1439-0310.1999.00461.x; GRIFFIN AS, 1999, THESIS EDINBURGH U; KELLER L, 1994, TRENDS ECOL EVOL, V9, P98, DOI 10.1016/0169-5347(94)90204-6; Koenig WD, 1998, AM NAT, V151, P243, DOI 10.1086/286115; MONFORT SL, 1991, J REPROD FERTIL, V91, P155, DOI 10.1530/jrf.0.0910155; MOSS A, 2000, THESIS G MASON U FAI; ORIAIN MJ, IN PRESS BEHAV ECOL; Reeve HK, 1998, BEHAV ECOL, V9, P267, DOI 10.1093/beheco/9.3.267; [No title captured]	15	253	256	5	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					478	481		10.1126/science.291.5503.478	http://dx.doi.org/10.1126/science.291.5503.478			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161200				2022-12-28	WOS:000166487500039
J	Ihee, H; Lobastov, VA; Gomez, UM; Goodson, BM; Srinivasan, R; Ruan, CY; Zewail, AH				Ihee, H; Lobastov, VA; Gomez, UM; Goodson, BM; Srinivasan, R; Ruan, CY; Zewail, AH			Direct imaging of transient molecular structures with ultrafast diffraction	SCIENCE			English	Article							ELECTRON-DIFFRACTION; TIME RESOLUTION; DYNAMICS; FEMTOCHEMISTRY; ENERGY	Ultrafast electron diffraction (UED) has been developed to study transient structures in complex chemical reactions initiated with femtosecond laser pulses. This direct imaging of reactions was achieved using our third-generation apparatus equipped with an electron pulse (1.07 +/- 0.27 picoseconds) source, a charge-coupled device camera, and a mass spectrometer. Two prototypical gas-phase reactions were studied: the nonconcerted elimination reaction of a haloethane, wherein the structure of the intermediate was determined, and the ring opening of a cyclic hydrocarbon containing no heavy atoms. These results demonstrate the vastly improved sensitivity, resolution, and versatility of UED for studying ultrafast structural dynamics in complex molecular systems.	CALTECH, Arthur Amos Noyes Lab Chem Phys, Lab Mol Sci, Pasadena, CA 91125 USA	California Institute of Technology	Zewail, AH (corresponding author), CALTECH, Arthur Amos Noyes Lab Chem Phys, Lab Mol Sci, Pasadena, CA 91125 USA.		Ihee, Hyotcherl/C-1614-2011					Cao J, 1998, CHEM PHYS LETT, V290, P1, DOI 10.1016/S0009-2614(98)00520-X; Cao JM, 1999, P NATL ACAD SCI USA, V96, P338, DOI 10.1073/pnas.96.2.338; Castleman AW, 1998, J PHYS CHEM A, V102, P4021; Chin AH, 1999, PHYS REV LETT, V83, P336, DOI 10.1103/PhysRevLett.83.336; DANTUS M, 1994, J PHYS CHEM-US, V98, P2782, DOI 10.1021/j100062a011; Fuss W, 1996, CHEM PHYS LETT, V262, P675, DOI 10.1016/S0009-2614(96)01149-9; Hargittai I., 1988, STEREOCHEMICAL APPL; HEDBERG L, 1993, J MOL SPECTROSC, V160, P117, DOI 10.1006/jmsp.1993.1162; Helliwell J. R., 1997, TIME RESOLVED DIFFRA; Ihee H, 1997, CHEM PHYS LETT, V281, P10, DOI 10.1016/S0009-2614(97)01167-6; IHEE H, UNPUB; ISCHENKO AA, 1993, J MOL STRUCT, V300, P115, DOI 10.1016/0022-2860(93)87011-W; Karle J, 2000, STRUCT CHEM, V11, P91, DOI 10.1023/A:1009297222400; Lobastov VA, 1998, REV SCI INSTRUM, V69, P2633, DOI 10.1063/1.1148991; OBERHAMMER H, 1969, J AM CHEM SOC, V91, P10, DOI 10.1021/ja01029a002; PANCHENKO YN, 1992, STRUCT CHEM, V3, P15, DOI 10.1007/BF00671976; SKELL PS, 1984, ACCOUNTS CHEM RES, V17, P160, DOI 10.1021/ar00101a002; SUNDSTROM V, 1997, FEMTOCHEMISTRY FEMTO; Tanimura Y, 1999, P NATL ACAD SCI USA, V96, P8823, DOI 10.1073/pnas.96.16.8823; THOMASSEN H, 1992, J AM CHEM SOC, V114, P2810, DOI 10.1021/ja00034a008; TRAETTEBERG M, 1968, ACTA CHEM SCAND, V22, P2294; Williamson JC, 1997, NATURE, V386, P159, DOI 10.1038/386159a0; WILLIAMSON JC, 1993, CHEM PHYS LETT, V209, P10, DOI 10.1016/0009-2614(93)87193-7; WILLIAMSON S, 1984, PHYS REV LETT, V52, P2364, DOI 10.1103/PhysRevLett.52.2364; Zeng XL, 1999, PHYS REV B, V59, P14907, DOI 10.1103/PhysRevB.59.14907; ZEWAIL AH, 1999, PREX NOBEL, P110; Zhong D, 1997, J AM CHEM SOC, V119, P5978, DOI 10.1021/ja9710013	27	412	424	7	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					458	462		10.1126/science.291.5503.458	http://dx.doi.org/10.1126/science.291.5503.458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161194				2022-12-28	WOS:000166487500033
J	Seo, SB; McNamara, P; Heo, S; Turner, A; Lane, WS; Chakravarti, D				Seo, SB; McNamara, P; Heo, S; Turner, A; Lane, WS; Chakravarti, D			Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein	CELL			English	Article							ACTIVATING FACTOR-I; PROTEIN PHOSPHATASE 2A; ACETYLTRANSFERASE ACTIVITY; STIMULATES TRANSCRIPTION; NUCLEAR PHOSPHOPROTEIN; MYELOID LEUKEMOGENESIS; CHROMATIN STRUCTURE; PUTATIVE ONCOGENE; COACTIVATORS P300; DNA-BINDING	Acetylation of histones by p300/CBP and PCAF is considered to be a critical step in transcriptional regulation. In order to understand the role of cellular activities that modulate histone acetylation and transcription, we have purified and characterized a multiprotein cellular complex that potently inhibits the histone acetyltransferase activity of p300/CBP and PCAF. We have mapped a novel acetyltransferase-inhibitory domain of this INHAT (inhibitor of acetyltransferases) complex that binds to histones and masks them from being acetyltransferase substrates. Endogenous INHAT subunits, which include the Set/TAF-I beta oncoprotein, associate with chromatin in vivo and can block coactivator-mediated transcription when transfected in cells. We propose that histone masking by INHAT plays a regulatory role in chromatin modification and serves as a novel mechanism of transcriptional regulation.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Harvard Univ, Harvard Microchem & Prot Facil, Cambridge, MA 02138 USA	University of Pennsylvania; Harvard University	Chakravarti, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	debu@pharm.med.upenn.edu		Chakravarti, Debabrata/0000-0001-8446-8599	NIDDK NIH HHS [R01-DK57079-01A1, P30-DK19925, R01 DK057079] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019925, R01DK057079] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 2000, GENE DEV, V14, P121; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; Kadkol SS, 1999, NAT MED, V5, P275, DOI 10.1038/6488; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Nagata K, 1998, EXP CELL RES, V240, P274, DOI 10.1006/excr.1997.3930; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Saito S, 1999, BIOCHEM BIOPH RES CO, V259, P471, DOI 10.1006/bbrc.1999.0790; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WALENSKY LD, 1993, CANCER RES, V53, P4720; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000	45	386	397	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					119	130		10.1016/S0092-8674(01)00196-9	http://dx.doi.org/10.1016/S0092-8674(01)00196-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163245	Bronze			2022-12-28	WOS:000166882300012
J	Chinn, S; Rona, RJ				Chinn, S; Rona, RJ			Prevalence and trends in overweight and obesity in three cross sectional studies of British children, 1974-94	BRITISH MEDICAL JOURNAL			English	Article							GROWTH; HEALTH	Objectives To report trends in overweight and obesity, defined by new internationally agreed cut-off points, in children in the United Kingdom. Design Three independent cross sectional surveys. Setting Primary schools in England and Scotland. Participants 10 414 boys and 9737 girls in England and 5385 boys and 5219 girls in Scotland aged 4 to 11 years. Main outcome measures Prevalence and change in prevalence of overweight and obesity as defined by the international obesity; task force, in 1974, 1984, and 1994, for each ses and country. Results Little change was found in the prevalence of overweight or obesity from 1974 to 1984. From 1984 lo 1994 overweight increased from 5.4% to 9.0% in English boys (increase 3.6%, 95% confidence interval 2.3% to 5.0%) and from 6.4% to 10.0% in Scottish boys (3.6%, 1.9% to 5.4%). Values for girls were 9.3% to 13.5% (4.1%, 2.4% to 5.9%) and 10.4% to 15.8% (5.4%, 3.2% to 7.6%) respectively. The prevalence of obesity increased correspondingly, reaching 1.7% (English boys), 2.1% (Scottish boys) 2.6% (English girls), and 3.2% (Scottish girls). Conclusion These results form a base from which trends can be monitored. The rising trends are likely; to be reflected in increases in adult obesity and associated morbidity.	Kings Coll London, Dept Publ Hlth Sci, London SE1 3QD, England	University of London; King's College London	Chinn, S (corresponding author), Kings Coll London, Dept Publ Hlth Sci, London SE1 3QD, England.	sue.chinn@kcl.ac.uk	Rona, Roberto J/C-2348-2011	Rona, Roberto/0000-0003-3739-5571				Chinn S, 1998, ARCH DIS CHILD, V78, P513, DOI 10.1136/adc.78.6.513; CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Hughes JM, 1997, ARCH DIS CHILD, V76, P182, DOI 10.1136/adc.76.3.182; PECKHAM CS, 1983, BMJ-BRIT MED J, V286, P1237, DOI 10.1136/bmj.286.6373.1237; Power C, 1997, INT J OBESITY, V21, P507, DOI 10.1038/sj.ijo.0800454; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; Reilly JJ, 1999, BRIT MED J, V319, P1039, DOI 10.1136/bmj.319.7216.1039; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005	10	363	380	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					24	26		10.1136/bmj.322.7277.24	http://dx.doi.org/10.1136/bmj.322.7277.24			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141148	Bronze, Green Published			2022-12-28	WOS:000166341400020
J	Siepmann, M; Kirch, W				Siepmann, M; Kirch, W			Drug points - Tachycardia associated with moxifloxacin	BRITISH MEDICAL JOURNAL			English	Letter							SAFETY PROFILE; GREPAFLOXACIN											Balfour JAB, 2000, DRUGS, V59, P115; JANSSEN MCH, 1995, J HUM HYPERTENS, V9, P363; Lode H, 1999, CLIN THER, V21, P61, DOI 10.1016/S0149-2918(00)88268-5; Stahlmann R, 1997, J ANTIMICROB CHEMOTH, V40, P83, DOI 10.1093/jac/40.suppl_1.83; TAKAYAMA S, 1995, J TOXICOL ENV HEALTH, V45, P1, DOI 10.1080/15287399509531978	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					23	23		10.1136/bmj.322.7277.23	http://dx.doi.org/10.1136/bmj.322.7277.23			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141146	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000166341400019
J	Monnin, E; Indermuhle, A; Dallenbach, A; Fluckiger, J; Stauffer, B; Stocker, TF; Raynaud, D; Barnola, JM				Monnin, E; Indermuhle, A; Dallenbach, A; Fluckiger, J; Stauffer, B; Stocker, TF; Raynaud, D; Barnola, JM			Atmospheric CO2 concentrations over the last glacial termination	SCIENCE			English	Article							POLAR ICE CORES; GREENLAND ICE; CLIMATE-CHANGE; ANTARCTICA; HOLOCENE; RECORD; DEGLACIATION; INCREASE; PERIOD; EVENT	A record of atmospheric carbon dioxide (CO2) concentration during the transition from the Last Glacial Maximum to the Holocene, obtained from the Dome Concordia, Antarctica, ice care, reveals that an increase of 76 parts per million by volume occurred over a period of 6000 years in four clearly distinguishable intervals. The close correlation between CO2 concentration and Antarctic temperature indicates that the Southern Ocean played an important role in causing the CO2 increase. However, the similarity of changes in CO2 concentration and variations of atmospheric methane concentration suggests that processes in the tropics and in the Northern Hemisphere, where the main sources for methane are Located, also had substantial effects on atmospheric CO2 concentrations.	Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; CNRS, Lab Glaciol & Geophys Environm, F-38402 St Martin Dheres, France	University of Bern; Centre National de la Recherche Scientifique (CNRS)	Monnin, E (corresponding author), Univ Bern, Inst Phys, Sidlerstr 5, CH-3012 Bern, Switzerland.		raynaud, dominique/ABG-4718-2020; Raynaud, Dominique/H-9626-2016; Fluckiger, Jacqueline/G-3457-2011; Stocker, Thomas/B-1273-2013					ANKLIN M, 1995, TELLUS B, V47, P461, DOI 10.1034/j.1600-0889.47.issue4.6.x; Anklin M, 1997, J GEOPHYS RES-OCEANS, V102, P26539, DOI 10.1029/97JC00182; BARNOLA JM, 1995, TELLUS B, V47, P264, DOI 10.1034/j.1600-0889.47.issue1.22.x; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Blunier T, 1997, GEOPHYS RES LETT, V24, P2683, DOI 10.1029/97GL02658; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Chappellaz J, 1997, J GEOPHYS RES-ATMOS, V102, P15987, DOI 10.1029/97JD01017; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Etheridge DM, 1996, J GEOPHYS RES-ATMOS, V101, P4115, DOI 10.1029/95JD03410; Fischer H, 1999, SCIENCE, V283, P1712, DOI 10.1126/science.283.5408.1712; Indermuhle A, 2000, GEOPHYS RES LETT, V27, P735, DOI 10.1029/1999GL010960; Indermuhle A, 1999, NATURE, V398, P121, DOI 10.1038/18158; JOUZEL J, 1995, CLIM DYNAM, V11, P151, DOI 10.1007/BF00223498; JOUZEL J, UNPUB; KEELING CD, 2000, TRENDS COMPENDIUM DA; Marchal O, 1999, CLIM DYNAM, V15, P341, DOI 10.1007/s003820050286; NEFTEL A, 1988, NATURE, V331, P609, DOI 10.1038/331609a0; NEFTEL A, 1985, NATURE, V315, P45, DOI 10.1038/315045a0; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Rothlisberger R, 2000, J GEOPHYS RES-ATMOS, V105, P20565, DOI 10.1029/2000JD900264; SCHWANDER J, UNPUB; Smith HJ, 1997, J GEOPHYS RES-OCEANS, V102, P26577, DOI 10.1029/97JC00163; Smith HJ, 1997, GEOPHYS RES LETT, V24, P1, DOI 10.1029/96GL03700; SOWERS T, 1995, SCIENCE, V269, P210, DOI 10.1126/science.269.5221.210; STAFFELBACH T, 1991, TELLUS B, V43, P91, DOI 10.1034/j.1600-0889.1991.t01-1-00003.x; Stauffer B, 1998, NATURE, V392, P59, DOI 10.1038/32133; Tschumi J, 2000, J GLACIOL, V46, P45, DOI 10.3189/172756500781833359	27	866	907	11	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					112	114		10.1126/science.291.5501.112	http://dx.doi.org/10.1126/science.291.5501.112			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141559				2022-12-28	WOS:000166259100045
J	Amico, G; Aizen, MA				Amico, G; Aizen, MA			Ecology - Mistletoe seed dispersal by a marsupial	NATURE			English	Article							TEMPERATE		Univ Nacl Comahue, CRUB, Lab Ecotono, RA-8400 Bariloche, Rio Negro, Argentina	Universidad Nacional del Comahue	Amico, G (corresponding author), Univ Nacl Comahue, CRUB, Lab Ecotono, Unidad Postal Univ, RA-8400 Bariloche, Rio Negro, Argentina.		Amico, Guillermo C c/HGD-9402-2022	Aizen, Marcelo/0000-0001-9079-9749; Amico, Guillermo/0000-0002-3709-3111				Armesto JJ, 1998, SCIENCE, V282, P1271, DOI 10.1126/science.282.5392.1271; AXELROD DI, 1991, REV CHIL HIST NAT, V64, P413; Goin F. J., 1997, VERTEBRATE PALEONTOL, P185; Kalin Arroyo M. T., 1996, High-latitude rainforests and associated ecosystems of the West Coast of the Americas: climate, hydrology, ecology and conservation., P134; MARSHALL L.G., 1978, MAMMALIAN SPECIES, V99, P1; REID N, 1991, AUST J ECOL, V16, P457, DOI 10.1111/j.1442-9993.1991.tb01075.x; Reid Nick, 1995, P285; Salle G., 1983, BIOL MISTLETOES, P145; SARGENT S, 1995, FUNCT ECOL, V9, P197, DOI 10.2307/2390565; Springer MS, 1998, P ROY SOC B-BIOL SCI, V265, P2381, DOI 10.1098/rspb.1998.0587; Tambussi Claudia, 1996, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V30, P245; Van der Pijl L, 1982, PRINCIPLES DISPERSAL, V214	12	118	126	2	41	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					929	930		10.1038/35050170	http://dx.doi.org/10.1038/35050170			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140671				2022-12-28	WOS:000165951100037
J	Buckling, A; Kassen, R; Bell, G; Rainey, PB				Buckling, A; Kassen, R; Bell, G; Rainey, PB			Disturbance and diversity in experimental microcosms	NATURE			English	Article							EXPERIMENTAL EVOLUTION; MAINTENANCE; COMPETITION; SELECTION; PEAKS	External agents of mortality (disturbances) occur over a wide range of scales of space and time, and are believed to have large effects on species diversity. The "intermediate disturbance hypothesis''(1-3), which proposes maximum diversity at intermediate frequencies of disturbance, has received support from both field(4,5) and laboratory(6,7) studies. Coexistence of species at intermediate frequencies of disturbance is thought to require trade-offs between competitive ability and disturbance tolerance(8), and a metapopulation structure, with disturbance affecting only a few patches at any given time(9-11). However, a unimodal relationship can also be generated by global disturbances that affect all patches simultaneously, provided that the environment contains spatial niches to which different species are adapted(12). Here we report the results of tests of this model using both isogenic and diverse populations of the bacterium Pseudomonas fluorescens. In both cases, a unimodal relationship between diversity and disturbance frequency was generated in heterogeneous, but not in homogeneous, environments. The cause of this relationship is competition among niche-specialist genotypes, which maintains diversity at intermediate disturbance, but not at high or low disturbance. Our results show that disturbance can modulate the effect of spatial heterogeneity on biological diversity in natural environments.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; McGill Univ, Redpath Museum, Montreal, PQ H3A 2K6, Canada	University of Oxford; McGill University; McGill University	Buckling, A (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	angus.buckling@plant-sciences.ox.ac.uk	Rainey, Paul/A-3207-2008	Rainey, Paul/0000-0003-0879-5795; Buckling, Angus/0000-0003-1170-4604				ATWOOD KC, 1951, COLD SPRING HARB SYM, V16, P345, DOI 10.1101/SQB.1951.016.01.026; Ayala F.J., 1974, Annual Rev Ecol Syst, V5, P115, DOI 10.1146/annurev.es.05.110174.000555; Bell GAC, 1997, HEREDITY, V78, P490, DOI 10.1038/sj.hdy.6881220; Chesson P, 1997, AM NAT, V150, P519, DOI 10.1086/286080; Collins SL, 1998, SCIENCE, V280, P745, DOI 10.1126/science.280.5364.745; COLLINS SL, 1987, ECOLOGY, V68, P1243, DOI 10.2307/1939208; CONNELL JH, 1978, SCIENCE, V199, P1302, DOI 10.1126/science.199.4335.1302; Crawley M.J., 1993, GLIM ECOLOGISTS; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; Floder S, 1999, LIMNOL OCEANOGR, V44, P1114; GAEDEKE A, 1986, OECOLOGIA, V71, P25, DOI 10.1007/BF00377315; Gause G. F., 1934, STRUGGLE EXISTENCE; GRIME JP, 1973, J ENVIRON MANAGE, V1, P151; Haldane JB., 1990, CAUSES EVOLUTION; Huston M.A., 1994, BIOL DIVERSITY; Kassen R, 2000, NATURE, V406, P508, DOI 10.1038/35020060; KORONA R, 1994, P NATL ACAD SCI USA, V91, P9037, DOI 10.1073/pnas.91.19.9037; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LEVENE H, 1953, AM NAT, V87, P331, DOI 10.1086/281792; LEVIN SA, 1974, P NATL ACAD SCI USA, V71, P2744, DOI 10.1073/pnas.71.7.2744; MILCHUNAS DG, 1993, ECOL MONOGR, V63, P327, DOI 10.2307/2937150; MILTON WEJ, 1947, J ECOL, V35, P65, DOI 10.2307/2256500; PETRAITIS PS, 1989, Q REV BIOL, V64, P393, DOI 10.1086/416457; Rainey PB, 2000, TRENDS ECOL EVOL, V15, P243, DOI 10.1016/S0169-5347(00)01871-1; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0; SLATKIN M, 1974, ECOLOGY, V55, P128, DOI 10.2307/1934625; SOUSA WP, 1979, ECOLOGY, V60, P1225, DOI 10.2307/1936969; WEIDER LJ, 1992, J EVOLUTION BIOL, V5, P505, DOI 10.1046/j.1420-9101.1992.5030505.x	30	192	199	1	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					961	964		10.1038/35050080	http://dx.doi.org/10.1038/35050080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140680				2022-12-28	WOS:000165951100046
J	Griffin, TM; Kram, R				Griffin, TM; Kram, R			Biomechanics - Penguin waddling is not wasteful	NATURE			English	Article							LOCOMOTION; ENERGETICS; FORCE; SPEED; COST		Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Colorado, Dept Kinesiol & Appl Physiol, Boulder, CO 80309 USA	University of California System; University of California Berkeley; University of Colorado System; University of Colorado Boulder	Griffin, TM (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.	tmgriff@uclink4.berkeley.edu	Griffin, Timothy M./V-8838-2019	Griffin, Timothy M./0000-0001-8840-9940				CAVAGNA GA, 1975, J APPL PHYSIOL, V39, P174, DOI 10.1152/jappl.1975.39.1.174; CAVAGNA GA, 1963, J APPL PHYSIOL, V18, P1, DOI 10.1152/jappl.1963.18.1.1; CAVAGNA GA, 1977, AM J PHYSIOL, V233, pR243, DOI 10.1152/ajpregu.1977.233.5.R243; DEWASMES G, 1980, J APPL PHYSIOL, V49, P888, DOI 10.1152/jappl.1980.49.5.888; Farley CT, 1997, J EXP BIOL, V200, P2177; Gatesy SM, 1999, J MORPHOL, V240, P115, DOI 10.1002/(SICI)1097-4687(199905)240:2<115::AID-JMOR3>3.0.CO;2-Y; GATESY SM, 1991, J ZOOL, V224, P127, DOI 10.1111/j.1469-7998.1991.tb04794.x; KRAM R, 1990, NATURE, V346, P265, DOI 10.1038/346265a0; PINSHOW B, 1977, SCIENCE, V195, P592, DOI 10.1126/science.835018; Rall J A, 1985, Exerc Sport Sci Rev, V13, P33; Roberts TJ, 1998, J EXP BIOL, V201, P2745	11	92	92	29	193	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					929	929		10.1038/35050167	http://dx.doi.org/10.1038/35050167			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140670	Bronze			2022-12-28	WOS:000165951100036
J	Zhang, MS; Barash, S				Zhang, MS; Barash, S			Neuronal switching of sensorimotor transformations for antisaccades	NATURE			English	Article							LATERAL INTRAPARIETAL AREA; POSTERIOR PARIETAL CORTEX; SACCADE-RELATED ACTIVITY; SUPERIOR COLLICULUS; TASK; RESPONSES; MACAQUE; MONKEY	The influence of cognitive context on orienting behaviour can be explored using the mixed memory-prosaccade, memory-antisaccade task. A symbolic cue, such as the colour of a visual stimulus, instructs the subject to make a brief, rapid eye movement (a saccade) either towards the stimulus (prosaccade) or in the opposite direction (antisaccade)(1-3). Thus, the appropriate sensorimotor transformation must be switched on to execute the instructed task. Despite advances in our understanding of the neuronal processing of antisaccades(4-8), it remains unclear how the brain selects and computes the sensorimotor transformation leading to an antisaccade. Here we show that area LIP of the posterior parietal cortex is involved in these processes. LIP's population activity turns from the visual direction to the motor direction during memory-antisaccade trials. About one-third of the visual neurons in LIP produce a brisk, transient discharge in certain memory-antisaccade trials. We call this discharge 'paradoxical' because its timing is visual-like but its direction is motor. The paradoxical discharge shows, first, that switching occurs already at the level of visual cells, as previously proposed by Schlag-Rey and colleagues(5); and second, that this switching is accomplished very rapidly, within 50 ms from the arrival of the visual signals in LIP.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Barash, S (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.							Amador N, 1998, J NEUROPHYSIOL, V80, P1775, DOI 10.1152/jn.1998.80.4.1775; Andersen RA, 1987, HDB PHYSL 1, VV, P483; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; Barash S, 1998, J NEUROPHYSIOL, V79, P2766, DOI 10.1152/jn.1998.79.5.2766; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; Colby CL, 1996, J NEUROPHYSIOL, V76, P2841, DOI 10.1152/jn.1996.76.5.2841; COLBY CL, 1988, J COMP NEUROL, V269, P392, DOI 10.1002/cne.902690307; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Everling S, 1998, NEUROPSYCHOLOGIA, V36, P885, DOI 10.1016/S0028-3932(98)00020-7; Everling S, 2000, J NEUROSCI, V20, P387, DOI 10.1523/JNEUROSCI.20-01-00387.2000; Everling S, 1999, J NEUROSCI, V19, P2740; Everling S, 1998, EXP BRAIN RES, V118, P27, DOI 10.1007/s002210050252; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; GNADT JW, 1988, EXP BRAIN RES, V70, P216; Gottlieb J, 1999, NAT NEUROSCI, V2, P906, DOI 10.1038/13209; Grunewald A, 1999, J NEUROPHYSIOL, V82, P330, DOI 10.1152/jn.1999.82.1.330; HALLETT PE, 1978, VISION RES, V18, P1279, DOI 10.1016/0042-6989(78)90218-3; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1268; Horwitz GD, 1999, SCIENCE, V284, P1158, DOI 10.1126/science.284.5417.1158; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; SchlagRey M, 1997, NATURE, V390, P398, DOI 10.1038/37114; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; Thier P, 1998, J NEUROPHYSIOL, V80, P1713, DOI 10.1152/jn.1998.80.4.1713	24	198	200	0	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					971	975		10.1038/35050097	http://dx.doi.org/10.1038/35050097			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140683				2022-12-28	WOS:000165951100049
J	Kaul, S; Koo, HL; Jenkins, J; Rizzo, M; Rooney, T; Tallon, LJ; Feldblyum, T; Nierman, W; Benito, MI; Lin, XY; Town, CD; Venter, JC; Fraser, CM; Tabata, S; Nakamura, Y; Kaneko, T; Sato, S; Asamizu, E; Kato, T; Kotani, H; Sasamoto, S; Ecker, JR; Theologis, A; Federspiel, NA; Palm, CJ; Osborne, BI; Shinn, P; Conway, AB; Vysotskaia, VS; Dewar, K; Conn, L; Lenz, CA; Kim, CJ; Hansen, NF; Liu, SX; Buehler, E; Altafi, H; Sakano, H; Dunn, P; Lam, B; Pham, PK; Chao, Q; Nguyen, M; Yu, GX; Chen, HM; Southwick, A; Lee, JM; Miranda, M; Toriumi, MJ; Davis, RW; Wambutt, R; Murphy, G; Dusterhoft, A; Stiekema, W; Pohl, T; Entian, KD; Terryn, N; Volckaert, G; Salanoubat, M; Choisne, N; Rieger, M; Ansorge, W; Unseld, M; Fartmann, B; Valle, G; Artiguenave, F; Weissenbach, J; Quetier, F; Wilson, RK; de la Bastide, M; Sekhon, M; Huang, E; Spiegel, L; Gnoj, L; Pepin, K; Murray, J; Johnson, D; Habermann, K; Dedhia, N; Parnell, L; Preston, R; Hillier, L; Chen, E; Marra, M; Martienssen, R; McCombie, WR; Mayer, K; White, O; Bevan, M; Lemcke, K; Creasy, TH; Bielke, C; Haas, B; Haase, D; Maiti, R; Rudd, S; Peterson, J; Schoof, H; Frishman, D; Morgenstern, B; Zaccaria, P; Ermolaeva, M; Pertea, M; Quackenbush, J; Volfovsky, N; Wu, DY; Lowe, TM; Salzberg, SL; Mewes, HW; Rounsley, S; Bush, D; Subramaniam, S; Levin, I; Norris, S; Schmidt, R; Acarkan, A; Bancroft, I; Quetier, F; Brennicke, A; Eisen, JA; Bureau, T; Legault, BA; Le, QH; Agrawal, N; Yu, Z; Martienssen, R; Copenhaver, GP; Luo, S; Pikaard, CS; Preuss, D; Paulsen, IT; Sussman, M; Britt, AB; Selinger, DA; Pandey, R; Mount, DW; Chandler, VL; Jorgensen, RA; Pikaard, C; Juergens, G; Meyerowitz, EM; Theologis, A; Dangl, J; Jones, JDG; Chen, M; Chory, J; Somerville, MC				Kaul, S; Koo, HL; Jenkins, J; Rizzo, M; Rooney, T; Tallon, LJ; Feldblyum, T; Nierman, W; Benito, MI; Lin, XY; Town, CD; Venter, JC; Fraser, CM; Tabata, S; Nakamura, Y; Kaneko, T; Sato, S; Asamizu, E; Kato, T; Kotani, H; Sasamoto, S; Ecker, JR; Theologis, A; Federspiel, NA; Palm, CJ; Osborne, BI; Shinn, P; Conway, AB; Vysotskaia, VS; Dewar, K; Conn, L; Lenz, CA; Kim, CJ; Hansen, NF; Liu, SX; Buehler, E; Altafi, H; Sakano, H; Dunn, P; Lam, B; Pham, PK; Chao, Q; Nguyen, M; Yu, GX; Chen, HM; Southwick, A; Lee, JM; Miranda, M; Toriumi, MJ; Davis, RW; Wambutt, R; Murphy, G; Dusterhoft, A; Stiekema, W; Pohl, T; Entian, KD; Terryn, N; Volckaert, G; Salanoubat, M; Choisne, N; Rieger, M; Ansorge, W; Unseld, M; Fartmann, B; Valle, G; Artiguenave, F; Weissenbach, J; Quetier, F; Wilson, RK; de la Bastide, M; Sekhon, M; Huang, E; Spiegel, L; Gnoj, L; Pepin, K; Murray, J; Johnson, D; Habermann, K; Dedhia, N; Parnell, L; Preston, R; Hillier, L; Chen, E; Marra, M; Martienssen, R; McCombie, WR; Mayer, K; White, O; Bevan, M; Lemcke, K; Creasy, TH; Bielke, C; Haas, B; Haase, D; Maiti, R; Rudd, S; Peterson, J; Schoof, H; Frishman, D; Morgenstern, B; Zaccaria, P; Ermolaeva, M; Pertea, M; Quackenbush, J; Volfovsky, N; Wu, DY; Lowe, TM; Salzberg, SL; Mewes, HW; Rounsley, S; Bush, D; Subramaniam, S; Levin, I; Norris, S; Schmidt, R; Acarkan, A; Bancroft, I; Quetier, F; Brennicke, A; Eisen, JA; Bureau, T; Legault, BA; Le, QH; Agrawal, N; Yu, Z; Martienssen, R; Copenhaver, GP; Luo, S; Pikaard, CS; Preuss, D; Paulsen, IT; Sussman, M; Britt, AB; Selinger, DA; Pandey, R; Mount, DW; Chandler, VL; Jorgensen, RA; Pikaard, C; Juergens, G; Meyerowitz, EM; Theologis, A; Dangl, J; Jones, JDG; Chen, M; Chory, J; Somerville, MC		Ar Gen In	Analysis of the genome sequence of the flowering plant Arabidopsis thaliana	NATURE			English	Review							PRE-MESSENGER-RNA; SIGNAL-TRANSDUCTION; DNA; REGIONS; GENES; PROTEINS; LIGHT; MAIZE; PREDICTION; DIVERGENCE	The flowering plant Arabidopsis thaliana is an important model system for identifying genes and determining their functions. Here we report the analysis of the genomic sequence of Arabidopsis. The sequenced regions cover 115.4 megabases of the 125-megabase genome and extend into centromeric regions. The evolution of Arabidopsis involved a whole-genome duplication, followed by subsequent gene loss and extensive local gene duplications, giving rise to a dynamic genome enriched by lateral gene transfer from a cyanobacterial-like ancestor of the plastid. The genome contains 25,498 genes encoding proteins from 11,000 families, similar to the functional diversity of Drosophila and Caenorhabditis elegans - the other sequenced multicellular eukaryotes. Arabidopsis has many families of new proteins but also lacks several common protein families, indicating that the sets of common proteins have undergone differential expansion and contraction in the three multicellular eukaryotes. This is the first complete genome sequence of a plant and provides the foundations for more comprehensive comparison of conserved processes in all eukaryotes, identifying a wide range of plant-specific gene functions and establishing rapid systematic ways to identify genes for crop improvement.	Inst Genom Res, Rockville, MD 20850 USA; Kazusa DNA Res Inst, Kisarazu, Chiba 292, Japan; Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA; Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Exelixis Inc, San Francisco, CA 94083 USA; AGOWA Gmbh, D-12489 Berlin, Germany; John Innes Ctr, Norwich NR4 7UH, Norfolk, England; QIAGEN Gmbh, D-40724 Hilden, Germany; Plant Res Int, Greenomics, NL-6700 AA Wageningen, Netherlands; GATC Gmbh, D-78467 Constance, Germany; SRD Gmbh, D-61440 Oberursel, Germany; Univ Ghent VIB, Dept Plant Genet, B-9000 Ghent, Belgium; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Leuven, Belgium; Genoscope & CNRS FRE2231, F-91057 Evry, France; Genotype Gmbh, D-69259 Wilhemlsfeld, Germany; European Mol Biol Lab, Biochem Instrumentat Program, D-69117 Heidelberg, Germany; LION Biosci AG, D-69120 Heidelberg, Germany; MWG Biotech AG, D-69117 Ebersberg, Germany; Univ Padua, CRIBI, I-35131 Padua, Italy; Washington Univ, St Louis Sch Med, Washington Univ Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Lita Annenberg Hazen Genome Ctr, Cold Spring Harbor, NY 11724 USA; Celera Genomics, Foster City, CA 94494 USA; Cold Spring Harbor Lab, Plant Biol Grp, Cold Spring Harbor, NY 11724 USA; Max Planck Inst Biochem, GSF Forschungszentrum Umwelt & Gesundheit, Munich Informat Ctr Protein Sequences, D-82152 Munich, Germany; Inst Genomic Res, Rockville, MD 20850 USA; John Innes Ctr, Molec Genet Dept, Norwich NR4 7UH, Norfolk, England; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Cereon Genomics LLC, Cambridge, MA 02139 USA; Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany; John Innes Ctr, Brassicas & Oilseeds Res Dept, Norwich NR4 7UJ, England; Ctr Natl Sequencage, Genoscope, F-91057 Evry, France; Univ Ulm, Molek Bot, D-89069 Ulm, Germany; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Univ Chicago, Howard Hughes Med Inst, Chicago, IL USA; Washington Univ, Biol Dept, St Louis, MO 63130 USA; Univ Wisconsin, Biotechnol Ctr, Madison, WI 53706 USA; Univ Calif Davis, Sect Plant Biol, Davis, CA 95616 USA; Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; Univ Arizona, Dept Molec & Cell Biol, Tucson, AZ 85721 USA; ZMBP, Ctr Plant Molec Biol, Entwicklungsgenet, D-72076 Tubingen, Germany; Calif Inst Biol, Div Biol, Pasadena, CA 91125 USA; Univ N Carolina, Dept Biol, Coker Hall, Chapel Hill, NC 27599 USA; John Innes Ctr, Sainsbury Lab, Norwich NR4 7UI, Norfolk, England; Salk Inst Biol Studies, Howard Hughes Med Inst, Plant Biol Lab, La Jolla, CA 92037 USA; Carnegie Inst, Stanford, CA 94305 USA	J. Craig Venter Institute; Kazusa DNA Research Institute; University of Pennsylvania; United States Department of Agriculture (USDA); University of California System; University of California Berkeley; Stanford University; Salk Institute; Exelixis, Inc.; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; QIAGEN GmbH; Flanders Institute for Biotechnology (VIB); Ghent University; KU Leuven; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); University of Padua; Saint Louis University; Washington University (WUSTL); Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; J. Craig Venter Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Stanford University; Max Planck Society; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Ulm University; McGill University; Howard Hughes Medical Institute; University of Chicago; Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Davis; University of Arizona; University of Arizona; Eberhard Karls University of Tubingen; University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; Salk Institute; Carnegie Institution for Science		genomeanalysis@tigr.org	Bancroft, Ian/AAH-3831-2020; Eisen, Jonathan A./H-2706-2019; Frishman, Dmitrij/AAT-7815-2020; Pikaard, Craig S/K-8772-2012; Somerville, Christopher R/A-4048-2009; Chen, Meng/C-7109-2014; Wilson, Richard K./AAF-4139-2019; Morgenstern, Burkhard/A-7486-2008; Mayer, Klaus FX/M-7941-2015; Salzberg, Steven/Q-6514-2019; Nakamura, Yasukazu/T-9038-2019; Salzberg, Steven L/F-6162-2011; Copenhaver, Gregory P/A-7549-2014; Pertea, Mihaela/AAT-2705-2021; Jones, Jonathan DG/J-5129-2012; Copenhaver, Gregory/AFL-9831-2022; Marra, Marco A/B-5987-2008; Entian, Karl-Dieter/D-3080-2011; Ansorge, Wilhelm/AAN-8780-2020; Meyerowitz, Elliot M/A-7118-2009; Schoof, Heiko/Y-7073-2018; Paulsen, Ian T/K-3832-2012; Sato, Shusei/A-3616-2015; Copenhaver, Gregory/AAH-2031-2022; Lowe, Todd Michael/ABJ-5261-2022; Rudd, Stephen A/A-6434-2013; Ecker, Joseph R/B-9144-2008	Eisen, Jonathan A./0000-0002-0159-2197; Pikaard, Craig S/0000-0001-8204-7459; Somerville, Christopher R/0000-0003-4647-0094; Chen, Meng/0000-0003-0351-5897; Wilson, Richard K./0000-0002-1992-1358; Morgenstern, Burkhard/0000-0002-7431-2862; Mayer, Klaus FX/0000-0001-6484-1077; Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Copenhaver, Gregory P/0000-0002-7962-3862; Pertea, Mihaela/0000-0003-0762-8637; Jones, Jonathan DG/0000-0002-4953-261X; Copenhaver, Gregory/0000-0002-7962-3862; Marra, Marco A/0000-0001-7146-7175; Schoof, Heiko/0000-0002-1527-3752; Paulsen, Ian T/0000-0001-9015-9418; Sato, Shusei/0000-0002-0293-5366; Copenhaver, Gregory/0000-0002-7962-3862; Rudd, Stephen A/0000-0002-0344-7487; Ecker, Joseph R/0000-0001-5799-5895; Chen, Huaming/0000-0001-5289-7882				Acarkan A, 2000, PLANT J, V23, P55, DOI 10.1046/j.1365-313x.2000.00790.x; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALONSOBLANCO C, 1999, TRENDS PLANT SCI, V5, P1360; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APWEILER R, 2000, 11 COLL COMP PROJ; Bassham DC, 2000, CURR OPIN CELL BIOL, V12, P491, DOI 10.1016/S0955-0674(00)00121-6; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Bent E, 1998, PLANT J, V13, P849, DOI 10.1046/j.1365-313X.1998.00082.x; Blanc G, 2000, PLANT CELL, V12, P1093, DOI 10.1105/tpc.12.7.1093; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; Brendel V, 1998, NUCLEIC ACIDS RES, V26, P4748, DOI 10.1093/nar/26.20.4748; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; Britt AB, 1999, TRENDS PLANT SCI, V4, P20, DOI 10.1016/S1360-1385(98)01355-7; Buchanan BB., 2000, BIOCH MOL BIOL PLANT, P1367; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Canaday J, 2000, MICROSC RES TECHNIQ, V49, P487, DOI 10.1002/(SICI)1097-0029(20000601)49:5<487::AID-JEMT11>3.0.CO;2-I; Cao XF, 2000, P NATL ACAD SCI USA, V97, P4979, DOI 10.1073/pnas.97.9.4979; Carpita N, 1998, SCIENCE, V279, P672, DOI 10.1126/science.279.5351.672; Cavell AC, 1998, GENOME, V41, P62, DOI 10.1139/gen-41-1-62; CHOI S, 1995, WEEDS WORLD, V2, P17; Chory J, 2000, PLANT PHYSIOL, V123, P423, DOI 10.1104/pp.123.2.423; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; D'Agostino IB, 1999, TRENDS BIOCHEM SCI, V24, P452, DOI 10.1016/S0968-0004(99)01465-6; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; DANGL M, 1998, SCIENCE, V280, P1167; de Vries H, 1900, CR HEBD ACAD SCI, V130, P845; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; den Boer BGW, 2000, TRENDS CELL BIOL, V10, P245, DOI 10.1016/S0962-8924(00)01765-7; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; ELLIS J, 2000, TRENDS PLANT SCI, V3, P278; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; Feschotte C, 2000, MOL BIOL EVOL, V17, P730, DOI 10.1093/oxfordjournals.molbev.a026351; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Fransz PF, 2000, CELL, V100, P367, DOI 10.1016/S0092-8674(00)80672-8; FRISHMAN D, IN PRESS BIOINFORMAT; Gaut BS, 1997, P NATL ACAD SCI USA, V94, P6809, DOI 10.1073/pnas.94.13.6809; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Heese M, 1998, CURR OPIN PLANT BIOL, V1, P486, DOI 10.1016/S1369-5266(98)80040-X; Henikoff S, 1998, GENETICS, V149, P307; Hirsch RE, 1998, SCIENCE, V280, P918, DOI 10.1126/science.280.5365.918; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kotani H, 1998, ANNU REV PLANT PHYS, V49, P151, DOI 10.1146/annurev.arplant.49.1.151; Ku HM, 2000, P NATL ACAD SCI USA, V97, P9121, DOI 10.1073/pnas.160271297; Le QH, 2000, P NATL ACAD SCI USA, V97, P7376, DOI 10.1073/pnas.97.13.7376; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LIU YG, 1995, PLANT J, V7, P351, DOI 10.1046/j.1365-313X.1995.7020351.x; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; LUI YG, 1999, P NATL ACAD SCI USA, V96, P6535; Lukashin AV, 1998, NUCLEIC ACIDS RES, V26, P1107, DOI 10.1093/nar/26.4.1107; MAIER RM, 1995, J MOL BIOL, V251, P614, DOI 10.1006/jmbi.1995.0460; Makino S, 2000, PLANT CELL PHYSIOL, V41, P791, DOI 10.1093/pcp/41.6.791; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Martienssen R, 1998, TRENDS GENET, V14, P263, DOI 10.1016/S0168-9525(98)01518-2; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; MAYER K, UNPUB GENOME RES; McCarty DR, 2000, CELL, V103, P201, DOI 10.1016/S0092-8674(00)00113-6; McCombie WR, 2000, CELL, V100, P377, DOI 10.1016/S0092-8674(00)80673-X; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mekhedov S, 2000, PLANT PHYSIOL, V122, P389, DOI 10.1104/pp.122.2.389; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; MEYEROWITZ EM, 1999, TRENDS GENET, V15, pM65; MEYEROWITZ EM, 1994, ARABIDOPSIS; MOORE G, 1995, CURR BIOL, V5, P737, DOI 10.1016/S0960-9822(95)00148-5; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Noel L, 1999, PLANT CELL, V11, P2099, DOI 10.1105/tpc.11.11.2099; O'Neill CM, 2000, PLANT J, V23, P233, DOI 10.1046/j.1365-313x.2000.00781.x; Palmer JD, 2000, P NATL ACAD SCI USA, V97, P6960, DOI 10.1073/pnas.97.13.6960; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Pavy N, 1999, BIOINFORMATICS, V15, P887, DOI 10.1093/bioinformatics/15.11.887; Pelaz S, 2000, NATURE, V405, P200, DOI 10.1038/35012103; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Richmond TA, 2000, PLANT PHYSIOL, V124, P495, DOI 10.1104/pp.124.2.495; Riechmann JL, 2000, CURR OPIN PLANT BIOL, V3, P423, DOI 10.1016/S1369-5266(00)00107-2; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Ryan CA, 1998, ANNU REV CELL DEV BI, V14, P1, DOI 10.1146/annurev.cellbio.14.1.1; Salanoubat M, 2000, NATURE, V408, P820, DOI 10.1038/35048706; Salzberg SL, 1999, GENOMICS, V59, P24, DOI 10.1006/geno.1999.5854; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Sato S, 1999, DNA Res, V6, P283, DOI 10.1093/dnares/6.5.283; Sato S, 1997, DNA Res, V4, P215, DOI 10.1093/dnares/4.3.215; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SINGER T, IN PRESS GENES DEV; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SLAYMAN CL, 1974, P NATL ACAD SCI USA, V71, P1935, DOI 10.1073/pnas.71.5.1935; SOMERVILLE CR, 1981, PLANT PHYSIOL, V67, P666, DOI 10.1104/pp.67.4.666; Stahl EA, 2000, CURR OPIN PLANT BIOL, V3, P299, DOI 10.1016/S1369-5266(00)00083-2; Stepanova AN, 2000, CURR OPIN PLANT BIOL, V3, P353, DOI 10.1016/S1369-5266(00)00096-0; Strayer C, 2000, SCIENCE, V289, P768, DOI 10.1126/science.289.5480.768; TANKSLEY SD, 1992, GENETICS, V132, P1141; Theologis A, 2000, NATURE, V408, P816, DOI 10.1038/35048500; Torii KU, 2000, CURR OPIN PLANT BIOL, V3, P361, DOI 10.1016/S1369-5266(00)00097-2; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; Urao T, 2000, TRENDS PLANT SCI, V5, P67, DOI 10.1016/S1360-1385(99)01542-3; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; van Dodeweerd AM, 1999, GENOME, V42, P887, DOI 10.1139/gen-42-5-887; WANG DYC, 1999, P ROY SOC LOND B BIO, V266, P63; WEISS CA, 1994, P NATL ACAD SCI USA, V91, P9554, DOI 10.1073/pnas.91.20.9554; Wendel JF, 2000, PLANT MOL BIOL, V42, P225, DOI 10.1023/A:1006392424384; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; YU Z, IN PRESS GENETICS; Zheng ZL, 2000, TRENDS PLANT SCI, V5, P298, DOI 10.1016/S1360-1385(00)01654-X	121	4700	4951	24	1076	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					796	815		10.1038/35048692	http://dx.doi.org/10.1038/35048692			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130711	Bronze			2022-12-28	WOS:000165831300037
J	Huang, DCS; Strasser, A				Huang, DCS; Strasser, A			BH3-Only proteins - Essential initiators of apoptotic cell death	CELL			English	Review							FAMILY; GENE; MITOCHONDRIA; INTERACTS; EGL-1; BIM		Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Huang, DCS (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Huang, David C. S./C-7586-2013; Strasser, Andreas/C-7581-2013	Huang, David C. S./0000-0002-3101-4873; Strasser, Andreas/0000-0002-5020-4891				Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	19	850	902	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					839	842		10.1016/S0092-8674(00)00187-2	http://dx.doi.org/10.1016/S0092-8674(00)00187-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136969	Bronze			2022-12-28	WOS:000165801300003
J	Abu-Saad, HH				Abu-Saad, HH			Challenge of pain in the cognitively impaired	LANCET			English	Editorial Material							INDIVIDUALS		Maastricht Univ, Ctr Nursing Res, NL-6200 MD Maastricht, Netherlands	Maastricht University	Abu-Saad, HH (corresponding author), Maastricht Univ, Ctr Nursing Res, NL-6200 MD Maastricht, Netherlands.							*AAMR, 1992, MENT RET DEF CLASS S; ABUSAAD HH, 1997, VERSTANDELIJKE HANDI; ABUSAAD HH, 1998, KIND ZIEKENHUIS, V3, P79; BIERSDORFF KK, 1994, AM J MENT RETARD, V98, P619; Giusiano B, 1995, METHOD INFORM MED, V34, P498; Grossman H. J., 1983, CLASSIFICATION MENTA; Hart V., 1988, HDB DEV PHYSICAL DIS, P370; McGrath PJ, 1998, DEV MED CHILD NEUROL, V40, P340; van Gennep A., 1994, ZORG BESTAAN VERSTAN; VANDONGEN KAJ, 1999, IASP 9 WORLD C PAIN; WHO, 1993, INT CLASS IMP DIS HA; World Health Organization, 1992, INT CLASS DIS ICD 10	12	18	18	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1867	1868		10.1016/S0140-6736(00)03253-0	http://dx.doi.org/10.1016/S0140-6736(00)03253-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130378				2022-12-28	WOS:000165665400005
J	Skelton, JR; Thomas, CP; Macleod, JAA				Skelton, JR; Thomas, CP; Macleod, JAA			Teaching literature and medicine to medical students, part I: the beginning	LANCET			English	Editorial Material									Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Skelton, JR (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.							BENSON J, 1996, LONG PALE CORRIDOR; Cameron L., 1999, RES APPL METAPHOR; CAMUS A, 1989, PLAGUE; COWPER W, 1995, POEMS W COWPER; Dickens Charles, 1994, BLEAK HOUSE; Dickens Charles, 1970, DOMBEY SON, P1846; Eliot G., 1994, MIDDLEMARCH; Empson William, 1930, 7 TYPES AMBIGUITY; Foden Giles, 1998, LAST KING SCOTLAND; General Medical Council, 1993, TOM DOCT; JAMES Henry, 1997, PORTRAIT LADY; Kafka F., 1981, F KAFKA STORIES 1904; Shelley Mary, 1992, FRANKENSTEIN MODERN; SMITH K, 1997, BEDLAM POEMS WRITTEN; SOLZHENITSYN A, 1997, CANC WARD; Sontag S, 2002, ILLNESS METAPHOR AID	16	21	24	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1920	1922		10.1016/S0140-6736(00)03270-0	http://dx.doi.org/10.1016/S0140-6736(00)03270-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130399				2022-12-28	WOS:000165665400038
J	Newman, MF; Kirchner, JL; Phillips-Bute, B; Gaver, V; Grocott, H; Jones, RH; Mark, DB; Reves, JG; Blumenthal, JA				Newman, MF; Kirchner, JL; Phillips-Bute, B; Gaver, V; Grocott, H; Jones, RH; Mark, DB; Reves, JG; Blumenthal, JA		Neurological Outcome Res Grp Cardi	Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; COGNITIVE DECLINE; RISK-FACTORS; APOE EPSILON-4; OUTCOMES; DYSFUNCTION; STATEMENT	Background: Cognitive decline complicates early recovery after coronary-artery bypass grafting (CABG) and may be evident in as many as three quarters of patients at the time of discharge from the hospital and a third of patients after six months. We sought to determine the course of cognitive change during the five years after CABG and the effect of perioperative decline on long-term cognitive function. Methods: In 261 patients who underwent CABG, neurocognitive tests were performed preoperatively (at base line), before discharge, and six weeks, six months, and five years after CABG surgery. Decline in postoperative function was defined as a drop of 1 SD or more in the scores on tests of any one of four domains of cognitive function. (A reduction of 1 SD represents a decline in function of approximately 20 percent.) Overall neurocognitive status was assessed with a composite cognitive index score representing the sum of the scores for the individual domains. Factors predicting long-term cognitive decline were determined by multivariable logistic and linear regression. Results: Among the patients studied, the incidence of cognitive decline was 53 percent at discharge, 36 percent at six weeks, 24 percent at six months, and 42 percent at five years. We investigated predictors of cognitive decline at five years and found that cognitive function at discharge was a significant predictor of long-term function (P<0.001). Conclusions: These results confirm the relatively high prevalence and persistence of cognitive decline after CABG and suggest a pattern of early improvement followed by a later decline that is predicted by the presence of early postoperative cognitive decline. Interventions to prevent or reduce short- and long-term cognitive decline after cardiac surgery are warranted. (N Engl J Med 2001;344:395-402.) Copyright (C) 2001 Massachusetts Medical Society.	Duke Univ, Med Ctr, Div Cardiothorac Anesthesia, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Newman, MF (corresponding author), Duke Univ, Med Ctr, Div Cardiothorac Anesthesia, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	newma005@mc.duke.edu		Mark, Daniel/0000-0001-6340-8087	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009663] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL54316] Funding Source: Medline; NIA NIH HHS [R01-AG09663] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benton A, 1978, PSYCHOL ASSESSMENT R; BLUMENTHAL JA, 1995, ANN THORAC SURG, V59, P1345, DOI 10.1016/0003-4975(95)00055-P; Carmelli D, 1998, NEUROLOGY, V50, P1580, DOI 10.1212/WNL.50.6.1580; Cohen RA, 1999, AM J CARDIOL, V83, P1374, DOI 10.1016/S0002-9149(99)00103-4; Emery CF, 1998, HEALTH PSYCHOL, V17, P232, DOI 10.1037/0278-6133.17.3.232; Haan MN, 1999, JAMA-J AM MED ASSOC, V282, P40, DOI 10.1001/jama.282.1.40; Hammon JW, 1997, ANN THORAC SURG, V63, P1613, DOI 10.1016/S0003-4975(97)00261-0; JONES EL, 1991, J THORAC CARDIOV SUR, V101, P108; Lloyd AJ, 2000, BRIT J SURG, V87, P443, DOI 10.1046/j.1365-2168.2000.01428.x; Murkin JM, 1997, ANN THORAC SURG, V64, P904, DOI 10.1016/S0003-4975(97)00743-1; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; MURKIN JM, 1996, ANESTH ANALG, V82, pS328; Newman MF, 2000, ANESTH ANALG, V90, pSCA4; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; NEWMAN MF, 1994, CIRCULATION, V90, P243; O'Hara R, 1998, J AM GERIATR SOC, V46, P1493, DOI 10.1111/j.1532-5415.1998.tb01532.x; RANDT CT, 1983, ADM MANUAL RANDT MEM; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; Selnes OA, 1999, LANCET, V353, P1601, DOI 10.1016/S0140-6736(98)07576-X; Slooter AJC, 1998, J NEURAL TRANSM-SUPP, P17; SOTANIEMI KA, 1986, STROKE, V17, P410, DOI 10.1161/01.STR.17.3.410; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Troster AI, 1999, NEUROLOGY, V53, P1774, DOI 10.1212/WNL.53.8.1774; TUMAN KJ, 1992, J THORAC CARDIOV SUR, V104, P1510, DOI 10.1016/S0022-5223(19)33877-2; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; WEINTRAUB WS, 1989, CIRCULATION, V80, P276, DOI 10.1161/01.CIR.80.2.276	27	1366	1442	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 8	2001	344	6					395	402		10.1056/NEJM200102083440601	http://dx.doi.org/10.1056/NEJM200102083440601			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	399FH	11172175				2022-12-28	WOS:000166800600001
J	Crawford, F; Hart, R; Bell-Syer, SEM; Torgerson, DJ; Young, P; Russell, I				Crawford, F; Hart, R; Bell-Syer, SEM; Torgerson, DJ; Young, P; Russell, I			Athlete's foot and fungally infected toenails	BRITISH MEDICAL JOURNAL			English	Review									Univ York, York YO10 5DD, N Yorkshire, England; Univ Wales Inst, Cardiff CF1 3NS, S Glam, Wales	University of York - UK	Crawford, F (corresponding author), Univ York, York YO10 5DD, N Yorkshire, England.		Young, Philip/ABI-1480-2020; Russell, Ian T/H-1181-2012; Torgerson, David/L-4566-2019	Young, Philip/0000-0003-0201-9277; Torgerson, David/0000-0002-1667-4275; Crawford, Fay/0000-0002-0473-9959				CRAWFORD F, 2000, TOPICAL TREATMENTS F; GENTLES JC, 1973, BMJ-BRIT MED J, V3, P260, DOI 10.1136/bmj.3.5874.260; Hart R, 1999, BMJ-BRIT MED J, V319, P79, DOI 10.1136/bmj.319.7202.79; ROBERTS DT, 1992, BRIT J DERMATOL, V126, P23, DOI 10.1111/j.1365-2133.1992.tb00005.x	4	4	4	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	2001	322	7281					288	289		10.1136/bmj.322.7281.288	http://dx.doi.org/10.1136/bmj.322.7281.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157535	Green Published			2022-12-28	WOS:000166917600037
J	Berger, A				Berger, A			Insulin-like growth factor and cognitive function	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1	1	17	21	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2001	322	7280					203	203		10.1136/bmj.322.7280.203	http://dx.doi.org/10.1136/bmj.322.7280.203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159614	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000166733700025
J	Pattani, S; Constantinovici, N; Williams, S				Pattani, S; Constantinovici, N; Williams, S			Who retires early from the NHS because of ill health and what does it cost? A national cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									UCL Royal Free Hampstead NHS Trust, Occupat Hlth & Safety Unit, London NW3 2QG, England; Univ London, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England	University of London; University College London; University of London; University College London	Williams, S (corresponding author), UCL Royal Free Hampstead NHS Trust, Occupat Hlth & Safety Unit, London NW3 2QG, England.	Sian.Williams@rfh.nthames.nhs.uk						*GOV STAT SERV, 1998, HLTH PERS SOC SERV S; *NHS PENS AG, 1999, NHS PENS AG ANN REP; Poole CJM, 1997, BRIT MED J, V314, P929, DOI 10.1136/bmj.314.7085.929	3	48	49	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					208	209		10.1136/bmj.322.7280.208	http://dx.doi.org/10.1136/bmj.322.7280.208			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159617	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000166733700027
J	Mechanic, D; McAlpine, DD; Rosenthal, M				Mechanic, D; McAlpine, DD; Rosenthal, M			Are patients' office visits with physicians getting shorter?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MANAGED-CARE; GENDER DIFFERENCES; PRACTICE STYLE; SATISFACTION; COMMUNICATION; ORGANIZATION; TRUST	Background: Many believe that managed care creates pressure on physicians to increase productivity, see more patients, and spend less time with each patient. Methods: We used nationally representative data from the National Ambulatory Medical Care Survey (NAMCS) of the National Center for Health Statistics and the American Medical Association's Socioeconomic Monitoring System (SMS) to examine the length of office visits with physicians from 1989 through 1998. We assessed the trends for visits covered by a managed-care or other prepaid health plan (prepaid visits) and non-prepaid visits for primary and specialty care, for new and established patients, and for common and serious diagnoses. Results: Between 1989 and 1998 the number of visits to physicians' offices increased significantly from 677 million to 797 million, although the rate of visits per 100 population did not change significantly. The average duration of office visits in 1989 was 16.3 minutes according to the NAMCS and 20.4 minutes according to the SMS survey. According to both sets of data, the average duration of visits increased by between one and two minutes between 1989 and 1998. The duration of the visits increased for both prepaid and non-prepaid visits. Non-prepaid visits were consistently longer than prepaid visits, although the gap declined from 1 minute in 1989 to 0.6 minute in 1998. There was an upward trend in the length of visits for both primary and specialty care and for both new and established patients. The average length of visits remained stable or increased for patients with the most common diagnoses and for those with the most serious diagnoses. Conclusions: Contrary to expectations, the growth of managed health care has not been associated with a reduction in the length of office visits. The observed trends cannot be explained by increases in physicians' availability, shifts in the distribution of physicians according to sex, or changes in the complexity of the case mix. (N Engl J Med 2001;344:198-204.) Copyright (C) 2001 Massachusetts Medical Society.	Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Mechanic, D (corresponding author), Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 30 Coll Ave, New Brunswick, NJ 08901 USA.							[Anonymous], DHHS PUBLICATION; BENSING JM, 1993, MED CARE, V31, P219, DOI 10.1097/00005650-199303000-00004; Bernzweig J, 1997, ARCH PEDIAT ADOL MED, V151, P586, DOI 10.1001/archpedi.1997.02170430052011; BERTAKIS KD, 1995, MED CARE, V33, P407, DOI 10.1097/00005650-199504000-00007; Blumenthal D, 1999, J FAM PRACTICE, V48, P264; Bodenheimer T, 1999, NEW ENGL J MED, V340, P584, DOI 10.1056/NEJM199902183400725; Burdi MD, 1999, HEALTH AFFAIR, V18, P134, DOI 10.1377/hlthaff.18.4.134; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; *DEP HLTH HUM SERV, 1994, INT CLASS DIS, V1; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; GLIED S, 1997, WOMEN HLTH, V2, P1; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GONZALEZ M, 1996, PHYSICIAN MARKETPLAC; GONZALEZ ML, 1998, SOCIOECONOMIC CHARAC; GONZALEZ ML, 1997, SOCIOECONOMIC CHARAC; GONZALEZ ML, 1990, PHYSICIAN MARKETPLAC; Gross DA, 1998, J FAM PRACTICE, V47, P133; Hadley J, 1999, HEALTH SERV RES, V34, P307; HOYERT DL, 1999, NATL VITAL STAT REPO, V47; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; LUDMERER KM, 1999, TIME HEAL AM MED ED, P370; Luft HS, 1999, J HEALTH POLIT POLIC, V24, P957; Mechanic D, 1996, MILBANK Q, V74, P171, DOI 10.2307/3350245; Mechanic D, 1999, MILBANK Q, V77, P283, DOI 10.1111/1468-0009.00137; MECHANIC D, 1975, MED CARE, V13, P189, DOI 10.1097/00005650-197503000-00001; MEEUWESEN L, 1991, SOC SCI MED, V32, P1143, DOI 10.1016/0277-9536(91)90091-P; *NAT CTR HLTH STAT, 1991, NAT AMB MED CAR SURV; *NAT CTR HLTH STAT, 1993, NAT AMB MED CAR SURV; *NAT CTR HLTH STAT, 1992, NAT AMB MED CAR SURV; National Center for Health Statistics, 1994, NAT AMB MED CAR SURV; *NCHS, 1995, NCHS PUBL US DAT FIL; *NCHS, 1997, NCHS PUBL US DAT FIL; *NCHS, 1998, NCHS PUBL US DAT FIL; *NCHS, 1994, NCHS PUBL US DAT FIL; *NCHS, 1996, NCHS PUBL US DAT FIL; *NCHS, 1993, NCHS PUBL US DAT FIL; PASKO T, 2000, PHYSICIAN CHARACTERI, P9; REARDON TR, 1999, VITAL SPEECHES DAY, V66, P114; ROBACK G, 1990, PHYSICIAN CHARACTERI; ROBINSON JC, 1999, CORPORATE PRACTICE M; ROTER D, 1991, MED CARE, V11, P1083; Roter DL, 1998, J WOMENS HEALTH, V7, P1093, DOI 10.1089/jwh.1998.7.1093; Shah BV, 1996, SUDAAN USERS MANUAL; Stafford RS, 1999, ARCH FAM MED, V8, P26, DOI 10.1001/archfami.8.1.26; Stone T T, 1999, J Health Care Finance, V26, P48; Sudman, 1988, POLLS SURVEYS UNDERS; Sudman S., 1986, ASKING QUESTIONS PRA; Ubel P.A., 2000, PRICING LIFE WHY ITS; ZHANG PTS, 1999, PHYSICIAN SOCIOECONO	49	280	282	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					198	204		10.1056/NEJM200101183440307	http://dx.doi.org/10.1056/NEJM200101183440307			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	392GF	11172143				2022-12-28	WOS:000166402800007
J	Petrovic, M; Roberts, R; Ramsay, M				Petrovic, M; Roberts, R; Ramsay, M			Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE EVENTS; SURVEILLANCE; CAUSAL	Objective To determine the knowledge, attitudes, and practices among health professionals regarding the measles, mumps, and rubella (MMR) vaccine, particularly the second dose. Design Self administered postal questionnaire survey. Setting North Wales Health Authority, 1998. Participants 148 health visitors, 239 practice nurses, and 206 general practitioners. Main outcome measures Respondents' views on MMR vaccination, including their views on the likelihood of an association with autism and Crohn's disease and on who is the best person to give advice to parents, whether they agree with the policy of a second dose of the vaccine, and how confident they are in explaining the rationale behind the second dose. Results Concerning the second dose of the vaccine, 48% of the professionals (220/460) had reservations and 3% (15) disagreed with the policy of giving it Over half the professionals nominated health visitors as the best initial source of advice on the second vaccine. 61% of health visitors (86/140), compared with 46% of general practitioners (73/158), reported feeling very confident about explaining the rationale of a two dose schedule to a well informed parent, but only 20% (28/138) would unequivocally recommend the second dose to a wavering parent 33% of the practice nurses (54/163) stated that the MMR vaccine was very likely or possibly associated with Crohn's disease and 27% (44/164) that it was associated with autism. Nearly a fifth of general practitioners (27/158) reported that they had not read the MMR section in the "green book," and 29% (44/152) reported that they had not received the Health Education Authority's factsheet on MMR immunisation. Conclusions Knowledge and practice among health professionals regarding the second dose of the MMR vaccine vary widely. Many professionals are not aware of or do not use the good written resources that exist, though local educational initiatives could remedy this.	N Wales Hlth Author, Dept Publ Hlth, Mold, Flint, Wales; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England	Public Health England	Petrovic, M (corresponding author), N Wales Hlth Author, Dept Publ Hlth, Mold, Flint, Wales.		Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				*CDCP, 1998, MMWR-MORBID MORTAL W, V47, P2; *CDSC, 1998, COMMUN DIS REP CDR W, V8, P345; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; CUTTS FT, 1994, J INFECT DIS, V170, pS32, DOI 10.1093/infdis/170.Supplement_1.S32; DEAN AG, 1995, EPI INFO VERS 6 WORD; FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9; GAY NJ, 1995, EPIDEMIOL INFECT, V115, P139, DOI 10.1017/S0950268800058209; *HLTH ED AUTH, 1997, MMR IMM FACTSH; HMSO, 1996, IMM INF DIS; PETOLA H, 1994, NEW ENGL J MED, V331, P1397; ROBERTS N, 1998, GP, P63; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P118; Taylor B, 1999, LANCET, V353, P2026, DOI 10.1016/S0140-6736(99)01239-8; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; *WELSH OFF, 1998, CMO987 WELSH OFF; WHO, 1999, EUR HLTH ALL SER; 1996, COMMUN DIS REP CDR W, V6, P259	17	58	58	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					82	85		10.1136/bmj.322.7278.82	http://dx.doi.org/10.1136/bmj.322.7278.82			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154622	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000166496100027
J	Greenhalgh, T				Greenhalgh, T			Computer assisted learning in undergraduate medical education	BRITISH MEDICAL JOURNAL			English	Article							INSTRUCTION; FEEDBACK; SEMINAR; LECTURE		UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Open Learning Unit, London N19 3UA, England	University of London; University College London; UCL Medical School	Greenhalgh, T (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Open Learning Unit, London N19 3UA, England.	p.greenhalgh@ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				BONK CJ, 2000, INSTRUCTIONAL COGNIT; Brown S., 1999, ASS LEARNING TECHNOL, V6, P30; Carr MM, 1999, OTOLARYNG HEAD NECK, V121, P430, DOI 10.1016/S0194-5998(99)70233-0; CONOLE G, 2000, P LEARN TECHN LIF CY; CONROY RM, 1999, CTITM UPDATE, V9, P10; D'Alessandro DM, 1997, ACAD RADIOL, V4, P719, DOI 10.1016/S1076-6332(97)80074-8; DANIEL JS, 1996, MEGAUNIVERSITES KNOW, P88; Daniel JS, 1996, MEGAUNIVERSITIES KNO, P101; Devitt P, 1999, MED EDUC, V33, P136, DOI 10.1046/j.1365-2923.1999.00284.x; ELTON L, 1999, TERTIARY ED MANAGEME, V5, P207; Elves AWS, 1997, BRIT J UROL, V80, P59; FENDER B, 2000, E U PROJECT; GRABINGER S, 2000, RICH ENV ACTIVE LEAR; Haag M, 1999, INT J MED INFORM, V53, P79, DOI 10.1016/S1386-5056(98)00118-X; Hamilton NM, 1999, MED EDUC, V33, P298; Hara N., 2000, STUDENTS FRUSTRATION; HAVNES B, 1999, BRIT MED J, V319, P652; Hilger AE, 1996, ARCH PEDIAT ADOL MED, V150, P629, DOI 10.1001/archpedi.1996.02170310063011; Kallinowski F, 1997, CHIRURG, V68, P433, DOI 10.1007/s001040050210; Kulik Ja, 1994, TECHNOLOGY ASSESSMEN, P52; Lehmann HP, 1999, J AM MED INFORM ASSN, V6, P38, DOI 10.1136/jamia.1999.0060038; LYON H C JR, 1991, Journal of Medical Systems, V15, P117, DOI 10.1007/BF00992704; Mehta M P, 1998, J Cancer Educ, V13, P197; PHILLIPS R, 1996, DEV GUIDE INTERACTIV; REINGOLD H, 1995, VIRTUAL COMMUNITY, P10; Rogers DA, 1998, AM J SURG, V175, P508, DOI 10.1016/S0002-9610(98)00087-7; Salmon G., 2000, E MODERATING GUIDE T; SCHWARTZ S, 1993, ACAD MED, V68, P862, DOI 10.1097/00001888-199311000-00017; Summers AN, 1999, SURGERY, V126, P330, DOI 10.1067/msy.1999.98482; Thorne M., 1999, U FUTURE; WEVERLING GJ, 1996, TIJDSCHRIFT VOOR GEN, V140, P440; 2000, ASSISTING COLLABORAT	32	244	254	0	17	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					40	44		10.1136/bmj.322.7277.40	http://dx.doi.org/10.1136/bmj.322.7277.40			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141156	Green Submitted, Green Published			2022-12-28	WOS:000166341400026
J	Whooley, MA; Simon, GE				Whooley, MA; Simon, GE			Primary care - Managing depression in medical outpatients.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TREATING MAJOR DEPRESSION; RANDOMIZED-TRIAL; HIGH UTILIZERS; RISK-FACTORS; SYMPTOMS; EFFICACY; FLUOXETINE; PLACEBO; ASSOCIATION; OUTCOMES		Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Group Health Cooperative; University of Washington; University of Washington Seattle	Whooley, MA (corresponding author), Dept Vet Affairs Med Ctr, 111A1,4150 Clement St, San Francisco, CA 94121 USA.	whooley@itsa.ucsf.edu	anand, amit/A-7222-2009					*AG HLTH CAR POL R, DEPR GUID PAN DEPR P; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BEASLEY CM, 1991, J CLIN PSYCHIAT, V52, P294; BROADHEAD WE, 1990, JAMA-J AM MED ASSOC, V264, P2524, DOI 10.1001/jama.264.19.2524; BRODY DS, 1994, J GEN INTERN MED, V9, P569, DOI 10.1007/BF02599285; Burns D. D., 1989, FEELING GOOD HDB; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; Cohen HW, 2000, AM J MED, V108, P2, DOI 10.1016/S0002-9343(99)00301-0; Coulehan JL, 1997, ARCH INTERN MED, V157, P1113, DOI 10.1001/archinte.157.10.1113; Covinsky KE, 1997, ANN INTERN MED, V126, P417, DOI 10.7326/0003-4819-126-6-199703150-00001; DOWRICK C, 1995, BMJ-BRIT MED J, V311, P1274, DOI 10.1136/bmj.311.7015.1274; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; Gaster B, 2000, ARCH INTERN MED, V160, P152, DOI 10.1001/archinte.160.2.152; Gerstman BB, 1996, J CLIN EPIDEMIOL, V49, P809, DOI 10.1016/0895-4356(96)00017-0; Gorman JM, 1999, J CLIN PSYCHIAT, V60, P33; HAYS RD, 1995, ARCH GEN PSYCHIAT, V52, P11; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; Judd LL, 1998, ARCH GEN PSYCHIAT, V55, P694, DOI 10.1001/archpsyc.55.8.694; Judd LL, 2000, PHARMACOPSYCHIATRY, V33, P3, DOI 10.1055/s-2000-7967; KATON W, 1982, AM J MED, V72, P127, DOI 10.1016/0002-9343(82)90599-X; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; KATON W, 1990, GEN HOSP PSYCHIAT, V12, P355, DOI 10.1016/0163-8343(90)90002-T; KATON W, 1994, J AFFECT DISORDERS, V31, P81, DOI 10.1016/0165-0327(94)90111-2; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katzelnick DJ, 2000, ARCH FAM MED, V9, P345, DOI 10.1001/archfami.9.4.345; Keller MB, 1998, JAMA-J AM MED ASSOC, V280, P1665, DOI 10.1001/jama.280.19.1665; Keller MB, 2000, NEW ENGL J MED, V342, P1462, DOI 10.1056/NEJM200005183422001; Kendler KS, 1998, AM J PSYCHIAT, V155, P172; Kessing LV, 1998, BRIT J PSYCHIAT, V172, P23, DOI 10.1192/bjp.172.1.23; Kroenke K, 1994, Arch Fam Med, V3, P774; Lin EHB, 1998, ARCH FAM MED, V7, P443, DOI 10.1001/archfami.7.5.443; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; Long T D, 1993, Ann Clin Psychiatry, V5, P259, DOI 10.3109/10401239309148826; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; Mason BJ, 1996, JAMA-J AM MED ASSOC, V275, P761, DOI 10.1001/jama.275.10.761; MCEVOY GK, 2000, AHFS DRUG INFORMATIO; *MED EC, 2000, 2000 DRUG TOP RED BO; MILLER MC, 1999, HARVARD MED SCH GUID, P520; Mortensen PB, 2000, LANCET, V355, P9, DOI 10.1016/S0140-6736(99)06376-X; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; Mulrow CD, 2000, AM J MED, V108, P54, DOI 10.1016/S0002-9343(99)00316-2; MULROW CD, 1995, ANN INTERN MED, V123, P966; Musselman DL, 2000, PROG BRAIN RES, V122, P43; *NAT COMM QUAL ASS, 2000, HEDIS 2000, V2; Reimherr FW, 1998, AM J PSYCHIAT, V155, P1247, DOI 10.1176/ajp.155.9.1247; Rubenstein LV, 1999, HEALTH AFFAIR, V18, P89, DOI 10.1377/hlthaff.18.5.89; Schulberg HC, 1999, J CLIN PSYCHIAT, V60, P19; Schulberg HC, 1998, ARCH GEN PSYCHIAT, V55, P1121, DOI 10.1001/archpsyc.55.12.1121; Schulberg HC, 1996, ARCH GEN PSYCHIAT, V53, P913; SIMON G, 2000, ARCH FAM MED, V320, P550; Simon GE, 1998, J CLIN PSYCHIAT, V59, P49, DOI 10.4088/JCP.v59n0202; Simon GE, 1999, ARCH FAM MED, V8, P319, DOI 10.1001/archfami.8.4.319; Simon GE, 1998, PSYCHOL MED, V28, P693, DOI 10.1017/S0033291798006588; Simon GE, 1997, J PSYCHOSOM RES, V42, P333, DOI 10.1016/S0022-3999(96)00367-4; SIMON GE, 1993, GEN HOSP PSYCHIAT, V15, P399, DOI 10.1016/0163-8343(93)90009-D; STURM R, 1995, JAMA-J AM MED ASSOC, V273, P51; Sturm R, 1996, MED CARE, V34, P723, DOI 10.1097/00005650-199607000-00005; Thase ME, 1999, J CLIN PSYCHIAT, V60, P3; Thase ME, 1996, ARCH GEN PSYCHIAT, V53, P777; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; TOLLEFSON GD, 1994, J CLIN PSYCHIAT, V55, P50; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; WELLS K, 1996, CARING DEPRESSION; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WELLS KB, 1988, AM J PSYCHIAT, V145, P976; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P3204; Whooley MA, 1998, ARCH INTERN MED, V158, P2129, DOI 10.1001/archinte.158.19.2129; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; Whooley MA, 2000, J GEN INTERN MED, V15, P293, DOI 10.1046/j.1525-1497.2000.04319.x; Williams JW, 1999, AM J MED, V106, P36, DOI 10.1016/S0002-9343(98)00371-4; Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519; YESAVAGE J, 1993, AM J MED, V94, pS23	77	277	285	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2000	343	26					1942	1950		10.1056/NEJM200012283432607	http://dx.doi.org/10.1056/NEJM200012283432607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	386VR	11136266				2022-12-28	WOS:000166082700007
J	Heaney, RP				Heaney, RP			Lead in calcium supplements - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BLOOD		Creighton Univ, Dept Med, Omaha, NE 68178 USA	Creighton University	Heaney, RP (corresponding author), Creighton Univ, Dept Med, Omaha, NE 68178 USA.							BLAKE KCH, 1983, ENVIRON RES, V30, P182, DOI 10.1016/0013-9351(83)90178-0; HEARD MJ, 1982, HUM TOXICOL, V1, P411, DOI 10.1177/096032718200100407; MAHAFFEY KR, 1986, PEDIATRICS, V78, P257; MULDOON SB, 1994, AM J EPIDEMIOL, V139, P599, DOI 10.1093/oxfordjournals.aje.a117049; Ross EA, 2000, JAMA-J AM MED ASSOC, V284, P1425, DOI 10.1001/jama.284.11.1425; *US DEP HHS, 1990, HLTH PEOP 2000	6	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3126	3127						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135772				2022-12-28	WOS:000165994100024
J	Havas, K; Flaus, A; Phelan, M; Kingston, R; Wade, PA; Lilley, DMJ; Owen-Hughes, T				Havas, K; Flaus, A; Phelan, M; Kingston, R; Wade, PA; Lilley, DMJ; Owen-Hughes, T			Generation of superhelical torsion by ATP-dependent chromatin remodeling activities	CELL			English	Article							T4 ENDONUCLEASE-VII; NUCLEOSOME DISRUPTION; DNA TRANSLOCATION; CELL-CYCLE; SWI-SNF; CRUCIFORM STRUCTURES; SUPERCOILED DNA; HUMAN SWI/SNF; YEAST; COMPLEX	ATP-dependent chromatin remodeling activities participate in the alteration of chromatin structure during gene regulation. Ail have DNA- or chromatin-stimulated ATPase activity and many can alter the structure of chromatin; however, the means by which they do this have remained unclear. Here we describe a novel activity for ATP-dependent chromatin remodeling activities, the ability to generate unconstrained negative superhelical torsion in DNA and chromatin. We find that the ability to distort DNA is shared by the yeast SWI/SNF complex, Xenopus Mi-2 complex, recombinant ISWI, and recombinant BRG1, suggesting that the generation of superhelical torsion represents a primary biomechanical activity shared by all Snf2-prelated ATPase motors. The generation of superhelical torque provides a potent means by which ATP-dependent chromatin remodeling activities can manipulate chromatin structure.	Univ Dundee, Wellcome Trust Bioctr, Div Gene Regulat, Dundee DD1 5EH, Scotland; Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02114 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	University of Dundee; Harvard University; Massachusetts General Hospital; Emory University	Owen-Hughes, T (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Div Gene Regulat, Dundee DD1 5EH, Scotland.	t.a.owenhughes@dundee.ac.uk	Wade, Paul A/D-2374-2019; Flaus, Andrew/D-5076-2011	Wade, Paul A/0000-0002-6042-357X; Flaus, Andrew/0000-0002-5720-7139; Owen-Hughes, Tom/0000-0002-0618-8185; Havas-Cavalletti, Kristina/0000-0002-6324-629X	Cancer Research UK [11722] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Auble DT, 1999, MOL CELL BIOL, V19, P412; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Bi X, 1997, MOL CELL BIOL, V17, P7077, DOI 10.1128/MCB.17.12.7077; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; COUREY AJ, 1983, CELL, V33, P817, DOI 10.1016/0092-8674(83)90024-7; Davies GP, 1999, J MOL BIOL, V292, P787, DOI 10.1006/jmbi.1999.3081; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Ellis DJ, 1999, NAT STRUCT BIOL, V6, P15; Firman K, 2000, EMBO J, V19, P2094, DOI 10.1093/emboj/19.9.2094; GiraudPanis MJE, 1996, J BIOL CHEM, V271, P33148, DOI 10.1074/jbc.271.51.33148; GODING CR, 1983, NUCLEIC ACIDS RES, V11, P21, DOI 10.1093/nar/11.1.21; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Janscak P, 2000, J MOL BIOL, V295, P1089, DOI 10.1006/jmbi.1999.3414; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LILLEY DMJ, 1984, J MOL BIOL, V180, P179, DOI 10.1016/0022-2836(84)90436-4; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MIZUUCHI K, 1982, J MOL BIOL, V156, P229, DOI 10.1016/0022-2836(82)90325-4; Owen-Hughes T, 1999, METH MOL B, V119, P319; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PECK LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4560, DOI 10.1073/pnas.79.15.4560; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Shimizu M, 2000, EMBO J, V19, P3358, DOI 10.1093/emboj/19.13.3358; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Szczelkun MD, 1996, EMBO J, V15, P6335, DOI 10.1002/j.1460-2075.1996.tb01023.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; van Holde KE, 1985, STRUCTURE FUNCTION G, P35, DOI DOI 10.1007/978-1-4684-5024-8_4; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472	78	212	215	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1133	1142		10.1016/S0092-8674(00)00215-4	http://dx.doi.org/10.1016/S0092-8674(00)00215-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163188	Bronze			2022-12-28	WOS:000166040600015
J	Morgan, D; Diamond, DM; Gottschall, PE; Ugen, KE; Dickey, C; Hardy, J; Duff, K; Jantzen, P; DiCarlo, G; Wilcock, D; Connor, K; Hatcher, J; Hope, C; Gordon, M; Arendash, GW				Morgan, D; Diamond, DM; Gottschall, PE; Ugen, KE; Dickey, C; Hardy, J; Duff, K; Jantzen, P; DiCarlo, G; Wilcock, D; Connor, K; Hatcher, J; Hope, C; Gordon, M; Arendash, GW			A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; TRANSGENIC MICE; PRESENILIN-1 TRANSGENES; MUTANT PRESENILIN-1; PHENOTYPE; PATHOLOGY; PLAQUES	Vaccinations with amyloid-beta peptide (AB) can dramatically reduce amyloid deposition in a transgenic mouse model of Alzheimer's disease(1). To determine if the vaccinations had deleterious or beneficial functional consequences, we tested eight months of A beta vaccination in a different transgenic model for Alzheimer's disease in which mice develop learning deficits as amyloid accumulates(2,3). Here we show that vaccination with A beta protects transgenic mice from the learning and age-related memory deficits that normally occur in this mouse model for Alzheimer's disease. During testing for potential deleterious effects of the vaccine, all mice performed superbly on the radial-arm water-maze test of working memory. Later, at an age when untreated transgenic mice show memory deficits, the A beta -vaccinated transgenic mice showed cognitive performance superior to that of the control transgenic mice and, ultimately, performed as well as nontransgenic mice. The A beta -vaccinated mice also had a partial reduction in amyloid burden at the end of the study. This therapeutic approach may thus prevent and, possibly, treat Alzheimer's dementia.	Univ S Florida, Dept Pharmacol, Alzheimer Res Lab, Tampa, FL 33612 USA; Univ S Florida, Dept Psychol, Tampa, FL 33612 USA; Univ S Florida, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, Dept Biol, Alzheimer Res Lab, Tampa, FL 33612 USA; James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA; Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Mayo Clinic; Nathan Kline Institute for Psychiatric Research	Morgan, D (corresponding author), Univ S Florida, Dept Pharmacol, Alzheimer Res Lab, Tampa, FL 33612 USA.		Gordon, Marcia N. N/K-2420-2012; Morgan, David G/J-5989-2012; Dickey, Chad A/H-4441-2011; Hardy, John/C-2451-2009; Duff, Karen EK/C-2510-2009; Wilcock, Donna M/J-7517-2016; Ugen, Kenneth E/H-6544-2011	Gordon, Marcia N. N/0000-0002-4051-9283; Hardy, John/0000-0002-3122-0423; Duff, Karen/0000-0002-6177-868X	NATIONAL INSTITUTE ON AGING [ZIAAG000950, Z01AG000950] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARENDASH GW, IN PRESS BRAIN RES; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Diamond DM, 1999, HIPPOCAMPUS, V9, P542, DOI 10.1002/(SICI)1098-1063(1999)9:5<542::AID-HIPO8>3.3.CO;2-E; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Frautschy SA, 1998, AM J PATHOL, V152, P307; Frenkel D, 2000, J NEUROIMMUNOL, V106, P23, DOI 10.1016/S0165-5728(99)00232-5; Gordon MN, 1997, J COMP NEUROL, V388, P106; GORDON MN, IN PRESS NEUROBIOL A; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Holcomb LA, 1999, BEHAV GENET, V29, P177, DOI 10.1023/A:1021691918517; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Masliah E, 1996, J NEUROSCI, V16, P5795; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; McGowan E, 1999, NEUROBIOL DIS, V6, P231, DOI 10.1006/nbdi.1999.0243; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Weiner HL, 2000, ANN NEUROL, V48, P567, DOI 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.3.CO;2-N	19	1290	1450	1	142	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					982	985		10.1038/35050116	http://dx.doi.org/10.1038/35050116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140686				2022-12-28	WOS:000165951100052
J	Manzanares, M; Wada, H; Itasaki, N; Trainor, PA; Krumlauf, R; Holland, PWH				Manzanares, M; Wada, H; Itasaki, N; Trainor, PA; Krumlauf, R; Holland, PWH			Conservation and elaboration of Hox gene regulation during evolution of the vertebrate head	NATURE			English	Article							HOMEOBOX-CONTAINING GENES; RETINOIC ACID; HINDBRAIN SEGMENTATION; NEURAL CREST; EXPRESSION; KREISLER; INSIGHTS; KROX-20; CLUSTER; EMBRYOS	The comparison of Hox genes between vertebrates and their closest invertebrate relatives (amphioxus and ascidia) highlights two derived features of Hox genes in vertebrates: duplication of the Hox gene cluster(1,2), and an elaboration of Hox expression patterns and roles compared with non-vertebrate chordates(3-8). We have investigated how new expression domains and their associated developmental functions evolved, by testing the cis-regulatory activity of genomic DNA fragments from the cephalochordate amphioxus Hox cluster in transgenic mouse and chick embryos. Here we present evidence for the conservation of cis-regulatory mechanisms controlling gene expression in the neural tube for half a billion years of evolution, including a dependence on retinoic acid signalling. We also identify amphioxus Hox gene regulatory elements that drive spatially localized expression in vertebrate neural crest cells, in derivatives of neurogenic placodes and in branchial arches, despite the fact that cephalochordates lack both neural crest and neurogenic placodes. This implies an elaboration of cis-regulatory elements in the Hox gene cluster of vertebrate ancestors during the evolution of craniofacial patterning.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Natl Inst Med Res, MRC, Div Dev Neurobiol, London NW7 1AA, England; Kyoto Univ, Seto Marine Biol Lab, Shirahama, Wakayama 6492211, Japan	University of Reading; MRC National Institute for Medical Research; Kyoto University	Krumlauf, R (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.	rek@stowers-institute.org; p.w.h.holland@reading.ac.uk	Manzanares, Miguel/AAZ-8305-2021; Manzanares, Miguel/E-1702-2015; Krumlauf, Robb/AAH-5012-2019	Manzanares, Miguel/0000-0003-4849-2836; Manzanares, Miguel/0000-0003-4849-2836; Krumlauf, Robb/0000-0001-9102-7927; Holland, Peter/0000-0003-1533-9376; Trainor, Paul/0000-0003-2774-3624; Itasaki, Nobue/0000-0003-0587-9141				Blumberg B, 1997, DEVELOPMENT, V124, P373; Finnerty JR, 1998, CURR OPIN GENET DEV, V8, P681, DOI 10.1016/S0959-437X(98)80037-3; GANS C, SCIENCE, V220, P268; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; Gionti M, 1998, DEV GENES EVOL, V207, P515, DOI 10.1007/s004270050142; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; Holland LZ, 1996, DEVELOPMENT, V122, P1829; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; Itasaki N, 1999, NAT CELL BIOL, V1, pE203, DOI 10.1038/70231; KATSUYAMA Y, 1995, DEVELOPMENT, V121, P3197; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KURATANI SC, 1992, DEV DYNAM, V195, P15, DOI 10.1002/aja.1001950103; LEDOUARIN NM, 1986, TRENDS NEUROSCI, V9, P175, DOI 10.1016/0166-2236(86)90055-X; Locascio A, 1999, DEVELOPMENT, V126, P4737; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Maconochie M, 1996, ANNU REV GENET, V30, P529, DOI 10.1146/annurev.genet.30.1.529; Manzanares M, 1999, DEVELOPMENT, V126, P759; Manzanares M, 1997, NATURE, V387, P191, DOI 10.1038/387191a0; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; MURPHY P, 1991, DEVELOPMENT, V111, P61; Nonchev S, 1996, P NATL ACAD SCI USA, V93, P9339, DOI 10.1073/pnas.93.18.9339; Nonchev S, 1996, DEVELOPMENT, V122, P543; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; Wada H, 1999, DEV BIOL, V213, P131, DOI 10.1006/dbio.1999.9369	28	144	148	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					854	857		10.1038/35048570	http://dx.doi.org/10.1038/35048570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130723				2022-12-28	WOS:000165831300049
J	Gershon, D				Gershon, D			Vaccine centres unite specialists in the battle against infectious diseases	NATURE			English	Article																			0	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					753	754		10.1038/35047215	http://dx.doi.org/10.1038/35047215			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130080				2022-12-28	WOS:000165815200059
J	Duley, L; Henderson-Smart, D; Knight, M; King, J				Duley, L; Henderson-Smart, D; Knight, M; King, J			Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-DOSE ASPIRIN; PREGNANCY-INDUCED HYPERTENSION; RANDOMIZED CONTROLLED-TRIAL; FETAL GROWTH-RETARDATION; HIGH-RISK; WOMEN; PROSTACYCLIN; THROMBOXANE; DOPPLER; PRIMIGRAVIDAE	Objective To assess the effectiveness and safety of antiplatelet drugs for prevention of pre-eclampsia and its consequences. Design Systematic review. Data sources Register of trials maintained by Cochrane Pregnancy and Childbirth Group, Cochrane Controlled Trials Register, and Embase. Included studies Randomised trials involving women at risk of pre-eclampsia, and its complications, allocated to antiplatelet drug(s) versus placebo or no antiplatelet drug. Main outcomes measures Pre-eclampsia, preterm birth, fetal or neonatal death, and small for gestational age baby. Studies were assessed for quality of concealment of allocation and losses to follow up. Results 39 trials (30 563 women) were included, and 45 trials ( > 3000 women) excluded. Use of antiplatelet drugs was associated with a 15% reduction in the risk of pre-eclampsia (32 trials, 29 331 women; relative risk 0.85, 95% confidence interval 0.78 to 0.92; number needed to treat 100, 59 to 167). There was also am 8% reduction in the risk of preterm birth (23 trials, 28 268 women; 0.92, 0.88 to 0.97; 72, 44 to 200), and a 14% reduction in the risk of fetal or neonatal death (30 trials, 30 093 women; 0.86, 0.75 to 0.98; 250, 125 to > 10 000) for women allocated antiplatelet drugs. Small for gestational age babies were reported in 25 trials (20 349 women), with no overall difference between the groups (relative risk 0.92, 0.81 to 1.01). There were no significant differences in other measures of outcome. Conclusions Antiplatelet drugs, largely low dose aspirin, have small to moderate benefits when used for prevention of pre-eclampsia.	Inst Hlth Sci, Resource Ctr Randomised Trials, Oxford OX3 7LF, England; Inst Hlth Sci, Hlth Serv Res Unit, Oxford, England; Queen Elizabeth II Inst Mothers & Infants, New S Wales Ctr Perinatal Hlth Serv Res, Sydney, NSW, Australia; Mater Hosp, Perinatal Epidemiol Unit, Brisbane, Qld, Australia	University of Oxford; University of Oxford	Duley, L (corresponding author), Inst Hlth Sci, Resource Ctr Randomised Trials, Oxford OX3 7LF, England.	lelia.duley@ndm.ox.ac.uk	Knight, Marian/B-6225-2009; Duley, Lelia/E-8107-2015	Knight, Marian/0000-0002-1984-4575; Duley, Lelia/0000-0001-6721-5178				[Anonymous], 1996, Br J Obstet Gynaecol, V103, P39; August P, 1994, 9 INT C INT SOC STUD; Azar R, 1990, P 7 WORLD C HYP PREG; Bassaw B., 1998, Journal of Obstetrics and Gynaecology (Abingdon), V18, P123; BEAUFILS M, 1985, LANCET, V1, P840, DOI 10.1016/S0140-6736(85)92207-X; BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604; BEROYZ G, 1994, LANCET, V343, P619; BUSSOLINO F, 1980, LANCET, V2, P702; Byaruhanga RN, 1998, INT J GYNECOL OBSTET, V60, P129, DOI 10.1016/S0020-7292(97)00257-9; CAPETTA P, 1986, LANCET, V1, P919; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; Carlson NJ., 1991, COMMUNICATION   0906; CASPI E, 1994, AM J REPROD IMMUNOL, V31, P19, DOI 10.1111/j.1600-0897.1994.tb00842.x; Cheng WW, 1991, CHUNG HUA FU CHAN KO, V26, P342; CLASP Collaborative Group, 1994, BRIT J OBSTET GYNAEC, V102, P861; *COCHR CONTR TRIAL, 1999, COCHR COLL COCHR LIB; COLLINS R, 1995, COCHRANE PREGNANCY C; DAVIES NJ, 1995, HYPERTENS PREGNANCY, V14, P49, DOI 10.3109/10641959509058050; DEKKER GA, 1989, THESIS U MED SCH, P150; *DEP HLTH WELSH OF, 1998, REP CONF ENQ MAT DEA; Department of Health, 1996, CONF ENQ STILLB DEAT; DULEY L, 1992, BRIT J OBSTET GYNAEC, V99, P547, DOI 10.1111/j.1471-0528.1992.tb13818.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; Erdmann M, 1999, Z GEBURTSH NEONATOL, V203, P18; Ferrier C, 1996, P 10 WORLD C INT SOC, P151; Gallery EDM, 1997, HYPERTENS PREGNANCY, V16, P229, DOI 10.3109/10641959709031640; GIFFORD RW, 1990, AM J OBSTET GYNECOL, V163, P1689; Gilani A., 1994, SPECIALIST, V10, P323; Golding J, 1998, BRIT J OBSTET GYNAEC, V105, P293, DOI 10.1111/j.1471-0528.1998.tb10089.x; Grab D, 1997, ACTA OBSTET GYN SCAN, V76, P38; Grant JM, 1996, BRIT J OBSTET GYNAEC, V103, P599, DOI 10.1111/j.1471-0528.1996.tb09823.x; Grover V, 1991, J PERINAT MED, V19, P104; GUIDOTTI R, 1988, AM J OBSTET GYNECOL, V158, P80; HACHICHA J, 1988, 6 INT C INT SOC STUD, P144; HAMID R, 1994, BRIT J OBSTET GYNAEC, V101, P481, DOI 10.1111/j.1471-0528.1994.tb13145.x; HAUTH JC, 1993, AM J OBSTET GYNECOL, V168, P1083, DOI 10.1016/0002-9378(93)90351-I; Heinrich J, 1988, P 11 EUR C PER MED 1, P274; Herabutya Y, 1996, INT J GYNECOL OBSTET, V54, P177, DOI 10.1016/0020-7292(96)02701-4; Hermida RC, 1997, HYPERTENSION, V30, P589, DOI 10.1161/01.HYP.30.3.589; Hernandez F., 1996, REV COLOMB OBSTET GI, V47, P197, DOI [10.18597/rcog.1446, DOI 10.18597/RCOG.1446]; HUTTON JD, 1990, NEW ZEAL MED J, V103, P511; IMPERIALE TF, 1991, JAMA-J AM MED ASSOC, V266, P261; *INT STUD ASP PREG, 1993, LANCET, V341, P396; KAAJA R, 1993, OBSTET GYNECOL, V81, P327; KNIGHT M, 2000, COCHRANE COLLABORATI; Kraayenbrink AA, 1994, P 9 INT C INT SOC ST, P125; Leitich H, 1997, BRIT J OBSTET GYNAEC, V104, P450, DOI 10.1111/j.1471-0528.1997.tb11497.x; LOUDEN KA, 1992, BRIT J OBSTET GYNAEC, V99, P371, DOI 10.1111/j.1471-0528.1992.tb13751.x; Martin C, 1996, PROSTAGLANDINS, V51, P321, DOI 10.1016/0090-6980(96)00024-X; McCowan LME, 1999, BRIT J OBSTET GYNAEC, V106, P647, DOI 10.1111/j.1471-0528.1999.tb08362.x; MCPARLAND P, 1992, American Journal of Obstetrics and Gynecology, V166, P438; MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; Michael CA, 1990, P 7 WORLD C HYP PREG, P73; Montenegro CA, 1992, P 8 WORLD C INT SOC, P66; Morris JM, 1996, OBSTET GYNECOL, V87, P74, DOI 10.1016/0029-7844(95)00340-1; NEWNHAM JP, 1995, AUST NZ J OBSTET GYN, V35, P370, DOI 10.1111/j.1479-828X.1995.tb02144.x; Niedner W, 1986, P INT SOC STUD HYP P, P101; North RA, 1990, P 7 WORLD C HYP PREG, P75; OBRIEN WF, 1993, AM J OBSTET GYNECOL, V168, P1164, DOI 10.1016/0002-9378(93)90362-M; OGRADY JP, 1991, COMMUNICATION   0319; PARAZZINI F, 1993, LANCET, V341, P396; Peterseim H, 1986, P 10 EUR C PER MED 1, P290; Pipkin FB, 1996, BRIT J OBSTET GYNAEC, V103, P603, DOI 10.1111/j.1471-0528.1996.tb09824.x; PORRECO RP, 1993, LANCET, V341, P312, DOI 10.1016/0140-6736(93)92672-G; Quenby S, 1992, P 26 BRIT C OBST GYN, P443; Railton A, 1988, P 6 WORLD C INT SOC, P60; Ramaiya C, 1995, E AFR MED J, V72, P690; Regan CL, 1998, BRIT J OBSTET GYNAEC, V105, P732, DOI 10.1111/j.1471-0528.1998.tb10203.x; REGI A, COMMUNICATION; Rey E, 1996, J SOGC J SOC OBSTET, V18, P51; Richards A, 1986, 23 S AFR C OBST GYN, P16; Roberts CS, 1990, P 10 ANN M SOC PER O, P89; Robinson JS, 1993, COMMUNICATION   0325; Rogers MS, 1999, HYPERTENS PREGNANCY, V18, P165, DOI 10.3109/10641959909023076; ROGOV VA, 1993, TERAPEVT ARKH, V65, P65; Rotchell YE, 1998, BRIT J OBSTET GYNAEC, V105, P286, DOI 10.1111/j.1471-0528.1998.tb10088.x; SAJINASTRITAR B, 1994, P 14 EUR C PER MED 1, P182; SAJINASTRITAR B, 1992, J PERINATAL MED S1, V20, P73; Sanchez-Ramos L., 1994, American Journal of Obstetrics and Gynecology, V170, P408; SCHIFF E, 1989, NEW ENGL J MED, V321, P351, DOI 10.1056/NEJM198908103210603; SCHROCKSNADEL H, 1992, GYNECOL OBSTET INVES, V34, P146, DOI 10.1159/000292748; Seki H, 1999, HYPERTENS PREGNANCY, V18, P157, DOI 10.3109/10641959909023075; Sharts-Engel NC, 1992, AM J MATERNAL CHILD, V17, P168; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; SIBAI BM, 1989, OBSTET GYNECOL, V74, P551; SILVER RK, 1993, AM J OBSTET GYNECOL, V169, P1411, DOI 10.1016/0002-9378(93)90410-K; TAYLOR DJ, 1988, HYPERTENS PREGNANCY, P223; Tewari S, 1997, J Indian Med Assoc, V95, P43; Tewari S, 1997, J INDIAN MED ASSOCID, V95, P47; TOPPOZADA M, 1991, INT J GYNECOL OBSTET, V35, P311, DOI 10.1016/0020-7292(91)90663-P; TRUDINGER B, 1988, LANCET, V2, P214; TRUDINGER BJ, 1989, LANCET, V2, P1214; UZAN S, 1991, LANCET, V337, P1427, DOI 10.1016/0140-6736(91)93124-R; UZAN S, 1989, AM J OBSTET GYNECOL, V160, P763, DOI 10.1016/S0002-9378(89)80079-1; VIINIKKA L, 1993, BRIT J OBSTET GYNAEC, V100, P809, DOI 10.1111/j.1471-0528.1993.tb14304.x; VOLPICELLI T, 1999, TRIAL PROSPETTICO SU, P159; Wallenburg HC, 1991, P 2 EUR C PROST REPR, P92; WALLENBURG HCS, 1986, LANCET, V1, P1; WALLENBURG HCS, 1991, AM J OBSTET GYNECOL, V164, P1169, DOI 10.1016/0002-9378(91)90678-K; Wang ZH, 1996, CHINESE MED J-PEKING, V109, P238; WILLIAMS HD, 1993, ANAESTHESIA, V48, P331, DOI 10.1111/j.1365-2044.1993.tb06956.x; Witten FR, 1991, COMMUNICATION   0906; WOLFRUM R, 1977, ARCH GYNAKOL, V224, P114, DOI 10.1007/BF00679468; Zimmermann P., 1997, EUR J ULTRASOUND, V5, P17	105	142	156	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2001	322	7282					329	333		10.1136/bmj.322.7282.329	http://dx.doi.org/10.1136/bmj.322.7282.329			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159655	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000167050000026
J	Cuvelier, C				Cuvelier, C			Psoas hematoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Clin St Elisabeth, B-5000 Namur, Belgium		Cuvelier, C (corresponding author), Clin St Elisabeth, B-5000 Namur, Belgium.		García-Morillo, José-Salvador/L-8365-2018	García-Morillo, José-Salvador/0000-0003-1311-5483					0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					349	349		10.1056/NEJM200102013440506	http://dx.doi.org/10.1056/NEJM200102013440506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172167				2022-12-28	WOS:000166675800006
J	Djimde, A; Doumbo, OK; Cortese, JF; Kayentao, K; Doumbo, S; Diourte, Y; Dicko, A; Su, XZ; Nomura, T; Fidock, DA; Wellems, TE; Plowe, CV; Coulibaly, D				Djimde, A; Doumbo, OK; Cortese, JF; Kayentao, K; Doumbo, S; Diourte, Y; Dicko, A; Su, XZ; Nomura, T; Fidock, DA; Wellems, TE; Plowe, CV; Coulibaly, D			A molecular marker for chloroquine-resistant falciparum malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMODIUM-FALCIPARUM; PFMDR1 GENE; IN-VIVO; AFRICA; ANTIMALARIALS; AMPLIFICATION; POLYMORPHISMS; EPIDEMIOLOGY; MUTATIONS; CAMEROON	Background: Chloroquine-resistant Plasmodium falciparum malaria is a major health problem, particularly in sub-Saharan Africa. Chloroquine resistance has been associated in vitro with point mutations in two genes, pfcrt and pfmdr 1, which encode the P. falciparum digestive-vacuole transmembrane proteins PfCRT and Pgh1, respectively. Methods: To assess the value of these mutations as markers for clinical chloroquine resistance, we measured the association between the mutations and the response to chloroquine treatment in patients with uncomplicated falciparum malaria in Mali. The frequencies of the mutations in patients before and after treatment were compared for evidence of selection of resistance factors as a result of exposure to chloroquine. Results: The pfcrt mutation resulting in the substitution of threonine (T76) for lysine at position 76 was present in all 60 samples from patients with chloroquine-resistant infections (those that persisted or recurred after treatment), as compared with a base-line prevalence of 41 percent in samples obtained before treatment from 116 randomly selected patients (P<0.001), indicating absolute selection for this mutation. The pfmdr 1 mutation resulting in the substitution of tyrosine (Y86) for asparagine at position 86 was also selected for, since it was present in 48 of 56 post-treatment samples from patients with chloroquine-resistant infections (86 percent), as compared with a base-line prevalence of 50 percent in 115 samples obtained before treatment (P<0.001). The presence of pfcrt T76 was more strongly associated with the development of chloroquine resistance (odds ratio, 18.8; 95 percent confidence interval, 6.5 to 58.3) than was the presence of pfmdr 1 Y86 (odds ratio, 3.2; 95 percent confidence interval, 1.5 to 6.8) or the presence of both mutations (odds ratio, 9.8; 95 percent confidence interval, 4.4 to 22.1). Conclusions: This study shows an association between the pfcrt T76 mutation in P. falciparum and the development of chloroquine resistance during the treatment of malaria. This mutation can be used as a marker in surveillance for chloroquine-resistant falciparum malaria. (N Engl J Med 2001;344:257-63.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Malaria Sect, Baltimore, MD 21201 USA; Univ Mali, Fac Med Pharm & Dent, Malaria Res & Training Ctr, Bamako, Mali; NIAID, Malaria Genet Sect, Parasit Dis Lab, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland Baltimore; University of Bamako; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Plowe, CV (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Malaria Sect, 685 W Baltimore St,HSF 480, Baltimore, MD 21201 USA.			Su, Xinzhuan/0000-0003-3246-3248; Fidock, David/0000-0001-6753-8938	NIAID NIH HHS [5P50AI39469, R37 AI050234, N01-AI-85346] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000892, Z01AI000483, N01AI085346, R37AI050234, P50AI039469] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adagu IS, 1999, PARASITOLOGY, V119, P343, DOI 10.1017/S0031182099004862; Anderson TJC, 1999, PARASITOLOGY, V119, P113, DOI 10.1017/S0031182099004552; BAIRD JK, 1991, AM J TROP MED HYG, V44, P640, DOI 10.4269/ajtmh.1991.44.640; Basco LK, 1998, AM J TROP MED HYG, V59, P577, DOI 10.4269/ajtmh.1998.59.577; Basco LK, 1998, AM J TROP MED HYG, V58, P374, DOI 10.4269/ajtmh.1998.58.374; Basco LK, 1999, AM J TROP MED HYG, V61, P807, DOI 10.4269/ajtmh.1999.61.807; Bhattacharya PR, 1997, T ROY SOC TROP MED H, V91, P454, DOI 10.1016/S0035-9203(97)90283-2; Bickii J, 1998, J CLIN MICROBIOL, V36, P243, DOI 10.1128/JCM.36.1.243-247.1998; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; *DIV CONTR TROP DI, 1996, ASS THER EFF ANT DRU; Doumbo OK, 2000, J INFECT DIS, V182, P993, DOI 10.1086/315787; Duraisingh MT, 1997, PARASITOLOGY, V114, P205, DOI 10.1017/S0031182096008487; Fidock DA, 2000, MOL BIOCHEM PARASIT, V110, P1, DOI 10.1016/S0166-6851(00)00249-8; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; FITCH CD, 1970, SCIENCE, V169, P289, DOI 10.1126/science.169.3942.289; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; McCutcheon KRG, 1999, T ROY SOC TROP MED H, V93, P300, DOI 10.1016/S0035-9203(99)90029-9; PETERS W, 1990, Recenti Progressi in Medicina, V81, P749; Plowe CV, 1996, AM J TROP MED HYG, V55, P467, DOI 10.4269/ajtmh.1996.55.467; Povoa MM, 1998, EXP PARASITOL, V88, P64, DOI 10.1006/expr.1998.4195; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7; vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x	36	747	778	0	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2001	344	4					257	263		10.1056/NEJM200101253440403	http://dx.doi.org/10.1056/NEJM200101253440403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	394WA	11172152				2022-12-28	WOS:000166545200003
J	Foster, KL; Plastridge, RA; Bottenheim, JW; Shepson, PB; Finlayson-Pitts, BJ; Spicer, CW				Foster, KL; Plastridge, RA; Bottenheim, JW; Shepson, PB; Finlayson-Pitts, BJ; Spicer, CW			The role of Br-2 and BrCl in surface ozone destruction at polar sunrise	SCIENCE			English	Article							BOUNDARY-LAYER; TEMPERATURE-DEPENDENCE; BROMINE; CHLORINE; O-3; ICE; TROPOSPHERE; ACTIVATION; DEPLETION; HOBR	Bromine atoms are believed to play a central role in the depletion of surface-level ozone in the Arctic at polar sunrise. Br-2, BrCl, and HOBr have been hypothesized as bromine atom precursors, and there is evidence for chlorine atom precursors as well, but these species have not been measured directly. We report here measurements of Br-2, BrCl, and Cl-2 made using atmospheric pressure chemical ionization-mass spectrometry at Alert, Nunavut, Canada. In addition to Br-2 at mixing ratios up to similar to 25 parts per trillion, BrCl was found at levels as high as similar to 35 parts per trillion. Molecular chlorine was not observed, implying that BrCl is the dominant source of chlorine atoms during polar sunrise, consistent with recent modeling studies. Similar formation of bromine compounds and tropospheric ozone destruction may also occur at mid-latitudes but may not be as apparent owing to more efficient mixing in the boundary layer.	Battelle Mem Inst, Columbus, OH 43201 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Environm Canada, Toronto, ON M3H 5T4, Canada; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA	Battelle Memorial Institute; University of California System; University of California Irvine; Environment & Climate Change Canada; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Spicer, CW (corresponding author), Battelle Mem Inst, 505 King Ave, Columbus, OH 43201 USA.		Shepson, Paul B/E-9955-2012	Finlayson-Pitts, Barbara/0000-0003-4650-168X				Abbatt JPD, 1998, J PHYS CHEM A, V102, P3719, DOI 10.1021/jp980932d; Barrie L, 1997, TELLUS B, V49, P450, DOI 10.1034/j.1600-0889.49.issue5.2.x; BARRIE LA, 1988, NATURE, V334, P138, DOI 10.1038/334138a0; Bartlett WP, 1999, ENVIRON SCI TECHNOL, V33, P3410, DOI 10.1021/es990300k; BOTTENHEIM JW, 1986, GEOPHYS RES LETT, V13, P113, DOI 10.1029/GL013i002p00113; Dickerson RR, 1999, J GEOPHYS RES-ATMOS, V104, P21385, DOI 10.1029/1999JD900023; EIGEN M, 1962, J AM CHEM SOC, V84, P1355, DOI 10.1021/ja00867a005; Fickert S, 1999, J GEOPHYS RES-ATMOS, V104, P23719, DOI 10.1029/1999JD900359; Ghosal S, 2000, GEOPHYS RES LETT, V27, P1879, DOI 10.1029/2000GL011381; HAUSMANN M, 1994, J GEOPHYS RES-ATMOS, V99, P25399, DOI 10.1029/94JD01314; HOPPER JF, 1994, J GEOPHYS RES-ATMOS, V99, P25315, DOI 10.1029/94JD02400; Impey GA, 1997, J GEOPHYS RES-ATMOS, V102, P16005, DOI 10.1029/97JD00851; Impey GA, 1999, J ATMOS CHEM, V34, P21, DOI 10.1023/A:1006264912394; KLANING UK, 1985, BER BUNSEN PHYS CHEM, V89, P243; Knipping EM, 2000, SCIENCE, V288, P301, DOI 10.1126/science.288.5464.301; Koop T, 2000, J GEOPHYS RES-ATMOS, V105, P26393, DOI 10.1029/2000JD900413; LEBRAS G, 1995, GEOPHYS RES LETT, V22, P599, DOI 10.1029/94GL03334; LEHRER E, 1997, TELLUS B, V49, P496; Martin S, 1996, J GEOPHYS RES-OCEANS, V101, P12111, DOI 10.1029/96JC00208; MCCONNELL JC, 1992, NATURE, V355, P150, DOI 10.1038/355150a0; Michalowski BA, 2000, J GEOPHYS RES-ATMOS, V105, P15131, DOI 10.1029/2000JD900004; OLTMANS SJ, 1986, J GEOPHYS RES-ATMOS, V91, P5229, DOI 10.1029/JD091iD04p05229; Orlando JJ, 2000, GEOPHYS RES LETT, V27, P2633, DOI 10.1029/2000GL011725; Oum KW, 1998, GEOPHYS RES LETT, V25, P3923, DOI 10.1029/1998GL900078; PEROVICH DK, 1994, J GEOPHYS RES-OCEANS, V99, P16341, DOI 10.1029/94JC01194; Pitts Jr J. N., 2000, CHEM UPPER LOWER ATM; Sander R, 1996, J GEOPHYS RES-ATMOS, V101, P9121, DOI 10.1029/95JD03793; SHEPSON PB, UNPUB; Solberg S, 1996, J ATMOS CHEM, V23, P301, DOI 10.1007/BF00055158; SPICER CW, 1994, ENVIRON SCI TECHNOL, V28, pA412, DOI 10.1021/es00058a001; Spicer CW, 1998, NATURE, V394, P353, DOI 10.1038/28584; Sumner AL, 1999, NATURE, V398, P230, DOI 10.1038/18423; TOOMSAUNTRY D, IN PRESS J GEOPHYS R; Tuckermann M, 1997, TELLUS B, V49, P533, DOI 10.1034/j.1600-0889.49.issue5.9.x; WANG TX, 1994, INORG CHEM, V33, P1050, DOI 10.1021/ic00084a014	35	302	309	4	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					471	474		10.1126/science.291.5503.471	http://dx.doi.org/10.1126/science.291.5503.471			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161198				2022-12-28	WOS:000166487500037
J	Vila, C; Leonard, JA; Gotherstrom, A; Marklund, S; Sandberg, K; Liden, K; Wayne, RK; Ellegren, H				Vila, C; Leonard, JA; Gotherstrom, A; Marklund, S; Sandberg, K; Liden, K; Wayne, RK; Ellegren, H			Widespread origins of domestic horse lineages	SCIENCE			English	Article							MITOCHONDRIAL-DNA; CONTROL REGION; MICROSATELLITES; EVOLUTION; EQUUS	Domestication entails control of wild species and is generally regarded as a complex process confined to a restricted area and culture. Previous DNA sequence analyses of several domestic species have suggested only a Limited number of origination events. We analyzed mitochondrial DNA (mtDNA) control region sequences of 191 domestic horses and found a high diversity of matrilines. Sequence analysis of equids from archaeological sites and Late Pleistocene deposits showed that this diversity was not due to an accelerated mutation rate or an ancient domestication event. Consequently, high mtDNA sequence diversity of horses implies an unprecedented and widespread integration of matrilines and an extensive utilization and taming of wild horses. However, genetic variation at nuclear markers is partitioned among horse breeds and may reflect sex-biased dispersal and breeding.	Uppsala Univ, Dept Evolutionary Biol, S-75236 Uppsala, Sweden; Univ Calif Los Angeles, Dept Organism Biol Ecol & Evolut, Los Angeles, CA 90095 USA; Stockholm Univ, Archeol Res Lab, S-10691 Stockholm, Sweden; Swedish Univ Agr Sci, Dept Anim Breeding & Genet, S-75007 Uppsala, Sweden	Uppsala University; University of California System; University of California Los Angeles; Stockholm University; Swedish University of Agricultural Sciences	Vila, C (corresponding author), Uppsala Univ, Dept Evolutionary Biol, Norbyvagen 18D, S-75236 Uppsala, Sweden.		Klein, Richard G/B-5910-2009; Vila, Carles/H-4893-2013; Leonard, Jennifer/A-7894-2010	Vila, Carles/0000-0002-4206-5246; Gotherstrom, Anders/0000-0001-8579-1304; Leonard, Jennifer/0000-0003-0291-7819				Anthony D., 1996, HORSES TIME, P57; ANTHONY DW, 1991, ANTIQUITY, V65, P22, DOI 10.1017/S0003598X00079278; ANTHONY DW, 1986, CURR ANTHROPOL, V27, P291, DOI 10.1086/203441; ARTANDER P, 1996, MOL GENETIC APPROACH, P399; BENIRSCHKE K, 1965, SCIENCE, V148, P382, DOI 10.1126/science.148.3668.382; BENNETT D, 1999, SPECIES, V628, P1; Braathen H., 1989, RYTTERGRAVER POLITIS; Clutton-Brock J., 1999, NATURAL HIST DOMESTI; Coogle L, 1997, ANIM GENET, V28, P309; DIAMOND JM, 1991, NATURE, V350, P275, DOI 10.1038/350275a0; ELLEGREN H, 1992, ANIM GENET, V23, P1, DOI 10.1111/j.1365-2052.1992.tb00012.x; Forsten A, 1992, ANN ZOOL FENN, V28, P301; GEORGE M, 1986, MOL BIOL EVOL, V3, P535; GLUFFRA E, 2000, GENETICS, V154, P1785; GUERIN G, 1994, ANIM GENET, V25, P62; HAGBERG UE, 1967, ARCHEOLOGY SKEDEMOSS, V2; Leonard JA, 2000, P NATL ACAD SCI USA, V97, P1651, DOI 10.1073/pnas.040453097; Levine MA, 1999, J ANTHROPOL ARCHAEOL, V18, P29, DOI 10.1006/jaar.1998.0332; Mannen H, 1998, GENETICS, V150, P1169; MARKLUND S, 1995, ANIM GENET, V26, P193, DOI 10.1111/j.1365-2052.1995.tb03162.x; MARKLUND S, 1994, ANIM GENET, V25, P19, DOI 10.1111/j.1365-2052.1994.tb00050.x; Oakenfull EA, 1998, ANIM GENET, V29, P456, DOI 10.1046/j.1365-2052.1998.296380.x; PAETKAU D, 1995, MOL ECOL, V4, P347, DOI 10.1111/j.1365-294X.1995.tb00227.x; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Raymond M, 1995, EVOLUTION, V49, P1280, DOI 10.1111/j.1558-5646.1995.tb04456.x; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; Schneider S., 1997, ARLEQUIN VER 1 1 SOF; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Vila C, 1997, SCIENCE, V276, P1687, DOI 10.1126/science.276.5319.1687; Wayne RK, 1999, ANNU REV ECOL SYST, V30, P457, DOI 10.1146/annurev.ecolsys.30.1.457; Winans MC, 1989, EVOLUTION PERISSODAC, V15, P262; ZEUNER FE, 1963, HIST DOMESTICATED AN; [No title captured]	34	319	350	2	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					474	477		10.1126/science.291.5503.474	http://dx.doi.org/10.1126/science.291.5503.474			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161199				2022-12-28	WOS:000166487500038
J	Passegue, E; Jochum, W; Schorpp-Kistner, M; Mohle-Steinlein, U; Wagner, EF				Passegue, E; Jochum, W; Schorpp-Kistner, M; Mohle-Steinlein, U; Wagner, EF			Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage	CELL			English	Article							COLONY-STIMULATING FACTOR; C-JUN; TRANSCRIPTION FACTORS; TRANSGENIC MICE; NEUTROPHILS; APOPTOSIS; PROMOTER; BETA; DIFFERENTIATION; IDENTIFICATION	The functions of JunB during myelopoiesis were studied in vivo. Transgenic mice specifically lacking JunB expression in the myeloid lineage (junB(-/-)Ubi-junB mice) develop a transplantable myeloproliferative disease eventually progressing to blast crisis, which resembles human chronic myeloid leukemia. Similarly, mice reconstituted with ES cell-derived junB(-/-) fetal liver cells also develop a myeloproliferative disease. In both cases, the absence of JunB expression results in increased numbers of granulocyte progenitors, which display enhanced GM-CSF-mediated proliferation and extended survival, associated with changes in the expression levels of the GM-CSF alpha receptor, the anti-apoptotic proteins Bcl2 and Bclx, and the cell cycle regulators p16(INK4a) and c-Jun. Importantly, ectopic expression of JunB fully reverts the immature and hyperproliferative phenotype of JunB-deficient myeloid cells. These results identify JunB as a key transcriptional regulator of myelopoiesis and a potential tumor suppressor gene.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Helmholtz Association; German Cancer Research Center (DKFZ)	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196; Passegue, Emmanuelle/0000-0002-3516-297X				Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; D'Andrea RJ, 1998, J CLIN INVEST, V102, P1951, DOI 10.1172/JCI3729; DRANOFF G, 1994, STEM CELLS, V12, P173; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HSU JC, 1993, CANCER RES, V53, P3789; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kieslinger M, 2000, GENE DEV, V14, P232; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; MOLLINEDO F, 1991, BIOCHEM J, V273, P477, DOI 10.1042/bj2730477; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schorpp M, 1996, NUCLEIC ACIDS RES, V24, P1787, DOI 10.1093/nar/24.9.1787; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Wang ZQ, 1997, MECH DEVELOP, V62, P137, DOI 10.1016/S0925-4773(97)00655-2	34	188	194	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2001	104	1					21	32		10.1016/S0092-8674(01)00188-X	http://dx.doi.org/10.1016/S0092-8674(01)00188-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163237	Bronze			2022-12-28	WOS:000166882300004
J	Whitehouse, CJ; Taylor, RM; Thistlethwaite, A; Zhang, H; Karimi-Busheri, F; Lasko, DD; Weinfeld, M; Caldecott, KW				Whitehouse, CJ; Taylor, RM; Thistlethwaite, A; Zhang, H; Karimi-Busheri, F; Lasko, DD; Weinfeld, M; Caldecott, KW			XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair	CELL			English	Article							BASE EXCISION-REPAIR; LIGASE-III; POLY(ADP-RIBOSE) POLYMERASE; MOLECULAR-CLONING; IONIZING-RADIATION; PROTEIN XRCC1; END-GROUPS; BETA; GENE; ALPHA	XRCC1 protein is required for DNA single-strand break repair and genetic stability but its biochemical role is unknown. Here, we report that XRCC1 interacts with human polynucleotide kinase in addition to its established interactions with DNA polymerase-beta and DNA ligase III. Moreover, these four proteins are coassociated in multiprotein complexes in human cell extract and together they repair single-strand breaks typical of those induced by reactive oxygen species and ionizing radiation. Strikingly, XRCC1 stimulates the DNA kinase and DNA phosphatase activities of polynucleotide kinase at damaged DNA termini and thereby accelerates the overall repair reaction. These data identify a novel pathway for mammalian single-strand break repair and demonstrate a concerted role for XRCC1 and PNK in the initial step of processing damaged DNA ends.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	University of Manchester; University of Alberta; Lady Davis Institute; McGill University	Caldecott, KW (corresponding author), Univ Manchester, Sch Biol Sci, G 38 Stopford Bldg, Manchester M13 9PT, Lancs, England.	caldecott@man.ac.uk	Caldecott, Keith/S-4245-2019; Karimi-Busheri, Feridoun/AAX-7541-2020	Caldecott, Keith/0000-0003-4255-9016; Karimi-Busheri, Feridoun/0000-0002-1936-0503				BAILLY V, 1989, BIOCHEM J, V261, P707, DOI 10.1042/bj2610707; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CALDECOTT KW, 1992, NUCLEIC ACIDS RES, V20, P4575, DOI 10.1093/nar/20.17.4575; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; COQUERELLE T, 1973, INT J RADIAT BIOL, V24, P397, DOI 10.1080/09553007314551251; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LENNARTZ M, 1975, INT J RADIAT BIOL, V27, P577, DOI 10.1080/09553007514550611; Lunn RM, 1999, CANCER RES, V59, P2557; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MILLER MR, 1982, J BIOL CHEM, V257, P46; MILLER MR, 1982, J BIOL CHEM, V257, P204; Miura M, 2000, RADIAT RES, V153, P773, DOI 10.1667/0033-7587(2000)153[0773:BRTIRI]2.0.CO;2; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Nitiss JL, 1998, CONT CANC RES, P517; Rice PA, 1999, NAT STRUCT BIOL, V6, P805, DOI 10.1038/12257; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shen MR, 1998, CANCER RES, V58, P604; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125; SUGIYAMA H, 1994, CHEM RES TOXICOL, V7, P673, DOI 10.1021/tx00041a013; Taylor RM, 2000, NUCLEIC ACIDS RES, V28, P3558, DOI 10.1093/nar/28.18.3558; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; Taylor RM, 1998, CURR BIOL, V8, P877, DOI 10.1016/S0960-9822(07)00350-8; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Ward JF, 1998, CONT CANC RES, P65; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wilson DM, 1998, CONT CANC RES, P29; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; Winters TA, 1999, NUCLEIC ACIDS RES, V27, P2423, DOI 10.1093/nar/27.11.2423	45	498	517	1	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					107	117		10.1016/S0092-8674(01)00195-7	http://dx.doi.org/10.1016/S0092-8674(01)00195-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163244	Bronze			2022-12-28	WOS:000166882300011
J	Kay, AB				Kay, AB			Advances in immunology - Allergy and allergic diseases - Second of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GRASS-POLLEN IMMUNOTHERAPY; FC-EPSILON-RI; MONOCLONAL-ANTIBODY; ATOPIC-DERMATITIS; CHRONIC URTICARIA; CONTROLLED TRIAL; RECEPTOR; ASTHMA; PHASE; AUTOANTIBODIES		Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England	Imperial College London	Kay, AB (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England.							Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Allsopp CEM, 1996, EUR J IMMUNOL, V26, P1951, DOI 10.1002/eji.1830260841; Borish L, 1998, J ALLERGY CLIN IMMUN, V101, P293, DOI 10.1016/S0091-6749(98)70238-6; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; CRETICOS PS, 1986, J CLIN INVEST, V78, P1421; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; LECKIE MJ, IN PRESS LANCET; Lipper GM, 2000, JAMA-J AM MED ASSOC, V283, P175, DOI 10.1001/jama.283.2.175; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Ryan JJ, 1997, J ALLERGY CLIN IMMUN, V99, P1; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; SAMPSON HA, 1992, ACTA DERM-VENEREOL, P34; Slater JW, 1999, DRUGS, V57, P31, DOI 10.2165/00003495-199957010-00004; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Texier C, 2000, J IMMUNOL, V164, P3177, DOI 10.4049/jimmunol.164.6.3177; Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633	33	228	247	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					109	113		10.1056/NEJM200101113440206	http://dx.doi.org/10.1056/NEJM200101113440206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150362				2022-12-28	WOS:000166281100006
J	Stark, AR; Carlo, WA; Tyson, JE; Papile, L; Wright, LL; Shankaran, S; Donovan, EF; Oh, W; Bauer, CR; Saha, S; Poole, WK; Stoll, BJ				Stark, AR; Carlo, WA; Tyson, JE; Papile, L; Wright, LL; Shankaran, S; Donovan, EF; Oh, W; Bauer, CR; Saha, S; Poole, WK; Stoll, BJ		Nat Inst Child Hlth Human Dev Ne	Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LUNG-DISEASE; PREVENT BRONCHOPULMONARY DYSPLASIA; RESPIRATORY-DISTRESS SYNDROME; EARLY ADRENAL INSUFFICIENCY; PREMATURE-INFANTS; NECROTIZING ENTEROCOLITIS; CONTROLLED TRIAL; PRETERM INFANTS; PERFORATION; THERAPY	Background: Early administration of high doses of dexamethasone may reduce the risk of chronic lung disease in premature infants but can cause complications. Whether moderate doses would be as effective but safer is not known. Methods: We randomly assigned 220 infants with a birth weight of 501 to 1000 g who were treated with mechanical ventilation within 12 hours after birth to receive dexamethasone or placebo with either routine ventilatory support or permissive hypercapnia. The dexamethasone was administered within 24 hours after birth at a dose of 0.15 mg per kilogram of body weight per day for three days, followed by a tapering of the dose over a period of seven days. The primary outcome was death or chronic lung disease at 36 weeks' postmenstrual age. Results: The relative risk of death or chronic lung disease in the dexamethasone-treated infants, as compared with those who received placebo, was 0.9 (95 percent confidence interval, 0.8 to 1.1). Since the effect of dexamethasone treatment did not vary according to the ventilatory approach, the two dexamethasone groups and the two placebo groups were combined. The infants in the dexamethasone group were less likely than those in the placebo group to be receiving oxygen supplementation 28 days after birth (P=0.004) or open-label dexamethasone (P=0.01), were more likely to have hypertension (P<0.001), and were more likely to be receiving insulin treatment for hyperglycemia (P=0.02). During the first 14 days, spontaneous gastrointestinal perforation occurred in a larger proportion of infants in the dexamethasone group (13 percent, vs. 4 percent in the placebo group; P=0.02). The dexamethasone-treated infants had a lower weight (P=0.02) and a smaller head circumference (P=0.04) at 36 weeks' postmenstrual age. Conclusions: In preterm infants, early administration of dexamethasone at a moderate dose has no effect on death or chronic lung disease and is associated with gastrointestinal perforation and decreased growth. (N Engl J Med 2001;344:95-101.) Copyright (C) 2001 Massachusetts Medical Society.	Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Alabama, Birmingham, AL USA; Univ Texas, Houston, TX USA; Univ New Mexico, Albuquerque, NM 87131 USA; NICHHD, Bethesda, MD 20892 USA; Wayne State Univ, Detroit, MI USA; Univ Cincinnati, Cincinnati, OH USA; Brown Univ, Women & Infants Hosp, Providence, RI USA; Univ Miami, Miami, FL 33152 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; Emory Univ, Atlanta, GA 30322 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Yale Univ, New Haven, CT USA; Univ Tennessee, Memphis, TN USA; Stanford Univ, Stanford, CA 94305 USA	Harvard University; Brigham & Women's Hospital; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of New Mexico; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Wayne State University; University System of Ohio; University of Cincinnati; Brown University; Women & Infants Hospital Rhode Island; University of Miami; Research Triangle Institute; Emory University; Case Western Reserve University; Yale University; University of Tennessee System; University of Tennessee Health Science Center; Stanford University	Stark, AR (corresponding author), Brigham & Womens Hosp, CWN-6,75 Francis St, Boston, MA 02115 USA.			Saha, Shampa/0000-0002-8305-3495; Stark, Ann/0000-0002-6051-1190	NICHD NIH HHS [U10 HD34167, U10 HD34216, U10 HD21373] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021373, U10HD034216] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD034167] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASCHNER JL, 1988, J PEDIATR-US, V113, P364, DOI 10.1016/S0022-3476(88)80285-3; BUCHHEIT JQ, 1994, PEDIATRICS, V93, P32; Carlo WA, 1999, PEDIATRICS, V104, P738; Cole CH, 1999, NEW ENGL J MED, V340, P1005, DOI 10.1056/NEJM199904013401304; Ehrenkranz RA, 1999, PEDIATRICS, V104, P280, DOI 10.1542/peds.104.2.280; Garland JS, 1999, PEDIATRICS, V104, P91, DOI 10.1542/peds.104.1.91; GoppeltStruebe M, 1997, BIOCHEM PHARMACOL, V53, P1389, DOI 10.1016/S0006-2952(97)00018-X; GRONECK P, 1993, J PEDIATR-US, V122, P938, DOI 10.1016/S0022-3476(09)90024-5; Halliday HL, 1999, BIOL NEONATE, V76, P29, DOI 10.1159/000047044; HARDMAN JG, 1996, GOODMAN GILMANS PHAR, P622; Jobe AH, 1998, EARLY HUM DEV, V53, P81, DOI 10.1016/S0378-3782(98)00045-0; Korte C, 1996, J PEDIATR-US, V128, P257, DOI 10.1016/S0022-3476(96)70404-3; Marinelli KA, 1997, J PEDIATR-US, V130, P594, DOI 10.1016/S0022-3476(97)70244-0; METZGER DL, 1993, J CLIN ENDOCR METAB, V77, P458, DOI 10.1210/jc.77.2.458; MEYER CL, 1991, J PEDIATR SURG, V26, P714, DOI 10.1016/0022-3468(91)90017-N; NG PC, 1991, ARCH DIS CHILD-FETAL, V66, P1164, DOI 10.1136/adc.66.10_Spec_No.1164; Ozdemir A, 1997, PEDIATR PULM, V23, P292, DOI 10.1002/(SICI)1099-0496(199704)23:4<292::AID-PPUL7>3.0.CO;2-O; Papile LA, 1998, NEW ENGL J MED, V338, P1112, DOI 10.1056/NEJM199804163381604; Rastogi A, 1996, PEDIATRICS, V98, P204; Shinwell ES, 1996, ARCH DIS CHILD-FETAL, V74, pF33, DOI 10.1136/fn.74.1.F33; Shorter NA, 1999, J PEDIATR SURG, V34, P442, DOI 10.1016/S0022-3468(99)90495-5; SOLL RF, IN PRESS PEDIATRICS; Stevenson DK, 1998, AM J OBSTET GYNECOL, V179, P1632, DOI 10.1016/S0002-9378(98)70037-7; Tapia JL, 1998, J PEDIATR-US, V132, P48, DOI 10.1016/S0022-3476(98)70483-4; Tsai FJ, 1996, ACTA PAEDIATR, V85, P1487, DOI 10.1111/j.1651-2227.1996.tb13957.x; Van Overmeire B, 2000, NEW ENGL J MED, V343, P674, DOI 10.1056/NEJM200009073431001; Watterberg KL, 1999, PEDIATRICS, V104, P1258, DOI 10.1542/peds.104.6.1258; WATTERBERG KL, 1995, PEDIATRICS, V95, P120; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; Wolfe MM, 1999, NEW ENGL J MED, V341, P548; YEH TF, 1997, PEDIATRICS, V100, P715; YODER MC, 1991, AM REV RESPIR DIS, V143, P1044, DOI 10.1164/ajrccm/143.5_Pt_1.1044	32	322	330	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					95	101		10.1056/NEJM200101113440203	http://dx.doi.org/10.1056/NEJM200101113440203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150359				2022-12-28	WOS:000166281100003
J	Bruner, AG; Gullison, RE; Rice, RE; da Fonseca, GAB				Bruner, AG; Gullison, RE; Rice, RE; da Fonseca, GAB			Effectiveness of parks in protecting tropical biodiversity	SCIENCE			English	Article								We assessed the impacts of anthropogenic threats on 93 protected areas in 22 tropical countries to test the hypothesis that parks are an effective means to protect tropical biodiversity. We found that the majority of parks are successful at stopping land clearing, and to a Lesser degree effective at mitigating logging, hunting, fire, and grazing. Park effectiveness correlates with basic management activities such as enforcement, boundary demarcation, and direct compensation to Local communities, suggesting that even modest increases in funding would directly increase the ability of parks to protect tropical biodiversity.	Conservat Int, Ctr Appl Biodivers Sci, Washington, DC 20037 USA; Univ British Columbia, Ctr Biodivers Res, Vancouver, BC V6T 1Z4, Canada	Conservation International; University of British Columbia	Bruner, AG (corresponding author), Conservat Int, Ctr Appl Biodivers Sci, 2501 M St NW,Suite 200, Washington, DC 20037 USA.	a.bruner@conservation.org	Wrbka, Thomas/A-5699-2010	Wrbka, Thomas/0000-0002-1451-9108				Baillie J., 1996, 1996 IUCN RED LIST T; FERREIRA LV, 1999, AREAS PROTEGIDAS ESP; GREEN MJB, 1996, BIODIVERSITY B WORLD, V1; HANNAH L, 1994, AMBIO, V23, P246; HOCKING M, 2000, EVALUATING EFFECTIVE; *IUCN, 1999, THREATS FOREST PROTE; *IUCN CNPPA, 1994, WCMC GUID PROT AR MA; James A. N., 1999, GLOBAL REV PROTECTED; McNeely JA, 1995, EXPANDING PARTNERSHIPS IN CONSERVATION, P1; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Pimbert M. P., 1997, SOCIAL CHANGE CONSER; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; REDFORD K, 1998, PARKS PERIL PEOPLE P, P455; SINGH S, 1999, ASSESSING MANAGEMENT	14	1005	1088	15	388	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					125	128		10.1126/science.291.5501.125	http://dx.doi.org/10.1126/science.291.5501.125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141563				2022-12-28	WOS:000166259100049
J	Henney, JE				Henney, JE			Devices for in-stent restenosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Henney, JE (corresponding author), US FDA, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					34	34		10.1001/jama.285.1.34	http://dx.doi.org/10.1001/jama.285.1.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150092				2022-12-28	WOS:000166114500004
J	Lawrence, RA; Delbanco, T; Hartman, EE				Lawrence, RA; Delbanco, T; Hartman, EE			A 35-year-old woman experiencing difficulty with breastfeeding	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TO-CHILD TRANSMISSION; COGNITIVE-DEVELOPMENT; OTITIS-MEDIA; RISK-FACTORS; MOTHER; MILK; LACTATION; MASTITIS; SUCKING; WOMEN		Univ Rochester, Sch Med & Dent, Rochester, NY USA	University of Rochester	Hartman, EE (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ABBOUD TK, 1983, ANESTH ANALG, V62, P914; ALHO OP, 1990, INT J PEDIATR OTORHI, V19, P151, DOI 10.1016/0165-5876(90)90221-C; Amin Sanjiv B., 1998, Pediatric Research, V43, p255A; Anderson JW, 1999, AM J CLIN NUTR, V70, P525; ANIANSSON G, 1994, PEDIATR INFECT DIS J, V13, P183, DOI 10.1097/00006454-199403000-00003; Ball TM, 1999, PEDIATRICS, V103, P870; Baumslag Naomi, 1995, MILK MONEY MADNESS C; BERGSTRAND O, 1983, SCAND J GASTROENTERO, V18, P903, DOI 10.3109/00365528309182113; BULOCK F, 1990, DEV MED CHILD NEUROL, V32, P669; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; CHANDRA RK, 1989, ALLERGY, V44, P135, DOI 10.1111/j.1398-9995.1989.tb04331.x; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; CRALL HD, 1991, GYNECOL OBSTET INVES, V31, P17; DATTA S, 1995, ANESTHESIOLOGY, V82, P1346, DOI 10.1097/00000542-199506000-00004; David I, 1998, PROF ENG, V11, P29; de Andraca I, 1995, World Rev Nutr Diet, V78, P1; FAIRBANK L, 2000, INTERVENTIONS PROMOT; FLOREY CDV, 1995, INT J EPIDEMIOL, V24, pS21, DOI 10.1093/ije/24.Supplement_1.S21; FORBES GB, 1988, J PEDIATR-US, V113, P90, DOI 10.1016/S0022-3476(88)80538-9; Foster S., 1999, TYLERS HONEST HERBAL; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; GARTNER LM, 1998, ACOG CLIN REV, V3, P1; HANSON LA, 1989, ACTA PAEDIATR SCAND, P122; Hattevig G, 1999, ACTA PAEDIATR, V88, P7, DOI 10.1080/080352599750029268; Horwood LJ, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e9; Ito S, 2000, NEW ENGL J MED, V343, P118, DOI 10.1056/NEJM200007133430208; Jelliffe D. B., 1978, HUMAN MILK MODERN WO; JELLIN JM, 1999, NATURAL MED COMPREHE; KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029-7844(95)00083-4; Kalkwarf HJ, 1996, AM J CLIN NUTR, V63, P526, DOI 10.1093/ajcn/63.4.526; KAUFMANN R, 1991, SOC SCI MED, V33, P701, DOI 10.1016/0277-9536(91)90024-7; LAWRENCE RA, 1997, REV MED BENEFITS CON; LAWRENCE RA, 1999, BREASTFEEDING GUIDE; *LECH LEAG INT, 1997, WOM ART BREASTF; LITTLEWOOD JM, 1980, LANCET, V2, P1359; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MORROWTLUCAK M, 1988, SOC SCI MED, V26, P635, DOI 10.1016/0277-9536(88)90028-7; NAYLOR AJ, 1994, SEMIN PERINATOL, V18, P525; NEIFERT M, 1996, CONT PEDIAT, V13, P142; NEIFERT MR, 1985, CLIN PERINATOL, V12, P319, DOI 10.1016/S0095-5108(18)30868-6; Newell ML, 1998, AIDS, V12, P831, DOI 10.1097/00002030-199808000-00004; NEWTON ER, 1996, ABM NEWS VIEWS, V2, P1; NEWTON ER, 1996, ABM NEWS VIEWS, V2, P4; NEWTON ER, 1996, ABM NEWS VIEWS, V2, P12; NEWTON N, 1971, AM J CLIN NUTR, V24, P993; NICOLL A, 1995, AIDS, V9, P107, DOI 10.1097/00002030-199509020-00001; NIEBURG P, 1995, AIDS, V9, P396, DOI 10.1097/00002030-199509040-00013; OGLE KS, 1988, J FAM PRACTICE, V26, P139; Peter G, 1997, RED BOOK REP COMM IN, P353; Powers N G, 1997, Pediatr Rev, V18, P147, DOI 10.1542/pir.18-5-147; Raphael Dana, 1973, TENDER GIFT BREASTFE; ROGAN WJ, 1993, EARLY HUM DEV, V31, P181, DOI 10.1016/0378-3782(93)90194-Y; ROSEN AR, 1994, J U ROCH MED CTR, V6, P3; SAPEIKA N, 1947, J OBSTET GYN BRIT EM, V54, P426; Simopoulos AP, 2000, PROSTAG LEUKOTR ESS, V63, P119, DOI 10.1054/plef.2000.0176; Slusser W, 1997, Pediatr Rev, V18, P111, DOI 10.1542/pir.18-4-111; SPISAK S, 1991, 2 FOLLOW UP REPORT S; STEER PL, 1992, CAN J ANAESTH, V39, P231, DOI 10.1007/BF03008782; TEMBOURY MC, 1994, J PEDIATR GASTR NUTR, V18, P32, DOI 10.1097/00005176-199401000-00005; Tess BH, 1998, AIDS, V12, P513, DOI 10.1097/00002030-199805000-00013; THOMSEN AC, 1984, AM J OBSTET GYNECOL, V149, P492, DOI 10.1016/0002-9378(84)90022-X; Tuttle CR, 1996, J AM DIET ASSOC, V96, P885, DOI 10.1016/S0002-8223(96)00241-6; VIRTANEN SM, 1991, DIABETES CARE, V14, P415, DOI 10.2337/diacare.14.5.415; WEBER F, 1986, DEV MED CHILD NEUROL, V28, P19; WHITTEMORE AS, 1994, GYNECOL ONCOL, V55, pS15, DOI 10.1006/gyno.1994.1334; WHO UNICEF, 1989, PROT PROM SUPP BREAS; Woolridge M W, 1986, Midwifery, V2, P164, DOI 10.1016/S0266-6138(86)80041-9; WOOLRIDGE MW, 1985, EARLY HUM DEV, V12, P269, DOI 10.1016/0378-3782(85)90148-3; WOOLRIDGE MW, 1980, LANCET, V2, P1292; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5; Zimmer P, 1997, AM J PUBLIC HEALTH, V87, P904, DOI 10.2105/AJPH.87.6.904	71	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					73	80		10.1001/jama.285.1.73	http://dx.doi.org/10.1001/jama.285.1.73			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150112				2022-12-28	WOS:000166114500027
J	Seidel, S; Kreutzer, R; Smith, D; McNeel, S; Gilliss, D				Seidel, S; Kreutzer, R; Smith, D; McNeel, S; Gilliss, D			Assessment of commercial laboratories performing hair mineral analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRACE-ELEMENT CONTENT; UNITED-STATES; REFERENCE INTERVALS; REFERENCE VALUES; POPULATION; MEDICINE; MELANIN; METALS; LEAD	Context Hair mineral analysis is being used by health care practitioners and promoted by laboratories as a clinical assessment tool and to identify toxic exposures, despite a 1985 study that found poor reliability for this test. Objective To assess whether the reliability of data from commercial laboratories advertising multimineral hair analyses for nutritional or toxicity assessment has improved since the 1985 study. Design, Setting, and Participants A split hair sample taken from near the scalp of a single healthy volunteer was submitted for analysis to 6 commercial US laboratories, which analyze 90% of samples submitted for mineral analysis in the United States. Main Outcome Measures Agreement of test results for each analyte, laboratory reference ranges, laboratory characteristics, and interpretation of health implications. Results Laboratory differences in highest and lowest reported mineral concentrations for the split sample exceeded 10-fold for 12 minerals, and statistically significant (P<.05) extreme Values were reported for 14 of the 31 minerals that were analyzed by 3 or more laboratories. Variations also were found in laboratory sample preparation methods and calibration standards. Laboratory designations of normal reference ranges varied greatly, resulting in conflicting classifications (high, normal, or low) of nearly all analyzed minerals. Laboratories also provided conflicting dietary and nutritional supplement recommendations based on their results. Conclusions Hair mineral analysis from these laboratories was unreliable, and we recommend that health care practitioners refrain from using such analyses to assess individual nutritional status or suspected environmental exposures. Problems with the regulation and certification of these laboratories also should be addressed.	Calif Dept Hlth Serv, Environm Hlth Invest Branch, Oakland, CA 94612 USA; Impact Assessment Inc, Oakland, CA USA	California Department of Health Care Services	Seidel, S (corresponding author), Calif Dept Hlth Serv, Environm Hlth Invest Branch, 1515 Clay St,Suite 1700, Oakland, CA 94612 USA.							ATTAR KM, 1990, CLIN CHEM, V36, P477; AUFREITER S, 1990, BIOL TRACE ELEM RES, V26-7, P721, DOI 10.1007/BF02992728; BARRETT S, 1985, JAMA-J AM MED ASSOC, V254, P1041, DOI 10.1001/jama.254.8.1041; BENCKO V, 1995, TOXICOLOGY, V101, P29, DOI 10.1016/0300-483X(95)03018-B; BOS AJJ, 1985, SCI TOTAL ENVIRON, V42, P157, DOI 10.1016/0048-9697(85)90015-4; CHITTLEBOROUGH G, 1980, SCI TOTAL ENVIRON, V14, P53, DOI 10.1016/0048-9697(80)90126-6; DELVES HT, 1985, CLIN ENDOCRINOL META, V14, P725, DOI 10.1016/S0300-595X(85)80014-1; DIPIETRO ES, 1989, BIOL TRACE ELEM RES, V22, P83, DOI 10.1007/BF02917419; DOI R, 1988, SCI TOTAL ENVIRON, V77, P153, DOI 10.1016/0048-9697(88)90052-6; Hoffmann K, 2000, J EXPO ANAL ENV EPID, V10, P126, DOI 10.1038/sj.jea.7500081; HOPPS HC, 1977, SCI TOTAL ENVIRON, V7, P71, DOI 10.1016/0048-9697(77)90018-3; IYENGAR GV, 1984, SCI TOTAL ENVIRON, V38, P125, DOI 10.1016/0048-9697(84)90211-0; IYENGAR V, 1988, CLIN CHEM, V34, P474; KLEVAY LM, 1987, AM J CLIN NUTR, V46, P233, DOI 10.1093/ajcn/46.2.233; KOONS RD, 1994, J ANAL TOXICOL, V18, P36, DOI 10.1093/jat/18.1.36; Kronstrand R, 1999, CLIN CHEM, V45, P1485; LARSSON BS, 1993, PIGM CELL RES, V6, P127, DOI 10.1111/j.1600-0749.1993.tb00591.x; Mahaffey KR, 1999, PUBLIC HEALTH REP, V114, P397, DOI 10.1093/phr/114.5.397; Miekeley N, 1998, SCI TOTAL ENVIRON, V218, P9, DOI 10.1016/S0048-9697(98)00185-5; OKAMOTO K, 1985, CLIN CHEM, V31, P1592; OTHMAN I, 1980, SCI TOTAL ENVIRON, V16, P267, DOI 10.1016/0048-9697(80)90111-4; PASCHAL DC, 1989, ENVIRON RES, V48, P17, DOI 10.1016/S0013-9351(89)80081-7; RABINOWITZ M, 1976, ARCH ENVIRON HEALTH, V31, P220, DOI 10.1080/00039896.1976.10667223; SALMELA S, 1981, ANAL CHIM ACTA, V125, P131, DOI 10.1016/S0003-2670(01)85057-1; Senofonte O, 1989, Ann Ist Super Sanita, V25, P385; *SHANGH I NUCL RES, 1988, CERT CERT REF MAT HU; SKYPECK HH, 1990, CLIN PHYSIOL BIOCH, V8, P70; Sokal R. R., 1981, BIOMETRY; *STAT CORP, 1999, STAT STAT SOFTW VERS; Stout PR, 2000, DRUG METAB DISPOS, V28, P113; Suzuki T., 1988, BIOL MONITORING TOXI, P623; TAYLOR A, 1986, ANN CLIN BIOCHEM, V23, P364, DOI 10.1177/000456328602300402; VANCE DE, 1988, BIOL TRACE ELEM RES, V17, P109, DOI 10.1007/BF02795450; *WHO, 1990, WHO SER, V101; WILHELM M, 1989, J ANAL TOXICOL, V13, P17, DOI 10.1093/jat/13.1.17; Wilhelm M, 1996, ZBL HYG UMWELTMED, V198, P485; YAMAMOTO R, 1978, INT ARCH OCC ENV HEA, V42, P1, DOI 10.1007/BF00385706; YOSHINAGA J, 1990, SCI TOTAL ENVIRON, V99, P125, DOI 10.1016/0048-9697(90)90217-I	38	109	120	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					67	72		10.1001/jama.285.1.67	http://dx.doi.org/10.1001/jama.285.1.67			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150111				2022-12-28	WOS:000166114500026
J	Altose, MD; Redline, S; Deitz, CD; Quinlan, KJ; Eichenhorn, MS; Conway, WA; Jentons, RL; Braden, K; Ketchum, M; Wise, RA; Permutt, S; Rand, CS; Daniel, M; Santopietro, V; Weeks, KA; Scanlon, PD; Patel, AM; Utz, JP; Williams, DE; Caron, GM; Micras, KS; Buist, AS; Johnson, LR; Bortz, VJ; Persons, SL; Schueler, HA; Bailey, WC; Brooks, CM; Gerald, LB; Montiel, L; Tashkin, DP; Coulson, AH; Kleerup, EC; Li, VC; Nides, MA; Zuniga, IP; Lee, YE; Anthonisen, NR; Manfreda, J; Rempel-Rossum, SC; Stoyko, JM; Connett, JE; Kjelsberg, MO; Bollenbeck, MT; Kurnow, KJ; Madhok, TC; Skeans, MA; Voelker, HT; Rogers, RM; Owens, GR; Vitale, FM; Pusateri, ME; Kanner, RE; Villegas, GM; Esplin, C; Stayner, RS; Bascom, R; Landis, JR; Maurer, JR; Phillips, Y; Rennard, SI; Stoller, JK; Tager, I; Thomas, A; Hyatt, RE; Lambrew, CT; Mason, BA; Hurd, SS; Weinmann, G; Wu, MC				Altose, MD; Redline, S; Deitz, CD; Quinlan, KJ; Eichenhorn, MS; Conway, WA; Jentons, RL; Braden, K; Ketchum, M; Wise, RA; Permutt, S; Rand, CS; Daniel, M; Santopietro, V; Weeks, KA; Scanlon, PD; Patel, AM; Utz, JP; Williams, DE; Caron, GM; Micras, KS; Buist, AS; Johnson, LR; Bortz, VJ; Persons, SL; Schueler, HA; Bailey, WC; Brooks, CM; Gerald, LB; Montiel, L; Tashkin, DP; Coulson, AH; Kleerup, EC; Li, VC; Nides, MA; Zuniga, IP; Lee, YE; Anthonisen, NR; Manfreda, J; Rempel-Rossum, SC; Stoyko, JM; Connett, JE; Kjelsberg, MO; Bollenbeck, MT; Kurnow, KJ; Madhok, TC; Skeans, MA; Voelker, HT; Rogers, RM; Owens, GR; Vitale, FM; Pusateri, ME; Kanner, RE; Villegas, GM; Esplin, C; Stayner, RS; Bascom, R; Landis, JR; Maurer, JR; Phillips, Y; Rennard, SI; Stoller, JK; Tager, I; Thomas, A; Hyatt, RE; Lambrew, CT; Mason, BA; Hurd, SS; Weinmann, G; Wu, MC		Lung Hlth Study Res Grp	Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM TREATMENT; RANDOMIZED CONTROLLED TRIAL; LUNG HEALTH; BRONCHODILATOR THERAPY; CORTICOSTEROID USE; COPD; ASTHMA; BUDESONIDE; HYPERRESPONSIVENESS; SMOKING	Background: Chronic obstructive pulmonary disease (COPD) results from a progressive decline in lung function, which is thought to be the consequence of airway inflammation. We hypothesized that antiinflammatory therapy with inhaled corticosteroids would slow this decline. Methods: We enrolled 1116 persons with COPD whose forced expiratory volume in one second (FEV1) was 30 to 90 percent of the predicted value in a 10-center, placebo-controlled, randomized trial of inhaled triamcinolone acetonide administered at a dose of 600 microg twice daily. The primary outcome measure was the rate of decline in FEV1) after the administration of a bronchodilator. The secondary outcome measures included respiratory symptoms, use of health care services, and airway reactivity. In a substudy of 412 participants, we measured bone density in the lumbar spine and femur at base line and one and three years after the beginning of treatment. Results: The mean duration of follow-up was 40 months. The rate of decline in the FEV1) after bronchodilator use was similar in the 559 participants in the triamcinolone group and the 557 participants in the placebo group (mean [+/-SE], 44.2+/-2.9 vs. 47.0+/-3.0 ml per year, P=0.50). Members of the triamcinolone group had fewer respiratory symptoms during the course of the study (21.1 per 100 person-years vs. 28.2 per 100 person-years, P=0.005) and had fewer visits to a physician because of a respiratory illness (1.2 per 100 person-years vs. 2.1 per 100 person-years, P=0.03). Those taking triamcinolone also had lower airway reactivity in response to methacholine challenge at 9 months and 33 months (P=0.02 for both comparisons). After three years, the bone density of the lumbar spine (P=0.007) and the femur (P<0.001) was significantly lower in the triamcinolone group. Conclusions: Inhaled triamcinolone does not slow the rate of decline in lung function in people with COPD, but it improves airway reactivity and respiratory symptoms and decreases the use of health care services for respiratory problems. These benefits should be weighed against the potential long-term adverse effects of triamcinolone on bone mineral density. (N Engl J Med 2000;343:1902-9.) (C) 2000, Massachusetts Medical Society.	Lung Hlth Study Coordinating Ctr, Minneapolis, MN 55414 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20205 USA	Mayo Clinic; Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Connett, JE (corresponding author), Lung Hlth Study Coordinating Ctr, 2221 Univ Ave SE,Suite 200, Minneapolis, MN 55414 USA.		Landis, J. Richard/A-9330-2010	Wise, Robert/0000-0002-8353-2349	NHLBI NIH HHS [5U01-HL50267-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL050267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Bourbeau J, 1998, THORAX, V53, P477, DOI 10.1136/thx.53.6.477; Boushey HA, 1999, NEW ENGL J MED, V340, P1990, DOI 10.1056/NEJM199906243402509; BUIST AS, 1993, CHEST, V103, P1863, DOI 10.1378/chest.103.6.1863; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Confalonieri M, 1998, THORAX, V53, P583, DOI 10.1136/thx.53.7.583; *COPD GUID GROUP S, 1997, THORAX S5, V52, pS1; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DOMPELING E, 1992, EUR RESPIR J, V5, P945; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312; Harper R, 1997, THORAX, V52, P879, DOI 10.1136/thx.52.10.879; Jackevicius C, 1997, CHEST, V111, P296, DOI 10.1378/chest.111.2.296; Jackevicius CA, 1997, ANN PHARMACOTHER, V31, P160, DOI 10.1177/106002809703100204; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Kerstjens HAM, 1996, AM J RESP CRIT CARE, V154, pS266, DOI 10.1164/ajrccm/154.6_Pt_2.S266; Lan KKG, 1982, COMMUN STATIST C, V1, P207, DOI DOI 10.1080/07474948208836014; Paggiaro PL, 1998, LANCET, V351, P1968; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Renkema TEJ, 1996, CHEST, V109, P1156, DOI 10.1378/chest.109.5.1156; Rutgers SR, 1998, AM J RESP CRIT CARE, V157, P880, DOI 10.1164/ajrccm.157.3.9709100; SAS Institute, 1997, SAS STAT SOFTW CHANG; SHERMAN CB, 1992, AM REV RESPIR DIS, V146, P855, DOI 10.1164/ajrccm/146.4.855; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; van Grunsven PM, 1999, THORAX, V54, P7, DOI 10.1136/thx.54.1.7; vanSchayck CP, 1996, EUR RESPIR J, V9, P1969, DOI 10.1183/09031936.96.09101969; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; WEINER P, 1995, CHEST, V108, P1568, DOI 10.1378/chest.108.6.1568; WEIR DC, 1993, THORAX, V48, P309, DOI 10.1136/thx.48.4.309; Wise RA, 1997, PREV MED, V26, P418, DOI 10.1006/pmed.1997.0181	39	544	554	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2000	343	26					1902	1909						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386VR	11136260				2022-12-28	WOS:000166082700001
J	Rajagopalan, S; Vivancos, V; Nicolas, E; Dickson, BJ				Rajagopalan, S; Vivancos, V; Nicolas, E; Dickson, BJ			Selecting a longitudinal pathway: Robo receptors specify the lateral position of axons in the Drosophila CNS	CELL			English	Article							NEURONAL GROWTH CONES; GRASSHOPPER EMBRYOS; NERVOUS-SYSTEM; GUIDANCE RECEPTORS; FASCICLIN-II; MIDLINE; SLIT; EXPRESSION; DOMAINS; FASCICULATION	On each side of the midline of the Drosophila CNS, axons are organized into a series of parallel pathways. Here we show that the midline repellent Slit, previously identified as a short-range signal that regulates midline crossing, also functions at long range to pattern these longitudinal pathways. In this long-range function, Slit signals through the receptors Robo2 and Robo3. Axons expressing neither, one, or both of these receptors project in one of three discrete lateral zones, each successively further from the midline. Loss of robo2 or robo3 function repositions axons closer to the midline, while gain of robo2 or robo3 function shifts axons further from the midline. Local cues further refine the lateral position. Together, these long- and short-range guidance cues allow growth cones to select with precision a specific longitudinal pathway.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Dickson, BJ (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	dickson@nt.imp.univie.ac.at	Dickson, Barry/AAE-7632-2019	Dickson, Barry/0000-0003-0715-892X				Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1984, J NEUROSCI, V4, P2311; Battye R, 1999, DEVELOPMENT, V126, P2475; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Chuang PT, 2000, CURR OPIN GENET DEV, V10, P515, DOI 10.1016/S0959-437X(00)00121-0; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; FRASER SE, 1980, ANNU REV NEUROSCI, V3, P319, DOI 10.1146/annurev.ne.03.030180.001535; Fritz JL, 2000, DEVELOPMENT, V127, P1991; GIERER A, 1981, BIOL CYBERN, V42, P69, DOI 10.1007/BF00335161; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Newsome TP, 2000, DEVELOPMENT, V127, P851; O'Keefe DD, 1998, DEVELOPMENT, V125, P3915; O'Leary DDM, 1999, CELL, V96, P255, DOI 10.1016/S0092-8674(00)80565-6; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PRESTIGE MC, 1975, PROC R SOC SER B-BIO, V190, P77, DOI 10.1098/rspb.1975.0080; Rajagopalan S, 2000, NEURON, V28, P767, DOI 10.1016/S0896-6273(00)00152-5; RAPER JA, 1983, J NEUROSCI, V3, P20; RAPER JA, 1984, J NEUROSCI, V4, P2329; RAPER JA, 1983, J NEUROSCI, V3, P31; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Simpson JH, 2000, CELL, V103, P1019, DOI 10.1016/S0092-8674(00)00206-3; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Sun Q, 2000, DEVELOPMENT, V127, P801; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; XU T, 1993, DEVELOPMENT, V117, P1223; Zoo YM, 2000, CELL, V102, P363, DOI 10.1016/S0092-8674(00)00041-6	42	230	233	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1033	1045		10.1016/S0092-8674(00)00207-5	http://dx.doi.org/10.1016/S0092-8674(00)00207-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163180	Bronze			2022-12-28	WOS:000166040600007
J	Pende, M; Kozma, SC; Jaquet, M; Oorschot, V; Burcelin, R; Le Marchand-Brustel, Y; Klumperman, J; Thorens, B; Thomas, G				Pende, M; Kozma, SC; Jaquet, M; Oorschot, V; Burcelin, R; Le Marchand-Brustel, Y; Klumperman, J; Thorens, B; Thomas, G			Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice	NATURE			English	Article							P70 S6 KINASE; INSULIN-RECEPTOR; YOUNG-RAT; DISRUPTION; RESISTANCE; SECRETION; GROWTH; GENE; MALNUTRITION; MECHANISM	Insulin controls glucose homeostasis by regulating glucose use in peripheral tissues, and its own production and secretion in pancreatic beta cells(1-3). These responses are largely mediated downstream of the insulin receptor substrates, IRS-1 and IRS-2 (refs 4-8), through distinct signalling pathways. Although a number of effectors of these pathways have been identified, their roles in mediating glucose homeostasis are poorly defined(9). Here we show that mice deficient for S6 kinase 1, an effector of the phosphatidylinositide-3-OH kinase signalling pathway(9), are hypoinsulinaemic and glucose intolerant. Whereas insulin resistance is not observed in isolated muscle, such mice exhibit a sharp reduction in glucose-induced insulin secretion and in pancreatic insulin content. This is not due to a lesion in glucose sensing or insulin production, but to a reduction in pancreatic endocrine mass, which is accounted for by a selective decrease in beta -cell size. The observed phenotype closely parallels those of preclinical type 2 diabetes mellitus, in which malnutrition-induced hypoinsulinaemia predisposes individuals to glucose intolerance(10-12).	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Res Inst Biomembranes, NL-3584 CX Utrecht, Netherlands; Fac Med, INSERM, E 99 11, F-06107 Nice, France	Friedrich Miescher Institute for Biomedical Research; University of Lausanne; Utrecht University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Thomas, G (corresponding author), Friedrich Miescher Inst, CH-4058 Basel, Switzerland.	gthomas@fmi.ch	Thomas, George/K-9235-2014; Pende, Mario/AFR-1348-2022	Thomas, George/0000-0003-3518-8149; Pende, Mario/0000-0002-7864-8937				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CASTELLINO P, 1987, J CLIN INVEST, V80, P1784, DOI 10.1172/JCI113272; CRACE CJ, 1990, DIABETES METAB, V16, P484; DeFronzo RA, 1997, DIABETES REV, V5, P177; Dumonteil E, 1998, ENDOCRINOLOGY, V139, P4540, DOI 10.1210/en.139.11.4540; FABIAN MC, 1993, TRANSPLANTATION, V56, P1137, DOI 10.1097/00007890-199311000-00017; GIORDANO E, 1993, AM J PHYSIOL, V265, pC358, DOI 10.1152/ajpcell.1993.265.2.C358; Guillam MT, 1997, NAT GENET, V17, P503, DOI 10.1038/ng1297-503b; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HOPCROFT DW, 1985, HORM METAB RES, V17, P559, DOI 10.1055/s-2007-1013606; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Phillips DIW, 1996, DIABETOLOGIA, V39, P1119; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shepherd PR, 1998, BIOCHEM J, V335, P711; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; SWENNE I, 1992, DIABETOLOGIA, V35, P939, DOI 10.1007/BF00401422; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; SWENNE I, 1988, J ENDOCRINOL, V118, P295, DOI 10.1677/joe.0.1180295; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; WEIBEL ER, 1979, B EUR PHYSIOPATH RES, V15, P999; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	32	360	377	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					994	997		10.1038/35050135	http://dx.doi.org/10.1038/35050135			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140689				2022-12-28	WOS:000165951100055
J	Sata, N; Eberman, K; Eberl, K; Maier, J				Sata, N; Eberman, K; Eberl, K; Maier, J			Mesoscopic fast ion conduction in nanometre-scale planar heterostructures	NATURE			English	Article							SPACE-CHARGE REGIONS; SOLID 2-PHASE SYSTEMS; DEFECT CHEMISTRY; ENHANCEMENT; ELECTROLYTES; FILMS; PHASE	Ion conduction is of prime importance for solid-state reactions in ionic systems, and for devices such as high-temperature batteries and fuel cells, chemical filters and sensors(1,2). Ionic conductivity in solid electrolytes can be improved by dissolving appropriate impurities into the structure or by introducing interfaces that cause the redistribution of ions in the space-charge regions(3-11). Heterojunctions in two-phase systems should be particularly efficient at improving ionic conduction(3,4), and a qualitatively different conductivity behaviour is expected when interface spacing is comparable to or smaller than the width of the space-charge regions in comparatively large crystals(12-15). Here we report the preparation, by molecular-beam epitaxy, of defined heterolayered films composed of CaF2 and BaF2 that exhibit ionic conductivity (parallel to the interfaces) increasing proportionally with interface density-for interfacial spacing greater than 50 nanometres. The results are in excellent agreement with semi-infinite space-charge calculations(3), assuming a redistribution of fluoride ions at the interfaces. If the spacing is reduced further, the boundary zones overlap and the predicted mesoscopic size effect(3,12) is observed. At this point, the single layers lose their individuality and an artificial ionically conducting material with anomalous transport properties is generated. Our results should lead to fundamental insight into ionic contact processes and to tailored ionic conductors of potential relevance for medium-temperature applications.	Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	Max Planck Society	Maier, J (corresponding author), Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany.							BOLLMANN W, 1973, PHYS STATUS SOLIDI A, V16, P187, DOI 10.1002/pssa.2210160120; BOLLMANN W, 1973, PHYS STATUS SOLIDI A, V18, P313, DOI 10.1002/pssa.2210180132; EBERL K, 1995, P NATO ADC RES WORKS; FARROW RFC, 1981, J VAC SCI TECHNOL, V19, P415, DOI 10.1116/1.571030; Fueki, 1990, SOLID STATE IONICS; Lee JS, 2000, J ELECTROCHEM SOC, V147, P2407, DOI 10.1149/1.1393545; LIANG CC, 1973, J ELECTROCHEM SOC, V120, P1289, DOI 10.1149/1.2403248; Maier J, 2000, ELECTROCHEMISTRY, V68, P395, DOI 10.5796/electrochemistry.68.395; Maier J, 2000, SOLID STATE IONICS, V131, P13, DOI 10.1016/S0167-2738(00)00618-4; MAIER J, 1990, SOLID STATE IONICS, V40-1, P463, DOI 10.1016/0167-2738(90)90380-A; MAIER J, 1987, J ELECTROCHEM SOC, V134, P1524, DOI 10.1149/1.2100703; MAIER J, 1985, J PHYS CHEM SOLIDS, V46, P309, DOI 10.1016/0022-3697(85)90172-6; MAIER J, 1985, BER BUNSEN PHYS CHEM, V89, P355, DOI 10.1002/bbpc.19850890402; MAIER J, 1987, SOLID STATE IONICS, V23, P59, DOI 10.1016/0167-2738(87)90082-8; MAIER J, 1995, PROG SOLID STATE CH, V23, P171, DOI 10.1016/0079-6786(95)00004-E; MAIER J, 1984, BER BUNSEN PHYS CHEM, V88, P1057, DOI 10.1002/bbpc.198400007; Puin W, 2000, SOLID STATE IONICS, V131, P159, DOI 10.1016/S0167-2738(00)00630-5; SAITO Y, 1995, J ELECTROCHEM SOC, V142, P3078, DOI 10.1149/1.2048691; Schoonman J., 1979, Fast ion transport in solids. Electrodes and electrolytes, P631; Schoonman J, 2000, SOLID STATE IONICS, V135, P5, DOI 10.1016/S0167-2738(00)00324-6; SHAHI K, 1980, APPL PHYS LETT, V37, P757, DOI 10.1063/1.92023; Tuller HL, 2000, SOLID STATE IONICS, V131, P143, DOI 10.1016/S0167-2738(00)00629-9; Wagner C, 1930, Z PHYS CHEM B-CHEM E, V11, P163	23	683	700	7	424	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					946	949		10.1038/35050047	http://dx.doi.org/10.1038/35050047			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140675				2022-12-28	WOS:000165951100041
J	Chibotaru, LF; Ceulemans, A; Bruyndoncx, V; Moshchalkov, VV				Chibotaru, LF; Ceulemans, A; Bruyndoncx, V; Moshchalkov, VV			Symmetry-induced formation of antivortices in mesoscopic superconductors	NATURE			English	Article							LATTICE	Recent progress in nanotechnology has stimulated interest in mesoscopic superconductors as components for quantum computing and cryoelectronics. The critical parameters for superconductivity (current and field) of a mesoscopic sample are determined by the pattern of vortices in it, which in turn is controlled by the symmetry imposed by the shape of the sample (see ref. 1 and references therein). Hitherto it has been unclear what happens when the number of vortices is not consistent with the natural symmetry. Here we show that additional vortex-antivortex pairs nucleate spontaneously so as to preserve the symmetry of the sample. For example, in a square with three vortices, the spontaneously generated pair, along with the original three vortices, distribute themselves so that the four vortices sit in the four corners, with the antivortex in the centre. The measured superconducting phase boundary (of superconducting transition temperature T-c versus magnetic field strength) is in very good agreement with the calculations, giving direct experimental evidence for these symmetry-induced vortex-antivortex pairs. Vortex entry into the sample is also changed: vortices enter a square in fours, with antivortices generated to preserve the imposed vorticity. The symmetry-induced nucleation of antivortices is not restricted to superconductors, but should also apply to symmetrically confined superfluids and Bose-Einstein condensates.	Katholieke Univ Leuven, Vaste Stof Fys Magnetisme Lab, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Afdeling Kwantumchem, B-3001 Louvain, Belgium	KU Leuven; KU Leuven	Moshchalkov, VV (corresponding author), Katholieke Univ Leuven, Vaste Stof Fys Magnetisme Lab, Celestijnenlaan 200D, B-3001 Louvain, Belgium.	victor.moshchalkov@fys.kuleuven.ac.be	Moshchalkov, Victor V/I-7232-2013	Chibotaru, Liviu/0000-0003-1556-0812				Abrikosov A. A., 2017, FUNDAMENTALS THEORY; [Anonymous], 1966, SUPERCONDUCTIVITY ME; Bruyndoncx V, 1996, EUROPHYS LETT, V36, P449, DOI 10.1209/epl/i1996-00250-2; CHANG AM, 1992, APPL PHYS LETT, V61, P1974, DOI 10.1063/1.108334; Harada K, 1996, SCIENCE, V274, P1167, DOI 10.1126/science.274.5290.1167; HESS HF, 1989, PHYS REV LETT, V62, P214, DOI 10.1103/PhysRevLett.62.214; Lifshitz E. M., 1975, QUANTUM MECH; MAGGIOAPRILE I, 1995, PHYS REV LETT, V75, P2754, DOI 10.1103/PhysRevLett.75.2754; MOSER A, 1995, PHYS REV LETT, V74, P1847, DOI 10.1103/PhysRevLett.74.1847; MOSHCHALKOV VV, 2000, HDB NANOSTRUCTURED M, V3, P451; Oral A, 1996, APPL PHYS LETT, V69, P1324, DOI 10.1063/1.117582; SAINTJAM.D, 1965, PHYS LETT, V15, P13, DOI 10.1016/0031-9163(65)91101-7; SAINTJAMES D, 1963, PHYS LETT, V7, P306, DOI 10.1016/0031-9163(63)90047-7	14	277	278	3	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					833	835		10.1038/35048521	http://dx.doi.org/10.1038/35048521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130716	Green Published			2022-12-28	WOS:000165831300042
J	Zhao, B; Moore, JS; Beebe, DJ				Zhao, B; Moore, JS; Beebe, DJ			Surface-directed liquid flow inside microchannels	SCIENCE			English	Article							MICROFLUIDIC SYSTEMS; ELECTROPHORESIS; REAGENTS	Self-assembled monolayer chemistry was used in combination with either multistream laminar flow or photolithography to pattern surface free energies inside microchannel networks. Aqueous Liquids introduced into these patterned channels are confined to the hydrophilic pathways, provided the pressure is maintained below a critical value. The maximum pressure is determined by the surface free energy of the liquid, the advancing contact angle of the Liquid on the hydrophobic regions, and the channel depth. Surface-directed liquid flow was used to create pressure-sensitive switches inside channel networks. The ability to confine Liquid flow inside microchannels with only two physical walls is expected to be useful in applications where a Large gas-liquid interface is critical, as demonstrated here by a gas-liquid reaction.	Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Wisconsin System; University of Wisconsin Madison	Moore, JS (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA.	moore@scs.uiuc.edu						ADAMSON AW, 1990, PHYSICAL CHEM SURFAC; Beebe DJ, 2000, P NATL ACAD SCI USA, V97, P13488, DOI 10.1073/pnas.250273097; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; BENI G, 1981, J APPL PHYS, V52, P6011, DOI 10.1063/1.329822; Burns MA, 1996, P NATL ACAD SCI USA, V93, P5556, DOI 10.1073/pnas.93.11.5556; Darhuber AA, 2000, J APPL PHYS, V87, P7768, DOI 10.1063/1.373452; Delamarche E, 1997, SCIENCE, V276, P779, DOI 10.1126/science.276.5313.779; FAHRENBERG J, 1995, J MICROMECH MICROENG, V5, P169, DOI 10.1088/0960-1317/5/2/029; Freemantle M, 1999, CHEM ENG NEWS, V77, P8, DOI 10.1021/cen-v077n005.p008a; Gau H, 1999, SCIENCE, V283, P46, DOI 10.1126/science.283.5398.46; Goll C, 1996, J MICROMECH MICROENG, V6, P77, DOI 10.1088/0960-1317/6/1/017; Handique K, 1997, P SOC PHOTO-OPT INS, V3224, P185, DOI 10.1117/12.284515; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; Ichimura K, 2000, SCIENCE, V288, P1624, DOI 10.1126/science.288.5471.1624; JACOBSON SC, 1995, ELECTROPHORESIS, V16, P481, DOI 10.1002/elps.1150160179; Kataoka DE, 1999, NATURE, V402, P794, DOI 10.1038/45521; Kenis PJA, 1999, SCIENCE, V285, P83, DOI 10.1126/science.285.5424.83; Kovacs GTA., 1998, MICROMACHINED TRANSD; McDonald JC, 2000, ELECTROPHORESIS, V21, P27, DOI 10.1002/(SICI)1522-2683(20000101)21:1<27::AID-ELPS27>3.0.CO;2-C; Oleschuk RD, 2000, ANAL CHEM, V72, P585, DOI 10.1021/ac990751n; RICH DH, 1975, J AM CHEM SOC, V97, P1575, DOI 10.1021/ja00839a052; SalimiMoosavi H, 1997, J AM CHEM SOC, V119, P8716, DOI 10.1021/ja971735f; Stroock AD, 2000, PHYS REV LETT, V84, P3314, DOI 10.1103/PhysRevLett.84.3314; Takayama S, 1999, P NATL ACAD SCI USA, V96, P5545, DOI 10.1073/pnas.96.10.5545; Ulman A, 1996, CHEM REV, V96, P1533, DOI 10.1021/cr9502357; Ulman A., 1991, INTRO ULTRATHIN ORGA; Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113; Weigl BH, 1999, SCIENCE, V283, P346, DOI 10.1126/science.283.5400.346; Yang X, 1998, SENSOR ACTUAT A-PHYS, V64, P101, DOI 10.1016/S0924-4247(97)01660-9; Zhao B, 1999, LANGMUIR, V15, P6856, DOI 10.1021/la9903088	30	661	707	10	312	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	2001	291	5506					1023	1026		10.1126/science.291.5506.1023	http://dx.doi.org/10.1126/science.291.5506.1023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161212				2022-12-28	WOS:000166860100040
J	Zwieniecki, MA; Melcher, PJ; Holbrook, NM				Zwieniecki, MA; Melcher, PJ; Holbrook, NM			Hydrogel control of xylem hydraulic resistance in plants	SCIENCE			English	Article							WATER TRANSPORT; CONDUCTIVITY; PRESSURE; PECTIN; CONDUCTANCE; L.	Increasing concentrations of ions flowing through the xylem of plants produce rapid, substantial, and reversible decreases in hydraulic resistance. Changes in hydraulic resistance in response to solution ion concentration, pH, and nonpolar solvents are consistent with this process being mediated by hydrogels, The effect is Localized to intervessel bordered pits, suggesting that microchannels in the pit membranes are altered by the swelling and deswelling of pectins, which are known hydrogels, The existence of an ion-mediated response breaks the Long-held paradigm of the xylem as a system of inert pipes and suggests a mechanism by which plants may regulate their internal flow regime.	Harvard Univ, Cambridge, MA 02138 USA	Harvard University	Zwieniecki, MA (corresponding author), Harvard Univ, 16 Divin Ave, Cambridge, MA 02138 USA.	mzwienie@oeb.harvard.edu	Melcher, Peter J/S-4579-2017; Zwieniecki, Maciej A/D-3078-2011	Melcher, Peter J/0000-0002-6778-5792; Zwieniecki, Maciej/0000-0002-3774-4455				Barker Martin, 1995, Selbyana, V16, P201; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; BRETT K, 1996, PHYSL BIOCH PLANT CE; Brodribb TJ, 2000, PLANT CELL ENVIRON, V23, P1381, DOI 10.1046/j.1365-3040.2000.00647.x; deBoer AH, 1997, J EXP BOT, V48, P441, DOI 10.1093/jxb/48.Special_Issue.441; Gartner B.L., 1995, PLANT STEMS PHYSL FU; HOLBROOK NM, 1995, SCIENCE, V270, P1193, DOI 10.1126/science.270.5239.1193; Hubbard RM, 1999, TREE PHYSIOL, V19, P165; LIDE DR, 1995, CRC HDB CHEM PHYSICS; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; MEINZER FC, 1990, PLANT CELL ENVIRON, V13, P383, DOI 10.1111/j.1365-3040.1990.tb02142.x; Melcher PJ, 1998, J EXP BOT, V49, P1757, DOI 10.1093/jexbot/49.327.1757; Mencuccini M, 1999, AUST J PLANT PHYSIOL, V26, P115, DOI 10.1071/PP98137; Musabayane CT, 2000, J ENDOCRINOL, V164, P1, DOI 10.1677/joe.0.1640001; Pate John S., 1995, P177, DOI 10.1016/B978-012276460-8/50010-2; POCKMAN WT, 1995, NATURE, V378, P715, DOI 10.1038/378715a0; SCHMID R, 1964, CELLULAR ULTRASTRUCT, P291; SCHURR U, 1995, PLANT CELL ENVIRON, V18, P409, DOI 10.1111/j.1365-3040.1995.tb00375.x; Sperry John S., 1995, P105, DOI 10.1016/B978-012276460-8/50007-2; SPERRY JS, 1988, PLANT CELL ENVIRON, V11, P35, DOI 10.1111/j.1365-3040.1988.tb01774.x; TANAKA T, 1981, SCI AM, V244, P124, DOI 10.1038/scientificamerican0181-124; Thakur BR, 1997, CRIT REV FOOD SCI, V37, P47, DOI 10.1080/10408399709527767; Tibbits CW, 1998, CARBOHYD RES, V310, P101, DOI 10.1016/S0008-6215(98)00172-4; TYREE MT, 1989, ANNU REV PLANT PHYS, V40, P19, DOI 10.1146/annurev.pp.40.060189.000315; van Ieperen W, 2000, J EXP BOT, V51, P769, DOI 10.1093/jexbot/51.345.769; Zimmermann M. H., 1982, Encyclopedia of plant physiology. New series. Volume 12B. Physiological plant ecology. II. Water relations and carbon assimilation. [Lange, O.L.; Nobel, P.S.; Osmond, C.B.; Ziegler, H. (Editors)], P135; Zimmermann M.H., 1984, XYLEM STRUCTURE ASCE, V26, P165; ZIMMERMANN MH, 1978, CAN J BOT, V56, P2286, DOI 10.1139/b78-274; Zimmermann U, 2000, BIOTECHNIQUES, V29, P564, DOI 10.2144/00293rv01; Zwieniecki MA, 2000, PLANT CELL ENVIRON, V23, P407, DOI 10.1046/j.1365-3040.2000.00554.x; Zwieniecki MA, 1998, PLANT CELL ENVIRON, V21, P1173, DOI 10.1046/j.1365-3040.1998.00342.x; ZWIENIECKI MA, IN PRESS J EXP BOT	32	425	455	5	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	2001	291	5506					1059	1062		10.1126/science.1057175	http://dx.doi.org/10.1126/science.1057175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161220				2022-12-28	WOS:000166860100049
J	Brent, J; McMartin, K; Phillips, S; Aaron, C; Kulig, K				Brent, J; McMartin, K; Phillips, S; Aaron, C; Kulig, K		Methylpyrazole Toxic Alcohols Stud	Fomepizole for the treatment of methanol poisoning	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METABOLIC INTERACTIONS; OCULAR TOXICITY; METHYL FORMATE; ANIMAL-MODEL; FORMIC-ACID; 4-METHYLPYRAZOLE; MONKEY; DEHYDROGENASE; ETHANOL; THERAPY	Background: Methanol poisoning may result in metabolic acidosis, blindness, and death. The inhibition of alcohol dehydrogenase is fundamental to the treatment of methanol poisoning. We performed a multicenter study to evaluate fomepizole, an inhibitor of alcohol dehydrogenase, in the treatment of patients with methanol poisoning. Methods: We administered intravenous fomepizole to 11 consecutive patients who presented with methanol poisoning at a participating center. Serial clinical and laboratory studies, including measurements of plasma formic acid and fomepizole, were performed. The outcomes measured were the preservation of visual acuity, the resolution of metabolic acidosis, the inhibition of formic acid production, the achievement of therapeutic plasma concentrations of fomepizole with the dosing regimen, residual illness or disability, and death. Results: Plasma formic acid concentrations were detectable in eight patients, and these concentrations were closely correlated with the initial arterial pH values (r = 0.92, P < 0.001). In response to fomepizole, plasma formic acid concentrations fell and metabolic abnormalities resolved in all patients. Nine patients survived. Seven patients initially had visual abnormalities, but at the end of the trial no surviving patient had any detectable visual deficits related to methanol poisoning. Fomepizole had few adverse effects. The two patients who died had anoxic brain injury that was present at the time of enrollment. During treatment, methanol had an elimination half-life of 54 hours. Conclusions: Fomepizole appears to be safe and effective in the treatment of methanol poisoning. (N Engl J Med 2001;344:424-9.) Copyright (C) 2001 Massachusetts Medical Society.	Toxicol Associates, Denver, CO 80210 USA; Univ Colorado, Hlth Sci Ctr, Sect Clin & Toxicol, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Div Emergency Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Sect Pediat Pharmacol, Denver, CO USA; Louisiana State Univ, Med Ctr, Dept Pharmacol, Shreveport, LA USA; Univ Massachusetts, Med Ctr, Dept Emergency Med, Worcester, MA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Massachusetts System; University of Massachusetts Worcester	Brent, J (corresponding author), Toxicol Associates, 2555 S Downing,Suite 260, Denver, CO 80210 USA.	jeffrey.brent@uchsc.edu	Aaron, Cynthia/AAZ-4258-2021	Aaron, Cynthia/0000-0003-1608-8345	FOOD AND DRUG ADMINISTRATION [R01FD001256] Funding Source: NIH RePORTER; FDA HHS [FDR-001256-01] Funding Source: Medline	FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); FDA HHS		ABOLIN C, 1980, BIOCHEM MED METAB B, V23, P209, DOI 10.1016/0006-2944(80)90073-3; AGNER K, 1949, Q J STUD ALCOHOL, V9, P516; ALHA AR, 1958, ANN MED EXP BIOL FEN, V36, P444; BAKER RN, 1969, J CHROMATOGR SCI, V7, P312, DOI 10.1093/chromsci/7.5.312; BAUD FJ, 1986, J TOXICOL-CLIN TOXIC, V24, P463, DOI 10.3109/15563658608995388; BLOMSTRAND R, 1979, P NATL ACAD SCI USA, V76, P3499, DOI 10.1073/pnas.76.7.3499; BLOMSTRAND R, 1980, ARCH BIOCHEM BIOPHYS, V199, P591, DOI 10.1016/0003-9861(80)90317-3; BLOMSTRAND R, 1984, DRUG ALCOHOL DEPEN, V13, P9, DOI 10.1016/0376-8716(84)90028-0; BLOMSTRAND R, 1984, DRUG ALCOHOL DEPEN, V13, P343, DOI 10.1016/0376-8716(84)90002-4; Borron SW, 1999, LANCET, V354, P831; Brent J, 1999, NEW ENGL J MED, V340, P832, DOI 10.1056/NEJM199903183401102; Burns MJ, 1997, ANN EMERG MED, V30, P829, DOI 10.1016/S0196-0644(97)70060-X; CLAY KL, 1975, TOXICOL APPL PHARM, V34, P49, DOI 10.1016/0041-008X(75)90174-X; DICZFALUSY U, 1904, BIOMED CHROMATOGR, V2, P226; FRASER AD, 1989, J ANAL TOXICOL, V13, P73, DOI 10.1093/jat/13.2.73; Girault C, 1999, J TOXICOL-CLIN TOXIC, V37, P777, DOI 10.1081/CLT-100102456; Hantson P, 1999, INTENS CARE MED, V25, P528, DOI 10.1007/s001340050893; Jacobsen D, 1997, J TOXICOL-CLIN TOXIC, V35, P127, DOI 10.3109/15563659709001182; JACOBSEN D, 1990, Journal of Emergency Medicine, V8, P455, DOI 10.1016/0736-4679(90)90176-V; JACOBSEN D, 1988, ALCOHOL CLIN EXP RES, V12, P516, DOI 10.1111/j.1530-0277.1988.tb00235.x; Jobard E, 1996, J TOXICOL-CLIN TOXIC, V34, P373, DOI 10.3109/15563659609013806; KAGER L, 1974, ACTA PATH MICRO IM A, VA 82, P534; Litovitz TL, 1998, AM J EMERG MED, V16, P443, DOI 10.1016/S0735-6757(98)90000-6; MARTINAMAT G, 1978, TOXICOL APPL PHARM, V45, P201, DOI 10.1016/0041-008X(78)90040-6; MCMARTIN KE, 1975, BIOCHEM MED METAB B, V13, P319, DOI 10.1016/0006-2944(75)90171-4; MCMARTIN KE, 1984, J TOXICOL-CLIN TOXIC, V22, P133, DOI 10.3109/15563658408992549; MCMARTIN KE, 1980, ARCH BIOCHEM BIOPHYS, V199, P606, DOI 10.1016/0003-9861(80)90318-5; ONEILL B, 1983, J STUD ALCOHOL, V44, P222, DOI 10.15288/jsa.1983.44.222; ROE O, 1946, ACTA MED SCAND, V182, P1; SEJERSTED OM, 1983, ACTA MED SCAND, V213, P105; STURTEVANT FM, 1976, N-S ARCH PHARMACOL, V293, P203, DOI 10.1007/BF00507342; UOTILA L, 1974, J BIOL CHEM, V249, P7653	32	220	226	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 8	2001	344	6					424	429		10.1056/NEJM200102083440605	http://dx.doi.org/10.1056/NEJM200102083440605			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399FH	11172179	Bronze			2022-12-28	WOS:000166800600005
J	Reynolds, TB; Fink, GR				Reynolds, TB; Fink, GR			Bakers' yeast, a model for fungal biofilm formation	SCIENCE			English	Article							SLIDING MOTILITY; INVASIVE GROWTH; SACCHAROMYCES; FLO11	Biofilms are formed by the aggregation of microorganisms into multicellular structures that adhere to surfaces. Here we show that bakers' yeast Saccharomyces cerevisiae can initiate biofilm formation. When grown in Low-glucose medium, the yeast cells adhered avidly to a number of plastic surfaces. On semi-solid (0.3% agar) medium they formed "mats": complex multicellular structures composed of yeast-form cells. Both attachment to plastic and mat formation require Flo11p, a member of a Large family of fungal cell surface glycoproteins involved in adherence. The ability to study biofilm formation in a tractable genetic system may facilitate the identification of new targets for antifungal therapy.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Fink, GR (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	gfink@wi.mit.edu		Reynolds, Todd/0000-0002-2867-7182	NIGMS NIH HHS [5 RO1 GM40266, GM20565] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020565, R01GM040266] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baillie GS, 1999, METHOD ENZYMOL, V310, P644; Cormack BP, 1999, SCIENCE, V285, P578, DOI 10.1126/science.285.5427.578; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Gagiano M, 1999, MOL MICROBIOL, V31, P103, DOI 10.1046/j.1365-2958.1999.01151.x; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Guo B, 2000, P NATL ACAD SCI USA, V97, P12158, DOI 10.1073/pnas.220420397; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HAZEN KC, 1987, J MICROBIOL METH, V6, P289, DOI 10.1016/0167-7012(87)90066-2; Hoyer LL, 1998, CURR GENET, V33, P451, DOI 10.1007/s002940050359; Liu HP, 1996, GENETICS, V144, P967; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Martinez A, 1999, J BACTERIOL, V181, P7331; O'Toole G, 2000, ANNU REV MICROBIOL, V54, P49, DOI 10.1146/annurev.micro.54.1.49; Recht J, 2000, J BACTERIOL, V182, P4348, DOI 10.1128/JB.182.15.4348-4351.2000; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Sundstrom P, 1999, CURR OPIN MICROBIOL, V2, P353, DOI 10.1016/S1369-5274(99)80062-9	19	428	445	4	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	2001	291	5505					878	881		10.1126/science.291.5505.878	http://dx.doi.org/10.1126/science.291.5505.878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157168				2022-12-28	WOS:000166771700046
J	Owen, DK; Lewith, G; Stephens, CR				Owen, DK; Lewith, G; Stephens, CR			Can doctors respond to patients' increasing interest in complementary and alternative medicine?	BRITISH MEDICAL JOURNAL			English	Article									Winchester Homeopath Practice, Winchester SO22 6RL, Hants, England; Southampton Gen Hosp, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Owen, DK (corresponding author), Homeopath Phys Teaching Grp Oxford, Oxford OX1 2NP, England.			Lewith, George/0000-0002-2364-3960				BARBERIS L, IN PRESS J ALTERNATI; Barker S, 2000, MED EDUC, V34, P159, DOI 10.1046/j.1365-2923.2000.00617.x; Berman B M, 1995, J Am Board Fam Pract, V8, P361; *BMA HOUS, 1999, REP M DIFF MED SCH P; British Medical Association, 1993, COMPL MED NEW APPR G; CARSTON M, 1997, FAM MED, V29, P559; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST E, 1995, ARCH INTERN MED, V155, P2405, DOI 10.1001/archinte.155.22.2405; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FREEMAN R, 1998, MENTORING GEN PRACTI, P103; FURNHAM A, 1993, COMPLEMENTARY THERAP, V1, P120; *GEN MED COUNC, 1993, TOM DOCT REC UND MED; GRIFFITHS M, 1992, J EDUC TEACHING, V18, P69, DOI 10.1080/0260747920180107; Hawkins P., 2000, SUPERVISION HELPING; LEWITH G, IN PRESS J R COLL PH; Lewith GT, 2000, COMPLEMENT THER MED, V8, P202, DOI 10.1054/ctim.2000.0377; Morgan D., 1998, COMPLEMENT THER MED, V6, P64; OWEN D, IN PRESS J MED ED; Rampes H, 1997, J ROY SOC MED, V90, P19, DOI 10.1177/014107689709000107; REILLY D, 1987, DEV INTEGRATED MED R; THOMAS K, 1995, NATL SURVEY ACCESS C; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; Zollman C, 2000, ABC COMPLEMENTARY ME	23	63	65	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					154	157		10.1136/bmj.322.7279.154	http://dx.doi.org/10.1136/bmj.322.7279.154			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159576	Green Published			2022-12-28	WOS:000166615300030
J	Madden, JC; Ruiz, N; Caparon, M				Madden, JC; Ruiz, N; Caparon, M			Cytolysin-mediated translocation (CMT): A functional equivalent of type III secretion in Gram-positive bacteria	CELL			English	Article							GROUP-A STREPTOCOCCI; CYCLIC ADP-RIBOSE; PROINFLAMMATORY RESPONSES; YERSINIA-ENTEROCOLITICA; CHOLESTEROL-BINDING; CYSTEINE PROTEASE; STREPTOLYSIN-O; VIRULENCE; PORE; MEMBRANE	Type III secretion for injection of effector proteins into host cells has not been described for Gram-positive bacteria despite their importance in disease. Here, we describe an injection pathway for the Gram-positive pathogen Streptococcus pyogenes that utilizes streptolysin O (SLO), a cholesterol-dependent cytolysin. The data support a model in which an effector is translocated through the SLO pore by a polarized process. The effector, SPN (S. pyogenes NAD-glycohydrolase), is capable of producing the potent second messenger cyclic ADP-ribose, and SLO and SPN act synergistically to trigger cytotoxicity. These data provide a novel paradigm for the function of the cholesterol-dependent cytolysin family and its wide distribution suggests that cytolysin-mediated translocation (CMT) may be the equivalent of type III secretion for Gram-positive pathogens.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Caparon, M (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	caparon@borcim.wustl.edu		Ruiz, Natividad/0000-0002-6369-2206	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045254] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38273] Funding Source: Medline; NIAMS NIH HHS [AR45254] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P616; Betschel SD, 1998, INFECT IMMUN, V66, P1671, DOI 10.1128/IAI.66.4.1671-1679.1998; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Billington SJ, 2000, FEMS MICROBIOL LETT, V182, P197, DOI 10.1016/S0378-1097(99)00536-4; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; BOMFORD R, 1980, INT ARCH ALLER A IMM, V63, P170, DOI 10.1159/000232623; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; CAPARON MG, 1992, J BACTERIOL, V174, P5693, DOI 10.1128/JB.174.17.5693-5701.1992; CARLSON AS, 1957, J EXP MED, V106, P15, DOI 10.1084/jem.106.1.15; Cheng LW, 2000, TRENDS MICROBIOL, V8, P214, DOI 10.1016/S0966-842X(99)01665-0; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; COSSART P, 1989, INFECT IMMUN, V57, P3629, DOI 10.1128/IAI.57.11.3629-3636.1989; Ellemor DM, 1999, INFECT IMMUN, V67, P4902, DOI 10.1128/IAI.67.9.4902-4907.1999; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Gerlach D, 1996, FEMS MICROBIOL LETT, V136, P71; GRECO R, 1995, RES MICROBIOL, V146, P551, DOI 10.1016/0923-2508(96)80561-4; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; HAKANSSON S, 1993, INFECT IMMUN, V61, P71; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Harshey RM, 1996, TRENDS MICROBIOL, V4, P226, DOI 10.1016/0966-842X(96)10037-8; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Ji YD, 1996, INFECT IMMUN, V64, P503, DOI 10.1128/IAI.64.2.503-510.1996; Jost BH, 1999, INFECT IMMUN, V67, P1723; KARASAWA T, 1995, FEMS MICROBIOL LETT, V130, P201; LAPENTA D, 1994, P NATL ACAD SCI USA, V91, P12115, DOI 10.1073/pnas.91.25.12115; Lee VT, 1999, MOL MICROBIOL, V31, P1619, DOI 10.1046/j.1365-2958.1999.01270.x; Lukomski S, 1999, INFECT IMMUN, V67, P1779; LUTTICKEN R, 1976, J CLIN MICROBIOL, V3, P533; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Miao EA, 2000, P NATL ACAD SCI USA, V97, P7539, DOI 10.1073/pnas.97.13.7539; Nagarajan Vasantha, 1993, P713; Neyt C, 1999, MOL MICROBIOL, V33, P971, DOI 10.1046/j.1365-2958.1999.01537.x; OKADA N, 1993, MOL MICROBIOL, V7, P893, DOI 10.1111/j.1365-2958.1993.tb01180.x; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Ruiz N, 1998, MOL MICROBIOL, V27, P337, DOI 10.1046/j.1365-2958.1998.00681.x; SCOTT JR, 1986, J EXP MED, V164, P1641, DOI 10.1084/jem.164.5.1641; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Tardy F, 1999, EMBO J, V18, P6793, DOI 10.1093/emboj/18.23.6793; Tsai PJ, 1998, INFECT IMMUN, V66, P1460, DOI 10.1128/IAI.66.4.1460-1466.1998; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207; Wang B, 1997, INFECT IMMUN, V65, P2119, DOI 10.1128/IAI.65.6.2119-2126.1997	44	228	239	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					143	152		10.1016/S0092-8674(01)00198-2	http://dx.doi.org/10.1016/S0092-8674(01)00198-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163247	Bronze			2022-12-28	WOS:000166882300014
J	Berger, A				Berger, A			Vaccine improves memory in "Alzheimer's" mice	BRITISH MEDICAL JOURNAL			English	News Item																		Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					9	9		10.1136/bmj.322.7277.9	http://dx.doi.org/10.1136/bmj.322.7277.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141137	Green Published			2022-12-28	WOS:000166341400009
J	Chiong, W				Chiong, W			Diagnosing and defining disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Chiong, W (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							CAPLAN AL, 1981, CONCEPTS HLTH DIS IN, P23; Engelhardt H, 1981, CONCEPTS HLTH DIS IN, P31; Groopman J, 2000, NEW YORKER, P78; Hacking Ian, 1998, MAD TRAVELERS; NAGEL T, 1986, VIEW NOWHERE; Rosenberg C, 1992, FRAMING DIS STUDIES, P13; Roueche B., 1991, MED DETECTIVES	7	17	17	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					89	90		10.1001/jama.285.1.89	http://dx.doi.org/10.1001/jama.285.1.89			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150118				2022-12-28	WOS:000166114500032
J	Juengst, E; Fossel, M				Juengst, E; Fossel, M			The ethics of embryonic stem cells - Now and forever, cells without end	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLONING; TRANSPLANTATION; DIFFERENTIATE; REPLACEMENT; DERIVATION; THERAPY; BIOLOGY		Case Western Reserve Univ, Sch Med, Ctr Biomed Eth, Cleveland, OH 44106 USA; Michigan State Univ, Coll Human Med, Dept Med, E Lansing, MI 48824 USA	Case Western Reserve University; Michigan State University; Michigan State University College of Human Medicine	Fossel, M (corresponding author), Box 630, Ada, MI 49301 USA.	Mfossel@aol.com		Juengst, Eric/0000-0002-8374-5774				Ad Hoc Group of Consultants to the Advisory Committee to the Director,NIH, 1994, REP HUM EMBR RES PAN; *AM ASS ADV SCI, 1999, STEM CELL RES APPL M; ANDREWS LB, 2000, ETHICAL ISSUES HUMAN, V2, pA1; Armstrong RJE, 2000, CELL TRANSPLANT, V9, P139, DOI 10.1177/096368970000900202; Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; Basser RL, 1998, RECENT RES CANCER, V152, P355; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Boogaerts MA, 1996, ANN ONCOL, V7, P1; Branick V, 1999, Health Prog, V80, P37; Brooks PM, 1997, J RHEUMATOL, V24, P19; Burt RK, 2000, J CLIN IMMUNOL, V20, P1, DOI 10.1023/A:1006673408343; CALLAHAN D, 1995, HASTINGS CENT REP, V25, P39, DOI 10.2307/3562493; Chapman AR., 1999, STEM CELL RES APPL M; Colman A, 2000, TRENDS BIOTECHNOL, V18, P192, DOI 10.1016/S0167-7799(00)01434-7; Dua HS, 2000, SURV OPHTHALMOL, V44, P415, DOI 10.1016/S0039-6257(00)00109-0; Edwards BE, 2000, FERTIL STERIL, V74, P1, DOI 10.1016/S0015-0282(00)00583-5; Exner BG, 1997, STEM CELLS, V15, P171, DOI 10.1002/stem.5530150822; FLANNERY EJ, 2000, ETHICAL ISSUES HUMAN, V2, pD1; Furton Edward J, 1999, Ethics Medics, V24, P3; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gearhart J, 1998, SCIENCE, V282, P1061, DOI 10.1126/science.282.5391.1061; Harris LH, 2000, WOMEN HEALTH ISS, V10, P146, DOI 10.1016/S1049-3867(00)00035-9; Kiger AA, 2000, NATURE, V407, P750, DOI 10.1038/35037606; Kikyo N, 2000, J CELL SCI, V113, P11; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kruse F E, 1997, Curr Opin Ophthalmol, V8, P46, DOI 10.1097/00055735-199708000-00007; Lake JA, 2000, J CELL SCI, V113, P555; Lavoir MC, 1998, REPROD FERT DEVELOP, V10, P557, DOI 10.1071/RD98083; Lazarus HM, 1998, CANCER INVEST, V16, P102, DOI 10.3109/07357909809039764; Lebacqz K, 1999, HASTINGS CENT REP, V29, P31; Lin HF, 1997, ANNU REV GENET, V31, P455, DOI 10.1146/annurev.genet.31.1.455; McGee G, 1999, KENNEDY INST ETHIC J, V9, P151, DOI 10.1353/ken.1999.0012; McGuire WP, 1998, CURR PROB CANCER, V22, P138, DOI 10.1016/S0147-0272(98)90005-8; Munsie MJ, 2000, CURR BIOL, V10, P989, DOI 10.1016/S0960-9822(00)00648-5; MURPHY TF, 1985, J MED ETHICS, V11, P79, DOI 10.1136/jme.11.2.79; *NAT BIOETH ADV CO, 2000, ETH ISS HUM STEM CEL, V2; *NAT BIOETH ADV CO, 1999, ETH ISS HUM STEM CEL, V1; Ourednik V, 1999, CLIN GENET, V56, P267, DOI 10.1034/j.1399-0004.1999.560403.x; Pedersen RA, 1999, SCI AM, V280, P68, DOI 10.1038/scientificamerican0499-68; Revel M, 2000, ISR MED ASSOC J, V2, P8; ROBERTSON JA, 1995, HASTINGS CENT REP, V25, P37, DOI 10.2307/3562492; Robertson JA, 1999, KENNEDY INST ETHIC J, V9, P109, DOI 10.1353/ken.1999.0013; Roche PA, 2000, WOMEN HEALTH ISS, V10, P136, DOI 10.1016/S1049-3867(00)00037-2; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SAULESCU J, 2000, AUST NZ J MED, V30, P492; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Snowden John A., 1999, Current Opinion in Rheumatology, V11, P167, DOI 10.1097/00002281-199905000-00003; Solter D, 1999, CROAT MED J, V40, P309; Steinbock B, 1992, LIFE BIRTH MORAL LEG; Stephenson J, 2000, JAMA-J AM MED ASSOC, V284, P1773, DOI 10.1001/jama.284.14.1773; Territo M, 1997, J RHEUMATOL, V24, P36; Thomas E. Donnall, 1997, Archivum Immunologiae et Therapiae Experimentalis, V45, P1; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tooley Michael, 1983, ABORTION INFANTICIDE; Tran J, 2000, NATURE, V407, P754, DOI 10.1038/35037613; Trounson A, 1998, REPROD FERT DEVELOP, V10, P121, DOI 10.1071/R98042; Tyndall A, 1997, J RHEUMATOL, V24, P94; Warren MA., 1997, MORAL STATUS OBLIGAT; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Young FE, 2000, SCIENCE, V287, P1424, DOI 10.1126/science.287.5457.1424; 1968, HUMANAE VITAE REGULA	63	33	33	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3180	3184		10.1001/jama.284.24.3180	http://dx.doi.org/10.1001/jama.284.24.3180			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	385FZ	11135785				2022-12-28	WOS:000165994100039
J	Gauthier-Clerc, M; Le Maho, Y; Clerquin, Y; Drault, S; Handrich, Y				Gauthier-Clerc, M; Le Maho, Y; Clerquin, Y; Drault, S; Handrich, Y			Ecophysiology - Penguin fathers preserve food for their chicks	NATURE			English	Article							KING PENGUIN; APTENODYTES-PATAGONICA		CNRS, Ctr Ecol & Physiol Energet, F-67087 Strasbourg 2, France; Inst Francais Rech Tecnol Polaire, F-29280 Plouzane, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gauthier-Clerc, M (corresponding author), CNRS, Ctr Ecol & Physiol Energet, 23 Rue Becquerel, F-67087 Strasbourg 2, France.		Handrich, Yves/AAD-6472-2022					Barrat A, 1976, COM NAT FR RECH ANTA, V40, P9, DOI DOI 10.1016/J.ATHEROSCLEROSIS.2014.12.010; BARRE H, 1978, J PHYSIOL-PARIS, V74, P555; CHEREL Y, 1992, IBIS, V134, P118, DOI 10.1111/j.1474-919X.1992.tb08388.x; Foxton P., 1956, Discovery Reports, V28, P191; Hart T. J., 1942, Discovery Reports Cambridge, V21, P261; JOUVENTIN P, 1994, MAR ECOL PROG SER, V106, P11, DOI 10.3354/meps106011; WEIMERSKIRCH H, 1992, IBIS, V134, P107, DOI 10.1111/j.1474-919X.1992.tb08387.x; WILSON RP, 1984, J FIELD ORNITHOL, V55, P109	8	38	40	1	30	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					928	929		10.1038/35050163	http://dx.doi.org/10.1038/35050163			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140669				2022-12-28	WOS:000165951100035
J	O'Connor, JM; Stoffers, P; Wijbrans, JR; Shannon, PM; Morrissey, T				O'Connor, JM; Stoffers, P; Wijbrans, JR; Shannon, PM; Morrissey, T			Evidence from episodic seamount volcanism for pulsing of the Iceland plume in the past 70 Myr	NATURE			English	Article							ROCKALL TROUGH; FLOOD BASALTS; CONTINENTAL MARGINS; GREENLAND; MAGMATISM; MANTLE; GEOCHRONOLOGY; EVOLUTION	The North Atlantic volcanic province has been attributed to continental rifting about 60 Myr ago over an Iceland plume head with a diameter of 1,000-2,000 km (refs 1, 2). But evidence from a few igneous centres(3,4) has been used to infer that earlier plume activity occurred in this region. The three seamounts in the Rockall trough off the Atlantic coast of Scotland are among the few accessible remnants of such early plume activity. Here we present Ar-40-(39) Ar incremental-heating ages of samples from these seamounts, which show that volcanism began there in the late Cretaceous period (70 +/- 1 Myr ago), and then continued for the next 30 Myr in at least four discrete phases: 62, 52, 47 and 42 Myr ago. We relate this activity to pulsing of large masses (similar to 10(8) km(3)) of hot Iceland plume material on timescales of 5-10 Myr. This significantly extends the time span for Iceland plume activity both backwards and forwards in time, and provides a possible alternative to the 'plume head' models for the formation of continental flood basalts.	Geomar, Res Ctr Marine Geosci, D-24148 Kiel, Germany; Univ Kiel, Inst Geosci, D-24118 Kiel, Germany; Vrije Univ Amsterdam, Dept Isotope Geochem, NL-1081 HV Amsterdam, Netherlands; Natl Univ Ireland Univ Coll Dublin, Dept Geol, Dublin 4, Ireland	Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; University of Kiel; Vrije Universiteit Amsterdam; University College Dublin	O'Connor, JM (corresponding author), Geomar, Res Ctr Marine Geosci, Wischhofstr 1-3, D-24148 Kiel, Germany.		Wijbrans, Jan/Q-1914-2016; Wijbrans, J.R./M-6067-2019	Wijbrans, Jan/0000-0002-8091-1239; 				Bijwaard H, 1999, EARTH PLANET SC LETT, V166, P121, DOI 10.1016/S0012-821X(99)00004-7; *BRIT OC DAT CTR, 1997, GEBCO DIGITAL ATLAS; Clague D. A., 1989, GEOLOGY N AM, VN, P187; DIETRICH VJ, 1980, MAR GEOL, V35, P287, DOI 10.1016/0025-3227(80)90122-X; FRAM MS, 1998, P OCEAN DRILLING PRO, V152, P373; Hamilton MA, 1998, NATURE, V394, P260, DOI 10.1038/28361; Hanan BB, 1997, EARTH PLANET SC LETT, V151, P43, DOI 10.1016/S0012-821X(97)00105-2; JONES EJW, 1994, OCEANOL ACTA, V17, P237; JONES EJW, 1974, NATURE, V251, P129, DOI 10.1038/251129a0; KENT RW, 1992, GEOLOGY, V20, P891, DOI 10.1130/0091-7613(1992)020<0891:LIPSOP>2.3.CO;2; KERR AC, 1995, J GEOL SOC LONDON, V152, P975, DOI 10.1144/GSL.JGS.1995.152.01.16; Larsen H.C., 1998, PROC OCEAN DRILL SCI, V152, P503, DOI DOI 10.2973/ODP.PROC.SR.152.240.1998; Larsen TB, 1999, TECTONOPHYSICS, V311, P31, DOI 10.1016/S0040-1951(99)00163-8; Larsen TB, 1997, EARTH PLANET SC LETT, V146, P393, DOI 10.1016/S0012-821X(96)00247-6; Meighan I. G., 1988, SPECIAL PUBLICATION, V39, P349; MORTON AC, 1995, J GEOL SOC LONDON, V152, P947, DOI 10.1144/GSL.JGS.1995.152.01.11; MUSSETT AE, 1988, SPEC PUBL GEOL SOC L, V39, P337; MUSSETT AE, 1992, SPECIAL PUBLICATION, V70; O'Connor JM, 1998, EARTH PLANET SC LETT, V164, P41, DOI 10.1016/S0012-821X(98)00165-4; Pearson DG, 1996, J GEOL SOC LONDON, V153, P815, DOI 10.1144/gsjgs.153.6.0815; RICHARDS MA, 1989, SCIENCE, V246, P103, DOI 10.1126/science.246.4926.103; Saunders A.D., 1997, GEOPHYS MONOGRAPH SE, P45, DOI 10.1029/GM100p0045; Sinton C. W., 1998, P OCEAN DRILLING PRO, V152, P387, DOI DOI 10.2973/0DP.PR0C.SR.152.234.1998; Storey M, 1998, EARTH PLANET SC LETT, V160, P569, DOI 10.1016/S0012-821X(98)00112-5; Tegner C, 1998, EARTH PLANET SC LETT, V156, P75, DOI 10.1016/S0012-821X(97)00206-9; Tegner C., 1999, P OCEAN DRILLING PRO, V163, P53; UPTON BGJ, 1995, J GEOL SOC LONDON, V152, P959, DOI 10.1144/GSL.JGS.1995.152.01.13; VOGT PR, 1971, EARTH PLANET SC LETT, V13, P153, DOI 10.1016/0012-821X(71)90118-X; White N, 1997, NATURE, V387, P888, DOI 10.1038/43151; WHITE R, 1989, J GEOPHYS RES-SOLID, V94, P7685, DOI 10.1029/JB094iB06p07685; WHITE RS, 1987, NATURE, V330, P439, DOI 10.1038/330439a0; WHITE RS, 1995, J GEOL SOC LONDON, V152, P1039, DOI 10.1144/GSL.JGS.1995.152.01.26	32	46	46	1	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					954	958		10.1038/35050066	http://dx.doi.org/10.1038/35050066			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140678				2022-12-28	WOS:000165951100044
J	Lay, AJ; Jiang, XM; Kisker, O; Flynn, E; Underwood, A; Condron, R; Hogg, PJ				Lay, AJ; Jiang, XM; Kisker, O; Flynn, E; Underwood, A; Condron, R; Hogg, PJ			Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase	NATURE			English	Article							PROTEIN DISULFIDE-ISOMERASE; LEWIS-LUNG-CARCINOMA; 3-PHOSPHOGLYCERATE KINASE; GLYCOLYTIC ENZYME; ANGIOSTATIN; INHIBITOR; SUPPRESSION; PROTEOLYSIS; PLASMIN; MATRIX	Disulphide bonds in secreted proteins are considered to be inert because of the oxidizing nature of the extracellular milieu. An exception to this rule is a reductase secreted by tumour cells that reduces disulphide bonds in the serine proteinase plasmin(1,2). Reduction of plasmin initiates proteolytic cleavage in the kringle 5 domain and release of the tumour blood vessel inhibitor angiostatin(3). New blood vessel formation or angiogenesis is critical for tumour expansion and metastasis(4,5). Here we show that the plasmin reductase isolated from conditioned medium of fibrosarcoma cells is the glycolytic enzyme phosphoglycerate kinase(6). Recombinant phosphoglycerate kinase had the same specific activity as the fibrosarcoma-derived protein. Plasma of mice bearing fibrosarcoma tumours contained several-fold more phosphoglycerate kinase, as compared with mice without tumours. Administration of phosphoglycerate kinase to tumour-bearing mice caused an increase in plasma levels of angiostatin, and a decrease in tumour vascularity and rate of tumour growth. Our findings indicate that phosphoglycerate kinase not only functions in glycolysis but is secreted by tumour cells and participates in the angiogenic process as a disulphide reductase.	Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Univ New S Wales, Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia; Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; CSIRO Mol Sci, N Ryde, NSW 2113, Australia; La Trobe Univ, Dept Biochem, Bundoora, Vic 3083, Australia	University of New South Wales Sydney; University of New South Wales Sydney; Harvard University; Boston Children's Hospital; Commonwealth Scientific & Industrial Research Organisation (CSIRO); La Trobe University	Hogg, PJ (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.			Hogg, Philip/0000-0001-6486-2863				Alloush HM, 1997, MICROBIOL-SGM, V143, P321, DOI 10.1099/00221287-143-2-321; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Cornelius LA, 1998, J IMMUNOL, V161, P6845; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; KUNTZ GWK, 1982, METHOD ENZYMOL, V90, P103; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; Ogino T, 1999, J BIOL CHEM, V274, P35999, DOI 10.1074/jbc.274.50.35999; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Popanda O, 1998, BBA-GENE STRUCT EXPR, V1397, P102, DOI 10.1016/S0167-4781(97)00229-7; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; UNDERWOOD PA, 1988, J IMMUNOL METHODS, V107, P119; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	23	214	229	0	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					869	873		10.1038/35048596	http://dx.doi.org/10.1038/35048596			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130727				2022-12-28	WOS:000165831300053
J	Reichert, H; Klein, O; Dosch, H; Denk, M; Honkimaki, V; Lippmann, T; Reiter, G				Reichert, H; Klein, O; Dosch, H; Denk, M; Honkimaki, V; Lippmann, T; Reiter, G			Observation of five-fold local symmetry in liquid lead	NATURE			English	Article							ENERGY SYNCHROTRON-RADIATION; X-RAY REFLECTIVITY; SURFACE; MERCURY; ORDER	The local point symmetry of the short-range order in simple monatomic liquids remains a fundamental open question in condensed-matter science. For more than 40 years it has been conjectured(1-4) that liquids with centrosymmetric interactions may be composed of icosahedral building blocks. But these proposed mobile, randomly orientated structures have remained experimentally inaccessible owing to the unavoidable averaging involved in scattering experiments, which can therefore determine only the isotropic radial distribution function. Here we overcome this limitation by capturing liquid fragments at a solid-liquid interface, and observing the scattering of totally internally reflected (evanescent) X-rays, which are sensitive only to the liquid structure at the interface. Using this method, we observe five-fold local symmetry in liquid lead adjacent to a silicon wall, and obtain an experimental portrait of the icosahedral fragments that are predicted to occur in all close-packed monatomic liquids. By shedding new light on local bond order in disordered structures such as liquids and glasses, these results should lead to a better microscopic understanding of melting, freezing and supercooling.	Max Planck Inst Met Res, D-70569 Stuttgart, Germany; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Hamburger Synchrontronstschlungslab HASYLAB, D-22607 Hamburg, Germany; Univ Houston, Dept Phys, Houston, TX 77204 USA	Max Planck Society; European Synchrotron Radiation Facility (ESRF); University of Houston System; University of Houston	Reichert, H (corresponding author), Max Planck Inst Met Res, D-70569 Stuttgart, Germany.	reichert@dxray.mpi-stuttgart.mpg.de	Reiter, Günter/O-3134-2017; Reichert, Harald/AAZ-9105-2021	Reichert, Harald/0000-0001-7730-6962				BARTON SW, 1986, NATURE, V321, P685, DOI 10.1038/321685a0; BERNAL JD, 1960, NATURE, V185, P68, DOI 10.1038/185068a0; BERNAL JD, 1964, PROC R SOC LON SER-A, V280, P299, DOI 10.1098/rspa.1964.0147; Bouchard R, 1998, J SYNCHROTRON RADIAT, V5, P90, DOI 10.1107/S090904959701457X; BROUGHTON JQ, 1981, J CHEM PHYS, V74, P4029, DOI 10.1063/1.441583; CURTIN WA, 1987, PHYS REV LETT, V59, P1228, DOI 10.1103/PhysRevLett.59.1228; DOSCH H, 1992, TRACTS MODERN PHYSIC, V126; Finney J. L., 1970, P ROY SOC LOND A MAT, V319A, P497; FRANK FC, 1952, PROC R SOC LON SER-A, V215, P43, DOI 10.1098/rspa.1952.0194; GREY F, 1990, PHYS REV B, V41, P9519, DOI 10.1103/PhysRevB.41.9519; Huisman WJ, 1997, NATURE, V390, P379, DOI 10.1038/37069; MAGNUSSEN OM, 1995, PHYS REV LETT, V74, P4444, DOI 10.1103/PhysRevLett.74.4444; MOSS SC, 1986, PHYS REV LETT, V57, P3191, DOI 10.1103/PhysRevLett.57.3191; NELSON DR, 1989, SOLID STATE PHYS, V42, P1; NORTH DM, 1968, J PHYS PART C SOLID, V1, P784, DOI 10.1088/0022-3719/1/3/329; OCKO B, 1999, SYNCHROTRON RAD NEWS, V12; REGAN MJ, PHYS REV LETT, V75, P2498; RHYKERD CL, 1987, NATURE, V330, P461, DOI 10.1038/330461a0; SCOTT GD, 1962, NATURE, V194, P956, DOI 10.1038/194956a0; STEINHARDT PJ, 1983, PHYS REV B, V28, P784, DOI 10.1103/PhysRevB.28.784; TOONEY MF, 1994, NATURE, V368, P444; Tschentscher T, 1998, J SYNCHROTRON RADIAT, V5, P286, DOI 10.1107/S0909049597014775; TURNBULL D, 1952, J CHEM PHYS, V20, P411, DOI 10.1063/1.1700435; Yu CJ, 1999, PHYS REV LETT, V82, P2326, DOI 10.1103/PhysRevLett.82.2326	24	271	275	2	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					839	841		10.1038/35048537	http://dx.doi.org/10.1038/35048537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130718				2022-12-28	WOS:000165831300044
J	Graham, TA; Weaver, C; Mao, F; Kimelman, D; Xu, WQ				Graham, TA; Weaver, C; Mao, F; Kimelman, D; Xu, WQ			Crystal structure of a beta-catenin/Tcf complex	CELL			English	Article							E-CADHERIN; ALPHA-CATENIN; TUMOR-SUPPRESSOR; XENOPUS-EMBRYOS; PROTEIN; ARMADILLO; BINDING; PROGRAM; AXIN; ASSOCIATION	The Wnt signaling pathway plays critical roles in embryonic development and tumorigenesis. Stimulation of the Wnt pathway results in the accumulation of a nuclear beta -catenin/Tcf complex, activating Wnt target genes. A crystal structure of beta -catenin bound to the beta -catenin binding domain of Tcf3 (Tcf3-CBD) has been determined. The Tcf3-CBD forms an elongated structure with three binding modules that runs antiparallel to beta -catenin along the positively charged groove formed by the armadillo repeats. Structure-based mutagenesis defines three sites in beta -catenin that are critical for binding the Tcf3-CBD and are differentially involved in binding APC, cadherin, and Axin. The structural and mutagenesis data reveal a potential target for molecular drug design studies.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Biomol Struct & Design Program, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Xu, WQ (corresponding author), Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA.		Mao, Feng/B-8280-2019	Xu, Wenqing/0000-0002-2884-3101	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027262] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27262, HD07183] Funding Source: Medline; NIGMS NIH HHS [GM07270] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hedgepeth CM, 1999, MECH DEVELOP, V80, P147, DOI 10.1016/S0925-4773(98)00203-2; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kato Y, 1999, J NEUROSCI, V19, P9364; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVINE E, 1994, DEVELOPMENT, V120, P901; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Omer CA, 1999, BIOCHEM BIOPH RES CO, V256, P584, DOI 10.1006/bbrc.1999.0379; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Otwinowski Z, 1997, PROCESSING XRAY DIFF, V276; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Polakis P, 2000, GENE DEV, V14, P1837; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zhurinsky J, 2000, J CELL SCI, V113, P3127	46	331	343	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					885	896		10.1016/S0092-8674(00)00192-6	http://dx.doi.org/10.1016/S0092-8674(00)00192-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136974	Bronze			2022-12-28	WOS:000165801300008
J	Evans, A				Evans, A			Let's not forget B G Babington	LANCET			English	Editorial Material									Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland	Queens University Belfast	Evans, A (corresponding author), Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland.							BABINGTON BG, 1850, LANCET, V2, P639; JENNER E, 1824, PHILOS T ROY SOC LON, V1, P11; MILROY G, 1867, T EPIDEMIOL SOC LOND, V2, P471; PENNANT T, 1812, BRIT ZOOLOGY, P553; WILSON PG, 1966, ARCH OTOLARYNGOL, V83, P98	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1870	1870		10.1016/S0140-6736(00)03256-6	http://dx.doi.org/10.1016/S0140-6736(00)03256-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130381				2022-12-28	WOS:000165665400008
J	Hatzor, A; Weiss, PS				Hatzor, A; Weiss, PS			Molecular rulers for scaling down nanostructures	SCIENCE			English	Article							LITHOGRAPHY; NANOTUBES; NANORODS	A method of constructing <30-nanometer structures in close proximity with precise spacings is presented that uses the step-by-step application of organic molecules and metal ions as size-controlled resists on predetermined patterns, such as those formed by electron-beam lithography. The organic molecules serve as a ruler for scaling down a Larger "parent" structure. After metal deposition and Lift-off of the organic multilayer resist, an isolated smaller structure remains on the surface. This approach is used to form thin parallel wires (15 to 70 nanometers in width and 1 micrometer long) of controlled thickness and spacing. The structures obtained were imaged with field emission scanning electron microscopy. A variety of nanostructures could be scaled down, including structures with hollow patterns.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Weiss, PS (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.		Weiss, Paul S/A-2575-2011; Weiss, Paul/P-8016-2019	Weiss, Paul S/0000-0001-5527-6248; Weiss, Paul/0000-0001-5527-6248				Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Chen J, 1999, APPL PHYS LETT, V75, P624, DOI 10.1063/1.124461; Chou SY, 1997, J VAC SCI TECHNOL B, V15, P2897, DOI 10.1116/1.589752; Clark SL, 1998, ADV MATER, V10, P1515, DOI 10.1002/(SICI)1521-4095(199812)10:18<1515::AID-ADMA1515>3.0.CO;2-E; Ebbesen TW, 1996, NATURE, V382, P54, DOI 10.1038/382054a0; Evans E, 1996, SCIENCE, V273, P933, DOI 10.1126/science.273.5277.933; EVANS SD, 1991, J AM CHEM SOC, V113, P5866, DOI 10.1021/ja00015a053; Goldstein J. I., 1981, SCANNING ELECTRON MI, P461; HATZOR A, IN PRESS; Hong SH, 1999, SCIENCE, V286, P523, DOI 10.1126/science.286.5439.523; Martin BR, 1999, ADV MATER, V11, P1021, DOI 10.1002/(SICI)1521-4095(199908)11:12<1021::AID-ADMA1021>3.0.CO;2-S; Natelson D, 2000, APPL PHYS LETT, V77, P1991, DOI 10.1063/1.1312256; RAICHOUDHURY P, 1997, PIE HDB MICROLITHOGR, V1, P139; Sugimura H, 1997, J AM CHEM SOC, V119, P9226, DOI 10.1021/ja971027u; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; TREVOR DJ, 1991, J VAC SCI TECHNOL B, V9, P964, DOI 10.1116/1.585504; VANDERBOOMMOAV T, COMMUNICATION; WANG Y, 1992, J VAC SCI TECHNOL B, V10, P2962, DOI 10.1116/1.585952; Wong EW, 1997, SCIENCE, V277, P1971, DOI 10.1126/science.277.5334.1971	19	188	197	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	2001	291	5506					1019	1020						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161210				2022-12-28	WOS:000166860100038
J	Rennie, SC; Crosby, JR				Rennie, SC; Crosby, JR			Are "tomorrow's doctors" honest? Questionnaire study exploring medical students' attitudes and reported behaviour on academic misconduct	BRITISH MEDICAL JOURNAL			English	Article							SCHOOL		Univ Dundee, Ninewells Hosp & Med Sch, Sch Med, Curriculum Off, Dundee DD1 9SY, Scotland	University of Dundee	Crosby, JR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Sch Med, Curriculum Off, Dundee DD1 9SY, Scotland.		Rennie, Sarah Catherine/ABC-6527-2020	Rennie, Sarah Catherine/0000-0001-8638-8955				ANDERSON RE, 1994, ACAD MED, V69, P323, DOI 10.1097/00001888-199405000-00002; Baldwin DC, 1996, ACAD MED, V71, P267, DOI 10.1097/00001888-199603000-00020; SIERLES F, 1980, J MED EDUC, V55, P124; WAGNER RF, 1993, ACAD MED, V68, P887, DOI 10.1097/00001888-199312000-00004; Walker J., 1998, HIGHER ED RES DEV, V17, P89, DOI [10.1080/0729436980170105, DOI 10.1080/0729436980170105]	5	95	98	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	2001	322	7281					274	275		10.1136/bmj.322.7281.274	http://dx.doi.org/10.1136/bmj.322.7281.274			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157528	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000166917600028
J	Friedrich, RW; Laurent, G				Friedrich, RW; Laurent, G			Dynamic optimization of odor representations by slow temporal patterning of mitral cell activity	SCIENCE			English	Article							RAT OLFACTORY-BULB; OSCILLATING NEURAL ASSEMBLIES; INTRACELLULAR-POTENTIALS; SINGLE NEURONS; TUFTED CELLS; STIMULATION; DISCRIMINATION; COMBINATORIAL; INFORMATION; INTENSITY	Mitral cells (MCs) in the olfactory bulb (OB) respond to odors with slow temporal firing patterns. The representation of each odor by activity patterns across the MC population thus changes continuously throughout a stimulus, in an odor-specific manner. In the zebrafish OB, we found that this distributed temporal patterning progressively reduced the similarity between ensemble representations of related odors, thereby making each odor's representation more specific over time. The tuning of individual MCs was not sharpened during this process. Hence, the individual responses of MCs did not become more specific, but the odor-coding MC assemblies changed such that their overlap decreased. This optimization of ensemble representations did not occur among olfactory afferents but resulted from OB circuit dynamics. Time can therefore gradually optimize stimulus representations in a sensory network.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol, MC 139-74, Pasadena, CA 91125 USA.		Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Friedrich, Rainer/0000-0001-9107-0482				ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; Carr W.E.S., 1988, P3; Dan Y, 1996, J NEUROSCI, V16, P3351; DuchampViret P, 1997, PROG NEUROBIOL, V53, P561, DOI 10.1016/S0301-0082(97)00049-X; EECKMAN FH, 1990, BRAIN RES, V528, P238, DOI 10.1016/0006-8993(90)91663-2; FRIEDRICH R, UNPUB; Friedrich RW, 1998, J NEUROSCI, V18, P9977; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; HAMILTON KA, 1985, BRAIN RES, V338, P181, DOI 10.1016/0006-8993(85)90265-3; HAMILTON KA, 1989, J NEUROPHYSIOL, V62, P609, DOI 10.1152/jn.1989.62.3.609; HARRISON TA, 1986, J NEUROPHYSIOL, V56, P1571, DOI 10.1152/jn.1986.56.6.1571; HARTLINE HK, 1957, J GEN PHYSIOL, V40, P357, DOI 10.1085/jgp.40.3.357; HASEGAWA T, 1994, COMP BIOCHEM PHYS A, V108, P17, DOI 10.1016/0300-9629(94)90048-5; Jvreskog, 1996, APPL FACTOR ANAL NAT; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P695, DOI 10.1113/jphysiol.1974.sp010772; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37, DOI 10.1152/jn.1953.16.1.37; Laurent G, 1999, SCIENCE, V286, P723, DOI 10.1126/science.286.5440.723; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; MACRIDES F, 1972, SCIENCE, V175, P84, DOI 10.1126/science.175.4017.84; MAIR RG, 1982, J PHYSIOL-LONDON, V326, P341, DOI 10.1113/jphysiol.1982.sp014197; MANCIA M, 1962, ARCH ITAL BIOL, V100, P449; MATHIESON WB, 1988, J COMP PHYSIOL A, V163, P489, DOI 10.1007/BF00604903; MEREDITH M, 1986, J NEUROPHYSIOL, V56, P572, DOI 10.1152/jn.1986.56.3.572; MEREDITH M, 1978, J GEN PHYSIOL, V71, P615, DOI 10.1085/jgp.71.6.615; MICHEL WC, UNPUB; Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711; Motokizawa F, 1996, EXP BRAIN RES, V112, P24; MOUNTCASTLE VB, 1968, MED PHYSIOL, V2, P1372; Olshausen BA, 1996, NATURE, V381, P607, DOI 10.1038/381607a0; ROLLS ET, 1995, J NEUROPHYSIOL, V73, P713, DOI 10.1152/jn.1995.73.2.713; SATOU M, 1990, PROG NEUROBIOL, V34, P115, DOI 10.1016/0301-0082(90)90004-Z; Shepherd G.M., 1998, SYNAPTIC ORG BRAIN, P159; Vinje WE, 2000, SCIENCE, V287, P1273, DOI 10.1126/science.287.5456.1273; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; WELLIS DP, 1989, J NEUROPHYSIOL, V61, P1161, DOI 10.1152/jn.1989.61.6.1161; YOUNG ED, 1984, HEARING SCI, P423	37	333	337	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 2	2001	291	5505					889	894		10.1126/science.291.5505.889	http://dx.doi.org/10.1126/science.291.5505.889			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157170				2022-12-28	WOS:000166771700049
J	Hooper, LV; Wong, MH; Thelin, A; Hansson, L; Falk, PC; Gordon, JI				Hooper, LV; Wong, MH; Thelin, A; Hansson, L; Falk, PC; Gordon, JI			Molecular analysis of commensal host-microbial relations hips in the intestine	SCIENCE			English	Article							GENE-EXPRESSION; ECOSYSTEM; ANGIOGENIN; INITIATION; PROTEIN; MOUSE; MICE	Human beings contain complex societies of indigenous microbes, yet little is known about how resident bacteria shape our physiology. We colonized germfree mice with Bacteroides thetaiotaomicron, a prominent component of the normal mouse and human intestinal microflora. Global intestinal transcriptional responses to colonization were observed with DNA microarrays, and the cellular origins of selected responses were established by laser-capture microdissection. The results reveal that this commensal bacterium modulates expression of genes involved in several important intestinal functions, including nutrient absorption, mucosal barrier fortification, xenobiotic metabolism, angiogenesis, and postnatal intestinal maturation. These findings provide perspectives about the essential nature of the interactions between resident microorganisms and their hosts.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; AstraZeneca R&D, SE-43183 Molndal, Sweden	Washington University (WUSTL); AstraZeneca	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu			NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; De Lisle RC, 1998, AM J PHYSIOL-GASTR L, V275, pG219, DOI 10.1152/ajpgi.1998.275.2.G219; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; Fu XY, 1999, GROWTH FACTORS, V17, P125, DOI 10.3109/08977199909103521; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; Hooper LV, 1999, P NATL ACAD SCI USA, V96, P9833, DOI 10.1073/pnas.96.17.9833; HUSEBYE E, 1994, DIGEST DIS SCI, V39, P946, DOI 10.1007/BF02087542; Ingelman-Sundberg M, 1999, TRENDS PHARMACOL SCI, V20, P342, DOI 10.1016/S0165-6147(99)01363-2; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; KRASINSKI SD, 1994, AM J PHYSIOL-GASTR L, V267, pG584, DOI 10.1152/ajpgi.1994.267.4.G584; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Liu MT, 1997, J NEUROSCI, V17, P4764; Lowe ME, 1998, J BIOL CHEM, V273, P31215, DOI 10.1074/jbc.273.47.31215; LUK GD, 1980, SCIENCE, V210, P195, DOI 10.1126/science.6774420; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; Nilsson J, 1997, EUR J BIOCHEM, V250, P223, DOI 10.1111/j.1432-1033.1997.0223a.x; Nobile V, 1996, P NATL ACAD SCI USA, V93, P4331, DOI 10.1073/pnas.93.9.4331; Skehel PA, 2000, P NATL ACAD SCI USA, V97, P1101, DOI 10.1073/pnas.97.3.1101; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Steuerwald N, 1999, MOL HUM REPROD, V5, P1034, DOI 10.1093/molehr/5.11.1034; Thim L, 2000, REGUL PEPTIDES, V90, P61, DOI 10.1016/S0167-0115(00)00110-5; USHIJIMA T, 1983, MICROBIOL IMMUNOL, V27, P985, DOI 10.1111/j.1348-0421.1983.tb02929.x; WOSTMANN BS, 1983, LAB ANIM SCI, V33, P46	26	1497	1686	9	243	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	2001	291	5505					881	884		10.1126/science.291.5505.881	http://dx.doi.org/10.1126/science.291.5505.881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157169				2022-12-28	WOS:000166771700047
J	Tang, DG; Tokumoto, YM; Apperly, JA; Lloyd, AC; Raff, MC				Tang, DG; Tokumoto, YM; Apperly, JA; Lloyd, AC; Raff, MC			Lack of replicative senescence in cultured rat - Oligodendrocyte precursor cells	SCIENCE			English	Article							THYROID-HORMONE; OPTIC-NERVE; P16(INK4A)/CDKN2A; PROGRESSION; INHIBITORS; NUMBER; CANCER; P53	Most mammalian somatic cells are thought to have a limited proliferative capacity because they permanently stop dividing after a finite number of divisions in culture, a state termed replicative cell senescence. Here we show that most oligodendrocyte precursor cells purified from postnatal rat optic nerve can proliferate indefinitely in serum-free culture if prevented from differentiating; various cell cycle-inhibitory proteins increase, but the cells do not stop dividing. The cells maintain high telomerase activity and p53- and Rb-dependent cell cycle checkpoint responses, and serum or genotoxic drugs induce them to acquire a senescence-like phenotype. Our findings suggest that some normal rodent precursor cells have an unlimited proliferative capacity if cultured in conditions that avoid both differentiation and the activation of checkpoint responses that arrest the cell cycle.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	University of London; University College London	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Messier, Claude/A-2322-2008; Tang, Dean/AAI-3457-2020	Messier, Claude/0000-0002-4791-1763; Tang, Dean/0000-0001-5029-1174				BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BARRES BA, 1994, DEVELOPMENT, V120, P1097; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Chang BD, 1999, CANCER RES, V59, P3761; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FFRENCHCONSTANT C, 1986, NATURE, V319, P499, DOI 10.1038/319499a0; Gao FB, 1998, DEV BIOL, V197, P54, DOI 10.1006/dbio.1998.8877; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Raff MC, 1998, INT J DEV BIOL, V42, P263; RAFF MC, 1993, NATURE, V303, P396; Ruas M, 1999, ONCOGENE, V18, P5423, DOI 10.1038/sj.onc.1202918; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tang DG, 2000, J CELL BIOL, V148, P971, DOI 10.1083/jcb.148.5.971; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592	26	180	187	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 2	2001	291	5505					868	871		10.1126/science.1056780	http://dx.doi.org/10.1126/science.1056780			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157165				2022-12-28	WOS:000166771700043
J	Confavreux, C; Suissa, S; Saddier, P; Bourdes, V; Vukusic, S				Confavreux, C; Suissa, S; Saddier, P; Bourdes, V; Vukusic, S		Vaccines Multiple Sclerosis Study	Vaccinations and the risk of relapse in multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-B VACCINATION; NERVOUS-SYSTEM DEMYELINATION; INFLUENZA VACCINATION; DISEASE-ACTIVITY; ADVERSE EVENTS; OPTIC NEURITIS; ACUTE MYELITIS; IMMUNIZATION	Background: There has been some concern that vaccination may precipitate the onset of multiple sclerosis or lead to relapses. Since the recent hepatitis B vaccination program in France, there have been new reports of an increased risk of active multiple sclerosis after vaccination. Methods: We conducted a case-crossover study to assess whether vaccinations increase the risk of relapse in multiple sclerosis. The subjects were patients included in the European Database for Multiple Sclerosis who had a relapse between 1993 and 1997. The index relapse was the first relapse confirmed by a visit to a neurologist and preceded by a relapse-free period of at least 12 months. Information on vaccinations was obtained in a standardized telephone interview and confirmed by means of medical records. Exposure to vaccination in the two-month risk period immediately preceding the relapse was compared with that in the four previous two-month control periods for the calculation of relative risks, which were estimated with the use of conditional logistic regression. Results: Of 643 patients with relapses of multiple sclerosis, 15 percent reported having been vaccinated during the preceding 12 months. The reports of 94 percent of these vaccinations were confirmed. Of all the patients, 2.3 percent had been vaccinated during the preceding two-month risk period as compared with 2.8 to 4.0 percent who were vaccinated during one or more of the four control periods. The relative risk of relapse associated with exposure to any vaccination during the previous two months was 0.71 (95 percent confidence interval, 0.40 to 1.26). There was no increase in the specific risk of relapse associated with tetanus, hepatitis B, or influenza vaccination (range of relative risks, 0.22 to 1.08). Analyses based on risk periods of one and three months yielded similar results. Conclusions: Vaccination does not appear to increase the short-term risk of relapse in multiple sclerosis. (N Engl J Med 2001;344:319-26.) Copyright (C) 2001 Massachusetts Medical Society.	Hop Neurol, EDMUS Coordinating Ctr, F-69394 Lyon 03, France; Hop Neurol, Serv Neurol A, F-69394 Lyon 03, France; McGill Univ, Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, McGill Pharmacoepidemiol Res Unit, Montreal, PQ H3A 1A1, Canada; Dept Epidemiol, Lyon, France	CHU Lyon; CHU Lyon; McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University	Confavreux, C (corresponding author), Hop Neurol, EDMUS Coordinating Ctr, 59 Pinel Bvd, F-69394 Lyon 03, France.							ANDERSEN O, 1976, ACTA NEUROL SCAND, V54, P312, DOI 10.1111/j.1600-0404.1976.tb04362.x; BAMFORD CR, 1978, ARCH NEUROL-CHICAGO, V35, P242, DOI 10.1001/archneur.1978.00500280060012; BERKMAN N, 1996, B SOC OPHTHALMOL FR, V96, P187; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Confavreux C, 1996, NEUROLOGY, V46, P1607, DOI 10.1212/WNL.46.6.1607; CONFAVREUX C, 1992, J NEUROL NEUROSUR PS, V55, P671, DOI 10.1136/jnnp.55.8.671; CONFAVREUX C, 1980, BRAIN, V103, P281, DOI 10.1093/brain/103.2.281; DAVIS LE, 1972, NEUROLOGY, V22, P989, DOI 10.1212/WNL.22.9.989; De Keyser J, 1998, J NEUROL SCI, V159, P51, DOI 10.1016/S0022-510X(98)00139-7; DUCLOS P, 1992, CAN MED ASSOC J, V147, P1023; Fourrier A., 1999, PHARMACOEPIDEMIOL DR, V8, pS140; GOUT O, 1925, NEUROLOGY S, V48, pA424; HERROELEN L, 1991, LANCET, V338, P1174, DOI 10.1016/0140-6736(91)92034-Y; KAPLANSKI G, 1995, J NEUROL NEUROSUR PS, V58, P758, DOI 10.1136/jnnp.58.6.758-a; KURLAND LT, 1984, JAMA-J AM MED ASSOC, V251, P2672, DOI 10.1001/jama.251.20.2672; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LAUER K, 1990, AKTUEL NEUROL, V17, P42, DOI 10.1055/s-2007-1020540; lLevy-Bruhl D, 1999, BEH, V9, P33; LU W, 1984, CHINESE MED J-PEKING, V97, P447; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MAHASSIN F, 1993, PRESSE MED, V22, P1997; MCMAHON BJ, 1992, AM J MED, V92, P254, DOI 10.1016/0002-9343(92)90073-K; MICHIELSENS B, 1990, EUR NEUROL, V30, P258, DOI 10.1159/000117358; Miller AE, 1997, NEUROLOGY, V48, P312, DOI 10.1212/WNL.48.2.312; MILLER H, 1967, BMJ-BRIT MED J, V2, P210, DOI 10.1136/bmj.2.5546.210; MYERS LW, 1977, J INFECT DIS, V136, pS546, DOI 10.1093/infdis/136.Supplement_3.S546; NADLER JP, 1993, CLIN INFECT DIS, V17, P928, DOI 10.1093/clinids/17.5.928-b; Niu MT, 1996, PEDIATR INFECT DIS J, V15, P771, DOI 10.1097/00006454-199609000-00007; PALFFY G, 1961, WORLD NEUROL, V2, P167; Pathak R, 1967, J Indian Med Assoc, V49, P484; Poch G F, 1966, Prensa Med Argent, V53, P1639; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; QUAST U, 1991, VACCINE, V9, P228, DOI 10.1016/0264-410X(91)90104-E; RIIKONEN R, 1989, ACTA NEUROL SCAND, V80, P425, DOI 10.1111/j.1600-0404.1989.tb03904.x; Ristori G, 1999, NEUROLOGY, V53, P1588, DOI 10.1212/WNL.53.7.1588; Sadovnick AD, 2000, LANCET, V355, P549, DOI 10.1016/S0140-6736(99)02991-8; SALVETTI M, 1995, J NEUROL, V242, P143, DOI 10.1007/BF00936886; *SAS I, 1966, SAS STAT SOFTW CHANG; Senejoux A, 1996, GASTROEN CLIN BIOL, V20, P401; SHAW FE, 1988, AM J EPIDEMIOL, V127, P337, DOI 10.1093/oxfordjournals.aje.a114808; SIBLEY WA, 1965, ANN NY ACAD SCI, V122, P457; SIBLEY WA, 1976, JAMA-J AM MED ASSOC, V236, P1965, DOI 10.1001/jama.236.17.1965; Sturkenboom MC, 1999, PHARMACOEPIDEM DR S, V8, pS170; TARTAGLINO LM, 1995, AM J NEURORADIOL, V16, P581; Touze E, 2000, REV NEUROL, V156, P242; TREVISANI F, 1993, J HEPATOL, V19, P317, DOI 10.1016/S0168-8278(05)80589-6; VANDEGEIJN EJ, 1994, DOC OPHTHALMOL, V86, P403, DOI 10.1007/BF01204599; WAISBREN BA, 1982, ANN INTERN MED, V97, P149, DOI 10.7326/0003-4819-97-1-149_1; YAHR MD, 1972, ARCH NEUROL-CHICAGO, V27, P182, DOI 10.1001/archneur.1972.00490140086012; Zipp F, 1999, NAT MED, V5, P964, DOI 10.1038/12376	51	333	340	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					319	326		10.1056/NEJM200102013440501	http://dx.doi.org/10.1056/NEJM200102013440501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172162				2022-12-28	WOS:000166675800001
J	Daniel, S; Chaudhury, MK; Chen, JC				Daniel, S; Chaudhury, MK; Chen, JC			Past drop movements resulting from the phase change on a gradient surface	SCIENCE			English	Article							CONDENSATION; LIQUIDS	The movement of Liquid drops on a surface with a radial surface tension gradient is described here. When saturated steam passes over a colder hydrophobic substrate, numerous water droplets nucleate and grow by coalescence with the surrounding drops. The merging droplets exhibit two-dimensional random motion somewhat Like the Brownian movements of colloidal particles. When a surface tension gradient is designed into the substrate surface, the random movements of droplets are biased toward the more wettable side of the surface. Powered by the energies of coalescence and collimated by the forces of the chemical gradient, small drops (0.1 to 0.3 millimeter) display speeds that are hundreds to thousands of times faster than those of typical Marangoni flows. This effect has implications for passively enhancing heat transfer in heat exchangers and heat pipes.	Lehigh Univ, Dept Chem Engn, Bethlehem, PA 18015 USA	Lehigh University	Chaudhury, MK (corresponding author), Lehigh Univ, Dept Chem Engn, Bethlehem, PA 18015 USA.		Daniel, Susan/A-3801-2010					Bejan A., 1993, HEAT TRANSF; BROCHARD F, 1989, LANGMUIR, V5, P432, DOI 10.1021/la00086a025; Burns MA, 1996, P NATL ACAD SCI USA, V93, P5556, DOI 10.1073/pnas.93.11.5556; CHAUDHURY MK, 1992, SCIENCE, V256, P1539, DOI 10.1126/science.256.5063.1539; de Gennes PG, 1985, REV MOD PHYS, V57, P828; Edwards D.A., 1991, INTERFACIAL TRANSPOR; Faghri A., 1995, HEAT PIPE SCI TECHNO; Gallardo BS, 1999, SCIENCE, V283, P57, DOI 10.1126/science.283.5398.57; GREENSPAN HP, 1978, J FLUID MECH, V84, P125, DOI 10.1017/S0022112078000075; Grunze M, 1999, SCIENCE, V283, P41, DOI 10.1126/science.283.5398.41; Ichimura K, 2000, SCIENCE, V288, P1624, DOI 10.1126/science.288.5471.1624; Koch G, 1997, HEAT MASS TRANSFER, V32, P149, DOI 10.1007/s002310050105; ONDARCUHU T, 1991, J PHYS II, V1, P75, DOI 10.1051/jp2:1991140; UMUR A, 1965, J HEAT TRANSF, V87, P275, DOI 10.1115/1.3689090; ZHAO H, 1995, LANGMUIR, V11, P627, DOI 10.1021/la00002a045	15	758	800	26	558	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					633	636		10.1126/science.291.5504.633	http://dx.doi.org/10.1126/science.291.5504.633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158672				2022-12-28	WOS:000166616000038
J	Moser, DE; Flowers, RM; Hart, RJ				Moser, DE; Flowers, RM; Hart, RJ			Birth of the Kaapvaal tectosphere 3.08 billion years ago	SCIENCE			English	Article							VREDEFORT STRUCTURE; SOUTH-AFRICA; WITWATERSRAND BASIN; CRUST; EVOLUTION; GEOCHRONOLOGY; LITHOSPHERE; ORIGIN; MANTLE; MODEL	The crustal remnants of Earth's Archean continents have been shielded from mantle convection by thick roots of ancient mantle Lithosphere. The precise time of crust-root coupling (tectosphere birth) is poorly known but is needed to test competing theories of continental plate genesis. Our mapping and geochronology of an impact-generated section through the Mesoarchean crust of the Kaapvaal craton indicates tectosphere birth at 3.08 +/- 0.07 billion years ago, roughly 0.12 billion years after crust assembly. Growth of the southern African mantle root by subduction processes occurred within about 0.2 billion years, The assembly of crust before mantle may be common to the tectosphere.	Univ Utah, Dept Geol & Geophys, Salt Lake City, UT 84112 USA; Univ Witwatersrand, Schonland Res Ctr, Johannesburg, South Africa	Utah System of Higher Education; University of Utah; University of Witwatersrand	Moser, DE (corresponding author), Univ Utah, Dept Geol & Geophys, 135S 1460E, Salt Lake City, UT 84112 USA.	demoser@mines.utab.edu						BOYD FR, 1989, EARTH PLANET SC LETT, V96, P15, DOI 10.1016/0012-821X(89)90120-9; BRANDL G, 1997, OXFORD MONOGRAPHS GE, V35, P581; CARLSON RW, 1999, P 7 INT KIMB C RED R, P99; DAVIS DW, 1982, CAN J EARTH SCI, V19, P2141, DOI 10.1139/e82-188; Dawson JB, 1997, J METAMORPH GEOL, V15, P253, DOI 10.1111/j.1525-1314.1997.00017.x; DEWIT MJ, 1992, NATURE, V357, P553, DOI 10.1038/357553a0; FLOWERS RM, 2000, THESIS U UTAH; Gibson RL, 1998, GEOL SOC SPEC PUBL, V138, P121, DOI 10.1144/GSL.SP.1996.138.01.08; Hart R, 1999, GEOLOGY, V27, P1091, DOI 10.1130/0091-7613(1999)027<1091:AAFTGF>2.3.CO;2; HART RJ, 1981, J GEOPHYS RES, V86, P663, DOI 10.1029/JB086iB11p10663; HART RJ, 1990, CHEM GEOL, V82, P21, DOI 10.1016/0009-2541(90)90072-F; Helmstaedt H., 1989, GEOLOGICAL SOC AUSTR, V14, P358; JACOB D, 1994, GEOCHIM COSMOCHIM AC, V58, P5191, DOI 10.1016/0016-7037(94)90304-2; JORDAN TH, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i003p00001; LUDWIG KR, 1991, 910445 US GEOL SURV; Moser DE, 1996, TECTONICS, V15, P1093, DOI 10.1029/96TC00130; Moser DE, 1997, GEOLOGY, V25, P7, DOI 10.1130/0091-7613(1997)025<0007:DTSWAT>2.3.CO;2; MOSER DE, 1998, P 7 INT KIMB C CAP T, P609; Nyblade AA, 1999, LITHOS, V48, P81, DOI 10.1016/S0024-4937(99)00024-9; PEARSON DG, 1995, P 6 INT KIMB C NOV 7, P427; Richardson Samuel, UNPUB, pXI; RICHARDSON SH, 1984, NATURE, V310, P198, DOI 10.1038/310198a0; ROBB LJ, 1992, NATURE, V357, P677, DOI 10.1038/357677a0; Royden L, 1996, J GEOPHYS RES-SOL EA, V101, P17679, DOI 10.1029/96JB00951; Schmitz MD, 2001, CHEM GEOL, V172, P59, DOI 10.1016/S0009-2541(00)00236-9; SHIREY SB, IN PRESS GEOPHYS RES; STACEY JS, 1975, EARTH PLANET SC LETT, V26, P207, DOI 10.1016/0012-821X(75)90088-6; STEPTO D, 1990, TECTONOPHYSICS, V171, P75, DOI 10.1016/0040-1951(90)90091-L; Therriault AM, 1997, METEORIT PLANET SCI, V32, P71, DOI 10.1111/j.1945-5100.1997.tb01242.x; Tredoux M, 1999, GEOLOGY, V27, P923, DOI 10.1130/0091-7613(1999)027<0923:URATCO>2.3.CO;2	30	77	82	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2001	291	5503					465	468		10.1126/science.291.5503.465	http://dx.doi.org/10.1126/science.291.5503.465			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161196				2022-12-28	WOS:000166487500035
J	Bisno, AL				Bisno, AL			Primary care: Acute pharyngitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GROUP-A STREPTOCOCCI; INFECTIOUS-MONONUCLEOSIS; OPTICAL IMMUNOASSAY; UNITED-STATES; DIAGNOSIS; VIRUS; PENICILLIN; DISEASE; PHARYNGOTONSILLITIS; TONSILLITIS		Miami Vet Affairs Med Ctr, Miami, FL 33215 USA; Univ Miami, Sch Med, Dept Med, Miami, FL USA	University of Miami	Bisno, AL (corresponding author), Miami Vet Affairs Med Ctr, 1201 NW 16th St, Miami, FL 33215 USA.							ANDERSSON J, 1987, INFECTION, V15, pS14, DOI 10.1007/BF01650106; Armstrong GL, 1999, ARCH INTERN MED, V159, P2531, DOI 10.1001/archinte.159.21.2531; Bisgard KM, 1998, AM J PUBLIC HEALTH, V88, P787, DOI 10.2105/AJPH.88.5.787; Bisno AL, 1997, CLIN INFECT DIS, V25, P574, DOI 10.1086/513768; BREESE BB, 1977, AM J DIS CHILD, V131, P514, DOI 10.1001/archpedi.1977.02120180028003; BRINK WR, 1951, AM J MED, V10, P300, DOI 10.1016/0002-9343(51)90274-4; DAJANI A, 1995, PEDIATRICS, V96, P758; Duff BA, 1999, CLIN PEDIATR, V38, P417, DOI 10.1177/000992289903800708; EVANS AS, 1975, J INFECT DIS, V132, P546, DOI 10.1093/infdis/132.5.546; Feder HM, 1999, PEDIATRICS, V103, P47, DOI 10.1542/peds.103.1.47; FRIES SM, 1995, J PEDIATR-US, V126, P933, DOI 10.1016/S0022-3476(95)70213-X; Gerber MA, 1997, JAMA-J AM MED ASSOC, V277, P899, DOI 10.1001/jama.277.11.899; Gerber MA, 1999, PEDIATRICS, V104, P911, DOI 10.1542/peds.104.4.911; GLEZEN WP, 1975, AM J EPIDEMIOL, V101, P111, DOI 10.1093/oxfordjournals.aje.a112077; GLEZEN WP, 1967, J AMER MED ASSOC, V202, P455, DOI 10.1001/jama.202.6.455; GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757; GWALTNEY JM, 2000, MANDELL DOUGLAS BENN, P656; HOAGLAND RJ, 1957, ANN INTERN MED, V46, P1184, DOI 10.7326/0003-4819-46-6-1184; Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; KARPATHIOS T, 1992, J PEDIATR-US, V121, P735, DOI 10.1016/S0022-3476(05)81903-1; KELLOGG JA, 1990, J CLIN MICROBIOL, V28, P165, DOI 10.1128/JCM.28.2.165-169.1990; KOMAROFF AL, 1986, J GEN INTERN MED, V1, P1, DOI 10.1007/BF02596317; KROBER MS, 1985, JAMA-J AM MED ASSOC, V253, P1271, DOI 10.1001/jama.253.9.1271; LINDERHOLM M, 1994, J CLIN MICROBIOL, V32, P259, DOI 10.1128/JCM.32.1.259-261.1994; MCMILLAN JA, 1986, J PEDIATR-US, V109, P747, DOI 10.1016/S0022-3476(86)80687-4; MCMILLAN JA, 1993, PEDIATR INFECT DIS J, V12, P280, DOI 10.1097/00006454-199304000-00004; McNeill KM, 1999, EMERG INFECT DIS, V5, P798; MILLER RA, 1986, ANN INTERN MED, V105, P867, DOI 10.7326/0003-4819-105-6-867; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P1702; Oster HR, 2000, GRAM-POSITIVE PATHOGENS, P184; PICHICHERO ME, 1991, PEDIATR INFECT DIS J, V10, P275, DOI 10.1097/00006454-199104000-00002; PICKERING LK, 2000, 2000 RED BOOK REPORT, P526; Pitetti RD, 1998, PEDIATR EMERG CARE, V14, P396, DOI 10.1097/00006565-199812000-00004; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; RANDOLPH MF, 1985, J PEDIATR-US, V106, P870, DOI 10.1016/S0022-3476(85)80228-6; READ RC, 1999, INFECT DIS; Schlager TA, 1996, ARCH PEDIAT ADOL MED, V150, P245, DOI 10.1001/archpedi.1996.02170280015002; SCHOOLEY RT, 2000, MANDELL DOUGLAS BENN, V2, P1599; Schwartz RH, 1998, ARCH PEDIAT ADOL MED, V152, P927; SCHWARTZ RH, 1981, JAMA-J AM MED ASSOC, V246, P1790, DOI 10.1001/jama.246.16.1790; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Shulman ST, 1999, STREPTOCOCCAL INFECTIONS, P76; Vanhems, 1997, CLIN INFECT DIS, V25, P352; Vanhems P, 1997, CLIN INFECT DIS, V24, P965, DOI 10.1093/clinids/24.5.965; Wald ER, 1998, PEDIATR EMERG CARE, V14, P109, DOI 10.1097/00006565-199804000-00005; Webb KH, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e2; WIESNER PJ, 1973, NEW ENGL J MED, V288, P181, DOI 10.1056/NEJM197301252880404; Williams W C, 1991, Fam Med, V23, P117; YOUNG EJ, 1978, JAMA-J AM MED ASSOC, V239, P1885, DOI 10.1001/jama.239.18.1885; 1998, MMWR MORB MORTAL WKL, V47, P59	51	251	276	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					205	211		10.1056/NEJM200101183440308	http://dx.doi.org/10.1056/NEJM200101183440308			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	392GF	11172144				2022-12-28	WOS:000166402800008
J	Inskip, PD; Tarone, RE; Hatch, EE; Wilcosky, TC; Shapiro, WR; Selker, RG; Fine, HA; Black, PM; Loeffler, JS; Linet, MS				Inskip, PD; Tarone, RE; Hatch, EE; Wilcosky, TC; Shapiro, WR; Selker, RG; Fine, HA; Black, PM; Loeffler, JS; Linet, MS			Cellular-telephone use and brain tumors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOBILE COMMUNICATION; EXPOSURE; HEAD; RADIATION; PHONE; RISK; SAR	Background: Concern has arisen that the use of hand-held cellular telephones might cause brain tumors. If such a risk does exist, the matter would be of considerable public health importance, given the rapid increase worldwide in the use of these devices. Methods: We examined the use of cellular telephones in a case-control study of intracranial tumors of the nervous system conducted between 1994 and 1998. We enrolled 782 patients through hospitals in Phoenix, Arizona; Boston; and Pittsburgh; 489 had histologically confirmed glioma, 197 had meningioma, and 96 had acoustic neuroma. The 799 controls were patients admitted to the same hospitals as the patients with brain tumors for a variety of nonmalignant conditions. Results: As compared with never, or very rarely, having used a cellular telephone, the relative risks associated with a cumulative use of a cellular telephone for more than 100 hours were 0.9 for glioma (95 percent confidence interval, 0.5 to 1.6), 0.7 for meningioma (95 percent confidence interval, 0.3 to 1.7), 1.4 for acoustic neuroma (95 percent confidence interval, 0.6 to 3.5), and 1.0 for all types of tumors combined (95 percent confidence interval, 0.6 to 1.5). There was no evidence that the risks were higher among persons who used cellular telephones for 60 or more minutes per day or regularly for five or more years. Tumors did not occur disproportionately often on the side of head on which the telephone was typically used. Conclusions: These data do not support the hypothesis that the recent use of hand-held cellular telephones causes brain tumors, but they are not sufficient to evaluate the risks among long-term, heavy users and for potentially long induction periods. (N Engl J Med 2001;344:79-86.) Copyright (C) 2001 Massachusetts Medical Society.	NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; NCI, Neurooncol Branch, Bethesda, MD 20892 USA; Res Triangle Inst, Epidemiol & Med Studies Program, Res Triangle Pk, NC 27709 USA; St Josephs Hosp, Barrow Neurol Inst, Dept Neurol, Phoenix, AZ USA; Western Penn Hosp, Div Neurosurg, Pittsburgh, PA 15224 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Research Triangle Institute; Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; West Penn Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Inskip, PD (corresponding author), Execut Plaza S,Rm 7052,6120 Execut Blvd, Rockville, MD 20852 USA.	inskippe@mail.nih.gov		Hatch, Elizabeth/0000-0001-7901-3928	NATIONAL CANCER INSTITUTE [Z01CP010135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000732] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEY WR, 1997, MOB COMMUN INT, P95, DOI DOI 10.1007/978-1-4613-1205-5_4; ANDERSON V, 1995, BIOELECTROMAGNETICS, V16, P60, DOI 10.1002/bem.2250160112; BALZANO Q, 1995, IEEE T VEH TECHNOL, V44, P390, DOI 10.1109/25.406605; Balzano Q, 1999, RADIAT PROT DOSIM, V83, P165, DOI 10.1093/oxfordjournals.rpd.a032654; Brusick D, 1998, ENVIRON MOL MUTAGEN, V32, P1; Cardis E, 1999, RADIAT PROT DOSIM, V83, P179, DOI 10.1093/oxfordjournals.rpd.a032657; *CELL TEL IND ASS, 2000, MAN PEOPL US WIR PHO; CLEVELAND RF, 1989, BIOELECTROMAGNETICS, V10, P173, DOI 10.1002/bem.2250100206; DIMBYLOW PJ, 1994, PHYS MED BIOL, V39, P1537, DOI 10.1088/0031-9155/39/10/003; Dimbylow PJ, 1999, RADIAT PROT DOSIM, V83, P139, DOI 10.1093/oxfordjournals.rpd.a032648; Dreyer NA, 1999, JAMA-J AM MED ASSOC, V282, P1814, DOI 10.1001/jama.282.19.1814-a; Dreyer NA, 1999, RADIAT PROT DOSIM, V83, P159, DOI 10.1093/oxfordjournals.rpd.a032653; Elwood JM, 1999, ENVIRON HEALTH PERSP, V107, P155, DOI 10.2307/3434480; Funch DP, 1996, EPIDEMIOLOGY, V7, P299, DOI 10.1097/00001648-199605000-00014; GANDHI OP, 1995, RADIO SCI, V30, P161, DOI 10.1029/94RS01158; Hardell L, 1999, INT J ONCOL, V15, P113; Hermann DM, 1997, J NEUROL SCI, V152, P1, DOI 10.1016/S0022-510X(97)00140-8; Inskip PD, 1999, RADIAT PROT DOSIM, V86, P45, DOI 10.1093/oxfordjournals.rpd.a032924; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kleihues P., 1997, PATHOLOGY GENETICS T; KUSTER N, 1997, MOB COMMUN INT, P13; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; Maier M, 2000, BMJ-BRIT MED J, V320, P1288, DOI 10.1136/bmj.320.7245.1288; Malyapa RS, 1997, RADIAT RES, V148, P618, DOI 10.2307/3579738; McKinlay A, 1997, RADIOL PROT B, V187, P9; MELTZ ML, 1987, RADIAT RES, V110, P255, DOI 10.2307/3576903; Miller R, 1997, HAEMOPHILIA, V3, P9, DOI 10.1046/j.1365-2516.1997.00058.x; Morgan RW, 2000, EPIDEMIOLOGY, V11, P118, DOI 10.1097/00001648-200003000-00007; Moulder JE, 1999, RADIAT RES, V151, P513, DOI 10.2307/3580028; *NAT RAD PROT BOAR, 2000, MOB PHON HLTH; Percy C., 1990, INT CLASSIFICATION D; PRESTON D. L., 1993, EPICURE USERS GUIDE; Ramsdale PA, 1999, RADIAT PROT DOSIM, V83, P125, DOI 10.1093/oxfordjournals.rpd.a032646; Repacholi MH, 1996, HEALTH PHYS, V70, P587; Repacholi MH, 1998, BIOELECTROMAGNETICS, V19, P1, DOI 10.1002/(SICI)1521-186X(1998)19:1<1::AID-BEM1>3.0.CO;2-5; Rothman KJ, 1996, EPIDEMIOLOGY, V7, P291, DOI 10.1097/00001648-199605000-00013; Valberg PA, 1997, CANCER CAUSE CONTROL, V8, P323, DOI 10.1023/A:1018449003394; Van Leeuwen GMJ, 1999, PHYS MED BIOL, V44, P2367, DOI 10.1088/0031-9155/44/10/301; WHO, 1993, EL FIELDS 300 HZ 300; 1998, ENV HLTH PERSPECT, V106, pA474	40	311	334	0	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					79	86		10.1056/NEJM200101113440201	http://dx.doi.org/10.1056/NEJM200101113440201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150357				2022-12-28	WOS:000166281100001
J	Anttila, T; Saikku, P; Koskela, P; Bloigu, A; Dillner, J; Ikaheimo, I; Jellum, E; Lehtinen, M; Lenner, P; Hakulinen, T; Narvanen, A; Pukkala, E; Thoresen, S; Youngman, L; Paavonen, J				Anttila, T; Saikku, P; Koskela, P; Bloigu, A; Dillner, J; Ikaheimo, I; Jellum, E; Lehtinen, M; Lenner, P; Hakulinen, T; Narvanen, A; Pukkala, E; Thoresen, S; Youngman, L; Paavonen, J			Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE-CHAIN-REACTION; HUMAN-PAPILLOMAVIRUS; IN-SITU; SEROVAR DETERMINATION; INFECTION; ANTIBODIES; DNA; IMMUNOTYPES; PERSISTENCE; STRAINS	Context Human papillomavirus (HPV) infection has been established as a cause of cervical cancer. Epidemiologic studies suggest that Chlamydia trachomatis infection. also confers increased risk for cervical squamous cell carcinoma (SCC). Whether this risk is serotype-specific is unknown. Objective To study the association between exposure to different C trachomatis serotypes and subsequent development of cervical SCC. Design and Setting Longitudinal, nested case-control study within a cohort of 530000 women who provided samples to serum banks in Finland, Norway, and Sweden, The data files were linked to respective national cancer registries. Subjects One hundred twenty-eight women who had developed invasive cervical SCC at least 12 months following serum donation. Each case had 3 matched controls. Main Outcome Measure Risk for the development of cervical SCC by Ige antibodies to 10 different C trachomatis serotypes, adjusted for antibodies to HPV types 16, 18, and 33 and for serum cotinine levels. Results Of specific C trachomatis serotypes, serotype CI was most strongly associated with SCC (adjusted odds ratio [OR], 6.6; 95 % confidence interval [CI], 1.6-27.0), Other serotypes associated with SCC were I (OR, 3.8; 95% CI, 1.3-11.0) and D (OR, 2.7; 95% CI, 1.3-5.6). Presence of serum IgG antibodies to more than 1 serotype increased the adjusted ORs for SCC (P<.001 for trend). Conclusions Chlamydia trachomatis serotype C is most strongly associated with subsequent development of cervical SCC. Increasing numbers of exposures to different C trachomatis serotypes also increases risk, Our results strengthen the evidence that there is a link between past C trachomatis infection and cervical SCC.	Univ Helsinki, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Oulu, Finland; Univ Oulu, Dept Med Microbiol, Oulu, Finland; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Oulu Univ Hosp, Microbiol Lab, Oulu, Finland; Univ Oslo, Rikshosp, Inst Clin Biochem, N-0027 Oslo, Norway; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland; Umea Univ, Dept Oncol, Umea, Sweden; Univ Helsinki, Dept Publ Hlth, FIN-00290 Helsinki, Finland; Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Finnish Canc Registry, FIN-00170 Helsinki, Finland; Canc Registry Norway, Oslo, Norway; Univ Oxford, Clin Trial Serv Unit, Oxford, England	University of Helsinki; Finland National Institute for Health & Welfare; University of Oulu; Karolinska Institutet; University of Oulu; University of Oslo; National Hospital Norway; Tampere University; Umea University; University of Helsinki; Finland National Institute for Health & Welfare; University of Eastern Finland; Finnish Cancer Registry; University of Oslo; University of Oxford	Paavonen, J (corresponding author), Univ Helsinki, Dept Obstet & Gynecol, Haartmaninkatu 2, FIN-00290 Helsinki, Finland.	jorma.paavonen@helsinki.fi	Narvanen, Ale/A-6002-2009	Paavonen, Jorma/0000-0003-4775-606X; lehtinen, matti/0000-0002-9481-0535				AnderssonEllstrom A, 1996, SEX TRANSM DIS, V23, P234, DOI 10.1097/00007435-199605000-00013; BARDY AH, 1993, BRIT J OBSTET GYNAEC, V100, P721, DOI 10.1111/j.1471-0528.1993.tb14262.x; BARNES RC, 1987, J INFECT DIS, V156, P953, DOI 10.1093/infdis/156.6.953; BARNES RC, 1985, J INFECT DIS, V152, P985, DOI 10.1093/infdis/152.5.985; BEATTY WL, 1994, MICROBIOL REV, V58, P686, DOI 10.1128/MMBR.58.4.686-699.1994; BRESLOW N, 1980, IARC MON EV CARC RIS, V32; Chow WH, 1998, CANCER RES, V58, P588; DEAN D, 1995, J INFECT DIS, V172, P1013, DOI 10.1093/infdis/172.4.1013; DEAN D, 1998, CHLAMYDIAL INFECT, P39; DILLNER J, 1994, CANCER RES, V54, P134; Dillner J, 1997, J NATL CANCER I, V89, P1293, DOI 10.1093/jnci/89.17.1293; Dillner J, 1996, J INFECT DIS, V173, P1394, DOI 10.1093/infdis/173.6.1394; Eck M, 1997, GASTROENTEROLOGY, V112, P1482, DOI 10.1016/S0016-5085(97)70028-3; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; *IARC, 1995, IARC MON EV CARC RIS, V64; ITO JI, 1990, INFECT IMMUN, V58, P2021, DOI 10.1128/IAI.58.6.2021-2023.1990; JELLUM E, 1995, ENVIRON HEALTH PERSP, V103, P85, DOI 10.2307/3432566; Josefsson AM, 2000, LANCET, V355, P2189, DOI 10.1016/S0140-6736(00)02401-6; Koskela P, 2000, INT J CANCER, V85, P35, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;35::AID-IJC6&gt;3.0.CO;2-A; Koutsky Laura, 1997, American Journal of Medicine, V102, P3; LAN J, 1995, J CLIN MICROBIOL, V33, P3194, DOI 10.1128/JCM.33.12.3194-3197.1995; Lehtinen M, 1996, BMJ-BRIT MED J, V312, P537, DOI 10.1136/bmj.312.7030.537; Lie AK, 1997, APMIS, V105, P115, DOI 10.1111/j.1699-0463.1997.tb00549.x; Lin JSL, 1998, J INFECT DIS, V178, P1707, DOI 10.1086/314485; MAYER J, 1993, INFECT IMMUN, V61, P491, DOI 10.1128/IAI.61.2.491-497.1993; MIYASHITA N, 1992, J CLIN MICROBIOL, V30, P2911, DOI 10.1128/JCM.30.11.2911-2916.1992; MONCAN T, 1990, RES MICROBIOL, V141, P695, DOI 10.1016/0923-2508(90)90063-V; Narvanen A, 1997, Infect Dis Obstet Gynecol, V5, P349; NEWHALL WJ, 1986, J CLIN MICROBIOL, V23, P333, DOI 10.1128/JCM.23.2.333-338.1986; Paavonen J, 1988, Obstet Gynecol Surv, V43, P373, DOI 10.1097/00006254-198807000-00001; POOLE E, 1992, INFECT IMMUN, V60, P1089, DOI 10.1128/IAI.60.3.1089-1094.1992; PUOLAKKAINEN M, 1986, J CLIN MICROBIOL, V23, P924, DOI 10.1128/JCM.23.5.924-928.1986; ROSIN MP, 1994, CANCER RES, V54, pS1929; SAIKKU P, 1987, ACTA PATH MICRO IM B, V95, P131; Schlott T, 1998, J HISTOCHEM CYTOCHEM, V46, P1017, DOI 10.1177/002215549804600905; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; WANG SP, 1991, J INFECT DIS, V163, P403, DOI 10.1093/infdis/163.2.403; WANG SP, 1970, AM J OPHTHALMOL, V70, P367, DOI 10.1016/0002-9394(70)90096-6; WORKOWSKI KA, 1992, J INFECT DIS, V166, P1445, DOI 10.1093/infdis/166.6.1445	42	258	287	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					47	51		10.1001/jama.285.1.47	http://dx.doi.org/10.1001/jama.285.1.47			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150108	hybrid			2022-12-28	WOS:000166114500023
J	Hujoel, PP; Drangsholt, MT; Spiekerman, C; DeRouen, TA				Hujoel, PP; Drangsholt, MT; Spiekerman, C; DeRouen, TA			Periodontal disease and risk of coronary heart disease - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Washington, Sch Dent, Dept Dent Publ Hlth Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hujoel, PP (corresponding author), Univ Washington, Sch Dent, Dept Dent Publ Hlth Sci, Seattle, WA 98195 USA.							Beck J, 1996, J PERIODONTOL, V67, P1123, DOI 10.1902/jop.1996.67.10s.1123; Christen WG, 1998, CIRCULATION, V97, P821; Danesh J, 1999, AM HEART J, V138, pS434, DOI 10.1016/S0002-8703(99)70270-X; Hujoel PP, 2000, JAMA-J AM MED ASSOC, V284, P1406, DOI 10.1001/jama.284.11.1406; HUJOEL PP, 1995, J CLIN PERIODONTOL, V22, P397, DOI 10.1111/j.1600-051X.1995.tb00167.x; Joshipura KJ, 1996, J DENT RES, V75, P1631, DOI 10.1177/00220345960750090301	6	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					40	41						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150099				2022-12-28	WOS:000166114500014
J	Hestmark, G				Hestmark, G			Temptations of the tree - A perennial image of life, history and enlightenment.	NATURE			English	Editorial Material									Univ Oslo, Dept Biol, N-0316 Oslo, Norway	University of Oslo	Hestmark, G (corresponding author), Univ Oslo, Dept Biol, N-0316 Oslo, Norway.								0	14	14	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					911	911		10.1038/35050204	http://dx.doi.org/10.1038/35050204			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140658	Bronze			2022-12-28	WOS:000165951100024
J	Premkumar, LS; Ahern, GP				Premkumar, LS; Ahern, GP			Induction of vanilloid receptor channel activity by protein kinase C	NATURE			English	Article							ROOT GANGLION NEURONS; SENSORY NEURONS; CAPSAICIN RECEPTOR; PEPTIDE RELEASE; IN-VITRO; BRADYKININ; ACTIVATION; HEAT; CURRENTS; SENSITIZATION	Capsaicin or vanilloid receptors (VRs) participate in the sensation of thermal and inflammatory pain(1-3). The cloned (VR1) and native VRs are non-selective cation channels directly activated by harmful heat, extracellular protons and vanilloid compounds(4-8). However, considerable attention has been focused on identifying other signalling pathways in VR activation; it is known that VR1 is also expressed in non-sensory tissue(1,9) and may mediate inflammatory rather than acute thermal pain(3). Here we show that activation of protein kinase C (PKC) induces VR1 channel activity at room temperature in the absence of any other agonist. We also observed this effect in native VRs from sensory neurons, and phorbol esters induced a vanilloid-sensitive Ca2+ rise in these cells. Moreover, the pro-inflammatory peptide, bradykinin, and the putative endogenous ligand, anandamide, respectively induced and enhanced VR activity, in a PKC-dependent manner. These results suggest that PKC may link a range of stimuli to the activation of VRs.	So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62702 USA	Southern Illinois University System; Southern Illinois University	Premkumar, LS (corresponding author), So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62702 USA.							Barber LA, 1996, J NEUROCHEM, V67, P72; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BURGESS GM, 1989, J NEUROSCI, V9, P3314; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; De Petrocellis L, 1995, BIOCHEM MOL BIOL INT, V36, P1127; Docherty RJ, 1996, PFLUG ARCH EUR J PHY, V431, P828, DOI 10.1007/BF02332166; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; DRAY A, 1988, NEUROSCI LETT, V91, P301, DOI 10.1016/0304-3940(88)90697-0; DUNN PM, 1990, BRIT J PHARMACOL, V100, P656, DOI 10.1111/j.1476-5381.1990.tb15863.x; Frayer SM, 1999, NEUROSCI LETT, V265, P17, DOI 10.1016/S0304-3940(99)00090-7; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Kessler F, 1999, PAIN, V83, P289, DOI 10.1016/S0304-3959(99)00108-6; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Mizumura K, 1997, NEUROSCI LETT, V237, P29, DOI 10.1016/S0304-3940(97)00793-3; Oh U, 1996, J NEUROSCI, V16, P1659; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WOOD JN, 1988, J NEUROSCI, V8, P3208; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	27	631	654	0	24	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					985	990		10.1038/35050121	http://dx.doi.org/10.1038/35050121			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140687				2022-12-28	WOS:000165951100053
J	Lever, MA; Th'ng, JPH; Sun, XJ; Hendzel, MJ				Lever, MA; Th'ng, JPH; Sun, XJ; Hendzel, MJ			Rapid exchange of histone H1.1 on chromatin in living human cells	NATURE			English	Article							H3 PHOSPHORYLATION; LINKER HISTONES; IN-VIVO; CHROMOSOME CONDENSATION; MOUSE FIBROBLASTS; GENE-EXPRESSION; KINASE-ACTIVITY; OKADAIC ACID; HELA-CELLS; TRANSCRIPTION	The considerable length of DNA in eukaryotic genomes requires packaging into chromatin to rt inside the small dimensions of the cell nucleus. Histone H1 functions in the compaction of chromatin into higher order structures derived from the repeating 'beads on a string' nucleosome polymer. Modulation of H1 binding activity is thought to be an important step in the potentiation/depotentiation of chromatin structure for transcription(1-4). It is generally accepted that H1 binds less tightly than other histones to DNA in chromatin and can readily exchange in living cells(5-8). Fusion proteins of Histone H1 and green fluorescent protein (GFP) have been shown(9) to associate with chromatin in an apparently identical fashion to native histone H1. This provides a means by which to study histone H1-chromatin interactions in living cells. Here we have used human cells with a stably integrated H1.1-GFP fusion protein to monitor histone H1 movement directly by fluorescence recovery after photobleaching in living cells. We rnd that exchange is rapid in both condensed and decondensed chromatin, occurs throughout the cell cycle, and does not require fibre-fibre interactions. Treatment with drugs that alter protein phosphorylation significantly reduces exchange rates. Our results show that histone H1 exchange in vivo is rapid, occurs through a soluble intermediate, and is modulated by the phosphorylation of a protein or proteins as yet to be determined.	Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Fac Med & Dent, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; NW Ontario Reg Canc Ctr, Thunder Bay, ON P7A 7T1, Canada	University of Alberta; University of Alberta	Hendzel, MJ (corresponding author), Univ Alberta, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.		Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945				Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; EICK S, 1989, EUR J CELL BIOL, V49, P110; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; JIN YJ, 1986, J BIOL CHEM, V261, P5805; Kruhlak MJ, 2000, J CELL BIOL, V150, P41, DOI 10.1083/jcb.150.1.41; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; LU MJ, 1994, CHROMOSOMA, V103, P111; PARSEGHIAN MH, 1994, CHROMOSOMA, V103, P198, DOI 10.1007/BF00368013; PAULSON JR, 1994, J CELL SCI, V107, P267; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Talasz H, 1998, J BIOL CHEM, V273, P32236, DOI 10.1074/jbc.273.48.32236; THNG JPH, 1994, J BIOL CHEM, V269, P9568; THOMAS JO, 1983, EUR J BIOCHEM, V134, P109, DOI 10.1111/j.1432-1033.1983.tb07538.x; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WU LH, 1986, J CELL BIOL, V103, P465, DOI 10.1083/jcb.103.2.465; ZLATANOVA J, 1992, J CELL SCI, V103, P889	30	326	333	0	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					873	876		10.1038/35048603	http://dx.doi.org/10.1038/35048603			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130728				2022-12-28	WOS:000165831300054
J	Tabata, S; Kaneko, T; Nakamura, Y; Kotani, H; Kato, T; Asamizu, E; Miyajima, N; Sasamoto, S; Kimura, T; Hosouchi, T; Kawashima, K; Kohara, M; Matsumoto, M; Matsuno, A; Muraki, A; Nakayama, S; Nakazaki, N; Naruo, K; Okumura, S; Shinpo, S; Takeuchi, C; Wada, T; Watanabe, A; Yamada, M; Yasuda, M; Sato, S; de la Bastide, M; Huang, E; Spiegel, L; Gnoj, L; O'Shaughnessy, A; Preston, R; Habermann, K; Murray, J; Johnson, D; Rohlrng, T; Nelson, J; Stoneking, T; Pepin, K; Spieth, J; Sekhon, M; Armstrong, J; Becker, M; Belter, E; Cordum, H; Cordes, M; Courtney, L; Courtney, W; Dante, M; Du, H; Edwards, J; Fryman, J; Haakensen, B; Lamar, E; Latreille, P; Leonard, S; Meyer, R; Mulvaney, E; Ozersky, P; Riley, A; Strowmatt, C; Wagner-McPherson, C; Wollam, A; Yoakum, M; Bell, M; Dedhia, N; Parnell, L; Shah, R; Rodriguez, M; See, LH; Vil, D; Baker, J; Kirchoff, K; Toth, K; King, L; Bahret, A; Miller, B; Marra, M; Martienssen, R; McCombie, WR; Wilson, RK; Murphy, G; Bancroft, I; Volckaert, G; Wambutt, R; Dusterhoft, A; Stiekema, W; Pohl, T; Entian, KD; Terryn, N; Hartley, N; Bent, E; Johnson, S; Langham, SA; McCullagh, B; Robben, J; Grymonprez, B; Zimmermann, W; Ramsperger, U; Wedler, H; Balke, K; Wedler, E; Peters, S; van Staveren, M; Dirkse, W; Mooijman, P; Lankhorst, RK; Weitzenegger, T; Bothe, G; Rose, M; Hauf, J; Berneiser, S; Hempel, S; Feldpausch, M; Lamberth, S; Villarroel, R; Gielen, J; Ardiles, W; Bents, O; Lemcke, K; Kolesov, G; Mayer, K; Rudd, S; Schoof, H; Schueller, C; Zaccaria, P; Mewes, HW; Bevan, M				Tabata, S; Kaneko, T; Nakamura, Y; Kotani, H; Kato, T; Asamizu, E; Miyajima, N; Sasamoto, S; Kimura, T; Hosouchi, T; Kawashima, K; Kohara, M; Matsumoto, M; Matsuno, A; Muraki, A; Nakayama, S; Nakazaki, N; Naruo, K; Okumura, S; Shinpo, S; Takeuchi, C; Wada, T; Watanabe, A; Yamada, M; Yasuda, M; Sato, S; de la Bastide, M; Huang, E; Spiegel, L; Gnoj, L; O'Shaughnessy, A; Preston, R; Habermann, K; Murray, J; Johnson, D; Rohlrng, T; Nelson, J; Stoneking, T; Pepin, K; Spieth, J; Sekhon, M; Armstrong, J; Becker, M; Belter, E; Cordum, H; Cordes, M; Courtney, L; Courtney, W; Dante, M; Du, H; Edwards, J; Fryman, J; Haakensen, B; Lamar, E; Latreille, P; Leonard, S; Meyer, R; Mulvaney, E; Ozersky, P; Riley, A; Strowmatt, C; Wagner-McPherson, C; Wollam, A; Yoakum, M; Bell, M; Dedhia, N; Parnell, L; Shah, R; Rodriguez, M; See, LH; Vil, D; Baker, J; Kirchoff, K; Toth, K; King, L; Bahret, A; Miller, B; Marra, M; Martienssen, R; McCombie, WR; Wilson, RK; Murphy, G; Bancroft, I; Volckaert, G; Wambutt, R; Dusterhoft, A; Stiekema, W; Pohl, T; Entian, KD; Terryn, N; Hartley, N; Bent, E; Johnson, S; Langham, SA; McCullagh, B; Robben, J; Grymonprez, B; Zimmermann, W; Ramsperger, U; Wedler, H; Balke, K; Wedler, E; Peters, S; van Staveren, M; Dirkse, W; Mooijman, P; Lankhorst, RK; Weitzenegger, T; Bothe, G; Rose, M; Hauf, J; Berneiser, S; Hempel, S; Feldpausch, M; Lamberth, S; Villarroel, R; Gielen, J; Ardiles, W; Bents, O; Lemcke, K; Kolesov, G; Mayer, K; Rudd, S; Schoof, H; Schueller, C; Zaccaria, P; Mewes, HW; Bevan, M		Kazusa DNA Res Inst; Cold Spring Harbor Washington Univ; European Union Arabidopsis Genome	Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana	NATURE			English	Article							STRUCTURAL-ANALYSIS; GENOME ANALYSIS; DNA; PREDICTION; PROTEIN; REGION; KNOB	The genome of the model plant Arabidopsis thaliana has been sequenced by an international collaboration, The Arabidopsis Genome Initiative. Here we report the complete sequence of chromosome 5. This chromosome is 26 megabases long; it is the second largest Arabidopsis chromosome and represents 21% of the sequenced regions of the genome. The sequence of chromosomes 2 and 4 have been reported previously(1,2) and that of chromosomes 1 and 3, together with an analysis of the complete genome sequence, are reported in this issue(3-5). Analysis of the sequence of chromosome 5 yields further insights into centromere structure and the sequence determinants of heterochromatin condensation. The 5,874 genes encoded on chromosome 5 reveal several new functions in plants, and the patterns of gene organization provide insights into the mechanisms and extent of genome evolution in plants.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Kazusa DNA Res Inst, Chiba 292, Japan; Cold Spring Harbor Lab, Lita Annenberg Hazen Genome Ctr, Cold Spring Harbor, NY 11724 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Plant Biol Grp, Cold Spring Harbor, NY 11724 USA; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium; AGOWA GmbH, D-12489 Berlin, Germany; QIAGEN GmbH, D-40724 Hilden, Germany; Plant Res Int, Greenom, NL-6700 AA Wageningen, Netherlands; GATC GmbH, D-78467 Constance, Germany; SRD GmbH, D-61440 Oberursel, Germany; Univ Ghent, Dept Plant Genet, B-9000 Ghent, Belgium; GSF Forschungszentrum Umwelt & Gesundheit, Munich Informat Ctr Prot Sequence, Max Planck Inst Biochem, D-82152 Munich, Germany; Inst Plant Genet & Crop Plant Res, D-06466 Gatersleben, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Kazusa DNA Research Institute; Cold Spring Harbor Laboratory; Washington University (WUSTL); Cold Spring Harbor Laboratory; KU Leuven; QIAGEN GmbH; Ghent University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Bevan, M (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.	michael.bevan@bbsrc.ac.uk	Mayer, Klaus FX/M-7941-2015; Klein Lankhorst, René/HGD-0360-2022; Wilson, Richard K./AAF-4139-2019; Rudd, Stephen A/A-6434-2013; Bancroft, Ian/AAH-3831-2020; Entian, Karl-Dieter/D-3080-2011; Marra, Marco A/B-5987-2008; Sato, Shusei/A-3616-2015; Schoof, Heiko/Y-7073-2018; Nakamura, Yasukazu/T-9038-2019; Mewes, Hans-Werner/A-8204-2019	Mayer, Klaus FX/0000-0001-6484-1077; Wilson, Richard K./0000-0002-1992-1358; Rudd, Stephen A/0000-0002-0344-7487; Marra, Marco A/0000-0001-7146-7175; Sato, Shusei/0000-0002-0293-5366; Schoof, Heiko/0000-0002-1527-3752; Kolesov, Grigory/0000-0001-5637-6371; Mewes, Hans-Werner/0000-0002-9713-6398; McCombie, W. Richard/0000-0003-1899-0682; Nakamura, Yasukazu/0000-0002-6782-5715; Bancroft, Ian/0000-0001-7707-1171				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ananiev EV, 1998, GENETICS, V149, P2025; BORODOVSKY M, 1994, COMPUT CHEM, V18, P259, DOI 10.1016/0097-8485(94)85022-4; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHOI S, 1995, WEEDS WORLD, V2, P17; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Fransz PF, 2000, CELL, V100, P367, DOI 10.1016/S0092-8674(00)80672-8; Frishman D, 1997, TRENDS GENET, V13, P415, DOI 10.1016/S0168-9525(97)01224-9; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kotani H, 1999, DNA Res, V6, P381, DOI 10.1093/dnares/6.6.381; LIMADEFARIER A, 1983, MOL EVOLUTION ORG CH; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LUI YG, 1995, PLANT J, V7, P351; LUI YG, 1999, P NATL ACAD SCI USA, V96, P6535; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; McCombie WR, 2000, CELL, V100, P377, DOI 10.1016/S0092-8674(00)80673-X; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Royet J, 1998, EMBO J, V17, P7351, DOI 10.1093/emboj/17.24.7351; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Salanoubat M, 2000, NATURE, V408, P820, DOI 10.1038/35048706; Sato S, 2000, DNA RES, V7, P31, DOI 10.1093/dnares/7.1.31; Sato S, 1997, DNA Res, V4, P215, DOI 10.1093/dnares/4.3.215; Theologis A, 2000, NATURE, V408, P816, DOI 10.1038/35048500; Tutois S, 1999, CHROMOSOME RES, V7, P143, DOI 10.1023/A:1009211603248; Wakasugi T, 1997, P NATL ACAD SCI USA, V94, P5967, DOI 10.1073/pnas.94.11.5967	28	132	1277	14	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					823	826						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130714				2022-12-28	WOS:000165831300040
J	Theologis, A; Ecker, JR; Palm, CJ; Federspiel, NA; Kaul, S; White, O; Alonso, J; Altafi, H; Araujo, R; Bowman, CL; Brooks, SY; Buehler, E; Chan, A; Chao, QM; Chen, HM; Cheuk, RF; Chin, CW; Chung, MK; Conn, L; Conway, AB; Conway, AR; Creasy, TH; Dewar, K; Dunn, P; Etgu, P; Feldblyum, TV; Feng, JD; Fong, B; Fujii, CY; Gill, JE; Goldsmith, AD; Haas, B; Hansen, NF; Hughes, B; Huizar, L; Hunter, JL; Jenkins, J; Johnson-Hopson, C; Khan, S; Khaykin, E; Kim, CJ; Koo, HL; Kremenetskaia, I; Kurtz, DB; Kwan, A; Lam, B; Langin-Hooper, S; Lee, A; Lee, JM; Lenz, CA; Li, JH; Li, YP; Lin, XY; Liu, SX; Liu, ZA; Luros, JS; Maiti, R; Marziali, A; Militscher, J; Miranda, M; Nguyen, M; Nierman, WC; Osborne, BI; Pai, G; Peterson, J; Pham, PK; Rizzo, M; Rooney, T; Rowley, D; Sakano, H; Salzberg, SL; Schwartz, JR; Shinn, P; Southwick, AM; Sun, H; Tallon, LJ; Tambunga, G; Toriumi, MJ; Town, CD; Utterback, T; Van Aken, S; Vaysberg, M; Vysotskaia, VS; Walker, M; Wu, DY; Yu, GX; Fraser, CM; Venter, JC; Davis, RW				Theologis, A; Ecker, JR; Palm, CJ; Federspiel, NA; Kaul, S; White, O; Alonso, J; Altafi, H; Araujo, R; Bowman, CL; Brooks, SY; Buehler, E; Chan, A; Chao, QM; Chen, HM; Cheuk, RF; Chin, CW; Chung, MK; Conn, L; Conway, AB; Conway, AR; Creasy, TH; Dewar, K; Dunn, P; Etgu, P; Feldblyum, TV; Feng, JD; Fong, B; Fujii, CY; Gill, JE; Goldsmith, AD; Haas, B; Hansen, NF; Hughes, B; Huizar, L; Hunter, JL; Jenkins, J; Johnson-Hopson, C; Khan, S; Khaykin, E; Kim, CJ; Koo, HL; Kremenetskaia, I; Kurtz, DB; Kwan, A; Lam, B; Langin-Hooper, S; Lee, A; Lee, JM; Lenz, CA; Li, JH; Li, YP; Lin, XY; Liu, SX; Liu, ZA; Luros, JS; Maiti, R; Marziali, A; Militscher, J; Miranda, M; Nguyen, M; Nierman, WC; Osborne, BI; Pai, G; Peterson, J; Pham, PK; Rizzo, M; Rooney, T; Rowley, D; Sakano, H; Salzberg, SL; Schwartz, JR; Shinn, P; Southwick, AM; Sun, H; Tallon, LJ; Tambunga, G; Toriumi, MJ; Town, CD; Utterback, T; Van Aken, S; Vaysberg, M; Vysotskaia, VS; Walker, M; Wu, DY; Yu, GX; Fraser, CM; Venter, JC; Davis, RW			Sequence and analysis of chromosome 1 of the plant Arabidopsis thaliana	NATURE			English	Article							GENOME SEQUENCE; DNA; LIBRARY; GENES; CONSTRUCTION; REGIONS; SYSTEM; TOOL; MAP	The genome of the flowering plant Arabidopsis thaliana has five chromosomes(1,2). Here we report the sequence of the largest, chromosome 1, in two contigs of around 14.2 and 14.6 megabases. The contigs extend from the telomeres to the centromeric borders, regions rich in transposons, retrotransposons and repetitive elements such as the 180-base-pair repeat. The chromosome represents 25% of the genome and contains about 6,850 open reading frames, 236 transfer RNAs (tRNAs) and 12 small nuclear RNAs. There are two clusters of tRNA genes at different places on the chromosome. One consists of 27 tRNA Pro genes and the other contains 27 tandem repeats of tRNA(Tyr)-tRNA(Tyr)-tRNA(Ser) genes. Chromosome 1 contains about 300 gene families with clustered duplications. There are also many repeat elements, representing 8% of the sequence.	Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA; Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; Inst Genom Res, Rockville, MD 20850 USA	United States Department of Agriculture (USDA); University of California System; University of California Berkeley; University of Pennsylvania; Stanford University; J. Craig Venter Institute	Theologis, A (corresponding author), Univ Calif Berkeley, USDA, Ctr Plant Gene Express, 800 Buchanan St, Albany, CA 94710 USA.	theo@nature.berkeley.edu; ecker@salk.edu	Salzberg, Steven/Q-6514-2019; Alonso, Jose M/K-6826-2014; Salzberg, Steven L/F-6162-2011; Ecker, Joseph R/B-9144-2008	Salzberg, Steven/0000-0002-8859-7432; Alonso, Jose M/0000-0001-7087-1571; Salzberg, Steven L/0000-0002-8859-7432; Ecker, Joseph R/0000-0001-5799-5895; Chen, Huaming/0000-0001-5289-7882; Fraser, Claire/0000-0003-1462-2428; Buehler, Eugen/0000-0001-7167-676X; Sakano, Hitomi/0000-0002-7471-8352				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BEIER D, 1991, MOL GEN GENET, V225, P72, DOI 10.1007/BF00282644; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Chory J, 2000, PLANT PHYSIOL, V123, P423, DOI 10.1104/pp.123.2.423; Conner JA, 1998, PLANT CELL, V10, P801, DOI 10.1105/tpc.10.5.801; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; Dietrich FS, 1997, NATURE, V387, P78, DOI 10.1038/387s078; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; EWENS WJ, 1991, GENOMICS, V11, P799, DOI 10.1016/0888-7543(91)90003-W; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Frishman D, 1997, TRENDS GENET, V13, P415, DOI 10.1016/S0168-9525(97)01224-9; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOODMAN HM, 1995, P NATL ACAD SCI USA, V92, P10831, DOI 10.1073/pnas.92.24.10831; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Lukashin AV, 1998, NUCLEIC ACIDS RES, V26, P1107, DOI 10.1093/nar/26.4.1107; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Marziali A, 1999, GENOME RES, V9, P457; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; MEYEROWITZ EM, 1994, ARABIDOPSIS, P21; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; Mozo T, 1999, NAT GENET, V22, P271, DOI 10.1038/10334; Oefner PJ, 1996, NUCLEIC ACIDS RES, V24, P3879, DOI 10.1093/nar/24.20.3879; RICHARDS EJ, 1992, NUCLEIC ACIDS RES, V20, P4039, DOI 10.1093/nar/20.15.4039; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; Salanoubat M, 2000, NATURE, V408, P820, DOI 10.1038/35048706; Salzberg SL, 1999, GENOMICS, V59, P24, DOI 10.1006/geno.1999.5854; Tabata S, 2000, NATURE, V408, P823, DOI 10.1038/35048507; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0	43	162	4408	9	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					816	820		10.1038/35048500	http://dx.doi.org/10.1038/35048500			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130712				2022-12-28	WOS:000165831300038
J	Satcher, D				Satcher, D			Eliminating global health disparities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2864	2864		10.1001/jama.284.22.2864	http://dx.doi.org/10.1001/jama.284.22.2864			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11155906				2022-12-28	WOS:000165717000009
J	Hennequin, H; Morin, C; Feine, JS				Hennequin, H; Morin, C; Feine, JS			Pain expression and stimulus localisation in individuals with Down's syndrome	LANCET			English	Article							SEX-DIFFERENCES; STIMULATION; INFANTS; RESPONSIVENESS; DISABILITIES; BIRTHS	Background Individuals with Down's syndrome do not always exhibit signs of distress in reaction to noxious stimuli comparable with the general population. This pilot study was designed to measure the ability of individuals with Down's syndrome to detect and express sensation in comparison with healthy volunteers. Methods In the first test, the latency of pain detection to self-administered cold stimuli on the wrist and on the temple was measured. The second test was designed to assess ability to localise cold stimuli on sites on the hand, on the face, and in the mouth. Findings 75 control individuals and 26 individuals with Down's syndrome were tested. individuals with Down's syndrome had significantly longer median latencies than controls: Down's syndrome median (quartiles) 28.7 s (1st 18.0, 3rd 47.6); controls 20.6 s (1st 12.4, 3rd 31.0); p=0.0005. in addition, more individuals with Down's syndrome had difficulties in localising the cold stimulus. The differences in distribution for precise localisation were significant for the hand (Down's syndrome [p<0.0005] 54%; control 99%), the mouth (31%; 84%), and the face (54%; 97%). Interpretation Individuals with Down's syndrome are not insensitive to pain. However, they do express pain or discomfort more slowly and less precisely than the general population. This implies that medical teams managing these patients should use pain-control procedures, even in the absence of obvious pain manifestations.	Univ Auvergne, Fac Chirurg Dent, Lab Physiol Orofaciale, F-63000 Clermont Ferrand, France; McGill Univ, Fac Med, Dept Oncol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Aerosp Med Res Unit, Montreal, PQ H3A 2B2, Canada	Universite Clermont Auvergne (UCA); McGill University; McGill University	Hennequin, H (corresponding author), Univ Auvergne, Fac Chirurg Dent, Lab Physiol Orofaciale, F-63000 Clermont Ferrand, France.	martine.hennequin@u-clermont1.fr	Hennequin, Martine/AAB-3004-2021	Hennequin, Martine/0000-0001-8173-2606				Astin M, 1996, SOC SCI MED, V42, P1457, DOI 10.1016/0277-9536(95)00253-7; BARNET AB, 1971, DEV MED CHILD NEUROL, V13, P321; BIERSDORFF KK, 1994, AM J MENT RETARD, V98, P619; Bromley J, 1998, J INTELL DISABIL RES, V42, P72, DOI 10.1046/j.1365-2788.1998.00078.x; CLARK DL, 1977, SCIENCE, V196, P1228, DOI 10.1126/science.300899; FEINE JS, 1991, PAIN, V44, P255, DOI 10.1016/0304-3959(91)90094-E; FRYERS T, 1986, J MENT DEFIC RES, V30, P101; GEDYE A, 1990, J MENT DEFIC RES, V34, P195; GIBSON SJ, 1995, RAIN REV, V2, P111; Giusiano B, 1995, METHOD INFORM MED, V34, P498; GOODKIN F, 1980, EARLY HUM DEV, V4, P373, DOI 10.1016/0378-3782(80)90042-0; Hahn J A, 1993, Paediatr Perinat Epidemiol, V7, P450, DOI 10.1111/j.1365-3016.1993.tb00426.x; Henderson S., 1987, CURRENT APPROACHES D, P187; HUETHER CA, 1983, AM J PUBLIC HEALTH, V73, P1186, DOI 10.2105/AJPH.73.10.1186; ISHII N, 1988, ARCH DERMATOL, V124, P564, DOI 10.1001/archderm.124.4.564; KUMAZAWA T, 1977, J PHYSIOL-LONDON, V273, P179, DOI 10.1113/jphysiol.1977.sp012088; LAUTENBACHER S, 1993, PAIN, V53, P255, DOI 10.1016/0304-3959(93)90221-A; LIND J, 1970, DEV MED CHILD NEUROL, V12, P478; Martinez-Cue C, 1999, NEUROREPORT, V10, P1119, DOI 10.1097/00001756-199904060-00039; MCGRATH PA, 1993, PAIN INFANTS CHILDRE, P39; MEH D, 1994, J NEUROL SCI, V127, P164, DOI 10.1016/0022-510X(94)90069-8; MERSKEY H, 1994, CLASSIFICATION CHRON, P213; MYERS BA, 1991, J NERV MENT DIS, V179, P609, DOI 10.1097/00005053-199110000-00004; Radovich F, 1991, Minerva Stomatol, V40, P701; Stoll C, 1998, ANN GENET-PARIS, V41, P44; SVENSSON P, 1992, PAIN, V49, P233, DOI 10.1016/0304-3959(92)90147-4; THRUSH DC, 1973, BRAIN, V96, P591, DOI 10.1093/brain/96.3.591	27	81	81	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	2000	356	9245					1882	1887		10.1016/S0140-6736(00)03259-1	http://dx.doi.org/10.1016/S0140-6736(00)03259-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	379WD	11130384				2022-12-28	WOS:000165665400011
J	Rigby, SP; Schott, JM; Bliss, P; Higgens, CS; Kamm, MA				Rigby, SP; Schott, JM; Bliss, P; Higgens, CS; Kamm, MA			Dilated stomach and weak muscles	LANCET			English	Article							IDIOPATHIC INTESTINAL PSEUDOOBSTRUCTION		Northwick Pk Hosp, NW London Hosp NHS Trust, Dept Rheumatol, Harrow HA1 3UJ, Middx, England; Northwick Pk Hosp, NW London Hosp NHS Trust, Dept Gastroenterol, Harrow HA1 3UJ, Middx, England; St Marks Hosp, NW London Hosp NHS Trust, Dept Gastroenterol, Harrow HA1 3UJ, Middx, England; St Marks Hosp, NW London Hosp NHS Trust, Dept Rheumatol, Harrow HA1 3UJ, Middx, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London	Rigby, SP (corresponding author), Warwick Hosp, Dept Rheumatol, Lakin Rd, Warwick CV34 5BW, England.		Schott, Jonathan M/A-9065-2011	Schott, Jonathan M/0000-0003-2059-024X				CHINN JS, 1988, GASTROENTEROLOGY, V95, P1279, DOI 10.1016/0016-5085(88)90362-9; Debinski HS, 1997, GUT, V41, P100, DOI 10.1136/gut.41.1.100; LOWSKY R, 1993, GUT, V34, P279, DOI 10.1136/gut.34.2.279; Mann SD, 1997, GUT, V41, P675, DOI 10.1136/gut.41.5.675	4	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1898	1898		10.1016/S0140-6736(00)03263-3	http://dx.doi.org/10.1016/S0140-6736(00)03263-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130388				2022-12-28	WOS:000165665400015
J	Nielsen, GL; Sorensen, HT; Larsen, H; Pedersen, L				Nielsen, GL; Sorensen, HT; Larsen, H; Pedersen, L			Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study	BRITISH MEDICAL JOURNAL			English	Article							ASPIRIN	Objective To estimate th risk of adverse birth outcome in women who take non-steroidal anti-inflammatory drugs during pregnancy. Design and setting Population based cohort study and a case-control study, both based on data from a prescription registry, the Danish birth registry, and cone country's hospital discharge registry. Participants Cohort study: 1462 pregnant women who had taken up prescriptions for non-steroidal anti-inflammatory drugs in the period from 30 days before conception to birth and 17 259 pregnant women who were not prescribed any drugs during pregnancy. Case-control study: 4268 women who had miscarriages, of whom 63 had taken non-steroidal anti-inflammatory drugs, and 29 750 primiparous controls who had live births. Main outcome measures Incidences of congenital abnormality, low birth weight, preterm birth, and miscarriage. Results Odds ratios for congenital abnormality, low birth weight, and preterm birth among women who took up prescriptions for no-steroidal anti-inflammatory drugs were 1.27 (95% confidence integral 0.93 to 1.75 (0.79 (0.45 to 1.38), and 1.05 (0.80 to 1.39) respectively. Odds ratios for the taking up of prescriptions in the weeks before miscarriage ranged from 6.99 (2.75 to 17.74) when prescriptions were taken up during the last week before the miscarriage to 2.69 (1.81 to 4.00) when taken up between 7 and 9 weeks before. The risk estimates were no different when the analysis was restricted to missed abortions. Conclusions Use of non-steroidal anti-inflammatory drugs during pregnancy does not seem of increase the risk of adverse birth outcome but is associated wit increased risk of miscarriage.	Odder Hosp, Dept Med, DK-8300 Odder, Denmark; Aarhus Univ Hosp, Dept Clin Epidemiol & Med 5, DK-8000 Aarhus C, Denmark; Aalborg Univ Hosp, Dept Clin Epidemiol & Med 5, DK-8000 Aarhus C, Denmark; Danish Epidemiol Sci Ctr, Inst Epidemiol & Social Med, DK-8000 Aarhus C, Denmark; Aalborg Hosp, Dept Obstet & Gynaecol & Med M, DK-9000 Aalborg, Denmark	Aarhus University; Aalborg University; Aarhus University; Aalborg University; Aalborg University Hospital	Nielsen, GL (corresponding author), Odder Hosp, Dept Med, DK-8300 Odder, Denmark.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040				Andersen TF, 1999, DAN MED BULL, V46, P263; BEROYZ G, 1994, LANCET, V343, P619; BONATI M, 1990, EUR J CLIN PHARMACOL, V38, P323; BRIGGS CG, 1998, DRUGS PREGNANCY LACT, P524; Gaist D, 1997, DAN MED BULL, V44, P445; Golding J, 1998, BRIT J OBSTET GYNAEC, V105, P293, DOI 10.1111/j.1471-0528.1998.tb10089.x; HERTZPICCIOTTO I, 1990, EPIDEMIOL REV, V12, P108, DOI 10.1093/oxfordjournals.epirev.a036049; Knudsen LB, 1998, DAN MED BULL, V45, P320; Kristensen J, 1996, J CLIN EPIDEMIOL, V49, P893, DOI 10.1016/0895-4356(96)00018-2; MITCHEL AA, 1995, PHARMACOEPIDEMIOLOGY, P598; Nielsen G L, 1997, Int J Risk Saf Med, V10, P203, DOI 10.3233/JRS-1997-10309; Norton ME, 1997, TERATOLOGY, V56, P282, DOI 10.1002/(SICI)1096-9926(199710)56:4<282::AID-TERA7>3.0.CO;2-0; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; Ostensen M, 1998, DRUG SAFETY, V19, P389; SHAPIRO S, 1970, LANCET, V1, P1375; TURNER G, 1975, LANCET, V2, P338; WERLER MM, 1989, NEW ENGL J MED, V321, P1639, DOI 10.1056/NEJM198912143212404	18	203	211	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	2001	322	7281					266	270		10.1136/bmj.322.7281.266	http://dx.doi.org/10.1136/bmj.322.7281.266			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157526	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000166917600026
J	Mathon, NF; Malcolm, DS; Harrisingh, MC; Cheng, LL; Lloyd, AC				Mathon, NF; Malcolm, DS; Harrisingh, MC; Cheng, LL; Lloyd, AC			Lack of replicative senescence in normal rodent glia	SCIENCE			English	Article							TELOMERASE ACTIVITY; CELLS; P16(INK4A); INHIBITORS; RAS	Replicative senescence is thought to be an intrinsic mechanism for Limiting the proliferative Life-span of normal somatic cells. We show here that rat Schwann cells can be expanded indefinitely in culture while maintaining checkpoints normally Lost during the immortalization process. These findings demonstrate that senescence is not an inevitable consequence of extended proliferation in culture.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	University of London; University College London	Lloyd, AC (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	alison.lloyd@ucl.ac.uk						Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; CHENG L, 1995, J CELL BIOL, V129, P789, DOI 10.1083/jcb.129.3.789; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; MATHON NF, UNPUB; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	14	149	152	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 2	2001	291	5505					872	875		10.1126/science.1056782	http://dx.doi.org/10.1126/science.1056782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157166				2022-12-28	WOS:000166771700044
J	Macintyre, S; Chalmers, I; Horton, R; Smith, R				Macintyre, S; Chalmers, I; Horton, R; Smith, R			Using evidence to inform health policy: case studs	BRITISH MEDICAL JOURNAL			English	Article									MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; UK Cochrane Ctr, NHS Res & Dev Programme, Oxford OX2 7LG, England; Lancet, London WC1B 3SL, England; BMJ, London WC1H 9JR, England	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; Cochrane Centre	Macintyre, S (corresponding author), MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.		Macintyre, Sally/P-6246-2014					Acheson D., 1998, INDEPENDENT INQUIRY; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; Benzeval M, 1995, TACKLING INEQUALITIE; Black D, 1980, INEQUALITIES HLTH RE; BORUCH R, 1999, EFFECTS SOCIAL ED IN, P12; Connor J, 1999, J EPIDEMIOL COMMUN H, V53, P725, DOI 10.1136/jech.53.11.725; DAVIES P, 1999, REPORT PAPERS EXPLOR; de Walle HEK, 1999, BRIT MED J, V319, P291, DOI 10.1136/bmj.319.7205.291; *DEP HLTH, 1995, VAR HLTH DEP HLTH NA; GEPKENS A, 1995, INTERVENTIONS REDUCE; Gordon D., 1999, INEQUALITIES HLTH EV; LUMLEY J, 2000, COCHRANE DATABASE SY; Macintyre S, 2000, J EPIDEMIOL COMMUN H, V54, P802, DOI 10.1136/jech.54.11.802; Macintyre S., 1999, INEQUALITIES HLTH EV, P148; McKee M, 1996, HEALTH POLICY, V37, P117, DOI 10.1016/0168-8510(95)00829-2; *MOD GOV PARL PRIM, 1999, CMND4310; *NHS CTR REV DISS, 1995, REV RES EFF HLTH SER; Redner, 1981, NEW DIRECTIONS REHAB, P394; Schou L., 1994, HLTH B, V52, P232; SOWDEN A, 2000, COCHRANE DATABASE SY; *STRAT POL MAK TEA, 2001, PROF POL MAK 21 CENT; THOMSON M, 1989, EFFECTIVE CARE PREGN, V2; Zoritch B., 2000, COCHRANE DATABASE SY	23	133	136	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					222	225		10.1136/bmj.322.7280.222	http://dx.doi.org/10.1136/bmj.322.7280.222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159625	Green Accepted, Green Published			2022-12-28	WOS:000166733700033
J	Baker, PA; Seltzer, GO; Fritz, SC; Dunbar, RB; Grove, MJ; Tapia, PM; Cross, SL; Rowe, HD; Broda, JP				Baker, PA; Seltzer, GO; Fritz, SC; Dunbar, RB; Grove, MJ; Tapia, PM; Cross, SL; Rowe, HD; Broda, JP			The history of South American tropical precipitation for the past 25,000 years	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; LAKE-TITICACA; ATLANTIC-OCEAN; ICE-AGE; CLIMATE; HOLOCENE; BOLIVIA; CALIBRATION; CIRCULATION; VARIABILITY	Long sediment cores recovered from the deep portions of Lake Titicaca are used to reconstruct the precipitation history of tropical South America for the past 25,000 years. Lake Titicaca was a deep, fresh, and continuously overflowing Lake during the Last glacial stage, from before 25,000 to 15,000 calibrated years before the present (cal yr B.P.), signifying that during the Last glacial maximum (LGM), the Altiplano of Bolivia and Peru and much of the Amazon basin were wetter than today. The LGM in this part of the Andes is dated at 21,000 cal yr B.P., approximately coincident with the global LGM. Maximum aridity and Lowest Lake Level occurred in the early and middle Holocene (8000 to 5500 cat yr B.P.) during a time of Low summer insolation. Today, rising Levels of Lake Titicaca and wet conditions in Amazonia are correlated with anomalously cold sea-surface temperatures in the northern equatorial Atlantic. Likewise, during the deglacial and Holocene periods, there were several millennial-scale wet phases on the Altiplano and in Amazonia that coincided with anomalously cold periods in the equatorial and high-latitude North Atlantic, such as the Younger Dryas.	Duke Univ, Div Earth & Ocean Sci, Durham, NC 27708 USA; Syracuse Univ, Dept Earth Sci, Syracuse, NY 13244 USA; Univ Nebraska, Dept Geosci, Lincoln, NE 68588 USA; Stanford Univ, Dept Geog & Environm Sci, Stanford, CA 94305 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	Duke University; Syracuse University; University of Nebraska System; University of Nebraska Lincoln; Stanford University; Woods Hole Oceanographic Institution	Baker, PA (corresponding author), Duke Univ, Div Earth & Ocean Sci, Durham, NC 27708 USA.		Tapia, Pedro/GYR-1147-2022	Tapia, Pedro M/0000-0002-0708-4468; Dunbar, Robert/0000-0002-9728-5609; Rowe, Harry/0000-0002-1665-6261				Abbott MB, 1997, QUATERNARY RES, V47, P169, DOI 10.1006/qres.1997.1881; [Anonymous], [No title captured]; Argollo J, 2000, QUATERN INT, V72, P37, DOI 10.1016/S1040-6182(00)00019-7; BAKER P, IN PRESS NATURE; Bard E, 1998, GEOCHIM COSMOCHIM AC, V62, P2025, DOI 10.1016/S0016-7037(98)00130-6; Bard E, 2000, SCIENCE, V289, P1321, DOI 10.1126/science.289.5483.1321; Baucom PC, 1999, J SEDIMENT RES, V69, P597, DOI 10.2110/jsr.69.597; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Chang P, 1997, NATURE, V385, P516, DOI 10.1038/385516a0; COLLINVAUX PA, 2000, QUAT SCI REV, V19; Cross SL, 2000, HOLOCENE, V10, P21, DOI 10.1191/095968300671452546; CROSS SL, IN PRESS QUAT RES; Curtis J. H., 1993, CLIMATE CHANGE CONTI, P135, DOI [10.1029/GM078p0135, DOI 10.1029/GM078P0135]; deMenocal P, 2000, SCIENCE, V288, P2198, DOI 10.1126/science.288.5474.2198; Enfield DB, 1997, J GEOPHYS RES-OCEANS, V102, P929, DOI 10.1029/96JC03296; Haberle SG, 1999, QUATERNARY RES, V51, P27, DOI 10.1006/qres.1998.2020; HASTENRATH S, 1978, J ATMOS SCI, V35, P2222, DOI 10.1175/1520-0469(1978)035<2222:OMOTCA>2.0.CO;2; HASTENRATH S, 1997, Q J R METEOROL SOC, V110, P77; Ledru MP, 1998, QUATERNARY RES, V49, P233, DOI 10.1006/qres.1997.1953; Melice JL, 1998, CLIM DYNAM, V14, P117, DOI 10.1007/s003820050213; Mix AC, 1999, PALEOCEANOGRAPHY, V14, P350, DOI 10.1029/1999PA900012; Mourguiart P, 1998, PALAEOGEOGR PALAEOCL, V143, P51, DOI 10.1016/S0031-0182(98)00068-6; Nobre P, 1996, J CLIMATE, V9, P2464, DOI 10.1175/1520-0442(1996)009<2464:VOSSTW>2.0.CO;2; Rajagopalan B, 1998, GEOPHYS RES LETT, V25, P3967, DOI 10.1029/1998GL900065; Ruhlemann C, 1999, NATURE, V402, P511, DOI 10.1038/990069; SELTZER GO, 1992, J QUATERNARY SCI, V7, P87, DOI 10.1002/jqs.3390070202; Seltzer GO, 1998, GEOLOGY, V26, P167, DOI 10.1130/0091-7613(1998)026<0167:HRSRPF>2.3.CO;2; SERVANT M, 1995, CR ACAD SCI II, V320, P729; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Sutton RT, 2000, J CLIMATE, V13, P3261, DOI 10.1175/1520-0442(2000)013<3261:TEOCVI>2.0.CO;2; Sylvestre F, 1999, QUATERNARY RES, V51, P54, DOI 10.1006/qres.1998.2017; THOMPSON LG, 1986, SCIENCE, V234, P361, DOI 10.1126/science.234.4774.361; Webster P., 1983, LARGE SCALE DYNAMICA, P235; WIRRMANN D, 1987, PALAEOGEOGR PALAEOCL, V59, P315, DOI 10.1016/0031-0182(87)90088-5; Xie SP, 1998, GEOPHYS RES LETT, V25, P2185, DOI 10.1029/98GL01525; Zhou JY, 1998, J CLIMATE, V11, P1020, DOI 10.1175/1520-0442(1998)011<1020:DAMCEO>2.0.CO;2	37	534	564	3	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					640	643		10.1126/science.291.5504.640	http://dx.doi.org/10.1126/science.291.5504.640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158674	Green Submitted			2022-12-28	WOS:000166616000040
J	Ryder, SD; Beckingham, IJ				Ryder, SD; Beckingham, IJ			ABC of diseases of liver, pancreas, and biliary system - Acute hepatitis	BRITISH MEDICAL JOURNAL			English	Article									Queens Med Ctr, Nottingham NG7 2UH, England	University of Nottingham	Ryder, SD (corresponding author), Queens Med Ctr, Nottingham NG7 2UH, England.			Ryder, Stephen David/0000-0001-9649-4444					0	28	28	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					151	153		10.1136/bmj.322.7279.151	http://dx.doi.org/10.1136/bmj.322.7279.151			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159575	Green Published			2022-12-28	WOS:000166615300029
J	Schellenberg, R				Schellenberg, R			Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study	BRITISH MEDICAL JOURNAL			English	Article							PROLACTIN SECRETION; TENSION SYNDROME; SCALES	Objectives To compare the efficacy and tolerability of agnus castus fruit (Vitex agnus castus L extract Ze 440) with placebo for women with the premenstrual syndrome. Design Randomised, double blind, placebo controlled, parallel group comparison over three menstrual cycles. Setting General medicine community clinics. Participants 178 women were screened and 170 were evaluated (active 86; placebo 84). Mean age was 36 years, mean cycle length was 28 days, mean duration of menses was 4.5 days. Interventions Agnus castus(dry extract tablets) one tablet daily or matching placebo, given for three consecutive cycles. Main outcome measured Main efficacy variable: change from baseline to end point (end of third cycle) in women's self assessment of irritability, mood alteration, anger, headache, breast fullness, and other menstrual symptoms including bloating. Secondary efficacy variables: changes in clinical global impression (severity of condition, global improvement, and risk of benefit) and responder rate (50% reduction in symptoms). Results Improvement in the main variable was greater in the active group compared wit placebo group (P<0.001). Analysis of the secondary variables showed significant (P<0.001) superiority of active treatment in each of the three global impression items. Responder rates were 52% and 24% for active and placebo, respectively. Seven women reported mild adverse events (four active; three placebo), none of which caused discontinuation of treatment. Conclusions Dry extract of agnus castus fruit is an effective and well tolerated treatment for the relief of symptoms of the premenstrual syndrome.	Inst Hlth Care & Sci, D-35625 Huttenberg, Germany		Schellenberg, R (corresponding author), Inst Hlth Care & Sci, D-35625 Huttenberg, Germany.							ABT K, 1987, METHOD INFORM MED, V26, P77; American Psychiatric Association, 1997, DIAGN STAT MAN MENT; BERGER D, 1999, Z PHYTOTHER, V20, P140; BRICKELL C, 1989, ROYAL HORTICULTURAL; Brugisser R, 1999, Z PHYTOTHERAPIE, V20, P140; CARROLL BJ, 1978, PSYCHONEUROENDOCRINO, V3, P171, DOI 10.1016/0306-4530(78)90005-7; CASPER RF, 1986, AM J OBSTET GYNECOL, V155, P862, DOI 10.1016/S0002-9378(86)80040-0; Chuong CJ, 1988, PREMENSTRUAL SYNDROM, P75; DUMEC G, 1993, AUST J MED HERBALISM, V5, P63; Guy E, 1976, ECDEU ASS MAN PSYCH, P217; HOBBS C, 1991, PHARM HIST, V23, P19; JARRY H, 1994, EXP CLIN ENDOCRINOL, V102, P448, DOI 10.1055/s-0029-1211317; JARRY H, 1991, Z PHYTOTHER, V12, P77; Kupper C, 1996, DTSCH APOTHEKER ZEIT, V136, P23; Lauritzen C, 1997, PHYTOMEDICINE, V4, P183, DOI 10.1016/S0944-7113(97)80066-9; MACHIN D, 1987, STAT TABLES DESIGN C, P81; Medina JH, 1998, PHYTOMEDICINE, V5, P235, DOI 10.1016/S0944-7113(98)80034-2; Merz PG, 1996, EXP CLIN ENDOCR DIAB, V104, P447, DOI 10.1055/s-0029-1211483; MILEWICZ A, 1993, ARZNEIMITTEL-FORSCH, V43-2, P752; PETERSWELTE C, 1994, TW GYNAKOLOGIE, V7, P49; ROEDER D, 1994, Z PHYTOTHER, V15, P155; SAMOCHOWIEC I, 1998, ARZTEZEITSCHR NATURH, V39, P213; Shiah IS, 1998, LIFE SCI, V63, P1289, DOI 10.1016/S0024-3205(98)00241-0; SLIUTZ G, 1993, HORM METAB RES, V25, P253, DOI 10.1055/s-2007-1002090; Smith S, 1994, MODERN MANAGEMENT PR, P46; STEINER M, 1980, ACTA PSYCHIAT SCAND, V62, P177, DOI 10.1111/j.1600-0447.1980.tb00605.x; WINTERHOFF H, 1991, Z PHYTOTHERAPIE, V12, P175; Wuttke W, 1995, PHYTOPHARMAKA FORSCH, P81	28	160	169	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					134	137		10.1136/bmj.322.7279.134	http://dx.doi.org/10.1136/bmj.322.7279.134			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159568	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000166615300023
J	Fiquet, G; Badro, J; Guyot, F; Requardt, H; Krisch, M				Fiquet, G; Badro, J; Guyot, F; Requardt, H; Krisch, M			Sound velocities in iron to 110 gigapascals	SCIENCE			English	Article							HIGH-PRESSURE; INNER-CORE; ELASTICITY; GPA	The dispersion of longitudinal acoustic phonons was measured by inelastic x-ray scattering in the hexagonal closed-packed (hcp) structure of iron from 19 to 110 gigapascals. Phonon dispersion curves were recorded on polycrystalline iron compressed in a diamond anvil cell, revealing an increase of the Longitudinal wave velocity (V-p) from 7000 to 8800 meters per second. We show that hcp iron follows a Birch law for V-p, which is used to extrapolate velocities to inner core conditions. Extrapolated Longitudinal acoustic wave velocities compared with seismic data suggest an inner core that is 4 to 5% Lighter than hcp iron.	Univ Paris 06, Lab Mineral & Cristallog, CNRS, UMR 7590, F-75252 Paris 06, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; European Synchrotron Radiation Facility (ESRF)	Fiquet, G (corresponding author), Univ Paris 06, Lab Mineral & Cristallog, CNRS, UMR 7590, 4 Pl Jussieu, F-75252 Paris 06, France.		Fiquet, Guillaume M/H-1219-2011; Fiquet, Guillaume/O-7077-2019; Krisch, Michael H/U-5662-2018; GUYOT, François J/C-3824-2016; Badro, James/A-6003-2011; Fiquet, Guillaume/M-6934-2014	Krisch, Michael H/0000-0001-7423-1715; GUYOT, François J/0000-0003-4622-2218; Badro, James/0000-0001-9337-4789; Fiquet, Guillaume/0000-0001-8961-3281				BIRCH F, 1961, GEOPHYS J ROY ASTR S, V4, P295, DOI 10.1111/j.1365-246X.1961.tb06821.x; BIRCH F, 1963, SOLIDS UNDER PRESSUR, P137; Boehier R., 1990, HIGH PRESSURE RES, V6, P133, DOI DOI 10.1080/08957959008203204; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; BURKEL E, 1991, INELASTIC SCATTERING; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GUINAN MW, 1968, J PHYS CHEM SOLIDS, V29, P541, DOI 10.1016/0022-3697(68)90131-5; JEPHCOAT A, 1987, NATURE, V325, P332, DOI 10.1038/325332a0; Krisch MH, 1997, PHYS REV B, V56, P8691, DOI 10.1103/PhysRevB.56.8691; Laio A, 2000, SCIENCE, V287, P1027, DOI 10.1126/science.287.5455.1027; Lubbers R, 2000, SCIENCE, V287, P1250, DOI 10.1126/science.287.5456.1250; MAO H, COMMUNICATION; Mao HK, 1998, NATURE, V396, P741, DOI 10.1038/25506; MAO HK, 1990, J GEOPHYS RES-SOLID, V95, P21737, DOI 10.1029/JB095iB13p21737; MAO HK, 1978, J APPL PHYS, V49, P3276, DOI 10.1063/1.325277; Merkel S, 2000, SCIENCE, V288, P1626, DOI 10.1126/science.288.5471.1626; MINKIEWICZ VJ, 1967, PHYS REV, V162, P528, DOI 10.1103/PhysRev.162.528; Ruocco G, 1996, NATURE, V379, P521, DOI 10.1038/379521a0; Singh AK, 1998, PHYS REV LETT, V80, P2157, DOI 10.1103/PhysRevLett.80.2157; Soderlind P, 1996, PHYS REV B, V53, P14063, DOI 10.1103/PhysRevB.53.14063; Steinle-Neumann G, 1999, PHYS REV B, V60, P791, DOI 10.1103/PhysRevB.60.791; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; WARREN JL, 1967, PHYS REV, V158, P805, DOI 10.1103/PhysRev.158.805; Wenk HR, 2000, NATURE, V405, P1044, DOI 10.1038/35016558	24	114	117	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					468	471		10.1126/science.291.5503.468	http://dx.doi.org/10.1126/science.291.5503.468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161197				2022-12-28	WOS:000166487500036
J	Beckingham, IJ				Beckingham, IJ			ABC of diseases of liver, pancreas, and biliary system - Gallstone disease	BRITISH MEDICAL JOURNAL			English	Review									Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England	University of Nottingham	Beckingham, IJ (corresponding author), Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England.							BECKINGHAM IJ, 2000, SURG LIVER BILIARY T; Cuschieri A, 1999, SURG ENDOSC-ULTRAS, V13, P952, DOI 10.1007/s004649901145; KALSER SC, 1993, AM J SURG, V165, P390	3	71	73	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					91	94		10.1136/bmj.322.7278.91	http://dx.doi.org/10.1136/bmj.322.7278.91			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154626	Green Published			2022-12-28	WOS:000166496100036
J	Reim, K; Mansour, M; Varoqueaux, F; McMahon, HT; Sudhof, TC; Brose, N; Rosenmund, C				Reim, K; Mansour, M; Varoqueaux, F; McMahon, HT; Sudhof, TC; Brose, N; Rosenmund, C			Complexins regulate a late step in Ca2+-dependent neurotransmitter release	CELL			English	Article							MEMBRANE-FUSION; SNARE COMPLEX; EXOCYTOSIS; PROTEINS; SYNAPTOTAGMIN; VESICLES; PROBABILITY; TERMINALS; SYNAPHIN; SYNAPSES	Synaptic vesicle fusion at synapses is triggered by increases in cytosolic Ca2+ levels. However, the identity of the Ca2+ sensor and the transduction mechanism of the Ca2+ trigger are unknown. We show that Complexins, stoichiometric components of the exocytotic core complex, are important regulators of transmitter release at a step immediately preceding vesicle fusion. Neurons lacking Complexins show a dramatically reduced transmitter release efficiency due to decreased Ca2+ sensitivity of the synaptic secretion process. Analyses of mutant neurons demonstrate that Complexins are acting at or following the Ca2+-triggering step of fast synchronous transmitter release by regulating the exocytotic Ca2+ sensor, its interaction with the core complex fusion machinery, or the efficiency of the fusion apparatus itself.	Max Planck Inst Expt Med, Abt Neurogenet, AG Mol Neurobiol, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, Abt Membranbiophys, D-37077 Gottingen, Germany; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Max Planck Society; Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brose, N (corresponding author), Max Planck Inst Expt Med, Abt Neurogenet, AG Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Rosenmund, Christian/AAC-3596-2020; Varoqueaux, Frederique/AAC-1834-2021	Rosenmund, Christian/0000-0002-3905-2444; Varoqueaux, Frederique/0000-0002-3614-3121				Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; CALAKOS N, 1999, ANNU REV PHYSIOL, V61, P753; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; ISHIZUKA T, 1995, BIOCHEM BIOPH RES CO, V213, P1107, DOI 10.1006/bbrc.1995.2241; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; PABST S, 2000, IN PRESS J BIOL CHEM; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takahashi S, 1999, EUR J NEUROSCI, V11, P2359, DOI 10.1046/j.1460-9568.1999.00652.x; TAKAHASHI S, 1995, FEBS LETT, V368, P455, DOI 10.1016/0014-5793(95)00713-J; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Yamada M, 1999, NEUROSCIENCE, V93, P7, DOI 10.1016/S0306-4522(99)00104-9; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	26	355	373	0	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2001	104	1					71	81		10.1016/S0092-8674(01)00192-1	http://dx.doi.org/10.1016/S0092-8674(01)00192-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163241	Green Published, Bronze			2022-12-28	WOS:000166882300008
J	Lanza, RP; Caplan, AL; Silver, LM; Cibelli, JB; West, MD; Green, RM				Lanza, RP; Caplan, AL; Silver, LM; Cibelli, JB; West, MD; Green, RM			The ethical validity of using nuclear transfer in human transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							STEM-CELL RESEARCH; CENTRAL-NERVOUS-SYSTEM; EMBRYO; BRAIN; DIFFERENTIATE; PRECURSORS; GENERATION; FETAL		Dartmouth Coll, Eth Inst, Hanover, NH 03755 USA; Adv Cell Technol, Worcester, MA USA; Univ Penn, Med Ctr, Ctr Bioeth, Philadelphia, PA 19104 USA; Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Dartmouth College; University of Pennsylvania; Pennsylvania Medicine; Princeton University; Princeton University	Green, RM (corresponding author), Dartmouth Coll, Eth Inst, Hanover, NH 03755 USA.	ronald.m.green@dartmouth.edu		West, Michael/0000-0002-4842-5468; Cibelli, Jose/0000-0002-2176-3854				Andrews L, 1998, HUM REPROD, V13, P1, DOI 10.1093/humrep/13.1.1; Annas George J., 1994, Kennedy Institute of Ethics Journal, V4, P235; Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; CARNEY D, 1997, CQ WEEKLY       0315; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; *CTR BIOETH HUM DI, 2000, HUM EMBR STEM CELL R; *DEP HLTH, 2000, STEM CELL RES MED PR; Doerflinger RM, 1999, KENNEDY INST ETHIC J, V9, P137, DOI 10.1353/ken.1999.0011; EHLERS VJ, 1997, USA TODAY       0618, pA14; FORD NM, 1988, WHEN DID BEGIN, P102; Grobstein C, 1988, SCI UNBORN; IBRAHIM YN, 1996, NY TIMES        0801, pAY; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Lanza R.P., 2000, PRINCIPLES TISSUE EN; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; Lebacqz K, 1999, HASTINGS CENT REP, V29, P31; Lim DA, 1997, P NATL ACAD SCI USA, V94, P14832, DOI 10.1073/pnas.94.26.14832; McCormick Richard A, 1991, Kennedy Inst Ethics J, V1, P1; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McGee G, 1999, HASTINGS CENT REP, V29, P36, DOI 10.2307/3528351; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; McKay RD, 1999, NAT MED, V5, P261, DOI 10.1038/6468; MCKINNELL RG, 1962, J HERED, V53, P199, DOI 10.1093/oxfordjournals.jhered.a107171; Meng L, 1997, BIOL REPROD, V57, P454, DOI 10.1095/biolreprod57.2.454; *NAT BIOETH ADV CO, 1999, ETH ISS HUM STEM CEL, V1, P55; NESMITH J, 1998, ATLANTA J CONST 0108, pE3; ORAHILLY R, 1992, HUMAN EMBRYOLOGY TER, P56; *PHARM RES MAN AM, 2000, GEN LEG REG US CLON; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SHANNON TA, 1990, THEOL STUD, V51, P603, DOI 10.1177/004056399005100403; Shapiro HT, 1999, SCIENCE, V285, P2065, DOI 10.1126/science.285.5436.2065; Steghaus-Kovac S, 1999, SCIENCE, V286, P31, DOI 10.1126/science.286.5437.31; Strain L, 1998, NEW ENGL J MED, V338, P166, DOI 10.1056/NEJM199801153380305; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Vogel G, 1999, SCIENCE, V286, P2238, DOI 10.1126/science.286.5448.2238; WARREN MA, 1973, MONIST, V57, P43, DOI 10.5840/monist197357133; WILLIAMS B, 1985, ORAL DILEMMAS MODERN, P126; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wright SJ, 1999, AM SCI, V87, P352, DOI 10.1511/1999.30.830; 1999, FED REG         1202, V64, P67576; 2000, FED REG         0825, V65, P51976; 1994, WASHINGTON POST 1002, P8	48	35	36	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3175	3179		10.1001/jama.284.24.3175	http://dx.doi.org/10.1001/jama.284.24.3175			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	385FZ	11135784				2022-12-28	WOS:000165994100038
J	Salih, A; Larkum, A; Cox, G; Kuhl, M; Hoegh-Guldberg, O				Salih, A; Larkum, A; Cox, G; Kuhl, M; Hoegh-Guldberg, O			Fluorescent pigments in corals are photoprotective	NATURE			English	Article							ULTRAVIOLET-RADIATION; PHOTOSYNTHESIS; PHOTOINHIBITION; ADAPTATION	All reef-forming corals depend on the photosynthesis performed by their algal symbiont, and such corals are therefore restricted to the photic zone. The intensity of light in this zone declines over several orders of magnitude-from high and damaging levels at the surface to extreme shade conditions at the lower limit(1). The ability of corals to tolerate this range implies effective mechanisms for light acclimation and adaptation(2). Here we show that the fluorescent pigments(3-9) (FPs) of corals provide a photobiological system for regulating the light environment of coral host tissue. Previous studies have suggested that under low light, FPs may enhance light availability(4,5). We now report that in excessive sunlight FPs are photoprotective; they achieve this by dissipating excess energy at wavelengths of low photosynthetic activity, as well as by reflecting of visible and infrared light by FP-containing chromatophores. We also show that FPs enhance the resistance to mass bleaching of corals during periods of heat stress, which has implications for the effect of environmental stress on the diversity of reef-building corals, such as enhanced survival of a broad range of corals allowing maintenance of habitat diversity.	Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia; Univ Sydney, Electron Microscope Unit, Sydney, NSW 2006, Australia; Univ Copenhagen, Marine Biol Lab, DK-3100 Hornbaek, Denmark	University of Sydney; University of Sydney; University of Copenhagen	Salih, A (corresponding author), Univ Sydney, Sch Biol Sci, A08, Sydney, NSW 2006, Australia.	anya@emu.usyd.edu.au	Hoegh-Guldberg, Ove/H-6169-2011; Kühl, Michael/A-1977-2009; Hoegh-Guldberg, Ove/ABA-5420-2020	Hoegh-Guldberg, Ove/0000-0001-7510-6713; Kühl, Michael/0000-0002-1792-4790; Hoegh-Guldberg, Ove/0000-0001-7510-6713				Brown BE, 2000, NATURE, V404, P142, DOI 10.1038/35004657; Brown BE, 1999, CORAL REEFS, V18, P99; Dove SG, 1995, BIOL BULL, V189, P288, DOI 10.2307/1542146; Dove SG, 2001, CORAL REEFS, V19, P197, DOI 10.1007/PL00006956; Dunlap WC, 1998, J PHYCOL, V34, P418, DOI 10.1046/j.1529-8817.1998.340418.x; Falkowski P.G., 1990, P89; FALKOWSKI PG, 1981, NATURE, V289, P172, DOI 10.1038/289172a0; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; HOEGHGULDBERG O, 1999, MAR ECOL-PROG SER, V22, P520; Iglesias-Prieto R, 1997, MAR BIOL, V130, P23, DOI 10.1007/s002270050221; JOKIEL PL, 1980, SCIENCE, V207, P1069, DOI 10.1126/science.207.4435.1069; Jones RJ, 1998, PLANT CELL ENVIRON, V21, P1219, DOI 10.1046/j.1365-3040.1998.00345.x; Kawaguti S., 1969, Micronesica, V5, P313; Kawaguti S, 1944, CONTR PALAO TROP BIO, V2, P616; KUHL M, 1992, LIMNOL OCEANOGR, V37, P1813; KUHL M, 1995, MAR ECOL PROG SER, V117, P159, DOI 10.3354/meps117159; Lesser MP, 1996, LIMNOL OCEANOGR, V41, P271, DOI 10.4319/lo.1996.41.2.0271; LONG SP, 1994, ANNU REV PLANT PHYS, V45, P633, DOI 10.1146/annurev.pp.45.060194.003221; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; MAZEL CH, 1995, MAR ECOL PROG SER, V120, P185, DOI 10.3354/meps120185; Rowan R, 1997, NATURE, V388, P265, DOI 10.1038/40843; Salih A, 1998, P AUSTR COR REEF SOC, P217; SALIH A, 1998, P AUST COR REEF SOC, P206; SCHLICHTER D, 1986, MAR BIOL, V91, P403, DOI 10.1007/BF00428634; Schreiber U, 1997, PLANT CELL PHYSIOL, V38, P945, DOI 10.1093/oxfordjournals.pcp.a029256; Shick JM, 1996, GLOBAL CHANGE BIOL, V2, P527, DOI 10.1111/j.1365-2486.1996.tb00065.x; SHIMOMURA O, 1962, AEQUOREA J CELL COMP, V77, P305; TAKABAYASHI M, 1995, MAR BIOL, V123, P705, DOI 10.1007/BF00349113; Veron J.E.N., 1986, CORALS AUSTR INDOPAC	30	466	477	2	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					850	853		10.1038/35048564	http://dx.doi.org/10.1038/35048564			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130722				2022-12-28	WOS:000165831300048
J	Hermosura, MC; Takeuchi, H; Fleig, A; Riley, AM; Potter, BVL; Hirata, M; Penner, R				Hermosura, MC; Takeuchi, H; Fleig, A; Riley, AM; Potter, BVL; Hirata, M; Penner, R			InsP(4) facilitates store-operated calcium influx by inhibition of InsP(3) 5-phosphatase	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CURRENT I-CRAC; ACINAR-CELLS; PROTEIN-KINASE; TRISPHOSPHATE; 1,3,4,5-TETRAKISPHOSPHATE; ACTIVATION; DEPLETION; LYMPHOCYTES; METABOLISM	Receptor-mediated generation of inositol 1,4,5-trisphosphate (InsP(3)) initiates Ca2+ release from intracellular stores and the subsequent activation of store-operated calcium influx(1). InsP(3) is metabolized within seconds by 5-phosphatase and 3-kinase(2), yielding Ins(1,4)P-2 and inositol 1,3,4,5-tetrakisphosphate (InsP(4)), respectively. Some studies have suggested that InsP(4) controls Ca2+ influx in combination with InsP(3) (refs 3 and 4), but another study did not find the same result(5). Some of the apparent conflicts between these previous studies have been resolved(6); however, the physiological function of InsP(4) remains elusive(7,8). Here we have investigated the function of InsP(4) in Ca2+ influx in the mast cell line RBL-2H3, and we show that InsP(4) inhibits InsP(3) metabolism through InsP(3) 5-phosphatase, thereby facilitating the activation of the store-operated Ca2+ current I-CRAC (ref. 9). Physiologically, this mechanism opens a discriminatory time window for coincidence detection that enables selective facilitation of Ca2+ influx by appropriately timed low-level receptor stimulation. At higher concentrations, InsP(4) acts as an inhibitor of InsP(3) receptors, enabling InsP(4) to act as a potent bi-modal regulator of cellular sensitivity to InsP(3), which provides both facilitatory and inhibitory feedback on Ca2+ signalling.	Univ Hawaii, Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signaling, Honolulu, HI 96813 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96813 USA; Kyushu Univ, Grad Sch Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan; Kyushu Univ, Stn Collaborat Res, Fukuoka 8128582, Japan; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England	The Queen's Medical Center; University of Hawaii System; University of Hawaii System; Kyushu University; Kyushu University; University of Bath	Potter, BVL (corresponding author), Univ Hawaii, Queens Med Ctr, Ctr Biomed Res, Lab Cell & Mol Signaling, Honolulu, HI 96813 USA.	prsbvlp@bath.ac.uk; rpenner@hawaii.edu	Potter, Barry VL/A-1845-2012; Riley, Andrew M/F-3526-2013; Potter, Barry/AAX-4781-2020	Riley, Andrew M/0000-0001-9003-3540; Penner, Reinhold/0000-0002-5366-1537; Fleig, Andrea/0000-0001-8396-7249				BALLA T, 1991, J BIOL CHEM, V266, P24719; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; Bird GSJ, 1996, J BIOL CHEM, V271, P6766, DOI 10.1074/jbc.271.12.6766; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; Communi D, 1999, J BIOL CHEM, V274, P14734, DOI 10.1074/jbc.274.21.14734; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; DASILVA CP, 1994, J BIOL CHEM, V269, P12521; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Glitsch MD, 2000, J PHYSIOL-LONDON, V523, P283, DOI 10.1111/j.1469-7793.2000.t01-2-00283.x; GUILLEMETTE G, 1990, EUR J PHARM-MOLEC PH, V188, P251, DOI 10.1016/0922-4106(90)90009-M; Hirata M, 1997, BIOCHEM J, V328, P93, DOI 10.1042/bj3280093; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Riley AM, 1997, ANGEW CHEM INT EDIT, V36, P1472, DOI 10.1002/anie.199714721; SAFRANY ST, 1994, BIOCHEMISTRY-US, V33, P10763, DOI 10.1021/bi00201a025; Smith PM, 2000, BIOCHEM J, V347, P77, DOI 10.1042/0264-6021:3470077; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Yoshimura K, 1999, CELL SIGNAL, V11, P117, DOI 10.1016/S0898-6568(98)00043-6	29	87	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					735	740		10.1038/35047115	http://dx.doi.org/10.1038/35047115			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130077				2022-12-28	WOS:000165815200053
J	Hulleman, F; van Kerkwijk, MH; Kulkarni, SR				Hulleman, F; van Kerkwijk, MH; Kulkarni, SR			An optical counterpart to the anomalous X-ray pulsar 4U0142+61	NATURE			English	Article							WHITE-DWARF; EMISSION; STARS	The energy source of the anomalous X-ray pulsars' (AXPs) is not understood, hence their designation as anomalous. Unlike binary X-ray pulsars, no companions are seen, so the energy cannot be supplied by accretion of matter from a companion star. The loss of rotational energy, which powers radio pulsars, is insufficient to power AXPs. Two models are generally considered: accretion from a large disk left over from the birth process(2,3), or decay of a very strong magnetic field (10(15) G) associated with a 'magnetar'(4). The lack of counterparts at other wavelengths has hampered progress in our understanding of these objects. Here we report deep optical observations of the field around 4U0142+61, which is the brightest AXP in X-rays. The source has no associated supernova remnant, which, together with its spin-down timescale of similar to 10(5)yr (ref. 5), suggests that it may be relatively old. We find an object with peculiar optical colours at the position of the X-ray source, and argue that it is the optical counterpart. The optical emission is too faint to admit the presence of a large accretion disk, but may be consistent with magnetospheric emission from a magnetar.	Univ Utrecht, Astron Inst, NL-3508 TA Utrecht, Netherlands; CALTECH, Palomar Observ 105 24, Pasadena, CA 91125 USA	Utrecht University; California Institute of Technology	Hulleman, F (corresponding author), Univ Utrecht, Astron Inst, POB 80000, NL-3508 TA Utrecht, Netherlands.	f.hulleman@astro.uu.nl						Baraffe I, 1998, ASTRON ASTROPHYS, V337, P403; BERGERON P, 1995, PUBL ASTRON SOC PAC, V107, P1047, DOI 10.1086/133661; Bessell M. S., 1992, IAU C, V136, P22; CARDELLI JA, 1989, ASTROPHYS J, V345, P245, DOI 10.1086/167900; Chatterjee P, 2000, ASTROPHYS J, V534, P373, DOI 10.1086/308748; Ferrario L, 1997, MON NOT R ASTRON SOC, V292, P205, DOI 10.1093/mnras/292.2.205; FUKUGITA M, 1995, PUBL ASTRON SOC PAC, V107, P945, DOI 10.1086/133643; Hulleman F, 2000, ASTRON ASTROPHYS, V358, P605; MARSDEN D, UNPUB ASTROPHYS J; MARSDEN D, 1999, ASTROPH9912207; MEREGHETTI S, 1995, ASTROPHYS J, V442, pL17, DOI 10.1086/187805; MEREGHETTI S, 1999, ASTROPH9911252; MEREGHETTI S, 1999, P NATO ASI SCH NEUTR; MONET D, 2000, USNO V20 CATALOG AST; MOTCH C, 1991, ASTRON ASTROPHYS, V246, pL24; OKE JB, 1995, PUBL ASTRON SOC PAC, V107, P375, DOI 10.1086/133562; PACZYNSKI B, 1990, ASTROPHYS J, V365, pL9, DOI 10.1086/185876; Perna R, 2000, ASTROPHYS J, V541, P344, DOI 10.1086/309404; PHELPS RL, 1994, ASTROPHYS J SUPPL S, V90, P31, DOI 10.1086/191857; Pivovaroff MJ, 2000, ASTROPHYS J, V535, P379, DOI 10.1086/308848; PREDEHL P, 1995, ASTRON ASTROPHYS, V293, P889; Schlegel DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772; STELLA L, 1987, ASTROPHYS J, V312, pL17, DOI 10.1086/184811; Thompson C, 1996, ASTROPHYS J, V473, P322, DOI 10.1086/178147; VANDENBERG M, UNPUB ASTRON ASTROPH; VRTILEK SD, 1990, ASTRON ASTROPHYS, V235, P162; White NE, 1996, ASTROPHYS J, V463, pL83, DOI 10.1086/310065; WHITE NE, 1987, MON NOT R ASTRON SOC, V226, P645, DOI 10.1093/mnras/226.3.645; Wilson CA, 1999, ASTROPHYS J, V513, P464, DOI 10.1086/306839	31	141	143	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					689	692		10.1038/35047024	http://dx.doi.org/10.1038/35047024			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130064	Green Submitted			2022-12-28	WOS:000165815200040
J	Kleinert, S				Kleinert, S			Next phase of priority-setting in health care	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Kleinert, S (corresponding author), Lancet, London WC1X 8RR, England.							Daniels N, 2000, BMJ-BRIT MED J, V321, P1300, DOI 10.1136/bmj.321.7272.1300; Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Kleinert S, 1998, LANCET, V352, P1244, DOI 10.1016/S0140-6736(05)70485-2; World Health Organization, 2000, HLTH SYST IMPR PERF	4	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1869	1870		10.1016/S0140-6736(00)03255-4	http://dx.doi.org/10.1016/S0140-6736(00)03255-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130380				2022-12-28	WOS:000165665400007
J	Nosten, F				Nosten, F			Prophylactic effect of Malarone against malaria: all good news?	LANCET			English	Editorial Material							CYTOCHROME-B; ATOVAQUONE; RESISTANCE; PROGUANIL; MUTATIONS		Shoklo Malaria Res Unit, Mae Sot, Thailand; Mahidol Univ, Fac Trop Med, Bangkok, Thailand; John Radcliffe Hosp, Dept Clin Med, Oxford OX3 9DU, England	Mahidol University; Mahidol University; University of Oxford	Nosten, F (corresponding author), Shoklo Malaria Res Unit, POB 46, Mae Sot, Thailand.		Nosten, Francois/AAC-5509-2019	Nosten, Francois/0000-0002-7951-0745				Christie B, 2000, BRIT MED J, V321, P913, DOI 10.1136/bmj.321.7266.913; Enosse S, 2000, T ROY SOC TROP MED H, V94, P77, DOI 10.1016/S0035-9203(00)90447-4; FRY M, 1992, BIOCHEM PHARMACOL, V43, P1545, DOI 10.1016/0006-2952(92)90213-3; Hughes W T, 1992, Am Fam Physician, V46, P1257; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Ringwald P, 1998, LANCET, V351, P673, DOI 10.1016/S0140-6736(05)78458-0; ROLAN PE, 1994, BRIT J CLIN PHARMACO, V37, P13, DOI 10.1111/j.1365-2125.1994.tb04232.x; Shretta R, 2000, LANCET, V355, P1718, DOI 10.1016/S0140-6736(00)02251-0; Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x; Srivastava IK, 1999, ANTIMICROB AGENTS CH, V43, P1334, DOI 10.1128/AAC.43.6.1334; Sukwa TY, 1999, AM J TROP MED HYG, V60, P521, DOI 10.4269/ajtmh.1999.60.521; White NJ, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P301	13	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	2000	356	9245					1864	1865		10.1016/S0140-6736(00)03250-5	http://dx.doi.org/10.1016/S0140-6736(00)03250-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130375				2022-12-28	WOS:000165665400002
J	Burslem, DFRP; Garwood, NC; Thomas, SC				Burslem, DFRP; Garwood, NC; Thomas, SC			Ecology - Tropical forest diversity - The plot thickens	SCIENCE			English	Editorial Material							PRODUCTS; TREES		Univ Aberdeen, Dept Plant & Soil Sci, Aberdeen AB24 3UU, Scotland; Nat Hist Museum, Dept Bot, London SW7 5BD, England; Univ Toronto, Fac Forestry, Toronto, ON M5S 3B3, Canada	University of Aberdeen; Natural History Museum London; University of Toronto	Burslem, DFRP (corresponding author), Univ Aberdeen, Dept Plant & Soil Sci, Aberdeen AB24 3UU, Scotland.		THOMAS, Sean C./B-6089-2008; Burslem, David FRP/F-1204-2019	THOMAS, Sean C./0000-0002-0686-2483; Burslem, David FRP/0000-0001-6033-0990				Condit R, 2000, SCIENCE, V288, P1414, DOI 10.1126/science.288.5470.1414; Condit R, 1996, J ECOL, V84, P549, DOI 10.2307/2261477; Condit R, 1998, TROPICAL FOREST CENS; Dalling JW, 1998, ECOLOGY, V79, P564, DOI 10.1890/0012-9658(1998)079[0564:DPASBD]2.0.CO;2; Davies SJ, 1998, ECOLOGY, V79, P2292, DOI 10.1890/0012-9658(1998)079[2292:PONPMS]2.0.CO;2; GODOY R, 1993, ECON BOT, V47, P220, DOI 10.1007/BF02862288; GUNATILLEKE IAUN, 1993, ECON BOT, V47, P282, DOI 10.1007/BF02862295; HALL P, 1993, ECON BOT, V47, P234, DOI 10.1007/BF02862289; *NAN TECHN U, 2000, EXPL FOR DIV CHANG S; Nason JD, 1998, NATURE, V391, P685, DOI 10.1038/35607; Thomas SC, 1999, ECOLOGY, V80, P1607	11	30	31	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					606	607		10.1126/science.1055873	http://dx.doi.org/10.1126/science.1055873			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158665				2022-12-28	WOS:000166616000031
J	Hurrell, JW; Kushnir, Y; Visbeck, M				Hurrell, JW; Kushnir, Y; Visbeck, M			Climate - The North Atlantic oscillation	SCIENCE			English	Editorial Material									Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Columbia Univ, Lamont Doherty Earth Observ, W Palisades, NY 10694 USA	National Center Atmospheric Research (NCAR) - USA; Columbia University	Hurrell, JW (corresponding author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA.	jhurrell@ucar.edu	Kushnir, Yochanan/B-4472-2013; Visbeck, Martin/G-2461-2011; zhu, xiaoting/E-9873-2011; Visbeck, Martin H/B-6541-2016	Visbeck, Martin/0000-0002-0844-834X; Visbeck, Martin H/0000-0002-0844-834X; Hurrell, James Wilson/0000-0002-3169-6384				Delworth TL, 2000, J CLIMATE, V13, P3721, DOI 10.1175/1520-0442(2000)013<3721:IOTRTI>2.0.CO;2; Mehta VM, 2000, GEOPHYS RES LETT, V27, P121, DOI 10.1029/1999GL002381; Rodwell MJ, 1999, NATURE, V398, P320, DOI 10.1038/18648; Thompson DWJ, 2000, J CLIMATE, V13, P1018, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2	4	412	419	9	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2001	291	5504					603	605		10.1126/science.1058761	http://dx.doi.org/10.1126/science.1058761			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158663				2022-12-28	WOS:000166616000029
J	Wasan, DT; Nikolov, AD; Brenner, H				Wasan, DT; Nikolov, AD; Brenner, H			Fluid dynamics - Droplets speeding on surfaces	SCIENCE			English	Editorial Material									IIT, Dept Chem Engn, Chicago, IL 60616 USA; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Illinois Institute of Technology; Massachusetts Institute of Technology (MIT)	Wasan, DT (corresponding author), IIT, Dept Chem Engn, Chicago, IL 60616 USA.							Daniel S, 2001, SCIENCE, V291, P633, DOI 10.1126/science.291.5504.633; DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827; EDWARDS DA, 1991, INTERFACIAL TRANSPOR, P161; LEVICH B, 1969, ANNU REV FLUID MECH, V1, P239; Maxwell James Clerk, 1878, ENCY BRITANNICA; Thomson J, 1855, PHILOS MAG, V10, P330, DOI DOI 10.1080/14786445508641982; Young T., 1805, PHILOS T R SOC LONDO, V95, P65, DOI [10.1098/rstl.1805.0005, DOI 10.1098/RSTL.1805.0005]; [No title captured]	8	76	80	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					605	606		10.1126/science.1058466	http://dx.doi.org/10.1126/science.1058466			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158664				2022-12-28	WOS:000166616000030
J	Escher, M; Desmeules, J; Giostra, E; Mentha, G				Escher, M; Desmeules, J; Giostra, E; Mentha, G			Hepatitis associated with Kava, a herbal remedy for anxiety	BRITISH MEDICAL JOURNAL			English	Letter																		MATHEWS JD, 1988, MED J AUSTRALIA, V148, P348; MOSTEFAKARA N, 1992, LANCET, V340, P674, DOI 10.1016/0140-6736(92)92209-X; Sheikh NM, 1997, ARCH INTERN MED, V157, P913, DOI 10.1001/archinte.157.8.913; Strahl S, 1998, DEUT MED WOCHENSCHR, V123, P1410, DOI 10.1055/s-2007-1024196; Yoshida EM, 1996, AM J GASTROENTEROL, V91, P2647	5	116	118	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					139	139		10.1136/bmj.322.7279.139	http://dx.doi.org/10.1136/bmj.322.7279.139			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159570	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000166615300025
J	Lee, KY; Peters, MC; Anderson, KW; Mooney, DJ				Lee, KY; Peters, MC; Anderson, KW; Mooney, DJ			Controlled growth factor release from synthetic extracellular matrices	NATURE			English	Article							PROTEIN DELIVERY; POLYMER MATRICES; TISSUE; HYDROGELS; INVIVO	Polymeric matrices can be used to grow new tissues and organs(1,2), and the delivery of growth factors from these matrices is one method to regenerate tissues(3,4). A problem with engineering tissues that exist in a mechanically dynamic environment, such as bone, muscle and blood vessels(5,6), is that most drug delivery systems have been designed to operate under static conditions. We thought that polymeric matrices, which release growth factors in response to mechanical signals, might provide a new approach to guide tissue formation in mechanically stressed environments. Critical design features for this type of system include the ability to undergo repeated deformation, and a reversible binding of the protein growth factors to polymeric matrices to allow for responses to repeated stimuli. Here we report a model delivery system that can respond to mechanical signalling and upregulate the release of a growth factor to promote blood vessel formation. This approach may rnd a number of applications, including regeneration and engineering of new tissues and more general drug-delivery applications.	Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.			Lee, Kuen Yong/0000-0002-5759-5952; Mooney, David/0000-0001-6299-1194				Baldwin SP, 1998, ADV DRUG DELIVER REV, V33, P71, DOI 10.1016/S0169-409X(98)00021-0; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; EDELMAN ER, 1987, J BIOMED MATER RES, V21, P339, DOI 10.1002/jbm.820210307; Jen AC, 1996, BIOTECHNOL BIOENG, V50, P357, DOI 10.1002/(SICI)1097-0290(19960520)50:4<357::AID-BIT2>3.3.CO;2-F; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Langer R, 1998, NATURE, V392, P5; MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Putnam AJ, 1996, NAT MED, V2, P824, DOI 10.1038/nm0796-824; Ripamonti U, 1997, CRIT REV ORAL BIOL M, V8, P154, DOI 10.1177/10454411970080020401; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092; Williams B, 1998, J HYPERTENS, V16, P1921, DOI 10.1097/00004872-199816121-00011	20	433	459	3	125	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					998	1000		10.1038/35050141	http://dx.doi.org/10.1038/35050141			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140690	Green Published			2022-12-28	WOS:000165951100056
J	Srianand, R; Petitjean, P; Ledoux, C				Srianand, R; Petitjean, P; Ledoux, C			The cosmic microwave background radiation temperature at a redshift of 2.34	NATURE			English	Article							DIFFUSE INTERSTELLAR CLOUDS; C-I; ABUNDANCES; EXCITATION; GALAXIES; CARBON	The existence of the cosmic microwave background radiation is a fundamental prediction of hot Big Bang cosmology, and its temperature should increase with increasing redshift. At the present time (redshift z = 0), the temperature has been determined with high precision to be T-CMBR(0) = 2.726 +/- 0.010 K. In principle, the background temperature can be determined using measurements of the relative populations of atomic fine-structure levels, which are excited by the background radiation. But all previous measurements have achieved only upper limits, thus still formally permitting the radiation temperature to be constant with increasing redshift. Here we report the detection of absorption lines from the first and second fine-structure levels of neutral carbon atoms in an isolated cloud of gas at z = 2.3371. We also detected absorption due to several rotational transitions of molecular hydrogen, and fine-structure lines of singly ionized carbon. These constraints enable us to determine that the background radiation was indeed warmer in the past: we rnd that T-CMBR(z = 2.3371) is between 6.0 and 14 K. This is in accord with the temperature of 9.1 K predicted by hot Big Bang cosmology.	IUCAA, Pune 411007, Maharashtra, India; CNRS, Inst Astrophys Paris, F-75014 Paris, France; Observ Paris Meudon, CNRS, F-92195 Meudon, France; European So Observ, D-85748 Garching, Germany	Inter-University Centre for Astronomy & Astrophysics; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; European Southern Observatory	Srianand, R (corresponding author), IUCAA, Post Bag 4, Pune 411007, Maharashtra, India.			Ledoux, Cedric/0000-0002-7864-3327				ALPHER RA, 1948, PHYS REV, V73, P803, DOI 10.1103/PhysRev.73.803; BAHCALL JN, 1968, ASTROPHYS J, V152, P701, DOI 10.1086/149589; BAHCALL JN, 1973, ASTROPHYS J, V182, pL95, DOI 10.1086/181227; D'Odorico S, 2000, P SOC PHOTO-OPT INS, V4005, P121, DOI 10.1117/12.390133; DALGARNO A, 1972, ASTROPHYS J, V174, pL49, DOI 10.1086/180946; Ge J, 1997, ASTROPHYS J, V474, P67, DOI 10.1086/303426; Ge J, 1999, ASTR SOC P, V156, P121; JENKINS EB, 1979, ASTROPHYS J, V231, P55, DOI 10.1086/157163; JURA M, 1975, ASTROPHYS J, V197, P581, DOI 10.1086/153546; KEENAN FP, 1986, MON NOT R ASTRON SOC, V220, P571, DOI 10.1093/mnras/220.3.571; LAUNAY JM, 1977, ASTRON ASTROPHYS, V56, P289; Lu LM, 1996, ASTROPHYS J SUPPL S, V107, P475, DOI 10.1086/192373; MATHER JC, 1994, ASTROPHYS J, V420, P439, DOI 10.1086/173574; MEYER DM, 1986, ASTROPHYS J, V308, pL37, DOI 10.1086/184739; MORTON DC, 1991, ASTROPHYS J SUPPL S, V77, P119, DOI 10.1086/191601; NUSSBAUMER H, 1979, ASTRON ASTROPHYS, V72, P129, DOI 10.1086/150969; Pettini M, 1997, ASTROPHYS J, V486, P665, DOI 10.1086/304564; Roth KC, 1999, ASTROPHYS J, V515, pL57, DOI 10.1086/311974; ROTH KC, 1995, ASTROPHYS J, V441, P129, DOI 10.1086/175343; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; Shull JM, 2000, ASTROPHYS J, V538, pL73, DOI 10.1086/312782; SONGAILA A, 1994, NATURE, V371, P43, DOI 10.1038/371043a0; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; Srianand R, 1998, ASTRON ASTROPHYS, V335, P33; SUNYAEV RA, 1980, MON NOT R ASTRON SOC, V190, P413, DOI 10.1093/mnras/190.3.413; TIMMES FX, 1995, ASTROPHYS J, V451, P468, DOI 10.1086/176235; Welty DE, 1999, ASTROPHYS J SUPPL S, V124, P465, DOI 10.1086/313263	28	143	146	1	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					931	935		10.1038/35050020	http://dx.doi.org/10.1038/35050020			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140672	Green Submitted			2022-12-28	WOS:000165951100038
J	White, HD				White, HD			Thrombolytic therapy in the elderly	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; OLDER; ANGIOPLASTY; TRIALS; AGE		Green Lane Hosp, Cardiovasc Res Unit, Auckland 1030, New Zealand		White, HD (corresponding author), Green Lane Hosp, Cardiovasc Res Unit, Private Bag 92189, Auckland 1030, New Zealand.							[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Ayanian JZ, 2000, CIRCULATION, V101, P2224, DOI 10.1161/01.CIR.101.19.2224; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Berger AK, 2000, J AM COLL CARDIOL, V36, P366, DOI 10.1016/S0735-1097(00)00723-3; Berger AK, 1999, JAMA-J AM MED ASSOC, V282, P341, DOI 10.1001/jama.282.4.341; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Holmes DR, 1999, J AM COLL CARDIOL, V33, P412, DOI 10.1016/S0735-1097(98)00579-8; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lesnefsky EJ, 1996, J AM COLL CARDIOL, V28, P331, DOI 10.1016/0735-1097(96)00148-9; Lundergan CF, 1998, J AM COLL CARDIOL, V32, P641, DOI 10.1016/S0735-1097(98)00278-2; Pocock SJ, 2000, NEW ENGL J MED, V342, P1907, DOI 10.1056/NEJM200006223422511; Thiemann DR, 2000, CIRCULATION, V101, P2239, DOI 10.1161/01.CIR.101.19.2239; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; White HD, 1996, CIRCULATION, V94, P1826, DOI 10.1161/01.CIR.94.8.1826; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632	16	113	122	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	2000	356	9247					2028	2030		10.1016/S0140-6736(00)03397-3	http://dx.doi.org/10.1016/S0140-6736(00)03397-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145486				2022-12-28	WOS:000165994300006
J	Shams, L; Kamitani, Y; Shimojo, S				Shams, L; Kamitani, Y; Shimojo, S			Illusions - What you see is what you hear	NATURE			English	Article									CALTECH, Div Biol, Pasadena, CA 91125 USA; NTT, Commun Sci Labs, Human & Informat Sci Lab, Kanagawa 2430198, Japan	California Institute of Technology; Nippon Telegraph & Telephone Corporation	Shams, L (corresponding author), CALTECH, Div Biol, MC 139-74, Pasadena, CA 91125 USA.							MEREDITH MA, 1987, J NEUROSCI, V7, P3215; SALDANA HM, 1993, PERCEPT PSYCHOPHYS, V54, P406, DOI 10.3758/BF03205276; Sekuler R, 1997, NATURE, V385, P308, DOI 10.1038/385308a0; Stein BE, 1996, J COGNITIVE NEUROSCI, V8, P497, DOI 10.1162/jocn.1996.8.6.497; WALLACE MT, 1994, J NEUROPHYSIOL, V71, P429, DOI 10.1152/jn.1994.71.1.429	5	756	768	2	127	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					788	788		10.1038/35048669	http://dx.doi.org/10.1038/35048669			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130706	Bronze			2022-12-28	WOS:000165831300031
J	Agerbo, E; Mortensen, PB; Eriksson, T; Qin, P; Westergaard-Nielsen, N				Agerbo, E; Mortensen, PB; Eriksson, T; Qin, P; Westergaard-Nielsen, N			Risk of suicide in relation to income level in people admitted to hospital with mental illness: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article									Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark; Psychiat Hosp Aarhus, Inst Basic Psychiat, Dept Psychiat Demog, DK-8240 Risskov, Denmark	Aarhus University; Aarhus University	Agerbo, E (corresponding author), Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark.		Agerbo, Esben/A-2645-2012; Mortensen, Preben B/D-2358-2015	Agerbo, Esben/0000-0002-2849-524X; Mortensen, Preben B/0000-0002-5230-9865				Goldberg DP., 1992, COMMON MENTAL DISORD; Lester D, 1997, SUICIDE LIFE-THREAT, V27, P352; Lewis G, 1998, BMJ-BRIT MED J, V317, P1283, DOI 10.1136/bmj.317.7168.1283; Mortensen PB, 2000, LANCET, V355, P9, DOI 10.1016/S0140-6736(99)06376-X; Penn DL, 1998, PSYCHIAT QUART, V69, P235, DOI 10.1023/A:1022153327316	5	38	39	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	2001	322	7282					334	335		10.1136/bmj.322.7282.334	http://dx.doi.org/10.1136/bmj.322.7282.334			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159656	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000167050000027
J	Waller, D				Waller, D			10-minute consultation - Binge eating	BRITISH MEDICAL JOURNAL			English	Article											Waller, D (corresponding author), 19 Beaumont St, Oxford OX1 2NA, England.								0	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	2001	322	7282					343	343		10.1136/bmj.322.7282.343	http://dx.doi.org/10.1136/bmj.322.7282.343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159659	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000167050000030
J	Jakes, RW; Khaw, KT; Day, NE; Bingham, S; Welch, A; Oakes, S; Luben, R; Dalzell, N; Reeve, J; Wareham, NJ				Jakes, RW; Khaw, KT; Day, NE; Bingham, S; Welch, A; Oakes, S; Luben, R; Dalzell, N; Reeve, J; Wareham, NJ			Patterns of physical activity and ultrasound attenuation by heel hone among Norfolk cohort of European Prospective Investigation of Cancer (EPIC Norfolk): population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BONE-DENSITY; CONTROLLED TRIAL; EXERCISE; PREDICTION; FRACTURES; WOMEN; SITES; MASS	Objectives To study associations between patterns of physical activity and ultrasound attenuation by the heel bone in men and women. Design Cross sectional, population based study. Setting Norfolk. Participants 2296 men and 2914 women aged 45-74 registered wit general practices participating in European Prospective Investigation into Cancer (EPIC Norfolk). Results Self reported time spent in high impact physical activity was strongly and positively associated with ultrasound attentuation by the heel bone, independently of age, weight, and other cofounding factors. Men who reported participating in greater than or equal to2 hours/week of high impact activity had 9.5% higher ultrasound attenuation than men who reported no activity of this type. Women who reported any high impact activity had 3.4% higher ultrasound attentuation than those who reported none. In women this effect was similar in size to that of age difference of four years. Moderate impact activity had no effect. However, climbing stairs was strongly independently associated wit ultrasound attenuation in women. There was a significant negative association in women between time spent watching television or video and heel bone ultrasound attenuation. Conclusions High impact physical activity is independently associated with ultrasound attenuation by the heel gone in men and women. As low ultrasound attenuation has been shown to predict increased risk of hip fracture, interventions to promote participation in high impact activities may help preserve bone density and reduce the risk of fracture. However, in older people such interventions may be inappropriate as the could increase the likelihood of falls.	Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England; Univ Cambridge, Strangeways Res Lab, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; Univ Cambridge, Strangeways Res Lab, Dept Med, Cambridge CB1 8RN, England; Dunn Human Nutr Unit, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Wareham, NJ (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England.	njw1004@medschl.cam.ac.uk	Luben, Robert N/H-5519-2015; Reeve, Jonathan/C-7551-2012; Welch, Ailsa Ann/A-4850-2008; Khaw, Kay-Tee/AAZ-3209-2021	Luben, Robert N/0000-0002-5088-6343; Reeve, Jonathan/0000-0002-4364-2682; Welch, Ailsa Ann/0000-0002-6702-3704; 				Baran D T, 1991, Osteoporos Int, V1, P110, DOI 10.1007/BF01880452; BASSEY EJ, 1994, OSTEOPOROSIS INT, V4, P72, DOI 10.1007/BF01623226; Bassey EJ, 1997, J BIOMECH, V30, P213, DOI 10.1016/S0021-9290(96)00043-7; CASPERSEN CJ, 1989, EXERCISE SPORT SCI R, V17, P423; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DONALDSON CL, 1970, METAB CLIN EXP, V19, P1074; Ebrahim S, 1997, AGE AGEING, V26, P253, DOI 10.1093/ageing/26.4.253; KROLNER B, 1983, CLIN SCI, V64, P541, DOI 10.1042/cs0640541; LANYON LE, 1992, J BONE MINER RES, V7, pS369, DOI 10.1002/jbmr.5650071403; Lanyon LE, 1996, BONE, V18, pS37, DOI 10.1016/8756-3282(95)00378-9; Layne JE, 1999, MED SCI SPORT EXER, V31, P25, DOI 10.1097/00005768-199901000-00006; MCCLOSKEY EV, 1990, CLIN SCI, V78, P227, DOI 10.1042/cs0780227; NIGG BM, 1985, SPORTS MED, V2, P367, DOI 10.2165/00007256-198502050-00005; Pluijm SMF, 1999, OSTEOPOROSIS INT, V9, P550, DOI 10.1007/s001980050275; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Wareham NJ, 1998, INT J OBESITY, V22, pS30; Wolff I, 1999, OSTEOPOROSIS INT, V9, P1, DOI 10.1007/s001980050109	18	31	32	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2001	322	7279					140	143		10.1136/bmj.322.7279.140	http://dx.doi.org/10.1136/bmj.322.7279.140			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159572	Green Published			2022-12-28	WOS:000166615300026
J	Bayer, M; Hawrylak, P; Hinzer, K; Fafard, S; Korkusinski, M; Wasilewski, ZR; Stern, O; Forchel, A				Bayer, M; Hawrylak, P; Hinzer, K; Fafard, S; Korkusinski, M; Wasilewski, ZR; Stern, O; Forchel, A			Coupling and entangling of quantum states in quantum dot molecules	SCIENCE			English	Article							COMPUTATION; GROWTH; GAAS; INFORMATION; SYSTEMS; ISLANDS; STRAIN	We demonstrate coupling and entangling of quantum states in a pair of vertically aligned, self-assembled quantum dots by studying the emission of an interacting electron-hole pair (exciton) in a single dot molecule as a function of the separation between the dots. An interaction-induced energy splitting of the exciton is observed that exceeds 30 millielectron volts for a dot layer separation of 4 nanometers. The results are interpreted by mapping the tunneling of a particle in a double dot to the problem of a single spin. The electron-hole complex is shown to be equivalent to entangled states of two interacting spins.	Univ Wurzburg, Inst Phys, D-97074 Wurzburg, Germany; Natl Res Council Canada, Inst Microstruct Sci, Ottawa, ON K1A 0R6, Canada; Univ Ottawa, Dept Phys, Ottawa, ON K1N 6N5, Canada	University of Wurzburg; National Research Council Canada; University of Ottawa	Bayer, M (corresponding author), Univ Wurzburg, Inst Phys, D-97074 Wurzburg, Germany.		Wasilewski, Zbigniew Roman/AGM-7788-2022; Bayer, Manfred/I-7947-2013	Bayer, Manfred/0000-0002-0893-5949; Forchel, Alfred/0000-0002-9377-9935; Wasilewski, Zbigniew Roman/0000-0001-7116-5863				Austing DG, 1998, PHYSICA B, V249, P206, DOI 10.1016/S0921-4526(98)00099-4; BARENCO A, 1995, PHYS REV LETT, V74, P4083, DOI 10.1103/PhysRevLett.74.4083; Bayer M, 2000, NATURE, V405, P923, DOI 10.1038/35016020; BENNETT CH, 1995, PHYS TODAY, V48, P24, DOI 10.1063/1.881452; BERGER PR, 1988, APPL PHYS LETT, V53, P684, DOI 10.1063/1.99850; Blick RH, 1998, PHYS REV LETT, V80, P4032, DOI 10.1103/PhysRevLett.80.4032; Brum JA, 1997, SUPERLATTICE MICROST, V22, P431, DOI 10.1006/spmi.1996.0263; Chuang IL, 1998, NATURE, V393, P143, DOI 10.1038/30181; DIVINCENZO DP, 1995, SCIENCE, V270, P255, DOI 10.1126/science.270.5234.255; Fafard S, 2000, APPL PHYS LETT, V76, P2707, DOI 10.1063/1.126450; Fafard S, 1999, PHYS REV B, V59, P15368, DOI 10.1103/PhysRevB.59.15368; Fonseca LRC, 1998, PHYS REV B, V58, P9955, DOI 10.1103/PhysRevB.58.9955; Fujisawa T, 1998, SCIENCE, V282, P932, DOI 10.1126/science.282.5390.932; GOLDSTEIN L, 1985, APPL PHYS LETT, V47, P1099, DOI 10.1063/1.96342; HAWRYLAK P, 1999, CONDENS MATTER NEWS, V7, P16; KORKUSINSKI M, UNPUB; KOUWENHOVEN L, 1995, SCIENCE, V268, P1440, DOI 10.1126/science.268.5216.1440; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Luyken RJ, 1999, NANOTECHNOLOGY, V10, P14, DOI 10.1088/0957-4484/10/1/004; MAHLER G, 1999, INFORMATION NEW QUES, P103; McCaffrey JP, 2000, J APPL PHYS, V88, P2272, DOI 10.1063/1.1287226; PALACIOS JJ, 1995, PHYS REV B, V51, P1769, DOI 10.1103/PhysRevB.51.1769; Pryor C, 1998, PHYS REV LETT, V80, P3579, DOI 10.1103/PhysRevLett.80.3579; Rouvimov S, 1998, J ELECTRON MATER, V27, P427, DOI 10.1007/s11664-998-0172-6; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Schedelbeck G, 1997, SCIENCE, V278, P1792, DOI 10.1126/science.278.5344.1792; Solomon GS, 1996, PHYS REV LETT, V76, P952, DOI 10.1103/PhysRevLett.76.952; Steane A, 1998, REP PROG PHYS, V61, P117, DOI 10.1088/0034-4885/61/2/002; Tokura Y, 1999, J PHYS-CONDENS MAT, V11, P6023, DOI 10.1088/0953-8984/11/31/310; Wasilewski ZR, 1999, J CRYST GROWTH, V201, P1131, DOI 10.1016/S0022-0248(98)01539-5; Wojs A, 1996, PHYS REV B, V54, P5604, DOI 10.1103/PhysRevB.54.5604; XIE QH, 1995, PHYS REV LETT, V75, P2542, DOI 10.1103/PhysRevLett.75.2542; Zanardi P, 1998, PHYS REV LETT, V81, P4752, DOI 10.1103/PhysRevLett.81.4752	33	741	751	2	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					451	453		10.1126/science.291.5503.451	http://dx.doi.org/10.1126/science.291.5503.451			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161192				2022-12-28	WOS:000166487500031
J	Battle, RW; Galvin, JM				Battle, RW; Galvin, JM			Critical tricuspid stenosis with severe venous hypertension.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Vermont, Coll Med, Burlington, VT 05401 USA	University of Vermont	Battle, RW (corresponding author), Univ Vermont, Coll Med, Burlington, VT 05401 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					196	197		10.1056/NEJM200101183440306	http://dx.doi.org/10.1056/NEJM200101183440306			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	392GF	11172142				2022-12-28	WOS:000166402800006
J	Straus, SE				Straus, SE			Recent advances - Geriatric medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CONGESTIVE-HEART-FAILURE; STROKE UNIT TREATMENT; ALZHEIMERS-DISEASE; POSTMENOPAUSAL WOMEN; TOTAL MORTALITY; DOUBLE-BLIND; RISK; METAANALYSIS; THERAPY; CHOLESTEROL		Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Straus, SE (corresponding author), Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.	sstraus@mtsinai.on.ca						Arrieta JL, 1998, AGE AGEING, V27, P161, DOI 10.1093/ageing/27.2.161; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Avezum A, 1998, CAN J CARDIOL, V14, P1045; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; *BUR CENS, 1993, CURR POP REP 65 PLUS; Cole MG, 1997, CAN MED ASSOC J, V157, P1055; Cryer PC, 1996, PUBLIC HEALTH, V110, P331, DOI 10.1016/S0033-3506(96)80004-7; CULLUM N, 2000, COCHRANE LIB; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Ensrud KE, 1997, ARCH INTERN MED, V157, P2617, DOI 10.1001/archinte.157.22.2617; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; GILLESPIE LD, 2000, COCHRANE LIB; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Hjalmarson A, 1999, LANCET, V353, P2001; Indredavik B, 1999, STROKE, V30, P1524, DOI 10.1161/01.STR.30.8.1524; Indredavik B, 1997, STROKE, V28, P1861, DOI 10.1161/01.STR.28.10.1861; *JOINT NAT COMM PR, 1997, ARCH INTERN MED, V157, P243; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; Leipzig RM, 1999, J AM GERIATR SOC, V47, P30, DOI 10.1111/j.1532-5415.1999.tb01898.x; Lemaitre RN, 1998, ARCH INTERN MED, V158, P1761, DOI 10.1001/archinte.158.16.1761; Lewis SJ, 1998, ANN INTERN MED, V129, P681, DOI 10.7326/0003-4819-129-9-199811010-00002; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; McCusker J, 1998, ARCH INTERN MED, V158, P705, DOI 10.1001/archinte.158.7.705; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; *MIN HLTH, 1993, PARTN LONG TERM HEAL; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; *NHS CTR REV DISS, 1996, EFFECTIVE HLTH CARE, V2, P1; PARKER MJ, 2000, COCHRANE LIB; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; Raskind MA, 1999, J CLIN PSYCHIAT, V60, P318, DOI 10.4088/JCP.v60n0510; Rizzo JA, 1998, MED CARE, V36, P1174, DOI 10.1097/00005650-199808000-00006; ROE B, 2000, COCHRANE LIB; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; SMEETH L, 2000, COCHRANE LIB; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Van Baar ME, 1999, ARTHRITIS RHEUM-US, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9; Yusuf S, 2000, NEW ENGL J MED, V342, P145	45	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2001	322	7278					86	89		10.1136/bmj.322.7278.86	http://dx.doi.org/10.1136/bmj.322.7278.86			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154624	Green Published			2022-12-28	WOS:000166496100028
J	Kaya, H; Shibahara, K; Taoka, K; Iwabuchi, M; Stillman, B; Araki, T				Kaya, H; Shibahara, K; Taoka, K; Iwabuchi, M; Stillman, B; Araki, T			FASCIATA genes for chromatin assembly factor-1 in Arabidopsis maintain the cellular organization of apical meristems	CELL			English	Article							DNA-REPLICATION; RADIAL ORGANIZATION; SHOOT; ROOT; INHERITANCE; PROTEIN; FATE; REGULATOR; HISTONES; DIVISION	Postembryonic development of plants depends on the activity of apical meristems established during embryogenesis. The shoot apical meristem (SAM) and the root apical meristem (RAM) have similar but distinct cellular organization. Arabidopsis FASCIATA1 (FAS1) and FAS2 genes maintain the cellular and functional organization of both SAM and RAM, and FAS gene products are subunits of the Arabidopsis counterpart of chromatin assembly factor-1 (CAF-1). fas mutants are defective in maintenance of the expression states of WUSCHEL (WUS) in SAM and SCARECROW (SCR) in RAM. We suggest that CAF-1 plays a critical role in the organization of SAM and RAM during postembryonic development by facilitating stable maintenance of gene expression states.	Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Japan Sci & Technol Corp, TOREST, Tokyo, Japan	Kyoto University; Cold Spring Harbor Laboratory; Japan Science & Technology Agency (JST)	Araki, T (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan.	taraqui@gr.bot.kyoto-u.ac.jp	Araki, Takashi/G-1760-2013	Araki, Takashi/0000-0002-3616-1493; Kaya, Hidetaka/0000-0003-4711-8236; Stillman, Bruce/0000-0002-9453-4091	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ach RA, 1997, PLANT CELL, V9, P1595, DOI 10.1105/tpc.9.9.1595; AXELOS M, 1992, PLANT PHYSIOL BIOCH, V30, P123; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Braissant O, 1998, BIOCHEMICA, V1, P10; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; CHABOUTE ME, 1987, PLANT MOL BIOL, V8, P179, DOI 10.1007/BF00025329; CLARK SE, 1995, DEVELOPMENT, V121, P2057; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; DOLAN L, 1993, DEVELOPMENT, V119, P71; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; GORTER CJ, 1965, ENCY PLANT PHYSL, V15, P330; Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X; JURGENS G, 1994, ARABIDOPSIS, P297; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kaya H, 2000, PLANT CELL PHYSIOL, V41, P1055, DOI 10.1093/pcp/pcd032; Keddie JS, 1998, PLANT CELL, V10, P877, DOI 10.1105/tpc.10.6.877; Kenzior AL, 1998, FEBS LETT, V440, P425, DOI 10.1016/S0014-5793(98)01500-2; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; Laufs P, 1998, PLANT CELL, V10, P1375, DOI 10.1105/tpc.10.8.1375; LEYSER HMO, 1992, DEVELOPMENT, V116, P397; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Ohtsubo N, 1997, PLANT J, V11, P1219, DOI 10.1046/j.1365-313X.1997.11061219.x; Okanami M, 1998, NUCLEIC ACIDS RES, V26, P2638, DOI 10.1093/nar/26.11.2638; Reinholz E, 1966, ARAB INF SERV, V3, P19; Ridgway P, 2000, J CELL SCI, V113, P2647; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; Running MP, 1995, METHOD CELL BIOL, V49, P217, DOI 10.1016/S0091-679X(08)61456-9; Scheres B, 1996, PLANT PHYSIOL, V111, P959, DOI 10.1104/pp.111.4.959; SCHERES B, 1995, DEVELOPMENT, V121, P53; Schiefelbein JW, 1994, ARABIDOPSIS, P335; Schoof H, 2000, CELL, V100, P635, DOI 10.1016/S0092-8674(00)80700-X; Serrano-Cartagena J, 1999, MOL GEN GENET, V261, P725, DOI 10.1007/s004380050016; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Shibahara K, 2000, P NATL ACAD SCI USA, V97, P7766, DOI 10.1073/pnas.97.14.7766; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; Taoka K, 1999, PLANT J, V18, P611, DOI 10.1046/j.1365-313x.1999.00486.x; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; Verreault A, 2000, GENE DEV, V14, P1430; Wysocka-Diller JW, 2000, DEVELOPMENT, V127, P595; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	51	372	395	1	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					131	142		10.1016/S0092-8674(01)00197-0	http://dx.doi.org/10.1016/S0092-8674(01)00197-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163246	Bronze			2022-12-28	WOS:000166882300013
J	von Eiff, C; Becker, K; Machka, K; Stammer, H; Peters, G				von Eiff, C; Becker, K; Machka, K; Stammer, H; Peters, G		Study Grp	Nasal carriage as a source of Staphylococcus aureus bacteremia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; METHICILLIN-RESISTANT; HEMODIALYSIS-PATIENTS; MUPIROCIN OINTMENT; SITE INFECTIONS; EXIT-SITE; COLONIZATION; PROPHYLAXIS; ELIMINATION; EFFICACY	Background: The consequences of infection with Staphylococcus aureus can be severe, so strategies for prevention are important. We examined S. aureus isolates from blood and from nasal specimens to determine whether the organisms in the bloodstream originated from the patient's own flora. Methods: In a multicenter study, swabs for culture were obtained from the anterior nares of 219 patients with S. aureus bacteremia. A total of 723 isolates were collected and genotyped. In a second study, 1640 S. aureus isolates from nasal swabs from 1278 patients were collected over a period of five years and then compared with isolates from the blood of patients who subsequently had S. aureus bacteremia. Results: In the multicenter study of S. aureus bacteremia, the blood isolates were identical to those from the anterior nares in 180 of 219 patients (82.2 percent). In the second study, 14 of 1278 patients who had nasal colonization with S. aureus subsequently had S. aureus bacteremia. In 12 of these 14 patients (86 percent), the isolates obtained from the nares were clonally identical to the isolates obtained from blood 1 day to 14 months later. Conclusions: A substantial proportion of cases of S. aureus bacteremia appear to be of endogenous origin since they originate from colonies in the nasal mucosa. These results provide support for strategies to prevent systemic S. aureus infections by eliminating nasal carriage of S. aureus. (N Engl J Med 2001;344:11-6.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Munster, Inst Med Microbiol, D-48149 Munster, Germany; SmithKline Beecham, Munich, Germany	University of Munster; GlaxoSmithKline	von Eiff, C (corresponding author), Univ Munster, Inst Med Microbiol, Domagkstr 10, D-48149 Munster, Germany.		Becker, Karsten/O-2302-2018	Becker, Karsten/0000-0002-6391-1341				ARMSTRONGESTHER CA, 1976, ANN HUM BIOL, V3, P221, DOI 10.1080/03014467600001381; Boelaert JR, 1996, INFECT CONT HOSP EP, V17, P809; BOELAERT JR, 1993, NEPHROL DIAL TRANSPL, V8, P235; BOYCE JM, 1997, STAPHYLOCOCCI HUMAN, P309, DOI DOI 10.1002/9781444308464.CH15; BRAKSTAD OG, 1992, J CLIN MICROBIOL, V30, P1654, DOI 10.1128/JCM.30.7.1654-1660.1992; CASEWELL MW, 1986, J ANTIMICROB CHEMOTH, V18, P1; CHOW JW, 1989, ARCH INTERN MED, V149, P1258, DOI 10.1001/archinte.149.6.1258; ENA J, 1994, INFECT CONT HOSP EP, V15, P78; Fierobe L, 1999, CLIN INFECT DIS, V29, P1231, DOI 10.1086/313454; HOLTON DL, 1991, J HOSP INFECT, V17, P133, DOI 10.1016/0195-6701(91)90177-A; Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P780; KLUYTMANS JAJW, 1995, J INFECT DIS, V171, P216, DOI 10.1093/infdis/171.1.216; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; LUZAR MA, 1991, PERITON DIALYSIS INT, V11, P333; Maslow Joel N., 1993, P563; MEST DR, 1994, ANESTH ANALG, V78, P644; Moellering RC, 1998, CLIN INFECT DIS, V26, P1177, DOI 10.1086/520288; MURAKAMI K, 1991, J CLIN MICROBIOL, V29, P2240, DOI 10.1128/JCM.29.10.2240-2244.1991; Nguyen MH, 1999, ANN INTERN MED, V130, P221, DOI 10.7326/0003-4819-130-3-199902020-00026; PARRAS F, 1995, ANTIMICROB AGENTS CH, V39, P175, DOI 10.1128/AAC.39.1.175; Pujol M, 1996, AM J MED, V100, P509, DOI 10.1016/S0002-9343(96)00014-9; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; Shuter J, 1996, INFECT IMMUN, V64, P310, DOI 10.1128/IAI.64.1.310-318.1996; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; Steinberg JP, 1996, CLIN INFECT DIS, V23, P255, DOI 10.1093/clinids/23.2.255; Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426; TENOVER FC, 1994, J CLIN MICROBIOL, V32, P407, DOI 10.1128/JCM.32.2.407-415.1994; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Thodis E, 1998, PERITON DIALYSIS INT, V18, P261; VandenBergh MFQ, 1999, J CLIN MICROBIOL, V37, P3133, DOI 10.1128/JCM.37.10.3133-3140.1999; Wallenstein S, 1997, STAT MED, V16, P1329, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1329::AID-SIM567>3.0.CO;2-I; WEINKE T, 1992, EUR J CLIN MICROBIOL, V11, P985, DOI 10.1007/BF01967787; WENZEL RP, 1995, J HOSP INFECT, V31, P13, DOI 10.1016/0195-6701(95)90079-9; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	35	1380	1419	1	85	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					11	16		10.1056/NEJM200101043440102	http://dx.doi.org/10.1056/NEJM200101043440102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136954				2022-12-28	WOS:000166160400002
J	Downs, JA; Lowndes, NF; Jackson, SP				Downs, JA; Lowndes, NF; Jackson, SP			A role for Saccharomyces cerevisiae histone H2A in DNA repair	NATURE			English	Article							DOUBLE-STRAND BREAKS; DEPENDENT PROTEIN-KINASE; CHECKPOINT PATHWAYS; CHROMATIN STRUCTURE; DAMAGE CHECKPOINT; BUDDING YEAST; IN-VIVO; NUCLEOSOME; RAD53; GENES	Histone proteins associate with and compact eukaryotic nuclear DNA to form chromatin. The basic unit of chromatin is the nucleosome, which is made up of 146 base pairs of DNA wrapped around two of each of four core histones(1), H2A, H2B, H3 and H4. Chromatin structure and its regulation are important in transcription and DNA replication(2-4). We therefore thought that DNA-damage signalling and repair components might also modulate chromatin structure. Here we have characterized a conserved motif in the carboxy terminus of the core histone H2A from Saccharomyces cerevisiae that contains a consensus phosphorylation site for phosphatidylinositol-3-OH kinase related kinases (PIKKs). This motif is important for survival in the presence of agents that generate DNA double-strand breaks, and the phosphorylation of this motif in response to DNA damage is dependent on the PIKK family member Mec1. The motif is not necessary for Mec1-dependent cell-cycle or transcriptional responses to DNA damage, but is required for efficient DNA double-strand break repair by non-homologous end joining. In addition, the motif has a role in determining higher order chromatin structure. Thus, phosphorylation of a core histone in response to DNA damage may cause an alteration of chromatin structure that facilitates DNA repair.	Univ Cambridge, Wellcome Trust & Canc Res Campaign, Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England; Imperial Canc Res Fund, Clare Hall Labs, CDC Lab, Potters Bar EN6 3LD, Herts, England	University of Cambridge; University of Cambridge	Jackson, SP (corresponding author), Univ Cambridge, Wellcome Trust & Canc Res Campaign, Inst Canc & Dev Biol, Tennis Court Rd, Cambridge CB2 1QR, England.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019; Lowndes, Noel F/B-9084-2008	Jackson, Stephen Philip/0000-0001-9317-7937; Lowndes, Noel F/0000-0002-3216-4427; Downs, Jessica/0000-0002-6600-849X				Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HIRSCHHORN JN, 1995, MOL CELL BIOL, V15, P1999; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Lee SE, 1999, CURR BIOL, V9, P767, DOI 10.1016/S0960-9822(99)80339-X; Lewis LK, 1999, GENETICS, V152, P1513; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; Wechser MA, 1997, EMBO J, V16, P2086, DOI 10.1093/emboj/16.8.2086; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461	27	503	521	1	27	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					1001	1004		10.1038/35050000	http://dx.doi.org/10.1038/35050000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140636				2022-12-28	WOS:000165951100057
J	Tyson, JE; Knudson, PL				Tyson, JE; Knudson, PL			Views of neonatologists and parents on consent for clinical trials	LANCET			English	Editorial Material									Univ Texas, Sch Med, Ctr Populat Hlth & Evidence Based Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Inst Review Board, Houston, TX 77030 USA	University of Texas System; University of Texas System	Tyson, JE (corresponding author), Univ Texas, Sch Med, Ctr Populat Hlth & Evidence Based Med, Houston, TX 77030 USA.							CHALMERS I, 1987, CONTROL CLIN TRIALS, V8, P388, DOI 10.1016/0197-2456(87)90157-7; COLLINS R, 1992, INTRO NEW TREATMENTS; EIDELMAN AI, 1993, OBSTET GYNECOL, V81, P764; Giacomini MK, 2000, JAMA-J AM MED ASSOC, V284, P357, DOI 10.1001/jama.284.3.357; Lantos JD, 1999, J PEDIATR-US, V134, P130, DOI 10.1016/S0022-3476(99)70400-2; OAKLEY A, 2000, EXPT KNOWING GENDER, P26; Rogers CG, 1998, J PEDIATR-US, V132, P606, DOI 10.1016/S0022-3476(98)70347-6; Truog RD, 1999, NEW ENGL J MED, V340, P804, DOI 10.1056/NEJM199903113401013; TYSON JE, 1995, SEMIN PERINATOL, V19, P98, DOI 10.1016/S0146-0005(05)80030-8; *US DEP HHS, 1993, PROT HUM RES SUBJ I, pG4	10	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2026	2027		10.1016/S0140-6736(00)03395-X	http://dx.doi.org/10.1016/S0140-6736(00)03395-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145484				2022-12-28	WOS:000165994300004
J	Losos, JB; Schluter, D				Losos, JB; Schluter, D			Analysis of an evolutionary species-area relationship	NATURE			English	Article							BIOGEOGRAPHY; VICARIANCE; DISPERSAL; DIVERSITY	Large islands typically have more species than comparable smaller islands. Ecological theories, the most influential being the equilibrium theory of island biogeography(1), explain the species-area relationship as the outcome of the effect of area on immigration and extinction rates. However, these theories do not apply to taxa on land masses, including continents and large islands, that generate most of their species in situ. In this case, species-area relationships should be driven by higher speciation rates in larger areas(2-6), a theory that has never been quantitatively tested. Here we show that Anolis lizards on Caribbean islands meet several expectations of the evolutionary theory. Within-island speciation exceeds immigration as a source of new species on all islands larger than 3,000 km(2), whereas speciation is rare on smaller islands. Above this threshold island size, the rate of species proliferation increases with island area, a process that results principally from the positive effects of area on speciation rate. Also as expected, the slope of the species-area relationship jumps sharply above the threshold. Although Anolis lizards have been present on large Caribbean islands for over 30 million years, there are indications that the current number of species still falls below the speciation-extinction equilibrium.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Ctr Biodivers Res, Vancouver, BC V6T 1Z4, Canada	Washington University (WUSTL); University of British Columbia; University of British Columbia	Losos, JB (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	losos@biology.wustl.edu	Villsen, Kurt/C-7965-2015	Schluter, Dolph/0000-0003-1683-7836				Bauer A.M., 1989, TUATARA, V30, P39; Brown J. H., 1998, BIOGEOGRAPHY; Case T., 1983, P307; CREER DA, IN PRESS J HERP; Crother BI, 1996, HERPETOLOGICA, V52, P440; DIAMOND JM, 1977, SYST ZOOL, V26, P263, DOI 10.2307/2412673; Donovan S. K, 1994, CARIBBEAN GEOLOGY IN; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Futuyma D. J., 1998, EVOLUTIONARY BIOL; Hedges SB, 1996, HERPETOLOGICA, V52, P466; Iturralde-Vinent MA, 1999, B AM MUS NAT HIST, P1; Jackman Todd, 1997, P535; Jackman TR, 1999, SYST BIOL, V48, P254, DOI 10.1080/106351599260283; Lomolino MV, 2000, J BIOGEOGR, V27, P17, DOI 10.1046/j.1365-2699.2000.00377.x; Losos JB, 1996, PHILOS T R SOC B, V351, P847, DOI 10.1098/rstb.1996.0079; MAC ARTHUR ROBERT H., 1967; MacArthur R. H., 1969, Biological Journal of the Linnean Society, V1, P19, DOI 10.1111/j.1095-8312.1969.tb01809.x; Mayr E., 1963, ANIMAL SPECIES EVOLU; NEE S, 1994, PHILOS T ROY SOC B, V344, P305, DOI 10.1098/rstb.1994.0068; Pimm S.L., 1991, BALANCE NATURE; Rand A. S., 1969, Breviora, VNo. 319, P1; Ricklefs RE, 1999, J ANIM ECOL, V68, P1142, DOI 10.1046/j.1365-2656.1999.00358.x; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Rosenzwieg M.L., 1975, P121; Schluter D, 1996, AM NAT, V148, pS40, DOI 10.1086/285901; SCHNEIDER CJ, IN PRESS J HERP; SHOCHAT D, 1981, COMP BIOCHEM PHYS A, V68, P67, DOI 10.1016/0300-9629(81)90319-4; TOFT CA, 1983, OIKOS, V41, P411, DOI 10.2307/3544101; Wagner WL, 1995, HAWAIIAN BIOGEOGRAPH; WILLIAMS EE, 1983, STUDIES MODEL ORGANI, P326	30	422	434	2	210	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					847	850		10.1038/35048558	http://dx.doi.org/10.1038/35048558			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130721				2022-12-28	WOS:000165831300047
J	Spyer, G; Hattersley, AT; MacDonald, IA; Amiel, S; MacLeod, KM				Spyer, G; Hattersley, AT; MacDonald, IA; Amiel, S; MacLeod, KM			Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes	LANCET			English	Article							GLYCEMIC CONTROL; PROTECTIVE RESPONSES; COUNTERREGULATION; INSULIN; NEUROENDOCRINE; MELLITUS	Background Intensive treatment to achieve goad glycaemic control in diabetic patients is limited by a high frequency of hypoglycaemia. The glucose concentrations at which symptoms and release of counter-regulatory hormones takes place have not been studied in patients with well controlled type-a diabetes. Methods We studied seven well controlled, non-insulin treated, type-2 diabetic patients (mean HbA(1c) [corrected according to Diabetes Control and Complications Trial] 7.4%, SD 1.0) and seven healthy controls matched for age, sex, and body mass index with a stepped hyperinsulinaemic hypoglycaemic glucose clamp. Symptoms, cognitive function, and counter-regulatory hormone concentrations were measured at each glucose plateau, and the glucose value at which there was a significant change from baseline was calculated. Findings Symptom response took place at higher whole-blood glucose concentrations in diabetic patients than in controls. Counter-regulatory release of epinephrine, norepinephrine, growth hormone, and cortisol showed a similar pattern-eg, at blood glucose concentrations of 3.8 mmol/L [SD 0.4] vs 2.6 [0.3] for epinephrine. Interpretation Glucose thresholds for counter-regulatory hormone secretion are altered in well controlled type-2 diabetic patients, so that both symptoms and counterregulatory hormone release can take place at normal glucose values. This effect might protect type-2 diabetic patients against episodes of profound hypoglycaemia and make the achievement of normoglycaemia more challenging in clinical practice.	Sch Postgrad Med & Hlth Sci, Dept Vasc Med & Diabet Res, Exeter EX2 5AX, Devon, England; Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Kings Coll London, Sch Med & Dent, Dept Med, London SE5, England	University of Exeter; University of Nottingham	MacLeod, KM (corresponding author), Sch Postgrad Med & Hlth Sci, Dept Vasc Med & Diabet Res, Exeter EX2 5AX, Devon, England.	K.M.Macleod@exeter.ac.uk	MacLeod, Kenneth/GWU-8940-2022	Hattersley, Andrew/0000-0001-5620-473X; Macdonald, Ian/0000-0002-7540-9850				AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; [Anonymous], 1997, DIABETES, V46, P271, DOI 10.2337/diab.46.2.271; BODEN G, 1983, DIABETES, V32, P1055, DOI 10.2337/diabetes.32.11.1055; BOLLI GB, 1984, J CLIN INVEST, V73, P1532, DOI 10.1172/JCI111359; CUNNAH D, 1987, J ENDOCRINOL, V113, P123, DOI 10.1677/joe.0.1130123; Forster CD, 1999, BIOMED CHROMATOGR, V13, P209, DOI 10.1002/(SICI)1099-0801(199905)13:3<209::AID-BMC820>3.0.CO;2-Z; GERICH JE, 1993, HYPOGLYCAEMIA DIABET, P253; HELLER SR, 1987, DIABETOLOGIA, V30, P924, DOI 10.1007/BF00295875; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; Korzon-Burakowska A, 1998, DIABETES CARE, V21, P283, DOI 10.2337/diacare.21.2.283; Levy CJ, 1998, DIABETES CARE, V21, P1330, DOI 10.2337/diacare.21.8.1330; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; Matyka K, 1997, DIABETES CARE, V20, P135, DOI 10.2337/diacare.20.2.135; POLONSKY KS, 1984, DIABETES, V33, P1112, DOI 10.2337/diabetes.33.11.1112; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	16	88	88	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 9	2000	356	9246					1970	1974		10.1016/S0140-6736(00)03322-5	http://dx.doi.org/10.1016/S0140-6736(00)03322-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130525				2022-12-28	WOS:000165867600011
J	Chu, WM; Gong, X; Li, ZW; Takabayashi, K; Ouyang, HH; Chen, Y; Lois, A; Chen, DJ; Li, GC; Karin, M; Raz, E				Chu, WM; Gong, X; Li, ZW; Takabayashi, K; Ouyang, HH; Chen, Y; Lois, A; Chen, DJ; Li, GC; Karin, M; Raz, E			DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA	CELL			English	Article							DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; CATALYTIC SUBUNIT; BACTERIAL-DNA; CPG MOTIFS; IKK-BETA; SEQUENCES; GENE; KU; PHOSPHORYLATION	Bacterial DNA and related synthetic immunostimulatory oligodeoxyribonucleotides (ISS-ODN) stimulate innate immunity. However, the molecular recognition mechanism that initiates signaling in response to bacterial DNA and ISS-ODN has not been identified. Herein, we demonstrate that administration of bacterial DNA and ISS-ODN to mice lacking the catalytic subunit of DNA-PK (DNA-PKcs) and in vitro stimulation of BMDM from these mice result in defective induction of IL-6 and IL-12. Further analysis using BMDM of IKK beta (-/-) revealed that both DNA-PKcs and IKK beta are essential for normal cytokine production in response to ISS-ODN or bacterial DNA. ISS-ODN and bacterial DNA activate DNA-PK, which in turn contributes to activation of IKK and NF-kappaB. These results reveal a novel role of DNA-PKcs in innate immune responses and a link between DNA repair and innate immunity.	Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, Dept Med 0663, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, Lab Signal Transduct & Gene Regulat, La Jolla, CA 92093 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Raz, E (corresponding author), Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, Dept Med 0663, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [CA-59609] Funding Source: Medline; NIAID NIH HHS [AI 40682, AI 43477] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477, P01AI040682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Bauer M, 1999, IMMUNOLOGY, V97, P699, DOI 10.1046/j.1365-2567.1999.00811.x; BIRD AP, 1993, COLD SPRING HARB SYM, V58, P281, DOI 10.1101/SQB.1993.058.01.033; CARROLL AM, 1991, GENE DEV, V13, P57; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FALZON M, 1993, J BIOL CHEM, V268, P10546; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Koike M, 1999, J CELL SCI, V112, P4031; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; LeesMiller SP, 1996, J VIROL, V70, P7471, DOI 10.1128/JVI.70.11.7471-7477.1996; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Martin-Orozco E, 1999, INT IMMUNOL, V11, P1111, DOI 10.1093/intimm/11.7.1111; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nilsson A, 1999, CELL PROLIFERAT, V32, P239, DOI 10.1046/j.1365-2184.1999.3240239.x; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Smider V, 1998, MOL CELL BIOL, V18, P6853, DOI 10.1128/MCB.18.11.6853; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stacey KJ, 1996, J IMMUNOL, V157, P2116; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TOKUNAGA T, 1984, J NATL CANCER I, V72, P955; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902, DOI 10.1016/S0091-6749(99)70066-7; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; Yi AK, 1998, J IMMUNOL, V160, P4755; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	49	149	159	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					909	918		10.1016/S0092-8674(00)00194-X	http://dx.doi.org/10.1016/S0092-8674(00)00194-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136976	Bronze			2022-12-28	WOS:000165801300010
J	Motohashi, H; Katsuoka, F; Shavit, JA; Engel, JD; Yamamoto, M				Motohashi, H; Katsuoka, F; Shavit, JA; Engel, JD; Yamamoto, M			Positive or negative MARE-dependent transcriptional regulation is by the abundance of small Maf proteins	CELL			English	Article							ERYTHROLEUKEMIA CELL-DIFFERENTIATION; LEUCINE ZIPPER PROTEIN; FACTOR NF-E2; IN-VITRO; V-MAF; FAMILY; GENE; EXPRESSION; MEGAKARYOCYTES; ONCOGENE	The small Maf transcription factor proteins bind to Maf Recognition Elements (MAREs) by dimerizing with CNC proteins or themselves. We undertook experiments to clarify the functional relationship between the small Mafs and their partners in vivo. Embryos expressing abundant transgene-derived MafK died of severe anemia, while lines expressing lower levels of small Maf lived to adulthood. Megakaryocytes from the latter overexpressing lines exhibited reduced proplatelet formation and MARE-dependent transcription, phenocopying mafG null mutant mice. When the mafG null mutants were bred to small Maf-overexpressing transgenic animals, both loss- and gain-of-function phenotypes were reversed. These results provide direct in vivo evidence that transcriptional regulation through MARE elements hinges on an exquisitely sensitive balance of activating CNC molecules and their small Maf partners.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	University of Tsukuba; University of Tsukuba; Northwestern University	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058577, Japan.	masi@tara.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010; Motohashi, Hozumi/AAZ-2628-2020	Yamamoto, Masayuki/0000-0002-9073-9436; Katsuoka, Fumiki/0000-0003-0939-7887	NCI NIH HHS [R01 CA80088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHOI ES, 1995, BLOOD, V85, P402; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; ENGEL JD, 1994, NATURE, V367, P516; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Katsuoka F, 2000, EMBO J, V19, P2980, DOI 10.1093/emboj/19.12.2980; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kotkow KJ, 1996, P NATL ACAD SCI USA, V93, P3514, DOI 10.1073/pnas.93.8.3514; Kuroha T, 1998, J BIOCHEM-TOKYO, V123, P376; Lecine P, 1998, J BIOL CHEM, V273, P7572, DOI 10.1074/jbc.273.13.7572; Lecine P, 1998, BLOOD, V92, P1608, DOI 10.1182/blood.V92.5.1608.417k27_1608_1616; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 1998, GENES CELLS, V3, P671, DOI 10.1046/j.1365-2443.1998.00222.x; Motohashi H, 1996, GENES CELLS, V1, P223, DOI 10.1046/j.1365-2443.1996.d01-230.x; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; Nakajima O, 1999, EMBO J, V18, P6282, DOI 10.1093/emboj/18.22.6282; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Onodera K, 1999, J BIOL CHEM, V274, P21162, DOI 10.1074/jbc.274.30.21162; Onodera K, 2000, EMBO J, V19, P1335, DOI 10.1093/emboj/19.6.1335; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Shavit JA, 1998, GENE DEV, V12, P2164, DOI 10.1101/gad.12.14.2164; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Suwabe N, 1998, BLOOD, V92, P4108, DOI 10.1182/blood.V92.11.4108.423k29_4108_4118; Takahashi S, 2000, BLOOD, V96, P910, DOI 10.1182/blood.V96.3.910.015k29_910_916; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611	44	121	122	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 8	2000	103	6					865	875		10.1016/S0092-8674(00)00190-2	http://dx.doi.org/10.1016/S0092-8674(00)00190-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136972	Bronze			2022-12-28	WOS:000165801300006
J	Worthylake, DK; Rossman, KL; Sondek, J				Worthylake, DK; Rossman, KL; Sondek, J			Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1	NATURE			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; RHO-FAMILY; DBL FAMILY; ACTIVATION; PROTEIN; RAS; INVASION; BINDING; GTPASE; CELL	The principal guanine nucleotide exchange factors for Rho family G proteins contain tandem Dbl-homology (DH) and pleckstrin-homology (PH) domains that catalyse nucleotide exchange and the activation of G proteins. Here we have determined the crystal structure of the DH and PH domains of the T-lymphoma invasion and metastasis factor 1 (Tiam1) protein in complex with its cognate Rho family G protein, Rac1. The two switch regions of Rac1 are stabilized in conformations that disrupt both magnesium binding and guanine nucleotide interaction. The resulting cleft in Rac1 is devoid of nucleotide and highly exposed to solvent. The PH domain of Tiam1 does not contact Rac1, and the position and orientation of the PH domain is markedly altered relative to the structure of the uncomplexed, GTPase-free DH/PH element from Sos1. The Tiam1/Rac1 structure highlights the interactions that catalyse nucleotide exchange on Rho family G proteins, and illustrates structural determinants dictating specificity between individual Rho family members and their associated Dbl-related guanine nucleotide exchange factors.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Sondek, J (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.			Sondek, John/0000-0002-1127-8310				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blomberg N, 1997, FOLD DES, V2, P343, DOI 10.1016/S1359-0278(97)00048-5; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1991, MAXIMUM LIKELIHOOD R; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Sheldrick G.M, 1986, SHELXS86 PROGRAM CRY; Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	290	303	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					682	688		10.1038/35047014	http://dx.doi.org/10.1038/35047014			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130063				2022-12-28	WOS:000165815200039
J	Mandl, KD; Szolovits, P; Kohane, IS				Mandl, KD; Szolovits, P; Kohane, IS			Public standards and patients' control: how to keep electronic medical records accessible but private	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN COMMUNICATION; HEALTH-CARE; INFORMATION; QUALITY		Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; MIT, Comp Sci Lab, Med Decis Grp, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Massachusetts Institute of Technology (MIT)	Mandl, KD (corresponding author), Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	Kenneth_Mandl@Harvard.edu	Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160; Szolovits, Peter/0000-0001-8411-6403	NATIONAL LIBRARY OF MEDICINE [R01LM006587, N01LM093536] Funding Source: NIH RePORTER; NLM NIH HHS [1 RO1 LM06587-01, N01-LM-9-3536] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bates DW, 1997, J LAW MED ETHICS, V25, P111, DOI 10.1111/j.1748-720X.1997.tb01886.x; *COMP SCI TEL BOAR, 1997, REC PROT EL HLTH INF; Computer Science and Telecommunications Board - National Research Council, 2000, NETW HLTH PRESCR INT; Ferguson T, 1997, JOINT COMM J QUAL IM, V23, P251, DOI 10.1016/S1070-3241(16)30315-7; Ferguson T, 1998, JAMA-J AM MED ASSOC, V280, P1361, DOI 10.1001/jama.280.15.1361; Gostin L, 1997, ANN INTERN MED, V127, P683, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00050; HARRISEQUIFAX, 1996, CONSUMER PRIVACY SUR; Hodge JG, 1999, JAMA-J AM MED ASSOC, V282, P1466, DOI 10.1001/jama.282.15.1466; *I HLTH CAR RES PO, 2000, HLTH PRIV PROJ 1999; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; Kohane I S, 1996, Proc AMIA Annu Fall Symp, P608; Mandl KD, 1998, ANN INTERN MED, V129, P495, DOI 10.7326/0003-4819-129-6-199809150-00012; *NEXT GEN INT IN, 2000, NGI IN HOM PAG; RIVA A, IN PRESS INT J MED I; Shortliffe EH, 1998, ANN INTERN MED, V129, P138, DOI 10.7326/0003-4819-129-2-199807150-00017; *US NAT LIBR MED, 1999, NEXT GEN INT PHASE 2; van Wingerde F J, 1996, Proc AMIA Annu Fall Symp, P643; Winker MA, 2000, JAMA-J AM MED ASSOC, V283, P1600, DOI 10.1001/jama.283.12.1600	18	159	162	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2001	322	7281					283	286		10.1136/bmj.322.7281.283	http://dx.doi.org/10.1136/bmj.322.7281.283			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157533	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000166917600034
J	Zeman, A; Douglas, N; Aylward, R				Zeman, A; Douglas, N; Aylward, R			Lesson of the week - Narcolepsy mistaken for epilepsy	BRITISH MEDICAL JOURNAL			English	Review									Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH2 2XU, Midlothian, Scotland; Royal Infirm, Sleep Lab, Edinburgh EH3 9YW, Midlothian, Scotland; Falkirk Royal Infirm, Epilepsy Clin, Falkirk FK1 5QE, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh	Zeman, A (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH2 2XU, Midlothian, Scotland.		Douglas, Neil/B-1491-2013	Zeman, Adam/0000-0003-4875-658X				Aldred M J, 1995, Oral Dis, V1, P2; ALDRICH MS, 1992, NEUROLOGY, V42, P34; DEMENT WC, 1973, SLEEP RES, V2, P147; Douglas NJ, 1998, NEUROLOGY, V50, pS27, DOI 10.1212/WNL.50.2_Suppl_1.S27; Gelineau J, 1880, GAZ HOPITAUX, V53, P735; Gelineau JBE, 1880, GAZ HOP PARIS, V54, P635; MCCARLEY R, 1999, SLEEP DISORDERS MED; MIGNOT E, 1999, SLEEP DISORDERS MED; Ohayon MM, 1996, BRIT J PSYCHIAT, V169, P459, DOI 10.1192/bjp.169.4.459; ROBINSON A, 1999, SLEEP DISORDERS MED	10	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					216	217		10.1136/bmj.322.7280.216	http://dx.doi.org/10.1136/bmj.322.7280.216			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159621	Green Published			2022-12-28	WOS:000166733700030
J	Glaser, N; Barnett, P; McCaslin, I; Nelson, D; Trainor, J; Louie, J; Kaufman, F; Quayle, K; Roback, M; Malley, R; Kuppermann, N				Glaser, N; Barnett, P; McCaslin, I; Nelson, D; Trainor, J; Louie, J; Kaufman, F; Quayle, K; Roback, M; Malley, R; Kuppermann, N		Amer Acad Pediat	Risk factors for cerebral edema in children with diabetic ketoacidosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine (SAEM)	MAY 23-25, 2000	SAN FRANCISCO, CA	Soc Acad Emergency Med			BRAIN HERNIATION; HYPERGLYCEMIA; BOOTSTRAP; ACIDOSIS; INSULIN	Background: Cerebral edema is an uncommon but devastating complication of diabetic ketoacidosis in children. Risk factors for this complication have not been clearly defined. Methods: In this multicenter study, we identified 61 children who had been hospitalized for diabetic ketoacidosis within a 15-year period and in whom cerebral edema had developed. Two additional groups of children with diabetic ketoacidosis but without cerebral edema were also identified: 181 randomly selected children and 174 children matched to those in the cerebral-edema group with respect to age at presentation, onset of diabetes (established vs. newly diagnosed disease), initial serum glucose concentration, and initial venous pH. Using logistic regression, we compared the three groups with respect to demographic characteristics and biochemical variables at presentation and compared the matched groups with respect to therapeutic interventions and changes in biochemical values during treatment. Results: A comparison of the children in the cerebral-edema group with those in the random control group showed that cerebral edema was significantly associated with lower initial partial pressures of arterial carbon dioxide (relative risk of cerebral edema for each decrease of 7.8 mm Hg [representing 1 SD], 3.4; 95 percent confidence interval, 1.9 to 6.3; P<0.001) and higher initial serum urea nitrogen concentrations (relative risk of cerebral edema for each increase of 9 mg per deciliter [3.2 mmol per liter] [representing 1 SD], 1.7; 95 percent confidence interval, 1.2 to 2.5; P = 0.003). A comparison of the children with cerebral edema with those in the matched control group also showed that cerebral edema was associated with lower partial pressures of arterial carbon dioxide and higher serum urea nitrogen concentrations. Of the therapeutic variables, only treatment with bicarbonate was associated with cerebral edema, after adjustment for other covariates (relative risk, 4.2; 95 percent confidence interval, 1.5 to 12.1; P = 0.008). Conclusions: Children with diabetic ketoacidosis who have low partial pressures of arterial carbon dioxide and high serum urea nitrogen concentrations at presentation and who are treated with bicarbonate are at increased risk for cerebral edema. (N Engl J Med 2001;344:264-9.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Internal Med, Div Emergency Med, Davis, CA 95616 USA; Royal Childrens Hosp, Div Emergency Med, Melbourne, Vic, Australia; Childrens Hosp & Hlth Ctr, Div Emergency Med, San Diego, CA USA; Brown Univ, Sch Med, Dept Pediat, Providence, RI 02912 USA; Childrens Mem Hosp, Div Emergency Med, Chicago, IL 60614 USA; Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90033 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	University of California System; University of California Davis; University of California System; University of California Davis; Royal Children's Hospital Melbourne; Brown University; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Southern California; Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Harvard Medical School	Glaser, N (corresponding author), Univ Calif Davis, Med Ctr, Div Pediat Endocrinol, 2516 Stockton Blvd, Sacramento, CA 95817 USA.	nsglaser@ucdavis.edu		Trainor, Jennifer/0000-0003-3566-9735				ALPERS J, 1988, CLIN LAB HDB; ARIEFF AI, 1974, J CLIN ENDOCR METAB, V38, P1057, DOI 10.1210/jcem-38-6-1057; BELLO FA, 1990, LANCET, V336, P64, DOI 10.1016/0140-6736(90)91587-Z; BINGAMAN WE, 1995, NEUROL CLIN, V13, P479, DOI 10.1016/S0733-8619(18)30031-8; BUREAU MA, 1980, J PEDIATR-US, V96, P968, DOI 10.1016/S0022-3476(80)80619-6; CHEN CH, 1985, STAT MED, V4, P39, DOI 10.1002/sim.4780040107; CHOUKAIR MK, 2000, H LANE HDB MANUAL PE, P229; COUCH RM, 1991, DIABETES CARE, V14, P78, DOI 10.2337/diacare.14.1.78b; DIETRICH WD, 1999, INFLAMMATORY CELLS M, P137; DUCK SC, 1988, J PEDIATR-US, V113, P10, DOI 10.1016/S0022-3476(88)80521-3; Edge JA, 1999, ARCH DIS CHILD, V81, P318, DOI 10.1136/adc.81.4.318; FAICH GA, 1983, AM J EPIDEMIOL, V117, P551, DOI 10.1093/oxfordjournals.aje.a113577; GANONG CA, 1993, AM J DIS CHILD, V147, P369; GANONG CA, 1993, AM J DIS CHILD, V147, P167, DOI 10.1001/archpedi.1993.02160260057022; GIOIA FR, 1987, TXB PEDIAT INTENSIVE, V1, P113; GLASGOW AM, 1991, DIABETES CARE, V14, P77, DOI 10.2337/diacare.14.1.77; HAMMOND P, 1992, BRIT MED J, V305, P203, DOI 10.1136/bmj.305.6847.203; HARRIS GD, 1990, J PEDIATR-US, V117, P22, DOI 10.1016/S0022-3476(05)82439-4; HARRIS GD, 1988, J PEDIATR-US, V113, P65, DOI 10.1016/S0022-3476(88)80529-8; HARRIS GD, 1991, J PEDIATR-US, V118, P167, DOI 10.1016/S0022-3476(05)81887-6; HOFFMAN WH, 1988, AM J NEURORADIOL, V9, P733; ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198; JONES MD, 1979, SEMIN PERINATOL, V3, P121; KATZ MA, 1973, NEW ENGL J MED, V289, P843, DOI 10.1056/NEJM197310182891607; Kleinbaum D, 1988, APPL REGRESSION ANAL; KRANE EJ, 1985, NEW ENGL J MED, V312, P1147, DOI 10.1056/NEJM198505023121803; Lin BW, 2000, NEUROSCI LETT, V278, P1, DOI 10.1016/S0304-3940(99)00889-7; LITTLE RJA, 1987, STAT ANAL MISSING DA, P44; Mahoney CP, 1999, PEDIATR NEUROL, V21, P721, DOI 10.1016/S0887-8994(99)00079-X; Muir A, 2000, J CLIN ENDOCR METAB, V85, P509, DOI 10.1210/jc.85.2.509; PINKNEY JH, 1994, DIABETOLOGIA, V37, P70; PROCKOP LD, 1971, ARCH NEUROL-CHICAGO, V25, P126, DOI 10.1001/archneur.1971.00490020044005; ROSENBLOOM AL, 1990, DIABETES CARE, V13, P22, DOI 10.2337/diacare.13.1.22; SCHEFFE H, 1953, BIOMETRIKA, V40, P87, DOI 10.1093/biomet/40.1-2.87; SCIBILIA J, 1986, ACTA ENDOCRINOL-COP, V113, P326; Silver SM, 1997, KIDNEY INT, V51, P1662; *STAT, 1999, STAT STAT SOFTW REL	38	460	477	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2001	344	4					264	269		10.1056/NEJM200101253440404	http://dx.doi.org/10.1056/NEJM200101253440404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	394WA	11172153				2022-12-28	WOS:000166545200004
J	Leon, MB; Teirstein, PS; Moses, JW; Tripuraneni, P; Lansky, AJ; Jani, S; Wong, SC; Fish, D; Ellis, S; Holmes, DR; Kerieakes, D; Kuntz, RE				Leon, MB; Teirstein, PS; Moses, JW; Tripuraneni, P; Lansky, AJ; Jani, S; Wong, SC; Fish, D; Ellis, S; Holmes, DR; Kerieakes, D; Kuntz, RE			Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; BALLOON ANGIOPLASTY; INTRAVASCULAR ULTRASOUND; BETA-RADIATION; ROTATIONAL ATHERECTOMY; PLACEMENT; RADIOTHERAPY; PREDICTORS; MECHANISMS	Background: Although the frequency of restenosis after coronary angioplasty is reduced by stenting, when restenosis develops within a stent, the risk of subsequent restenosis is greater than 50 percent. We report on a multicenter, double-blind, randomized trial of intracoronary radiation therapy for the treatment of in-stent restenosis. Methods: Of 252 eligible patients in whom in-stent restenosis had developed, 131 were randomly assigned to receive an indwelling intracoronary ribbon containing a sealed source of iridium-192, and 121 were assigned to receive a similar-appearing nonradioactive ribbon (placebo). Results: The primary end point, a composite of death, myocardial infarction, and the need for repeated revascularization of the target lesion during nine months of follow-up, occurred in 53 patients assigned to placebo (43.8 percent) and 37 patients assigned to iridium-192 (28.2 percent, P = 0.02). However, the reduction in the incidence of major adverse cardiac events was determined solely by a diminished need for revascularization of the target lesion, not by reductions in the incidence of death or myocardial infarction. Late thrombosis occurred in 5.3 percent of the iridium-192 group, as compared with 0.8 percent of the placebo group (P = 0.07), resulting in more late myocardial infarctions in the iridium-192 group (9.9 percent vs. 4.1 percent, P = 0.09). Late thrombosis occurred in irradiated patients only after the discontinuation of oral antiplatelet therapy (with ticlopidine or clopidogrel) and only in patients who had received new stents at the time of radiation treatment. Conclusions: Intracoronary irradiation with iridium-192 resulted in lower rates of clinical and angiographic restenosis, although it was also associated with a higher rate of late thrombosis, resulting in an increased risk of myocardial infarction. If the problem of late thrombosis within the stent can be overcome, intracoronary irradiation with iridium-192 may become a useful approach to the treatment of in-stent restenosis. (N Engl J Med 2001;344:250-6.) Copyright (C) 2001 Massachusetts Medical Society.	Lenox Hill Hosp, Cardiovasc Res Fdn, New York, NY 10021 USA; Scripps Clin, La Jolla, CA USA; Cornell New York Hosp, New York, NY USA; Texas Heart Inst, Houston, TX 77025 USA; Cleveland Clin, Cleveland, OH 44106 USA; Mayo Clin, Rochester, MN USA; Christ Hosp, Cincinnati, OH 45219 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Cardiovascular Research Foundation (CRF); Northwell Health; Scripps Research Institute; Cornell University; NewYork-Presbyterian Hospital; Texas Heart Institute; Cleveland Clinic Foundation; Mayo Clinic; Christ Hospital - Ohio; Harvard University; Brigham & Women's Hospital	Leon, MB (corresponding author), Lenox Hill Hosp, Cardiovasc Res Fdn, 130 E 77th St,9 Blackhall, New York, NY 10021 USA.							Bauters C, 1998, CIRCULATION, V97, P318; Condado JA, 1997, CIRCULATION, V96, P727; Costa MA, 1999, CIRCULATION, V100, P789, DOI 10.1161/01.CIR.100.8.789; Dauerman HL, 1998, AM J CARDIOL, V82, P277, DOI 10.1016/S0002-9149(98)00311-7; Elezi S, 1998, J AM COLL CARDIOL, V32, P1866, DOI 10.1016/S0735-1097(98)00467-7; Elezi S, 1999, CATHETER CARDIO INTE, V48, P151, DOI 10.1002/(SICI)1522-726X(199910)48:2<151::AID-CCD6>3.0.CO;2-C; Ellis SG, 1999, CIRCULATION, V100, P799; Eltchaninoff H, 1998, J AM COLL CARDIOL, V32, P980, DOI 10.1016/S0735-1097(98)00333-7; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Jolly N, 1999, AM J CARDIOL, V83, P1565, DOI 10.1016/S0002-9149(99)00150-2; Kasaoka S, 1998, J AM COLL CARDIOL, V32, P1630, DOI 10.1016/S0735-1097(98)00404-5; Kastrati A, 1999, AM J CARDIOL, V83, P1617, DOI 10.1016/S0002-9149(99)00165-4; King SB, 1998, CIRCULATION, V97, P2025, DOI 10.1161/01.CIR.97.20.2025; Kuntz RE, 2000, CIRCULATION, V101, P2130, DOI 10.1161/01.CIR.101.18.2130; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; Lansky Alexandra J., 1999, Journal of the American College of Cardiology, V33, p17A; Lau KW, 1998, AM HEART J, V136, P150, DOI 10.1016/S0002-8703(98)70195-4; Lee DP, 1998, HERZ, V23, P362, DOI 10.1007/BF03043601; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Meerkin D, 1999, CIRCULATION, V99, P1660, DOI 10.1161/01.CIR.99.13.1660; Mintz GS, 1996, AM J CARDIOL, V78, P18, DOI 10.1016/S0002-9149(96)00493-6; Moreno PR, 1999, AM J CARDIOL, V84, P462, DOI 10.1016/S0002-9149(99)00334-3; Narins C R, 1998, Semin Interv Cardiol, V3, P91; Nath R, 1996, INT J RADIAT ONCOL, V36, P977, DOI 10.1016/S0360-3016(96)00441-5; POST MJ, 1994, CIRCULATION, V89, P2816, DOI 10.1161/01.CIR.89.6.2816; Radke PW, 1999, J AM COLL CARDIOL, V34, P33, DOI 10.1016/S0735-1097(99)00151-5; Sabate M, 1999, CIRCULATION, V100, P1182, DOI 10.1161/01.CIR.100.11.1182; Serruys P, 1998, LANCET, V352, P1478; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; vom Dahl J, 1999, AM J CARDIOL, V83, P862, DOI 10.1016/S0002-9149(98)01074-1; Waksman R, 2000, CIRCULATION, V101, P2165, DOI 10.1161/01.CIR.101.18.2165	33	473	499	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2001	344	4					250	256		10.1056/NEJM200101253440402	http://dx.doi.org/10.1056/NEJM200101253440402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	394WA	11172151				2022-12-28	WOS:000166545200002
J	Lewith, GT; Kenyon, JN; Broomfield, J; Prescott, P; Goddard, J; Holgate, ST				Lewith, GT; Kenyon, JN; Broomfield, J; Prescott, P; Goddard, J; Holgate, ST			Is electrodermal testing as effective as skin prick tests for diagnosing allergies? A double blind, randomised block design study	BRITISH MEDICAL JOURNAL			English	Article								Objective To evaluate whether electrodermal testing for environmental allergies can distinguish between volunteers who had previously reacted positively on skin prick tests for allergy to house dust mite or eat dander and volunteers who had reacted negatively to both allergens. Design Double blind, randomised block design. Setting A general practice in southern England. Participants 15 volunteers who had a positive result and 15 volunteers who had a negative result on a previous skin prick test for allergy to house dust mite or cat dander. Intervention Each participant was tested with 6 items by each of 3 operator of the Vegatest electrodermal testing device in 3 separate sessions (a total of 54 tests per participant). For each participant the 54 items comprised 18 samples each of house dust mite, cat dander, and distilled water, though thee were randomly allocated among the operators in each session. A research nurse sat with the participant and operator in all sessions to ensure blinding and adherence to the protocol and to record the outcome of each test. Outcome The presence or absence of an allergy according to the standard protocol for electrodermal testing. Results All the non-atopic participants completed all 3 testing sessions (810 individual tests); 774 (95.5%) of the individual tests conducted on the atopic participants complied wit the testing protocol. The results of the electrodermal tests did not correlate with those of the skin prick tests. Electrodermal testing could not distinguish between atopic and non-atopic participants. No operator of the Vegatest device was better than any other,and no single participant's atopic status was consistently correctly diagnosed. Conclusion electrodermal testing cannot be used to diagnose environmental allergies.	Univ Southampton, Dept Med, Southampton SO16 6YD, Hants, England; Univ Southampton, Fac Math Studies, Southampton SO16 6YD, Hants, England; Univ Southampton, Dept Med Stat & Comp, Southampton SO16 6YD, Hants, England; Ctr Study Complementary Med, Southampton SO15 2DT, Hants, England	University of Southampton; University of Southampton; University of Southampton	Lewith, GT (corresponding author), Univ Southampton, Dept Med, Southampton SO16 6YD, Hants, England.		Kenyon, Julian/AAC-9622-2019	Lewith, George/0000-0002-2364-3960				ALI M, 1989, AM J CLIN PATHOL, V91, P357; BASOMBA A, 1993, ALLERGY, V14, P71; DREBORG A, 1993, ALLERGY, V14, P48; FOX A, 1987, BR HOMOEOPATHIC J, V76, P230; GALLANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P245; HO MW, 1993, RAINBOW WORM PHYSICS; KENYON J, 1981, SHORT MANUAL VEGATES; KROP J, 1985, AM J ACUPUNCTURE, V13, P253; Krop J, 1997, J Altern Complement Med, V3, P241, DOI 10.1089/acm.1997.3.241; ROYAL FF, 1991, BR HOMOEOPATHIC J, V18, P166; TSUEI JJ, 1984, AM J ACUPUNCTURE, V12, P105; VANWIJK R, 1989, HOMOEOPATHIC REMEDIE	12	36	39	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 20	2001	322	7279					131	134		10.1136/bmj.322.7279.131	http://dx.doi.org/10.1136/bmj.322.7279.131			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159567	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000166615300022
J	Annas, GJ				Annas, GJ			"Partial-birth abortion" and the Supreme Court.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; ANNAS GJ, 1992, NEW ENGL J MED, V327, P651, DOI 10.1056/NEJM199208273270920; Annas GJ, 1998, NEW ENGL J MED, V339, P279, DOI 10.1056/NEJM199807233390420; BELLUCK P, 2000, NY TIMES, pA18	4	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					152	156		10.1056/NEJM200101113440220	http://dx.doi.org/10.1056/NEJM200101113440220			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150367	Green Published			2022-12-28	WOS:000166281100030
J	Donskey, CJ; Chowdhry, TK; Hecker, MT; Hoyen, CK; Hanrahan, JA; Hujer, AM; Hutton-Thomas, RA; Whalen, CC; Bonomo, RA; Rice, LB				Donskey, CJ; Chowdhry, TK; Hecker, MT; Hoyen, CK; Hanrahan, JA; Hujer, AM; Hutton-Thomas, RA; Whalen, CC; Bonomo, RA; Rice, LB			Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTESTINAL MICROFLORA; HEALTHY-VOLUNTEERS; INFECTION; FAECIUM; BACTEREMIA; OUTBREAK; FLORA; EPIDEMIOLOGY; EMERGENCE; TRACT	Background: Colonization and infection with vancomycin-resistant enterococci have been associated with exposure to antibiotics that are active against anaerobes. In mice that have intestinal colonization with vancomycin-resistant enterococci, these agents promote high-density colonization, whereas antibiotics with minimal antianaerobic activity do not. Methods: We conducted a seven-month prospective study of 51 patients who were colonized with vancomycin-resistant enterococci, as evidenced by the presence of the bacteria in stool. We examined the density of vancomycin-resistant enterococci in stool during and after therapy with antibiotic regimens and compared the effect on this density of antianaerobic agents and agents with minimal antianaerobic activity. In a subgroup of 10 patients, cultures of environmental specimens (e.g., from bedding and clothing) were obtained. Results: During treatment with 40 of 42 antianaerobic-antibiotic regimens (95 percent), high-density colonization with vancomycin-resistant enterococci was maintained (mean [+/-SD] number of organisms, 7.8+/-1.5 log per gram of stool). The density of colonization decreased after these regimens were discontinued. Among patients who had not received antianaerobic antibiotics for at least one week, 10 of 13 patients who began such regimens had an increase in the number of organisms of more than 1.0 log per gram (mean increase, 2.2 log per gram), whereas among 10 patients who began regimens of antibiotics with minimal antianaerobic activity, there was a mean decrease in the number of enterococci of 0.6 log per gram (P=0.006 for the difference between groups). When the density of vancomycin-resistant enterococci in stool was at least 4 log per gram, 10 of 12 sets of cultures of environmental specimens had at least one positive sample, as compared with 1 of 9 sets from patients with a mean number of organisms in stool of less than 4 log per gram (P=0.002). Conclusions: For patients with vancomycin-resistant enterococci in stool, treatment with antianaerobic antibiotics promotes high-density colonization. Limiting the use of such agents in these patients may help decrease the spread of vancomycin-resistant enterococci. (N Engl J Med 2000;343:1925-32.) (C) 2000, Massachusetts Medical Society.	Louis Stokes Cleveland Vet Affairs Med Ctr, Infect Dis Sect 1110 W, Cleveland, OH 44106 USA; Louis Stokes Cleveland Vet Affairs Med Ctr, Med Serv, Cleveland, OH 44106 USA; Case Western Reserve Univ, Div Infect Dis, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Epidemiol, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Div Infect Dis, Cleveland, OH USA; Rainbow Babies & Childrens Hosp, Div Pediat Infect Dis, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Donskey, CJ (corresponding author), Louis Stokes Cleveland Vet Affairs Med Ctr, Infect Dis Sect 1110 W, 10701 East Blvd, Cleveland, OH 44106 USA.			Hanrahan, Jennifer/0000-0002-7443-5985	FIC NIH HHS [D43 TW000011, D43 TW000011-16] Funding Source: Medline; NIAID NIH HHS [T32 AI007024, AI 07024] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARVIDSSON A, 1988, EUR J CLIN INVEST, V18, P261, DOI 10.1111/j.1365-2362.1988.tb01256.x; BACHER K, 1992, J ANTIMICROB CHEMOTH, V30, P365, DOI 10.1093/jac/30.3.365; BARRALL DT, 1985, ARCH SURG-CHICAGO, V120, P57; Beezhold DW, 1997, CLIN INFECT DIS, V24, P704, DOI 10.1093/clind/24.4.704; BODEY GP, 1983, J INFECT DIS, V148, P892, DOI 10.1093/infdis/148.5.892; BORDERON JC, 1986, J ANTIMICROB CHEMOTH, V18, P121, DOI 10.1093/jac/18.Supplement_E.121; BOYCE JM, 1992, ANTIMICROB AGENTS CH, V36, P1032, DOI 10.1128/AAC.36.5.1032; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; DEVRIESHOSPERS HG, 1984, J INFECT DIS, V150, P636, DOI 10.1093/infdis/150.5.636; Donskey CJ, 1999, J INFECT DIS, V180, P384, DOI 10.1086/314874; Edlund C, 1997, SCAND J INFECT DIS, V29, P383, DOI 10.3109/00365549709011835; Edlund C, 1997, CLIN INFECT DIS, V25, P729, DOI 10.1086/513755; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; EDMOND MB, 1997, PREVENTION CONTROL N, P339; GIULIANO M, 1987, ANTIMICROB AGENTS CH, V31, P202, DOI 10.1128/AAC.31.2.202; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; Hoyen C, 1999, PEDIATR INFECT DIS J, V18, P357, DOI 10.1097/00006454-199904000-00010; JONES JP, 1984, ACTA ELECTRON, V26, P3; Krueger WA, 1997, ANTIMICROB AGENTS CH, V41, P1725, DOI 10.1128/AAC.41.8.1725; Lorber B, 1995, MANDELL DOUGLAS BENN, V2, P2182; LORBER B, 1995, MANDELL DOUGLAS BENN, V2, P2195; LOUIE TJ, 1985, REV INFECT DIS, V7, pS747; Lucas GM, 1998, CLIN INFECT DIS, V26, P1127, DOI 10.1086/520311; MOELLERING RC, 1982, REV INFECT DIS, V4, pS708; MORENO F, 1995, CLIN INFECT DIS, V21, P1234, DOI 10.1093/clinids/21.5.1234; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; Nord C E, 1988, Rev Infect Dis, V10 Suppl 1, pS193; NORD CE, 1984, REV INFECT DIS, V6, pS270; NORD CE, 1992, SCAND J INFECT DIS, V24, P209, DOI 10.3109/00365549209052614; SAKATA H, 1986, ANTIMICROB AGENTS CH, V29, P225, DOI 10.1128/AAC.29.2.225; SEXTON DJ, 1993, INFECT CONT HOSP EP, V14, P629; SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993; VANSAENE JJM, 1986, J INFECT DIS, V153, P999, DOI 10.1093/infdis/153.5.999; VOLLAARD EJ, 1992, J ANTIMICROB CHEMOTH, V30, P685, DOI 10.1093/jac/30.5.685; VOLLAARD EJ, 1994, ANTIMICROB AGENTS CH, V38, P409, DOI 10.1128/AAC.38.3.409; WEIGELT JA, 1993, J TRAUMA, V34, P579, DOI 10.1097/00005373-199304000-00016; Weinstein JT, 1996, INFECT CONT HOSP EP, V17, P36; YU VL, 1981, ANN INTERN MED, V94, P784, DOI 10.7326/0003-4819-94-6-784	38	483	495	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2000	343	26					1925	1932		10.1056/NEJM200012283432604	http://dx.doi.org/10.1056/NEJM200012283432604			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386VR	11136263	Bronze, Green Accepted			2022-12-28	WOS:000166082700004
J	McGrath, PD; Wennberg, DE; Dickens, JD; Siewers, AE; Lucas, FL; Malenka, DJ; Kellett, MA; Ryan, TJ				McGrath, PD; Wennberg, DE; Dickens, JD; Siewers, AE; Lucas, FL; Malenka, DJ; Kellett, MA; Ryan, TJ			Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLLEGE-OF-CARDIOLOGY; NORTHERN NEW-ENGLAND; ANGIOPLASTY VOLUME; SURGICAL VOLUME; TASK-FORCE; ASSOCIATION; MORTALITY; SURGERY; EXPERIENCE; CALIFORNIA	Context Studies have found an association between physician and institution procedure volume for percutaneous coronary interventions (PCIs) and patient outcomes, but whether implementation of coronary stents has allowed low-volume physicians and centers to achieve outcomes similar to their high-volume counterparts is unknown. Objective To assess the relationship between physician and hospital PCI volumes and patient outcomes following PCIs, given the availability of coronary stents. Design, Setting, and Participants Analysis of data from Medicare National Claims History files for 167208 patients aged 65 to 99 years who had PCIs performed by 6534 physicians at 1003 hospitals during 1997, Of these procedures, 57.7% involved coronary stents. Main Outcome Measures Rates of coronary artery bypass graft (CABG) surgery and 30-day mortality occurring during the index episode of care, stratified by physician and hospital PCI volume. Results Overall unadjusted rates of CABG during the index hospitalization and 30-day mortality were 1.87% and 3.30%, respectively. After adjustment for case mix, patients treated by low-volume (<30 Medicare procedures) physicians had an increased risk of CABG vs patients treated by high-volume (>60 Medicare procedures) physicians (2.25% vs 1.55%; P<.001), but there was no difference in 30-day mortality rates (3.25% vs 3.39%; P=.27), Patients treated at low-volume (<80 Medicare procedures) centers had an increased risk of 30-day mortality vs patients treated at high-volume (>160 Medicare procedures) centers (4.29% vs 3.15%; P<.001), but there was no difference in the risk of CABG (1.83% vs 1.83 %; P=.96). In patients who received coronary stents, the CABG rate was 1.20% vs 2.78% for patients not receiving stents, and the 30-day mortality rate was 2.83 % vs 3.94%, Among patients who received stents, those treated at low-volume centers had an increased risk of 30-day mortality vs those treated at high-volume centers, whereas those treated by low-volume physicians had an increased risk of CABG vs those treated by high-volume physicians. Conclusion In the era of coronary stents, Medicare patients treated by high-volume physicians and at high-volume centers experience better outcomes following PCIs.	Maine Med Ctr, Ctr Outcomes Res & Evaluat, Portland, ME 04102 USA; Maine Med Ctr, Dept Med, Div Cardiol, Portland, ME 04102 USA; Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH USA; Dartmouth Hitchcock Med Ctr, Cardiol Sect, Lebanon, NH 03766 USA	Maine Medical Center; Maine Medical Center; Dartmouth College; Dartmouth College	McGrath, PD (corresponding author), Maine Med Ctr, Ctr Outcomes Res & Evaluat, 22 Bramhall St, Portland, ME 04102 USA.							*AM MED ASS, 1995, PHYS CURR PROC TERM; BUNKER JP, 1982, SURG CLIN N AM, V62, P657; Califf RM, 1996, CIRCULATION, V93, P403, DOI 10.1161/01.CIR.93.3.403; Fleiss J. L., 1981, STAT METHODS RATES P, V2; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; Hirshfeld JW, 1998, J AM COLL CARDIOL, V31, P722; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; Kahn HA, 1989, STAT METHODS EPIDEMI; Kastrati A, 1998, J AM COLL CARDIOL, V32, P970, DOI 10.1016/S0735-1097(98)00334-9; KATO NS, 1996, CIRCULATION S1, V94, P532; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Malenka DJ, 1999, J AM COLL CARDIOL, V34, P1471, DOI 10.1016/S0735-1097(99)00393-9; Maynard C, 1999, Eff Clin Pract, V2, P108; McGrath P, 1998, J AM COLL CARDIOL, V31, P570, DOI 10.1016/S0735-1097(97)00541-X; McGrath PD, 1999, J AM COLL CARDIOL, V34, P674, DOI 10.1016/S0735-1097(99)00257-0; PHILLIPS KA, 1995, MED CARE, V33, P502, DOI 10.1097/00005650-199505000-00005; Ritchie JL, 1999, AM HEART J, V138, P437, DOI 10.1016/S0002-8703(99)70144-4; RITCHIE JL, 1993, CIRCULATION, V88, P2735, DOI 10.1161/01.CIR.88.6.2735; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; RYAN TJ, 1993, CIRCULATION, V88, P2987, DOI 10.1161/01.CIR.88.6.2987; RYAN TJ, 1988, CIRCULATION, V78, P486, DOI 10.1161/01.CIR.78.2.486; RYAN TJ, 1995, JAMA-J AM MED ASSOC, V274, P1169, DOI 10.1001/jama.274.14.1169; *SAS I INC, 1986, STAT AN SYST SAS; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; *STAT CORP, 2000, STAT 6 0; *US DEP HHS CDCP, 1997, 1994 NAT HLTH INT SU; World Health Organization, 1977, INT CLASS DIS; ZELEN J, 1991, NEW YORK STATE J MED, V91, P290	32	220	222	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3139	3144		10.1001/jama.284.24.3139	http://dx.doi.org/10.1001/jama.284.24.3139			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135777	Bronze			2022-12-28	WOS:000165994100031
J	Snider, LA; Swedo, SE				Snider, LA; Swedo, SE			Pediatric obsessive-compulsive disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILDHOOD; CHILDREN; ADOLESCENTS		NIMH, Pediat & Dev Neuropsychiat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Snider, LA (corresponding author), NIMH, Pediat & Dev Neuropsychiat Branch, NIH, 10 Ctr dr,MSC 1255,Bldg 10,Room 4N208, Bethesda, MD 20892 USA.	sniderl@intra.nimh.nih.gov			NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002666, ZIAMH002666] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBANO A, 1999, HDB PRESCRIPTIVE TRE, P193; CALVOCORESSI L, 1995, AM J PSYCHIAT, V152, P441; Cavallini MC, 1999, AM J MED GENET, V88, P38, DOI 10.1002/(SICI)1096-8628(19990205)88:1<38::AID-AJMG7>3.0.CO;2-#; Fitzgerald KD, 1999, CHILD ADOL PSYCH CL, V8, P533; FLAMENT MF, 1985, ARCH GEN PSYCHIAT, V42, P977; Garvey MA, 1998, J CHILD NEUROL, V13, P413, DOI 10.1177/088307389801300901; Giedd JN, 2000, AM J PSYCHIAT, V157, P281, DOI 10.1176/appi.ajp.157.2.281; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1012; Grados M, 1999, CHILD ADOL PSYCH CL, V8, P617; JANET P, 1903, OBSESSIONS PSYCHIAT; Kanner L., 1962, CHILD PSYCHIAT, V3rd; King RA, 1999, CHILD ADOL PSYCH CL, V8, P577; King RA, 1998, J AM ACAD CHILD PSY, V37, P1110; LEONARD HL, 1990, J AM ACAD CHILD PSY, V29, P17, DOI 10.1097/00004583-199001000-00004; Leonard HL, 1999, CHILD ADOL PSYCH CL, V8, P497; MARCH J, 1999, MASC MULTIDIMENSIONA; Perlmutter SJ, 1999, LANCET, V354, P1153, DOI 10.1016/S0140-6736(98)12297-3; Piacentini J, 1999, CHILD ADOL PSYCH CL, V8, P599; Rapoport J.I., 1994, CHILD ADOLESCENT PSY; SWEDO SE, 1989, AM J PSYCHIAT, V146, P246; SWEDO SE, 1989, ARCH GEN PSYCHIAT, V46, P335; Zohar AH, 1999, CHILD ADOL PSYCH CL, V8, P445; Zohar AH, 1997, J CHILD PSYCHOL PSYC, V38, P993, DOI 10.1111/j.1469-7610.1997.tb01616.x	23	22	22	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3104	3106		10.1001/jama.284.24.3104	http://dx.doi.org/10.1001/jama.284.24.3104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	385FZ	11135753				2022-12-28	WOS:000165994100002
J	Bunger, MK; Wilsbacher, LD; Moran, SM; Clendenin, C; Radcliffe, LA; Hogenesch, JB; Simon, MC; Takahashi, JS; Bradfield, CA				Bunger, MK; Wilsbacher, LD; Moran, SM; Clendenin, C; Radcliffe, LA; Hogenesch, JB; Simon, MC; Takahashi, JS; Bradfield, CA			Mop3 is an essential component of the master circadian pacemaker in mammals	CELL			English	Article							DROSOPHILA CLOCK GENE; SUPRACHIASMATIC NUCLEUS; PROTEIN BMAL1; CDNA CLONING; COMMON VOLE; DOUBLE-TIME; RHYTHMS; PAS; TRANSCRIPTION; LIGHT	Circadian oscillations in mammalian physiology and behavior are regulated by an endogenous biological clock. Here we show that loss of the PAS protein MOP3 (also known as BMAL1) in mice results in immediate and complete loss of circadian rhythmicity in constant darkness. Additionally, locomotor activity in light-dark (LD) cycles is impaired and activity revels are reduced in Mop3(-/-) mice. Analysis of Period gene expression in the suprachiasmatic nucleus (SCN) indicates that these behavioral phenotypes arise from loss of circadian function at the molecular level. These results provide genetic evidence that MOP3 is the bona fide heterodimeric partner of mCLOCK. Furthermore, these data demonstrate that MOP3 is a nonredundant and essential component of the circadian pacemaker in mammals.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Northwestern Univ, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Univ Chicago, Howard Hughes Med Inst, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; Northwestern University; Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA.	bradfield@oncology.wisc.edu	Simon, Celeste/AAG-3941-2021; Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878	NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005703, R37ES005703, F32ES005703, R29ES005703] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P30-CA07175] Funding Source: Medline; NIEHS NIH HHS [ES05703, F32 ES005703, R01 ES005703, R37 ES005703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GERKEMA MP, 1993, J BIOL RHYTHM, V8, P151, DOI 10.1177/074873049300800205; GERKEMA MP, 1990, J BIOL RHYTHM, V5, P81, DOI 10.1177/074873049000500201; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Ikeda M, 2000, BIOCHEM BIOPH RES CO, V275, P493, DOI 10.1006/bbrc.2000.3248; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 1999, MOL CELL BIOL, V19, P5316; LEHMANN U, 1977, International Journal of Chronobiology, V4, P223; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P223, DOI 10.1007/BF01417856; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REDIN U, 1999, J COMP PHYSIOL A, V184, P429; REDIN U, 1999, J COMP PHYSIOL A, V184, P439; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Ripperger JA, 2000, GENE DEV, V14, P679; ROSBASH M, 1995, CURR OPIN GENET DEV, V5, P662, DOI 10.1016/0959-437X(95)80037-9; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SCHWARTZ WJ, 1991, PHYSIOL BEHAV, V49, P1283, DOI 10.1016/0031-9384(91)90364-T; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shearman LP, 2000, MOL CELL BIOL, V20, P6269, DOI 10.1128/MCB.20.17.6269-6275.2000; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Tamaru T, 2000, J NEUROSCI, V20, P7525; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Wachulec M, 1997, J BIOL RHYTHM, V12, P226, DOI 10.1177/074873049701200304; Wager-Smith K, 2000, NAT GENET, V26, P23, DOI 10.1038/79134; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yu WJ, 1999, BIOCHEM BIOPH RES CO, V260, P760, DOI 10.1006/bbrc.1999.0970; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	60	1110	1154	2	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1009	1017		10.1016/S0092-8674(00)00205-1	http://dx.doi.org/10.1016/S0092-8674(00)00205-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163178	Bronze, Green Accepted			2022-12-28	WOS:000166040600005
J	McKeith, I; Del Ser, T; Spano, P; Emre, M; Wesnes, K; Anand, R; Cicin-Sain, A; Ferrara, R; Spiegel, R				McKeith, I; Del Ser, T; Spano, P; Emre, M; Wesnes, K; Anand, R; Cicin-Sain, A; Ferrara, R; Spiegel, R			Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study	LANCET			English	Article							ALZHEIMERS-DISEASE; SENILE DEMENTIA; BODY DEMENTIA; TACRINE	Background Dementia with Lewy bodies is a common form of dementia in the elderly, characterised clinically by fluctuating cognitive impairment, attention deficits, Visual hallucinations, parkinsonism, and other neuropsychiatric features. Neuroleptic medication can provoke severe sensitivity reactions in patients with dementia of this type. Many deficits in cholinergic neurotransmission are seen in the brain of patients with Lewy-body dementia; therefore, drugs enhancing central cholinergic function represent a rationally-based therapeutic approach to this disorder. Rivastigmine, a cholinesterase inhibitor, was tested in a group of clinically characterised patients with Lewy-body dementia. Methods A placebo-controlled, double-blind, multicentre study was done in 120 patients with Lewy-body dementia from the UK, Spain, and Italy. Individuals were given up to 12 mg rivastigmine daily or placebo for 20 weeks, followed by 3 weeks rest. Assessment by means of the neuropsychiatric inventory was made at baseline, and again at weeks 12, 20, and 23. A computerised cognitive assessment system and neuropsychological tests were also used, and patients underwent close medical and laboratory safety analysis. Findings Patients taking rivastigmine were significantly less apathetic and anxious, and had fewer delusions and hallucinations while on treatment than controls. Almost twice as many patients on rivastigmine (37, 63%), than on placebo (18, 30%), showed at least a 30% improvement from baseline. In the computerised cognitive assessment system and the neuropsychological tests, patients were significantly faster and better than those oh placebo, particularly on tasks with a substantial attentional component. Both predefined primary efficacy measures differed significantly between rivastigmine and placebo. After drug discontinuation differences between rivastigmine and placebo tended to disappear. Known adverse events of cholinesterase inhibitors (nausea, vomiting, anorexia) were seen more frequently with rivastigmine than with placebo, but safety and tolerability of the drug in these mostly multimorbid patients were judged acceptable. Interpretation Rivastigmine 6-12 mg daily produces statistically and clinically significant behavioural effects in patients with Lewy-body dementia, and seems safe and well tolerated if titrated individually.	Newcastle Univ, Inst Hlth Elderly, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Hosp Severo Ochoa, Neurol Sect, Leganes, Spain; Univ Brescia, Fac Med & Chirurg, Brescia, Italy; Instanbul Med Sch, Dept Neurol, Istanbul, Turkey; Cognit Drug Res Ltd, Reading, Berks, England; Novartis Pharmaceut, Summit, NJ 07901 USA; Novartis Pharma AG, Basel, Switzerland; Novartis Farma, Milan, Italy	Newcastle University - UK; Severo Ochoa University Hospital; University of Brescia; Istanbul University; Novartis; Novartis; Novartis	McKeith, I (corresponding author), Newcastle Univ, Inst Hlth Elderly, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	i.g.mckeith@ncl.ac.uk	Spano, Pier Franco A/E-7621-2010; McKeith, Ian/AAH-3382-2021; Wesnes, Keith A/D-7148-2018; del Ser, Teodoro/U-3711-2019; Spano, Pier Franco F/J-9944-2016	Spano, Pier Franco F/0000-0002-9906-0964; Wesnes, Keith/0000-0002-4498-8511; McKeith, Ian/0000-0002-9250-0568				COREYBLOOM J, 1998, INT J GERIATR PSYCHO, V1, P55; Cummings JL, 2000, AM J PSYCHIAT, V157, P4, DOI 10.1176/ajp.157.1.4; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; CUTLER NR, 1998, INT J GERIAT PSYCHOP, V1, P20; DELSER T, IN PRESS INT J GERIA; Fahn S., 1987, RECENT DEV PARKINSON, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HANSEN L, 1990, NEUROLOGY, V40, P1; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Kaufer DI, 1998, NEUROLOGY, V51, P1512, DOI 10.1212/WNL.51.5.1512; LEVY R, 1994, LANCET, V343, P176, DOI 10.1016/S0140-6736(94)90966-0; Liberini P, 1996, TRENDS PHARMACOL SCI, V17, P155, DOI 10.1016/0165-6147(96)81592-6; MCKEITH I, 1992, BRIT MED J, V305, P673, DOI 10.1136/bmj.305.6855.673; McKeith IG, 2000, INT J GERIATR PSYCH, V15, P387, DOI 10.1002/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9; Perry E. K., 1996, P397, DOI 10.1017/CBO9780511601187.036; PERRY EK, 1994, NEUROREPORT, V5, P747, DOI 10.1097/00001756-199403000-00002; PERRY RH, 1990, J NEUROL SCI, V95, P119, DOI 10.1016/0022-510X(90)90236-G; PIGGOTT MA, 1994, LANCET, V343, P1044; RICHARDS M, 1991, ARCH NEUROL-CHICAGO, V48, P1147, DOI 10.1001/archneur.1991.00530230055021; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Shea C, 1998, Int Psychogeriatr, V10, P229, DOI 10.1017/S1041610298005341; SIEGFRIED KR, 1993, ACTA NEUROL SCAND, V88, P26; SIMPSON PM, 1991, INT J GERIATR PSYCH, V6, P95, DOI 10.1002/gps.930060208; VELLAS B, 1998, INT J GERIAT PSYCHOP, V1, P140; WILCOCK GK, 1994, LANCET, V344, P544, DOI 10.1016/S0140-6736(94)91933-X	25	754	774	1	57	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	2000	356	9247					2031	2036		10.1016/S0140-6736(00)03399-7	http://dx.doi.org/10.1016/S0140-6736(00)03399-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145488				2022-12-28	WOS:000165994300008
J	Tcheng, JE; O'Shea, JC; Cohen, EA; Pacchiana, CM; Kitt, MM; Lorenz, TJ; Greenberg, S; Strony, J; Califf, RM; Buller, C; Cantor, WJ; Joseph, DM; Kitt, MM; Lincoff, AM; Madan, M; Popma, J; Teirstein, P; Cohen, E; Balleza, L; Parsons, P; Lui, H; Young, J; Fox, R; Labinaz, M; Jelley, J; Williams, J; Cohen, D; Trovato, M; Smith, J; Henry, P; Chisholm, R; O'Donnell, D; Talley, JD; Pacheco, R; Timmis, S; Muraka, A; Mann, T; Cubeddu, G; Tannenbaum, M; Greene, J; Santoian, E; Wash, M; Sheldon, S; Pronesti, L; Jain, A; Alonzo, M; Seidelin, P; Richards, J; Lopez, M; Dittenber, R; Johnson, K; Levine, G; Maresh, K; Ferrando, T; Sarembock, I; Snyder, L; Kieval, J; Herlan, L; Miller, M; Bembridge, D; Nair, R; Hickel, L; Kiernan, F; Murphy, D; Cloutier, J; Conn, E; Beardsley, J; Ritchie, M; Cragen, D; Jafar, MZ; Counihan, P; Rosenfelder, D; Ducas, J; Montebruno, L; Carere, R; Radons, B; Williams, L; Owens, W; Dougal, R; Feldman, R; Audrain, D; Karamali, A; Smith, M; Blankenship, J; Demko, SL; Thompson, M; Gacoich, G; Chiodo, V; Noll, P; Ledley, G; Miller, C; Felten, W; Garner, B; Chandler, AB; Easler, P; Albin, G; Page, A; Maddox, W; Allen, S; Gilchrist, I; Moore, R; Zimmerman, H; Curtis, M; Hildebrand, K; Greene, R; Healy, E; Meengs, W; Carson, D; George, J; Roncevich, T; Aharonian, V; Browning, R; Kostuk, W; Carr, S; Feit, F; Gostomsky, B; Butman, S; Hannah, E; Hassel, CD; Hartley, D; Shook, T; Hiller-Mullin, S; Brill, D; Dillion, M; Armstrong, B; Kerns, D; Pichard, A; Okubagzi, P; Nasser, T; Driver, L; Garrett, J; Boltey, L; Stouffer, G; Potter, M; Amidon, T; Eggert, S; Taussig, A; Potter, K; Natarajan, M; Tartaglia, C; Werner, J; Dunlap, T; Harrold-Runge, P; Davidson, C; Goodreau, L; Herzog, W; Calamunci, N; Slater, A; Tormey, D; Phillips, W; White, D; Sridhar, K; White, J; Goodman, D; Buchbinder, M; Nasser, V; Rapeport, K; Vorman, P; Weiner, B; Borbone, M; Shadoff, N; Paap, C; Rehman, A; Haag, E; Burchenal, J; Kioussopoulos, K; Senior, D; Senior, J; Piana, R; Kirshenbaum, J; Chan, S; Chowdry, A; Kraft, P; Clark, V; Fox, M; Deutsch, E; Shannon, T; Quesada, R; Brotherton, J; Murrin, C; Cinderella, J; Hearne, S; Seefried, V; Farah, T; Pakstis, D; Bartolet, B; Bond, C; Debarardinis, C; Montory, D; Smith, G; Gray, D; Phillips, P; Hathaway, S; Manoukian, S; Patrick, C; Yakubov, S; Brooks, J; Block, P; Block, B; Muhlestein, JB; Kim, S; Shalev, Y; Schmidt, W; Resar, J; Citro, K; Stine, R; Zumbuhl, J; Moreyra, A; Kreiger, S; Berger, P; Cannon, CP; Fisher, L; Hasselblad, V; Foster, A; Joseph, D; Madan, M; McLendon, C; Rund, M; Tillery, N; Wood, F; Mahaffey, KW; Irwin, C; Kulick, D; Johnson, N; Chen, J; Greenberg, S; Hogeboom, C; Lorenz, TJ; Terifay, R; Strony, J; Veltri, E				Tcheng, JE; O'Shea, JC; Cohen, EA; Pacchiana, CM; Kitt, MM; Lorenz, TJ; Greenberg, S; Strony, J; Califf, RM; Buller, C; Cantor, WJ; Joseph, DM; Kitt, MM; Lincoff, AM; Madan, M; Popma, J; Teirstein, P; Cohen, E; Balleza, L; Parsons, P; Lui, H; Young, J; Fox, R; Labinaz, M; Jelley, J; Williams, J; Cohen, D; Trovato, M; Smith, J; Henry, P; Chisholm, R; O'Donnell, D; Talley, JD; Pacheco, R; Timmis, S; Muraka, A; Mann, T; Cubeddu, G; Tannenbaum, M; Greene, J; Santoian, E; Wash, M; Sheldon, S; Pronesti, L; Jain, A; Alonzo, M; Seidelin, P; Richards, J; Lopez, M; Dittenber, R; Johnson, K; Levine, G; Maresh, K; Ferrando, T; Sarembock, I; Snyder, L; Kieval, J; Herlan, L; Miller, M; Bembridge, D; Nair, R; Hickel, L; Kiernan, F; Murphy, D; Cloutier, J; Conn, E; Beardsley, J; Ritchie, M; Cragen, D; Jafar, MZ; Counihan, P; Rosenfelder, D; Ducas, J; Montebruno, L; Carere, R; Radons, B; Williams, L; Owens, W; Dougal, R; Feldman, R; Audrain, D; Karamali, A; Smith, M; Blankenship, J; Demko, SL; Thompson, M; Gacoich, G; Chiodo, V; Noll, P; Ledley, G; Miller, C; Felten, W; Garner, B; Chandler, AB; Easler, P; Albin, G; Page, A; Maddox, W; Allen, S; Gilchrist, I; Moore, R; Zimmerman, H; Curtis, M; Hildebrand, K; Greene, R; Healy, E; Meengs, W; Carson, D; George, J; Roncevich, T; Aharonian, V; Browning, R; Kostuk, W; Carr, S; Feit, F; Gostomsky, B; Butman, S; Hannah, E; Hassel, CD; Hartley, D; Shook, T; Hiller-Mullin, S; Brill, D; Dillion, M; Armstrong, B; Kerns, D; Pichard, A; Okubagzi, P; Nasser, T; Driver, L; Garrett, J; Boltey, L; Stouffer, G; Potter, M; Amidon, T; Eggert, S; Taussig, A; Potter, K; Natarajan, M; Tartaglia, C; Werner, J; Dunlap, T; Harrold-Runge, P; Davidson, C; Goodreau, L; Herzog, W; Calamunci, N; Slater, A; Tormey, D; Phillips, W; White, D; Sridhar, K; White, J; Goodman, D; Buchbinder, M; Nasser, V; Rapeport, K; Vorman, P; Weiner, B; Borbone, M; Shadoff, N; Paap, C; Rehman, A; Haag, E; Burchenal, J; Kioussopoulos, K; Senior, D; Senior, J; Piana, R; Kirshenbaum, J; Chan, S; Chowdry, A; Kraft, P; Clark, V; Fox, M; Deutsch, E; Shannon, T; Quesada, R; Brotherton, J; Murrin, C; Cinderella, J; Hearne, S; Seefried, V; Farah, T; Pakstis, D; Bartolet, B; Bond, C; Debarardinis, C; Montory, D; Smith, G; Gray, D; Phillips, P; Hathaway, S; Manoukian, S; Patrick, C; Yakubov, S; Brooks, J; Block, P; Block, B; Muhlestein, JB; Kim, S; Shalev, Y; Schmidt, W; Resar, J; Citro, K; Stine, R; Zumbuhl, J; Moreyra, A; Kreiger, S; Berger, P; Cannon, CP; Fisher, L; Hasselblad, V; Foster, A; Joseph, D; Madan, M; McLendon, C; Rund, M; Tillery, N; Wood, F; Mahaffey, KW; Irwin, C; Kulick, D; Johnson, N; Chen, J; Greenberg, S; Hogeboom, C; Lorenz, TJ; Terifay, R; Strony, J; Veltri, E		ESPRIT Investigators	Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial	LANCET			English	Article							PLATELET GLYCOPROTEIN-IIB/IIIA; MULTICENTER; ANTAGONISTS; INHIBITION; BLOCKADE; DESIGN	Background The platelet glycoprotein IIb/IIIa inhibitors, although effective in reducing ischaemic complications of percutaneous coronary intervention. are used in few coronary stent implantation procedures. ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) is a randomised, placebo-controlled trial to assess whether a novel, double-bolus dose of eptifibatide could improve outcomes of patients undergoing coronary stenting. Methods We recruited 2064 patients undergoing stent implantation in a native coronary artery. Immediately before percutaneous coronary intervention, patients were randomly allocated to receive eptifibatide, given as two 180 mug/kg boluses 10 min apart and a continuous infusion of 2.0 mug/kg/min for 18-24 h, or placebo, in addition to aspirin, heparin, and a thienopyridine. The primary endpoint was the composite of death, myocardial infarction, urgent target vessel revascularisation, and thrombotic bailout glycoprotein IIb/IIIa inhibitor therapy within 48 h after randomisation. The key secondary endpoint was the composite of death, myocardial infarction, or urgent target vessel revascularisation at 30 days. Findings The trial was terminated early for efficacy. The primary endpoint was reduced from 10.5% (108 of 1024 patients on placebo [95% CI 8.7-12.4%]) to 6.6% (69 of 1040 [5.1-8.1%]) with treatment (p=0.0015). The key 30 day secondary endpoint was also reduced, from 10.5% (107 of 1024 patients on placebo [8.6-12.3%]) to 6.8% (71 of 1040 [5.3-8.4%]; p=0.0034). There was consistency in reduction of events across all components of the composite endpoint and among the major subgroups. Major bleeding was infrequent but arose more often with eptifibatide than placebo (1.3%, 13 of 1040 [0.7-2.1%]) vs 0.4%, 4 of 1024 [0.1-1.0%]; p=0.027). Interpretation Routine glycoprotein IIb/IIIa inhibitor pretreatment with eptifibatide substantially reduces ischaemic complications in coronary stent intervention and is better than a strategy of reserving treatment to the bailout situation.	Duke Univ, Med Ctr, Durham, NC 27710 USA; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Jackson Madison Cty Gen Hosp, Jackson, TN 38301 USA; Vancouver Gen Hosp, Vancouver, BC, Canada; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; St Vincent Hosp, Erie, PA 16501 USA; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Hosp Arkansas, Cent Arkansas Vet Healthcare, Little Rock, AR 72201 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Wake Heart Associates, Raleigh, NC 27601 USA; Mercy Hosp, Med Ctr, Des Moines, IA 50301 USA; Orlando Heart Ctr, Orlando, FL 32801 USA; EMH Reg Med Ctr, Elyria, OH 44035 USA; S Texas Hosp, San Antonio, TX 78284 USA; Toronto Hosp, Toronto, ON M5T 2S8, Canada; Charlotte Reg Med Ctr, Port Charlotte, FL 33948 USA; Baylor Ben Taub & VA, Houston, TX 77030 USA; UVA Hlth Syst, Charlottesville, VA 22903 USA; JFK Med Ctr, Atlantis, FL 33462 USA; Pitt Cty Mem Hosp, Greenville, NC 27834 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Hartford Hosp, Hartford, CT 06115 USA; Mem Hosp, Chattanooga, TN 37401 USA; Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; Hlth Sci Ctr, Winnipeg, MB, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; St Alphonsus Reg Med Ctr, Boise, ID 83701 USA; Monroe Reg Med Ctr, Ocala, FL 34470 USA; St Vincents Med Ctr, Toledo, OH 43601 USA; Geisinger Med Ctr, Danville, PA 17822 USA; Rochester Gen Hosp, Rochester, NY 14621 USA; Albert Einstein Med Ctr, Philadelphia, PA 19141 USA; Covenant Healthcare, Saginaw, MI 48601 USA; Univ Hosp, Augusta, GA 30912 USA; St Marys Hosp, Duluth, MN 55801 USA; Mission St Josephs, Asheville, NC 28801 USA; Penn State Univ Hosp, Hershey, PA 17033 USA; Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada; Alta Bates, Berkeley, CA 94720 USA; No Michigan Hosp, Petoskey, MI 49770 USA; Western Penn Hosp, Pittsburgh, PA 15224 USA; Kaiser Los Angeles Med Ctr, Los Angeles, CA 90027 USA; London Hlth Sci Ctr Univ, London, ON, Canada; NYU, Med Ctr, New York, NY 10016 USA; Univ Arizona, Med Ctr, Tucson, AZ 85724 USA; Baptist Med Ctr, Jacksonville Beach, FL 32240 USA; Hosp Good Samaritan, Los Angeles, CA 90017 USA; Washington Adventist Hosp, Takoma Pk, MD 20912 USA; Holston Valley Hosp & Med Ctr, Kingsport, TN 37660 USA; Washington Hosp Ctr, Washington, DC 20010 USA; Western Penn Hosp, Pittsburgh, PA 15224 USA; Univ Texas, Sch Med, Galveston, TX 77550 USA; Florida Hosp Med Ctr, Orlando, FL 32803 USA; Hamilton Hlth Sci Corp, Hamilton, ON, Canada; Santa Rosa Mem Hosp, Santa Rosa, CA 95401 USA; NW Mem Hosp, Chicago, IL 60611 USA; Univ Maryland, Med Ctr, Baltimore, MD 21204 USA; St Lukes Roosevelt Hosp, New York, NY 10019 USA; Wilson Reg Med Ctr, Johnson City, NY 13790 USA; London Hlth Sci Ctr Victoria, London, ON, Canada; Scripps Mem Hosp, La Jolla, CA 92037 USA; Alvarado Hosp, Med Ctr, San Diego, CA 92107 USA; Univ Massachusetts, Med Ctr, Worcester, MA 01605 USA; Presbyterian Heart Grp, Albuquerque, NM 87101 USA; St Francis Hosp, Roslyn, NY 11576 USA; Univ Colorado, Ctr Hlth, Denver, CO 80206 USA; Jewish Hosp, Louisville, KY 40202 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Henry Ford Hosp, Detroit, MI 48202 USA; New York Hosp, Cornell Univ Med Ctr, New York, NY 10021 USA; Baptist Hosp Miami, Miami, FL 33176 USA; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; N Mississippi Med Ctr, Tupelo, MS 38801 USA; Deborah Heart & Lung Ctr, Browns Mills, NJ 08015 USA; Methodist Hlth Syst, Memphis, TN 38104 USA; Scripps Mercy Hosp, San Diego, CA 92103 USA; Emory Univ, Atlanta, GA 30322 USA; Grant Riverside Methodist, Columbus, OH 43215 USA; Providence St Vincent Med Ctr, Portland, OR 97201 USA; Latter Day St Hosp, Salt Lake City, UT 84101 USA; Sinai Samaritan Med Ctr, Milwaukee, WI USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; Sentara Norfolk Gen Hosp, Norfolk, VA 23507 USA; Robert Wood Johnson Univ Hosp, New Brunswick, NJ USA	Duke University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of British Columbia; University of Ottawa; University of Ottawa Heart Institute; Harvard University; Beth Israel Deaconess Medical Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; Beaumont Health; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University Hospitals of Cleveland; Hartford Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Manitoba; Children's Hospital Research Institute of Manitoba; St. Paul's Hospital; University of Saskatchewan; Saint Alphonsus Regional Medical Center; Geisinger Medical Center; Rochester General Hospital; Yeshiva University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Calgary; West Penn Hospital; London Health Sciences Centre; New York University; University of Arizona; MedStar Washington Hospital Center; West Penn Hospital; University of Texas System; University of Texas Medical Branch Galveston; Adventist Health Services; AdventHealth; McMaster University; Northwestern Memorial Hospital; University System of Maryland; University of Maryland Baltimore; Mount Sinai St. Luke's; Mount Sinai West; London Health Sciences Centre; University of Massachusetts System; University of Massachusetts Worcester; University of Colorado System; University of Colorado Denver; Harvard University; Brigham & Women's Hospital; Henry Ford Health System; Henry Ford Hospital; Cornell University; NewYork-Presbyterian Hospital; Baptist Hospital Miami; Allegheny General Hospital; Emory University; Johns Hopkins University; Johns Hopkins Medicine; Sentara Healthcare; Rutgers State University New Brunswick; Rutgers State University Medical Center	Tcheng, JE (corresponding author), Duke Univ, Med Ctr, Box 3275, Durham, NC 27710 USA.	tchen001@mc.duke.edu	Stouffer, George/AAK-4763-2021; Blankenship, James/AAX-4084-2020; Cannon, Christopher P/AAY-7644-2020	Blankenship, James/0000-0003-4966-533X; Cannon, Christopher P/0000-0003-4596-2791				Abdelmeguid AE, 1996, CIRCULATION, V94, P3369, DOI 10.1161/01.CIR.94.12.3369; Belli G, 1997, PROG CARDIOVASC DIS, V40, P159, DOI 10.1016/S0033-0620(97)80007-2; Berkowitz SD, 1997, CIRCULATION, V95, P809; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Califf RM, 1998, J AM COLL CARDIOL, V31, P241, DOI 10.1016/S0735-1097(97)00506-8; GOLD HK, 1990, J CLIN INVEST, V86, P651, DOI 10.1172/JCI114757; Hanrath P, 1997, CIRCULATION, V96, P1445; HARRINGTON RA, 1995, AM J CARDIOL, V76, P1222, DOI 10.1016/S0002-9149(99)80345-2; Hillegass WB, 1999, AM HEART J, V138, pS24, DOI 10.1053/hj.1999.v138.99079; Jacobs AK, 1998, CIRCULATION, V98, P16; Kosoglou T., 1998, European Heart Journal, V19, P52; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; O'Shea JC, 2000, AM HEART J, V140, P834, DOI 10.1067/mhj.2000.110458; Phillips DR, 1997, CIRCULATION, V96, P1488, DOI 10.1161/01.CIR.96.5.1488; Rankin JM, 1999, NEW ENGL J MED, V341, P1957, DOI 10.1056/NEJM199912233412602; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; Simoons ML, 1997, LANCET, V349, P1429; Steinhubl SR, 1998, CIRCULATION, V98, P573; TCHENG JE, 1995, CIRCULATION, V91, P2151, DOI 10.1161/01.CIR.91.8.2151; Tcheng JE, 1997, LANCET, V349, P1422; TCHENG JE, 1994, CIRCULATION, V90, P1757, DOI 10.1161/01.CIR.90.4.1757; TCHENG JE, 1997, EUR HEART J, V18, pPOLUK; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1999, LANCET, V354, P2019, DOI 10.1016/S0140-6736(99)10018-7; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; Topol EJ, 1997, NEW ENGL J MED, V336, P1689	28	588	605	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	2000	356	9247					2037	2044						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145489				2022-12-28	WOS:000165994300009
J	Zhang, J; Childress, S; Libchaber, A; Shelley, M				Zhang, J; Childress, S; Libchaber, A; Shelley, M			Flexible filaments in a flowing soap film as a model for one-dimensional flags in a two-dimensional wind	NATURE			English	Article							SHEAR FLOWS; LAMINAR; FLUIDS; WAKES	The dynamics of swimming fish and flapping flags involves a complicated interaction of their deformable shapes with the surrounding fluid flow. Even in the passive case of a flag, the flag exerts forces on the fluid through its own inertia and elastic responses, and is likewise acted on by hydrodynamic pressure and drag. But such couplings are not well understood. Here we study these interactions experimentally, using an analogous system of flexible filaments in flowing soap films. We rnd that, for a single filament (or 'flag') held at its upstream end and otherwise unconstrained, there are two distinct, stable dynamical states. The first is a stretched-straight state: the filament is immobile and aligned in the flow direction. The existence of this state seems to refute the common belief that a flag is always unstable and will flap(1,2). The second is a flapping state: the filament executes a sinuous motion in a manner akin to the flapping of a flag in the wind. We study further the hydrodynamically coupled interaction between two such filaments, and demonstrate the existence of four different dynamical states.	NYU, Courant Inst, Appl Math Lab, New York, NY 10012 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	New York University; Rockefeller University	Zhang, J (corresponding author), NYU, Courant Inst, Appl Math Lab, New York, NY 10012 USA.			Shelley, Michael/0000-0002-4835-0339				Anderson JM, 1998, J FLUID MECH, V360, P41, DOI 10.1017/S0022112097008392; Benard H, 1908, CR HEBD ACAD SCI, V147, P839; CHOMAZ JM, 1990, PHYS REV A, V41, P2243, DOI 10.1103/PhysRevA.41.2243; COUDER Y, 1989, PHYSICA D, V37, P384, DOI 10.1016/0167-2789(89)90144-9; DRAZIN PG, 1981, HYDRODYNAMIC STABILI, P374; FITT AD, UNPUB J ENG SCI; GHARIB M, 1989, PHYSICA D, V37, P406, DOI 10.1016/0167-2789(89)90145-0; KELLAY H, 1995, PHYS REV LETT, V74, P3975, DOI 10.1103/PhysRevLett.74.3975; LopezRuiz R, 1997, PHYS REV E, V55, pR3820, DOI 10.1103/PhysRevE.55.R3820; Martin B, 1995, REV SCI INSTRUM, V66, P5603, DOI 10.1063/1.1146027; Paidousis M. P, 1998, FLUID STRUCTURE INTE, V1; PEDLEY TJ, 1979, FLUID MECH LARGE BLO; Peschard I, 1999, EXP FLUIDS, V26, P188, DOI 10.1007/s003480050279; Peschard I, 1996, PHYS REV LETT, V77, P3122, DOI 10.1103/PhysRevLett.77.3122; PRANDTL L, 1952, ESSENTIALS FLUID MEC; RAYLEIGH, 1879, P LOND MATH SOC, V10, P4; Rutgers MA, 1996, PHYS FLUIDS, V8, P2847, DOI 10.1063/1.869105; Scanlan RH, 1951, INTRO STUDY AIRCRAFT; THORPE SA, 1971, J FLUID MECH, V46, P299, DOI 10.1017/S0022112071000557; TRIANTAFYLLOU MS, 1995, SCI AM, V272, P64, DOI 10.1038/scientificamerican0395-64; TRITTON DT, 1988, PHYSICAL FLUID DYNAM	21	348	368	6	98	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					835	839		10.1038/35048530	http://dx.doi.org/10.1038/35048530			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130717				2022-12-28	WOS:000165831300043
J	Pahor, M; Psaty, BM; Alderman, MH; Applegate, WB; Williamson, JD; Cavazzini, C; Furberg, CD				Pahor, M; Psaty, BM; Alderman, MH; Applegate, WB; Williamson, JD; Cavazzini, C; Furberg, CD			Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials	LANCET			English	Article							CARDIOVASCULAR MORTALITY; CHANNEL BLOCKADE; HYPERTENSION; ATHEROSCLEROSIS; ENALAPRIL; OLD	Background Several observational studies and individual randomised trials in hypertension have suggested that, compared with other drugs, calcium antagonists may be associated with a higher risk of coronary events, despite similar blood-pressure control. The aim of this meta-analysis was to compare the effects of calcium antagonists and other antihypertensive drugs on major cardiovascular events. Methods We undertook a meta-analysis of trials hypertension that assessed cardiovascular events and included at least 100 patients, who were randomly assigned intermediate-acting or long-acting calcium antagonists or other antihypertensive drugs and who were followed up for at least 2 years. in and Findings The nine eligible trials included 27 743 participants. Calcium antagonists and other drugs achieved similar control of both systolic and diastolic blood pressure. Compared with patients assigned diuretics, P-blockers, angiotensin-converting-enzyme inhibitors, or clonidine (n=15 044), those assigned calcium antagonists (n=12 699) had a significantly higher risk of acute myocardial infarction (odds ratio 1.26 [95% CI 1.11-1.43], p=0.0003), congestive heart failure (1.25 [1.07-1.46], p=0.005), and major cardiovascular events (1.10 [1.02-1.18], p=0.018). The treatment differences were within the play of chance for the outcomes of stroke (0.90 [0.80-1.02], p=0.10) and all-cause mortality (1.03 [0.94-1.13], p=0.54). Interpretation In randomised controlled trials, the large available database suggests that calcium antagonists are-inferior to other types of antihypertensive drugs as first-line agents in reducing the risks of several major complications of hypertension. On the basis of these data, the longer-acting calcium antagonists cannot be recommended as first-line therapy for hypertension.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sticht Ctr Aging, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA; Univ Washington, Dept Epidemiol & Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA USA; Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yeshiva University; Albert Einstein College of Medicine	Pahor, M (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sticht Ctr Aging, Med Ctr Blvd, Winston Salem, NC 27157 USA.							Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; CASIGLIA E, 1994, JPN HEART J, V35, P589; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; GLEERUP G, 1995, J CARDIOVASC PHARM, V25, P87, DOI 10.1097/00005344-199501000-00014; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; LIEBSON PR, 1995, CIRCULATION, V91, P698, DOI 10.1161/01.CIR.91.3.698; Ligtenberg G, 1999, NEW ENGL J MED, V340, P1321, DOI 10.1056/NEJM199904293401704; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Rosei EA, 1997, J HYPERTENS, V15, P1337, DOI 10.1097/00004872-199715110-00019; Sakata K, 1999, AM HEART J, V137, P1094, DOI 10.1016/S0002-8703(99)70368-6; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Yusuf S, 2000, NEW ENGL J MED, V342, P145	17	265	275	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1949	1954		10.1016/S0140-6736(00)03306-7	http://dx.doi.org/10.1016/S0140-6736(00)03306-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130522				2022-12-28	WOS:000165867600008
J	Shaulian, E; Schreiber, M; Piu, F; Beeche, M; Wagner, EF; Karin, M				Shaulian, E; Schreiber, M; Piu, F; Beeche, M; Wagner, EF; Karin, M			The mammalian UV response: c-jun induction is required for exit from p53-imposed growth arrest	CELL			English	Article							CELL-CYCLE PROGRESSION; HUMAN FIBROBLASTS; PROTEIN-KINASE; G(1) ARREST; DNA-DAMAGE; IONIZING-RADIATION; EMBRYO FIBROBLASTS; ACTIVATION DOMAIN; ULTRAVIOLET-LIGHT; GENOTOXIC STRESS	The mammalian UV response results in rapid and dramatic induction of c-jun. Induction of a protooncogene, normally involved in mitogenic responses, by a genotoxic agent that causes growth arrest seems paradoxical. We now provide an explanation for the role of c-Jun in the UV response of mouse fibroblasts. c-Jun is necessary for cell-cycle reentry of UV-irradiated cells, but does not participate in the response to ionizing radiation. Cells lacking c-Jun undergo prolonged cell-cycle arrest, but resist apoptosis, whereas cells that express c-Jun constitutively do not arrest and undergo apoptosis. This function of c-Jun is exerted through negative regulation of p53 association with the p21 promoter. Cells lacking c-Jun exhibit prolonged p21 induction, whereas constitutive c-Jun inhibits UV-mediated p21 induction.	Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Res Inst Mol Biol, A-1030 Vienna, Austria; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Salk Institute	Karin, M (corresponding author), Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Martin, Schreiber/F-2175-2013	Martin, Schreiber/0000-0003-1102-7789; Wagner, Erwin F/0000-0001-7872-0196; Shaulian, Eitan/0000-0001-6242-6849	NCI NIH HHS [CA76188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ANGEL P, 1995, PROG GENE EXPRESS, V1, P62; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUSCHER M, 1988, ONCOGENE, V3, P301; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Herrlich P, 1997, BIOL CHEM, V378, P1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko JL, 1996, GENE DEV, V10, P1054; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Loignon M, 1997, CANCER RES, V57, P3390; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	64	250	253	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					897	907		10.1016/S0092-8674(00)00193-8	http://dx.doi.org/10.1016/S0092-8674(00)00193-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136975	Bronze			2022-12-28	WOS:000165801300009
J	Gasperini, D; Blichert-Toft, J; Bosch, D; Del Moro, A; Macera, P; Telouk, P; Albarede, F				Gasperini, D; Blichert-Toft, J; Bosch, D; Del Moro, A; Macera, P; Telouk, P; Albarede, F			Evidence from Sardinian basalt geochemistry for recycling of plume heads into the Earth's mantle	NATURE			English	Article							OCEANIC BASALTS; MAUNA-LOA; EVOLUTION; ELEMENT; PB; LAVAS; ND	Up to 10 per cent of the ocean floor consists of plateaux(1)-regions of unusually thick oceanic crust thought to be formed by the heads of mantle plumes. Given the ubiquitous presence of recycled oceanic crust in the mantle source of hotspot basalts, it follows that plateau material should also be an important mantle constituent. Here we show that the geochemistry of the Pleistocene basalts from Logudoro, Sardinia, is compatible with the remelting of ancient ocean plateau material that has been recycled into the mantle. The Sr, Nd and Hf isotope compositions of these basalts do not show the signature of pelagic sediments. The basalts' low CaO/Al2O3 and Ce/Pb ratios, their unradiogenic Pb-206 and Pb-208, and their Sr, Ba, Eu and Pb excesses indicate that their mantle source contains ancient gabbros formed initially by plagioclase accumulation, typical of plateau material. Also, the high Th/U ratios of the mantle source resemble those of plume magmas. Geochemically, the Logudoro basalts resemble those from Pitcairn Island, which contain the controversial EM-1 component that has been interpreted as arising from a mantle source sprinkled with remains of pelagic sediments(2,3). We argue, instead, that the EM-1 source from these two localities is essentially free of sedimentary material, the geochemical characteristics of these lavas being better explained by the presence of recycled oceanic plateaux. The storage of plume heads in the deep mantle through time offers a convenient explanation for the persistence of chemical and mineralogical layering in the mantle.	Ecole Normale Super, F-69364 Lyon 07, France; Univ Pisa, Dipartimento Sci Terra, I-56126 Pisa, Italy; Univ Montpellier 2, F-34095 Montpellier 05, France; CNR, Ist Geocronol & Geochim Isotop, I-56010 Pisa, Italy	Ecole Normale Superieure de Lyon (ENS de LYON); University of Pisa; Universite de Montpellier; Consiglio Nazionale delle Ricerche (CNR)	Blichert-Toft, J (corresponding author), Ecole Normale Super, F-69364 Lyon 07, France.	jblicher@ens-lyon.fr	Bosch, Delphine C/D-8233-2015; TELOUK, Philippe/AAY-6708-2021; Blichert-Toft, Janne/C-8280-2012; Bosch, Delphine/AAB-3805-2020; Bosch, Delphine/F-1302-2010; Albarede, Francis/A-8871-2011	Bosch, Delphine C/0000-0002-7903-710X; Blichert-Toft, Janne/0000-0002-4932-4079; Albarede, Francis/0000-0003-1994-1428				ABOUCHAMI W, 1990, J GEOPHYS RES-SOLID, V95, P17605, DOI 10.1029/JB095iB11p17605; Albarede F, 1998, GEOPHYS RES LETT, V25, P3895, DOI 10.1029/1998GL900008; ALLEGRE CJ, 1982, NATURE, V299, P21, DOI 10.1038/299021a0; ARNDT NT, 1999, P BUSHV WORKSH LOSK, V6; BECCALUVA L, 1990, P OCEAN DRILLING PRO, V0107; BENAVRAHAM Z, 1981, SCIENCE, V213, P47, DOI 10.1126/science.213.4503.47; Blichert-Toft J, 1999, SCIENCE, V285, P879, DOI 10.1126/science.285.5429.879; CHAUVEL C, 1992, EARTH PLANET SC LETT, V110, P99, DOI 10.1016/0012-821X(92)90042-T; Hanan BB, 1996, SCIENCE, V272, P991, DOI 10.1126/science.272.5264.991; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; HOFMANN AW, 1986, EARTH PLANET SC LETT, V79, P33, DOI 10.1016/0012-821X(86)90038-5; Hofmann AW, 1996, J GEOPHYS RES-SOL EA, V101, P11831, DOI 10.1029/95JB03701; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KLEIN EM, 1987, J GEOPHYS RES-SOLID, V92, P8089, DOI 10.1029/JB092iB08p08089; Lassiter JC, 1998, EARTH PLANET SC LETT, V164, P483, DOI 10.1016/S0012-821X(98)00240-4; MCDONOUGH WF, 1999, ENCY GEOCHEMISTRY, P151; Morra V, 1997, LITHOS, V40, P69, DOI 10.1016/S0024-4937(96)00028-X; NEAL CR, 1997, ONTONGJAVA PLATEAU; NEWSOM HE, 1986, EARTH PLANET SC LETT, V80, P299, DOI 10.1016/0012-821X(86)90112-3; RICHARDSON SH, 1982, EARTH PLANET SC LETT, V59, P327, DOI 10.1016/0012-821X(82)90135-2; Ringwood A.E, 1975, COMPOSITION PETROLOG; Sims KWW, 1997, GEOCHIM COSMOCHIM AC, V61, P765, DOI 10.1016/S0016-7037(96)00372-9; Sobolev AV, 2000, NATURE, V404, P986, DOI 10.1038/35010098; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; Vervoort JD, 1999, EARTH PLANET SC LETT, V168, P79, DOI 10.1016/S0012-821X(99)00047-3; VOGT PR, 1976, SPEC PAP GEOL SOC AM, V172, P1, DOI DOI 10.1130/SPE172-P1; WEAVER BL, 1991, EARTH PLANET SC LETT, V104, P381, DOI 10.1016/0012-821X(91)90217-6; WHITE WM, 1993, EARTH PLANET SC LETT, V115, P211, DOI 10.1016/0012-821X(93)90223-V; WOODHEAD JD, 1989, EARTH PLANET SC LETT, V94, P257, DOI 10.1016/0012-821X(89)90145-3	30	81	85	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					701	704		10.1038/35047049	http://dx.doi.org/10.1038/35047049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130068	Green Published			2022-12-28	WOS:000165815200044
J	Grimson, MJ; Coates, JC; Reynolds, JP; Shipman, M; Blanton, RL; Harwood, AJ				Grimson, MJ; Coates, JC; Reynolds, JP; Shipman, M; Blanton, RL; Harwood, AJ			Adherens junctions and beta-catenin-mediated cell signalling in a non-metazoan organism	NATURE			English	Article							TRANSCRIPTION FACTOR LEF-1; DICTYOSTELIUM-DISCOIDEUM; CYTOPLASMIC DOMAIN; ADHESION MOLECULE; C-ELEGANS; PROTEIN; VACUOLE; BINDING; SPECIFICATION; INHERITANCE	Mechanical forces between cells have a principal role in the organization of animal tissues. Adherens junctions are an important component of these tissues, connecting cells through their actin cytoskeleton and allowing the assembly of tensile structures(1-4). At least one adherens junction protein, beta -catenin, also acts as a signalling molecule, directly regulating gene expression(5-7). To date, adherens junctions have only been detected in metazoa, and therefore we looked for them outside the animal kingdom to examine their evolutionary origins. The non-metazoan Dictyostelium discoideum forms a multicellular, differentiated structure(8). Here we describe the discovery of actin-associated intercellular junctions in Dictyostelium. We have isolated a gene encoding a beta -catenin homologue, aardvark, which is a component of the junctional complex, and, independently, is required for cell signalling. Our discovery of adherens junctions outside the animal kingdom shows that the dual role of beta -catenin in cell-cell adhesion and cell sig-nailing evolved before the origins of metazoa.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA	University of London; University College London; Texas Tech University System; Texas Tech University	Harwood, AJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	a.harwood@ucl.ac.uk	Coates, Juliet C/A-3608-2013; Harwood, Adrian/A-4350-2010	Coates, Juliet C/0000-0002-2381-0298; Harwood, Adrian/0000-0003-3124-5169				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Fleckenstein D, 1998, J CELL SCI, V111, P3109; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morio T, 1998, DNA Res, V5, P335, DOI 10.1093/dnares/5.6.335; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Pan XZ, 1998, J CELL SCI, V111, P2137; Pang KM, 1998, CURR BIOL, V8, P405, DOI 10.1016/S0960-9822(98)70159-9; Plyte SE, 1999, DEVELOPMENT, V126, P325; Raper KB, 1935, J AGRIC RES, V50, P0135; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Schlesinger A, 1999, GENE DEV, V13, P2028, DOI 10.1101/gad.13.15.2028; Sokol SY, 1999, CURR OPIN GENET DEV, V9, P405, DOI 10.1016/S0959-437X(99)80061-6; Stevenson BR, 1989, CURR OPIN CELL BIOL, V1, P884, DOI 10.1016/0955-0674(89)90054-9; STRAFSTROM J, 1988, PLANTA, V174, P321; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X	27	108	113	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					727	731		10.1038/35047099	http://dx.doi.org/10.1038/35047099			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130075				2022-12-28	WOS:000165815200051
J	Hemmi, H; Takeuchi, O; Kawai, T; Kaisho, T; Sato, S; Sanjo, H; Matsumoto, M; Hoshino, K; Wagner, H; Takeda, K; Akira, S				Hemmi, H; Takeuchi, O; Kawai, T; Kaisho, T; Sato, S; Sanjo, H; Matsumoto, M; Hoshino, K; Wagner, H; Takeda, K; Akira, S			A Toll-like receptor recognizes bacterial DNA	NATURE			English	Article							CELL WALL COMPONENTS; DENDRITIC CELLS; CUTTING EDGE; CPG-DNA; DROSOPHILA TOLL; ACTIVATION; MATURATION; MOTIFS; MICE; TLR4	DNA from bacteria has stimulatory effects on mammalian immune cells(1-3) which depend on the presence of unmethylated CpG dinucleotides in the bacterial DNA. In contrast, mammalian DNA has a low frequency of CpG dinucleotides, and these are mostly methylated; therefore, mammalian DNA does not have immune-stimulatory activity. CpG DNA induces a strong T-helper-1-like inflammatory response(4-7). Accumulating evidence has revealed the therapeutic potential of CpG DNA as adjuvants for vaccination strategies for cancer, allergy and infectious diseasess(8-10). Despite its promising clinical use, the molecular mechanism by which CpG DNA activates immune cells remains unclear. Here we show that cellular response to CpG DNA is mediated by a Toll-like receptor, TLR9. TLR9-deficient (TLR9(-/-)) mice did not show any response to CpG DNA, including proliferation of splenocytes, inflammatory Cytokine production from macrophages and maturation of dendritic cells. TLR9(-/-) mice showed resistance to the lethal effect of CPG DNA without any elevation of serum pro-inflammatory cytokine levels. The in vivo CpG-DNA-mediated T-helper type-1 response was also abolished in TLR9(-/-) mice. Thus, vertebrate immune systems appear to have evolved a specific Toll-like receptor that distinguishes bacterial DNA from self-DNA.	Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka, Japan; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	Osaka University; Japan Science & Technology Agency (JST); Technical University of Munich	Akira, S (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Host Def, 3-1 Yamada Oka, Osaka 5650871, Japan.		Akira, Shizuo/C-3134-2009; Takeuchi, Osamu/AAG-9359-2019; Hoshino, Katsuaki/L-9162-2014; Takeuchi, Osamu/D-6007-2011; Hoshino, Katsuaki/AAE-2830-2022; Takeda, Kiyoshi/C-9331-2009; Kaisho, Tsuneyasu/B-4130-2012	Takeuchi, Osamu/0000-0002-1260-6232; Hoshino, Katsuaki/0000-0003-0493-4815; Hoshino, Katsuaki/0000-0003-0493-4815; Kawai, Taro/0000-0001-7510-4662; Sato, Shintaro/0000-0001-5156-3354				Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1999, EMBO J, V18, P6973, DOI 10.1093/emboj/18.24.6973; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jakob T, 1998, J IMMUNOL, V161, P3042; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 1996, TRENDS MICROBIOL, V4, P73, DOI 10.1016/0966-842X(96)81515-0; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; Liang H, 2000, J IMMUNOL, V165, P1438, DOI 10.4049/jimmunol.165.3.1438; Lipford GB, 2000, J IMMUNOL, V165, P1228, DOI 10.4049/jimmunol.165.3.1228; Lipford GB, 1998, TRENDS MICROBIOL, V6, P496, DOI 10.1016/S0966-842X(98)01408-5; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Yamamoto S, 2000, SPRINGER SEMIN IMMUN, V22, P11, DOI 10.1007/s002810000019; Yi AK, 1998, J IMMUNOL, V161, P4493; Yoshimura A, 1999, J IMMUNOL, V163, P1	31	4996	5378	17	531	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					740	745		10.1038/35047123	http://dx.doi.org/10.1038/35047123			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130078				2022-12-28	WOS:000165815200054
J	Berset, T; Hoier, EF; Battu, G; Canevascini, S; Hajnal, A				Berset, T; Hoier, EF; Battu, G; Canevascini, S; Hajnal, A			Notch inhibition of RAS signaling through MAP kinase phosphatase LIP-1 during C-elegans vulval development	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; CELL FATE; INDUCTION; PROTEIN; EGFR; SPECIFICITY; EXPRESSION; PATHWAYS; ENCODES; DEFINES	During Caenorhabditis elegans vulval development, a signal from the anchor cell stimulates the RTK/RAS/MAPK (receptor tyrosine kinase/RAS/mitogen-activated protein kinase) signaling pathway in the closest vulval precursor cell P6.p to induce the primary fate. A Lateral signal from P6.p then activates the Notch signaling pathway in the neighboring tells P5.p and P7.p to prevent them from adopting the primary fate and to specify the secondary fate. The MAP kinase phosphatase LIP-1 mediates this lateral inhibition of the primary fate. LIN-12/NOTCH up-regulates lip-1 transcription in P5.p and P7.p where LIP-1 inactivates the MAP kinase to inhibit primary fate specification. LIP-1 thus Links the two signaling pathways to generate a pattern.	Univ Zurich, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland	University of Zurich	Hajnal, A (corresponding author), Univ Zurich, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.			Hajnal, Alex/0000-0002-4098-3721				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Ambros V, 1999, DEVELOPMENT, V126, P1947; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Burdine RD, 1998, DEVELOPMENT, V125, P1083; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Christensen S, 1996, DEVELOPMENT, V122, P1373; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FERGUSON EL, 1989, GENETICS, V123, P109; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; Ikeya T, 1999, DEVELOPMENT, V126, P4455; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; Lackner MR, 1998, GENETICS, V150, P103; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; Price JV, 1997, GENETICS, V147, P1139; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; Tan PB, 1998, CELL, V93, P569, DOI 10.1016/S0092-8674(00)81186-1; TUCK S, 1995, GENE DEV, V9, P341, DOI 10.1101/gad.9.3.341; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; zur Lage P, 1999, DEVELOPMENT, V126, P3149	25	206	227	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	2001	291	5506					1055	1058		10.1126/science.1055642	http://dx.doi.org/10.1126/science.1055642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161219				2022-12-28	WOS:000166860100048
J	Gu, LQ; Cheley, S; Bayley, H				Gu, LQ; Cheley, S; Bayley, H			Capture of a single molecule in a nanocavity	SCIENCE			English	Article							STAPHYLOCOCCAL ALPHA-HEMOLYSIN; POLYMER-CHAIN; PROTEIN; PORE; ANALYTES	We describe a heptameric protein pore that has been engineered to accommodate two different cyclodextrin adapters simultaneously within the Lumen of a transmembrane beta barrel. The volume between the adapters is a cavity of similar to 4400 cubic angstroms. Analysis of single-channel recordings reveals that individual charged organic molecules can be pulled into the cavity by an electrical potential. Once trapped, an organic molecule shuttles back and forth between the adapters for hundreds of milliseconds. Such self-assembling nanostructures are of interest for the fabrication of multianalyte sensors and could provide a means to control chemical reactions.	Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Bayley, H (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA.	bayley@tamu.edu		Bayley, Hagan/0000-0003-2499-6116				Bayley H, 2000, ADV MATER, V12, P139, DOI 10.1002/(SICI)1521-4095(200001)12:2<139::AID-ADMA139>3.3.CO;2-H; Braha O, 2000, NAT BIOTECHNOL, V18, P1005, DOI 10.1038/79275; Gu LQ, 2000, BIOPHYS J, V79, P1967, DOI 10.1016/S0006-3495(00)76445-9; Gu LQ, 2000, P NATL ACAD SCI USA, V97, P3959, DOI 10.1073/pnas.97.8.3959; Gu LQ, 1999, NATURE, V398, P686, DOI 10.1038/19491; Hille B., 1991, IONIC CHANNELS EXCIT; Howorka S, 2000, J AM CHEM SOC, V122, P2411, DOI 10.1021/ja993221h; Moczydlowski E., 1986, ION CHANNEL RECONSTI, P75; Movileanu L, 2000, NAT BIOTECHNOL, V18, P1091, DOI 10.1038/80295; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Olenyuk B, 1999, NATURE, V398, P796, DOI 10.1038/19740; Rebek J, 2000, CHEM COMMUN, P637, DOI 10.1039/a910339m; Rudkevich DM, 1999, EUR J ORG CHEM, V1999, P1991; Sanchez-Quesada J, 2000, J AM CHEM SOC, V122, P11757, DOI 10.1021/ja002436k; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Soong RK, 2000, SCIENCE, V290, P1555, DOI 10.1126/science.290.5496.1555; Takeda N, 1999, NATURE, V398, P794, DOI 10.1038/19734; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	18	131	160	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2001	291	5504					636	640		10.1126/science.291.5504.636	http://dx.doi.org/10.1126/science.291.5504.636			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158673				2022-12-28	WOS:000166616000039
J	Weiss, H; Bradley, RS				Weiss, H; Bradley, RS			Archaeology - What drives societal collapse?	SCIENCE			English	Editorial Material									Yale Univ, Dept Anthropol, New Haven, CT 06520 USA; Yale Univ, Dept Near Eastern Languages & Civilizat, New Haven, CT 06520 USA; Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA	Yale University; Yale University; University of Massachusetts System; University of Massachusetts Amherst	Weiss, H (corresponding author), Yale Univ, Dept Anthropol, New Haven, CT 06520 USA.		Bradley, Raymond S/P-9358-2015	Bradley, Raymond S/0000-0002-4032-9519				Adams RMcC, 1981, HEARTLAND CITIES; Bar-Matthews M, 1999, EARTH PLANET SC LETT, V166, P85, DOI 10.1016/S0012-821X(98)00275-1; Bar-Yosef O, 2000, RADIOCARBON, V42, P23, DOI 10.1017/S0033822200053029; Belfer-Cohen, 1997, PALEORIENT, V23, P71, DOI 10.3406/paleo.1997.4653; BENNER M, 2001, INTERHEMISPHERIC CLI, P87; Cullen HM, 2000, GEOLOGY, V28, P379, DOI 10.1130/0091-7613(2000)28<379:CCATCO>2.0.CO;2; DEAN JS, 1993, THEMES SW PREHISTORY, P53; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; Kolata AL, 2000, ANTIQUITY, V74, P424, DOI 10.1017/S0003598X00059512; Kozlowski SK., 1999, BAR INT SERIES, V760; Lemcke G, 1997, NATO ASI SER SER I, V49, P653; SHIMADA I, 1991, WORLD ARCHAEOL, V22, P247, DOI 10.1080/00438243.1991.9980145; Weiss H., 2000, ENV DISASTER ARCHAEO, V7, P75	13	371	420	6	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					609	610		10.1126/science.1058775	http://dx.doi.org/10.1126/science.1058775			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158667				2022-12-28	WOS:000166616000033
J	Clemons, M; Goss, P				Clemons, M; Goss, P			Mechanisms of disease - Estrogen and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ORAL-CONTRACEPTIVE USE; MAMMOGRAPHIC PARENCHYMAL PATTERNS; SERUM HORMONE CONCENTRATIONS; BONE-MINERAL DENSITY; ENDOGENOUS ESTROGEN; ENDOMETRIAL CANCER; FAMILY-HISTORY; POSTMENOPAUSAL WOMEN; RECEPTOR EXPRESSION; CIGARETTE-SMOKING		Princess Margaret Hosp, Dept Med Oncol, Univ Hlth Network, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Goss, P (corresponding author), Princess Margaret Hosp, Dept Med Oncol, Univ Hlth Network, 5-303,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	pegoss@interlog.com						Albrektsen G, 1999, STAT MED, V18, P1261, DOI 10.1002/(SICI)1097-0258(19990530)18:10<1261::AID-SIM119>3.0.CO;2-A; Atkinson C, 1999, CANCER EPIDEM BIOMAR, V8, P863; Barnes S, 1998, BAILLIERE CLIN ENDOC, V12, P559, DOI 10.1016/S0950-351X(98)80004-9; BARTOW SA, 1990, CANCER, V66, P1721, DOI 10.1002/1097-0142(19901015)66:8<1721::AID-CNCR2820660812>3.0.CO;2-I; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; Boyd NF, 1999, J NATL CANCER I, V91, P1404, DOI 10.1093/jnci/91.16.1404; BRISSON J, 1982, AM J EPIDEMIOL, V115, P438, DOI 10.1093/oxfordjournals.aje.a113321; Brzezinski A, 1999, EUR J OBSTET GYN R B, V85, P47, DOI 10.1016/S0301-2115(98)00281-4; BUCHANAN JR, 1988, J BONE MINER RES, V3, P673, DOI 10.1002/jbmr.5650030613; Cade J, 1998, J EPIDEMIOL COMMUN H, V52, P105, DOI 10.1136/jech.52.2.105; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Calle EE, 1996, CONTRACEPTION, V54, pS1; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; CAULEY JA, 1986, AM J EPIDEMIOL, V124, P752, DOI 10.1093/oxfordjournals.aje.a114451; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; Col NF, 1999, ARCH INTERN MED, V159, P1458, DOI 10.1001/archinte.159.13.1458; Collaborative Group on Hormonal Factors in Breast Cancer, 1997, LANCET, V350, P1484; Cummings S, 1998, P AN M AM SOC CLIN, V17, p2a; Dickson RB, 2000, DIS BREAST, P15; Enger SM, 1998, CANCER EPIDEM BIOMAR, V7, P365; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Feigelson HS, 1997, CANCER RES, V57, P1063; Ferguson LR, 1999, EUR J CANCER PREV, V8, P17, DOI 10.1097/00008469-199902000-00003; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gammon MD, 1998, CANCER CAUSE CONTROL, V9, P583, DOI 10.1023/A:1008868922799; Greendale GA, 1999, ANN INTERN MED, V130, P262, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00003; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Haiman CA, 1999, CANCER RES, V59, P1015; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hankinson SE, 1997, CANCER CAUSE CONTROL, V8, P65, DOI 10.1023/A:1018435205695; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; Helzlsouer KJ, 1998, CANCER EPIDEM BIOMAR, V7, P945; HENDERSON BE, 1982, CANCER RES, V42, P3232; HENDERSON BE, 1985, CANCER, V56, P1206, DOI 10.1002/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9; Holmes MD, 1999, JAMA-J AM MED ASSOC, V281, P914, DOI 10.1001/jama.281.10.914; Huang CS, 1999, CANCER RES, V59, P4870; Hulka BS, 1997, PROG CLIN BIOL RES, V396, P17; Jin TR, 2000, BREAST CANCER RES TR, V62, P151, DOI 10.1023/A:1006481228794; Kabat GC, 1997, CANCER EPIDEM BIOMAR, V6, P505; KAUFMAN Z, 1991, CLIN RADIOL, V43, P385, DOI 10.1016/S0009-9260(05)80565-3; Key TJA, 1996, BRIT J CANCER, V74, P1313, DOI 10.1038/bjc.1996.536; KEY TJA, 1990, BRIT J CANCER, V62, P631, DOI 10.1038/bjc.1990.344; KHAN SA, 1994, CANCER RES, V54, P993; Knight JA, 1999, CANCER EPIDEM BIOMAR, V8, P123; Lambe M, 1996, BREAST CANCER RES TR, V38, P305, DOI 10.1007/BF01806150; Lavigne JA, 1997, CANCER RES, V57, P5493; Lawson JS, 1999, LANCET, V354, P1787, DOI 10.1016/S0140-6736(99)04936-3; LEON DA, 1995, CANCER CAUSE CONTROL, V6, P283, DOI 10.1007/BF00051403; Leygue E, 1998, CANCER RES, V58, P3197; Lucas FL, 1998, AM J EPIDEMIOL, V148, P22, DOI 10.1093/oxfordjournals.aje.a009554; LUPULESCU A, 1995, CANCER INVEST, V13, P287, DOI 10.3109/07357909509094464; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Manjer J, 1999, MED HYPOTHESES, V52, P561, DOI 10.1054/mehy.1997.0694; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; Meilahn EN, 1998, BRIT J CANCER, V78, P1250, DOI 10.1038/bjc.1998.663; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Newcomb PA, 1996, CANCER CAUSE CONTROL, V7, P525, DOI 10.1007/BF00051885; OLSSON H, 1992, AM J EPIDEMIOL, V136, P422, DOI 10.1093/oxfordjournals.aje.a116515; Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659; PAFFENBARGER RS, 1980, AM J EPIDEMIOL, V112, P258, DOI 10.1093/oxfordjournals.aje.a112992; Pankow JS, 1997, J NATL CANCER I, V89, P549, DOI 10.1093/jnci/89.8.549; PARAZZINI F, 1995, GYNECOL ONCOL, V56, P195, DOI 10.1006/gyno.1995.1031; Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110; PERSSON I, 1994, CANCER CAUSE CONTROL, V5, P523, DOI 10.1007/BF01831380; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; PIKE MC, 1983, LANCET, V2, P926; Potischman N, 1999, INT J CANCER, V82, P315, DOI 10.1002/(SICI)1097-0215(19990730)82:3&lt;315::AID-IJC1&gt;3.0.CO;2-N; Ramon JM, 1996, EUR J EPIDEMIOL, V12, P449, DOI 10.1007/BF00143995; SAFTLAS AF, 1989, AM J EPIDEMIOL, V129, P518, DOI 10.1093/oxfordjournals.aje.a115163; SAFTLAS AF, 1991, CANCER, V67, P2833, DOI 10.1002/1097-0142(19910601)67:11<2833::AID-CNCR2820671121>3.0.CO;2-U; SANTEN RJ, 1986, ANN NY ACAD SCI, V464, P126, DOI 10.1111/j.1749-6632.1986.tb16000.x; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Shapiro S, 2000, AM J EPIDEMIOL, V151, P396, DOI 10.1093/oxfordjournals.aje.a010219; Shapiro S, 2000, AM J EPIDEMIOL, V151, P1134; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Shoker BS, 1999, J PATHOL, V188, P237; Siegelmann-Danieli N, 1999, BRIT J CANCER, V79, P456, DOI 10.1038/sj.bjc.6690071; TAIOLI E, 1995, CANCER RES, V55, P3757; Thomas HV, 1997, CANCER CAUSE CONTROL, V8, P922, DOI 10.1023/A:1018476631561; Thomas HV, 1997, BRIT J CANCER, V75, P1075, DOI 10.1038/bjc.1997.183; Thomas HV, 1997, BRIT J CANCER, V76, P401, DOI 10.1038/bjc.1997.398; Thomas HV, 1997, J NATL CANCER I, V89, P396, DOI 10.1093/jnci/89.5.396; Thompson LU, 1996, CARCINOGENESIS, V17, P1373, DOI 10.1093/carcin/17.6.1373; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Tryggvadottir L, 1997, BRIT J CANCER, V75, P139, DOI 10.1038/bjc.1997.23; Ursin G, 1998, BREAST CANCER RES TR, V50, P175, DOI 10.1023/A:1006037823178; Ursin G, 1997, CANCER RES, V57, P3678; Ursin G, 1998, CANCER EPIDEM BIOMAR, V7, P43; Ursin G, 1999, J NATL CANCER I, V91, P1067, DOI 10.1093/jnci/91.12.1067; Ursin G, 1996, J NATL CANCER I, V88, P128, DOI 10.1093/jnci/88.2.128-a; VERMEULEN A, 1986, J STEROID BIOCHEM, V25, P799, DOI 10.1016/0022-4731(86)90311-0; Weston A, 1998, CANCER EPIDEM BIOMAR, V7, P941; WOLFE JN, 1976, AM J ROENTGENOL, V126, P1130, DOI 10.2214/ajr.126.6.1130; Wu AH, 1998, AM J CLIN NUTR, V68, p1437S, DOI 10.1093/ajcn/68.6.1437S; Yager JD, 1996, ANNU REV PHARMACOL, V36, P203, DOI 10.1146/annurev.pa.36.040196.001223; Yue W, 1998, CANCER RES, V58, P927; Zhang NLW, 1996, ARTIF INTELL, V88, P359, DOI 10.1016/S0004-3702(96)00035-5; Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P547, DOI 10.1093/jnci/91.6.547; Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8	103	746	781	0	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2001	344	4					276	285		10.1056/NEJM200101253440407	http://dx.doi.org/10.1056/NEJM200101253440407			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	394WA	11172156				2022-12-28	WOS:000166545200007
J	Meagher, DJ				Meagher, DJ			Regular review - Delirium: optimising management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ELDERLY PATIENTS; HALOPERIDOL; DIAGNOSIS		Crichton Royal Hosp, Dept Clin Res, Dumfries DG1 4TG, Scotland		Meagher, DJ (corresponding author), Crichton Royal Hosp, Dept Clin Res, Dumfries DG1 4TG, Scotland.	davidjmeagher@ireland.com						Adams F, 1986, Psychosomatics, V27, P33; American Psychiatric Association, 1999, PRACT GUID TREATM PA; Beuzen JN, 1999, J PSYCHOPHARMACOL, V13, P152, DOI 10.1177/026988119901300207; Bostwick JM, 1998, PSYCHOSOMATICS, V39, P112, DOI 10.1016/S0033-3182(98)71357-X; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Cole MG, 1998, J GERIATR PSYCH NEUR, V11, P126, DOI 10.1177/089198879801100303; Culp K, 1997, J Neurosci Nurs, V29, P86; EASTON C, 1988, HEART LUNG, V17, P229; FARRELL KR, 1995, ARCH INTERN MED, V155, P2459, DOI 10.1001/archinte.155.22.2459; FISH DN, 1991, CLIN PHARMACY, V10, P456; George J, 1997, AGE AGEING, V26, P423, DOI 10.1093/ageing/26.6.423; Hassan E, 1998, PHARMACOTHERAPY, V18, P113; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; Kaneko T, 1997, SURG TODAY, V27, P107, DOI 10.1007/BF02385897; Kerr IB, 1997, J PSYCHOPHARMACOL, V11, P271, DOI 10.1177/026988119701100311; Khaw KT, 1999, BRIT MED J, V319, P1350, DOI 10.1136/bmj.319.7221.1350; LEVKOFF SE, 1994, AM J GERIAT PSYCHIAT, V2, P230, DOI 10.1097/00019442-199400230-00007; MARK BZ, 1993, PSYCHOSOMATICS, V34, P446, DOI 10.1016/S0033-3182(93)71850-2; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; Meagher DJ, 1996, BRIT J PSYCHIAT, V168, P512, DOI 10.1192/bjp.168.4.512; MENZA MA, 1988, HEART LUNG, V17, P238; MENZA MA, 1987, J CLIN PSYCHIAT, V48, P278; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Nakamura J, 1997, INT CLIN PSYCHOPHARM, V12, P147, DOI 10.1097/00004850-199705000-00005; O'Keeffe ST, 1999, DEMENT GERIATR COGN, V10, P380, DOI 10.1159/000017174; Okamoto Y, 1999, J CLIN PSYCHOPHARM, V19, P280, DOI 10.1097/00004714-199906000-00018; PLATT MM, 1991, J NEUROPSYCHIATRY CL, V6, P66; ROCKWOOD K, 1994, J AM GERIATR SOC, V42, P252, DOI 10.1111/j.1532-5415.1994.tb01747.x; Rudberg MA, 1997, AGE AGEING, V26, P169, DOI 10.1093/ageing/26.3.169; SANDERS KM, 1993, TEX HEART I J, V20, P180; Schofield I, 1997, J ADV NURS, V25, P942, DOI 10.1046/j.1365-2648.1997.1997025942.x; Simon L, 1997, GERIATR NURS, V18, P150, DOI 10.1016/S0197-4572(97)90040-9; Sipahimalani A, 1998, PSYCHOSOMATICS, V39, P422, DOI 10.1016/S0033-3182(98)71301-5; Sipahimalani A, 1997, INT J GERIATR PSYCH, V1, P24; Trzepacz PT, 1996, PSYCHIAT CLIN N AM, V19, P429, DOI 10.1016/S0193-953X(05)70299-9; Trzepacz PT, 1998, J NEUROPSYCH CLIN N, V10, P199, DOI 10.1176/jnp.10.2.199; TUNE L, 1992, AM J PSYCHIAT, V149, P1393	39	171	181	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2001	322	7279					144	149		10.1136/bmj.322.7279.144	http://dx.doi.org/10.1136/bmj.322.7279.144			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	396AZ	11159573	Green Published			2022-12-28	WOS:000166615300027
J	Muravyova, E; Golovnin, A; Gracheva, E; Parshikov, A; Belenkaya, T; Pirrotta, V; Georgiev, P				Muravyova, E; Golovnin, A; Gracheva, E; Parshikov, A; Belenkaya, T; Pirrotta, V; Georgiev, P			Loss of insulator activity by paired Su(Hw) chromatin insulators	SCIENCE			English	Article							ENHANCER-PROMOTER INTERACTIONS; YELLOW LOCUS; DROSOPHILA; PROTEIN; TRANSCRIPTION; EXPRESSION; ELEMENT; SPECIFICATION; REPRESSION; SUPPRESSOR	Chromatin insulators are regulatory elements that block the action of transcriptional enhancers when interposed between enhancer and promoter. The Drosophila Suppressor of Hairy wing [Su(Hw)] protein binds the Su(Hw) insulator and prevents enhancer-promoter interaction by a mechanism that is not understood. We show that when two copies of the Su(Hw) insulator element, instead of a single one, are inserted between enhancer and promoter, insulator activity is neutralized and the enhancer-promoter interaction may instead be facilitated. This paradoxical phenomenon could be explained by interactions between protein complexes bound at the insulators.	Univ Geneva, Dept Zool, CH-1211 Geneva, Switzerland; Russian Acad Sci, Inst Gene Biol, Biomed Ctr Oslo, Moscow 117334, Russia; Russian Acad Sci, Inst Gene Biol, Dept Control Genet Proc, Moscow 117334, Russia	University of Geneva; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Pirrotta, V (corresponding author), Univ Geneva, Dept Zool, CH-1211 Geneva, Switzerland.	pirrotta@zoo.unige.ch		Georgiev, Pavel/0000-0002-6509-3194				CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cai HN, 2001, SCIENCE, V291, P493, DOI 10.1126/science.291.5503.493; Gause M, 1998, GENETICS, V149, P1393; Georgiev P, 1996, GENETICS, V142, P425; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GEYER PK, 1987, GENE DEV, V1, P996, DOI 10.1101/gad.1.9.996; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; JACK J, 1991, DEVELOPMENT, V113, P735; Mihaly J, 1998, CELL MOL LIFE SCI, V54, P60, DOI 10.1007/s000180050125; QIAN S, 1992, GENETICS, V131, P79; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; Scott KS, 1995, EMBO J, V14, P6258, DOI 10.1002/j.1460-2075.1995.tb00316.x; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195; Zhou JM, 1999, CELL, V99, P567, DOI 10.1016/S0092-8674(00)81546-9	18	162	168	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2001	291	5503					495	498		10.1126/science.291.5503.495	http://dx.doi.org/10.1126/science.291.5503.495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161206				2022-12-28	WOS:000166487500045
J	de Quiros, JCLB; Miro, JM; Pena, JM; Podzamczer, D; Alberdi, JC; Martinez, E; Cosin, J; Claramonte, X; Gonzalez, J; Domingo, P; Casado, JL; Ribera, E				de Quiros, JCLB; Miro, JM; Pena, JM; Podzamczer, D; Alberdi, JC; Martinez, E; Cosin, J; Claramonte, X; Gonzalez, J; Domingo, P; Casado, JL; Ribera, E		Grp Estudio SIDA 04 98	A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 26-29, 1999	SAN FRANCISCO, CA				TRIMETHOPRIM-SULFAMETHOXAZOLE; OPPORTUNISTIC INFECTIONS; AEROSOLIZED PENTAMIDINE; VIRUS; AIDS; CHEMOPROPHYLAXIS; PREVENTION; ZIDOVUDINE; MORTALITY; DAPSONE	Background: Prophylaxis against Pneumocystis carinii pneumonia is indicated in patients with human immunodeficiency virus (HIV) infection who have less than 200 CD4 cells per cubic millimeter and in those with a history of P. carinii pneumonia. However, it is not clear whether prophylaxis can be safely discontinued after CD4 cell counts increase in response to highly active antiretroviral therapy. Methods: We conducted a randomized trial of the discontinuation of primary or secondary prophylaxis against P. carinii pneumonia in HIV-infected patients with a sustained response to antiretroviral therapy, defined by a CD4 cell count of 200 or more per cubic millimeter and a plasma HIV type 1 (HIV-1) RNA level of less than 5000 copies per milliliter for at least three months. Prophylactic treatment was restarted if the CD4 cell count declined to less than 200 per cubic millimeter. Results: The 474 patients receiving primary prophylaxis had a median CD4 cell count at entry of 342 per cubic millimeter, and 38 percent had detectable HIV-1 RNA. After a median follow-up period of 20 months (388 person-years), there had been no episodes of P. carinii pneumonia in the 240 patients who discontinued prophylaxis (95 percent confidence interval, 0 to 0.85 episode per 100 person-years). For the 113 patients receiving secondary prophylaxis, the median CD4 cell count at entry was 355 per cubic millimeter, and 24 percent had detectable HIV-1 RNA. After a median follow-up period of 12 months (65 person-years), there had been no episodes of P. carinii pneumonia in the 60 patients who discontinued prophylaxis (95 percent confidence interval, 0 to 4.57 episodes per 100 person-years). Conclusions: In HIV-infected patients receiving highly active antiretroviral therapy, primary and secondary prophylaxis against P. carinii pneumonia can be safely discontinued after the CD4 cell count has increased to 200 or more per cubic millimeter for more than three months. (N Engl J Med 2001;344:159-67.) Copyright (C) 2001 Massachusetts Medical Society.	Hosp Gen Gregorio Maranon, Div Infect Dis, E-28007 Madrid, Spain; Inst Invest Biomed August Pi I Sunyer, Barcelona, Spain; Hosp Clin Univ, Barcelona, Spain; Ciudad Sanitaria Seguridad Social La Paz, Madrid, Spain; Bellvitge Hosp, Barcelona, Spain; Consejeria Sanidad Comunidad Autonoma Madrid, Madrid, Spain; Hosp Santa Creu & Sant Pau, Barcelona, Spain; Hosp Ramon & Cajal, E-28034 Madrid, Spain; Hosp Univ Vall dHebron, Barcelona, Spain; Hosp Univ Gregorio Maranon, Madrid, Spain	General University Gregorio Maranon Hospital; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Hospital of Santa Creu i Sant Pau; Hospital Universitario Ramon y Cajal; Hospital Universitari Vall d'Hebron; General University Gregorio Maranon Hospital	de Quiros, JCLB (corresponding author), Hosp Gen Gregorio Maranon, Div Infect Dis, Doctor Esquerdo 46, E-28007 Madrid, Spain.	juanclopez@retemail.es	Domingo, Pere/AAP-7571-2021; Montejo, Jose Miguel/E-1755-2012; Domingo, Pere/CAF-3577-2022	Domingo, Pere/0000-0003-1138-5770; Ribera, Esteban/0000-0002-3752-8808; Casado, Jose Luis/0000-0002-7639-8591				[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Atzori C, 2000, J INFECT DIS, V181, P1629, DOI 10.1086/315437; BOZZETTE SA, 1995, AM J MED, V98, P177, DOI 10.1016/S0002-9343(99)80401-X; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; CARCELAIN G, 1999, AIDS REV, V1, P51; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; Forrest DM, 1998, CLIN INFECT DIS, V27, P1379, DOI 10.1086/515030; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Gea-Banacloche JC, 1999, AIDS, V13, pS25; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HUANG L, 1999, MED MANAGEMENT AIDS, P305; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; KAPLAN JE, 1999, 39 INT C ANT AG CHEM, P124; Kirk O, 1999, AIDS, V13, P1647, DOI 10.1097/00002030-199909100-00007; Ledergerber B, 2001, NEW ENGL J MED, V344, P168, DOI 10.1056/NEJM200101183440302; LOPEZ JC, 1999, 6 C RETR OPP INF CHI, P206; MARTIN MA, 1992, ARCH INTERN MED, V152, P523, DOI 10.1001/archinte.152.3.523; Masur H, 1999, NEW ENGL J MED, V340, P1356, DOI 10.1056/NEJM199904293401709; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, SCIENCE, V275, P14; Michelet C, 1998, AIDS, V12, P1815, DOI 10.1097/00002030-199814000-00013; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; MOORE RD, 1999, 5 C RETR OPP INF CHI, P113; Mussini C, 2000, J INFECT DIS, V181, P1635, DOI 10.1086/315471; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PODZAMCZER D, 1995, ANN INTERN MED, V122, P755, DOI 10.7326/0003-4819-122-10-199505150-00004; RAVIGLIONE MC, 1990, LANCET, V336, P180, DOI 10.1016/0140-6736(90)91701-B; Romeu J, 1999, SCAND J INFECT DIS, V31, P37, DOI 10.1080/00365549950161862; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SELIK RM, 1987, AIDS, V1, P175; Soriano V, 2000, AIDS, V14, P383, DOI 10.1097/00002030-200003100-00011; Stansell JD, 1997, AM J RESP CRIT CARE, V155, P60, DOI 10.1164/ajrccm.155.1.9001290; [U.S. Public Health Service (USPHS) Infectious Diseases Society of America (IDSA)], 1999, MMWR-MORBID MORTAL W, V48, p[1, 61]; VALDEZ H, 1999, 6 C RETR OPP INF CHI, P130; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; 1989, JAMA, V262, P335	44	109	113	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					159	167		10.1056/NEJM200101183440301	http://dx.doi.org/10.1056/NEJM200101183440301			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	392GF	11172138	Green Published, Green Submitted			2022-12-28	WOS:000166402800001
J	Nachury, MV; Maresca, TJ; Salmon, WG; Waterman-Storer, CM; Heald, R; Weis, K				Nachury, MV; Maresca, TJ; Salmon, WG; Waterman-Storer, CM; Heald, R; Weis, K			Importin beta is a mitotic target of the small GTPase ran in spindle assembly	CELL			English	Article							NUCLEAR-PORE COMPLEX; XENOPUS EGG EXTRACTS; KINESIN-RELATED PROTEIN; MICROTUBULE ASTERS; SELF-ORGANIZATION; BOUND RAN; NUMA; BINDING; CELL; CHROMATIN	The GTPase Ran has recently been shown to stimulate microtubule polymerization in mitotic extracts, but its mode of action is not understood. Here we show that the mitotic role of Ran is largely mediated by the nuclear transport factor importin beta. Importin beta inhibits spindle formation in vitro and in vivo and sequesters an aster promoting activity (APA) that consists of multiple, independent factors. One component of APA is the microtubule-associated protein NuMA. NuMA and other APA components are discharged from importin beta by RanGTP and induce spindle-like structures in the absence of centrosomes, chromatin, or Ran. We propose that RanGTP functions in mitosis as in interphase by locally releasing cargoes from transport factors. In mitosis, this promotes spindle assembly by organizing microtubules in the vicinity of chromosomes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, Berkeley, CA 94720 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA	University of California System; University of California Berkeley; Scripps Research Institute; Scripps Research Institute	Heald, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, Berkeley, CA 94720 USA.	heald@socrates.berkeley.edu; kweis@uclink4.berkeley.edu	Nachury, Maxence/A-8759-2008; Nachury, Maxence/H-3695-2019; Weis, Karsten/F-5719-2011	Nachury, Maxence/0000-0003-4918-1562; Nachury, Maxence/0000-0003-4918-1562; Weis, Karsten/0000-0001-7224-925X; Salmon, Wendy/0000-0002-0036-597X; Waterman, Clare/0000-0001-6142-6775; Heald, Rebecca/0000-0001-6671-6528	NIGMS NIH HHS [GM57839, GM61804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061804, R01GM057839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen SSL, 1999, INT REV CYTOL, V187, P51; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Andersen SSL, 1997, J CELL BIOL, V139, P975, DOI 10.1083/jcb.139.4.975; Azuma Y, 2000, CURR OPIN CELL BIOL, V12, P302, DOI 10.1016/S0955-0674(00)00093-4; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; GuethHallonet C, 1996, EXP CELL RES, V225, P207, DOI 10.1006/excr.1996.0171; Heald R, 2000, CELL, V102, P399, DOI 10.1016/S0092-8674(00)00044-1; Heald R, 2000, TRENDS CELL BIOL, V10, P1, DOI 10.1016/S0962-8924(99)01691-8; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; HUITOREL P, 1988, J CELL BIOL, V106, P151, DOI 10.1083/jcb.106.1.151; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1991, J CELL SCI, P125; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; Koepp DM, 1998, BBA-REV CANCER, V1377, pM39, DOI 10.1016/S0304-419X(97)00036-X; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Saredi A, 1996, J CELL SCI, V109, P619; TANG TK, 1994, J CELL SCI, V107, P1389; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang CM, 1999, J CELL SCI, V112, P2453	59	313	321	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					95	106		10.1016/S0092-8674(01)00194-5	http://dx.doi.org/10.1016/S0092-8674(01)00194-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163243	Bronze			2022-12-28	WOS:000166882300010
J	Serup, P; Madsen, OD; Mandrup-Poulsen, T				Serup, P; Madsen, OD; Mandrup-Poulsen, T			Science, medicine, and the future - Islet and stem cell transplantation for treating diabetes	BRITISH MEDICAL JOURNAL			English	Review							ENDOGENOUS RETROVIRUS; INFECTION		Hagedorn Res Inst, Dept Dev Biol, DK-2820 Gentofte, Denmark; Steno Diabet Ctr, DK-2820 Gentofte, Denmark	Novo Nordisk; Hagedorn Research Institute; Steno Diabetes Center	Serup, P (corresponding author), Hagedorn Res Inst, Dept Dev Biol, Niels Steensenvej 6, DK-2820 Gentofte, Denmark.		Madsen, Ole D./A-7415-2011; Serup, Palle/A-7407-2011	Madsen, Ole D./0000-0002-2753-5203; Serup, Palle/0000-0002-0858-590X; Mandrup-Poulsen, Thomas/0000-0002-3215-9273				Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; Brendel M, 1999, INT ISLET TRANSPLANT, P1; Heneine W, 1998, LANCET, V352, P695, DOI 10.1016/S0140-6736(98)07145-1; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Ramiya VK, 2000, NAT MED, V6, P278; Ricordi C., 1996, DIABETES REV, V4, P356; Serup P, 2000, NAT GENET, V25, P134, DOI 10.1038/75960; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; van der Laan LJW, 2000, NATURE, V407, P90, DOI 10.1038/35024089; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; ZENG YJ, 1993, SURGERY, V113, P98	15	63	86	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					29	32		10.1136/bmj.322.7277.29	http://dx.doi.org/10.1136/bmj.322.7277.29			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141151	Green Published			2022-12-28	WOS:000166341400023
J	Sacks, FM; Svetkey, LP; Vollmer, WM; Appel, LJ; Bray, GA; Harsha, D; Obarzanek, E; Conlin, PR; Miller, ER; Simons-Morton, DG; Karanja, N; Lin, PH				Sacks, FM; Svetkey, LP; Vollmer, WM; Appel, LJ; Bray, GA; Harsha, D; Obarzanek, E; Conlin, PR; Miller, ER; Simons-Morton, DG; Karanja, N; Lin, PH		DASH-Sodium Collaborative Res Grp	Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC HYPERTENSION; CLINICAL-TRIAL; RESTRICTION; POTASSIUM; PATTERNS; CATECHOLAMINES; POPULATION; REDUCTION; CALCIUM; WHITES	Background: The effect of dietary composition on blood pressure is a subject of public health importance. We studied the effect of different levels of dietary sodium, in conjunction with the Dietary Approaches to Stop Hypertension (DASH) diet, which is rich in vegetables, fruits, and low-fat dairy products, in persons with and in those without hypertension. Methods: A total of 412 participants were randomly assigned to eat either a control diet typical of intake in the United States or the DASH diet. Within the assigned diet, participants ate foods with high, intermediate, and low levels of sodium for 30 consecutive days each, in random order. Results: Reducing the sodium intake from the high to the intermediate level reduced the systolic blood pressure by 2.1 mm Hg (P<0.001) during the control diet and by 1.3 mm Hg (P = 0.03) during the DASH diet. Reducing the sodium intake from the intermediate to the low level caused additional reductions of 4.6 mm Hg during the control diet (P<0.001) and 1.7 mm Hg during the DASH diet (P<0.01). The effects of sodium were observed in participants with and in those without hypertension, blacks and those of other races, and women and men. The DASH diet was associated with a significantly lower systolic blood pressure at each sodium level; and the difference was greater with high sodium levels than with low ones. As compared with the control diet with a high sodium level, the DASH diet with a low sodium level led to a mean systolic blood pressure that was 7.1 mm Hg lower in participants without hypertension, and 11.5 mm Hg lower in participants with hypertension. Conclusions: The reduction of sodium intake to levels below the current recommendation of 100 mmol per day and the DASH diet both lower blood pressure substantially, with greater effects in combination than singly. Long-term health benefits will depend on the ability of people to make long-lasting dietary changes and the increased availability of lower-sodium foods. (N Engl J Med 2001;344:3-10.) Copyright (C) 2001 Massachusetts Medical Society.	Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Duke Univ, Sch Med, Sarah W Stedman Ctr Nutr Studies, Durham, NC USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA; Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Pennington Biomed Res Ctr, Baton Rouge, LA USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University; Kaiser Permanente; Johns Hopkins University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sacks, FM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Appel, Larry/GLT-2608-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL057114, U01HL057190, U01HL057173] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01-HL57190, U01-HL57173, U01-HL57114] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Black HR, 1998, ARCH INTERN MED, V158, P573; Black HR, 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CHAPMAN CB, 1950, NEW ENGL J MED, V243, P899, DOI 10.1056/NEJM195012072432301; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; ELLIOTT P, 1988, BRIT MED J, V297, P319; FLACK JM, 1991, HYPERTENSION S1, V17, P115; GILL JR, 1988, HYPERTENSION, V11, P312, DOI 10.1161/01.HYP.11.4.312; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; GRIMM RH, 1990, NEW ENGL J MED, V322, P569, DOI 10.1056/NEJM199003013220901; HATCH FT, 1954, AM J MED, V17, P499, DOI 10.1016/0002-9343(54)90125-4; HOLM S, 1979, SCAND J STAT, V6, P65; Karanja NM, 1999, J AM DIET ASSOC, V99, pS19, DOI 10.1016/S0002-8223(99)00412-5; KAWASAKI T, 1978, AM J MED, V64, P193, DOI 10.1016/0002-9343(78)90045-1; KRISHNA GG, 1989, NEW ENGL J MED, V320, P1177, DOI 10.1056/NEJM198905043201804; KUMANYIKA SK, 1993, HYPERTENSION, V22, P502, DOI 10.1161/01.HYP.22.4.502; LAW MR, 1991, BRIT MED J, V302, P939; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUFT FC, 1979, CIRCULATION, V59, P643, DOI 10.1161/01.CIR.59.4.643; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; MATERSON BJ, 1994, NEW ENGL J MED, V330, P1689, DOI 10.1056/NEJM199406093302316; MATTES RD, 1991, J AM COLL NUTR, V10, P383; MILLER JZ, 1987, J CHRON DIS, V40, P245, DOI 10.1016/0021-9681(87)90160-3; National Heart Lung and Blood Institute, 1998, NIH PUBL, V98-4083; NEATON JD, 1991, ARCH INTERN MED, V151, P1413, DOI 10.1001/archinte.151.7.1413; PARFREY PS, 1981, BRIT MED J, V283, P94, DOI 10.1136/bmj.283.6284.94; RICH GM, 1991, AM J HYPERTENS, V4, pS642, DOI 10.1093/ajh/4.11S.642S; SAITO K, 1989, HYPERTENSION, V13, P219, DOI 10.1161/01.HYP.13.3.219; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Svetkey LP, 1999, ARCH INTERN MED, V159, P285, DOI 10.1001/archinte.159.3.285; Svetkey LP, 1999, J AM DIET ASSOC, V99, pS96, DOI 10.1016/S0002-8223(99)00423-X; *US SEN, 1977, DIET GOALS US; VOORS AW, 1983, AM J CLIN NUTR, V37, P583, DOI 10.1093/ajcn/37.4.583; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; ZEMEL MB, 1986, J HYPERTENS, V4, pS343	39	3311	3400	12	345	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					3	10		10.1056/NEJM200101043440101	http://dx.doi.org/10.1056/NEJM200101043440101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136953	Bronze			2022-12-28	WOS:000166160400001
J	Davidson, EA; Trumbore, SE; Amundson, R				Davidson, EA; Trumbore, SE; Amundson, R			Biogeochemistry - Soil warming and organic carbon content	NATURE			English	Article							RESPIRATION; DECOMPOSITION; BALANCE; MATTER		Woods Hole Res Ctr, Woods Hole, MA 02543 USA; Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; Univ Calif Berkeley, Div Ecosyst Sci, Berkeley, CA 94720 USA	Woods Hole Research Center; University of California System; University of California Irvine; University of California System; University of California Berkeley	Davidson, EA (corresponding author), Woods Hole Res Ctr, POB 296, Woods Hole, MA 02543 USA.	edavidson@whrc.org	Davidson, Eric A/K-4984-2013; Trumbore, Susan/B-1948-2013; Amundson, Ronald/E-2654-2015	Davidson, Eric A/0000-0002-8525-8697; Amundson, Ronald/0000-0003-1510-7313				DAVIDSON EA, 1993, BIOGEOCHEMISTRY, V20, P161, DOI 10.1007/BF00000786; Giardina CP, 2000, NATURE, V404, P858, DOI 10.1038/35009076; Goulden ML, 1998, SCIENCE, V279, P214, DOI 10.1126/science.279.5348.214; Grace J, 2000, NATURE, V404, P819, DOI 10.1038/35009170; HOLLAND EA, 1995, GLOB CHANGE BIOL, V1, P115, DOI 10.1111/j.1365-2486.1995.tb00011.x; Jenny H., 1941, FACTORS SOIL FORMATI; Kirschbaum MUF, 2000, BIOGEOCHEMISTRY, V48, P21, DOI 10.1023/A:1006238902976; LAVELLE P, 1993, BIOTROPICA, V25, P130, DOI 10.2307/2389178; NEILL C, 2000, CARBON POOLS DYNAMIC, P197; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; RAICH JW, 1992, TELLUS B, V44, P81, DOI 10.1034/j.1600-0889.1992.t01-1-00001.x; TIESSEN H, 1994, NATURE, V371, P783, DOI 10.1038/371783a0; Trumbore S, 2000, ECOL APPL, V10, P399, DOI 10.1890/1051-0761(2000)010[0399:AOSOMA]2.0.CO;2; Trumbore SE, 1996, SCIENCE, V272, P393, DOI 10.1126/science.272.5260.393; Valentini R, 2000, NATURE, V404, P861, DOI 10.1038/35009084	15	320	452	40	325	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					789	790		10.1038/35048672	http://dx.doi.org/10.1038/35048672			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130707	Green Published			2022-12-28	WOS:000165831300032
J	Stuphorn, V; Taylor, TL; Schall, JD				Stuphorn, V; Taylor, TL; Schall, JD			Performance monitoring by the supplementary eye field	NATURE			English	Article							ANTERIOR CINGULATE CORTEX; NEURONAL-ACTIVITY; ERROR-DETECTION; COUNTERMANDING SACCADES; NEURAL SYSTEM; MOVEMENTS; MACAQUE; THOUGHT	Intelligent behaviour requires self-control based on the consequences of actions. The countermanding task is designed to study self-control; it requires subjects to withhold planned movements in response to an imperative stop signal, which they can do with varying success. In humans, the medial frontal cortex has been implicated in the supervisory control of action(1-3). In monkeys, the supplementary eye field in the dorsomedial frontal cortex is involved in producing eye movements, but its precise function has not been clarified(4). To investigate the role of the supplementary eye field in the control of eye movements, we recorded neural activity in macaque monkeys trained to perform an eye movement countermanding task. Distinct groups of neurons were active after errors, after successful withholding of a partially prepared movement, or in association with reinforcement. These three forms of activation could not be explained by sensory or motor factors. Our results lead us to put forward the hypothesis that the supplementary eye field contributes to monitoring the context and consequences of eye movements.	Vanderbilt Univ, Dept Psychol, Vanderbilt Vis Res Ctr, Nashville, TN 37240 USA	Vanderbilt University	Schall, JD (corresponding author), Vanderbilt Univ, Dept Psychol, Vanderbilt Vis Res Ctr, Nashville, TN 37240 USA.							Amador N, 2000, J NEUROPHYSIOL, V84, P2166, DOI 10.1152/jn.2000.84.4.2166; BOTVINICK MM, IN PRESS PSYCHOL REV; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Carter CS, 1999, REV NEUROSCIENCE, V10, P49; CHEN LL, 1995, J NEUROPHYSIOL, V73, P1101, DOI 10.1152/jn.1995.73.3.1101; COLES MGH, 1995, ACTA PSYCHOL, V90, P129, DOI 10.1016/0001-6918(95)00020-U; DEHAENE S, 1994, PSYCHOL SCI, V5, P385; Everling S, 2000, J NEUROSCI, V20, P387, DOI 10.1523/JNEUROSCI.20-01-00387.2000; FALKENSTEIN M, 1995, EVOKED POTENTIAL, V96, P36, DOI 10.1016/0013-4694(94)00182-K; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; GEMBA H, 1986, NEUROSCI LETT, V70, P223, DOI 10.1016/0304-3940(86)90467-2; Hanes DP, 1996, SCIENCE, V274, P427, DOI 10.1126/science.274.5286.427; HANES DP, 1995, VISUAL NEUROSCI, V12, P929, DOI 10.1017/S0952523800009482; Hanes DP, 1998, J NEUROPHYSIOL, V79, P817, DOI 10.1152/jn.1998.79.2.817; Heinen S. J., 1998, Society for Neuroscience Abstracts, V24, P1147; LOGAN GD, 1985, ACTA PSYCHOL, V60, P193, DOI 10.1016/0001-6918(85)90055-1; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Miltner WHR, 1997, J COGNITIVE NEUROSCI, V9, P788, DOI 10.1162/jocn.1997.9.6.788; NIKI H, 1979, BRAIN RES, V171, P213, DOI 10.1016/0006-8993(79)90328-7; OLSON CR, 1995, SCIENCE, V269, P985, DOI 10.1126/science.7638625; PENFIELD W, 1951, AMA ARCH NEUROL PSY, V66, P289, DOI 10.1001/archneurpsyc.1951.02320090038004; Posner MI, 1998, ATTENTIVE BRAIN, P401; Sadeghpour S., 1998, Society for Neuroscience Abstracts, V24, P522; Schall J. D., 1998, Society for Neuroscience Abstracts, V24, P172; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; Schall JD, 1997, CEREBR CORT, V12, P527; Schiller PH, 1998, NAT NEUROSCI, V1, P248, DOI 10.1038/693; SchlagRey M, 1997, NATURE, V390, P398, DOI 10.1038/37114; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; [No title captured]	30	304	307	0	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					857	860		10.1038/35048576	http://dx.doi.org/10.1038/35048576			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130724				2022-12-28	WOS:000165831300050
J	Zebrowski, G				Zebrowski, G			The holdouts - The contrarians of physics get strung out in Chicago.	NATURE			English	Article																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					775	775		10.1038/35048640	http://dx.doi.org/10.1038/35048640			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130699	Bronze			2022-12-28	WOS:000165831300022
J	Graham, D				Graham, D			Revisiting hippocrates - Does an oath really matter?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Nutton V, 1995, J ROY COLL PHYS LOND, V29, P518; Orr RD, 1997, J CLIN ETHIC, V8, P377	2	16	17	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2841	2842		10.1001/jama.284.22.2841	http://dx.doi.org/10.1001/jama.284.22.2841			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11147972				2022-12-28	WOS:000165717000001
J	Delaney, BC; Wilson, S; Roalfe, A; Roberts, L; Redman, V; Wearn, A; Briggs, A; Hobbs, FDR				Delaney, BC; Wilson, S; Roalfe, A; Roberts, L; Redman, V; Wearn, A; Briggs, A; Hobbs, FDR			Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care	LANCET			English	Article							HELICOBACTER-PYLORI; MANAGEMENT; THERAPY; DECISION	Background Dyspepsia can be managed by initial endoscopy and treatment based on endoscopic findings, or by empirical prescribing. We aimed to determine the cost effectiveness of initial endoscopy compared with usual management in patients with dyspepsia over age 50 years presenting to their primary care physician. Methods 422 patients were recruited and randomly assigned to initial endoscopy or usual management. Primary outcomes were effect of treatment on dyspepsia symptoms and cost effectiveness. Secondary outcomes were quality of life and patient satisfaction. Total costs were calculated from individual patient's use of resources with unit costs applied from national data. Statistical analysis of uncertainty on incremental cost-effectiveness ratio (ICER) was done along with a sensitivity analysis on unit costs with cost-effectiveness acceptability curves. Findings In the 12 months following recruitment, 213 (84%) patients had an endoscopy compared with 75 (41%) controls. Initial endoscopy resulted in a significant improvement in symptom score (p=0.03), and quality of life pain dimension (p=0.03), and a 48% reduction in the use of proton pump inhibitors (p=0.005). The ICER was pound 1728 (UK pound) per patient symptom-free at 12 months. The ICER was very sensitive to the cost of endoscopy, and could be reduced to pound 165 if the unit cost of this procedure fell from pound 246 to pound 100. Interpretation Initial endoscopy in dyspeptic patients over age 50 might be a cost-effective intervention.	Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford, England	University of Birmingham; University of Oxford	Delaney, BC (corresponding author), Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.		Briggs, Andrew/ABA-9009-2020; Delaney, Brendan C/C-5578-2008	Briggs, Andrew/0000-0002-0777-1997; hobbs, richard/0000-0001-7976-7172; Delaney, Brendan/0000-0002-3518-0131				Asante M, 1999, EUR J GASTROEN HEPAT, V11, P851, DOI 10.1097/00042737-199908000-00007; AXON ATR, 1995, BMJ-BRIT MED J, V310, P853, DOI 10.1136/bmj.310.6983.853; Baker R, 1996, BRIT J GEN PRACT, V46, P601; BATE CM, 1991, BR J MED EC, V1, P53; Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; Briggs A, 1997, HEALTH ECON, V6, P491, DOI 10.1002/(SICI)1099-1050(199709)6:5<491::AID-HEC293>3.0.CO;2-R; BRIGGS A, 1999, HLTH TECHNOL ASSES S, V3, pS68; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; COLINJONES DG, 1988, LANCET, V1, P576; Ebell MH, 1997, J FAM PRACTICE, V44, P545; Fendrick AM, 1996, AM J GASTROENTEROL, V91, P1544; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; Hansen JM, 1998, SCAND J GASTROENTERO, V33, P799; Hobbs FDR, 1996, FAM PRACT, V13, P225, DOI 10.1093/fampra/13.3.225; HUNGIN APS, 1994, BRIT J GEN PRACT, V44, P519; JONES R, 1988, PRACTITIONER, V232, P75; KORMAN MG, 1993, SCAND J GASTROENTERO, V28, P28, DOI 10.3109/00365529309098352; Laska EM, 1999, HEALTH ECON, V8, P171, DOI 10.1002/(SICI)1099-1050(199903)8:2<171::AID-HEC424>3.0.CO;2-E; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; Malfertheiner P, 1997, GUT, V41, P8; Mandelblatt JS, 1997, J GEN INTERN MED, V12, P551, DOI 10.1046/j.1525-1497.1997.07107.x; MCCORMICK A, 1995, MORBIDITY STAT GEN P; Ofman JJ, 1997, ANN INTERN MED, V126, P280, DOI 10.7326/0003-4819-126-4-199702150-00004; Silverstein MD, 1996, GASTROENTEROLOGY, V110, P72, DOI 10.1053/gast.1996.v110.pm8536890; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P1259; Townsend PP., 1988, HLTH DEPRIVATION INE; Wilson S, 2000, BMJ-BRIT MED J, V321, P24, DOI 10.1136/bmj.321.7252.24; 1994, AM FAM PHYSICIAN, V50, P667	30	99	101	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1965	1969		10.1016/S0140-6736(00)03308-0	http://dx.doi.org/10.1016/S0140-6736(00)03308-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130524				2022-12-28	WOS:000165867600010
J	Rubin, KH; Fletcher, CH; Sherman, C				Rubin, KH; Fletcher, CH; Sherman, C			Fossiliferous Lana'i deposits formed by multiple events rather than a single giant tsunami	NATURE			English	Article							LAST INTERGLACIAL PERIOD; SEA-LEVEL; TH-230 AGES; HAWAII; CORALS; OAHU; ISLAND; WAVE; DIAGENESIS; SUBSIDENCE	Giant tsunamis, generated by submarine landslides in the Hawaiian Islands, have been thought to be responsible for the deposition of chaotic gravels high on the southern coastal slopes of the islands of Lana'i and Moloka'i, Hawaii. Here we investigate this hypothesis, using uranium-thorium dating of the Hulopoe gravel (on Lana'i) and a study of stratigraphic relationships, such as facies changes and hiatuses, within the deposit. The Hulopoe gravel contains corals of two age groups, representing marine isotope stages be and 7 (similar to 135,000 and 240,000 years ago, respectively), with significant geographical and stratigraphic ordering. We show that the Hulopoe gravel was formed by multiple depositional events, separated by considerable periods of time, thus invalidating the main premise of the 'giant wave' hypothesis. Instead, the gravels were probably deposited during interglacial periods (when sea level was relatively high) by typical Hawaiian shoreline processes such as seasonal wave patterns, storm events and possibly 'normal' tsunamis, and reached their present height by uplift: of Lana'i.	Univ Hawaii, Dept Geol & Geophys, SOEST, Honolulu, HI 96822 USA	University of Hawaii System	Rubin, KH (corresponding author), Univ Hawaii, Dept Geol & Geophys, SOEST, 2525 Correa Rd, Honolulu, HI 96822 USA.		Rubin, Kenneth H/B-3685-2008	Rubin, Kenneth H/0000-0002-8554-1337; Sherman, Clark/0000-0003-0758-7900				Bard E, 1996, GEOPHYS RES LETT, V23, P1473, DOI 10.1029/96GL01279; BASSINOT FC, 1994, EARTH PLANET SC LETT, V126, P91, DOI 10.1016/0012-821X(94)90244-5; Bruckner H., 1989, ESSENER GEOGRAPHISCH, V17, P291; CHEN JH, 1986, EARTH PLANET SC LETT, V80, P241, DOI 10.1016/0012-821X(86)90108-1; Chen X., 1991, PLASMA CHEM PLASMA P, V11, P103; Cox D. C., 1985, LANAI EARTHQUAKE FEB; EDWARDS RL, 1986, EARTH PLANET SC LETT, V81, P175; Felton EA, 2000, PURE APPL GEOPHYS, V157, P1257, DOI 10.1007/s000240050025; Fletcher CH, 1996, J SEDIMENT RES, V66, P632; GALLUP CD, 1994, SCIENCE, V263, P796, DOI 10.1126/science.263.5148.796; Grigg RW, 1997, MAR GEOL, V141, P11, DOI 10.1016/S0025-3227(97)00069-8; HAMELIN B, 1991, EARTH PLANET SC LETT, V106, P169, DOI 10.1016/0012-821X(91)90070-X; HARMON RS, 1983, PALAEOGEOGR PALAEOCL, V44, P41, DOI 10.1016/0031-0182(83)90004-4; HENDERSON GM, 1993, EARTH PLANET SC LETT, V115, P65, DOI 10.1016/0012-821X(93)90213-S; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; Johnson C, 1994, SCI TSUNAMI HAZARDS, V12, P33; McMurtry GM, 1999, J VOLCANOL GEOTH RES, V94, P35, DOI 10.1016/S0377-0273(99)00097-9; Moore AL, 2000, GEOLOGY, V28, P247, DOI 10.1130/0091-7613(2000)028<0247:LFIOGA>2.3.CO;2; MOORE GW, 1988, GEOL SOC AM SPEC PAP, V229, P101; MOORE JG, 1984, SCIENCE, V226, P1312, DOI 10.1126/science.226.4680.1312; MOORE JG, 1984, J GEOL, V92, P752, DOI 10.1086/628910; MOORE JG, 1994, GEOL SOC AM BULL, V106, P962, DOI 10.1130/0016-7606(1994)106<0962:CDBAGW>2.3.CO;2; MOORE JG, 1987, VOLCANISM HAWAII, P85; MUHS DR, 1994, MAR GEOL, V118, P315, DOI 10.1016/0025-3227(94)90091-4; Nisbet EG, 1998, NATURE, V392, P329, DOI 10.1038/32765; RUBIN KH, IN PRESS CHEM GEOL; RUBIN KH, 1995, T AM GEOPHYS UNION, V76, pF307; SAWSON AG, 2000, PURE APPL GEOPHYS, V157, P875; Sherman CE, 1999, J SEDIMENT RES, V69, P1083, DOI 10.2110/jsr.69.1083; Smith JR, 2000, PURE APPL GEOPHYS, V157, P1097, DOI 10.1007/s000240050019; Stearns H.T., 1978, BISHOP MUSEUM B, V237, P57; Stearns H. T., 1940, HAWAII DIV HYDROGRAP, V6, P1; Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3; SZABO BJ, 1994, SCIENCE, V266, P93, DOI 10.1126/science.266.5182.93; WATTS AB, 1989, J GEOPHYS RES-SOLID, V94, P10473, DOI 10.1029/JB094iB08p10473; WESSEL P, 1994, J GEOPHYS RES-SOL EA, V99, P2747, DOI 10.1029/93JB02876; YOUNG RW, 1992, GEOLOGY, V20, P199, DOI 10.1130/0091-7613(1992)020<0199:CWEOTS>2.3.CO;2	37	47	49	1	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					675	681		10.1038/35047008	http://dx.doi.org/10.1038/35047008			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130062				2022-12-28	WOS:000165815200038
J	Berridge, V				Berridge, V			History in public health: who needs it?	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Promot Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Berridge, V (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Promot Res Unit, London WC1E 7HT, England.			berridge, virginia/0000-0001-8011-8348				Berridge V., 1996, AIDS UK MAKING POLIC; *EC SOC RES COUNC, 2000, THEM PRIOR UPD; FISHER K, 1997, THESIS OXFORD U OXFO; FOSTER J, 1990, AIDS ARCH UK; Hamlin C., 1998, PUBLIC HLTH SOCIAL J; Hammersley M., 1983, ETHNOGRAPHY PRINCIPL; Lewis J, 1986, WHAT PRICE COMMUNITY; Nathanson CA, 1996, POPUL DEV REV, V22, P609, DOI 10.2307/2137803; *ROYAL COLL PHYS, 2000, NIC ADD BRIT REP TOB; Tansey E., 2000, LOOKING UNBORN HIST, V5; 1999, SAVING LIVES OUR HLT	11	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1923	1925		10.1016/S0140-6736(00)03271-2	http://dx.doi.org/10.1016/S0140-6736(00)03271-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130400				2022-12-28	WOS:000165665400039
J	Nenner, F				Nenner, F			Listen to the voices	BRITISH MEDICAL JOURNAL			English	Editorial Material									Lutheran Med Ctr, Eth Comm, Brooklyn, NY 11220 USA		Nenner, F (corresponding author), Lutheran Med Ctr, Eth Comm, Brooklyn, NY 11220 USA.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	2001	322	7282					372	372		10.1136/bmj.322.7282.372	http://dx.doi.org/10.1136/bmj.322.7282.372			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159672	Green Published			2022-12-28	WOS:000167050000072
J	Roskell, D				Roskell, D			Learning to let go of our organs	BRITISH MEDICAL JOURNAL			English	Editorial Material									John Radcliffe Hosp, Oxford OX3 9DU, England	University of Oxford	Roskell, D (corresponding author), John Radcliffe Hosp, Oxford OX3 9DU, England.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	2001	322	7282					373	373		10.1136/bmj.322.7282.373	http://dx.doi.org/10.1136/bmj.322.7282.373			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159674	Green Published			2022-12-28	WOS:000167050000073
J	Goto, A; Kawauchi, N				Goto, A; Kawauchi, N			Captopril-augmented renal scan	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Tokyo, Tokyo 113, Japan	University of Tokyo	Goto, A (corresponding author), Univ Tokyo, Tokyo 113, Japan.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	2001	344	6					430	430		10.1056/NEJM200102083440606	http://dx.doi.org/10.1056/NEJM200102083440606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399FH	11172180				2022-12-28	WOS:000166800600006
J	Mitchell, E; Sullivan, F				Mitchell, E; Sullivan, F			A descriptive feast but an evaluative famine: systematic review of published articles on primary care computing during 1980-97	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; COMPUTERIZED DECISION-SUPPORT; PRIMARY HEALTH-CARE; GENERAL-PRACTICE; MEDICAL-RECORD; INFLUENZA VACCINATION; PREVENTIVE CARE; SCREENING MAMMOGRAPHY; PATIENTS ATTITUDES; CLINICAL-PRACTICE	Objectives To appraise findings from studies examining the impact of computers on primary care consultations. Design Systematic review of world literature from 1980 to 1997. Data sources 5475 references were identified from electronic databases (Medline, Science Citation Index, Social Sciences Citation Index, Index of Scientific and Technical Proceedings, Embase, OCLC FirstSearch Proceedings), bibliographies, books, identified articles, and by authors active in the field. 1892 eligible abstracts were independently rated, and 89 studies met the inclusion criteria. Main outcome measures Effect on doctors' performance and patient outcomes; attitudes towards computerisation. Results 61 studies examined effects of computers on practitioners' performance, 17 evaluated their impact on patient outcome,and 20 studied practitioners' or patients' attitudes. Computer use during consultations lengthened the consultation. Reminder systems for preventive tasks and disease management improved process rates, although some returned to pre-intervention levels when reminders were stopped. Use of computers for issuing prescriptions increased prescribing of generic drugs, and use of computers for test ordering led to cost savings and fewer unnecessary tests. There were no negative effects on those patient outcomes evaluated. Doctors and patients were generally positive about use of computers, but issues of concern included their impact on privacy, the doctor-patient relationship, cost, time, and training needs. Conclusions Primary care computing systems can improve practitioner performance, particularly for health promotion interventions. This may be at the expense of patient initiated activities, making many practitioners suspicious of the negative impact on relationships with patients. There remains a dearth of evidence evaluating effects on patient outcomes.	Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland; Univ Dundee, Tayside Ctr Gen Practice, Dundee DD1 4HN, Scotland	University of Glasgow; University of Dundee	Mitchell, E (corresponding author), Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland.	edm1a@clinmed.gla.ac.uk	Greiver, Michelle/N-8764-2015; Sullivan, Frank m/A-7767-2009; Sullivan, Frank/L-8286-2019	Greiver, Michelle/0000-0001-8957-0285; Sullivan, Frank/0000-0002-6623-4964; Mitchell, Elizabeth/0000-0002-2833-1632				Als AB, 1997, FAM PRACT, V14, P17, DOI 10.1093/fampra/14.1.17; BALDWIN DW, 1985, PRACTITIONER, V229, P643; BARNETT GO, 1984, NEW ENGL J MED, V310, P1643, DOI 10.1056/NEJM198406213102506; BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; BARTON MB, 1990, AM J PUBLIC HEALTH, V80, P534, DOI 10.2105/AJPH.80.5.534; Bolton P, 1995, Aust Fam Physician, V24, P1882; BRADLEY P, 1993, COMPUTING B, V49, P151; BRIGHT S, 1991, BRIT J HEALTHC COMP, V8, P58; BROWNBRIDGE G, 1985, SOC SCI MED, V20, P47, DOI 10.1016/0277-9536(85)90310-7; BROWNBRIDGE G, 1986, J ROY COLL GEN PRACT, V36, P198; BROWNBRIDGE G, 1985, BRIT MED J, V291, P639, DOI 10.1136/bmj.291.6496.639; BURACK RC, 1994, MED CARE, V32, P609, DOI 10.1097/00005650-199406000-00006; Burack RC, 1996, CANCER, V78, P1708, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1708::AID-CNCR11>3.3.CO;2-9; Campbell SM, 1996, BRIT J GEN PRACT, V46, P477; CARMAN D, 1995, BRIT J GEN PRACT, V45, P485; Chambers C V, 1991, J Am Board Fam Pract, V4, P19; CHAMBERS CV, 1989, J FAM PRACTICE, V29, P273; CHRISTENSENSZALANSKI JJJ, 1982, AM J PUBLIC HEALTH, V72, P16, DOI 10.2105/AJPH.72.1.16; CRUICKSHANK PJ, 1984, J ROY COLL GEN PRACT, V34, P77; DAVIDSON KW, 1987, J FAM PRACTICE, V25, P371; *DEP HLTH, 1993, COMP GP PRACT 1993 S; Department of Health, 1997, NEW NHS; DEVORE PA, 1991, SOUTH MED J, V84, P953, DOI 10.1097/00007611-199108000-00005; DONALD JB, 1986, BRIT MED J, V292, P937, DOI 10.1136/bmj.292.6525.937; DONALD JB, 1989, BRIT MED J, V299, P28, DOI 10.1136/bmj.299.6690.28; FIHN SD, 1994, J GEN INTERN MED, V9, P131, DOI 10.1007/BF02600026; Fitzmaurice DA, 1996, BRIT J GEN PRACT, V46, P533; Frame P S, 1994, Arch Fam Med, V3, P581, DOI 10.1001/archfami.3.7.581; GARR DR, 1993, AM J PREV MED, V9, P55, DOI 10.1016/S0749-3797(18)30769-4; GEHLBACH SH, 1984, MED CARE, V22, P193, DOI 10.1097/00005650-198403000-00002; GILLILAND AEW, 1992, FAM PRACT, V9, P441, DOI 10.1093/fampra/9.4.441; GREATBATCH D, 1995, FAM PRACT, V12, P32, DOI 10.1093/fampra/12.1.32; HARRIS RP, 1990, AM J PREV MED, V6, P145, DOI 10.1016/S0749-3797(18)31019-5; HERZMARK G, 1984, J ROY COLL GEN PRACT, V34, P649; Hobbs FDR, 1996, FAM PRACT, V13, P133, DOI 10.1093/fampra/13.2.133; Hutchison B G, 1989, Fam Med, V21, P433; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Jones DL, 1996, JAMA-J AM MED ASSOC, V275, P926, DOI 10.1001/jama.275.12.926; Krall M A, 1995, Proc Annu Symp Comput Appl Med Care, P708; Landis S E, 1992, N C Med J, V53, P575; Lewis G, 1996, FAM PRACT, V13, P120, DOI 10.1093/fampra/13.2.120; LIAW ST, 1994, FAM PRACT, V11, P44, DOI 10.1093/fampra/11.1.44; Liaw T, 1996, FAM PRACT, V13, P289, DOI 10.1093/fampra/13.3.289; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; Lobach D F, 1996, Proc AMIA Annu Fall Symp, P493; LOBACH DF, 1994, J AM MED INFORM ASSN, P787; Lobach DF, 1997, AM J MED, V102, P89, DOI 10.1016/S0002-9343(96)00382-8; MARGOLIS CZ, 1992, ACAD MED, V67, P282, DOI 10.1097/00001888-199204000-00021; MAZZUCA SA, 1990, AM EDUC RES J, V27, P473, DOI 10.3102/00028312027003473; MCALISTER NH, 1986, BRIT MED J, V293, P670, DOI 10.1136/bmj.293.6548.670; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; McDowell I, 1990, Fam Med, V22, P303; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MITCHELL ED, 1996, IMPACT INFORMATION T; MOIDU K, 1992, INT J BIOMED COMPUT, V30, P27, DOI 10.1016/0020-7101(92)90059-2; MORAN WP, 1992, J GEN INTERN MED, V7, P535, DOI 10.1007/BF02599460; MOWATT G, 1997, HLTH TECHNOL ASSESS, V1; ORNSTEIN S, 1994, J FAM PRACTICE, V38, P606; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; Potter A R, 1981, J R Coll Gen Pract, V31, P683; PRINGLE M, 1985, BRIT MED J, V290, P1789, DOI 10.1136/bmj.290.6484.1789; PRINGLE M, 1986, BRIT MED J, V293, P20, DOI 10.1136/bmj.293.6538.20; PRINGLE M, 1985, BRIT MED J, V290, P1709, DOI 10.1136/bmj.290.6483.1709; PRINGLE M, 1984, BRIT MED J, V288, P289, DOI 10.1136/bmj.288.6413.289; QUATTLEBAUM TG, 1991, PEDIATRICS, V88, P801; RETHANS JJ, 1988, BRIT MED J, V296, P1446, DOI 10.1136/bmj.296.6634.1446; RIDSDALE L, 1994, BRIT J GEN PRACT, V44, P367; ROBSON J, 1989, BMJ-BRIT MED J, V298, P433, DOI 10.1136/bmj.298.6671.433; ROLAND MO, 1985, BRIT MED J, V291, P456, DOI 10.1136/bmj.291.6493.456; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; ROSSER WW, 1991, CAN MED ASSOC J, V145, P807; ROWE BH, 1995, CAN MED ASSOC J, V153, P267; RUBENSTEIN LV, 1995, J GEN INTERN MED, V10, P607, DOI 10.1007/BF02602744; Safran C, 1996, M D COMPUT, V13, P55; SINGH AK, 1992, COMPUT METH PROG BIO, V37, P55, DOI 10.1016/0169-2607(92)90029-7; SOLOMON GL, 1995, J FAM PRACTICE, V41, P241; STRECHER VJ, 1994, J FAM PRACTICE, V39, P262; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; SULLIVAN FM, 1992, THEOR SURG, V7, P161; TAPE TG, 1993, AM J MED, V94, P619, DOI 10.1016/0002-9343(93)90214-A; Thakurdas P, 1996, NEW ZEAL MED J, V109, P419; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; TURNER BJ, 1989, J GEN INTERN MED, V4, P403, DOI 10.1007/BF02599691; TURNER RC, 1994, ARCH INTERN MED, V154, P1957, DOI 10.1001/archinte.154.17.1957; Valenta A L, 1996, Proc AMIA Annu Fall Symp, P65; VANBEMMEL JH, 1999, YB MED INFORMATICS 1; VANBEMMEL JH, 1997, HDB MED INFORMATIONS; VANDENHOOGEN JPH, 1990, J HUM HYPERTENS, V4, P365; VANDEVEN AH, 1974, ACAD MANAGE J, V17, P605, DOI 10.2307/255641; WARSHAWSKY SS, 1994, COMPUT METH PROG BIO, V43, P269, DOI 10.1016/0169-2607(94)90079-5; WEINGARTEN MA, 1989, FAM PRACT, V6, P120, DOI 10.1093/fampra/6.2.120; WYATT JC, 1994, LANCET, V344, P1682, DOI 10.1016/S0140-6736(94)90463-4	101	160	160	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2001	322	7281					279	282E		10.1136/bmj.322.7281.279	http://dx.doi.org/10.1136/bmj.322.7281.279			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157532	Green Submitted, Green Accepted, Green Published, Bronze			2022-12-28	WOS:000166917600030
J	Albert, MR; Ostheimer, KG; Breman, JG				Albert, MR; Ostheimer, KG; Breman, JG			The last smallpox epidemic in Boston and the vaccination controversy, 1901-1903	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NCI, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Fogarty Int Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Breman, JG (corresponding author), Fogarty Int Ctr, NIH, 31 Center Dr, MSC 2220, Bethesda, MD 20892 USA.							BANCROFT IR, 1907, S CALIF PRACTITIONER, V22, P78; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; *FA COUNTW LIB MED, 1902, CLIN REC SMALLP HOSP; Fabro J A, 1970, Conn Med, V34, P654; Fenner F., 1988, SMALLPOX ITS ERADICA; *HLTH DEP CIT BOST, 1904, 32 HLTH DEP CIT BOST; *HLTH DEP CIT BOST, 1902, 30 HLTH DEP CIT BOST; *HLTH DEP CIT BOST, 1903, 31 HLTH DEP CIT BOST; *HLTH DEP CIT BOST, 1927, 55 HLTH DEP CIT BOST; *HLTH DEP CIT BOST, 1938, 66 HLTH DEP CIT BOST; PRATT CM, 1907, MARIT MED NEWS, V19, P6; Smith T, 1902, BOSTON MED SURG J, V147, P197, DOI 10.1056/NEJM190208211470801; *STAT BOARD HLTH M, 1906, 37 STAT BOARD HLTH M; *US CENS OFF, 1901, US 12 CENS 1900 2, V2; WHITE JT, 1906, NATL ENCY AM BIOGRAP, V13; Winslow CEA, 1940, AM J PUBLIC HEALTH N, V30, P325, DOI 10.2105/AJPH.30.4.325; 1902, BOSTON HERALD   0212, P10; 1902, BOSTON GLOBE    0210, P4; 1904, LANCET, V1, P446; 1902, BOSTON GLOBE    0217, P1; 1902, BOSTON GLOBE    0227, P6; 1902, BOSTON EVENING  0220, P3; 1902, BOSTON HERALD   0211, P6; 1901, BOSTON GLOBE    1126, P4; 1902, BOSTON EVENING  0219, P1; 1902, BOSTON GLOBE    0205, P4; 1901, BOSTON GLOBE    1227, P7; 1901, BOSTON GLOBE    1129, P7; 1902, BOSTON GLOBE    0128, P14; 1902, BOSTON HERALD   0209, P1; 1902, BOSTON GLOBE    0210, P1; 1902, BOSTON HERALD   0210, P6; 1904, JAMA, V43, P1974; 1902, BOSTON HERALD   0210, P9; 1902, BOSTON MED SURG J, V146, P22; 1901, BOSTON GLOBE    1118, P7	36	53	54	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					375	379		10.1056/NEJM200102013440511	http://dx.doi.org/10.1056/NEJM200102013440511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172172				2022-12-28	WOS:000166675800011
J	Abbasi, K				Abbasi, K			Death underfunded - The mortuary service needs resources not resignations	BRITISH MEDICAL JOURNAL			English	Editorial Material																		Abbasi K, 2001, BRIT MED J, V322, P125, DOI 10.1136/bmj.322.7279.125; CARVEL J, 2001, GUARDIAN        0119; *CLIN PATH ACCR UK, 2001, STAND MED LAB; *DEP HLTH, 2001, MILL EX TEAM REP WIN; *DEP HLTH, 2001, EM SERV ACT LEARN RE; du Boulay C, 2000, BRIT MED J, V320, P1490, DOI 10.1136/bmj.320.7248.1490; Kmietowicz Z, 2001, BRIT MED J, V322, P127, DOI 10.1136/bmj.322.7279.127; LAURENCE J, 2001, INDEPENDENT     0117; *PATH MOD PROGR, 2001, REV BIDS MAD MOD FUN; WILSON R, 2001, ADDRESSING WORKLOAD	10	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					186	186		10.1136/bmj.322.7280.186	http://dx.doi.org/10.1136/bmj.322.7280.186			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159599				2022-12-28	WOS:000166733700003
J	Kanzok, SM; Fechner, A; Bauer, H; Ulschmid, JK; Muller, HM; Botella-Munoz, J; Schneuwly, S; Schirmer, RH; Becker, K				Kanzok, SM; Fechner, A; Bauer, H; Ulschmid, JK; Muller, HM; Botella-Munoz, J; Schneuwly, S; Schirmer, RH; Becker, K			Substitution of the thioredoxin system for glutathione reductase in Drosophila melanogaster	SCIENCE			English	Article							HUMAN PLACENTA; GENE	The disulfide reducing enzymes glutathione reductase and thioredoxin reductase are highly conserved among bacteria, fungi, worms, and mammals. These proteins maintain intracellular redox homeostasis to protect the organism from oxidative damage. Here we demonstrate the absence of glutathione reductase in Drosophila melanogaster, identify a new type of thioredoxin reductase, and provide evidence that a thioredoxin system supports GSSG reduction. Our data suggest that antioxidant defense in Drosophila, and probably in related insects, differs fundamentally from that in other organisms.	Univ Giessen, Interdisciplinary Res Ctr, D-35392 Giessen, Germany; Univ Heidelberg, Ctr Biochem, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Regensburg, Inst Zool, D-93040 Regensburg, Germany	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); University of Regensburg	Becker, K (corresponding author), Univ Giessen, Interdisciplinary Res Ctr, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.			Schneuwly, Stephan/0000-0001-7711-8902				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; [Anonymous], 1989, COENZYMES COFACTORS; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Candas M, 1997, ARCH BIOCHEM BIOPHYS, V339, P323, DOI 10.1006/abbi.1996.9872; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; KANZOK SM, UNPUB; Kirkpatrick DL, 1997, ONCOL RES, V9, P351; Mockett RJ, 1999, FASEB J, V13, P1733, DOI 10.1096/fasebj.13.13.1733; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; PellicenaPalle A, 1997, MECH DEVELOP, V62, P61, DOI 10.1016/S0925-4773(96)00650-8; SALZ HK, 1994, GENETICS, V136, P1075; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	20	328	347	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					643	646		10.1126/science.291.5504.643	http://dx.doi.org/10.1126/science.291.5504.643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158675				2022-12-28	WOS:000166616000041
J	Salama, H; da Silva, O				Salama, H; da Silva, O			Neonatal necrotizing enterocolitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									St Josephs Hlth Ctr, London, ON N6A 4V2, Canada	Western University (University of Western Ontario)	Salama, H (corresponding author), St Josephs Hlth Ctr, London, ON N6A 4V2, Canada.								0	1	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					108	108		10.1056/NEJM200101113440205	http://dx.doi.org/10.1056/NEJM200101113440205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150361				2022-12-28	WOS:000166281100005
J	Leibson, CL; Katusic, SK; Barbaresi, WJ; Ransom, J; O'Brien, PC				Leibson, CL; Katusic, SK; Barbaresi, WJ; Ransom, J; O'Brien, PC			Use and costs of medical care for children and adolescents with and without Attention-Deficit/Hyperactivity disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIT HYPERACTIVITY DISORDER; MENTAL-HEALTH CONDITIONS; YOUNG-ADULTS; POPULATION; PREVALENCE; MANAGEMENT; CRITERIA; PROJECT; IMPACT; RISKS	Context A shortage of data exists on medical care use by persons with attention-deficit/hyperactivity disorder (ADHD), Objective To compare medical care use and costs among persons with and without ADHD. Design and Setting Population-based cohort study conducted in Rochester, Minn. Subjects All children born in 1976-1982 were followed up through 1995, using school and medical records to identify those with ADHD, The 4880 birth cohort members (mean age, 7.3 years) still residing in Rochester in 1987 were followed up in medical facility-linked billing databases until death, emigration, or December 31, 1995, Main Outcome Measures Clinical diagnoses, likelihood and frequency of inpatient and outpatient hospitalizations, emergency department (ED) visits, and total medical costs (including ambulatory care), compared among individuals with and without ADHD, Results Among the 4119 birth cohort members who remained in the area through 1995 (mean age, 15.3 years), 7.5% (n=309) had met criteria for ADHD, Compared with persons without ADHD, those with ADHD were more likely to have diagnoses in multiple categories, including major injuries (59% vs 49%; P<.001) and asthma (22% vs 13%; P<.001). The proportion with any hospital inpatient, hospital outpatient, or ED admission was higher for persons with ADHD vs those without ADHD (26% vs 18% [P<.001], 41% vs 33% [P=.006], and 81% vs 74% [P=.005], respectively). The 9-year median costs for persons with ADHD corn pared with those without ADHD were more than double ($4306 vs $1944; P<.001), even for the subset with no hospital or ED admissions (eg, median 1987 costs, $128 vs $65; P<.001), The differences between individuals with and without ADHD were similar for males and females and across age groups. Conclusion In our cohort, compared with persons without ADHD, those with ADHD substantially greater use of medical care in multiple care delivery settings.	Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Leibson, CL (corresponding author), Mayo Clin, Dept Hlth Sci Res, Harwick 655,200 1st St SW, Rochester, MN 55905 USA.				NICHD NIH HHS [HD29745] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029745] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*ACG CAS MIX DEV T, 1998, CLIN GUID J HOPK U A; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON J, 1994, EPIDEMIOLOGY CHILDHO, P304; Barbaresi WJ, 2000, PEDIATR RES, V47, p22A; Barbaresi WJ, 1996, MAYO CLIN PROC, V71, P463, DOI 10.4065/71.5.463; BARKLEY RA, 1993, PEDIATRICS, V92, P212; BARKLEY RA, 1990, J AM ACAD CHILD PSY, V29, P546, DOI 10.1097/00004583-199007000-00007; Barkley RA, 1996, PEDIATRICS, V98, P1089; BAUMGARTEL A, 1994, J AM ACAD CHILD ADOL, V34, P629; CAMPION ME, 1992, MAYO CLIN PROC, V67, P5, DOI 10.1016/S0025-6196(12)60270-5; Costello EJ, 1999, J AM ACAD CHILD PSY, V38, P610, DOI 10.1097/00004583-199905000-00024; Halfon N, 1999, J AM ACAD CHILD PSY, V38, P600, DOI 10.1097/00004583-199905000-00023; Hansen C, 1999, J AM ACAD CHILD PSY, V38, P165, DOI 10.1097/00004583-199902000-00015; *HLTH CAR FIN ADM, 1997, FED REGISTER, V62, P460; Homer CJ, 2000, PEDIATRICS, V105, P1158; Katusic SK, 1998, MAYO CLIN PROC, V73, P1053, DOI 10.4065/73.11.1053; Kelleher KJ, 2000, PEDIATRICS, V105, P1313, DOI 10.1542/peds.105.6.1313; LEIBSON C, 1990, GERONTOLOGIST, V30, P316, DOI 10.1093/geront/30.3.316; Leibson CL, 1996, NEUROLOGY, V46, P861; LEIBSON CL, 1991, J AM GERIATR SOC, V39, P895, DOI 10.1111/j.1532-5415.1991.tb04457.x; Melton LJ, 1997, NEW ENGL J MED, V337, P1466, DOI 10.1056/NEJM199711133372012; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; *NIH, 1998, DIAGN TREATM ATT DEF, P1; OFFORD DR, 1989, CAN J PSYCHIAT, V34, P483, DOI 10.1177/070674378903400602; *PROSP PAYM ASS CO, 1997, MED AM HLTH CAR SYST; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P205, DOI 10.1111/j.1469-7610.1989.tb00235.x; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P219, DOI 10.1111/j.1469-7610.1989.tb00236.x; Wagner JL, 1999, JNCI-J NATL CANCER I, V91, P847, DOI 10.1093/jnci/91.10.847; Wolraich ML, 1996, J AM ACAD CHILD PSY, V35, P319, DOI 10.1097/00004583-199603000-00013	30	259	262	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					60	66		10.1001/jama.285.1.60	http://dx.doi.org/10.1001/jama.285.1.60			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	387GH	11150110				2022-12-28	WOS:000166114500025
J	Shin, SJ; Meininger, G				Shin, SJ; Meininger, G			Alpha(1)-antitrypsin deficiency.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital	Shin, SJ (corresponding author), Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, New York, NY 10021 USA.								0	0	0	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2000	343	26					1933	1933		10.1056/NEJM200012283432605	http://dx.doi.org/10.1056/NEJM200012283432605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386VR	11136264				2022-12-28	WOS:000166082700005
J	Dunne, EF; Fey, PD; Kludt, P; Reporter, R; Mostashari, F; Shillam, P; Wicklund, J; Miller, C; Holland, B; Stamey, E; Barrett, TJ; Rasheed, JK; Tenover, FC; Ribot, EM; Angulo, FJ				Dunne, EF; Fey, PD; Kludt, P; Reporter, R; Mostashari, F; Shillam, P; Wicklund, J; Miller, C; Holland, B; Stamey, E; Barrett, TJ; Rasheed, JK; Tenover, FC; Ribot, EM; Angulo, FJ			Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPANDED-SPECTRUM CEPHALOSPORINS; UNITED-STATES; ESCHERICHIA-COLI; TYPHIMURIUM; CEFOTAXIME; OUTBREAK; THERAPY; GASTROENTERITIS; ENTERITIDIS; INFANTS	Context Ceftriaxone, an expanded-spectrum cephalosporin, is an antimicrobial agent commonly used to treat severe Salmonella infections, especially in children, Ceftriaxone-resistant Salmonella infections have recently been reported in the United States, but the extent of the problem is unknown. Objectives To summarize national surveillance data for ceftriaxone-resistant Salmonella infections in the United States and to describe mechanisms of resistance. Design and Setting Case series and laboratory evaluation of human isolates submitted to the Centers for Disease Control and Prevention from 17 state and community health departments participating in the National Antimicrobial Resistance Monitoring System (NARMS) for enteric bacteria between 1996 and 1998. Patients Patients with ceftriaxone-resistant Salmonella infections between 1996 and 1998 were interviewed and isolates with decreased ceftriaxone susceptibility were further characterized. Main Outcome Measures Exposures and illness outcomes, mechanisms of resistance. Results The prevalence of ceftriaxone-resistant Salmonella was 0.1% (1 of 1326) in 1996, 0.4% (5 of 1301) in 1997, and 0.5% (7 of 1466) in 1998. Ten (77%) of the 13 patients with ceftriaxone-resistant infections were aged 18 years or younger. The patients lived in 8 states (California, Colorado, Kansas. Massachusetts, Maryland, Minnesota, New York, and Oregon). Nine (82%) of 11 patients interviewed did not take antimicrobial agents and 10 (91%) did not travel outside the United States before illness onset. Twelve of the 15 Salmonella isolates with ceftriaxone minimum inhibitory concentrations of 16 mug/mL or higher were serotype Typhimurium but these isolates had different pulsed-field gel electrophoresis patterns. Thirteen of these 15 isolates collected between 1996 and 1998 were positive for a 631-base pair polymerase chain reaction product obtained by using primers specific for the ampC gene of Citrobacter freundii. Conclusions Domestically acquired ceftriaxone-resistant Salmonella has emerged in the United States. Most ceftriaxone-resistant Salmonella isolates had similar AmpC plasmid-mediated resistance.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Angulo, FJ (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Foodborne & Diarrheal Dis Branch, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA.	FAngulo@cdc.gov						ANDERSON ES, 1987, J HYG LONDON, V78, P297; BACHMAN BJ, 1987, ESCHERICHIA COLI SAL, P1197; Barnaud G, 1998, ANTIMICROB AGENTS CH, V42, P2352, DOI 10.1128/AAC.42.9.2352; Bradford PA, 1998, ANTIMICROB AGENTS CH, V42, P1980, DOI 10.1128/AAC.42.8.1980; Bradford PA, 1999, J ANTIMICROB CHEMOTH, V44, P607, DOI 10.1093/jac/44.5.607; BRYAN JP, 1992, ANTIMICROB AGENTS CH, V36, P949, DOI 10.1128/AAC.36.5.949; *CDCP, 2000, FOODN 1998 WEB SIT; *CDCP, 1998, STAND MOL SUBT FOODB; CHERUBIN CE, 1986, ARCH INTERN MED, V146, P2149, DOI 10.1001/archinte.146.11.2149; Fey PD, 2000, NEW ENGL J MED, V342, P1242, DOI 10.1056/NEJM200004273421703; *FOOD DRUG ADM USD, 1998, NAT ANT RES MON PROG; Gazouli M, 1998, J ANTIMICROB CHEMOTH, V41, P119, DOI 10.1093/jac/41.1.119; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; HAMMAMI A, 1991, EUR J CLIN MICROBIOL, V10, P641, DOI 10.1007/BF01975816; Herikstad H, 1997, PEDIATR INFECT DIS J, V16, P904, DOI 10.1097/00006454-199709000-00015; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; Horton JM, 1999, CLIN INFECT DIS, V29, P1348, DOI 10.1086/313476; LEE CKK, 1995, DIAGN MICR INFEC DIS, V22, P231, DOI 10.1016/0732-8893(95)00081-K; LEE LA, 1994, J INFECT DIS, V170, P128, DOI 10.1093/infdis/170.1.128; M'Zali FH, 1997, J ANTIMICROB CHEMOTH, V40, P823, DOI 10.1093/jac/40.6.823; MATTHEW M, 1975, J GEN MICROBIOL, V88, P169, DOI 10.1099/00221287-88-1-169; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; MOOSDEEN F, 1989, J ANTIMICROB CHEMOTH, V23, P797, DOI 10.1093/jac/23.5.797; Pitout JDD, 1998, ANTIMICROB AGENTS CH, V42, P1350, DOI 10.1128/AAC.42.6.1350; SANDERS CC, 1993, INFECT DIS CLIN N AM, V7, P411; Shannon K, 1998, LANCET, V352, P490, DOI 10.1016/S0140-6736(05)79231-X; Sinnett D, 1998, BIOTECHNIQUES, V24, P752, DOI 10.2144/98245bm12; Sirinavin S, 1999, CLIN INFECT DIS, V29, P1151, DOI 10.1086/313469; STUTMAN HR, 1994, PEDIATR ANN, V23, P538, DOI 10.3928/0090-4481-19941001-07; Tassios PT, 1999, J CLIN MICROBIOL, V37, P3774, DOI 10.1128/JCM.37.11.3774-3777.1999; TI TY, 1985, ANTIMICROB AGENTS CH, V28, P540, DOI 10.1128/AAC.28.4.540; TORREY S, 1986, J PEDIATR-US, V108, P718, DOI 10.1016/S0022-3476(86)81050-2; *US FDA, 2000, PROP FRAM EV ASS HUM; Wayne P.A, 1997, PERF VOL ANT SUSC FL, Vsixth; WINOKUR PL, 2000, ANTIMICROB AGENTS CH, V44, P1	35	195	202	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3151	3156		10.1001/jama.284.24.3151	http://dx.doi.org/10.1001/jama.284.24.3151			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135779	Bronze			2022-12-28	WOS:000165994100033
J	Yoshida, Y; Tanaka, S; Umemori, H; Minowa, O; Usui, M; Ikematsu, N; Hosoda, E; Imamura, T; Kuno, J; Yamashita, T; Miyazono, K; Noda, M; Noda, T; Yamamoto, T				Yoshida, Y; Tanaka, S; Umemori, H; Minowa, O; Usui, M; Ikematsu, N; Hosoda, E; Imamura, T; Kuno, J; Yamashita, T; Miyazono, K; Noda, M; Noda, T; Yamamoto, T			Negative regulation of BMP/Smad signaling by Tob in osteoblasts	CELL			English	Article							NERVE GROWTH-FACTOR; BONE-FORMATION; TOB/BTG1 FAMILY; PROTEIN; GENE; SMAD; IDENTIFICATION; COMPONENT; CLONING; BETA	Bone morphogenetic protein (BMP) controls osteoblast proliferation and differentiation through Smad proteins. Here we show that Tob, a member of the emerging family of antiproliferative proteins, is a negative regulator of BMP/Smad signaling in osteoblasts. Mice carrying a targeted deletion of the tob gene have a greater bone mass resulting from increased numbers of osteoblasts. Orthotopic bone formation in response to BMP2 is elevated in tob-deficient mice. Overproduction of Tob represses BMP2-induced, Smad-mediated transcriptional activation. Finally, Tob associates with receptor-regulated Smads (Smad1, 5, and 8) and colocalizes with these Smads in the nuclear bodies upon BMP2 stimulation. The results indicate that Tob negatively regulates osteoblast proliferation and differentiation by suppressing the activity of the receptor-regulated Smad proteins.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 113865, Japan; Inst Canc Res, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan; Inst Canc Res, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 1010062, Japan	University of Tokyo; University of Tokyo; Tokyo Medical & Dental University (TMDU)	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Minowa, Osamu/AAM-1238-2020; Tanaka, Shinya/D-3586-2011; Tanaka, Sakae/Y-3061-2019; Noda, Tetsuo/B-1667-2016	Tanaka, Sakae/0000-0001-9210-9414; Usui, Michihiko/0000-0002-5208-1848; Umemori, Hisashi/0000-0001-7198-2062				Beppu H, 2000, DEV BIOL, V221, P249, DOI 10.1006/dbio.2000.9670; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; DENIS CL, 1984, GENETICS, V108, P833; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Eriebacher Adrian, 1995, Cell, V80, P371; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P439, DOI 10.1007/BF02411282; MARKS SC, 1989, AM J MED GENET, V34, P43, DOI 10.1002/ajmg.1320340110; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda S, 1996, ONCOGENE, V12, P705; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Yoshida Y, 1997, GENE, V191, P109, DOI 10.1016/S0378-1119(97)00049-8	42	259	279	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1085	1097		10.1016/S0092-8674(00)00211-7	http://dx.doi.org/10.1016/S0092-8674(00)00211-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163184	Bronze			2022-12-28	WOS:000166040600011
J	Farthing, M; Horton, R; Smith, R				Farthing, M; Horton, R; Smith, R			UK's failure to act on research misconduct	LANCET			English	Editorial Material																		BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; CHRISTIE B, 1999, BRIT MED J, V318, P1222; *COMM PUBL ETH, 2000, ANN REP 2000; DOYAL L, 2000, INFORMED CONSENT MED; Ferriman A, 2000, BRIT MED J, V321, P1429, DOI 10.1136/bmj.321.7274.1429; Horton R, 1999, LANCET, V354, P7, DOI 10.1016/S0140-6736(99)00227-5; LOCK S, 1996, FRAUD MISCONDUCT MED; LOCK S, 2000, P R COLL PHYSICIA S7, V3, P23; NIMMO WS, 2000, P R COLL PHYSICIA S7, V3, P2; Pappworth M., 1967, HUMAN GUINEA PIGS; *ROYAL COLL PHYS L, 1991, FRAUD MISC MED RES	11	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2030	2030		10.1016/S0140-6736(00)03398-5	http://dx.doi.org/10.1016/S0140-6736(00)03398-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145487				2022-12-28	WOS:000165994300007
J	Stokes, C; Ford, N; Sanchez, O; Perrin, JM; Poncin, M; Joly, M				Stokes, C; Ford, N; Sanchez, O; Perrin, JM; Poncin, M; Joly, M			Angola's suffering behind a pretence of normality	LANCET			English	Editorial Material									Med Sans Frontieres, London, England	Doctors Without Borders	Stokes, C (corresponding author), Med Sans Frontieres, 124-132 Clerkenwell Rd, London, England.							*MED SANS FRONT, 2000, ANG FAC NORM MAN VIO	1	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2093	2094		10.1016/S0140-6736(00)03415-2	http://dx.doi.org/10.1016/S0140-6736(00)03415-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145509				2022-12-28	WOS:000165994300036
J	Tomilin, A; Remenyi, A; Lins, K; Bak, H; Leidel, S; Vriend, G; Wilmanns, M; Scholer, HR				Tomilin, A; Remenyi, A; Lins, K; Bak, H; Leidel, S; Vriend, G; Wilmanns, M; Scholer, HR			Synergism with the coactivator OBF-1 (OCA-B, BOB-1) is mediated by a specific POU dimer configuration	CELL			English	Article							CELL-SPECIFIC COACTIVATOR; BINDING TRANSCRIPTION FACTORS; HEAVY-CHAIN PROMOTER; DNA-BINDING; CRYSTAL-STRUCTURE; DOMAIN; OCT-4; PROTEINS; COMPLEX; EXPRESSION	POU domain proteins contain a bipartite DNA binding domain divided by a flexible linker that enables them to adopt various monomer configurations on DNA. The versatility of POU protein operation is additionally conferred at the dimerization level. The POU dimer formed on the PORE (ATTTGAAATGCAAAT) can recruit the transcriptional coactivator OBF-1, whereas POU dimers formed on the consensus MORE (ATGCATATG CAT) or on MOREs from immunoglobulin heavy chain promoters (AT[G/A][C/A]ATATGCAA) fail to interact. An interaction with OBF-1 is precluded since the same Oct-1 residues that form the MORE dimerization interface are also used for OBF-1/Oct-1 interactions on the PORE. Our findings provide a paradigm of how specific POU dimer assemblies can differentially recruit a coregulatory activity with distinct transcriptional readouts.	Univ Penn, New Bolton Ctr, Sch Vet Med,Dept Anim Biol, Ctr Anim Transgenesis & Germ Cells Res, Kennett Square, PA 19348 USA; European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Biocomp Programme, D-69117 Heidelberg, Germany; DESY, EMBL, Hamburg Outstn, D-2263 Hamburg, Germany	University of Pennsylvania; European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Scholer, HR (corresponding author), Univ Penn, New Bolton Ctr, Sch Vet Med,Dept Anim Biol, Ctr Anim Transgenesis & Germ Cells Res, Kennett Square, PA 19348 USA.		, HS/AAB-4434-2019; Remenyi, Attila/N-1345-2016; Vriend, Gert/D-6730-2011; Tomilin, Alexey/AAK-3068-2021; Tomilin, Alexey N/C-3361-2014; Leidel, Sebastian/K-9507-2019; Tomilin, Alexey/AAA-8774-2022; Vriend, G./H-8112-2014	, HS/0000-0003-2643-5136; Tomilin, Alexey N/0000-0002-1137-7167; Leidel, Sebastian/0000-0002-0523-6325; Tomilin, Alexey/0000-0002-1137-7167; Remenyi, Attila/0000-0002-8345-1311; Bak, Hanne/0000-0001-9080-4667; Wilmanns, Matthias/0000-0002-4643-5435				Babb R, 1997, MOL CELL BIOL, V17, P7295, DOI 10.1128/MCB.17.12.7295; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Brehm A, 1999, MOL CELL BIOL, V19, P2635; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; Brehm A, 1998, APMIS, V106, P114, DOI 10.1111/j.1699-0463.1998.tb01326.x; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; Chasman D, 1999, GENE DEV, V13, P2650, DOI 10.1101/gad.13.20.2650; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;452::AID-MRD14&gt;3.0.CO;2-S; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; Rhee JM, 1998, J BIOL CHEM, V273, P34196, DOI 10.1074/jbc.273.51.34196; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sauter P, 1998, MOL CELL BIOL, V18, P7397, DOI 10.1128/MCB.18.12.7397; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Stevens S, 2000, J IMMUNOL, V164, P5306, DOI 10.4049/jimmunol.164.10.5306; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SYLVESTER I, 1994, NUCLEIC ACIDS RES, V22, P901, DOI 10.1093/nar/22.6.901; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309	37	107	111	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					853	864		10.1016/S0092-8674(00)00189-6	http://dx.doi.org/10.1016/S0092-8674(00)00189-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136971	Bronze			2022-12-28	WOS:000165801300005
J	Itoh, T; Koshiba, S; Kigawa, T; Kikuchi, A; Yokoyama, S; Takenawa, T				Itoh, T; Koshiba, S; Kigawa, T; Kikuchi, A; Yokoyama, S; Takenawa, T			Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding and endocytosis	SCIENCE			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CLATHRIN; PHOSPHOINOSITIDES; IDENTIFICATION; VISUALIZATION; COMPLEX; SYSTEM	Endocytic proteins such as epsin, AP180, and Hip1R (SLa2p) share a conserved modular region termed the epsin NH2-terminal homology (ENTH) domain, which plays a crucial role in clathrin-mediated endocytosis through an unknown target. Here, we demonstrate a strong affinity of the ENTH domain for phosphatidylinositol-4,5-bisphosphate [Ptdlns(4,5)P-2]. With nuclear magnetic resonance analysis of the epsin ENTH domain, we determined that a cleft formed with positively charged residues contributed to phosphoinositide binding. Overexpression of a mutant, epsin Lys(76) --> Ala(76), with an ENTH domain defective in phosphoinositide binding, blocked epidermal growth factor internalization in COS-7 cells. Thus, interaction between the ENTH domain and Ptdlns(4,5)P-2 is essential for endocytosis mediated by clathrin-coated pits.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; RIKEN, Genom Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN, Harima Inst SPring 8, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; RIKEN; RIKEN; Hiroshima University; University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Kigawa, Takanori/A-7679-2010; Yokoyama, Shigeyuki/N-6911-2015	Kigawa, Takanori/0000-0003-0146-9719; Yokoyama, Shigeyuki/0000-0003-3133-7338				BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Hao WH, 1999, J BIOL CHEM, V274, P22785, DOI 10.1074/jbc.274.32.22785; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Itoh T, 2000, J BIOL CHEM, V275, P19389, DOI 10.1074/jbc.M000426200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kay BK, 1999, PROTEIN SCI, V8, P435; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KOSHIBA S, IN PRESS J STRUCT FU; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	28	376	384	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	2001	291	5506					1047	1051		10.1126/science.291.5506.1047	http://dx.doi.org/10.1126/science.291.5506.1047			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161217				2022-12-28	WOS:000166860100046
J	Naya, Y; Yoshida, M; Miyashita, Y				Naya, Y; Yoshida, M; Miyashita, Y			Backward spreading of memory-retrieval signal in the primate temporal cortex	SCIENCE			English	Article							STIMULUS ASSOCIATION; PERIRHINAL CORTEX; INFEROTEMPORAL CORTEX; NEURONS; CORTICES; MONKEY; DISSOCIATION; ORGANIZATION; RESPONSES; AREAS	Bidirectional signaling between neocortex and Limbic cortex has been hypothesized to contribute to the retrieval of Long-term memory. We tested this hypothesis by comparing the time courses of perceptual and memory-retrieval signals in two neighboring areas in temporal cortex, area TE (TE) and perirhinal cortex (PRh), while monkeys were performing a visual pair-association task. Perceptual signal reached TE before PRh, confirming its forward propagation. In contrast, memory-retrieval signal appeared earlier in PRh, and TE neurons were then gradually recruited to represent the sought target. A reasonable interpretation of this finding is that the rich backward fiber projections from PRh to TE may underlie the activation of TE neurons that represent a visual object retrieved from Long-term memory.	Natl Inst Physiol Sci, Cognit Neurosci Lab, Aichi 4448585, Japan; Japan Sci & Technol Corp, ICORP, Mind Articulat Project, Tokyo 1130034, Japan; Univ Tokyo, Sch Med, Tokyo 1130033, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Japan Science & Technology Agency (JST); University of Tokyo	Miyashita, Y (corresponding author), Natl Inst Physiol Sci, Cognit Neurosci Lab, Aichi 4448585, Japan.	yasushi_miyashita@m.u-tokyo.ac.jp	Yoshida, Masatoshi/X-2312-2018; Miyashita, Yasushi/B-7171-2019	Yoshida, Masatoshi/0000-0002-2566-1820; Miyashita, Yasushi/0000-0003-3496-8637				AMIT DJ, 1994, J NEUROSCI, V14, P6435; Buckley MJ, 1997, J NEUROPHYSIOL, V77, P587, DOI 10.1152/jn.1997.77.2.587; Buffalo EA, 1999, LEARN MEMORY, V6, P572, DOI 10.1101/lm.6.6.572; CELEBRINI S, 1994, J NEUROSCI, V14, P4109; DOTY RW, 1994, BEHAV BRAIN RES, V64, P79, DOI 10.1016/0166-4328(94)90120-1; Erickson CA, 1999, J NEUROSCI, V19, P10404; Fuster JM, 1995, MEMORY CEREBRAL CORT; Hasegawa I, 1998, SCIENCE, V281, P814, DOI 10.1126/science.281.5378.814; Higuchi S, 1996, P NATL ACAD SCI USA, V93, P739, DOI 10.1073/pnas.93.2.739; Janssen P, 2000, SCIENCE, V288, P2054, DOI 10.1126/science.288.5473.2054; Liu Z, 2000, J NEUROPHYSIOL, V83, P1677, DOI 10.1152/jn.2000.83.3.1677; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; Mishkin M, 1997, PHILOS T R SOC B, V352, P1461, DOI 10.1098/rstb.1997.0132; Miyashita Y, 2000, CURR OPIN NEUROBIOL, V10, P187, DOI 10.1016/S0959-4388(00)00071-4; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; Movshon JA, 1996, J NEUROSCI, V16, P7733; MURRAY EA, 1993, J NEUROSCI, V13, P4549; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; NAYA Y, 1999, 29 ANN M SOC NEUR MI; Orlov T, 2000, NATURE, V404, P77, DOI 10.1038/35003571; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; Saleem KS, 1996, J NEUROSCI, V16, P4757; Schacter DL, 1998, NEUROBIOL LEARN MEM, V70, P284, DOI 10.1006/nlme.1998.3854; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; Thompson KG, 1996, J NEUROPHYSIOL, V76, P4040, DOI 10.1152/jn.1996.76.6.4040; Tokuyama W, 2000, NAT NEUROSCI, V3, P1134, DOI 10.1038/80655; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; YAKOVIEV V, 1998, NAT NEUROSCI, V4, P310	30	176	177	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2001	291	5504					661	664		10.1126/science.291.5504.661	http://dx.doi.org/10.1126/science.291.5504.661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158679				2022-12-28	WOS:000166616000046
J	Tuna, IC; Harrison, MR				Tuna, IC; Harrison, MR			Images in clinical medicine - Fungal prosthetic-valve endocarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Evansville Heart Ctr, Evansville, IN 47710 USA		Tuna, IC (corresponding author), Evansville Heart Ctr, Evansville, IN 47710 USA.		Harrison, Michael/GYD-8608-2022						0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2001	344	4					275	275		10.1056/NEJM200101253440406	http://dx.doi.org/10.1056/NEJM200101253440406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	394WA	11172155				2022-12-28	WOS:000166545200006
J	Jankowsky, E; Gross, CH; Shuman, S; Pyle, AM				Jankowsky, E; Gross, CH; Shuman, S; Pyle, AM			Active disruption of an RNA-protein interaction by a DExH/D RNA helicase	SCIENCE			English	Article							U1A PROTEIN; ATP HYDROLYSIS; MESSENGER-RNA; BOX; SPECIFICITY; SPLICEOSOME; BINDING	All aspects of cellular RNA metabolism and the replication of many viruses require DExH/D proteins that manipulate RNA in a manner that requires nucleoside triphosphates. Although DExH/D proteins have been shown to unwind purified RNA duplexes, most RNA molecules in the cellular environment are complexed with proteins. It has therefore been speculated that DExH/D proteins may also affect RNA-protein interactions. We demonstrate that the DExH protein NPH-II from vaccinia virus can displace the protein U1A from RNA in an active adenosine triphosphate-dependent fashion. NPH-II increases the rate of U1A dissociation by more than three orders of magnitude while retaining helicase processivity. This indicates that DExH/D proteins can effectively catalyze protein displacement from RNA and thereby participate in the structural reorganization of ribonucleoprotein assemblies.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Sloan Kettering Inst, New York, NY 10021 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Columbia University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Pyle, AM (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.			Jankowsky, Eckhard/0000-0001-7677-7412				AUBELE DT, 1997, MOL CELL BIOL, V17, P4842; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Grainger RJ, 1999, J MOL BIOL, V288, P585, DOI 10.1006/jmbi.1999.2717; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; JANKOWSKY E, UNPUB; Kadare G, 1997, J VIROL, V71, P2583; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SHUMAN S, 1993, J BIOL CHEM, V268, P11798; STALEY JP, 1998, CELL, V90, P1041; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Varani L, 2000, NAT STRUCT BIOL, V7, P329; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677	19	248	258	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					121	125		10.1126/science.291.5501.121	http://dx.doi.org/10.1126/science.291.5501.121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141562				2022-12-28	WOS:000166259100048
J	Henney, JE				Henney, JE			Nominations for advisory panels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Henney, JE (corresponding author), US FDA, HF-1,14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					34	34		10.1001/jama.285.1.34	http://dx.doi.org/10.1001/jama.285.1.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150092				2022-12-28	WOS:000166114500006
J	Jankowski, JA; Harrison, RF; Perry, I; Balkwill, F; Tselepis, C				Jankowski, JA; Harrison, RF; Perry, I; Balkwill, F; Tselepis, C			Barrett's metaplasia	LANCET			English	Review							HELICOBACTER-PYLORI INFECTION; GASTROESOPHAGEAL-REFLUX; INTESTINAL METAPLASIA; CATENIN COMPLEXES; TNF-ALPHA; ESOPHAGUS; PREVALENCE; CELLS; ADENOCARCINOMA; ASSOCIATION	The rate of oesophageal adenocarcinoma is increasing In the western world and has a poor prognosis mainly because individuals present at a late stage. Attempts to intervene at an early stage of tumour progression have not proven cost effective, although lesions identified during surveillance programmes have a better prognosis. As a consequence, there has been renewed interest in strategies that might prevent the precursor lesion Barrett's oesophagus. Furthermore, there is an improved understanding of genetic and environmental interactions necessary for the clonal expansion and propagation of metaplastic premalignant lesions. Clearly, three mechanisms promote cancer progression-inheritance of germ-line mutations or polymorphisms, sporadic mutagenesis, and local epigenetic alterations. Locally produced cytokines and bile acids in the refluxate create a microenvironment that sets the scene for metaplastic transformation of the oesophageal epithelium, mainly by directly affecting metaplastic stem cells.	Univ Birmingham, Div Med Sci, Epithelial Lab, Birmingham B15 2TH, W Midlands, England; Imperial Canc Res Fund, Histopathol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Biol Therapy Lab, London WC2A 3PX, England	University of Birmingham; Cancer Research UK; Cancer Research UK	Jankowski, JA (corresponding author), Univ Birmingham, Div Med Sci, Epithelial Lab, Birmingham B15 2TH, W Midlands, England.	J.jankowski@bham.ac.uk	Jankowski, Janusz/H-2706-2012	Jankowski, Janusz/0000-0003-2130-9181; Balkwill, Frances/0000-0002-5587-9759				Bailey T, 1998, AM J PATHOL, V152, P135; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Biddleston LR, 1998, AM J SURG PATHOL, V22, P239, DOI 10.1097/00000478-199802000-00013; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; CAMERON AJ, 1992, GASTROENTEROLOGY, V103, P1241, DOI 10.1016/0016-5085(92)91510-B; CAMERON AJ, 1990, GASTROENTEROLOGY, V99, P918, DOI 10.1016/0016-5085(90)90607-3; CHAMPION G, 1994, GASTROENTEROLOGY, V107, P747, DOI 10.1016/0016-5085(94)90123-6; DAHMS BB, 1987, CANCER, V60, P2896, DOI 10.1002/1097-0142(19871215)60:12<2896::AID-CNCR2820601208>3.0.CO;2-P; Di Sebastiano P, 2000, GUT, V47, P423, DOI 10.1136/gut.47.3.423; Dixon MF, 2000, BEST PRACT RES CL GA, V14, P27, DOI 10.1053/bega.1999.0057; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fass R, 2000, ENDOSCOPY, V32, P27, DOI 10.1055/s-2000-82; Galipeau PC, 1999, J NATL CANCER I, V91, P2087, DOI 10.1093/jnci/91.24.2087; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Garewal H, 1996, CANCER RES, V56, P1480; GILLEN P, 1988, BRIT J SURG, V75, P540, DOI 10.1002/bjs.1800750612; Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1; GRAY MR, 1993, GUT, V34, P727, DOI 10.1136/gut.34.6.727; Harrison RF, 2000, J PATHOL, V192, P1; Higaki S, 1999, J GASTROEN HEPATOL, V14, P709, DOI 10.1046/j.1440-1746.1999.01938.x; Ishikawa N, 1997, GASTROENTEROLOGY, V113, P542, DOI 10.1053/gast.1997.v113.pm9247474; JANKOWSKI J, 1993, AM J GASTROENTEROL, V56, P1480; Jankowski JA, 2000, BRIT MED J, V321, P463, DOI 10.1136/bmj.321.7259.463; Jankowski JA, 1999, AM J PATHOL, V154, P965, DOI 10.1016/S0002-9440(10)65346-1; Jones BE, 2000, AM J PHYSIOL-GASTR L, V278, pG693, DOI 10.1152/ajpgi.2000.278.5.G693; Kaiser GC, 1999, EXP CELL RES, V249, P349, DOI 10.1006/excr.1999.4488; Kim MH, 2000, J IMMUNOL, V164, P5883, DOI 10.4049/jimmunol.164.11.5883; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lagergren J, 1999, ANN INTERN MED, V130, P883, DOI 10.7326/0003-4819-130-11-199906010-00003; Lagergren J, 2000, ANN INTERN MED, V133, P165, DOI 10.7326/0003-4819-133-3-200008010-00007; Lee HM, 2000, AM J PHYSIOL-LUNG C, V278, pL185, DOI 10.1152/ajplung.2000.278.1.L185; Lu L, 1997, LAB INVEST, V76, P336; MENKEPLUYMERS MBE, 1993, CANCER, V72, P1155, DOI 10.1002/1097-0142(19930815)72:4<1155::AID-CNCR2820720404>3.0.CO;2-C; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Morales TG, 1999, ARCH INTERN MED, V159, P1411, DOI 10.1001/archinte.159.13.1411; Naya MJ, 1997, GUT, V40, P175, DOI 10.1136/gut.40.2.175; Nomura S, 1998, GUT, V42, P663, DOI 10.1136/gut.42.5.663; Ouatu-Lascar R, 1999, GASTROENTEROLOGY, V117, P327, DOI 10.1053/gast.1999.0029900327; Perry I, 2000, GUT, V46, pA54; POKOWSKI W, 2000, AM J GASTROENTEROL, V95, P617; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; Poynton AR, 1996, AM J GASTROENTEROL, V91, P1855; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Romero Y, 1997, GASTROENTEROLOGY, V113, P1449, DOI 10.1053/gast.1997.v113.pm9352846; SARR MG, 1985, AM J SURG, V149, P187, DOI 10.1016/S0002-9610(85)80031-3; Schmidt PH, 1999, LAB INVEST, V79, P639; Schouten WR, 1998, MEDIAT INFLAMM, V7, P175, DOI 10.1080/09629359891117; Sharma P, 1997, Am J Gastroenterol, V92, P903; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; SIDRANSKY D, 1992, NEW ENGL J MED, V117, P218; SKINNER DB, 1983, ANN SURG, V198, P554, DOI 10.1097/00000658-198310000-00016; Sodhani P, 1999, CYTOPATHOLOGY, V10, P122, DOI 10.1046/j.1365-2303.1999.00154.x; Spechler SJ, 1999, GASTROENTEROLOGY, V117, P218, DOI 10.1016/S0016-5085(99)70571-8; SPECHLER SJ, 1983, DIGEST DIS SCI, V28, P769, DOI 10.1007/BF01296897; Sung JJY, 2000, GASTROENTEROLOGY, V119, P7, DOI 10.1053/gast.2000.8550; Takeda H, 2000, ENDOSCOPY, V32, P651; THOMAS GA, 1988, J PATHOL, V155, P101, DOI 10.1002/path.1711550205; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; Triadafilopoulos G, 2000, GUT, V46, P144, DOI 10.1136/gut.46.2.144; TSELEPIS C, 1999, GUT, V45, pA238; Voutilainen M, 1999, GUT, V45, P644, DOI 10.1136/gut.45.5.644; Vujanic GM, 2000, HISTOPATHOLOGY, V36, P41; Wallner B, 2000, SCAND J GASTROENTERO, V35, P17; Weston AP, 2000, AM J GASTROENTEROL, V95, P387, DOI 10.1111/j.1572-0241.2000.01758.x; Weston AP, 1997, AM J GASTROENTEROL, V92, P800; Younes M, 1999, HUM PATHOL, V30, P1309, DOI 10.1016/S0046-8177(99)90061-8	67	273	279	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	2000	356	9247					2079	2085		10.1016/S0140-6736(00)03411-5	http://dx.doi.org/10.1016/S0140-6736(00)03411-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145505				2022-12-28	WOS:000165994300033
J	Neal, B; MacMahon, S; Chapman, N; Cutler, J; Fagard, R; Neal, B; Whelton, P; Yusuf, S; Agodoa, L; Baigent, C; Black, H; Boissel, JP; Brenner, B; Brown, M; Bulpitt, C; Byington, R; Chalmers, J; Collins, R; Dahlof, B; Davis, B; Estacio, R; Fox, K; Hansson, L; Holman, R; Hunsicker, L; Kostis, J; Kuramoto, K; Kusek, J; Lees, R; Lewis, E; Lindholm, LH; Liu, L; Lubsen, J; Malacco, E; Mancia, G; Martin, I; Pepine, C; Pfeffer, M; Pitt, B; Poole-Wilson, P; Remuzzi, G; Rodgers, A; Ruggenenti, P; Schrier, R; Sever, P; Sleight, P; Staessen, J; Teo, K; Turner, R; Wing, L; Zanchetti, A; Algert, C; Woodward, M				Neal, B; MacMahon, S; Chapman, N; Cutler, J; Fagard, R; Neal, B; Whelton, P; Yusuf, S; Agodoa, L; Baigent, C; Black, H; Boissel, JP; Brenner, B; Brown, M; Bulpitt, C; Byington, R; Chalmers, J; Collins, R; Dahlof, B; Davis, B; Estacio, R; Fox, K; Hansson, L; Holman, R; Hunsicker, L; Kostis, J; Kuramoto, K; Kusek, J; Lees, R; Lewis, E; Lindholm, LH; Liu, L; Lubsen, J; Malacco, E; Mancia, G; Martin, I; Pepine, C; Pfeffer, M; Pitt, B; Poole-Wilson, P; Remuzzi, G; Rodgers, A; Ruggenenti, P; Schrier, R; Sever, P; Sleight, P; Staessen, J; Teo, K; Turner, R; Wing, L; Zanchetti, A; Algert, C; Woodward, M		Blood Pressure Lowering Treatment	Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials	LANCET			English	Article							CONVERTING-ENZYME-INHIBITION; CORONARY-HEART-DISEASE; CARDIOVASCULAR MORBIDITY; MYOCARDIAL-INFARCTION; BETA-BLOCKERS; HYPERTENSION; MORTALITY; ATHEROSCLEROSIS; OUTCOMES; THERAPY	Background This programme of overviews of randomised trials was established to investigate the effects of angiotensin-converting.enzyme (ACE) inhibitors, calcium antagonists, and other blood-pressure-lowering drugs on mortality and major cardiovascular morbidity in several populations of patients. We did separate overviews of trials comparing active treatment regimens with placebo, trials comparing more intensive and less intensive blood-pressure-lowering strategies, and trials comparing treatment regimens based on different drug classes. Methods The hypotheses to be investigated, the trials to be included, and the outcomes to be studied were all selected before the results of any participating trial were known. Individual participant data or group tabular data were provided by each trial and combined by standard statistical techniques. Findings The overview of placebo-controlled trials of ACE inhibitors (four trials, 12 124 patients mostly with coronary heart disease) revealed reductions in stroke (30% [95% CI 15-43]), coronary heart disease (20% [11-28]), and major cardiovascular events (21% [14-27]). The overview of placebo-controlled trials of calcium antagonists (two trials, 5520 patients mostly with hypertension) showed reductions in stroke (39% [15-56]) and major cardiovascular events (28% [13-41]). In the overview of trials comparing blood-pressure-lowering strategies of different intensity (three trials, 20 408 patients with hypertension), there were reduced risks of stroke (20% [2-35]), coronary heart disease (19% [2-33]), and major cardiovascular events (15% [4-24]) with more intensive therapy. In the overviews comparing different antihypertensive regimens (eight trials, 37 872 patients with hypertension), several differences in cause-specific effects were seen between calcium-antagonist-based therapy and other regimens, but each was of borderline significance. Interpretation Strong evidence of benefits of ACE inhibitors and calcium antagonists is provided by the overviews of placebo-controlled trials. There is weaker evidence of differences between treatment regimens of differing intensities and of differences between treatment regimens based on different drug classes. Data from continuing trials of blood-pressure-lowering drugs will substantially increase the evidence available about any real differences that might exist between regimens.	Univ Sydney, Inst Int Hlth, Blood Pressure Lowering Treatment Trialists Colla, Sydney, NSW 2042, Australia	University of Sydney	Neal, B (corresponding author), Univ Sydney, Inst Int Hlth, Blood Pressure Lowering Treatment Trialists Colla, POB 576, Sydney, NSW 2042, Australia.		Woodward, Mark/D-8492-2015; Woodward, Mark/L-6817-2017; Staessen, Jan A/A-1065-2011; Remuzzi, Giuseppe/V-9766-2017	Staessen, Jan A/0000-0002-3026-1637; Rodgers, Anthony/0000-0003-1282-1896; MacMahon, Stephen/0000-0003-2064-7699; zanchetti, alberto/0000-0003-4796-7959; Kearney, Patricia/0000-0001-9599-3540; Remuzzi, Giuseppe/0000-0002-6194-3446; Chalmers, John/0000-0002-9931-0580; Algert, Charles/0000-0003-2525-9361; Neal, Bruce/0000-0002-0490-7465				Alderman M, 1997, J HYPERTENS, V15, P105; [Anonymous], 1985, J Hypertens, V3, P379; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Cashin-Hemphill L, 1999, AM J CARDIOL, V83, P43, DOI 10.1016/S0002-9149(98)00780-2; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COLLINS R, IN PRESS LANCET; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Flather M D, 1995, J Cardiovasc Risk, V2, P423; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; Kuramoto K, 1999, HYPERTENSION, V34, P1129; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MacMahon S, 2000, J AM COLL CARDIOL, V36, P438, DOI 10.1016/S0735-1097(00)00736-1; MACMAHON S, 1993, J VASC MED BIOL, V4, P265; MATERSON B, 1993, AM J HYPERTENS, V8, P189; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; Pitt B, 2000, CIRCULATION, V102, P1503, DOI 10.1161/01.CIR.102.13.1503; Pocock S, 1999, LANCET, V353, P943, DOI 10.1016/S0140-6736(98)00379-1; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Qizilbash N, 1995, LANCET, V346, P1647; Rodgers A, 1998, LANCET, V352, P1801; Rosei EA, 1997, J HYPERTENS, V15, P1337, DOI 10.1097/00004872-199715110-00019; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Teo KK, 2000, CIRCULATION, V102, P1748; The GLANT (Study Group on Long Term Antihypertensive Therapy) Study Group, 1995, HYPERTENS RES, V18, P235; WHO Int Soc Hyperten Blood Press Lower, 1998, J HYPERTENS, V16, P127; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; Woodward M., 2014, EPIDEMIOLOGY STUDY D; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; Yusuf S, 2000, NEW ENGL J MED, V342, P145; YUSUF S, 1989, HYPERTENSION, V0013; Zanchetti A, 1998, J HYPERTENS, V16, P1667, DOI 10.1097/00004872-199816110-00014	46	1234	1292	1	60	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 9	2000	356	9246					1955	1964						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130523				2022-12-28	WOS:000165867600009
J	Torgerson, DJ				Torgerson, DJ			Contamination in trials: is cluster randomisation the answer?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GENERAL-PRACTICE; PREVENTION; CHILDREN; DISEASE; DESIGN; CARE; RISK		Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	University of York - UK	Torgerson, DJ (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	djt6@york.ac.uk	Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				Alexander FE, 1999, LANCET, V353, P1903, DOI 10.1016/S0140-6736(98)07413-3; Altman DG, 1995, EUR J CANCER, V31A, P1934, DOI 10.1016/0959-8049(95)00470-X; Aveyard P, 1999, BRIT MED J, V319, P948, DOI 10.1136/bmj.319.7215.948; Campbell M, 2000, J Health Serv Res Policy, V5, P12; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; Grossman DC, 1997, JAMA-J AM MED ASSOC, V277, P1605, DOI 10.1001/jama.277.20.1605; Gulliford MC, 1998, HLTH SERVICES RES ME; Kendrick D, 1999, BRIT MED J, V318, P980, DOI 10.1136/bmj.318.7189.980; Kerry SM, 1998, BRIT MED J, V316, P1455, DOI 10.1136/bmj.316.7142.1455; Kerse NM, 1999, BRIT MED J, V319, P683, DOI 10.1136/bmj.319.7211.683; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; Steptoe A, 1999, BRIT MED J, V319, P943, DOI 10.1136/bmj.319.7215.943; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	14	310	312	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2001	322	7282					355	357		10.1136/bmj.322.7282.355	http://dx.doi.org/10.1136/bmj.322.7282.355			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159665	Green Published, Green Accepted			2022-12-28	WOS:000167050000034
J	Lelieveld, J; Crutzen, PJ; Ramanathan, V; Andreae, MO; Brenninkmeijer, CAM; Campos, T; Cass, GR; Dickerson, RR; Fischer, H; de Gouw, JA; Hansel, A; Jefferson, A; Kley, D; de Laat, ATJ; Lal, S; Lawrence, MG; Lobert, JM; Mayol-Bracero, OL; Mitra, AP; Novakov, T; Oltmans, SJ; Prather, KA; Reiner, T; Rodhe, H; Scheeren, HA; Sikka, D; Williams, J				Lelieveld, J; Crutzen, PJ; Ramanathan, V; Andreae, MO; Brenninkmeijer, CAM; Campos, T; Cass, GR; Dickerson, RR; Fischer, H; de Gouw, JA; Hansel, A; Jefferson, A; Kley, D; de Laat, ATJ; Lal, S; Lawrence, MG; Lobert, JM; Mayol-Bracero, OL; Mitra, AP; Novakov, T; Oltmans, SJ; Prather, KA; Reiner, T; Rodhe, H; Scheeren, HA; Sikka, D; Williams, J			The Indian Ocean Experiment: Widespread air pollution from South and Southeast Asia	SCIENCE			English	Article							CHLORINE EMISSIONS INVENTORY; MARINE BOUNDARY-LAYER; TROPOSPHERIC OZONE; CARBONACEOUS AEROSOLS; AIRCRAFT MEASUREMENTS; OPTICAL-PROPERTIES; REACTIVE CHLORINE; SULFUR-DIOXIDE; CHEMISTRY; PARTICLES	The Indian Ocean Experiment (INDOEX) was an international, multiplatform field campaign to measure Long-range transport of air pollution from South and Southeast Asia toward the Indian Ocean during the dry monsoon season in January to March 1999. Surprisingly high pollution Levels were observed over the entire northern Indian Ocean toward the Intertropical Convergence Zone at about 6 degreesS. We show that agricultural burning and especially biofuel use enhance carbon monoxide concentrations. Fossil fuel combustion and biomass burning cause a high aerosol Loading. The growing pollution in this region gives rise to extensive air quality degradation with Local, regional, and global implications, including a reduction of the oxidizing power of the atmosphere.	Max Planck Inst Chem, D-55020 Mainz, Germany; Univ Calif San Diego, Scripps Inst Oceanog, Ctr Atmospher Sci, La Jolla, CA 92093 USA; Natl Ctr Atmospher Res, Boulder, CO 80303 USA; Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA; Univ Maryland, Dept Meteorol, College Pk, MD 20742 USA; Univ Utrecht, NL-3584 CC Utrecht, Netherlands; Univ Innsbruck, A-6020 Innsbruck, Austria; NOAA, Climate Monitoring & Diagnost Lab, Boulder, CO 80303 USA; Res Ctr Julich, D-52428 Julich, Germany; Phys Res Lab, Ahmadabad 380009, Gujarat, India; Natl Phys Lab, New Delhi 110012, India; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Riverside, Riverside, CA 92521 USA; Stockholm Univ, Dept Meteorol, S-10691 Stockholm, Sweden	Max Planck Society; University of California System; University of California San Diego; Scripps Institution of Oceanography; National Center Atmospheric Research (NCAR) - USA; University System of Georgia; Georgia Institute of Technology; University System of Maryland; University of Maryland College Park; Utrecht University; University of Innsbruck; National Oceanic Atmospheric Admin (NOAA) - USA; Helmholtz Association; Research Center Julich; Department of Space (DoS), Government of India; Physical Research Laboratory - India; Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Physical Laboratory (NPL); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Riverside; Stockholm University	Lelieveld, J (corresponding author), Max Planck Inst Chem, POB 3060, D-55020 Mainz, Germany.	lelieveld@mpch-mainz.mpg.de	Hansel, Armin/F-3915-2010; Prather, Kim/A-3892-2008; Williams, Jonathan/K-7686-2017; de Gouw, Joost/A-9675-2008; Jefferson, Anne/K-4793-2012; Crutzen, Paul J/F-6044-2012; Oltmans, Samuel/AAC-8987-2022; Brenninkmeijer, Carl/B-6860-2013; Andreae, Meinrat O./B-1068-2008; Dickerson, Russell R/F-2857-2010; Dickerson, Russell/ABB-1512-2020; Lelieveld, Jos/A-1986-2013; Reid, David W/B-3263-2011	Hansel, Armin/0000-0002-1062-2394; Prather, Kim/0000-0003-3048-9890; Williams, Jonathan/0000-0001-9421-1703; de Gouw, Joost/0000-0002-0385-1826; Andreae, Meinrat O./0000-0003-1968-7925; Dickerson, Russell R/0000-0003-0206-3083; Dickerson, Russell/0000-0003-0206-3083; Lelieveld, Jos/0000-0001-6307-3846; Lawrence, Mark/0000-0002-2178-4903; Scheeren, Bert/0000-0001-6333-8402				Ackerman AS, 2000, SCIENCE, V288, P1042, DOI 10.1126/science.288.5468.1042; Anderson TL, 1999, J GEOPHYS RES-ATMOS, V104, P26793, DOI 10.1029/1999JD900172; Andreae MO, 2000, TELLUS B, V52, P1066, DOI 10.1034/j.1600-0889.2000.00105.x; Andres R.J., 1999, GLOBAL REGIONAL NATL; Arndt RL, 1997, ATMOS ENVIRON, V31, P1553, DOI 10.1016/S1352-2310(96)00236-1; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Brenninkmeijer C. A. M., 1999, CHEMOSPHERE GLOBAL C, V1, P33; BRENNINKMEIJER CAM, 1993, J GEOPHYS RES-ATMOS, V98, P10595, DOI 10.1029/93JD00587; CARSEY TP, UNPUB; Chameides WL, 1999, GEOPHYS RES LETT, V26, P867, DOI 10.1029/1999GL900068; COGAN M, 1998, P 43 ANN ISA AN DIV, V31, P229; Cooke WF, 1999, J GEOPHYS RES-ATMOS, V104, P22137, DOI 10.1029/1999JD900187; CRUTZEN PJ, 1990, SCIENCE, V250, P1669, DOI 10.1126/science.250.4988.1669; Crutzen PJ, 1999, TELLUS A, V51, P123, DOI 10.1034/j.1600-0870.1999.t01-1-00010.x; de Laat ATJ, 1999, J GEOPHYS RES-ATMOS, V104, P13881, DOI 10.1029/1999JD900176; Dickerson R. R., 1988, Journal of Atmospheric and Oceanic Technology, V5, P424, DOI 10.1175/1520-0426(1988)005<0424:MOACGF>2.0.CO;2; Elliott S, 1997, GEOPHYS RES LETT, V24, P2671, DOI 10.1029/97GL02800; Fischer H, 1997, J GEOPHYS RES-ATMOS, V102, P23559, DOI 10.1029/97JD02012; Gard EE, 1998, SCIENCE, V279, P1184, DOI 10.1126/science.279.5354.1184; HALL DO, 1994, CHEMOSPHERES, V29, P711; Heintzenberg J, 1989, TELLUS B, V41, P149, DOI 10.1111/j.1600-0889.1989.tb00132.x; Holzinger R, 1999, GEOPHYS RES LETT, V26, P1161, DOI 10.1029/1999GL900156; Hughes LS, 1998, ENVIRON SCI TECHNOL, V32, P1153, DOI 10.1021/es970280r; Keene WC, 1999, J GEOPHYS RES-ATMOS, V104, P8429, DOI 10.1029/1998JD100084; Kentarchos AS, 2000, J ATMOS SCI, V57, P2824, DOI 10.1175/1520-0469(2000)057<2824:SOESSS>2.0.CO;2; Kley D, 1997, Q J ROY METEOR SOC, V123, P2009, DOI 10.1002/qj.49712354312; KOMHYR WD, 1995, J GEOPHYS RES-ATMOS, V100, P9231, DOI 10.1029/94JD02175; Krishnamurti TN, 1997, METEOROL ATMOS PHYS, V64, P123, DOI 10.1007/BF01029689; Lal S, 1998, J GEOPHYS RES-ATMOS, V103, P18907, DOI 10.1029/98JD01566; Leck C, 1996, TELLUS B, V48, P272, DOI 10.1034/j.1600-0889.48.issue2.1.x; Lelieveld J, 1999, J GEOPHYS RES-ATMOS, V104, P8201, DOI 10.1029/1998JD100111; Lindinger W, 1998, INT J MASS SPECTROM, V173, P191, DOI 10.1016/S0168-1176(97)00281-4; Lobert JM, 1999, J GEOPHYS RES-ATMOS, V104, P8373, DOI 10.1029/1998JD100077; LOBERT JM, 1991, GLOBAL BIOMASS BURNING, P289; MADAN OP, 1999, METEOROLOGICAL ANAL; Mahapatra AK, 1999, BIOMASS BIOENERG, V17, P291, DOI 10.1016/S0961-9534(99)00056-2; Maring H, 2000, J GEOPHYS RES-ATMOS, V105, P14677, DOI 10.1029/2000JD900106; Naja M, 1999, CURR SCI INDIA, V76, P931; Novakov T, 1997, J GEOPHYS RES-ATMOS, V102, P30023, DOI 10.1029/97JD02793; Novakov T, 2000, GEOPHYS RES LETT, V27, P4061, DOI 10.1029/2000GL011759; OLIVIER JGJ, 1996, 77106002 RIVM NAT I; RAMANA MV, 1999, CURR SCI, V76, P931; RAMANATHAN V, UNPUB; RAMANATHAN V, 1996, C4 PUBLICATION, V162; Ravindranath NH, 1997, ENERG POLICY, V25, P63, DOI 10.1016/S0301-4215(96)00105-X; Rhoads KP, 1997, J GEOPHYS RES-ATMOS, V102, P18981, DOI 10.1029/97JD01078; Roeckner E, 1999, J CLIMATE, V12, P3004, DOI 10.1175/1520-0442(1999)012<3004:TCCSWA>2.0.CO;2; Roelofs GJ, 1997, TELLUS B, V49, P38, DOI 10.1034/j.1600-0889.49.issue1.3.x; Roelofs GJ, 2000, J GEOPHYS RES-ATMOS, V105, P22697, DOI 10.1029/2000JD900316; SATHAYE J, 1994, ENERGY, V19, P573, DOI 10.1016/0360-5442(94)90053-1; Satheesh SK, 2000, NATURE, V405, P60, DOI 10.1038/35011039; Scheele M. P., 1996, METEOROL APPL, V3, P267, DOI [DOI 10.1002/MET.5060030308, 10.1002/met.5060030308]; Schroder F, 1997, ATMOS RES, V44, P333, DOI 10.1016/S0169-8095(96)00034-8; Seinfeld J. H., 1998, ATMOSPHERIC CHEM PHY; Sheridan PJ, 1999, J GEOPHYS RES-ATMOS, V104, P16793, DOI 10.1029/1999JD900241; Silva PJ, 1997, ENVIRON SCI TECHNOL, V31, P3074, DOI 10.1021/es961063d; Sinha CS, 1998, BIOMASS BIOENERG, V14, P489, DOI 10.1016/S0961-9534(97)10059-9; Srivastava L, 1997, ENERG POLICY, V25, P941, DOI 10.1016/S0301-4215(97)00090-6; Streets DG, 1998, ENERGY, V23, P1029, DOI 10.1016/S0360-5442(98)00033-4; Streets DG, 1999, ENERGY, V24, P841, DOI 10.1016/S0360-5442(99)00030-4; Wang YH, 1998, J GEOPHYS RES-ATMOS, V103, P31123, DOI 10.1029/1998JD100004; Webster PJ, 1998, J GEOPHYS RES-OCEANS, V103, P14451, DOI 10.1029/97JC02719; Wienhold FG, 1998, APPL PHYS B-LASERS O, V67, P411, DOI 10.1007/s003400050524	63	576	596	5	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	2001	291	5506					1031	1036		10.1126/science.1057103	http://dx.doi.org/10.1126/science.1057103			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161214				2022-12-28	WOS:000166860100042
J	Guo, HW; Mockler, T; Duong, H; Lin, CT				Guo, HW; Mockler, T; Duong, H; Lin, CT			SUB1, an Arabidopsis Ca2+-binding protein involved in cryptochrome and phytochrome coaction	SCIENCE			English	Article							LIGHT RECEPTOR CRYPTOCHROME-2; SIGNAL-TRANSDUCTION PATHWAYS; GENE-EXPRESSION; CA2+ BINDING; UV-B; THALIANA; HYPOCOTYL; INDUCTION; DIVERSITY; ENCODES	Cryptochromes and phytochromes are the major photosensory receptors in plants and often regulate similar photomorphogenic responses. The molecular mechanisms underlying functional interactions of cryptochromes and phytochromes remain Largely unclear. We have identified an Arabidopsis photomorphogenic mutant, sub1, which exhibits hypersensitive responses to blue light and far-red Light. Genetic analyses indicate that SUB1 functions as a component of a cryptochrome signaling pathway and as a modulator of a phytochrome signaling pathway. The SUB1 gene encodes a Ca2+-binding protein that suppresses Light-dependent accumulation of the transcription factor HY5.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Lin, CT (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	clin@mcdb.ucla.edu	Ecker, Joseph R/B-9144-2008; Mockler, Todd C/L-2609-2013	Ecker, Joseph R/0000-0001-5799-5895; Mockler, Todd C/0000-0002-0462-5775	NIGMS NIH HHS [GM 56265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056265, R29GM056265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1997, PLANT J, V11, P421, DOI 10.1046/j.1365-313X.1997.11030421.x; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Baum G, 1999, P NATL ACAD SCI USA, V96, P13554, DOI 10.1073/pnas.96.23.13554; Casal JJ, 2000, PHOTOCHEM PHOTOBIOL, V71, P1, DOI 10.1562/0031-8655(2000)071&lt;0001:PCPPII&gt;2.0.CO;2; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Clough RC, 1997, PLANT CELL ENVIRON, V20, P713, DOI 10.1046/j.1365-3040.1997.d01-107.x; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Fuglevand G, 1996, PLANT CELL, V8, P2347, DOI 10.1105/tpc.8.12.2347; GUO H, UNPUB; Guo HW, 1999, PLANT J, V19, P279, DOI 10.1046/j.1365-313X.1999.00525.x; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; Long JC, 1998, PLANT CELL, V10, P2077, DOI 10.1105/tpc.10.12.2077; LUNDBERG S, 1992, BIOCHEMISTRY-US, V31, P5665, DOI 10.1021/bi00139a034; Martinez-Garcia JF, 2000, SCIENCE, V288, P859, DOI 10.1126/science.288.5467.859; Mas P, 2000, NATURE, V408, P207, DOI 10.1038/35041583; Mathur J, 1998, PLANT J, V13, P707, DOI 10.1046/j.1365-313X.1998.00059.x; Mockler TC, 1999, DEVELOPMENT, V126, P2073; MOHR H, 1994, PHOTOMORPHOGENESIS P; Neff MM, 1998, PLANT PHYSIOL, V118, P27, DOI 10.1104/pp.118.1.27; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Oyama T, 1997, GENE DEV, V11, P2983, DOI 10.1101/gad.11.22.2983; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	34	108	127	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2001	291	5503					487	490		10.1126/science.291.5503.487	http://dx.doi.org/10.1126/science.291.5503.487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161203				2022-12-28	WOS:000166487500042
J	Gandhi, SK; Powers, JC; Nomeir, A; Fowle, K; Kitzman, DW; Rankin, KM; Little, WC				Gandhi, SK; Powers, JC; Nomeir, A; Fowle, K; Kitzman, DW; Rankin, KM; Little, WC			The pathogenesis of acute pulmonary edema associated with hypertension.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; DIASTOLIC DYSFUNCTION	Background: Patients with acute pulmonary edema often have marked hypertension but, after reduction of the blood pressure, have a normal left ventricular ejection fraction (greater/equal 0.50). However, the pulmonary edema may not have resulted from isolated diastolic dysfunction but, instead, may be due to transient systolic dysfunction, acute mitral regurgitation, or both. Methods: We studied 38 patients (14 men and 24 women; mean [+/-SD] age, 67+/-13 years) with acute pulmonary edema and systolic blood pressure greater than 160 mm Hg. We evaluated the ejection fraction and regional function by two-dimensional Doppler echocardiography, both during the acute episode and one to three days after treatment. Results: The mean systolic blood pressure was 200+/-26 mm Hg during the initial echocardiographic examination and was reduced to 139+/-17 mm Hg (P<0.05) at the time of the follow-up examination. Despite the marked difference in blood pressure, the ejection fraction was similar during the acute episode (0.50+/-0.15) and after treatment (0.50+/-0.13). The left ventricular regional wall-motion index (the mean value for 16 segments) was also the same during the acute episode (1.6+/-0.6) and after treatment (1.6+/-0.6). No patient had severe mitral regurgitation during the acute episode. Eighteen patients had a normal ejection fraction (at least 0.50) after treatment. In 16 of these 18 patients, the ejection fraction was at least 0.50 during the acute episode. Conclusions: In patients with hypertensive pulmonary edema, a normal ejection fraction after treatment suggests that the edema was due to the exacerbation of diastolic dysfunction by hypertension - not to transient systolic dysfunction or mitral regurgitation. (N Engl J Med 2001;344:17-22.) Copyright (C) 2001 Massachusetts Medical Society.	Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Little, WC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NIA NIH HHS [R01 AG12257] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012257] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Dauterman KW, 1998, AM HEART J, V135, pS310, DOI 10.1016/S0002-8703(98)70258-3; EAGLE KA, 1988, ARCH INTERN MED, V148, P882, DOI 10.1001/archinte.148.4.882; GAASCH WH, 1994, JAMA-J AM MED ASSOC, V271, P1276; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; Grossman W, 2000, CIRCULATION, V101, P2020, DOI 10.1161/01.CIR.101.17.2020; IRIARTE M, 1993, AM J CARDIOL, V71, P308, DOI 10.1016/0002-9149(93)90796-F; KASS DA, 1988, CIRCULATION, V77, P559; KASS DA, 1987, CIRCULATION, V76, P1422, DOI 10.1161/01.CIR.76.6.1422; Kramer K, 2000, AM HEART J, V140, P451, DOI 10.1067/mhj.2000.108828; LITTLE WC, 1995, CIRCULATION, V92, P1933, DOI 10.1161/01.CIR.92.7.1933; Little WC, 1997, HEART DIS TXB CARDIO, P421; Mosterd A, 1999, EUR HEART J, V20, P447, DOI 10.1053/euhj.1998.1239; Oh JK, 1997, J AM SOC ECHOCARDIOG, V10, P246, DOI 10.1016/S0894-7317(97)70062-2; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; SPAIN MG, 1989, J AM COLL CARDIOL, V13, P585, DOI 10.1016/0735-1097(89)90597-4; Vasan RS, 2000, CIRCULATION, V101, P2118, DOI 10.1161/01.CIR.101.17.2118; WEXLER LF, 1989, HYPERTENSION, V13, P598, DOI 10.1161/01.HYP.13.6.598	18	454	477	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					17	22		10.1056/NEJM200101043440103	http://dx.doi.org/10.1056/NEJM200101043440103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136955				2022-12-28	WOS:000166160400003
J	Audet, AM; Hartman, EE				Audet, AM; Hartman, EE			An 82-year-old woman with mood changes following a stroke, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Robinson RG, 2000, JAMA-J AM MED ASSOC, V283, P1607, DOI 10.1001/jama.283.12.1607	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					80	80		10.1001/jama.285.1.80	http://dx.doi.org/10.1001/jama.285.1.80			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150113				2022-12-28	WOS:000166114500028
J	Brodersen, DE; Clemons, WM; Carter, AP; Morgan-Warren, RJ; Wimberly, BT; Ramakrishnan, V				Brodersen, DE; Clemons, WM; Carter, AP; Morgan-Warren, RJ; Wimberly, BT; Ramakrishnan, V			The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit	CELL			English	Article							TRANSFER-RIBONUCLEIC-ACID; PROTEIN-SYNTHESIS; TRANSFER-RNA; P-SITE; FUNCTIONAL SITES; A-SITE; BINDING; RESISTANCE; INITIATION; TRANSLOCATION	We have used the recently determined atomic structure of the 30S ribosomal subunit to determine the structures of its complexes with the antibiotics tetracycline, pactamycin, and hygromycin B. The antibiotics bind to discrete sites on the 30S subunit in a manner consistent with much but not all biochemical data. For each of these antibiotics, interactions with the 30S subunit suggest a mechanism for its effects on ribosome function.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	MRC Laboratory Molecular Biology; Utah System of Higher Education; University of Utah	Ramakrishnan, V (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ramak@mrc-lmb.cam.ac.uk	Clemons, William M/D-1026-2009; Brodersen, Ditlev E./AAQ-5241-2020	Clemons, William M/0000-0002-0021-889X; Ramakrishnan, V/0000-0002-4699-2194; Brodersen, Ditlev/0000-0002-5413-4667; Carter, Andrew/0000-0001-7292-5430				ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BHUYAN BK, 1961, ANTIMICROB AGENTS CH, P184; BROWN CM, 1993, NUCLEIC ACIDS RES, V21, P2109, DOI 10.1093/nar/21.9.2109; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCK MA, 1990, BIOCHEMISTRY-US, V29, P5374, DOI 10.1021/bi00474a024; Burdett V, 1996, J BACTERIOL, V178, P3246, DOI 10.1128/jb.178.11.3246-3251.1996; CABANAS MJ, 1978, BIOCHEM BIOPH RES CO, V83, P991; CABANAS MJ, 1978, EUR J BIOCHEM, V87, P21, DOI 10.1111/j.1432-1033.1978.tb12347.x; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P245, DOI 10.1093/jac/29.3.245; COHEN LB, 1969, BIOCHEMISTRY-US, V8, P1327, DOI 10.1021/bi00832a005; COHEN LB, 1969, BIOCHEMISTRY-US, V8, P1312, DOI 10.1021/bi00832a004; DAHLBERG AE, 1973, BIOCHEMISTRY-US, V12, P948, DOI 10.1021/bi00729a025; DESTASIO EA, 1990, J MOL BIOL, V212, P127, DOI 10.1016/0022-2836(90)90309-A; EGEBJERG J, 1991, BIOCHIMIE, V73, P1145, DOI 10.1016/0300-9084(91)90158-W; EPE B, 1987, FEBS LETT, V213, P443, DOI 10.1016/0014-5793(87)81539-9; EUSTICE DC, 1984, BIOCHEMISTRY-US, V23, P1462, DOI 10.1021/bi00302a019; EUSTICE DC, 1984, ANTIMICROB AGENTS CH, V26, P53, DOI 10.1128/AAC.26.1.53; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; Garrett R. A., 2000, RIBOSOME STRUCTURE F; GEIGENMULLER U, 1986, EUR J BIOCHEM, V161, P723, DOI 10.1111/j.1432-1033.1986.tb10499.x; GONZALEZ A, 1978, BIOCHIM BIOPHYS ACTA, V521, P459, DOI 10.1016/0005-2787(78)90287-3; GORDON J, 1969, J BIOL CHEM, V244, P5680; GUTELL RR, 1996, RIBOSOMAL RNA STRUCT, P111; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Hlavka J. J., 1985, TETRACYCLINES; KAPPEN LS, 1976, BIOCHEMISTRY-US, V15, P811, DOI 10.1021/bi00649a013; Kolesnikov IV, 1996, BIOCHIMIE, V78, P868, DOI 10.1016/S0300-9084(97)84340-4; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; MANAVATHU EK, 1990, ANTIMICROB AGENTS CH, V34, P71, DOI 10.1128/AAC.34.1.71; Mankin AS, 1997, J MOL BIOL, V274, P8, DOI 10.1006/jmbi.1997.1387; MANN RL, 1958, J AM CHEM SOC, V80, P2714, DOI 10.1021/ja01544a032; MAXWELL IH, 1967, BIOCHIM BIOPHYS ACTA, V138, P337, DOI 10.1016/0005-2787(67)90494-7; MOAZED D, 1995, J MOL BIOL, V248, P207, DOI 10.1016/S0022-2836(95)80042-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Noah JW, 1999, J BIOL CHEM, V274, P16576, DOI 10.1074/jbc.274.23.16576; Oehler R, 1997, NUCLEIC ACIDS RES, V25, P1219, DOI 10.1093/nar/25.6.1219; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pestka S, 1974, Methods Enzymol, V30, P261; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Ross JI, 1998, ANTIMICROB AGENTS CH, V42, P1702, DOI 10.1128/AAC.42.7.1702; SALYERS AA, 1990, MOL MICROBIOL, V4, P151, DOI 10.1111/j.1365-2958.1990.tb02025.x; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; SEMENKOV YP, 1982, FEBS LETT, V144, P125, DOI 10.1016/0014-5793(82)80584-X; SPANGLER EA, 1985, J BIOL CHEM, V260, P6334; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STEZOWSKI JJ, 1976, J AM CHEM SOC, V98, P6012, DOI 10.1021/ja00435a039; TAI PC, 1973, BIOCHEMISTRY-US, V12, P616, DOI 10.1021/bi00728a008; Taylor DE, 1996, ANTIMICROB AGENTS CH, V40, P1; VAZQUEZ D, 1974, FEBS LETT, V43, pS63; WHITE JP, 1971, J MOL BIOL, V58, P397, DOI 10.1016/0022-2836(71)90255-5; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; Yoshizawa S, 1998, EMBO J, V17, P6437, DOI 10.1093/emboj/17.22.6437; ZIERHUT G, 1979, EUR J BIOCHEM, V98, P577, DOI 10.1111/j.1432-1033.1979.tb13219.x	63	637	685	6	132	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1143	1154		10.1016/S0092-8674(00)00216-6	http://dx.doi.org/10.1016/S0092-8674(00)00216-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163189	Bronze			2022-12-28	WOS:000166040600016
J	Sudol, M; Hunter, T				Sudol, M; Hunter, T			NeW wrinkles for an old domain	CELL			English	Review							PROLYL ISOMERASE; WW DOMAINS; PROTEIN; BINDING		Mt Sinai Med Ctr, New York, NY 10029 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Icahn School of Medicine at Mount Sinai; Salk Institute	Sudol, M (corresponding author), Mt Sinai Med Ctr, New York, NY 10029 USA.							Bedford MT, 1999, TRENDS BIOCHEM SCI, V24, P264, DOI 10.1016/S0968-0004(99)01417-6; Bednarek AK, 2000, CANCER RES, V60, P2140; Carty SM, 2000, P NATL ACAD SCI USA, V97, P9015, DOI 10.1073/pnas.160266597; Chang A, 2000, J BIOL CHEM, V275, P20562, DOI 10.1074/jbc.M002479200; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; MORRIS DP, 2000, IN PRESS J BIOL CHEM; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727	18	292	296	2	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 22	2000	103	7					1001	1004		10.1016/S0092-8674(00)00203-8	http://dx.doi.org/10.1016/S0092-8674(00)00203-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163176	Bronze			2022-12-28	WOS:000166040600003
J	Skelton, JR; Macleod, JA; Thomas, CP				Skelton, JR; Macleod, JA; Thomas, CP			Teaching literature and medicine to medical students, part II: why literature and medicine?	LANCET			English	Editorial Material							HUMANITIES; EDUCATION		Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Skelton, JR (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	j.r.skeiton@bham.ac.uk						Barry Peter., 1995, BEGINNING THEORY INT; Bloor D., 1976, KNOWLEDGE SOCIAL IMA; CARROLL J, 1964, SELECTED LETT S RICH; CHALMERS A, 1990, SCI ITS FAB FABRICAT; Charon R, 1996, J MED PHILOS, V21, P243; CHARON R, 1986, LIT MED, V5, P58; COULEHAN J, 1993, EMPATHY PRACTICE MED, P147; Eagleton T., 2008, LIT THEORY INTRO ANN; General Medical Council, 1993, TOM DOCT; GILLON R, 1997, MED ETHICS, V23, P45; HOLLANDER J, 1973, LIT RENAISANCE ENGLA; Horowitz HW, 1996, LANCET, V347, P447, DOI 10.1016/S0140-6736(96)90015-X; Hume David, 1875, ESSAYS MORAL POLITIC; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; JONES AH, 1990, ST COMPAR L, V22, P11; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; Lodge David, 1987, LINGUISTICS WRITING, P89; MCMANUS IC, 1995, LANCET, V346, P1143, DOI 10.1016/S0140-6736(95)91806-X; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Pickering N, 1998, J MED ETHICS, V24, P171, DOI 10.1136/jme.24.3.171; Popper K., 1974, UNENDED QUEST INTELL; REED J, 1999, STUDENT BMJ, V7, P127; Richards I. A., 1925, PRINCIPLES LIT CRITI; RICHARDSON S, 1775, COMMUNICATION   0922; ROSENZWEIG S, 1994, ACAD MED, V69, P732, DOI 10.1097/00001888-199409000-00010; SHAKESPEARE W, 1989, W SHAKESPERE COLLECT; Smith BH, 1998, BRIT J GEN PRACT, V48, P1337; SPIRO H, 1992, ANN INTERN MED, V116, P843, DOI 10.7326/0003-4819-116-10-843; STEVENS W, 1953, SELECTED POEMS W STE; WAFER A, 1999, BMA NEWS REV    1127, P26; Wittgenstein L.J.J., 1992, TRACTATUS LOGICOPHIL	31	29	33	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					2001	2003		10.1016/S0140-6736(00)03318-3	http://dx.doi.org/10.1016/S0140-6736(00)03318-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	383DJ	11130538				2022-12-28	WOS:000165867600040
J	Ye, KQ; Hurt, J; Wu, FY; Fang, M; Luo, HBR; Hong, JJ; Blackshaw, S; Ferris, CD; Snyder, SH				Ye, KQ; Hurt, J; Wu, FY; Fang, M; Luo, HBR; Hong, JJ; Blackshaw, S; Ferris, CD; Snyder, SH			PIKE: A nuclear GTPase that enhances PI3Kinase activity and is regulated by protein 4.1N	CELL			English	Article							NERVE GROWTH-FACTOR; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; GUANINE-NUCLEOTIDE-EXCHANGE; MITOTIC APPARATUS PROTEIN; HUMAN MXB PROTEIN; PC12 CELLS; NEURITE OUTGROWTH; PHOSPHOINOSITIDE 3-KINASE; CYCLIN D1; ACTIVATION	While cytoplasmic PI3Kinase (PI3K) is well characterized, regulation of nuclear PI3K has been obscure. A novel protein, PIKE (PI3Kinase Enhancer), interacts with nuclear PI3K to stimulate its lipid kinase activity. PIKE encodes a 753 amino acid nuclear GTPase. Dominant-negative PIKE prevents the NGF enhancement of PI3K and upregulation of cyclin D1. NGF treatment also leads to PIKE interactions with 4.1N, which has translocated to the nucleus, fitting with the initial identification of PIKE based on its binding 4.1N in a yeast two-hybrid screen. Overexpression of 4.1N abolishes PIKE effects on PI3K. Activation of nuclear PI3K by PIKE is inhibited by the NGF-stimulated 4.1N translocation to the nucleus. Thus, PIKE physiologically modulates the activation by NGF of nuclear PI3K.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu	Hurt, K. Joseph/J-8266-2019	Hurt, K. Joseph/0000-0001-6906-350X	NCI NIH HHS [CA00266] Funding Source: Medline; NIDA NIH HHS [DA-00074] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; Bavelloni A, 1999, J CELL SCI, V112, P631; Blackshaw S, 1997, J NEUROSCI, V17, P8074; Boglari G, 1998, EUR J CELL BIOL, V75, P54, DOI 10.1016/S0171-9335(98)80046-0; BRANDT DR, 1985, J BIOL CHEM, V260, P266; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; D'Mello SR, 1997, J NEUROSCI, V17, P1548; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Jackson TR, 1996, J CELL SCI, V109, P289; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kim SH, 1998, J VIROL, V72, P994, DOI 10.1128/JVI.72.2.994-1004.1998; Kim SJ, 1998, BIOCHEM MOL BIOL INT, V46, P187; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Krugmann S, 1998, CURR BIOL, V8, pR828; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; LYDERSEN BK, 1980, CELL, V22, P489, DOI 10.1016/0092-8674(80)90359-1; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Marchisio M, 1998, BIOCHEM BIOPH RES CO, V253, P346, DOI 10.1006/bbrc.1998.9787; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; Melen K, 1996, J BIOL CHEM, V271, P23478, DOI 10.1074/jbc.271.38.23478; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NERI LM, 1994, CELL MOL BIOL, V40, P619; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRICE CM, 1986, EXP CELL RES, V166, P295, DOI 10.1016/0014-4827(86)90478-7; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Salehi A, 1996, NEUROSCIENCE, V75, P373, DOI 10.1016/0306-4522(96)00273-4; SANO M, 1995, BRAIN RES, V688, P213, DOI 10.1016/0006-8993(95)00558-8; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Walensky LD, 1999, J NEUROSCI, V19, P6457; WARD SG, 1993, EUR J IMMUNOL, V23, P2572, DOI 10.1002/eji.1830231029; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; YAN GZ, 1995, J NEUROSCI, V15, P6200; YANG CH, 1992, MOL BIOL CELL, V3, P1259, DOI 10.1091/mbc.3.11.1259; YANKNER BA, 1979, P NATL ACAD SCI USA, V76, P1269, DOI 10.1073/pnas.76.3.1269; Ye KQ, 1999, J NEUROSCI, V19, P10747, DOI 10.1523/JNEUROSCI.19-24-10747.1999; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	73	140	146	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					919	930		10.1016/S0092-8674(00)00195-1	http://dx.doi.org/10.1016/S0092-8674(00)00195-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136977	Bronze			2022-12-28	WOS:000165801300011
J	Simpson, AA; Tao, YZ; Leiman, PG; Badasso, MO; He, YN; Jardine, PJ; Olson, NH; Morais, MC; Grimes, S; Anderson, DL; Baker, TS; Rossmann, MG				Simpson, AA; Tao, YZ; Leiman, PG; Badasso, MO; He, YN; Jardine, PJ; Olson, NH; Morais, MC; Grimes, S; Anderson, DL; Baker, TS; Rossmann, MG			Structure of the bacteriophage phi 29 DNA packaging motor	NATURE			English	Article							IN-VITRO; RNA; CONNECTOR; RESOLUTION; SYMMETRY; PROTEIN; PROHEAD; MACHINE; DOMAIN; ATPASE	Motors generating mechanical force, powered by the hydrolysis of ATP, translocate double-stranded DNA into preformed capsids (proheads) of bacterial viruses(1,2) and certain animal viruses(3). Here we describe the motor that packages the double-stranded DNA of the Bacillus subtilis bacteriophage phi 29 into a precursor capsid. We determined the structure of the head-tail connector-the central component of the phi 29 DNA packaging motor-to 3.2 Angstrom resolution by means of X-ray crystallography. We then fitted the connector into the electron densities of the prohead and of the partially packaged prohead as determined using cryo-electron microscopy and image reconstruction analysis. Our results suggest that the prohead plus dodecameric connector, prohead RNA, viral ATPase and DNA comprise a rotary motor with the head-prohead RNA-ATPase complex acting as a stator, the DNA acting as a spindle, and the connector as a ball-race. The helical nature of the DNA converts the rotary action of the connector into translation of the DNA.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Oral Sci, Minneapolis, MN 55455 USA; Univ New Brunswick, Dept Biol, Fredericton, NB E3B 6E1, Canada	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of New Brunswick	Rossmann, MG (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.		Leiman, Petr G/E-5120-2010	Leiman, Petr G/0000-0002-9091-0918; Jardine, Paul/0000-0002-1090-0550; , Timothy/0000-0001-6543-8968	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033050] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM033050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANDERSON DL, 1966, J BACTERIOL, V91, P2081, DOI 10.1128/JB.91.5.2081-2089.1966; Badasso MO, 2000, ACTA CRYSTALLOGR D, V56, P1187, DOI 10.1107/S0907444900009239; BAILEY S, 1990, J BIOL CHEM, V265, P22365; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; DONATE LE, 1993, J BIOL CHEM, V268, P20198; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; Guasch A, 1998, J MOL BIOL, V281, P219, DOI 10.1006/jmbi.1998.1928; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; Ibarra B, 2000, J MOL BIOL, V298, P807, DOI 10.1006/jmbi.2000.3712; Muller DJ, 1997, EMBO J, V16, P2547, DOI 10.1093/emboj/16.10.2547; REID RJD, 1994, J BIOL CHEM, V269, P9084; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; ROSSMANN MG, IN PRESS INT TABLE C, VF; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; Tao YZ, 1998, CELL, V95, P431, DOI 10.1016/S0092-8674(00)81773-0; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Valle M, 1999, J MOL BIOL, V288, P899, DOI 10.1006/jmbi.1999.2731; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; Valpuesta JM, 1999, STRUCTURE, V7, P289, DOI 10.1016/S0969-2126(99)80039-2; VLCEK C, 1986, GENE, V46, P215, DOI 10.1016/0378-1119(86)90406-3; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9; Zhou ZH, 1999, J VIROL, V73, P3210, DOI 10.1128/JVI.73.4.3210-3218.1999	28	428	441	2	47	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					745	750		10.1038/35047129	http://dx.doi.org/10.1038/35047129			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130079	Green Accepted			2022-12-28	WOS:000165815200055
J	[Anonymous]				[Anonymous]			Developing countries and poorest people targeted by UN centre	NATURE			English	Article																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					754	754		10.1038/35047219	http://dx.doi.org/10.1038/35047219			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130081	Bronze			2022-12-28	WOS:000165815200060
J	Hardy, J				Hardy, J			Sedation in terminally ill patients	LANCET			English	Editorial Material							HOSPICE		Royal Marsden, Dept Palliat Med, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust	Hardy, J (corresponding author), Royal Marsden, Dept Palliat Med, Sutton SM2 5PT, Surrey, England.		Hardy, Janet/F-2501-2012	Hardy, Janet/0000-0003-1127-9951				Back Ian N., 1992, Palliative Medicine, V6, P293, DOI 10.1177/026921639200600404; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P287, DOI 10.1016/0885-3924(95)00005-J; Chater S, 1998, PALLIATIVE MED, V12, P255, DOI 10.1191/026921698671831786; Fainsinger RL, 2000, PALLIATIVE MED, V14, P257, DOI 10.1191/026921600666097479; Fainsinger RL, 1998, J PAIN SYMPTOM MANAG, V16, P145, DOI 10.1016/S0885-3924(98)00066-9; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Stone P, 1997, PALLIATIVE MED, V11, P140, DOI 10.1177/026921639701100208; SYKES N, 2000, PAIN EUROPE, V3, P71	9	21	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1866	1867		10.1016/S0140-6736(00)03252-9	http://dx.doi.org/10.1016/S0140-6736(00)03252-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130377				2022-12-28	WOS:000165665400004
J	Pasquarello, A; Petri, I; Salmon, PS; Parisel, O; Car, R; Toth, E; Powell, DH; Fischer, HE; Helm, L; Merbach, AE				Pasquarello, A; Petri, I; Salmon, PS; Parisel, O; Car, R; Toth, E; Powell, DH; Fischer, HE; Helm, L; Merbach, AE			First solvation shell of the Cu(II) aqua ion: Evidence for fivefold coordination	SCIENCE			English	Article							HYDRATED COPPER(II) ION; AQUEOUS-SOLUTION; MOLECULAR-DYNAMICS; NEUTRON-DIFFRACTION; LIQUID WATER; TELLER; CU2+; DEPENDENCE; RELAXATION; EXCHANGE	We determined the structure of the hydrated Cu(II) complex by both neutron diffraction and first-principles molecular dynamics, In contrast with the generally accepted picture, which assumes an octahedrally solvated Cu(II) ion, our experimental and theoretical results favor fivefold coordination. The simulation reveals that the solvated complex undergoes frequent transformations between square pyramidal and trigonal bipyramidal configurations. We argue that this picture is also consistent with experimental data obtained previously by visible near-infrared absorption, x-ray absorption near-edge structure, and nuclear magnetic resonance methods. The preference of the Cu(II) ion for fivefold instead of sixfold coordination, which occurs for other cations of comparable charge and size, results from a Jahn-Teller destabilization of the octahedral complex.	PPH Ecublens, Inst Romand Rech Numer Phys Mat, CH-1015 Lausanne, Switzerland; Ecole Polytech Fed Lausanne, PPH Ecublens, CH-1015 Lausanne, Switzerland; Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England; Princeton Univ, Frick Chem Lab, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Frick Chem Lab, Princeton Mat Inst, Princeton, NJ 08544 USA; Univ Lausanne, Inst Chim Minerale & Analyt, CH-1015 Lausanne, Switzerland; Univ Durham, Dept Chem, Durham DH1 3LE, England; Ctr Univ Paris Sud, LURE, F-91898 Orsay, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Bath; Princeton University; Princeton University; University of Lausanne; Durham University	Pasquarello, A (corresponding author), PPH Ecublens, Inst Romand Rech Numer Phys Mat, CH-1015 Lausanne, Switzerland.	Alfredo.Pasquarello@epfl.ch	Fischer, Henry E/D-5299-2012; Pasquarello, Alfredo/G-2883-2011; Salmon, Philip S/Q-9512-2016; Toth, Eva/F-5806-2011	Fischer, Henry E/0000-0002-1204-0750; Pasquarello, Alfredo/0000-0002-9142-2799; Salmon, Philip S/0000-0001-8671-1011; Toth, Eva/0000-0002-3200-6752				BEAGLEY B, 1989, J PHYS-CONDENS MAT, V1, P2395, DOI 10.1088/0953-8984/1/13/012; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; BURGESS J, 1988, IONS SOLUTION BASIS, P34; GALLUCCI JC, 1989, ACTA CRYSTALLOGR C, V45, P1279, DOI 10.1107/S0108270189000818; Garber D. I, 1976, 325 BNL, VII; GARCIA J, 1989, CHEM PHYS, V132, P295, DOI 10.1016/0301-0104(89)80095-3; Hathaway B.J., 1987, COMPREHENSIVE COORDI, P533; LAASONEN K, 1993, PHYS REV B, V47, P10142, DOI 10.1103/PhysRevB.47.10142; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; LICHERI G, 1984, J CHEM PHYS, V80, P5308, DOI 10.1063/1.446559; Lincoln S.F., 1995, ADV INORG CHEM, V42, P1; MAGINI M, 1982, INORG CHEM, V21, P1535, DOI 10.1021/ic00134a053; NOMURA M, 1988, J PHYS CHEM-US, V92, P6157, DOI 10.1021/j100332a061; OCHIAL E, 1977, BIOINORGANIC CHEM IN; OHTAKI H, 1974, B CHEM SOC JPN, V47, P2197, DOI 10.1246/bcsj.47.2197; OKAN SE, 1995, MOL PHYS, V85, P981, DOI 10.1080/00268979500101601; PASQUARELLO A, 1992, PHYS REV LETT, V69, P1982, DOI 10.1103/PhysRevLett.69.1982; POUPKO R, 1972, J CHEM PHYS, V57, P3311, DOI 10.1063/1.1678760; POWELL DH, 1993, J PHYS-CONDENS MAT, V5, P5723, DOI 10.1088/0953-8984/5/32/003; POWELL DH, 1991, J CHEM PHYS, V95, P9258, DOI 10.1063/1.461206; POWELL DH, 1989, J PHYS-CONDENS MAT, V1, P8721, DOI 10.1088/0953-8984/1/44/040; Richens DT., 1997, CHEM AQUA IONS; SALMON PS, 1989, J PHYS-CONDENS MAT, V1, P5291, DOI 10.1088/0953-8984/1/31/028; SALMON PS, 1988, J PHYS C SOLID STATE, V21, P1335, DOI 10.1088/0022-3719/21/8/010; SALMON PS, 1987, J PHYS C SOLID STATE, V20, pS727; Sears V.F., 1992, NEUTRON NEWS, V3, P26, DOI [10.1080/10448639208218770, DOI 10.1080/10448639208218770]; SHAM TK, 1981, CHEM PHYS LETT, V83, P391, DOI 10.1016/0009-2614(81)85486-3; Silvestrelli PL, 1999, J CHEM PHYS, V111, P3572, DOI 10.1063/1.479638; Sprik M, 1996, J CHEM PHYS, V105, P1142, DOI 10.1063/1.471957; TAJIRI Y, 1986, B CHEM SOC JPN, V59, P2285, DOI 10.1246/bcsj.59.2285	31	332	333	3	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 2	2001	291	5505					856	859		10.1126/science.291.5505.856	http://dx.doi.org/10.1126/science.291.5505.856			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157161				2022-12-28	WOS:000166771700039
J	Stevens, TE; Wahlstrand, JK; Kuhl, J; Merlin, R				Stevens, TE; Wahlstrand, JK; Kuhl, J; Merlin, R			Cherenkov radiation at speeds below the light threshold: Phonon-assisted phase matching	SCIENCE			English	Article							POLARITON; PULSES; LITAO3; MEDIA	Charged particles traveling through matter at speeds larger than the phase velocity of Light in the medium emit Cherenkov radiation. Calculations reveal that a given angle of the radiation conical wavefront is associated with two velocities, one above and one below a certain speed threshold. Emission at subluminal but not superluminal speeds is predicted and verified experimentally for relativistic dipoles generated with an optical method based on subpicosecond pulses moving in a nonlinear medium. The dipolar Cherenkov field, in the range of infrared-active phonons, is identical to that of phonon polaritons produced by impulsive Laser excitation.	Univ Michigan, Harrison M Randall Lab Phys, Ann Arbor, MI 48109 USA; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany	University of Michigan System; University of Michigan; Max Planck Society	Merlin, R (corresponding author), Univ Michigan, Harrison M Randall Lab Phys, Ann Arbor, MI 48109 USA.							Afanasiev GN, 1999, PHYSICA B, V269, P95, DOI 10.1016/S0921-4526(99)00078-2; Albert O, 1998, SOLID STATE COMMUN, V107, P567, DOI 10.1016/S0038-1098(98)00272-5; AUSTON DH, 1984, PHYS REV LETT, V53, P1555, DOI 10.1103/PhysRevLett.53.1555; Bakker HJ, 1998, REV MOD PHYS, V70, P523, DOI 10.1103/RevModPhys.70.523; BORN M, 1996, DYNAMICAL THEORY CRY, P100; Cherenkov P A, 1934, CR DOKL ACAD SCI URS, V2, P451; Fermi E, 1940, PHYS REV, V57, P485, DOI 10.1103/PhysRev.57.485; Frank I.M., 1988, VAVILOV CHERENKOV RA; GALE GM, 1986, PHYS REV LETT, V57, P1867, DOI 10.1103/PhysRevLett.57.1867; Gobel A, 1999, PHYS REV B, V59, P2749, DOI 10.1103/PhysRevB.59.2749; GRENIER P, 1994, PHYS REV B, V50, P16295, DOI 10.1103/PhysRevB.50.16295; Hattori T., 1973, Optics Communications, V7, P229, DOI 10.1016/0030-4018(73)90015-1; JENSEN B, 1983, INFRARED PHYS, V23, P359, DOI 10.1016/0020-0891(83)90011-8; KLEINMAN DA, 1984, IEEE J QUANTUM ELECT, V20, P964, DOI 10.1109/JQE.1984.1072489; Koehl RM, 1999, J CHEM PHYS, V110, P1317, DOI 10.1063/1.478007; LI H, 1984, J PHYS CHEM REF DATA, V13, P102; Perry HM, 1997, PHYS REV B, V55, P5778, DOI 10.1103/PhysRevB.55.5778; Seguinot J, 1999, NUCL INSTRUM METH A, V433, P1, DOI 10.1016/S0168-9002(99)00543-4; Shen Y. R., 1984, PRINCIPLES NONLINEAR; STEVENS TE, 2000, THESIS U MICHIGAN; Tamm I, 1939, J PHYS-USSR, V1, P439; Tamm I.E., 1937, DOKL AKAD NAUK SSSR, V14, P109; Vavilov S.I., 1934, CR DOKL AKAD SCI, V2, P457, DOI [10.3367/UFNr.0093.196710m.0383, DOI 10.3367/UFNR.0093.196710M.0383]; WIEDERRECHT GP, 1995, PHYS REV B, V51, P916, DOI 10.1103/PhysRevB.51.916; ZRELOR VP, 1998, CERN COURIER, V38, P7; ZRELOV VP, 1998, JINR RAPID COMMUN, V1, P23; ZRELOV VP, 1970, CHERENKOV RAD HIGH E	27	60	62	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					627	630		10.1126/science.291.5504.627	http://dx.doi.org/10.1126/science.291.5504.627			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158670				2022-12-28	WOS:000166616000036
J	Blumberg, H; Conklin, D; Xu, WF; Grossmann, A; Brender, T; Carollo, S; Eagan, M; Foster, D; Haldeman, BA; Hammond, A; Haugen, H; Jelinek, L; Kelly, JD; Madden, K; Maurer, MF; Parrish-Novak, J; Prunkard, D; Sexson, S; Sprecher, C; Waggie, K; West, J; Whitmore, TE; Yao, L; Kuechle, MK; Dale, BA; Chandrasekher, YA				Blumberg, H; Conklin, D; Xu, WF; Grossmann, A; Brender, T; Carollo, S; Eagan, M; Foster, D; Haldeman, BA; Hammond, A; Haugen, H; Jelinek, L; Kelly, JD; Madden, K; Maurer, MF; Parrish-Novak, J; Prunkard, D; Sexson, S; Sprecher, C; Waggie, K; West, J; Whitmore, TE; Yao, L; Kuechle, MK; Dale, BA; Chandrasekher, YA			Interleukin 20: Discovery, receptor identification, and role in epidermal function	CELL			English	Article							DIFFERENTIATION-ASSOCIATED GENE; TRANSGENIC MICE; MELANOMA DIFFERENTIATION; EXPRESSION; PSORIASIS; CYTOKINE; SEQUENCE; PROTEINS; ANTIGEN; GROWTH	A structural, profile-based algorithm was used to identify interleukin 20 (IL-20), a novel IL-10 homolog. Chromosomal localization of IL-20 led to the discovery of an IL-10 family cytokine cluster. Overexpression of IL-20 in transgenic (TG) mice causes neonatal lethality with skin abnormalities including aberrant epidermal differentiation. Recombinant IL-20 protein stimulates a signal transduction pathway through STAT3 in a keratinocyte cell line, demonstrating a direct action of this ligand. An IL-20 receptor was identified as a heterodimer of two orphan class II cytokine receptor subunits. Both receptor subunits are expressed in skin and are dramatically upregulated in psoriatic skin. Taken together, these results demonstrate a role in epidermal function and psoriasis for IL-20, a novel cytokine identified solely by bioinformatics analysis.	Zymogenet Inc, In Vitro Biol, Seattle, WA 98102 USA; Zymogenet Inc, Dept Genet, Seattle, WA 98102 USA; Zymogenet Inc, Biomol Informat, Seattle, WA 98102 USA; Zymogenet Inc, Funct Cloning, Seattle, WA 98102 USA; Univ Washington, Dept Oral Biol & Med Dermatol, Seattle, WA 98195 USA	Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.; University of Washington; University of Washington Seattle	Chandrasekher, YA (corresponding author), Zymogenet Inc, In Vitro Biol, 1201 Eastlake Ave E, Seattle, WA 98102 USA.							Asadullah K, 1998, J CLIN INVEST, V101, P783, DOI 10.1172/JCI1476; Asadullah K, 1999, ARCH DERMATOL RES, V291, P628, DOI 10.1007/s004030050467; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bos JD, 1999, IMMUNOL TODAY, V20, P40, DOI 10.1016/S0167-5699(98)01381-4; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; Castelijns FACM, 1999, J AM ACAD DERMATOL, V40, P901, DOI 10.1016/S0190-9622(99)70077-0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DIETRICH DR, 1993, CRIT REV TOXICOL, V23, P77, DOI 10.3109/10408449309104075; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; Eskdale J, 1997, IMMUNOGENETICS, V46, P120, DOI 10.1007/s002510050250; GIJBELS MJJ, 1995, ULTRASTRUCT PATHOL, V19, P107, DOI 10.3109/01913129509014610; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; JAHN H, 1988, APMIS, V96, P723, DOI 10.1111/j.1699-0463.1988.tb00936.x; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Karasek MA, 1999, CUTIS, V64, P319; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Koller M R, 1996, J Hematother, V5, P449, DOI 10.1089/scd.1.1996.5.449; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Michel G, 1997, J IMMUNOL, V159, P6291; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; ROSEN CA, 1999, Patent No. 5985614; SCHERINGPLOUGH CORP, 1999, Patent No. 9946379; SHEEHAN DC, 1980, THEORY PRACTICE HIST, P59; SUN TT, 1985, ANN NY ACAD SCI, V455, P307, DOI 10.1111/j.1749-6632.1985.tb50419.x; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219; ZYMOGENETICS INC, 2000, Patent No. 0053761	44	438	557	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2001	104	1					9	19		10.1016/S0092-8674(01)00187-8	http://dx.doi.org/10.1016/S0092-8674(01)00187-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163236	Bronze			2022-12-28	WOS:000166882300003
J	Gruss, OJ; Carazo-Salas, RE; Schatz, CA; Guarguaglini, G; Kast, J; Wilm, M; Le Bot, N; Vernos, I; Karsenti, E; Mattaj, IW				Gruss, OJ; Carazo-Salas, RE; Schatz, CA; Guarguaglini, G; Kast, J; Wilm, M; Le Bot, N; Vernos, I; Karsenti, E; Mattaj, IW			Ran induces spindle assembly by reversing the inhibitory effect of importin alpha on TPX2 activity	CELL			English	Article							XENOPUS EGG EXTRACTS; NUCLEAR-PROTEIN IMPORT; SMALL GTPASE RAN; SELF-ORGANIZATION; NUCLEOTIDE EXCHANGE; POLYACRYLAMIDE GELS; MICROTUBULE ASTERS; TRANSPORT FACTORS; CELL-CYCLE; BOUND RAN	The small GTPase Ran, bound to GTP, is required for the induction of spindle formation by chromosomes in M phase. High concentrations of Ran.GTP are proposed to surround M phase chromatin. We show that the action of Ran.GTP in spindle formation requires TPX2, a microtubule-associated protein previously known to target a motor protein, Xklp2, to microtubules. TPX2 is normally inactivated by binding to the nuclear import factor, importin alpha, and is displaced from importin alpha by the action of Ran.GTP. TPX2 is required for Ran.GTP and chromatin-induced microtubule assembly in M phase extracts and mediates spontaneous microtubule assembly when present in excess over free importin alpha. Thus, components of the nuclear transport machinery serve to regulate spindle formation in M phase.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Vernos, Isabelle/C-1687-2015	Vernos, Isabelle/0000-0003-1469-9214; Le Bot, Nathalie/0000-0002-5258-2837; Carazo-Salas, Rafael E/0000-0002-5943-3981; Wilm, Matthias/0000-0002-5461-6834; Mattaj, Iain/0000-0002-5537-8284				Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; [Anonymous], 1990, METHOD ENZYMOL, DOI 10.1016/0076-6879(90)82024-v; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; Bonaccorsi S, 2000, NAT CELL BIOL, V2, P54, DOI 10.1038/71378; Bonaccorsi S, 1998, J CELL BIOL, V142, P751, DOI 10.1083/jcb.142.3.751; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; CARAZOSALAS RE, 2001, IN PRESS NAT CELL BI; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Heidebrecht HJ, 1997, BLOOD, V90, P226; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Hubner S, 1999, J BIOL CHEM, V274, P22610, DOI 10.1074/jbc.274.32.22610; Hyman A, 1998, J CELL SCI, V111, P2077; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KARSENTI E, 1984, J CELL BIOL, V98, P1763, DOI 10.1083/jcb.98.5.1763; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MURRAY A, 1991, XENOPUS LAEVIS PRACT; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Saitoh H, 1996, MOL BIOL CELL, V7, P1319, DOI 10.1091/mbc.7.9.1319; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang CM, 1999, J CELL SCI, V112, P2453	55	477	484	3	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2001	104	1					83	93		10.1016/S0092-8674(01)00193-3	http://dx.doi.org/10.1016/S0092-8674(01)00193-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163242	Bronze			2022-12-28	WOS:000166882300009
J	Hennecke, J; Wiley, DC				Hennecke, J; Wiley, DC			T cell receptor-MHC interactions up close	CELL			English	Review							STRUCTURAL BASIS; PEPTIDE; COMPLEX; RECOGNITION		Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Howard Hughes Medical Institute	Hennecke, J (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.							Bjorkman PJ, 1997, CELL, V89, P167, DOI 10.1016/S0092-8674(00)80195-6; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Hennecke J, 2000, EMBO J, V19, P5611, DOI 10.1093/emboj/19.21.5611; Kranz DM, 2000, NAT IMMUNOL, V1, P277, DOI 10.1038/79716; Pecorari F, 1999, J MOL BIOL, V285, P1831, DOI 10.1006/jmbi.1998.2422; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5	16	149	154	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2001	104	1					1	4		10.1016/S0092-8674(01)00185-4	http://dx.doi.org/10.1016/S0092-8674(01)00185-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163234	Bronze			2022-12-28	WOS:000166882300001
J	Zhou, Z; Hartwieg, E; Horvitz, HR				Zhou, Z; Hartwieg, E; Horvitz, HR			CED-1 is a transmembrane receptor that mediates cell corpse engulfment in C-elegans	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DENSITY-LIPOPROTEIN RECEPTOR; APOPTOTIC CELLS; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; KNOCKOUT MICE; GENE-TRANSFER; PROTEIN; PHAGOCYTOSIS; DEATH	We cloned the C. elegans gene ced-1, which is required for the engulfment of cells undergoing programmed cell death, ced-1 encodes a transmembrane protein similar to human SREC (Scavenger Receptor from Endothelial Cells). We showed that ced-1 is expressed in and functions in engulfing cells. The CED-1 protein localizes to cell membranes and clusters around neighboring cell corpses. CED-1 failed to cluster around cell corpses in mutants defective in the engulfment gene ced-7. Motifs in the intracellular domain of CED-1 known to interact with PTB and SH2 domains were necessary for engulfment but not for clustering. Our results indicate that CED-1 is a cell surface phagocytic receptor that recognizes cell corpses. We suggest that the ABC transporter CED-7 promotes cell corpse recognition by CED-1, possibly by exposing a phospholipid ligand on the surfaces of cell corpses.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, Bldg 68,Room 425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	horvitz@mit.edu						Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; ELLIS RE, 1991, GENETICS, V129, P79; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Giles KM, 2000, BRIT J HAEMATOL, V109, P1, DOI 10.1046/j.1365-2141.2000.01805.x; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hall DH, 1999, DEV BIOL, V212, P101, DOI 10.1006/dbio.1999.9356; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; Kimble J, 1998, TRENDS BIOCHEM SCI, V23, P353, DOI 10.1016/S0968-0004(98)01263-8; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Riddle DL, 1997, C ELEGANS; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Stryer L., 1988, BIOCHEMISTRY-US; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Tait JF, 1999, J BIOL CHEM, V274, P3048, DOI 10.1074/jbc.274.5.3048; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	49	427	440	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					43	56		10.1016/S0092-8674(01)00190-8	http://dx.doi.org/10.1016/S0092-8674(01)00190-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163239	Bronze			2022-12-28	WOS:000166882300006
J	Lane, B; Challen, K; Harris, HJ; Harris, R				Lane, B; Challen, K; Harris, HJ; Harris, R			Existence and quality of written antenatal screening policies in the United Kingdom: postal survey	BRITISH MEDICAL JOURNAL			English	Article									St Marys Hosp, Genet Enquiry Ctr, Manchester M13 0JH, Lancs, England	University of Manchester	Challen, K (corresponding author), St Marys Hosp, Genet Enquiry Ctr, Manchester M13 0JH, Lancs, England.		Challen, Kirsty/AAU-3421-2021	Challen, Kirsty/0000-0003-4032-5531				Harris R, 1999, BRIT J OBSTET GYNAEC, V106, P658, DOI 10.1111/j.1471-0528.1999.tb08364.x; *ROYAL COLL OBST G, 1997, EFF PROC MAT CAR SUI; 2000, CONFIDENTIAL ENQUIRY	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					22	23		10.1136/bmj.322.7277.22	http://dx.doi.org/10.1136/bmj.322.7277.22			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141145	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000166341400018
J	Muldoon, MF; Manuck, SB; Mendelsohn, AB; Kaplan, JR; Belle, SH				Muldoon, MF; Manuck, SB; Mendelsohn, AB; Kaplan, JR; Belle, SH			Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials	BRITISH MEDICAL JOURNAL			English	Article							LIPID-LOWERING DRUGS; SERUM-CHOLESTEROL; RISK; SUICIDE; LOVASTATIN; PRAVASTATIN; VIOLENCE; BENEFIT; SLEEP; DEATH	Objective To investigate the association between cholesterol lowering interventions and risk of death from suicide, accident, or trauma (non-illness mortality). Design Meta-analysis of the non-illness mortality outcomes of large, randomised clinical trials of cholesterol lowering treatments. Studies reviewed 19 out of 21 eligible trials that had data available on non-illness mortality. Interventions reviewed Dietary modification, drug treatment, Or partial ileal bypass surgery for 1-10 years Main outcome measure Deaths from suicides, accidents, and violence in treatment groups compared with control groups, Results Across all trials, the odds ratio Of non-illness mortality in the treated groups, relative to control groups, was 1.18 (95% confidence interval 0.91 to 1.52; P = 0.20). The odds ratios were 1.28 (0.94 to 1.74; P = 0.12) for primary prevention trials and 1.00 (0.65 to 1.55; P = 0.98) for secondary prevention trials. Randomised clinical trials using statins did not show a treatment related rise in non-illness mortality (0.84, 0.50 to 1.41;P = 0.50), whereas a trend toward increased deaths from suicide and violence was observed in trials of dietary interventions and non-statin drugs (1.32, 0.98 to 1.77; P = 0.06). No relation was found between the magnitude of cholesterol:reduction and non-illness mortality (P = 0.23). Conclusion Currently available evidence does not indicate that non-illness mortality is increased significantly by cholesterol lowering treatments. A modest increase may occur with dietary interventions and non-statin drugs.	Univ Pittsburgh, Sch Med, Ctr Clin Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; Wake Forest Univ, Bowman Gray Sch Med, Comparat Med Clin Res Ctr, Winston Salem, NC 27103 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Muldoon, MF (corresponding author), Univ Pittsburgh, Sch Med, Ctr Clin Pharmacol, 506 Old Engn Hall, Pittsburgh, PA 15260 USA.			Mendelsohn, Aaron/0000-0002-0560-1177	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040962, R01HL046328] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL040962, HL40962, HL46328] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baxter C, 1998, BMJ-BRIT MED J, V317, P1134; Bovbjerg VE, 1999, J CLIN EPIDEMIOL, V52, P1197, DOI 10.1016/S0895-4356(99)00125-0; Bucher HC, 1999, ARTERIOSCL THROM VAS, V19, P187, DOI 10.1161/01.ATV.19.2.187; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; *CDC, 1999, OV INJ EXCL ADV EV R; DOWNS JR, 1993, JAMA-J AM MED ASSOC, V269, P3107, DOI 10.1001/jama.269.24.3107; Ehrenberg BL, 1999, SLEEP, V22, P117, DOI 10.1093/sleep/22.1.117; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P507, DOI 10.1093/oxfordjournals.aje.a117465; Garland M, 2000, BRIT J PSYCHIAT, V177, P77, DOI 10.1192/bjp.177.1.77; Golomb BA, 1998, ANN INTERN MED, V128, P478, DOI 10.7326/0003-4819-128-6-199803150-00009; GOLOMB BA, IN PRESS J PSYCHIAT; HEADY JA, 1992, LANCET, V340, P1405, DOI 10.1016/0140-6736(92)92588-7; HILLBRAND M, 1995, J BEHAV MED, V18, P33, DOI 10.1007/BF01857703; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Kaplan J, 1997, LIPIDS HLTH BEHAV, P139; Kaplan JR, 1996, AM J PRIMATOL, V38, P333, DOI 10.1002/(SICI)1098-2345(1996)38:4<333::AID-AJP4>3.0.CO;2-#; Kaplan JR, 1997, ANN NY ACAD SCI, V836, P57, DOI 10.1111/j.1749-6632.1997.tb52355.x; Kretsch MJ, 1997, INT J OBESITY, V21, P14, DOI 10.1038/sj.ijo.0800353; KRITCHEVSKY SB, 1992, ANNU REV NUTR, V12, P391, DOI 10.1146/annurev.nu.12.070192.002135; Kunugi H, 1997, BIOL PSYCHIAT, V41, P196, DOI 10.1016/S0006-3223(95)00672-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Muldoon MF, 2000, AM J MED, V108, P538, DOI 10.1016/S0002-9343(00)00353-3; MULDOON MF, 1993, METABOLISM, V42, P45, DOI 10.1016/0026-0495(93)90259-Q; New AS, 1999, PSYCHIAT RES, V85, P145, DOI 10.1016/S0165-1781(99)00007-4; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; Pedersen TR, 1996, ARCH INTERN MED, V156, P2085, DOI 10.1001/archinte.156.18.2085; POLMAKI A, 1997, FEBS LETT, V410, P254; RISE P, 1997, J LIPID RES, V38, P1298; Ross SD, 1999, ARCH INTERN MED, V159, P1793, DOI 10.1001/archinte.159.15.1793; ROTH T, 1992, CLIN CARDIOL, V15, P426; RYMAN A, 1994, BRIT MED J, V309, P425; Shepherd J, 1999, J AM COLL CARDIOL, V33, P909; SMITH GD, 1992, BRIT MED J, V304, P341; Tang JL, 1998, BMJ-BRIT MED J, V316, P1213, DOI 10.1136/bmj.316.7139.1213; Walsh KM, 1996, TOXICOL PATHOL, V24, P468, DOI 10.1177/019262339602400409; Wardle J, 2000, AM J MED, V108, P547, DOI 10.1016/S0002-9343(00)00330-2; Wardle J, 1996, BRIT MED J, V313, P75, DOI 10.1136/bmj.313.7049.75; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Zureik M, 1996, BMJ-BRIT MED J, V313, P649, DOI 10.1136/bmj.313.7058.649	41	122	124	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					11	15		10.1136/bmj.322.7277.11	http://dx.doi.org/10.1136/bmj.322.7277.11			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141142	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000166341400015
J	Meier, DL; Koide, S; Uchida, Y				Meier, DL; Koide, S; Uchida, Y			Magnetohydrodynamic production of relativistic jets	SCIENCE			English	Review							ACCRETION DISKS; BLACK-HOLE; ASTROPHYSICAL JETS; RADIO JET; SIMULATIONS; DRIVEN; STAR; M87; EXPLOSIONS; COLLAPSE	A number of astronomical systems have been discovered that generate collimated flows of plasma with velocities close to the speed of light. In all cases, the central object is probably a neutron star or black hole and is either accreting material from other stars or is in the initial violent stages of formation. Supercomputer simulations of the production of relativistic jets have been based on a magnetohydrodynamic model, in which differential rotation in the system creates a magnetic coil that simultaneously expels and pinches some of the infalling material. The model may explain the basic features of observed jets, including their speed and amount of collimation, and some of the details in the behavior and statistics of different jet-producing sources.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Toyama Univ, Fac Engn, Toyama 9308555, Japan; Tokyo Univ Sci, Dept Phys, Shinjuku Ku, Tokyo 162, Japan	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Toyama; Tokyo University of Science	Meier, DL (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	David.L.Meier@jpl.nasa.gov						Biretta JA, 1999, ASTROPHYS J, V520, P621, DOI 10.1086/307499; BISNOVATYIKOGAN GS, 1971, SOV ASTRON, V14, P652; BLANDFORD RD, 1982, MON NOT R ASTRON SOC, V199, P883, DOI 10.1093/mnras/199.4.883; BLANDFORD RD, 1977, MON NOT R ASTRON SOC, V179, P433, DOI 10.1093/mnras/179.3.433; BLANDFORD RD, 1976, MON NOT R ASTRON SOC, V176, P465, DOI 10.1093/mnras/176.3.465; Blandford RD, 1999, MON NOT R ASTRON SOC, V303, pL1, DOI 10.1046/j.1365-8711.1999.02358.x; BRANDT WN, 2000, IAU S, V195, P207; COLGATE SA, 2000, IAU S, V195, P255; Dhawan V, 2000, ASTROPHYS J, V543, P373, DOI 10.1086/317088; DODORICO S, 1991, NATURE, V353, P329, DOI 10.1038/353329a0; Fender R, 1999, ASTROPHYS J, V519, pL165, DOI 10.1086/312128; GOLDREICH P, 1970, ASTROPHYS J, V160, P971, DOI 10.1086/150486; Junor W, 1999, NATURE, V401, P891, DOI 10.1038/44780; Khokhlov AM, 1999, ASTROPHYS J, V524, pL107, DOI 10.1086/312305; Koide S, 1999, ASTROPHYS J, V522, P727, DOI 10.1086/307667; Koide S, 2000, ASTROPHYS J, V536, P668, DOI 10.1086/308986; Koide S, 1998, ASTROPHYS J, V495, pL63, DOI 10.1086/311204; KOIDE S, 1999, P 19 TEX S REL ASTR, P1; Krasnopolsky R, 1999, ASTROPHYS J, V526, P631, DOI 10.1086/308023; Kudoh T, 1998, ASTROPHYS J, V508, P186, DOI 10.1086/306377; LEBLANC JM, 1970, ASTROPHYS J, V161, P541, DOI 10.1086/150558; Ledlow MJ, 1996, ASTRON J, V112, P9, DOI 10.1086/117985; LI ZY, 1992, ASTROPHYS J, V394, P459, DOI 10.1086/171597; Livio M, 1999, ASTROPHYS J, V512, P100, DOI 10.1086/306777; LOVELACE RVE, 1976, NATURE, V262, P649, DOI 10.1038/262649a0; Macchetto F, 1997, ASTROPHYS J, V489, P579, DOI 10.1086/304823; MacFadyen AI, 1999, ASTROPHYS J, V524, P262, DOI 10.1086/307790; MARGON B, 1984, ANNU REV ASTRON ASTR, V22, P507; Matsumoto R, 1996, ASTROPHYS J, V461, P115, DOI 10.1086/177041; Meier DL, 1997, NATURE, V388, P350, DOI 10.1038/41034; MEIER DL, 1976, ASTROPHYS J, V204, P869, DOI 10.1086/154235; MEIER DL, IN PRESS ASTROPHYS J; MEIER DL, 2000, ASTROPHYSICAL PHENOM, P31; MICHEL FC, 1969, ASTROPHYS J, V158, P727, DOI 10.1086/150233; Mirabel IF, 1999, ANNU REV ASTRON ASTR, V37, P409, DOI 10.1146/annurev.astro.37.1.409; Mirabel IF, 1998, ASTRON ASTROPHYS, V330, pL9; Nakamura M, 1999, ASTROPHYS SPACE SC L, V240, P239; NAKAMURA M, IN PRESS NEW ASTRON; Narayan R, 2000, ASTROPHYS J, V539, P798, DOI 10.1086/309268; NARAYAN R, 1995, ASTROPHYS J, V444, P231, DOI 10.1086/175599; Ouyed R, 1997, ASTROPHYS J, V482, P712, DOI 10.1086/304170; SHAKURA NI, 1973, ASTRON ASTROPHYS, V24, P337; SHIBATA K, 1986, PUBL ASTRON SOC JPN, V38, P631; UCHIDA Y, 1985, PUBL ASTRON SOC JPN, V37, P515; Uchida Y, 1998, ASTROPHYS SPACE SCI, V264, P195, DOI 10.1023/A:1002450221625; UCHIDA Y, 2000, IAU S, V195, P213; USTYUGOVA GV, 1995, ASTROPHYS J, V439, pL39, DOI 10.1086/187739; Ustyugova GV, 2000, ASTROPHYS J, V541, pL21, DOI 10.1086/312890; VERMEULEN RC, 1996, IAU S, V175, P57; Wang LF, 1996, ASTROPHYS J, V467, P435, DOI 10.1086/177617; WHEELER JA, UNPUB; Wijers RAMJ, 1998, MON NOT R ASTRON SOC, V294, pL13, DOI 10.1046/j.1365-8711.1998.01328.x; WILSON AS, 1995, ASTROPHYS J, V438, P62, DOI 10.1086/175054	53	318	322	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					84	92		10.1126/science.291.5501.84	http://dx.doi.org/10.1126/science.291.5501.84			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141552				2022-12-28	WOS:000166259100038
J	Ouyang, M; Huang, JL; Cheung, CL; Lieber, CM				Ouyang, M; Huang, JL; Cheung, CL; Lieber, CM			Atomically resolved single-walled carbon nanotube intramolecular junctions	SCIENCE			English	Article							ELECTRONIC-PROPERTIES; TIGHT-BINDING; SPECTROSCOPY; CONDUCTANCE; DEFECTS; DEVICES	Intramolecular junctions in single-walled carbon nanotubes are potentially ideal structures for building robust, molecular-scale electronics but have only been studied theoretically at the atomic Level. Scanning tunneling microscopy was used to determine the atomic structure and electronic properties of such junctions in single-walled nanotube samples. Metal-semiconductor junctions are found to exhibit an electronically sharp interface without Localized junction states, whereas a more diffuse interface and Low-energy states are found in metal-metal junctions. Tight-binding calculations for models based on observed atomic structures show good agreement with spectroscopy and provide insight into the topological defects forming intramolecular junctions. These: studies have important implications for applications of present materials and provide a means for assessing efforts designed to tailor intramolecular junctions for nanoelectronics.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.		Cheung, Chin Li/B-8270-2013	Cheung, Chin Li/0000-0001-8210-2833				Charlier JC, 1996, PHYS REV B, V53, P11108, DOI 10.1103/PhysRevB.53.11108; Chico L, 1996, PHYS REV LETT, V76, P971, DOI 10.1103/PhysRevLett.76.971; Chico L, 1996, PHYS REV B, V54, P2600, DOI 10.1103/PhysRevB.54.2600; Collins PG, 1997, SCIENCE, V278, P100, DOI 10.1126/science.278.5335.100; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; DUNLAP BI, 1994, PHYS REV B, V49, P5643, DOI 10.1103/PhysRevB.49.5643; Han J, 1998, PHYS REV B, V57, P14983, DOI 10.1103/PhysRevB.57.14983; Kim P, 1999, PHYS REV LETT, V82, P1225, DOI 10.1103/PhysRevLett.82.1225; LAMBIN P, 1995, CHEM PHYS LETT, V245, P85, DOI 10.1016/0009-2614(95)00961-3; McEuen PL, 1998, NATURE, V393, P15, DOI 10.1038/29874; Meunier V, 1999, PHYS REV B, V60, P7792, DOI 10.1103/PhysRevB.60.7792; Meunier V, 1998, PHYS REV LETT, V81, P5588, DOI 10.1103/PhysRevLett.81.5588; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; Odom TW, 1998, J MATER RES, V13, P2380, DOI 10.1557/JMR.1998.0331; Odom TW, 2000, J PHYS CHEM B, V104, P2794, DOI 10.1021/jp993592k; Orlikowski D, 1999, PHYS REV LETT, V83, P4132, DOI 10.1103/PhysRevLett.83.4132; Orlikowski D, 2000, PHYS REV B, V61, P14194, DOI 10.1103/PhysRevB.61.14194; OUYANG M, UNPUB; Rubio A, 1999, APPL PHYS A-MATER, V68, P275, DOI 10.1007/s003390050888; Saito R, 1996, PHYS REV B, V53, P2044, DOI 10.1103/PhysRevB.53.2044; Saito S, 1997, SCIENCE, V278, P77, DOI 10.1126/science.278.5335.77; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	24	264	278	3	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					97	100		10.1126/science.291.5501.97	http://dx.doi.org/10.1126/science.291.5501.97			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141554	Green Published			2022-12-28	WOS:000166259100040
J	Kallianpur, AR; Poehling, KA; Dittus, RS				Kallianpur, AR; Poehling, KA; Dittus, RS			Clinical problem solving: High time for action.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SPECTRUM; ERROR		Vanderbilt Univ, Med Ctr, Div Gen Internal Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Div Gen Pediat, Nashville, TN 37232 USA; Nashville Vet Affairs Med Ctr, Tennessee Valley Geriatr Res Educ & Clin Ctr, Nashville, TN USA; Nashville Vet Affairs Med Ctr, Qual Scholars Program, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Kallianpur, AR (corresponding author), Vanderbilt Univ, Med Ctr, Div Gen Internal Med, S-1121 MCN, Nashville, TN 37232 USA.	asha.kallianpur@mcmail.vanderbilt.edu						Aboulafia DM, 1996, ANN VASC SURG, V10, P396, DOI 10.1007/BF02286787; Allan E L, 1995, Am Pharm, VNS35, P25; ALLNUTT MF, 1987, BRIT J ANAESTH, V59, P856, DOI 10.1093/bja/59.7.856; ANSELL JE, 1977, JAMA-J AM MED ASSOC, V238, P40, DOI 10.1001/jama.238.1.40; Bennett CL, 2000, NEW ENGL J MED, V342, P1773, DOI 10.1056/NEJM200006153422402; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Davis N M, 1994, Am Pharm, VNS34, P22; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Langley Gj., 1996, IMPROVEMENT GUIDE PR; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; ORTEL TL, 1994, AM J HEMATOL, V45, P128, DOI 10.1002/ajh.2830450206	16	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					48	51		10.1056/NEJM200101043440108	http://dx.doi.org/10.1056/NEJM200101043440108			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136960				2022-12-28	WOS:000166160400008
J	Troisi, RJ; Cowie, CC; Harris, MI				Troisi, RJ; Cowie, CC; Harris, MI			Diurnal variation in pasting plasma glucose - Implications for diagnosis of diabetes in patients examined in the afternoon	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAWN PHENOMENON; GROWTH-HORMONE; INSULIN; MELLITUS; PATTERNS; ABSENCE; ROLES; SLEEP	Context Current diagnostic criteria for diabetes are based on plasma glucose levels in blood samples obtained in the morning after an overnight fast, with a value of 7.0 mmol/L (126 mg/dL) or more indicating diabetes. However, many patients are seen by their physicians in the afternoon. Because plasma glucose levels are higher in the morning, it is unclear whether these diagnostic criteria can be applied to patients who are tested for diabetes in the afternoon. Objectives To document diurnal variation in fasting plasma glucose levels in adults not known to have diabetes, and to examine the applicability to afternoon-examined patients of the current diagnostic criteria for diabetes. Design, Setting, and Participants Analysis of data from the US population-based Third National Health and Nutrition Examination Survey (1988-1994) on participants aged 20 years or older who had no previously diagnosed diabetes, who were randomly assigned to morning (n=6483) or afternoon (n=6399) examinations, and who fasted prior to blood sampling. Main Outcome Measures Fasting plasma glucose levels in morning- vs afternoon-examined participants; diabetes diagnostic value for afternoon-examined participants. Results The morning and afternoon groups did not differ in age, body mass index, waist-to-hip ratio, physical activity index, glycosylated hemoglobin level, and other factors. Mean (SD) fasting plasma glucose levels were higher in the morning group (5.41 [0.01] mmol/L [97.4 {0.3} mg/dL]) than in the afternoon group (5.12 [0.02] mmol/L [92.4 {0.4} mg/dL]; P<.001). Consequently, prevalence of afternoon-examined participants with fasting plasma glucose levels of 7.0 mmol/L (126 mg/dL) or greater was half that of participants examined in the morning. The diagnostic fasting plasma glucose value for afternoon-examined participants that resulted in the same prevalence of diabetes found in moming-examined participants was 6.33 mmol/L (114 mg/dL) or greater. Conclusions Our results indicate that if current diabetes diagnostic criteria are applied to patients seen in the afternoon, approximately half of all cases of undiagnosed diabetes in these patients will be missed.	NIDDKD, Room 695,6707 Democracy Blvd,MSC-5460, Bethesda, MD 20892 USA; Social & Sci Syst Inc, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Social & Scientific Systems	Harris, MI (corresponding author), NIDDKD, Room 695,6707 Democracy Blvd,MSC-5460, Bethesda, MD 20892 USA.	mh63q@nih.gov						ARSLANIAN S, 1990, HORM RES, V34, P27, DOI 10.1159/000181791; BOLLI GB, 1984, DIABETES, V33, P1150, DOI 10.2337/diabetes.33.12.1150; BOLLI GB, 1984, NEW ENGL J MED, V310, P746, DOI 10.1056/NEJM198403223101203; CAMPBELL PJ, 1985, NEW ENGL J MED, V312, P1473, DOI 10.1056/NEJM198506063122302; Gavin JR, 1999, DIABETES CARE, V22, pS5; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; MARIN G, 1988, DIABETES CARE, V11, P393, DOI 10.2337/diacare.11.5.393; MAURAS N, 1986, J CLIN ENDOCR METAB, V62, P975, DOI 10.1210/jcem-62-5-975; Scheen AJ, 1998, HORM RES, V49, P191, DOI 10.1159/000023170; SCHMIDT MI, 1984, DIABETES CARE, V7, P32, DOI 10.2337/diacare.7.1.32; SIMON C, 1988, J CLIN ENDOCR METAB, V67, P203, DOI 10.1210/jcem-67-1-203; TRUMPER BG, 1995, HORM METAB RES, V27, P141, DOI 10.1055/s-2007-979926; VanCauter E, 1997, ENDOCR REV, V18, P716, DOI 10.1210/er.18.5.716	13	81	82	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3157	3159		10.1001/jama.284.24.3157	http://dx.doi.org/10.1001/jama.284.24.3157			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135780				2022-12-28	WOS:000165994100034
J	Cummings, JL				Cummings, JL			Cholinesterase inhibitors: expanding applications	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; DOUBLE-BLIND; DEMENTIA; PLACEBO		Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cummings, JL (corresponding author), Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA.							COREYBLOOM J, 1998, INT J GERIATR PSYCHO, V1, P55; Cummings JL, 2000, AM J PSYCHIAT, V157, P4, DOI 10.1176/ajp.157.1.4; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Giacobini E., 2000, CHOLINESTERASES CHOL, V2000, P181; HANSEN L, 1990, NEUROLOGY, V40, P1; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; MCKEITH I, 1992, BRIT MED J, V305, P673, DOI 10.1136/bmj.305.6855.673; MCKEITH I, 2000, LANCET; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Perry E. K., 1996, P397, DOI 10.1017/CBO9780511601187.036; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445	16	25	25	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2024	2025		10.1016/S0140-6736(00)03393-6	http://dx.doi.org/10.1016/S0140-6736(00)03393-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145482				2022-12-28	WOS:000165994300002
J	Sartorius, N; Emsley, RA				Sartorius, N; Emsley, RA			Psychiatry and technological advances: implications for developing countries	LANCET			English	Editorial Material									Dept Psychiat, ZA-7505 Tygerberg, Cape Town, South Africa; Univ Hosp Geneva, Dept Psychiat, Geneva, Switzerland	University of Geneva	Emsley, RA (corresponding author), Dept Psychiat, POB 19063, ZA-7505 Tygerberg, Cape Town, South Africa.							DESJARLAIS R, 1995, WORLD MENTAL HLTH NP, P3; EMSLEY RA, 1986, S AFR MED J, V70, P212; HARPHAM T, 1994, SOC SCI MED, V39, P233, DOI 10.1016/0277-9536(94)90332-8; LEFF J, 1990, BRIT J PSYCHIAT, V156, P351, DOI 10.1192/bjp.156.3.351; POITRAS S, IN PRESS PSYCHIAT GE, V3; ROBERTS MC, 1992, S AFR MED J, V82, P16; SADIK N, 1992, CHANGE THREAT OPPORT, V4, P13; Saraceno B, 1997, CAN J PSYCHIAT, V42, P285, DOI 10.1177/070674379704200306; SARTORIUS N, 1992, AUST NZ J PSYCHIAT, V26, P550, DOI 10.3109/00048679209072087; SARTORIUS N, 2000, PSYCHIAT GEGENWART, V3, P425; Shah A, 2000, ACTA PSYCHIAT SCAND, V101, P87, DOI 10.1034/j.1600-0447.2000.9r004.x; *WHO, 1997, 973 MSANAM WHO	12	5	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2090	2092		10.1016/S0140-6736(00)03413-9	http://dx.doi.org/10.1016/S0140-6736(00)03413-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	385GB	11145507				2022-12-28	WOS:000165994300035
J	Breitbart, W; Rosenfeld, B; Pessin, H; Kaim, M; Funesti-Esch, J; Galietta, M; Nelson, CJ; Brescia, R				Breitbart, W; Rosenfeld, B; Pessin, H; Kaim, M; Funesti-Esch, J; Galietta, M; Nelson, CJ; Brescia, R			Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; ATTITUDES; QUESTIONNAIRE; EUTHANASIA; ONCOLOGY; CARE	Context Understanding why some terminally ill patients desire a hastened death has become an important issue in palliative care and the debate regarding legalization of assisted suicide. Objectives To assess the prevalence of desire for hastened death among terminally ill cancer patients and to identify factors corresponding to desire for hastened death. Design Prospective survey conducted in a 200-bed palliative care hospital in New York, NY. Patients Ninety-two terminally ill cancer patients (60% female; 70% white; mean age, 65.9 years) admitted between June 1998 and January 1999 for end-of-life care who passed a cognitive screening test and provided sufficient data to permit analysis. Main Outcome Measure Scores on the Schedule of Attitudes Toward Hastened Death (SAHD), a self-report measure assessing desire for hastened death among individuals with life-threatening medical illness. Results Sixteen patients (17%) were classified as having a high desire for hastened death based on the SAHD and 15 (16%) of 89 patients met criteria for a current major depressive episode. Desire for hastened death was significantly associated with a clinical diagnosis of depression (P =.001) as well as with measures of depressive symptom severity (P<.001) and hopelessness (P<.001), In multivariate analyses, depression (P=.003) and hopelessness (P<.001) provided independent and unique contributions to the prediction of desire for hastened death, while social support (P=.05) and physical functioning (P=.02) added significant but smaller contributions. Conclusions Desire for hastened death among terminally ill cancer patients is not uncommon. Depression and hopelessness are the strongest predictors of desire for hastened death in this population and provide independent and unique contributions. Interventions addressing depression, hopelessness, and social support appear to be important aspects of adequate palliative care, particularly as it relates to desire for hastened death.	Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10021 USA; Fordham Univ, Dept Psychol, Bronx, NY USA; Calvary Hosp, Palliat Care Inst, Bronx, NY USA	Memorial Sloan Kettering Cancer Center; Fordham University	Breitbart, W (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 1242 2nd Ave, New York, NY 10021 USA.							BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Brady MJ, 1999, PSYCHO-ONCOLOGY, V8, P417, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<417::AID-PON398>3.0.CO;2-4; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; Chochinov HM, 1998, PSYCHOSOMATICS, V39, P366, DOI 10.1016/S0033-3182(98)71325-8; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GLOCK SD, 2000, ANN INTERN MED, V132, P209; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HENDIN H, 1993, AM J PSYCHIAT, V150, P143; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Moorey S, 1998, PSYCHO-ONCOL, V7, P218, DOI 10.1002/(SICI)1099-1611(199805/06)7:3<218::AID-PON308>3.3.CO;2-4; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Rosenfeld B, 2000, CANCER, V88, P2868, DOI 10.1002/1097-0142(20000615)88:12<2868::AID-CNCR30>3.0.CO;2-K; Rosenfeld B, 1999, AM J PSYCHIAT, V156, P94, DOI 10.1176/ajp.156.1.94; ROSENFELD B, IN PRESS PSYCHOL PUB; Rousseau P, 2000, J CLIN ONCOL, V18, P2000, DOI 10.1200/JCO.2000.18.9.2000; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; SPIEGEL D, 1995, SUPPORT CARE CANCER, V3, P252; Spitzer R.L., 1996, STRUCTURED CLIN INTE; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822	29	640	651	5	115	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2907	2911		10.1001/jama.284.22.2907	http://dx.doi.org/10.1001/jama.284.22.2907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11147988	Bronze			2022-12-28	WOS:000165717000031
J	Hayden, MR				Hayden, MR			Predictive testing for Huntington's disease: the calm after the storm	LANCET			English	Editorial Material							WORLDWIDE; DIAGNOSIS		Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	University of British Columbia	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada.		Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				ADAM S, 1993, J MED GENET, V30, P549, DOI 10.1136/jmg.30.7.549; Almqvist EW, 1999, AM J HUM GENET, V64, P1293, DOI 10.1086/302374; BENJAMIN CM, 1994, AM J HUM GENET, V55, P606; Benjamin CM, 2000, CLIN GENET, V58, P41, DOI 10.1034/j.1399-0004.2000.580107.x; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; Brinkman RR, 1997, AM J HUM GENET, V60, P1202; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Harper PS, 2000, J MED GENET, V37, P567, DOI 10.1136/jmg.37.8.567; HAYDEN MR, 1987, LANCET, V1, P1284; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Marteau TM, 1997, HEALTH PSYCHOL, V16, P51; Orr HT, 2000, CELL, V101, P1, DOI 10.1016/S0092-8674(00)80617-0; Wellington CL, 2000, CLIN GENET, V57, P1, DOI 10.1034/j.1399-0004.2000.570101.x; WENT L, 1994, J MED GENET, V31, P555	15	33	33	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1944	1945		10.1016/S0140-6736(00)03301-8	http://dx.doi.org/10.1016/S0140-6736(00)03301-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130517				2022-12-28	WOS:000165867600003
J	Entchev, EV; Schwabedissen, A; Gonzalez-Gaitan, M				Entchev, EV; Schwabedissen, A; Gonzalez-Gaitan, M			Gradient formation of the TGF-beta homolog Dpp	CELL			English	Article							WING IMAGINAL DISC; DROSOPHILA-MELANOGASTER; MORPHOGEN GRADIENT; CELL-PROLIFERATION; ENDOCYTIC PATHWAY; GENE; PROTEIN; RECEPTOR; PATTERN; DYNAMIN	Secreted morphogens such as the Drosophila TGF-beta homolog Decapentaplegic (Dpp) are thought to spread through target tissues and form long-range concentration gradients providing positional information. Using a GFP-Dpp fusion, we monitored a TGF-beta family member trafficking in situ throughout the target tissue and forming a long-range concentration gradient. Evidence is presented that long-range Dpp movement involves Dpp receptor and Dynamin functions. We also show that the rates of endocytic trafficking and degradation determine Dpp signaling range. We propose a model where the gradient is formed via intracellular trafficking initiated by receptor-mediated endocytosis of the ligand in receiving cells with the gradient slope controlled by endocytic sorting of Dpp toward recycling versus degradation.	Max Planck Inst Mol Zellbiol & Genet, D-01307 Dresden, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany	Max Planck Society; Max Planck Society	Gonzalez-Gaitan, M (corresponding author), Max Planck Inst Mol Zellbiol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.		Entchev, Eugeni V/D-2606-2009	Gonzalez-Gaitan, Marcos/0000-0002-6295-7321; Entchev, Eugeni/0000-0003-0744-5929				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BAZINET C, 1993, GENETICS, V134, P1119; BEJSOVEC A, 1995, GENETICS, V139, P309; BRAND A, 1996, DROSOPHILA MELANOGAS, P635; Brock P, 1999, CYTOMETRY, V35, P353, DOI 10.1002/(SICI)1097-0320(19990401)35:4<353::AID-CYTO8>3.0.CO;2-M; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burke R, 1996, DEVELOPMENT, V122, P2261; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; GARCIABE.A, 1972, MOL GEN GENET, V115, P54, DOI 10.1007/BF00272218; Gonzalez-Gaitan M, 1999, MECH DEVELOP, V87, P143, DOI 10.1016/S0925-4773(99)00156-2; GONZALEZGAITAN M, 1994, MECH DEVELOP, V46, P183, DOI 10.1016/0925-4773(94)90070-1; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GONZALEZGAITAN MA, 1996, MOL BIOL INSECT DIS, P283; Grant D, 1998, GENETICS, V149, P1019; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; Jackson SM, 1997, DEVELOPMENT, V124, P4113; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lecuit T, 1998, DEVELOPMENT, V125, P4901; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MASUR SK, 1990, J NEUROGENET, V6, P191, DOI 10.3109/01677069009107110; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; MERESSE S, 1995, J CELL SCI, V108, P3349; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; Pfeiffer S, 2000, CURR BIOL, V10, P321, DOI 10.1016/S0960-9822(00)00381-X; Pignoni F, 1997, DEVELOPMENT, V124, P271; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; Seugnet L, 1997, DEV BIOL, V192, P585, DOI 10.1006/dbio.1997.8723; Staples RR, 1999, J NEUROGENET, V13, P119, DOI 10.3109/01677069909083470; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; Strigini M, 1999, SEMIN CELL DEV BIOL, V10, P335, DOI 10.1006/scdb.1999.0293; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; XU T, 1994, DROSOPHILA MELANOGAS, P655	47	487	502	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					981	991		10.1016/S0092-8674(00)00200-2	http://dx.doi.org/10.1016/S0092-8674(00)00200-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136982	Bronze			2022-12-28	WOS:000165801300016
J	Miki, H; Yamaguchi, H; Suetsugu, S; Takenawa, T				Miki, H; Yamaguchi, H; Suetsugu, S; Takenawa, T			IRSp53 is an essential intermediate between Rac and WAVE in the regulation of membrane ruffling	NATURE			English	Article							ACTIN-BASED MOTILITY; RECEPTOR TYROSINE KINASE; ALDRICH-SYNDROME PROTEIN; WASP-RELATED PROTEIN; ARP2/3 COMPLEX; N-WASP; DEPOLYMERIZING PROTEIN; SHIGELLA-FLEXNERI; NUCLEATION; FILAMENTS	Neural Wiskott-Aldrich syndrome protein (N-WASP)(1) functions in several intracellular events including filopodium formation(2), vesicle transport(3) and movement of Shigella frexneri(4,5) and vaccinia virus(6), by stimulating rapid actin polymerization through the Arp2/3 complex. N-WASP is regulated by the direct binding of Cdc42 (refs 7, 8), which exposes the domain in N-WASP that activates the Arp2/3 complex(2,9). A WASP-related protein, WAVE/ Scar, functions in pac-induced membrane ruffling(10,11); however, pac does not bind directly to WAVE(10), raising the question of how WAVE is regulated by Rac. Here we demonstrate that IRSp53, a substrate for insulin receptor(12) with unknown function, is the 'missing link' between pac and WAVE. Activated Rac binds to the amino terminus of IRSp53, and carboxy-terminal Src-homology-3 domain of IRSp53 binds to WAVE to form a trimolecular complex. From studies of ectopic expression, we found that IRSp53 is essential for Rac to induce membrane ruffling, probably because it recruits WAVE, which stimulates actin polymerization mediated by the Arp2/3 complex.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, CREST, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/B-3300-2010; Yamaguchi, Hideki/AAP-1767-2021; Suetsugu, Shiro/ABB-6033-2020	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; Yamaguchi, Hideki/0000-0003-2125-9655; 				Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Miki H, 1999, J BIOL CHEM, V274, P27605, DOI 10.1074/jbc.274.39.27605; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921	23	425	441	1	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					732	735		10.1038/35047107	http://dx.doi.org/10.1038/35047107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130076				2022-12-28	WOS:000165815200052
J	Kendall, JM; Reeves, BC; Latter, VS				Kendall, JM; Reeves, BC; Latter, VS		Nasal Diamorphine Trial Grp	Multicentre randomised controlled trial of nasal diamorphine for analgesia in children and teenagers with clinical fractures	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRANASAL; PAIN; TITRATION; MIDAZOLAM; SAFETY	Objective To compare the effectiveness of nasal diamorphine spray with intramuscular morphine for analgesia in children and teenagers wit acute pain due to a clinical fracture, and to describe the safety profile of the spray. Design Multicentre randomised controlled trial. Setting Emergency departments in eight UK hospitals. Participants Patients aged between 3 and 16 years presenting with a clinical fracture of an upper or lower limb. Main outcome measures Patients' reported pain using the Wong Baker face pain scale, ratings of reaction to treatment of the patients and acceptability of treatment by staff and parents, and adverse events. Results 404 eligible patients completed the trial (204 patients given nasal diamorphine spray and 200 given intramuscular morphine). Onset of pain relief was faster in the spray group than in the intramuscular group, with lower pain scores in the spray group at 5, 10, and 20 minutes after treatment but no difference between the groups after 30 minutes. 80% of patients given the spray showed no obvious discomfort compared with 9% given intramuscular morphine (difference 71% 95% confidence interval 65% to 78%). Treatment administration was judged acceptable by staff and parents, respectively, for 98% (199 of 203) and 97% (186 of 192) of patients in the spray group compared wit 32% (64 of 199) and 72% (142 of 197) in the intramuscular group. No serious adverse events occurred in the spray group, and the frequencies of all adverse events were similar in both groups (spray 24.1% v intramuscular morphine 18.5%, difference 5.6%-2.3% to 13.6%). Conclusion Nasal diamorphine spray should be the preferred method of pain relief in children and teenagers presenting to emergency departments in acute pain with clinical fractures. The diamorphine spray should be used in place of intramuscular morphine.	Frenchay Hosp, Emergency Dept, Bristol BS16 1LE, Avon, England; Royal Coll Surgeons England, Clin Effectiveness Unit, London WC2A 3PN, England; Royal Free Hosp, Univ Coll London Clin Res Network, London NW3 2QG, England	Royal College of Surgeons of England; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Kendall, JM (corresponding author), Frenchay Hosp, Emergency Dept, Bristol BS16 1LE, Avon, England.	frenchayed@cableinet.co.uk						*BRIT MED ASS ROYA, 2000, BRIT NATIONAL FO MAR, V39; CAUNA N, 1969, ANN OTO RHINOL LARYN, V78, P865, DOI 10.1177/000348946907800418; CONE EJ, 1993, J ANAL TOXICOL, V17, P327, DOI 10.1093/jat/17.6.327; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; *ICH SECR, 1996, ICH HARM TRIP GUID G; KARL HW, 1992, ANESTHESIOLOGY, V76, P209, DOI 10.1097/00000542-199202000-00009; LJUNG B, 1996, J NUCL MED TECHNOL, V24, P32; MITCHELL J, 1995, BRIT MED J, V10, P43; REYNOLDS JEF, 1999, MARTINDALE EXTRA PHA; ROBINSON SL, 1991, ANAESTHESIA, V46, P538, DOI 10.1111/j.1365-2044.1991.tb09650.x; Simini B, 2000, LANCET, V355, P1076, DOI 10.1016/S0140-6736(00)02045-6; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; STRIEBEL WH, 1993, ANESTH ANALG, V76, P1047; WALBERGH EJ, 1991, ANESTHESIOLOGY, V74, P233, DOI 10.1097/00000542-199102000-00007; Williams PL, 1989, GRAYS ANATOMY; Wilson JA, 1997, J ACCID EMERG MED, V14, P70	16	88	92	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2001	322	7281					261	265		10.1136/bmj.322.7281.261	http://dx.doi.org/10.1136/bmj.322.7281.261			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157525	Green Published, Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000166917600024
J	Li, X; Kuznetsov, AE; Zhang, HF; Boldyrev, AI; Wang, LS				Li, X; Kuznetsov, AE; Zhang, HF; Boldyrev, AI; Wang, LS			Observation of all-metal aromatic molecules	SCIENCE			English	Article								Aromaticity is a concept invented to account for the unusual stability of an important class of organic molecules: the aromatic compounds. Here we report experimental and theoretical evidence of aromaticity in all-metal systems. A series of bimetallic clusters with chemical composition MAl4- (M = Li, Na, or Cu), was created and studied with photoelectron spectroscopy and ab initio calculations. All the MAl4- species possess a pyramidal structure containing an M+ cation interacting with a square Al-4(2-) unit. Ab initio studies indicate that Al-4(2-) exhibits characteristics of aromaticity with two delocalized pi electrons (thus following the 4n + 2 electron counting rule) and a square planar structure and maintains its structural and electronic features in all the MAl4- complexes. These findings expand the aromaticity concept into the arena of all-metal species.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA; Washington State Univ, Dept Phys, Richland, WA 99352 USA; Pacific NW Natl Lab, WR Wiley Environm Mol Sci Lab, Richland, WA 99352 USA	Utah System of Higher Education; Utah State University; Washington State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Boldyrev, AI (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.		Kuznetsov, Aleksey E/F-1345-2010; Boldyrev, Alexander I./C-5940-2009	Boldyrev, Alexander I./0000-0002-8277-3669; Kuznetsov, Aleksey/0000-0001-8857-3118				BERGMAN ED, 1971, AROMATICITY PSEUDOAR; Corbett JD, 2000, ANGEW CHEM INT EDIT, V39, P670, DOI 10.1002/(SICI)1521-3773(20000218)39:4<670::AID-ANIE670>3.0.CO;2-M; FRISCH MJ, 1998, GAUSSIAN 98 PROGRAM; Garratt P. J., 1986, AROMATICITY; Hehre W. J., 1986, AB INITIO MOL ORBITA; Kauzlarich S.M., 1996, CHEM STRUCTURE BONDI; Minkin V. J., 1994, AROMATICITY ANTIAROM; SCHAFTENAAR G, 1998, MOL ORBITAL PICTURES; Schleyer PV, 1996, PURE APPL CHEM, V68, P209, DOI 10.1351/pac199668020209; Schleyer PV, 1997, J AM CHEM SOC, V119, P12669, DOI 10.1021/ja9719135; SHAIK S, 1997, J MOL STRUC-THEOCHEM, V155, P398; Wang LS, 1998, ADV MET SEM, V4, P299; WANG LS, 1995, J CHEM PHYS, V102, P9480, DOI 10.1063/1.468817; Wang LS, 2000, J AM CHEM SOC, V122, P7681, DOI 10.1021/ja993081b; XIE Y, 1991, J MOL STRUC-THEOCHEM, V234, P247	15	543	550	4	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 2	2001	291	5505					859	861		10.1126/science.291.5505.859	http://dx.doi.org/10.1126/science.291.5505.859			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157162				2022-12-28	WOS:000166771700040
J	Ryder, SD; Beckingham, IJ				Ryder, SD; Beckingham, IJ			ABC of diseases of liver, pancreas, and biliary system - Chronic viral hepatitis	BRITISH MEDICAL JOURNAL			English	Review									Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England	University of Nottingham	Ryder, SD (corresponding author), Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England.			Ryder, Stephen David/0000-0001-9649-4444				KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; Szmuness W, 1978, Prog Med Virol, V24, P40	3	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					219	221		10.1136/bmj.322.7280.219	http://dx.doi.org/10.1136/bmj.322.7280.219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159624	Green Published			2022-12-28	WOS:000166733700032
J	Cai, HN; Shen, P				Cai, HN; Shen, P			Effects of cis arrangement of chromatin insulators on enhancer-blocking activity	SCIENCE			English	Article							DOMAIN BOUNDARIES; GYPSY INSULATOR; DROSOPHILA; SUPPRESSOR; PROTEIN; GENE; METHYLATION; EXPRESSION; REPRESSION; ELEMENTS	Chromatin boundary elements or insulators are believed to regulate gene activity in complex genetic Loci by organizing specialized chromatin structures. Here, we report that the enhancer-blocking activity of the Drosophila suHw insulator is sensitive to insulator copy number and position. Two tandem copies of suHw were ineffective in blocking various enhancers from a downstream promoter. Moreover, an enhancer was blocked more effectively from a promoter by two flanking suHw insulators than by a single intervening one. Thus, insulators may modulate enhancer-promoter interactions by interacting with each other and facilitating the formation of chromatin Loop domains.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Cai, HN (corresponding author), Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.			Shen, Ping/0000-0001-5024-3893	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058458] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058458] Funding Source: Medline; PHS HHS [5RO158458-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cai HN, 1997, EMBO J, V16, P1732, DOI 10.1093/emboj/16.7.1732; Cai HN, 1996, P NATL ACAD SCI USA, V93, P9309, DOI 10.1073/pnas.93.18.9309; CORCES VG, 1995, NATURE, V376, P462, DOI 10.1038/376462a0; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; Georgiev P, 1996, GENETICS, V142, P425; Gerasimova TI, 1996, CURR OPIN GENET DEV, V6, P185, DOI 10.1016/S0959-437X(96)80049-9; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; Geyer PK, 1997, CURR OPIN GENET DEV, V7, P242, DOI 10.1016/S0959-437X(97)80134-7; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Kellum R, 1998, CURR BIOL, V8, pR521, DOI 10.1016/S0960-9822(07)00337-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; Kim J, 1996, MOL CELL BIOL, V16, P3381; Mihaly J, 1998, CELL MOL LIFE SCI, V54, P60, DOI 10.1007/s000180050125; Muravyova E, 2001, SCIENCE, V291, P495, DOI 10.1126/science.291.5503.495; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Scott KC, 1999, GENETICS, V153, P787; SHEN B, 1994, MOL CELL BIOL, V14, P5645, DOI 10.1128/MCB.14.9.5645; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SPANA C, 1990, GENE DEV, V4, P1505, DOI 10.1101/gad.4.9.1505; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Zhou JM, 1999, DEVELOPMENT, V126, P3057; Zhou JM, 1999, CELL, V99, P567, DOI 10.1016/S0092-8674(00)81546-9	29	156	160	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2001	291	5503					493	495		10.1126/science.291.5503.493	http://dx.doi.org/10.1126/science.291.5503.493			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161205				2022-12-28	WOS:000166487500044
J	Bensinger, WI; Martin, PJ; Storer, B; Clift, R; Forman, SJ; Negrin, R; Kashyap, A; Flowers, MED; Lilleby, K; Chauncey, TR; Storb, R; Appelbaum, FR; Rowley, S; Heimfeld, S; Blume, K				Bensinger, WI; Martin, PJ; Storer, B; Clift, R; Forman, SJ; Negrin, R; Kashyap, A; Flowers, MED; Lilleby, K; Chauncey, TR; Storb, R; Appelbaum, FR; Rowley, S; Heimfeld, S; Blume, K			Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VERSUS-HOST DISEASE; COLONY-STIMULATING FACTOR; PROGENITOR-CELL; STEM-CELLS; HIGH-RISK; MALIGNANCIES; GVHD; ENGRAFTMENT; LEUKEMIA; DONORS	Background: In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood cells mobilized with the use of filgrastim (recombinant granulocyte colony-stimulating factor) engraft more rapidly than bone marrow. However, the relative effects of these techniques on the rates of acute and chronic graft-versus-host disease, overall survival, and disease-free survival have not been determined in randomized studies. Methods: Between March 1996 and July 1999, 172 patients (12 to 55 years of age) with hematologic cancer were randomly assigned to receive either bone marrow or filgrastim-mobilized peripheral-blood cells from HLA-identical relatives for hematopoietic rescue after the treatment of hematologic cancer with high doses of chemotherapy, with or without radiation. Results: The recovery of both neutrophils and platelets was faster with peripheral-blood cells than with marrow (P<0.001 for both comparisons). The cumulative incidence of grade II, III, or IV acute graft-versus-host disease at 100 days was 64 percent with peripheral-blood cells and 57 percent with marrow (hazard ratio, 1.21; 95 percent confidence interval, 0.81 to 1.81; P=0.35). The cumulative incidence of chronic graft-versus-host disease was 46 percent with peripheral-blood cells and 35 percent with marrow (hazard ratio, 1.16; 95 percent confidence interval, 0.71 to 1.90; P=0.54). The estimated overall probability of survival at two years was 66 percent with peripheral-blood cells and 54 percent with marrow (hazard ratio for death, 0.62; 95 percent confidence interval, 0.38 to 1.02; P=0.06). The rate of disease-free survival at two years was 65 percent with peripheral-blood cells and 45 percent with marrow (hazard ratio for relapse or death, 0.60; 95 percent confidence interval, 0.38 to 0.95; P=0.03). Conclusions: In patients given high-dose chemotherapy, with or without radiation, for the treatment of hematologic cancer, allogeneic peripheral-blood cells used for hematopoietic rescue restore blood counts faster than allogeneic bone marrow, without increasing the risk of graft-versus-host disease. (N Engl J Med 2001;344:175-81.) Copyright (C) 2001 Massachusetts Medical Society.	Fred Hutchinson Canc Res Ctr, Clin Div, Seattle, WA 98104 USA; Univ Washington, Div Oncol, Seattle, WA 98195 USA; City Hope Natl Med Ctr, Div Hematol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Div Bone Marrow Transplantat, Duarte, CA 91010 USA; Stanford Univ, Div Bone Marrow Transplantat, Stanford, CA 94305 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; City of Hope; City of Hope; Stanford University	Bensinger, WI (corresponding author), Fred Hutchinson Canc Res Ctr, Div Oncol, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Chauncey, Thomas/AAK-1331-2021	Chauncey, Thomas/0000-0003-2815-7301	NATIONAL CANCER INSTITUTE [P01CA018029, P30CA015704, P01CA018221] Funding Source: NIH RePORTER; NCI NIH HHS [CA15704, CA18029, CA18221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arpinati M, 2000, BLOOD, V95, P2484, DOI 10.1182/blood.V95.8.2484; BENSINGER W, 1995, J CLIN ONCOL, V13, P2547, DOI 10.1200/JCO.1995.13.10.2547; BENSINGER WI, 1995, BLOOD, V85, P1655, DOI 10.1182/blood.V85.6.1655.bloodjournal8561655; Bensinger WI, 1996, BLOOD, V88, P2794, DOI 10.1182/blood.V88.7.2794.bloodjournal8872794; Blaise D, 2000, J CLIN ONCOL, V18, P537, DOI 10.1200/JCO.2000.18.3.537; Brown RA, 1999, J CLIN ONCOL, V17, P806, DOI 10.1200/JCO.1999.17.3.806; Cavallaro AM, 2000, BONE MARROW TRANSPL, V25, P85, DOI 10.1038/sj.bmt.1702072; Champlin RE, 2000, BLOOD, V95, P3702; Elmaagacli AH, 1999, BLOOD, V94, P384, DOI 10.1182/blood.V94.2.384.414k06_384_389; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORBLING M, 1995, BLOOD, V85, P1659, DOI 10.1182/blood.V85.6.1659.bloodjournal8561659; Majolino I, 1996, BONE MARROW TRANSPL, V17, P555; Mielcarek M, 1996, BLOOD, V87, P574, DOI 10.1182/blood.V87.2.574.bloodjournal872574; Mielcarek M, 1999, BRIT J HAEMATOL, V105, P361, DOI 10.1111/j.1365-2141.1999.01349.x; Miflin G, 1997, BONE MARROW TRANSPL, V19, P9, DOI 10.1038/sj.bmt.1700603; NASH RA, 1992, BLOOD, V80, P1838; PAN LY, 1995, BLOOD, V86, P4422, DOI 10.1182/blood.V86.12.4422.bloodjournal86124422; Powles R, 2000, LANCET, V355, P1231, DOI 10.1016/S0140-6736(00)02090-0; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Przepiorka D, 1997, BONE MARROW TRANSPL, V19, P455, DOI 10.1038/sj.bmt.1700692; SCHMITZ N, 1995, BLOOD, V85, P1666, DOI 10.1182/blood.V85.6.1666.bloodjournal8561666; Schmitz N, 1996, BRIT J HAEMATOL, V95, P715, DOI 10.1046/j.1365-2141.1996.d01-1958.x; Schmitz N, 1998, BONE MARROW TRANSPL, V21, P995, DOI 10.1038/sj.bmt.1701234; Solano C, 1998, BONE MARROW TRANSPL, V22, P1129, DOI 10.1038/sj.bmt.1701500; Storek J, 1997, BLOOD, V90, P4705, DOI 10.1182/blood.V90.12.4705.4705_4705_4709; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; Talmadge JE, 1996, BONE MARROW TRANSPL, V17, P101; UrbanoIspizua A, 1996, BONE MARROW TRANSPL, V18, P35; Vigorito AC, 1998, BONE MARROW TRANSPL, V22, P1145, DOI 10.1038/sj.bmt.1701510	30	729	754	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					175	181		10.1056/NEJM200101183440303	http://dx.doi.org/10.1056/NEJM200101183440303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	392GF	11172139				2022-12-28	WOS:000166402800003
J	Meszaros, P				Meszaros, P			Gamma-ray bursts: Accumulating afterglow implications, progenitor glues, and prospects	SCIENCE			English	Review							HIGH-ENERGY NEUTRINOS; 28 FEBRUARY 1997; FIREBALL MODEL; ASTROPHYSICAL SOURCES; STAR-FORMATION; BLACK-HOLES; ERROR BOX; GRB-990123; TRANSIENTS; RADIATION	Gamma-ray bursts (GRBs) are sudden, intense flashes of gamma rays that, for a few blinding seconds, Light up in an otherwise fairly dark gamma-ray sky. They are detected at the rate of about once a day, and while they are on, they outshine every other gamma-ray source in the sky, including the sun. Major advances have been made in the Last 3 or 4 years, including the discovery of slowly fading x-ray, optical and radio afterglows of GRBs, the identification of host galaxies at cosmological distances, and evidence showing that many GRBs are associated with star-forming regions and possibly supernovae. Progress has been made in understanding how the GRB and afterglow radiation arises in terms of a relativistic fireball shock model. These advances have opened new vistas and questions on the nature of the central engine, the identity of their progenitors, the effects of the environment, and their possible gravitational wave, cosmic ray, and neutrino Luminosity. The debates on these issues indicate that GRBs remain among the most mysterious puzzles in astrophysics.	Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16803 USA; Univ Calif Santa Barbara, Inst Theoret Phys, Santa Barbara, CA 93106 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California Santa Barbara	Meszaros, P (corresponding author), Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16803 USA.	pmeszaros@astro.psu.edu		Meszaros, Peter/0000-0002-4132-1746				Akerlof C, 1999, NATURE, V398, P400, DOI 10.1038/18837; Amati L, 2000, SCIENCE, V290, P953, DOI 10.1126/science.290.5493.953; Atkins R, 2000, ASTROPHYS J, V533, pL119, DOI 10.1086/312629; Bahcall JN, 2000, PHYS REV LETT, V85, P1362, DOI 10.1103/PhysRevLett.85.1362; BAND D, 1993, ASTROPHYS J, V413, P281, DOI 10.1086/172995; Blain AW, 2000, MON NOT R ASTRON SOC, V312, pL35, DOI 10.1046/j.1365-8711.2000.03318.x; BLANDFORD R, 1987, PHYS REP, V154, P1, DOI 10.1016/0370-1573(87)90134-7; BLANDFORD R, UNPUB; BLOOM JW, UNPUB; BOTTCHER M, UNPUB; Castro-Tirado AJ, 1999, SCIENCE, V283, P2069, DOI 10.1126/science.283.5410.2069; Costa E, 1997, NATURE, V387, P783, DOI 10.1038/42885; Derishev EV, 1999, ASTROPHYS J, V521, P640, DOI 10.1086/307574; Dermer CD, 1999, ASTROPHYS J, V513, pL5, DOI 10.1086/311898; DERMER CD, UNPUB; EICHLER D, 1989, NATURE, V340, P126, DOI 10.1038/340126a0; FENIMORE E, UNPUB; Fenimore EE, 1999, ASTROPHYS J, V518, pL73, DOI 10.1086/312075; Finn LS, 1999, PHYS REV D, V60, DOI 10.1103/PhysRevD.60.121101; FISHMAN GJ, 1995, ANNU REV ASTRON ASTR, V33, P415, DOI 10.1146/annurev.astro.33.1.415; FRAIL D, IN PRESS P 5 HUNTSV; FRUCHTER A, UNPUB; Fryer CL, 1999, ASTROPHYS J, V526, P152, DOI 10.1086/307992; GALAMA T, UNPUB; Galama TJ, 1998, NATURE, V395, P670, DOI 10.1038/27150; Gehrels N, 1999, ASTROPART PHYS, V11, P277, DOI 10.1016/S0927-6505(99)00066-3; GOODMAN J, 1986, ASTROPHYS J, V308, pL47, DOI 10.1086/184741; Goodman J, 1997, NEW ASTRON, V2, P449, DOI 10.1016/S1384-1076(97)00031-6; HALZEN F, 17 INT C WEAK INT NE; HURLEY K, 1994, NATURE, V372, P652, DOI 10.1038/372652a0; KATZ JI, 1994, APJ, V432, P107; KOUVELIOTOU C, 1993, ASTROPHYS J, V413, pL101, DOI 10.1086/186969; Kulkarni SR, 1999, NATURE, V398, P389, DOI 10.1038/18821; KULKARNI SR, IN PRESS P 5 HUNTSV; LAMB DQ, 2000, APJ, V536, pL1; LOEB A, IN PRESS ANN REV AST; Mao S, 1998, ASTRON ASTROPHYS, V339, pL1; MESZAROS P, 1993, ASTROPHYS J, V405, P278, DOI 10.1086/172360; MESZAROS P, 1994, ASTROPHYS J, V432, P181, DOI 10.1086/174559; Meszaros P, 1997, ASTROPHYS J, V476, P232, DOI 10.1086/303625; Meszaros P, 1998, MON NOT R ASTRON SOC, V299, pL10, DOI 10.1046/j.1365-8711.1998.01992.x; Meszaros P, 1999, NEW ASTRON, V4, P303, DOI 10.1016/S1384-1076(99)00013-5; Meszaros P, 1997, ASTROPHYS J, V482, pL29, DOI 10.1086/310692; MESZAROS P, IN PRESS ASTROPHYS J; Metzger MR, 1997, NATURE, V387, P878, DOI 10.1038/43132; Norris JP, 2000, ASTROPHYS J, V534, P248, DOI 10.1086/308725; PACZYNSKI B, 1986, ASTROPHYS J, V308, pL43, DOI 10.1086/184740; PACZYNSKI B, 1993, ASTROPHYS J, V418, pL5, DOI 10.1086/187102; Paczynski B, 1998, ASTROPHYS J, V494, pL45, DOI 10.1086/311148; Perna R, 1998, ASTROPHYS J, V503, pL135, DOI 10.1086/311544; Piran T, 1999, PHYS REP, V314, P575, DOI 10.1016/S0370-1573(98)00127-6; Piro L, 2000, SCIENCE, V290, P955, DOI 10.1126/science.290.5493.955; Rachen JP, 1998, PHYS REV D, V58, DOI 10.1103/PhysRevD.58.123005; REES MJ, 1994, ASTROPHYS J, V430, pL93, DOI 10.1086/187446; REES MJ, 1992, MON NOT R ASTRON SOC, V258, pP41, DOI 10.1093/mnras/258.1.41P; REES MJ, IN PRESS ASTROPHYS J; REICHART D, UNPUB; Reichart DE, 1997, ASTROPHYS J, V485, pL57, DOI 10.1086/310819; Sari R, 1999, ASTROPHYS J, V519, pL17, DOI 10.1086/312109; Sari R, 1999, ASTROPHYS J, V517, pL109, DOI 10.1086/312039; Sari R, 1998, ASTROPHYS J, V497, pL17, DOI 10.1086/311269; SHEMI A, 1990, ASTROPHYS J, V365, pL55, DOI 10.1086/185887; Spruit HC, 1999, ASTRON ASTROPHYS, V341, pL1; Takeda M, 1999, ASTROPHYS J, V522, P225, DOI 10.1086/307646; Tavani M, 1997, ASTROPHYS J, V483, pL87, DOI 10.1086/310751; THOMPSON C, 1994, MON NOT R ASTRON SOC, V270, P480, DOI 10.1093/mnras/270.3.480; Totani T, 1999, ASTROPHYS J, V511, P41, DOI 10.1086/306664; USOV VV, 1994, MON NOT R ASTRON SOC, V267, P1035, DOI 10.1093/mnras/267.4.1035; van Paradijs J, 1999, SCIENCE, V286, P693; vanParadijs J, 1997, NATURE, V386, P686, DOI 10.1038/386686a0; VANPARADIJS J, IN PRESS ANN REV AST; Vietri M, 1999, MON NOT R ASTRON SOC, V308, pL29, DOI 10.1046/j.1365-8711.1999.02918.x; Vietri M, 1997, ASTROPHYS J, V478, pL9, DOI 10.1086/310542; Waxman E, 1997, PHYS REV LETT, V78, P2292, DOI 10.1103/PhysRevLett.78.2292; WAXMAN E, 1995, PHYS REV LETT, V75, P386, DOI 10.1103/PhysRevLett.75.386; Waxman E, 1998, ASTROPHYS J, V497, P288, DOI 10.1086/305467; WAXMAN E, 1999, PHYS REV D, V59; Weth C, 2000, ASTROPHYS J, V534, P581, DOI 10.1086/308792; WHEELER JC, INPRESS SUPERNOVAE G; Wijers R., 1997, MNRAS, V288, P51; Wijers RAMJ, 1999, ASTROPHYS J, V523, P177, DOI 10.1086/307705; Wijers RAMJ, 1998, MON NOT R ASTRON SOC, V294, pL13, DOI 10.1046/j.1365-8711.1998.01328.x; WOOSLEY SE, 1993, ASTROPHYS J, V405, P273, DOI 10.1086/172359	83	107	110	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					79	84		10.1126/science.291.5501.79	http://dx.doi.org/10.1126/science.291.5501.79			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141551	Green Submitted			2022-12-28	WOS:000166259100037
J	Lefkowith, JB; Geis, GS; Silverstein, F				Lefkowith, JB; Geis, GS; Silverstein, F			Safety of celecoxib vs other nonsteroidal anti-inflammatory drugs - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RHEUMATOID-ARTHRITIS		Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle								Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6; GOLDSTEIN JL, 2000, ANN RHEUM DIS S1, V59, P159; Rodriguez LAG, 2000, EPIDEMIOLOGY, V11, P382, DOI 10.1097/00001648-200007000-00004; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827	5	6	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3123	3124						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135765				2022-12-28	WOS:000165994100017
J	Magid, DJ; Calonge, BN; Rumsfeld, JS; Canto, JG; Frederick, PD; Every, NR; Barron, HV				Magid, DJ; Calonge, BN; Rumsfeld, JS; Canto, JG; Frederick, PD; Every, NR; Barron, HV		Natl Registry Myocardial Infarctio	Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PRACTICE GUIDELINES COMMITTEE; PRIMARY CORONARY ANGIOPLASTY; ASSOCIATION TASK-FORCE; NEW-YORK-STATE; NATIONAL REGISTRY; IMMEDIATE ANGIOPLASTY; ACC/AHA GUIDELINES; AMERICAN-COLLEGE; SURGICAL VOLUME	Context institutional experience with primary angioplasty has been suggested as a factor in selecting a reperfusion strategy for patients with acute myocardial infarction (AMI). However, no large studies have directly compared outcomes of primary angioplasty vs thrombolytic therapy as a function of institutional experience. Objective To compare outcomes among patients with AMI who were treated with primary angioplasty vs thrombolytic therapy at hospitals with different volumes of primary angioplasty. Design Retrospective cohort. Setting A total of 446 acute care hospitals with 112 classified as low volume (less than or equal to 16 procedures), 223 as intermediate volume (17-48 procedures), and 111 as high volume (greater than or equal to 49 procedures) based on their annual primary angioplasty volume. Patients A total of 62 299 patients with AMI treated with primary angioplasty or thrombolytic therapy from June 1, 1994, through July 31, 1999. Main Outcome Measure In-hospital mortality, Results Mortality was lower among patients who received primary angioplasty compared with those who received thrombolysis at hospitals with intermediate volumes (4.5% vs 5.9%; P<.001) and high volumes (3.4% vs 5.4%; P<.001) of primary angioplasty. At low-volume hospitals, there was no significant difference in mortality between patients treated with primary angioplasty vs those treated with thrombolysis (6.2% vs 5.9%; P=.58). Adjusting for differences in demographic, medical history, clinical presentation, treatment, and hospital characteristics did not significantly alter these findings. Conclusions in this study, patients with AMI treated at hospitals with high or intermediate volumes of primary angioplasty had lower mortality with primary angioplasty than with thrombolysis, whereas patients with AMI treated at hospitals with low angioplasty volumes had similar mortality outcomes with primary angioplasty or thrombolysis.	Colorado Permanente Med Grp, Clin Res Unit, Denver, CO 80231 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Div Emergency Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Family Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA; Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA; Denver VA Med Ctr, Denver, CO 80220 USA; Univ Washington, Cardiovasc Outcomes Res Ctr, Seattle, WA 98195 USA; VA Puget Sound Healthcare Syst, Seattle, WA 98115 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Genentech Inc, San Francisco, CA 94080 USA	Permanente Medical Groups; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of California System; University of California San Francisco; Roche Holding; Genentech	Magid, DJ (corresponding author), Colorado Permanente Med Grp, Clin Res Unit, 10350 E Dakota Ave, Denver, CO 80231 USA.	David.J.Magid@kp.org		Frederick, Paul/0000-0002-7936-5488				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; Betriu A, 1997, NEW ENGL J MED, V336, P1621; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; Canto JG, 2000, NEW ENGL J MED, V342, P1573, DOI 10.1056/NEJM200005253422106; Danchin N, 1999, CIRCULATION, V99, P2639, DOI 10.1161/01.CIR.99.20.2639; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; KARIM MR, 1988, 674 J HOPK U DEP BIO; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUFT HS, 1993, JAMA-J AM MED ASSOC, V270, P331, DOI 10.1001/jama.270.3.331; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROGERS WJ, 1994, AM J CARDIOL, V74, P111, DOI 10.1016/0002-9149(94)90082-5; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WILSON JM, 1987, JAMA-J AM MED ASSOC, V257, P2434, DOI 10.1001/jama.1987.03390180052010; Zijlstra F, 1999, NEW ENGL J MED, V341, P1413, DOI 10.1056/NEJM199911043411901; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	34	219	229	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3131	3138		10.1001/jama.284.24.3131	http://dx.doi.org/10.1001/jama.284.24.3131			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135776	Bronze			2022-12-28	WOS:000165994100030
J	Byrne, ME; Barley, R; Curtis, M; Arroyo, JM; Dunham, M; Hudson, A; Martienssen, RA				Byrne, ME; Barley, R; Curtis, M; Arroyo, JM; Dunham, M; Hudson, A; Martienssen, RA			Asymmetric leaves1 mediates leaf patterning and stem cell function in Arabidopsis	NATURE			English	Article							SHOOT APICAL MERISTEM; ROUGH SHEATH2 GENE; HOMEOBOX GENE; THALIANA; PLANTS; DORSOVENTRALITY; PHANTASTICA; ANTIRRHINUM; EXPRESSION; TRAP	Meristem function in plants requires both the maintenance of stem cells and the specification of founder cells from which lateral organs arise. Lateral organs are patterned along proximodistal, dorsoventral and mediolateral axes(1,2). Here we show that the Arabidopsis mutant asymmetric leaves(1) (as1) disrupts this process. AS1 encodes a myb domain protein, closely related to PHANTASTICA in Antirrhinum and ROUGH SHEATH2 in maize, both of which negatively regulate knotted-class homeobox genes. AS1 negatively regulates the homeobox genes KNAT1 and KNAT2 and is, in turn, negatively regulated by the meristematic homeobox gene SHOOT MERISTEMLESS. This genetic pathway defines a mechanism for differentiating between stem cells and organ founder cells within the shoot apical meristem and demonstrates that genes expressed in organ primordia interact with meristematic genes to regulate shoot morphogenesis.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cold Spring Harbor Laboratory; University of Edinburgh	Martienssen, RA (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.			Dunham, Maitreya/0000-0001-9944-2666; Byrne, Mary/0000-0003-4309-3086				Aida M, 1999, DEVELOPMENT, V126, P1563; BARTON MK, 1993, DEVELOPMENT, V119, P823; Chuck G, 1996, PLANT CELL, V8, P1277, DOI 10.1105/tpc.8.8.1277; Clark SE, 1996, DEVELOPMENT, V122, P1567; CLARK SE, 1995, DEVELOPMENT, V121, P2057; DOCKX J, 1995, PLANT MOL BIOL, V28, P723, DOI 10.1007/BF00021196; ENDRIZZI K, 1996, PLANT J, V10, P101; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Hudson A, 2000, ANNU REV PLANT PHYS, V51, P349, DOI 10.1146/annurev.arplant.51.1.349; JACKSON D, 1994, DEVELOPMENT, V120, P405; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; Long J, 2000, DEV BIOL, V218, P341, DOI 10.1006/dbio.1999.9572; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; MARTIENSSEN R, 1998, ARABIDOPSIS ANN PLAN, P262; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; REIDEI GP, 1965, GENETICS, V51, P857; REINHOLZ E, 1965, SERVICE, P24; Reiser L, 2000, PLANT MOL BIOL, V42, P151, DOI 10.1023/A:1006384122567; Schneeberger R, 1998, DEVELOPMENT, V125, P2857; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Timmermans MCP, 1999, SCIENCE, V284, P151, DOI 10.1126/science.284.5411.151; Tsiantis M, 1999, SCIENCE, V284, P154, DOI 10.1126/science.284.5411.154; Vollbrecht E, 2000, DEVELOPMENT, V127, P3161; WAITES R, 1995, DEVELOPMENT, V121, P2143; Waites R, 1998, CELL, V93, P779, DOI 10.1016/S0092-8674(00)81439-7	30	588	639	7	113	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					967	971		10.1038/35050091	http://dx.doi.org/10.1038/35050091			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140682	Green Published			2022-12-28	WOS:000165951100048
J	Nir, E; Kleinermanns, K; de Vries, MS				Nir, E; Kleinermanns, K; de Vries, MS			Pairing of isolated nucleic-acid bases in the absence of the DNA backbone	NATURE			English	Article							VIBRATIONAL-MODES; FREE NUCLEOBASES; SPECTROSCOPY; CYTOSINE; GUANINE; THYMINE; MONONUCLEOSIDES; ULTRAVIOLET; SPECTRA; ADENINE	The two intertwined strands of DNA are held together through base pairing-the formation of hydrogen bonds between bases located opposite each other on the two strands. DNA replication and transcription involve the breaking and re-forming of these hydrogen bonds, but it is difficult to probe these processes directly. For example, conventional DNA spectroscopy(1-3) is dominated by solvent interactions, crystal modes and collective modes of the DNA backbone; gas-phase studies, in contrast, can in principle measure interactions between individual molecules in the absence of external effects, but require the vaporization of the interacting species without thermal degradation(4-9). Here we report the generation of gas-phase complexes comprising paired bases, and the spectroscopic characterization of the hydrogen bonding in isolated guanine-cytosine (G-C) and guanine-guanine (G-G) base pairs. We rnd that the gas-phase G-C base pair adopts a single configuration, which may be Watson-Crick, whereas G-G exists in two different configurations, and we see evidence for proton transfer in the G-C pair, an important step in radiation-induced DNA damage pathways(10). Interactions between different bases and between bases and water molecules can also be characterized by our approach, providing stringent tests for high-level ab initio computations that aim to elucidate the fundamental aspects of nucleotide interactions(11-13).	Hebrew Univ Jerusalem, Dept Chem, IL-91904 Jerusalem, Israel; Univ Dusseldorf, Inst Phys Chem & Elektrochem, D-40225 Dusseldorf, Germany; Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	Hebrew University of Jerusalem; Heinrich Heine University Dusseldorf; University of California System; University of California Santa Barbara	de Vries, MS (corresponding author), Hebrew Univ Jerusalem, Dept Chem, IL-91904 Jerusalem, Israel.	devries@chem.ucsb.edu	NIR, EYAL/F-1621-2012	NIR, EYAL/0000-0002-6656-3282				BRADY BB, 1988, CHEM PHYS LETT, V147, P538, DOI 10.1016/0009-2614(88)80264-1; Cocco S, 2000, J CHEM PHYS, V112, P10017, DOI 10.1063/1.481646; COLSON AO, 1992, J PHYS CHEM-US, V96, P9787, DOI 10.1021/j100203a039; DEY M, 1994, J AM CHEM SOC, V116, P9211, DOI 10.1021/ja00099a042; DEY M, 1994, Z NATURFORSCH A, V49, P776; FLORIAN J, 1995, J MOL STRUCT, V349, P421, DOI 10.1016/0022-2860(95)08799-2; FODOR SPA, 1986, J RAMAN SPECTROSC, V17, P471, DOI 10.1002/jrs.1250170609; Hobza P, 1997, J COMPUT CHEM, V18, P1136, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1136::AID-JCC3>3.0.CO;2-S; Hobza P, 1996, CHEM PHYS LETT, V261, P379, DOI 10.1016/0009-2614(96)00954-2; Hutter M, 1996, J AM CHEM SOC, V118, P7574, DOI 10.1021/ja953370+; Janzen C, 1999, J CHEM PHYS, V110, P9898, DOI 10.1063/1.478863; MEIJER G, 1990, APPL PHYS B-PHOTO, V51, P395, DOI 10.1007/BF00329101; Nir E, 1999, J AM CHEM SOC, V121, P4896, DOI 10.1021/ja984088g; Santamaria R, 1999, J COMPUT CHEM, V20, P511, DOI 10.1002/(SICI)1096-987X(19990415)20:5<511::AID-JCC4>3.0.CO;2-8; Schmitt M, 1998, J CHEM PHYS, V108, P4486, DOI 10.1063/1.475860; SCHUTZ M, 1993, J CHEM PHYS, V98, P3763, DOI 10.1063/1.464055; Shishkin OV, 1999, J MOL STRUCT, V477, P15, DOI 10.1016/S0022-2860(98)00603-6; Sponer J, 1996, J PHYS CHEM-US, V100, P1965, DOI 10.1021/jp952760f; URABE H, 1985, J CHEM PHYS, V82, P531, DOI 10.1063/1.448775; VIANT MR, 1995, J CHEM PHYS, V103, P9502, DOI 10.1063/1.469960; YASON IK, 1997, BIOPOLYMERS, V18, P1149	21	234	236	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					949	951		10.1038/35050053	http://dx.doi.org/10.1038/35050053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140676				2022-12-28	WOS:000165951100042
J	Strassmann, JE; Zhu, Y; Queller, DC				Strassmann, JE; Zhu, Y; Queller, DC			Altruism and social cheating in the social amoeba Dictyostelium discoideum	NATURE			English	Article							CELLULAR SLIME-MOLDS; EVOLUTION; HETEROCYTOSIS; CHIMERAS; BEHAVIOR	The social amoeba, Dictyostelium discoideum, is widely used as a simple model organism for multicellular development(1,2), but its multicellular fruiting stage is really a society. Most of the time, D. discoideum lives as haploid, free-living, amoeboid cells that divide asexually. When starved, 10(4)-10(5) of these cells aggregate into a slug. The anterior 20% of the slug altruistically differentiates into a non-viable stalk, supporting the remaining cells, most of which become viable spores(3-5). If aggregating cells come from multiple clones, there should be selection for clones to exploit other clones by contributing less than their proportional share to the sterile stalk. Here we use microsatellite markers to show that different clones collected from a field population readily mix to form chimaeras. Half of the chimaeric mixtures show a clear cheater and victim. Thus, unlike the clonal and highly cooperative development of most multicellular organisms, the development of D. discoideum is partly competitive, with conflicts of interests among cells. These conflicts complicate the use of D. discoideum as a model for some aspects of development, but they make it highly attractive as a model system for social evolution.	Rice Univ, Dept Ecol & Evolutionary Biol, Houston, TX 77251 USA	Rice University	Strassmann, JE (corresponding author), Rice Univ, Dept Ecol & Evolutionary Biol, POB 1892, Houston, TX 77251 USA.	strassm@rice.edu		Strassmann, Joan/0000-0003-0638-8440				ARMSTRONG DP, 1984, J THEOR BIOL, V109, P271, DOI 10.1016/S0022-5193(84)80006-5; Atzmony D, 1997, CURR SCI INDIA, V72, P142; BONNER JT, 1967, CELLULAR SLIME MOLDS; Dawkins R., 1978, P282; ELGAR MA, 1988, ANIM BEHAV, V36, P1511, DOI 10.1016/S0003-3472(88)80221-5; Ennis HL, 2000, P NATL ACAD SCI USA, V97, P3292, DOI 10.1073/pnas.050005097; FRANCIS D, 1993, MOL ECOL, V2, P385, DOI 10.1111/j.1365-294X.1993.tb00031.x; GADAGKAR R, 1994, J BIOSCIENCES, V19, P219, DOI 10.1007/BF02703057; GROSBERG RK, 1988, Q REV BIOL, V63, P377, DOI 10.1086/416026; GROSBERG RK, 1986, NATURE, V322, P456, DOI 10.1038/322456a0; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HILSON JA, 1994, ETHOL ECOL EVOL, V6, P529, DOI 10.1080/08927014.1994.9522977; HOLM S, 1979, SCAND J STAT, V6, P65; HOULE J, 1989, P NATL ACAD SCI USA, V86, P3679; HUSS MJ, 1989, MYCOLOGIA, V81, P677, DOI 10.2307/3759871; Kay RR, 1999, TRENDS GENET, V15, P294, DOI 10.1016/S0168-9525(99)01770-9; KESSIN RH, 1997, DICTYOSTELIUM MODEL, P3; KETCHAM RB, 1989, ECOLOGY, V70, P1425, DOI 10.2307/1938201; LOOMIS W F, 1988, 4 BILLION YEARS ESSA; Maeda Y., 1997, DICTYOSTELIUM MODEL; Queller DC, 1998, BIOSCIENCE, V48, P165, DOI 10.2307/1313262; Raper K. B., 1984, DICTYOSTELIDS; RAPER KENNETH B., 1940, JOUR ELISHA MITCHELL SCI SOC, V56, P241; Stoner DS, 1999, P NATL ACAD SCI USA, V96, P9148, DOI 10.1073/pnas.96.16.9148; Velicer GJ, 2000, NATURE, V404, P598, DOI 10.1038/35007066; Williams G. C., 1966, P307; WILSON DS, 1989, J THEOR BIOL, V136, P337, DOI 10.1016/S0022-5193(89)80169-9	30	318	326	2	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					965	967		10.1038/35050087	http://dx.doi.org/10.1038/35050087			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140681				2022-12-28	WOS:000165951100047
J	Buckingham, M				Buckingham, M			A cellular cornucopia - Stem cells generate new possibilities for research and therapy.	NATURE			English	Editorial Material									Inst Pasteur, Dept Mol Biol, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Buckingham, M (corresponding author), Inst Pasteur, Dept Mol Biol, 25 Rue Dr Roux, F-75015 Paris, France.								0	1	1	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					773	773		10.1038/35048635	http://dx.doi.org/10.1038/35048635			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130698				2022-12-28	WOS:000165831300021
J	Johnston, SC; Gress, DR; Browner, WS; Sidney, S				Johnston, SC; Gress, DR; Browner, WS; Sidney, S			Short-term prognosis after emergency department diagnosis of TIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSIENT-ISCHEMIC-ATTACKS; HEALTH-CARE PROFESSIONALS; AD-HOC-COMMITTEE; STROKE-COUNCIL; INTEROBSERVER AGREEMENT; MANAGEMENT; GUIDELINES; STATEMENT; MINNESOTA; ROCHESTER	Context Management of patients with acute transient ischemic attack (TIA) varies widely, with some institutions admitting all patients and others proceeding with outpatient evaluations. Defining the short-term prognosis and risk factors for stroke after TIA may provide guidance in determining which patients need rapid evaluation. Objective To determine the short-term risk of stroke and other adverse events after emergency department (ED) diagnosis of TIA. Design and Setting Cohort study conducted from March 1997 through February 1998 in 16 hospitals in a health maintenance organization in northern California. Patients A total of 1707 patients (mean age, 72 years) identified by ED physicians as having presented with TIA. Main Outcome Measures Risk of stroke during the 90 days after index TIA; other events, including death, recurrent TIA, and hospitalization for cardiovascular events. Results During the 90 days after index TIA, 180 patients (10.5%) returned to the ED with a stroke, 91 of which occurred in the first 2 days. Five factors were independently associated with stroke: age greater than 60 years (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.1-2.7; P=.01), diabetes mellitus (OR, 2.0; 95% CI, 1.4-2.9; P<.001), symptom duration longer than 10 minutes (OR, 2.3; 95% CI, 1.3-4.2; P=.005), weakness (OR, 1.9, 95% CI, 1.4-2.6; P<.001), and speech impairment (OR, 1.5, 95% CI, 1.1-2.1; P=.01). Stroke or other adverse events occurred in 428 patients (25.1%) in the 90 days after the TIA and included 44 hospitalizations for cardiovascular events (2.6%), 45 deaths (2.6%), and 216 recurrent TIAs (12.7%). Conclusions Our results indicate that the short-term risk of stroke and other adverse events among patients who present to an ED with a TIA is substantial. Characteristics of the patient and the TIA may be useful for identifying patients who may benefit from expeditious evaluation and treatment.	Univ Calif San Francisco, Dept Neurol, Neurovasc Serv, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA; Kaiser Permanente No Calif, Div Res, Oakland, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; Kaiser Permanente	Johnston, SC (corresponding author), Univ Calif San Francisco, Dept Neurol, Neurovasc Serv, 505 Parnassus Ave,M-798, San Francisco, CA 94143 USA.	clayj@itsa.ucsf.edu			NINDS NIH HHS [NS 02042, NS 36016] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036016] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; Albers GW, 1999, STROKE, V30, P2502, DOI 10.1161/01.STR.30.11.2502; BRAININ M, 1995, STROKE, V26, P1348, DOI 10.1161/01.STR.26.8.1348; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Brown RD, 1996, STROKE, V27, P373; Brown RD, 1998, STROKE, V29, P2109, DOI 10.1161/01.STR.29.10.2109; CALANDRE L, 1990, ACTA NEUROL SCAND, V82, P104; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DYKEN ML, 1977, JAMA-J AM MED ASSOC, V237, P882, DOI 10.1001/jama.237.9.882; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FEINBERG WM, 1994, CIRCULATION, V89, P2950, DOI 10.1161/01.CIR.89.6.2950; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P171, DOI 10.1136/jnnp.55.3.171; HANKEY GJ, 1982, STROKE, V13, P24; HEYMAN A, 1979, NEUROLOGY, V29, P214, DOI 10.1212/WNL.29.2.214; HEYMAN A, 1984, NEUROLOGY, V34, P626, DOI 10.1212/WNL.34.5.626; *HLTH CAR FIN ADM, 1996, FED REGISTER, V61, P46166; Johnston SC, 1999, EUR NEUROL, V42, P105, DOI 10.1159/000069419; KERNAN WN, 1991, ANN INTERN MED, V114, P552, DOI 10.7326/0003-4819-114-7-552; KOTHARI RU, 1995, STROKE, V26, P2238, DOI 10.1161/01.STR.26.12.2238; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; KOUDSTAAL PJ, 1989, STROKE, V20, P300, DOI 10.1161/01.STR.20.2.300; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; *NAT STROK ASS, 2000, TIA MIN STROK PUBL K; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SORENSEN PS, 1989, ACTA NEUROL SCAND, V79, P204, DOI 10.1111/j.1600-0404.1989.tb03740.x; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WHISNANT JP, 1973, MAYO CLIN PROC, V48, P194; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523; Wolf PA, 1999, STROKE, V30, P1991, DOI 10.1161/01.STR.30.9.1991	37	924	986	0	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2901	2906		10.1001/jama.284.22.2901	http://dx.doi.org/10.1001/jama.284.22.2901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11147987	Bronze			2022-12-28	WOS:000165717000030
J	Ingman, M; Kaessmann, H; Paabo, S; Gyllensten, U				Ingman, M; Kaessmann, H; Paabo, S; Gyllensten, U			Mitochondrial genome variation and the origin of modern humans	NATURE			English	Article							CONTROL REGION; DNA; POPULATION; EVOLUTION; RECOMBINATION; SEQUENCES; LINKAGE	The analysis of mitochondrial DNA (mtDNA) has been a potent tool in our understanding of human evolution, owing to characteristics such as high copy number, apparent lack of recombination(1), high substitution rate(2) and maternal mode of inheritance(3). However, almost all studies of human evolution based on mtDNA sequencing have been confined to the control region, which constitutes less than 7% of the mitochondrial genome. These studies are complicated by the extreme variation in substitution rate between sites, and the consequence of parallel mutations(4) causing difficulties in the estimation of genetic distance and making phylogenetic inferences questionable(5). Most comprehensive studies of the human mitochondrial molecule have been carried out through restriction-fragment length polymorphism analysis(6), providing data that are ill suited to estimations of mutation rate and therefore the timing of evolutionary events. Here, to improve the information obtained from the mitochondrial molecule for studies of human evolution, We describe the global mtDNA diversity in humans based on analyses of the complete mtDNA sequence of 53 humans of diverse origins. Our mtDNA data, in comparison with those of a parallel study of the Xq13.3 region(7) in the same individuals, provide a concurrent view on human evolution with respect to the age of modern humans.	Uppsala Univ, Rudbeck Lab, Med Genet Sect, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany	Uppsala University; Max Planck Society	Gyllensten, U (corresponding author), Uppsala Univ, Rudbeck Lab, Med Genet Sect, Dept Genet & Pathol, S-75185 Uppsala, Sweden.	ulf.gyllensten@genpat.uu.se	Kaessmann, Henrik/B-4989-2013	Kaessmann, Henrik/0000-0001-7563-839X				ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; Awadalla P, 1999, SCIENCE, V286, P2524, DOI 10.1126/science.286.5449.2524; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; Eyre-Walker A, 1999, P ROY SOC B-BIOL SCI, V266, P477, DOI 10.1098/rspb.1999.0662; FU YX, 1993, GENETICS, V133, P693; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; Kaessmann H, 1999, NAT GENET, V22, P78, DOI 10.1038/8785; Klein RG, 1989, HUMAN CAREER HUMAN B; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LEWONTIN RC, 1964, GENETICS, V49, P49; MADDISON DR, 1992, SYST BIOL, V41, P111, DOI 10.2307/2992510; NEI M, 1992, MOL BIOL EVOL, V9, P1176; OLIVO PD, 1983, NATURE, V306, P400, DOI 10.1038/306400a0; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; ROGERS AR, 1992, MOL BIOL EVOL, V9, P552; Rozas J, 1995, COMPUT APPL BIOSCI, V11, P621; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SARICH VM, 1973, SCIENCE, V179, P1144, DOI 10.1126/science.179.4078.1144; Sharma A, 2000, SCIENCE, V288, P977; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAJIMA F, 1989, GENETICS, V123, P585; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; Torroni A, 1998, AM J HUM GENET, V62, P1137, DOI 10.1086/301822; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62; Zietkiewicz E, 1998, J MOL EVOL, V47, P146, DOI 10.1007/PL00006371	30	957	1051	9	298	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					708	713		10.1038/35047064	http://dx.doi.org/10.1038/35047064			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130070				2022-12-28	WOS:000165815200046
J	Xu, X; Zhou, ZH; Wang, XL				Xu, X; Zhou, ZH; Wang, XL			The smallest known non-avian theropod dinosaur	NATURE			English	Article							CHINA	Non-avian dinosaurs are mostly medium to large-sized animals, and to date all known mature specimens are larger than the most primitive bird, Archaeopteryx(1). Here we report on a new dromaeosaurid dinosaur, Microraptor zhaoianus gen. et sp. nov., from the Early Cretaceous Jiufotang Formation of Liaoning, China(2). This is the first mature non-avian dinosaur to be found that is smaller than Archaeopteryx(1), and it eliminates the size disparity between the earliest birds and their closest non-avian theropod relatives. The more bird-like teeth, the Rahonavis-like ischium and the small number of caudal vertebrae of Microraptor are unique among dromaeosaurids and improve our understanding of the morphological transition to birds. The nearly completely articulated foot shows features, such as distally positioned digit I, slender and recurved pedal claws, and elongated penultimate phalanges, that are comparable to those of arboreal birds(3-6). The discovery of these in non-avian theropods provides new insights for studying the palaeoecology of some bird-like theropod dinosaurs.	Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; China Univ Geosci, Coll Earth Sci & Resources, Beijing 100083, Peoples R China	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; China University of Geosciences	Xu, X (corresponding author), Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, POB 643, Beijing 100044, Peoples R China.	xxu@midwest.com.cn						Buffetaut E, 1996, NATURE, V381, P689, DOI 10.1038/381689a0; Chatterjee S., 1997, THE RISE OF BIRDS; Chiappe Luis M., 1997, Archaeopteryx, V15, P109; Clark James M., 1994, American Museum Novitates, V3115, P1; Clark JM, 1998, NATURE, V391, P886, DOI 10.1038/36092; Currie P, 1994, CAN J EARTH SCI, V30, P2224, DOI 10.1139/e93-193.; Currie P.J., 1987, Journal of Vertebrate Paleontology, V7, P72; Currie P.J., 1990, DINOSAUR SYSTEMATICS, P108; Currie PJ, 1995, J VERTEBR PALEONTOL, V15, P576, DOI 10.1080/02724634.1995.10011250; FEDUCCIA A, 1993, SCIENCE, V259, P790, DOI 10.1126/science.259.5096.790; Forster CA, 1998, SCIENCE, V279, P1915, DOI 10.1126/science.279.5358.1915; HOLTZ TR, 1994, J PALEONTOL, V68, P1100, DOI 10.1017/S0022336000026706; Jin F, 1996, VERTEBRATA PALASIATI, V34, P102; Makovicky Peter J., 1998, American Museum Novitates, V3240, P1; Martin L.D., 1991, P485; Norell Mark A., 1997, American Museum Novitates, V3215, P1; Ostrom J. H., 1969, Bulletin of the Peabody Museum of Natural History, VNo. 30, P1; OSTROM JH, 1986, MEM CALIF ACAD SCI, V8, P73; RUSSELL DA, 1993, CAN J EARTH SCI, V30, P2163, DOI 10.1139/e93-187; Sereno PC, 1999, SCIENCE, V284, P2137, DOI 10.1126/science.284.5423.2137; Wellnhofer P., 1988, Archaeopteryx, V6, P1; Wellnhofer Peter, 1993, Archaeopteryx, V11, P1; Wellnhofer Peter, 1992, Natural History Museum of Los Angeles County Science Series, V36, P3; Xu X, 1999, NATURE, V401, P262, DOI 10.1038/45769; Xu X, 1999, NATURE, V399, P350, DOI 10.1038/20670; Xu Xing, 1998, Vertebrata Palasiatica, V36, P147; YADEN DW, 1985, BEGINNINGS BIRDS, P91; Yalden D.W., 1997, Archaeopteryx, V15, P107; Zhou ZH, 1999, SM C PALEOB, P289; Zhou Zhonghe, 1998, Vertebrata Palasiatica, V36, P136	30	224	273	6	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2000	408	6813					705	708		10.1038/35047056	http://dx.doi.org/10.1038/35047056			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130069	Green Published			2022-12-28	WOS:000165815200045
J	Deng, J; Jones, R; Kahrilas, P; Talley, NJ				Deng, J; Jones, R; Kahrilas, P; Talley, NJ			Management of gastro-oesophageal reflux disease in general practice	BRITISH MEDICAL JOURNAL			English	Review							SYMPTOMATIC GASTROESOPHAGEAL REFLUX; QUALITY-OF-LIFE; ENDOSCOPIC ASSESSMENT; LONG-TERM; ESOPHAGITIS; OMEPRAZOLE; GUIDELINES; HEARTBURN; DIAGNOSIS		Guys Kings & St Thomas Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England; Royal Adelaide Hosp, Dept Gastroenterol Hepatol & Gen Med, Adelaide, SA 5000, Australia; Northwestern Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA; Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2751, Australia	University of London; King's College London; Royal Adelaide Hospital; Northwestern University; Nepean Hospital; University of Sydney	Jones, R (corresponding author), Guys Kings & St Thomas Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England.		Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Armstrong D, 1996, GASTROENTEROLOGY, V111, P85, DOI 10.1053/gast.1996.v111.pm8698230; Bardhan KD, 1998, GUT, V43, P458, DOI 10.1136/gut.43.4.458; Bardhan KD, 1999, BRIT MED J, V318, P502, DOI 10.1136/bmj.318.7182.502; Bate CM, 1998, ALIMENT PHARM THERAP, V12, P41; Blustein PK, 1998, AM J GASTROENTEROL, V93, P2508, DOI 10.1016/S0002-9270(98)00475-4; Carlsson R, 1998, SCAND J GASTROENTERO, V33, P1023; Dent J, 1999, GUT, V44, pS1, DOI 10.1136/gut.44.2008.S1; Dent J, 1998, DIGESTION, V59, P433, DOI 10.1159/000007521; DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434; DIMENAS E, 1993, SCAND J GASTROENTERO, V28, P18, DOI 10.3109/00365529309098350; *FRENCH BELG CONS, 2000, EUR J GASTROEN HEPAT, V12, P129; Galmiche JP, 1998, BRIT MED J, V316, P1720, DOI 10.1136/bmj.316.7146.1720; Gambitta P, 1998, CURR THER RES CLIN E, V59, P275, DOI 10.1016/S0011-393X(98)85068-6; Gillen D, 1999, AM J GASTROENTEROL, V94, P2329, DOI 10.1111/j.1572-0241.1999.2329a.x; GLISE H, 1995, SCAND J GASTROENTERO, V30, P38, DOI 10.3109/00365529509090268; Hatlebakk JG, 1999, BMJ-BRIT MED J, V319, P550, DOI 10.1136/bmj.319.7209.550; Kahrilas PJ, 1996, JAMA-J AM MED ASSOC, V276, P983, DOI 10.1001/jama.276.12.983; Klinkenberg-Knol EC, 2000, GASTROENTEROLOGY, V118, P661, DOI 10.1016/S0016-5085(00)70135-1; Kroes RM, 1999, EUR J GEN PRACT, V5, P88; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lundell L, 2000, EUR J GASTROEN HEPAT, V12, P879, DOI 10.1097/00042737-200012080-00007; LUNDELL L, 1999, GUT, V45, pA40; Lundell LR, 1999, GUT, V45, P172, DOI 10.1136/gut.45.2.172; McDougall NI, 1998, SCAND J GASTROENTERO, V33, P1016; Revicki DA, 1998, AM J MED, V104, P252, DOI 10.1016/S0002-9343(97)00354-9; Sampliner RE, 1998, AM J GASTROENTEROL, V93, P1028; Spechler SJ, 1996, GASTROENTEROLOGY, V110, P614, DOI 10.1053/gast.1996.v110.agast960614; Talley NJ, 1999, GUT, V45, P37; Thomson ABR, 1998, CAN J GASTROENTEROL, V12, P551, DOI 10.1155/1998/925346; VIGNERI S, 1995, NEW ENGL J MED, V333, P1106, DOI 10.1056/NEJM199510263331703	30	79	83	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	2001	322	7282					344	347		10.1136/bmj.322.7282.344	http://dx.doi.org/10.1136/bmj.322.7282.344			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159660	Green Published, Green Submitted			2022-12-28	WOS:000167050000031
J	Eskola, J; Kilpi, T; Palmu, A; Jokinen, J; Haapakoski, J; Herva, E; Takala, A; Kayhty, H; Karma, P; Kohberger, R; Siber, G; Makela, PH; Lockhart, S; Ecrola, M				Eskola, J; Kilpi, T; Palmu, A; Jokinen, J; Haapakoski, J; Herva, E; Takala, A; Kayhty, H; Karma, P; Kohberger, R; Siber, G; Makela, PH; Lockhart, S; Ecrola, M		Finnish Otitis Media Study Grp	Efficacy of a pneumococcal conjugate vaccine against acute otitis media	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; POLYSACCHARIDE VACCINE; ANTIBODY-RESPONSE; UNITED-STATES; EARLY INFANCY; CHILDREN; IMMUNOGENICITY; PREVENTION; REDUCTION	Background: Ear infections are a common cause of illness during the first two years of life. New conjugate vaccines may be able to prevent a substantial portion of cases of acute otitis media caused by Streptococcus pneumoniae. Methods: We enrolled 1662 infants in a randomized, double-blind efficacy trial of a heptavalent pneumococcal polysaccharide conjugate vaccine in which the carrier protein is the nontoxic diphtheria-toxin analogue CRM197. The children received either the study vaccine or a hepatitis B vaccine as a control at 2, 4, 6, and 12 months of age. The clinical diagnosis of acute otitis media was based on predefined criteria, and the bacteriologic diagnosis was based on a culture of middle-ear fluid obtained by myringotomy. Results: Of the children who were enrolled, 95.1 percent completed the trial. With the pneumococcal vaccine, there were more local reactions than with the hepatitis B vaccine but fewer than with the combined whole-cell diphtheria-tetanus-pertussis and Haemophilus influenzae type b vaccine that was administered simultaneously. There were 2596 episodes of acute otitis media during the follow-up period between 6.5 and 24 months of age. The vaccine reduced the number of episodes of acute otitis media from any cause by 6 percent (95 percent confidence interval, -4 to 16 percent [the negative number indicates a possible increase in the number of episodes]), culture-confirmed pneumococcal episodes by 34 percent (95 percent confidence interval, 21 to 45 percent), and the number of episodes due to the serotypes contained in the vaccine by 57 percent (95 percent confidence interval, 44 to 67 percent). The number of episodes attributed to serotypes that are cross-reactive with those in the vaccine was reduced by 51 percent, whereas the number of episodes due to all other serotypes increased by 33 percent. Conclusions: The heptavalent pneumococcal polysaccharide-CRM197 conjugate vaccine is safe and efficacious in the prevention of acute otitis media caused by the serotypes included in the vaccine. (N Engl J Med 2001;344:403-9.) Copyright (C) 2001 Massachusetts Medical Society.	Natl Publ Hlth Inst, SF-00300 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland; Wyeth Lederle Vaccines, Pearl River, NY USA	Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital; Pfizer	Kilpi, T (corresponding author), Natl Publ Hlth Inst, Mannerheimintie 166, SF-00300 Helsinki, Finland.	terrhi.kilpi@ktl.fi		Lockhart, Stephen/0000-0002-0805-2193; Palmu, Arto A./0000-0001-8071-8896				Ahman H, 1998, PEDIATR INFECT DIS J, V17, P211, DOI 10.1097/00006454-199803000-00008; Ahman H, 1999, VACCINE, V17, P2726, DOI 10.1016/S0264-410X(99)00048-1; Ahman H, 1996, PEDIATR INFECT DIS J, V15, P134, DOI 10.1097/00006454-199602000-00009; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; BLACK S, 1999, 39 INT C ANT AG CHEM, P379; Block SL, 1997, PEDIATR INFECT DIS J, V16, P449, DOI 10.1097/00006454-199704000-00029; BLOCK SL, 1999, 39 INT C ANT AG CHEM, P677; BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002; Bondy J, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e72; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BUTLER JC, 1995, J INFECT DIS, V171, P885, DOI 10.1093/infdis/171.4.885; Dagan R, 1997, PEDIATR INFECT DIS J, V16, P1060, DOI 10.1097/00006454-199711000-00011; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; DOUGLAS RM, 1984, J INFECT DIS, V149, P861, DOI 10.1093/infdis/149.6.861; EEROLA M, 1989, B INT STAT I, V53, P213; FREID VM, 1998, VITAL HLTH STAT SERI, V13; Gates GA, 1996, OTOLARYNG HEAD NECK, V114, P525, DOI 10.1016/S0194-5998(96)70243-7; HOWIE VM, 1984, PEDIATRICS, V73, P79; JOHNSON CE, 1991, J PEDIATR-US, V119, P117, DOI 10.1016/S0022-3476(05)81051-0; Kaplan B, 1997, PEDIATR INFECT DIS J, V16, pS9, DOI 10.1097/00006454-199702001-00003; KARMA P, 1987, ANN OTO RHINOL LARYN, V96, P1; KARMA P, 1985, AM J OTOLARYNG, V6, P173, DOI 10.1016/S0196-0709(85)80081-8; KAYHTY H, 1995, J INFECT DIS, V172, P1273, DOI 10.1093/infdis/172.5.1273; Korkeila M, 2000, VACCINE, V18, P1218, DOI 10.1016/S0264-410X(99)00393-X; Leach A, 1996, PEDIATR INFECT DIS J, V15, P333, DOI 10.1097/00006454-199604000-00010; LEINONEN MK, 1980, J CLIN MICROBIOL, V11, P135, DOI 10.1128/JCM.11.2.135-140.1980; LUOTONEN J, 1981, SCAND J INFECT DIS, V13, P177, DOI 10.3109/inf.1981.13.issue-3.04; MAKELA PH, 1980, LANCET, V2, P547; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; Niemela M, 1999, ACTA PAEDIATR, V88, P553, DOI 10.1080/08035259950169585; Obaro SK, 1997, PEDIATR INFECT DIS J, V16, P1135, DOI 10.1097/00006454-199712000-00007; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Rennels MB, 1998, PEDIATRICS, V101, P604, DOI 10.1542/peds.101.4.604; Ryding M, 1997, ACTA PAEDIATR, V86, P1208, DOI 10.1111/j.1651-2227.1997.tb14848.x; Shinefield HR, 1999, PEDIATR INFECT DIS J, V18, P757, DOI 10.1097/00006454-199909000-00004; TEELE DW, 1981, REV INFECT DIS, V3, pS113; TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685	39	1076	1154	1	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 8	2001	344	6					403	409		10.1056/NEJM200102083440602	http://dx.doi.org/10.1056/NEJM200102083440602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399FH	11172176				2022-12-28	WOS:000166800600002
J	McClung, MR; Geusens, P; Miller, PD; Zippel, H; Bensen, WG; Roux, C; Adami, S; Fogelman, I; Diamond, T; Eastell, R; Meunier, PJ; Reginster, JY; Wasnich, RD; Greenwald, M; Kaufman, J; Chestnut, CH				McClung, MR; Geusens, P; Miller, PD; Zippel, H; Bensen, WG; Roux, C; Adami, S; Fogelman, I; Diamond, T; Eastell, R; Meunier, PJ; Reginster, JY; Wasnich, RD; Greenwald, M; Kaufman, J; Chestnut, CH		Hip Intervention Program Study Grp	Effect of risedronate on the risk of hip fracture in elderly women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; VERTEBRAL FRACTURES; OLDER WOMEN; CALCIUM; TRIAL; OSTEOPOROSIS; ALENDRONATE; PREVALENCE; ESTROGENS	Background: Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. Methods: We studied 5445 women 70 to 79 years old who had osteoporosis (indicated by a T score for bone mineral density at the femoral neck that was more than 4 SD below the mean peak value in young adults [-4] or lower than -3 plus a nonskeletal risk factor for hip fracture, such as poor gait or a propensity to fall) and 3886 women at least 80 years old who had at least one nonskeletal risk factor for hip fracture or low bone mineral density at the femoral neck (T score, lower than -4 or lower than -3 plus a hip-axis length of 11.1 cm or greater). The women were randomly assigned to receive treatment with oral risedronate (2.5 or 5.0 mg daily) or placebo for three years. The primary end point was the occurrence of hip fracture. Results: Overall, the incidence of hip fracture among all the women assigned to risedronate was 2.8 percent, as compared with 3.9 percent among those assigned to placebo (relative risk, 0.7; 95 percent confidence interval, 0.6 to 0.9; P=0.02). In the group of women with osteoporosis (those 70 to 79 years old), the incidence of hip fracture among those assigned to risedronate was 1.9 percent, as compared with 3.2 percent among those assigned to placebo (relative risk, 0.6; 95 percent confidence interval, 0.4 to 0.9; P=0.009). In the group of women selected primarily on the basis of nonskeletal risk factors (those at least 80 years of age), the incidence of hip fracture was 4.2 percent among those assigned to risedronate and 5.1 percent among those assigned to placebo (P=0.35). Conclusions: Risedronate significantly reduces the risk of hip fracture among elderly women with confirmed osteoporosis but not among elderly women selected primarily on the basis of risk factors other than low bone mineral density. (N Engl J Med 2001;344:333-40.) Copyright (C) 2001 Massachusetts Medical Society.	Oregon Osteoporosis Ctr, Portland, OR 97213 USA; Providence Med Ctr, Portland, OR USA; Limburgs Univ Ctr, Diepenbeek, Belgium; Univ Maastricht, Maastricht, Netherlands; Colorado Ctr Bone Res, Lakewood, CO USA; Humboldt Univ, Charite, Berlin, Germany; McMaster Univ, St Josephs Hosp, Hamilton, ON, Canada; Hop Cochin, F-75674 Paris, France; Ctr Osped, Clin Valeggio, Valeggio, Italy; Guys Hosp, London SE1 9RT, England; St George Hosp, Kogarah, NSW 2217, Australia; Univ Sheffield, Sheffield, S Yorkshire, England; Hop Edouard Herriot, Lyon, France; Univ Liege, Liege, Belgium	Oregon Osteoporosis Center; Hasselt University; Maastricht University; Colorado Center For Bone Research; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; McGill University; McMaster University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Guy's & St Thomas' NHS Foundation Trust; St George Hospital; University of Sheffield; CHU Lyon; University of Liege	McClung, MR (corresponding author), Oregon Osteoporosis Ctr, 5050 NE Hoyt,Suite 651, Portland, OR 97213 USA.		Eastell, Richard/G-5851-2011; McClung, Michael/ABA-4100-2021	Eastell, Richard/0000-0002-0323-3366; McClung, Michael/0000-0002-7827-0778				Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHRISCHILLES EA, 1992, ARCH INTERN MED, V152, P655; CUMMING RG, 1994, AM J EPIDEMIOL, V139, P493, DOI 10.1093/oxfordjournals.aje.a117032; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DargentMolina P, 1996, LANCET, V348, P416; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Ensrud KE, 1997, AM J MED, V103, P274, DOI 10.1016/S0002-9343(97)00025-9; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HUTCHINSON TA, 1979, LANCET, V2, P705; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOTOWICZ MA, 1994, J BONE MINER RES, V9, P599; Law MR, 1997, BMJ-BRIT MED J, V315, P841, DOI 10.1136/bmj.315.7112.841; LOOKER AC, 1995, J BONE MINER RES, V10, P796; MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P113, DOI 10.1007/BF01623271; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; Pattie A., 1979, MANUAL CLIFTON ASSES; Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010; Schott AM, 1998, OSTEOPOROSIS INT, V8, P247, DOI 10.1007/s001980050061	24	1392	1443	1	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					333	340		10.1056/NEJM200102013440503	http://dx.doi.org/10.1056/NEJM200102013440503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172164				2022-12-28	WOS:000166675800003
J	Sterne, JAC; Smith, GD				Sterne, JAC; Smith, GD			Sifting the evidence - what's wrong with significance tests?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							P-VALUES; SAMPLE-SIZE; CONFIDENCE-INTERVALS; MEDICAL STATISTICS; CLINICAL RESEARCH; PUBLICATION BIAS; TRIALS; HYPOTHESIS; DESIGN; DEBATE		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Sterne, JAC (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	jonathan.sterne@bristol.ac.uk	Sterne, Jonathan/Z-3106-2019; Davey Smith, George/A-7407-2013	Sterne, Jonathan/0000-0001-8496-6053; Davey Smith, George/0000-0002-1407-8314; s, hema/0000-0002-3440-9475				ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; BERGER JO, 1987, J AM STAT ASSOC, V82, P112, DOI 10.2307/2289131; Berkson J, 1942, J AM STAT ASSOC, V37, P325, DOI 10.2307/2279000; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; Burton PR, 1998, J EPIDEMIOL COMMUN H, V52, P318, DOI 10.1136/jech.52.5.318; COLE P, 1993, EPIDEMIOLOGY, V4, P271, DOI 10.1097/00001648-199305000-00012; COX DR, 1982, BRIT J CLIN PHARMACO, V14, P325, DOI 10.1111/j.1365-2125.1982.tb01987.x; Danesh J, 2000, BRIT MED J, V321, P208, DOI 10.1136/bmj.321.7255.208; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EDWARDS W, 1963, PSYCHOL REV, V70, P193, DOI 10.1037/h0044139; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; Feinstein AR, 1998, J CLIN EPIDEMIOL, V51, P355, DOI 10.1016/S0895-4356(97)00295-3; Fisher R.A., 1950, STAT METHODS RES WOR, P80; Fisher Ronald A., 1973, STAT METHODS SCI INF; Freiman J.A., 1992, MED USES STAT, P357, DOI [10.1201/9780429187445, DOI 10.1201/9780429187445]; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GOODMAN SN, 1993, AM J EPIDEMIOL, V137, P485, DOI 10.1093/oxfordjournals.aje.a116700; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Hopkins P N, 1986, Cardiol Clin, V4, P3; Le Fanu J., 1999, RISE FALL MODERN MED; LEHMANN EL, 1993, J AM STAT ASSOC, V88, P1242; Lilford RJ, 1996, BRIT MED J, V313, P603; MAYES LC, 1988, INT J EPIDEMIOL, V17, P680, DOI 10.1093/ije/17.3.680; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; Morris JN, 1975, USES OF EPIDEMIOLOGY; Mulward S, 1996, DAN MED BULL, V43, P96; Neyman J, 1933, PHILOS T R SOC LOND, V231, P289, DOI 10.1098/rsta.1933.0009; Oakes M, 1986, STAT INFERENCE; PHILLIPS AN, 1993, J CLIN EPIDEMIOL, V46, P1203, DOI 10.1016/0895-4356(93)90120-P; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; ROZEBOOM WW, 1960, PSYCHOL BULL, V57, P416, DOI 10.1037/h0042040; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, IN PRESS J CLIN EPID; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	39	974	993	1	98	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2001	322	7280					226	+		10.1136/bmj.322.7280.226	http://dx.doi.org/10.1136/bmj.322.7280.226			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159626	Green Published			2022-12-28	WOS:000166733700034
J	Kirchmaier, AL; Rine, J				Kirchmaier, AL; Rine, J			DNA replication-independent silencing in S-cerevisiae	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; CELL-CYCLE PROGRESSION; ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; YEAST; CHROMATIN; SIR1; INHERITANCE; REGION; LOCI	In Saccharomyces cerevisiae, the silent mating Loci are repressed by their assembly into heterochromatin. The formation of this heterochromatin requires a cell cycle event that occurs between early S phase and G(2)/M phase, which has been widely assumed to be DNA replication. To determine whether DNA replication through a silent mating-type Locus, HMRa, is required for silencing to be established, we monitored heterochromatin formation at HMRa on a chromosome and on a nonreplicating extrachromosomal cassette as cells passed through S phase. Cells that passed through S phase established silencing at both the chromosomal HMRa Locus and the extrachromosomal HMRa Locus with equal efficiency. Thus, in contrast to the prevailing view, the establishment of silencing occurred in the absence of passage of the DNA replication fork through or near the HMR Locus, but retained a cell cycle dependence.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet & Dev, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Rine, J (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet & Dev, 401 Barker Hall, Berkeley, CA 94720 USA.	jrine@uclink4.berkeley.edu		Kirchmaier, Ann/0000-0001-9938-9105	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019392] Funding Source: NIH RePORTER; NHGRI NIH HHS [NIHGM31105] Funding Source: Medline; NIGMS NIH HHS [NIHF32GM19392] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; Bi X, 1997, MOL CELL BIOL, V17, P7077, DOI 10.1128/MCB.17.12.7077; BROACH JR, 1991, MOL CELLULAR BIOL YE, V1, P297; Cheng TH, 2000, GENE DEV, V14, P452; Dalgaard LZ, 1999, NATURE, V400, P181, DOI 10.1038/22139; Dillin A, 1997, GENETICS, V147, P1053; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; Friedman KL, 1995, J CELL SCI, P51; Gardner KA, 1999, GENETICS, V151, P31; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Holmes SG, 1996, GENE DEV, V10, P1021, DOI 10.1101/gad.10.8.1021; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; KAUFMAN P, COMMUNICATION; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIRCHMAIER AL, UNPUB; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MEYERLEON L, 1987, NUCLEIC ACIDS RES, V15, P6469, DOI 10.1093/nar/15.16.6469; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Rivier DH, 1999, GENETICS, V151, P521; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Singer MS, 1998, GENETICS, V150, P613; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	32	109	110	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2001	291	5504					646	650		10.1126/science.291.5504.646	http://dx.doi.org/10.1126/science.291.5504.646			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158676				2022-12-28	WOS:000166616000042
J	Petticrew, M				Petticrew, M			Systematic reviews from astronomy to zoology: myths and misconceptions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							META-ANALYSIS; METAANALYSIS; INFORMATION; EXPERTS		Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow	Petticrew, M (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	m.petticrew@msoc.mrc.gla.ac.uk	Petticrew, Mark/AAY-6274-2021					Allen M, 1996, J HOMOSEXUAL, V32, P19; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; CHALMERS I, IN PRESS EVAL HLTH P; *CONTR COCHR COLL, 2000, EV SYST REV RES REL; Davies P, 1999, BRIT J EDUC STUD, V47, P108, DOI 10.1111/1467-8527.00106; DeNeve KM, 1998, PSYCHOL BULL, V124, P197, DOI 10.1037/0033-2909.124.2.197; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; EAGLY AH, 1995, PSYCHOL BULL, V117, P125, DOI 10.1037/0033-2909.117.1.125; Fiske P, 1998, BEHAV ECOL, V9, P328, DOI 10.1093/beheco/9.4.328; Forza C, 1998, INT J PROD RES, V36, P837, DOI 10.1080/002075498193714; GARTRELL CD, 1985, RURAL SOCIOL, V50, P38; Glanville J, 1998, BRIT MED J, V317, P200, DOI 10.1136/bmj.317.7152.200; Glass G.V., 1976, ED RES, V5, P3, DOI [DOI 10.3102/0013189X005010003, 10.2307/1174772ISSN0536-1036]; Grewal D, 1997, J MARKETING, V61, P1, DOI 10.2307/1252083; Hedges L. V., 1994, EDUC RESEARCHER, V23, P5, DOI [10.3102/0013189X023003005, DOI 10.3102/0013189X023003005]; Hsieh C.-C., 1993, CRIMINAL JUSTICE REV, V18, P182, DOI [10.1177/073401689301800203, DOI 10.1177/073401689301800203]; LIPSEY M, 1995, WHAT WORKS REDUCING; McManus RJ, 1998, BMJ-BRIT MED J, V317, P1562, DOI 10.1136/bmj.317.7172.1562; Milton J, 1999, PSYCHOL BULL, V125, P387, DOI 10.1037/0033-2909.125.4.387; MULROW C, 1995, SYSTEMATIC REV; *NHS CTR REV DISS, 1996, 4 CRD U YORK; Petticrew M, 1999, INT J TECHNOL ASSESS, V15, P671, DOI 10.1017/S0266462399015469; Popay J, 1998, QUAL HEALTH RES, V8, P341, DOI 10.1177/104973239800800305; SCOTT KD, 1985, ACAD MANAGE J, V28, P599, DOI 10.2307/256116; SIEGAL M, 1987, DEV REV, V7, P183, DOI 10.1016/0273-2297(87)90012-8; Sutton A J, 1998, Health Technol Assess, V2, P1; SWEENEY LT, 1992, BEHAV SCI LAW, V10, P179, DOI 10.1002/bsl.2370100204; *US GEN ACC OFF, 1997, GAOHEHS9759; Wiseman R, 1996, NATURE, V383, P212, DOI 10.1038/383212a0	30	287	299	2	50	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2001	322	7278					98	101		10.1136/bmj.322.7278.98	http://dx.doi.org/10.1136/bmj.322.7278.98			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	393XZ	11154628	Green Accepted, Green Published			2022-12-28	WOS:000166496100038
J	Uppal, S; Saravanappa, N; Davis, JP; Farmer, CKT; Goldsmith, DJA				Uppal, S; Saravanappa, N; Davis, JP; Farmer, CKT; Goldsmith, DJA			Lesson of the week - Pulmonary Wegener's granulomatosis misdiagnosed as malignancy	BRITISH MEDICAL JOURNAL			English	Review							NEEDLE ASPIRATION BIOPSY; CYTOLOGY		Medway Maritime Hosp, Dept Otorhinolaryngol Head & Neck Surg, Gillingham ME7 5NY, Kent, England; Guys Hosp, Renal Unit, London SE1 9RT, England	Medway Maritime Hospital; Guy's & St Thomas' NHS Foundation Trust	Davis, JP (corresponding author), Medway Maritime Hosp, Dept Otorhinolaryngol Head & Neck Surg, Gillingham ME7 5NY, Kent, England.		Goldsmith, David J A/H-6965-2018	Goldsmith, David J A/0000-0002-4349-9193; Farmer, Christopher/0000-0003-1736-8242				BLENNERHASSETT JB, 1976, THORAX, V31, P576, DOI 10.1136/thx.31.5.576; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FEKETE PS, 1990, ACTA CYTOL, V34, P155; GOEKEN JA, 1991, J CLIN IMMUNOL, V11, P161, DOI 10.1007/BF00917422; KANEISHI NK, 1995, ACTA CYTOL, V39, P1094; KATZENSTEIN ALA, 1995, AM J SURG PATHOL, V19, P545, DOI 10.1097/00000478-199505000-00006; LEAVITT R Y, 1991, Current Opinion in Rheumatology, V3, P8, DOI 10.1097/00002281-199102000-00003; MARK EJ, 1988, HUM PATHOL, V19, P1065, DOI 10.1016/S0046-8177(88)80088-1; NARYSHKIN S, 1993, DIAGN CYTOPATHOL, V9, P89, DOI 10.1002/dc.2840090120; PITMAN MB, 1992, ACTA CYTOL, V36, P222; Schnabel A, 1997, EUR RESPIR J, V10, P2738, DOI 10.1183/09031936.97.10122738	11	8	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					89	90		10.1136/bmj.322.7278.89	http://dx.doi.org/10.1136/bmj.322.7278.89			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154625	Green Published			2022-12-28	WOS:000166496100029
J	DeAngelis, LM				DeAngelis, LM			Medical progress: Brain tumors	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NERVOUS-SYSTEM LYMPHOMA; LOW-GRADE OLIGODENDROGLIOMA; HIGH-DOSE METHOTREXATE; NON-HODGKINS-LYMPHOMA; ONCOLOGY-GROUP RTOG; PHASE-II TRIAL; RADIATION-THERAPY; GLIOBLASTOMA-MULTIFORME; INTRACRANIAL MENINGIOMAS; ANAPLASTIC ASTROCYTOMA		Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	DeAngelis, LM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA.	deangell@mskcc.org		DeAngelis, Lisa/0000-0002-6290-7818				Abrey LE, 1998, J CLIN ONCOL, V16, P859, DOI 10.1200/JCO.1998.16.3.859; Antinheimo J, 2000, NEUROLOGY, V54, P71, DOI 10.1212/WNL.54.1.71; Bampoe J, 1999, J NEURO-ONCOL, V42, P259, DOI 10.1023/A:1006103010109; Bataille B, 2000, J NEUROSURG, V92, P261, DOI 10.3171/jns.2000.92.2.0261; Bauman G, 1999, INT J RADIAT ONCOL, V45, P923, DOI 10.1016/S0360-3016(99)00284-9; Biernat W, 1997, ACTA NEUROPATHOL, V94, P303, DOI 10.1007/s004010050711; Bigner S H, 1999, Neuro Oncol, V1, P52, DOI 10.1093/neuonc/1.1.52; Blay JY, 1998, J CLIN ONCOL, V16, P864, DOI 10.1200/JCO.1998.16.3.864; Bondy M, 1996, J NEURO-ONCOL, V29, P197, DOI 10.1007/BF00165649; Braunstein JB, 1997, NEUROLOGY, V48, P1459, DOI 10.1212/WNL.48.5.1459; CAIRNCROSS G, 1994, J CLIN ONCOL, V12, P2013, DOI 10.1200/JCO.1994.12.10.2013; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; CAIRNCROSS JG, 1988, ANN NEUROL, V23, P360, DOI 10.1002/ana.410230408; Chamberlain MC, 1996, J NEUROSURG, V84, P733, DOI 10.3171/jns.1996.84.5.0733; Corn BW, 1997, CANCER, V79, P2409; DeAngelis LM, 1999, J NEUROL NEUROSUR PS, V66, P699, DOI 10.1136/jnnp.66.6.699; DeAngelis LM, 1998, ANN NEUROL, V44, P691, DOI 10.1002/ana.410440418; DeAngelis LM, 1999, CURR OPIN NEUROL, V12, P687, DOI 10.1097/00019052-199912000-00005; DEANGELIS LM, 1987, PAIN, V30, P211, DOI 10.1016/0304-3959(87)91076-1; DeAngelis LM, 1999, J NEURO-ONCOL, V43, P249, DOI 10.1023/A:1006258619757; DEPREZ RHL, 1995, J NEUROPATH EXP NEUR, V54, P224, DOI 10.1097/00005072-199503000-00009; DeWitte O, 1996, NEUROSURGERY, V39, P470, DOI 10.1097/00006123-199609000-00007; Dziuk TW, 1998, J NEURO-ONCOL, V37, P177, DOI 10.1023/A:1005853720926; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; FADUL C, 1988, NEUROLOGY, V38, P1374, DOI 10.1212/WNL.38.9.1374; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; Fine HA, 2000, J CLIN ONCOL, V18, P708, DOI 10.1200/JCO.2000.18.4.708; FORSYTH PA, 1993, NEUROLOGY, V43, P1678, DOI 10.1212/WNL.43.9.1678; Fortin D, 1999, NEUROSURGERY, V45, P1279, DOI 10.1097/00006123-199912000-00001; Go RS, 1998, NEUROLOGY, V51, P1718, DOI 10.1212/WNL.51.6.1718; Hermanson M, 1996, CANCER RES, V56, P164; Herrlinger U, 1999, J NEURO-ONCOL, V43, P219, DOI 10.1023/A:1006298201101; Hess KR, 1999, J NEURO-ONCOL, V42, P227, DOI 10.1023/A:1006118018770; Hiraga S, 1999, J NEUROSURG, V91, P221, DOI 10.3171/jns.1999.91.2.0221; Huncharek M, 1998, ANTICANCER RES, V18, P4693; Inskip PD, 2001, NEW ENGL J MED, V344, P79, DOI 10.1056/NEJM200101113440201; Inskip PD, 1998, CANCER CAUSE CONTROL, V9, P109, DOI 10.1023/A:1008861722901; JENNINGS MT, 1995, J CHILD NEUROL, V10, P37, DOI 10.1177/088307389501000111; Jung V, 1999, J NEUROPATH EXP NEUR, V58, P993, DOI 10.1097/00005072-199909000-00009; Kaplan S, 1997, AM J EPIDEMIOL, V146, P832, DOI 10.1093/oxfordjournals.aje.a009201; KARIM AB, 1998, P AN M AM SOC CLIN, V17, pA400; Karim ABMF, 1996, INT J RADIAT ONCOL, V36, P549, DOI 10.1016/S0360-3016(96)00352-5; KELLY PJ, 1987, MAYO CLIN PROC, V62, P450, DOI 10.1016/S0025-6196(12)65470-6; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 1993, HISTOLOGICAL TYPING; Kleihues P, 2000, PATHOLOGY GENETICS T; Kondziolka D, 1999, J NEUROSURG, V91, P44, DOI 10.3171/jns.1999.91.1.0044; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; LEGLER JM, 1999, JNCI-J NATL CANCER I, V91, P1693; MAIRE JP, 1995, INT J RADIAT ONCOL, V33, P315, DOI 10.1016/0360-3016(94)00661-4; Markopoulos C, 1998, EUR J SURG ONCOL, V24, P332, DOI 10.1016/S0748-7983(98)80019-X; Mason WP, 1996, NEUROLOGY, V46, P203, DOI 10.1212/WNL.46.1.203; MCCORMACK BM, 1992, NEUROSURGERY, V31, P636; NELSON DF, 1992, INT J RADIAT ONCOL, V23, P9, DOI 10.1016/0360-3016(92)90538-S; Olson JD, 2000, NEUROLOGY, V54, P1442, DOI 10.1212/WNL.54.7.1442; ONEILL BP, 1995, INT J RADIAT ONCOL, V33, P663, DOI 10.1016/0360-3016(95)00207-F; Paleologos NA, 1999, NEUROLOGY, V53, P1141, DOI 10.1212/WNL.53.5.1141; Perry A, 1999, CANCER, V86, P672, DOI 10.1002/(SICI)1097-0142(19990815)86:4<672::AID-CNCR17>3.0.CO;2-G; Peterson K, 1996, J NEUROSURG, V85, P597, DOI 10.3171/jns.1996.85.4.0597; Pollak L, 1998, TUMORI, V84, P65, DOI 10.1177/030089169808400114; Posner JB, 1995, NEUROLOGIC COMPLICAT; Prados MD, 1999, J CLIN ONCOL, V17, P3389, DOI 10.1200/JCO.1999.17.11.3389; ProbstCousin S, 1997, CANCER-AM CANCER SOC, V79, P2003, DOI 10.1002/(SICI)1097-0142(19970515)79:10<2003::AID-CNCR23>3.0.CO;2-X; RADHAKRISHNAN K, 1995, ANN NEUROL, V37, P67, DOI 10.1002/ana.410370113; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; RECHT LD, 1992, ANN NEUROL, V31, P431, DOI 10.1002/ana.410310413; RIGGS JE, 1995, ARCH NEUROL-CHICAGO, V52, P571, DOI 10.1001/archneur.1995.00540300043011; Salvatore J R, 1996, Oncology (Williston Park), V10, P563; Sasaki M, 1998, EUR J NUCL MED, V25, P1261, DOI 10.1007/s002590050294; Schabet M, 1999, J NEURO-ONCOL, V43, P199, DOI 10.1023/A:1006290032052; Schrell UMH, 1997, J NEUROSURG, V86, P840, DOI 10.3171/jns.1997.86.5.0840; Schultz C, 1996, J CLIN ONCOL, V14, P556, DOI 10.1200/JCO.1996.14.2.556; Scott JN, 1999, ANN NEUROL, V46, P183, DOI 10.1002/1531-8249(199908)46:2<183::AID-ANA7>3.3.CO;2-Z; SHAW EG, 1998, P AN M AM SOC CLIN, V17, pA401; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Suh JH, 1999, HEMATOL ONCOL CLIN N, V13, P635, DOI 10.1016/S0889-8588(05)70080-0; Surawicz T S, 1999, Neuro Oncol, V1, P14, DOI 10.1093/neuonc/1.1.14; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; Tokuuye K, 1998, INT J RADIAT ONCOL, V42, P989, DOI 10.1016/S0360-3016(98)00293-4; VERTOSICK FT, 1991, NEUROSURGERY, V28, P496, DOI 10.1227/00006123-199104000-00002; Videtic GMM, 1999, INT J RADIAT ONCOL, V45, P687, DOI 10.1016/S0360-3016(99)00244-8; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; Walter AW, 1998, J CLIN ONCOL, V16, P3761, DOI 10.1200/JCO.1998.16.12.3761; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; WERNER MH, 1995, CANCER, V76, P1634, DOI 10.1002/1097-0142(19951101)76:9<1634::AID-CNCR2820760921>3.0.CO;2-0; Yung, 1999, J CLIN ONCOL, V17, P3693; Yung WKA, 1999, J CLIN ONCOL, V17, P2762, DOI 10.1200/JCO.1999.17.9.2762; Zhu JJG, 1999, NEUROSURGERY, V45, P409, DOI 10.1097/00006123-199908000-00049	90	1298	1352	5	132	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					114	123		10.1056/NEJM200101113440207	http://dx.doi.org/10.1056/NEJM200101113440207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150363				2022-12-28	WOS:000166281100007
J	Schrader, H; Stovner, LJ; Helde, G; Sand, T; Bovim, G				Schrader, H; Stovner, LJ; Helde, G; Sand, T; Bovim, G			Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION	Objective To determine the efficacy of an angiotensin converting enzyme inhibitor in the prophylaxis of migraine. Design Double blind, placebo controlled, crossover study. Setting Neurological outpatient clinic. Participants Sixty patients aged 19-59 years with migraine with two to six episodes a month. Interventions Treatment period of 12 weeks with one 10 mg lisinopril tablet once daily for one week then two 10 mg lisinopril tablets once daily for 11 weeks, followed by a two week wash out period. Second treatment period of one placebo tablet once daily for one week and then two placebo tablets for 11 weeks. Thirty participants followed this schedule, and 30 received placebo followed by lisinopril. Main outcome measures Primary end points: number of hours with headache, number of days with headache. number of days with migraine. Secondary end points: headache severity index, use of drugs for symptomatic relief, quality of life and number of days taken as sick leave, acceptability of treatment Results In the 47 participants with complete data, hours with headache, days with headache, days with migraine, and headache severity index were significantly reduced by 20% (95%, confidence interval 5%, to 36%), 17% (5% to 30%), 21% (9% to 34%), and 20% (3% to 37%), respectively, with lisinopril compared with placebo. Days with migraine were fewer by at least 50% in 14 participants for active treatment versus placebo. Intention to treat analysis of data from 55 patients supported the differences in favour of lisinopril for the primary end points. Conclusion The angiotensin converting enzyme inhibitor, lisinopril, has a clinically important prophylactic effect in migraine.	Norwegian Univ Sci & Technol, Dept Neurol, N-7006 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Schrader, H (corresponding author), Norwegian Univ Sci & Technol, Dept Neurol, N-7006 Trondheim, Norway.	harald.schrader@medisin.ntnu.no		Schrader, Harald/0000-0001-9975-1960				Altman DG, 1991, PRACTICAL STAT MED R, P447; [Anonymous], 1991, Cephalalgia, V11, P1; BENDER WI, 1995, HEADACHE, V35, P470, DOI 10.1111/j.1526-4610.1995.hed3508470.x; Fogari R, 1998, AM J HYPERTENS, V11, P1244, DOI 10.1016/S0895-7061(98)00139-3; Goa KL, 1996, DRUGS, V52, P564, DOI 10.2165/00003495-199652040-00011; HOLROYD KA, 1991, HEADACHE, V31, P333, DOI 10.1111/j.1526-4610.1991.hed3105333.x; HUCKELL VF, 1993, CLIN THER, V15, P407; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; Paterna S, 2000, EUR NEUROL, V43, P133, DOI 10.1159/000008151; SKIDGEL RA, 1987, CLIN EXP HYPERTENS A, V9, P243, DOI 10.3109/10641968709164184; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Tfelt-Hansen Peer, 1993, P363; Tomlinson AJ, 2000, ANN PHARMACOTHER, V34, P180; WARE JE, 1994, INT J MENT HEALTH, V23, P49, DOI 10.1080/00207411.1994.11449283	14	183	186	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2001	322	7277					19	22		10.1136/bmj.322.7277.19	http://dx.doi.org/10.1136/bmj.322.7277.19			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141144	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000166341400017
J	Collins, T				Collins, T			Toward sustainable chemistry	SCIENCE			English	Article									Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Collins, T (corresponding author), Carnegie Mellon Univ, Dept Chem, 4400 5th Ave, Pittsburgh, PA 15213 USA.		Collins, Terrence/A-9807-2017	Collins, Terrence/0000-0003-2611-9184					0	106	108	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					48	49		10.1126/science.291.5501.48	http://dx.doi.org/10.1126/science.291.5501.48			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141549				2022-12-28	WOS:000166259100023
J	Davis, ST; Benson, BG; Bramson, HN; Chapman, DE; Dickerson, SH; Dold, KM; Eberwein, DJ; Edelstein, M; Frye, SV; Gampe, RT; Griffin, RJ; Harris, PA; Hassell, AM; Holmes, WD; Hunter, RN; Knick, VB; Lackey, K; Lovejoy, B; Luzzio, MJ; Murray, D; Parker, P; Rocque, WJ; Shewchuk, L; Veal, JM; Walker, DH; Kuyper, LF				Davis, ST; Benson, BG; Bramson, HN; Chapman, DE; Dickerson, SH; Dold, KM; Eberwein, DJ; Edelstein, M; Frye, SV; Gampe, RT; Griffin, RJ; Harris, PA; Hassell, AM; Holmes, WD; Hunter, RN; Knick, VB; Lackey, K; Lovejoy, B; Luzzio, MJ; Murray, D; Parker, P; Rocque, WJ; Shewchuk, L; Veal, JM; Walker, DH; Kuyper, LF			RETRACTED: Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors (Retracted Article. See vol 298, pg 2327, 2002)	SCIENCE			English	Article; Retracted Publication							CYCLIN-DEPENDENT KINASE; CELL-CYCLE; 1,25-DIHYDROXYVITAMIN D-3; PROTEIN-KINASE; PROTECTION; GROWTH; ACTIVATION; APOPTOSIS; RECEPTOR; DESIGN	Most traditional cytotoxic anticancer agents ablate the rapidly dividing epithelium of the hair follicle and induce alopecia (hair Loss). Inhibition of cyclin-dependent kinase 2 (CDK2), a positive regulator of eukaryotic cell cycle progression, may represent a therapeutic strategy for prevention of chemotherapy-induced alopecia (CIA) by arresting the cell cycle and reducing the sensitivity of the epithelium to many cell cycle-active antitumor agents. Potent small-molecule inhibitors of CDK2 were developed using structure-based methods. Topical application of these compounds in a neonatal rat model of CIA reduced hair loss at the site of application in 33 to 50% of the animals. Thus, inhibition of CDK2 represents a potentially useful approach for the prevention of CIA in cancer patients.	Glaxo Wellcome Inc, Res & Dev, Dept Canc Biol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Discovery Genet, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Biomet Res Support, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Struct Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Sci, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Davis, ST (corresponding author), Glaxo Wellcome Inc, Res & Dev, Dept Canc Biol, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	std41085@glaxowellcome.com	ID, IMCACAT/D-5867-2014	Harris, Philip/0000-0002-5189-3326				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNO S, 1992, CANCER RES, V52, P470; BuquetFagot C, 1997, ANTI-CANCER DRUG, V8, P623, DOI 10.1097/00001813-199707000-00011; Chen G, 1998, INT J CANCER, V75, P303, DOI 10.1002/(SICI)1097-0215(19980119)75:2<303::AID-IJC21>3.0.CO;2-C; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; DOLD KM, UNPUB; Dorr VJ, 1998, SEMIN ONCOL, V25, P562; Duvic M, 1996, J AM ACAD DERMATOL, V35, P74, DOI 10.1016/S0190-9622(96)90500-9; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; Hidalgo M, 1999, ANTI-CANCER DRUG, V10, P393, DOI 10.1097/00001813-199904000-00007; JIMENEZ JJ, 1992, CANCER RES, V52, P5123; Kim SH, 1998, PURE APPL CHEM, V70, P555, DOI 10.1351/pac199870030555; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LOBE DC, UNPUB; McCormack ES, 1997, BIOCHEM PHARMACOL, V53, P1149, DOI 10.1016/S0006-2952(97)00094-4; MEHTA S, UNPUB; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Munstedt K, 1997, SUPPORT CARE CANCER, V5, P139, DOI 10.1007/s005200050056; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SchulzeGahmen U, 1996, J MED CHEM, V39, P4540, DOI 10.1021/jm960402a; Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Sundberg JP, 1996, DERMATOL CLIN, V14, P619, DOI 10.1016/S0733-8635(05)70389-2; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	30	147	171	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					134	137		10.1126/science.291.5501.134	http://dx.doi.org/10.1126/science.291.5501.134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141566				2022-12-28	WOS:000166259100052
J	Petersen, LA; Normand, ST; Daley, J; McNeil, BJ				Petersen, LA; Normand, ST; Daley, J; McNeil, BJ			Outcome of myocardial infarction in Veterans Health Administration patients as compared with medicare patients.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-CARE; CORONARY-ANGIOGRAPHY; PRIVATE-SECTOR; AFFAIRS; MORTALITY; SERVICES; VA	Background: Some have the opinion that patients cared for in Veterans Health Administration (VHA) hospitals receive care of poorer quality than those cared for in non-VHA institutions. To assess the quality of care in VHA hospitals, we compared the outcome of acute myocardial infarction among patients in VHA and non-VHA institutions while controlling for potential confounders, including coexisting conditions and severity of illness. Methods: We studied 2486 veterans discharged from 81 VHA hospitals and 29,249 Medicare patients discharged from 1530 non-VHA hospitals, restricting our samples to men at least 65 years of age who were discharged with confirmed acute myocardial infarction. We compared coexisting conditions, severity of illness, and 30-day and 1-year mortality in the two samples. Results: VHA patients were significantly more likely than Medicare patients to have a recorded history of hypertension (64.3 percent vs. 57.3 percent), chronic obstructive pulmonary disease or asthma (30.9 percent vs. 23.5 percent), diabetes (34.8 percent vs. 29.0 percent), stroke (20.4 percent vs. 14.2 percent), or dementia (7.2 percent vs. 4.8 percent) (P<0.001 for all comparisons). According to both multivariate logistic regression and an analysis using 2265 matched pairs of VHA and Medicare patients, there were no significant differences in 30-day or 1-year mortality. The matched-pairs analysis found that the difference in mortality at 30 days (the mortality rate among Medicare patients minus the mortality rate among VHA patients), averaged over the 5-year age groups, was -0.8 percent (95 percent confidence interval, -2.8 to 1.3), and the difference in mortality at 1 year was -1.3 percent (95 percent confidence interval, -3.9 to 1.3). Conclusions: VHA patients had more coexisting conditions than Medicare patients. Nevertheless, we found no significant difference in mortality between VHA and Medicare patients, a result that suggests a similar quality of care for acute myocardial infarction. (N Engl J Med 2000;343:1934-41.) (C) 2000, Massachusetts Medical Society.	Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Partners Hlth Care Syst, Inst Hlth Policy, Boston, MA USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Harvard University; Harvard Medical School; Partners Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Petersen, LA (corresponding author), Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA.			Normand, Sharon-Lise/0000-0001-7027-4769	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008071] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		A Donabedian, 1980, EXPLORATIONS QUALITY, VI; Ayanian JZ, 1998, NEW ENGL J MED, V338, P1896, DOI 10.1056/NEJM199806253382608; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; Chassin MR, 1997, HEALTH AFFAIR, V16, P151, DOI 10.1377/hlthaff.16.3.151; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; FISHER SG, 1995, AM J EPIDEMIOL, V141, P242, DOI 10.1093/oxfordjournals.aje.a117426; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; Gordon HS, 2000, AM J MED QUAL, V15, P207, DOI 10.1177/106286060001500505; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; Iglehart JK, 1996, NEW ENGL J MED, V335, P1407, DOI 10.1056/NEJM199610313351821; Iglehart JK, 1999, NEW ENGL J MED, V340, P327, DOI 10.1056/NEJM199901283400424; JENCKS SF, 1994, ANN THORAC SURG, V58, P1858, DOI 10.1016/0003-4975(94)91727-2; Kazis LE, 1998, ARCH INTERN MED, V158, P626, DOI 10.1001/archinte.158.6.626; KRESS DC, 1988, ARCH SURG-CHICAGO, V123, P439; Krumholz HM, 1999, JAMA-J AM MED ASSOC, V281, P37; Landrum MB, 1999, STAT MED, V18, P117, DOI 10.1002/(SICI)1097-0258(19990130)18:2<117::AID-SIM8>3.0.CO;2-7; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Peabody JW, 1998, ARCH INTERN MED, V158, P2291, DOI 10.1001/archinte.158.21.2291; Petersen LA, 1999, J GEN INTERN MED, V14, P555, DOI 10.1046/j.1525-1497.1999.10198.x; *PHS HLTH CAR FIN, 1980, DHHS PUBL, V1980, P80; Ritchie JL, 1998, AM J CARDIOL, V81, P1094, DOI 10.1016/S0002-9149(98)00125-8; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; ROSENTHAL GE, 1994, J GEN INTERN MED, V9, P455, DOI 10.1007/BF02599064; STREMPLE JF, 1993, ANN SURG, V217, P277, DOI 10.1097/00000658-199303000-00010; Wright SM, 1997, MED CARE, V35, P128, DOI 10.1097/00005650-199702000-00004; Wright SM, 1999, MED CARE, V37, P529, DOI 10.1097/00005650-199906000-00002	33	118	118	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2000	343	26					1934	1941		10.1056/NEJM200012283432606	http://dx.doi.org/10.1056/NEJM200012283432606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386VR	11136265				2022-12-28	WOS:000166082700006
J	Bai, JW; Uehara, Y; Montell, DJ				Bai, JW; Uehara, Y; Montell, DJ			Regulation of invasive cell behavior by taiman, a Drosophila protein related to AlB1, a steroid receptor coactivator amplified in breast cancer	CELL			English	Article							FOCAL ADHESION KINASE; ECDYSONE RECEPTOR; MOSAIC ANALYSIS; DE-CADHERIN; MELANOGASTER; OOGENESIS; MIGRATION; HOMOLOG; REVEALS; GENES	Steroid hormones are key regulators of numerous physiological and developmental processes, including metastasis of breast and ovarian cancer. Here we report the identification of a Drosophila gene, named taiman, which encodes a steroid hormone receptor coactivator related to AIB1. Mutations in tai caused defects in the migration of specific follicle cells, the border cells, in the Drosophila ovary. Mutant cells exhibited abnormal accumulation of E-cadherin, beta -catenin, and focal adhesion kinase. TAI protein colocalized with the ecdysone receptor in vivo and augmented transcriptional activation by the ecdysone receptor in cultured cells. The finding of this type of coactivator required for cell motility suggests a novel role for steroid hormones, in stimulating invasive cell behavior, independent of effects on proliferation.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Montell, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIGMS NIH HHS [R01 GM46425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW DJ, 1994, METHOD CELL BIOL, V44, P353, DOI 10.1016/S0091-679X(08)60923-1; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BEHRENS J, 1993, BREAST CANCER RES TR, V24, P175, DOI 10.1007/BF01833258; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buszczak M, 1999, DEVELOPMENT, V126, P4581; Carney GE, 2000, GENETICS, V154, P1203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chou TB, 1996, GENETICS, V144, P1673; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; CUZICK J, 1996, IARC SCI PUBL, V139, P99; DePasquale JA, 1999, HISTOCHEM CELL BIOL, V112, P341, DOI 10.1007/s004180050415; Fox GL, 1999, P NATL ACAD SCI USA, V96, P14978, DOI 10.1073/pnas.96.26.14978; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Fujimoto J, 1999, J BIOL CHEM, V274, P29196, DOI 10.1074/jbc.274.41.29196; Green S, 1999, ENDOCR-RELAT CANCER, V6, P349, DOI 10.1677/erc.0.0060349; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jordan VC, 1999, TRENDS ENDOCRIN MET, V10, P312, DOI 10.1016/S1043-2760(99)00181-2; King R. C., 1970, OVARIAN DEV DROSOPHI; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; LIU Y, 2001, IN PRESS DEVELOPMENT; Liu YR, 1999, DEVELOPMENT, V126, P1869; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; Montell DJ, 1999, DEVELOPMENT, V126, P3035; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NEUBAUER BL, 1995, PROSTATE, V27, P220, DOI 10.1002/pros.2990270407; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; Oda H, 1997, GENES CELLS, V2, P29, DOI 10.1046/j.1365-2443.1997.d01-284.x; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; ORO AE, 1992, DEVELOPMENT, V115, P449; Palmer RH, 1999, J BIOL CHEM, V274, P35621, DOI 10.1074/jbc.274.50.35621; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Riddiford Lynn M., 1993, P899; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; Schneider H P, 1995, Int J Fertil Menopausal Stud, V40 Suppl 1, P40; SCHWARTZ MB, 1985, J INSECT PHYSIOL, V31, P947, DOI 10.1016/0022-1910(85)90029-0; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; Tinker R, 1998, DEV BIOL, V199, P1, DOI 10.1006/dbio.1998.8941; Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2; Tworoger M, 1999, GENETICS, V151, P739; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0	49	222	224	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 22	2000	103	7					1047	1058		10.1016/S0092-8674(00)00208-7	http://dx.doi.org/10.1016/S0092-8674(00)00208-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163181	Bronze			2022-12-28	WOS:000166040600008
J	Lemarchand, D; Gaillardet, J; Lewin, E; Allegre, CJ				Lemarchand, D; Gaillardet, J; Lewin, E; Allegre, CJ			The influence of rivers on marine boron isotopes and implications for reconstructing past ocean pH	NATURE			English	Article							ATMOSPHERIC CO2; SEAWATER; PALEOCLIMATE; CARBONATES; CRUST; CYCLE	Ocean pH is particularly sensitive to atmospheric carbon dioxide content(1-3). Records of ocean pH can therefore be used to estimate past atmospheric carbon dioxide concentrations. The isotopic composition of boron (delta B-11) contained in the carbonate shells of marine organisms varies according to pH, from which ocean pH can be reconstructed(4-11). This requires independent estimates of the delta B-11 of dissolved boron in sea water through time. The marine delta B-11 budget, however, is still largely unconstrained. Here we show that, by incorporating the global flux of riverine boron (as estimated from delta B-11 measurements in 22 of the world's main rivers), the marine boron isotope budget can be balanced. We also derive ocean delta B-11 budgets for the past 120 Myr. Estimated isotope compositions of boron in sea water show a remarkable consistency with records of delta B-11 in foraminiferal carbonates(9-11), suggesting that foraminifera delta B-11 records may in part reflect changes in the marine boron isotope budget rather than changes in ocean pH over the Cenozoic era.	Inst Phys Globe, Lab Geochim & Cosmochim, F-75252 Paris 05, France	UDICE-French Research Universities; Universite Paris Cite	Lemarchand, D (corresponding author), Inst Phys Globe, Lab Geochim & Cosmochim, 4 Pl Jussieu, F-75252 Paris 05, France.	lemarcha@ipgp.jussieu.fr	LEWIN, Éric/F-1451-2017; GAILLARDET, Jerome/F-9096-2010	GAILLARDET, Jerome/0000-0001-7982-1159; Lemarchand, Damien/0000-0002-3610-0113				Berner RA, 1997, SCIENCE, V276, P544, DOI 10.1126/science.276.5312.544; BERNER RA, 1994, AM J SCI, V294, P56, DOI 10.2475/ajs.294.1.56; Gaillardet J, 1995, EARTH PLANET SC LETT, V136, P665, DOI 10.1016/0012-821X(95)00180-K; Gibbs MT, 1999, AM J SCI, V299, P611, DOI 10.2475/ajs.299.7-9.611; Godderis Y, 1996, GEOPHYS RES LETT, V23, P3743, DOI 10.1029/96GL03575; GODDERIS Y, 1997, THESIS U LIEGE; HARRISS RC, 1969, NATURE, V223, P290, DOI 10.1038/223290a0; HEMMING NG, 1992, GEOCHIM COSMOCHIM AC, V56, P537, DOI 10.1016/0016-7037(92)90151-8; LARSON RL, 1995, SCI AM, V272, P82, DOI 10.1038/scientificamerican0295-82; LEMARCHAND D, UNPUB CHEM GEOL; MCCAULEY SE, 1997, TECTONIC UPLIFT CLIM; MILLIMAN JD, 1992, J GEOL, V100, P525, DOI 10.1086/629606; Opdyke BN, 1988, PALEOCEANOGRAPHY, V3, P685, DOI 10.1029/PA003i006p00685; Palmer MR, 1998, SCIENCE, V282, P1468, DOI 10.1126/science.282.5393.1468; Pearson PN, 2000, NATURE, V406, P695, DOI 10.1038/35021000; Pearson PN, 1999, SCIENCE, V284, P1824, DOI 10.1126/science.284.5421.1824; Reimann C., 1998, CHEM ELEMENTS ENV; Rose EF, 2000, GEOCHIM COSMOCHIM AC, V64, P397, DOI 10.1016/S0016-7037(99)00117-9; SANYAL A, 1995, NATURE, V373, P234, DOI 10.1038/373234a0; SCHWARCZ HP, 1969, EARTH PLANET SC LETT, V6, P1, DOI 10.1016/0012-821X(69)90084-3; Smith HJ, 1995, CHEM GEOL, V126, P119, DOI 10.1016/0009-2541(95)00113-6; SPIVACK AJ, 1987, GEOCHIM COSMOCHIM AC, V51, P1939, DOI 10.1016/0016-7037(87)90183-9; SPIVACK AJ, 1993, NATURE, V363, P149, DOI 10.1038/363149a0; SPIVACK AJ, 1987, GEOCHIM COSMOCHIM AC, V51, P1033, DOI 10.1016/0016-7037(87)90198-0; SPIVACK AJ, 1986, THESIS MIT WOODS HOL; Vengosh A, 1999, WATER RESOUR RES, V35, P1877, DOI 10.1029/1999WR900024; VENGOSH A, 1991, GEOCHIM COSMOCHIM AC, V55, P2901, DOI 10.1016/0016-7037(91)90455-E; YOU CF, 1995, GEOCHIM COSMOCHIM AC, V59, P2435, DOI 10.1016/0016-7037(95)00137-9; YOU CF, 1993, GEOLOGY, V21, P207, DOI 10.1130/0091-7613(1993)021<0207:MOBICM>2.3.CO;2	29	155	171	2	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					951	954		10.1038/35050058	http://dx.doi.org/10.1038/35050058			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140677				2022-12-28	WOS:000165951100043
J	Hurwitz, B				Hurwitz, B			Narrative and the practice of medicine	LANCET			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, London W6 8RP, England	Imperial College London	Hurwitz, B (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, London W6 8RP, England.							CALVINO I, 1994, ROAD SAN GIOVANNI, P10; CARR EH, 1968, WHAT IS HIST; DAVIDOFF F, 1996, WHO SEEN BLOOD SUGAR, P91; FISH D, 1998, APPRECIATING PRACTIC, P157; Greenhalgh T, 1998, BRIT MED J, P3; HUNTER KM, 1991, NARRATIVE STRUCTURE; HURWITZ B, 1998, NARRATIVE BASED MED, P234; KERBY AP, 1991, NARRATIVE SELF, P63; Kleinman A., 1998, ILLNESS NARRATIVES S; Launer J., 1998, NARRATIVE BASED MED, P93; LERNER G, 1998, WHY HIST MATTERS; MacIntyre Alasdair, 1981, VIRTUE STUDY MORAL T, P201; Maoz B, 1992, DOCTORS THEIR FEELIN; Marinker M, 1978, J R Coll Gen Pract, V28, P199; Peschel R. E., 1986, DOCTOR HATES PATIENT; PLATT FW, 1995, CONVERSATION REPAIR, P30; REISSMAN CK, 1993, NARRATIVE ANAL, P2; Ricoeur Paul, 1983, TIME NARRATIVE; RIMMONKENAN S, 1983, NARRATIVE FICTION CO, P6; RUKEYSER M, 1991, STORIES SPIRIT STORI; SEARLE J, 1969, SPEECH ACTS, P3; SMITH RC, 1996, PATIENTS STORY; White Hayden, 1996, NARRATOLOGY, P273; [No title captured]	24	53	55	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2086	2089		10.1016/S0140-6736(00)03412-7	http://dx.doi.org/10.1016/S0140-6736(00)03412-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145506				2022-12-28	WOS:000165994300034
J	Cifu, B; Levinson, W				Cifu, B; Levinson, W			Influenza	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NEURAMINIDASE INHIBITOR OSELTAMIVIR; COST-EFFECTIVENESS; ELDERLY PERSONS; HEALTHY-ADULTS; WORKING ADULTS; VACCINATION; EFFICACY; VIRUS; LIVE; INTRANASAL		Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Levinson, W (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.	wendy@medicine.bsd.uchicago.edu						[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; *BLA SUBM, 1999, MOUNT VIEW; *BLA SUBM TIM, 2000, MOUNT VIEW; Boivin G, 2000, J INFECT DIS, V181, P1471, DOI 10.1086/315392; Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655; CHANCE JF, 1990, NEW ENGL J MED, V322, P1753; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; DOUGLAS RG, 1990, NEW ENGL J MED, V322, P443, DOI 10.1056/NEJM199002153220706; *FDA FLUM, 1998, MOUNT VIEW; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; GLEZEN WP, 1991, AM J EPIDEMIOL, V133, P296, DOI 10.1093/oxfordjournals.aje.a115874; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; LAFORCE FM, 1994, AM J PREV MED, V10, P31, DOI 10.1016/S0749-3797(18)30513-0; Longini IM, 2000, VACCINE, V18, P1902, DOI 10.1016/S0264-410X(99)00419-3; LUI KJ, 1987, AM J PUBLIC HEALTH, V77, P712, DOI 10.2105/AJPH.77.6.712; Marwick C, 2000, JAMA-J AM MED ASSOC, V283, P1814, DOI 10.1001/jama.283.14.1814; Monto AS, 2000, JAMA-J AM MED ASSOC, V284, P1699, DOI 10.1001/jama.284.13.1699; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; Muszkat M, 2000, J MED VIROL, V61, P100, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;100::AID-JMV16&gt;3.0.CO;2-5; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Nichol KL, 1999, JAMA-J AM MED ASSOC, V282, P137, DOI 10.1001/jama.282.2.137; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; Treanor JJ, 1998, VACCINE, V16, P1756, DOI 10.1016/S0264-410X(98)00136-4; VANVORIS LP, 1981, JAMA-J AM MED ASSOC, V245, P1128, DOI 10.1001/jama.245.11.1128; 1999, MED LETT, V41, P121	33	13	13	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2847	2849		10.1001/jama.284.22.2847	http://dx.doi.org/10.1001/jama.284.22.2847			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11147973				2022-12-28	WOS:000165717000002
J	Duchek, P; Rorth, P				Duchek, P; Rorth, P			Guidance of cell migration by EGF receptor signaling during Drosophila oogenesis	SCIENCE			English	Article							GROWTH; ACTIVATION; PATHWAY; KINASE; CHEMOTAXIS; COMPONENT; MEMBRANE; ENCODES; GURKEN; C/EBP	Directed cell migration is important for many aspects of normal animal development, but Little is known about how cell migrations are guided or the mechanisms by which guidance cues are translated into directed cell movement. Here we present evidence that signaling mediated by the epidermal growth factor receptor (EGFR) guides dorsal migration of border cells during Drosophila oogenesis. The transforming growth factor-alpha (TGF-alpha)-like ligand Gurken appears to serve as the guidance cue. To mediate this guidance function, EGFR signals via a pathway that is independent of Raf-MAP kinase and receptor-specific.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Rorth, P (corresponding author), European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany.		Rørth, Pernille/H-3020-2011					CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Han DD, 2000, DEVELOPMENT, V127, P573; King R. C., 1970, OVARIAN DEV DROSOPHI; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lee T, 1996, DEVELOPMENT, V122, P409; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Michelson AM, 1998, DEVELOPMENT, V125, P4379; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; MURPHY AM, 1995, DEVELOPMENT, V121, P2255; NeumanSilberberg FS, 1996, MECH DEVELOP, V59, P105, DOI 10.1016/0925-4773(96)00567-9; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Queenan AM, 1999, MECH DEVELOP, V89, P35, DOI 10.1016/S0925-4773(99)00196-3; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Rorth P, 2000, MOL CELL, V6, P23; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Thackeray JR, 1998, DEVELOPMENT, V125, P5033; Van Buskirk C, 1999, TRENDS CELL BIOL, V9, P1, DOI 10.1016/S0962-8924(98)01413-5; Vincent S, 1998, MOL CELL, V2, P515, DOI 10.1016/S1097-2765(00)80151-3; WENNSTROM S, 1994, ONCOGENE, V9, P651	26	197	202	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					131	133		10.1126/science.291.5501.131	http://dx.doi.org/10.1126/science.291.5501.131			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141565				2022-12-28	WOS:000166259100051
J	Mota, MM; Pradel, G; Vanderberg, JP; Hafalla, JCR; Frevert, U; Nussenzweig, RS; Nussenzweig, V; Rodriguez, A				Mota, MM; Pradel, G; Vanderberg, JP; Hafalla, JCR; Frevert, U; Nussenzweig, RS; Nussenzweig, V; Rodriguez, A			Migration of Plasmodium sporozoites through cells before infection	SCIENCE			English	Article							CIRCUMSPOROZOITE PROTEIN; EXOERYTHROCYTIC STAGE; MALARIA PARASITES; FINE-STRUCTURE; MIDGUT CELLS; IN-VITRO; INVASION; BERGHEI; ULTRASTRUCTURE; MICROSCOPY	Intracellular bacteria and parasites typically invade host cells through the formation of an internalization vacuole around the invading pathogen. Plasmodium sporozoites, the infective stage of the malaria parasite transmitted by mosquitoes, have an alternative mechanism to enter cells. We observed breaching of the plasma membrane of the host cell followed by rapid repair. This mode of entry did not result in the formation of a vacuole around the sporozoite, and was followed by exit of the parasite from the host cell. Sporozoites traversed the cytosol of several cells before invading a hepatocyte by formation of a parasitophorous vacuole, in which they developed into the next infective stage. Sporozoite migration through several cells in the mammalian host appears to be essential for the completion of the life cycle.	NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25 St, New York, NY 10010 USA; NYU, Sch Med, Dept Pathol, New York, NY 10010 USA	New York University; New York University	Rodriguez, A (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25 St, New York, NY 10010 USA.	rodria02@popmail.med.nyu.edu	Mota, Maria/AAF-2048-2019	Mota, Maria Manuel/0000-0002-2858-1041; Rodriguez, Ana/0000-0002-0060-3405				AIKAWA M, 1984, AM J TROP MED HYG, V33, P792, DOI 10.4269/ajtmh.1984.33.792; BOYD MARK F., 1939, AMER JOUR TROP MED, V19, P27; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHOBOTAR B, 1993, PARASITOL RES, V79, P15, DOI 10.1007/BF00931212; DANFORTH HD, 1992, PARASITOL RES, V78, P570, DOI 10.1007/BF00936454; Entzeroth R, 1998, INT J PARASITOL, V28, P1015, DOI 10.1016/S0020-7519(98)00079-4; GARNHAM PCC, 1969, T ROY SOC TROP MED H, V63, P328, DOI 10.1016/0035-9203(69)90005-4; GRIFFITHS RB, 1952, ANN TROP MED PARASIT, V46, P311, DOI 10.1080/00034983.1952.11685536; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Hugel FU, 1996, MOL BIOCHEM PARASIT, V81, P151, DOI 10.1016/0166-6851(96)02701-6; Jiang ST, 1999, KIDNEY INT, V56, P92, DOI 10.1046/j.1523-1755.1999.00520.x; MCNEIL PL, 1999, CURRENT PROTOCOLS CE; MEIS JFGM, 1983, NATURE, V302, P424, DOI 10.1038/302424a0; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; MOTA MM, IN PRESS EXP PARASIT; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; SHIN SCJ, 1982, J PROTOZOOL, V29, P448, DOI 10.1111/j.1550-7408.1982.tb05431.x; Sidjanski S, 1997, AM J TROP MED HYG, V57, P426, DOI 10.4269/ajtmh.1997.57.426; SODEMAN T, 1970, SCIENCE, V170, P340, DOI 10.1126/science.170.3955.340; Speer CA, 1997, J PARASITOL, V83, P565, DOI 10.2307/3284226; SPITALNY GL, 1972, P HELM SOC WASH, V39, P506; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; TSUJI M, 1994, PARASITOL RES, V80, P16, DOI 10.1007/BF00932618; VANDERBERG JP, 1990, J PROTOZOOL, V37, P528, DOI 10.1111/j.1550-7408.1990.tb01260.x; Zieler H, 2000, P NATL ACAD SCI USA, V97, P11516, DOI 10.1073/pnas.97.21.11516	28	371	385	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					141	144		10.1126/science.291.5501.141	http://dx.doi.org/10.1126/science.291.5501.141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141568				2022-12-28	WOS:000166259100054
J	Petersen, M; Brodersen, P; Naested, H; Andreasson, E; Lindhart, U; Johansen, B; Nielsen, HB; Lacy, M; Austin, MJ; Parker, JE; Sharma, SB; Klessig, DF; Martienssen, R; Mattsson, O; Jensen, AB; Mundy, J				Petersen, M; Brodersen, P; Naested, H; Andreasson, E; Lindhart, U; Johansen, B; Nielsen, HB; Lacy, M; Austin, MJ; Parker, JE; Sharma, SB; Klessig, DF; Martienssen, R; Mattsson, O; Jensen, AB; Mundy, J			Arabidopsis MAP kinase 4 negatively regulates systemic acquired resistance	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SALICYLIC-ACID INDUCTION; PROGRAMMED CELL-DEATH; DEFENSE RESPONSES; GENE-EXPRESSION; FUNCTIONAL-ANALYSIS; DISEASE-RESISTANCE; TOBACCO; SIGNAL; TRANSDUCTION	Transposon inactivation of Arabidopsis MAP kinase 4 produced the mpk4 mutant exhibiting constitutive systemic acquired resistance (SAR) including elevated salicylic acid (SA) revels, increased resistance to virulent pathogens, and constitutive pathogenesis-related gene expression shown by Northern and microarray hybridizations. MPK4 kinase activity is required to repress SAR, as an inactive MPK4 form failed to complement mpk4. Analysis of mpk4 expressing the SA hydroxylase NahG and of mpk4/npr1 double mutants indicated that SAR expression in mpk4 is dependent upon elevated SA levels but is independent of NPR1. PDF1.2 and THI2.1 gene induction by jasmonate was blocked in mpk4 expressing NahG, suggesting that MPK4 is required for jasmonic acid-responsive gene expression.	Univ Copenhagen, Inst Mol Biol, DK-1353 Copenhagen K, Denmark; Univ Copenhagen, Inst Bot, DK-1353 Copenhagen K, Denmark; Danish Tech Univ, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; Monsanto Co, St Louis, MO 63167 USA; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7U11, Norfolk, England; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of Copenhagen; University of Copenhagen; Technical University of Denmark; Monsanto; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Rutgers State University New Brunswick; Cold Spring Harbor Laboratory	Mundy, J (corresponding author), Univ Copenhagen, Inst Mol Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.	mundy@biobase.dk	Nielsen, Henrik/B-8961-2019; mundy, john/A-2361-2013; Petersen, Morten/J-5023-2014	Nielsen, Henrik/0000-0003-2281-5713; mundy, john/0000-0001-7490-4588; Petersen, Morten/0000-0002-3035-5991; Andreasson, Erik/0000-0003-0666-7204; Austin, Mark/0000-0003-4943-7265				Blatt MR, 1999, PLANT J, V19, P453, DOI 10.1046/j.1365-313x.1999.00534.x; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Clarke JD, 1998, PLANT CELL, V10, P557, DOI 10.1105/tpc.10.4.557; Clough SJ, 2000, P NATL ACAD SCI USA, V97, P9323, DOI 10.1073/pnas.150005697; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; Eulgem T, 1999, EMBO J, V18, P4689, DOI 10.1093/emboj/18.17.4689; Falk A, 1999, P NATL ACAD SCI USA, V96, P3292, DOI 10.1073/pnas.96.6.3292; Felton GW, 1999, CURR BIOL, V9, P317, DOI 10.1016/S0960-9822(99)80140-7; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Glazebrook J, 1997, ANNU REV GENET, V31, P547, DOI 10.1146/annurev.genet.31.1.547; Glazebrook J, 1999, CURR OPIN PLANT BIOL, V2, P280, DOI 10.1016/S1369-5266(99)80050-8; GRANTZ A, 1995, PLANT PHYSIOL, V108, P411, DOI 10.1104/pp.108.1.411; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Gupta V, 2000, MOL PLANT MICROBE IN, V13, P503, DOI 10.1094/MPMI.2000.13.5.503; HAMMONDKOSACK KE, 1994, P NATL ACAD SCI USA, V91, P10445, DOI 10.1073/pnas.91.22.10445; Hoyos ME, 2000, PLANT PHYSIOL, V122, P1355, DOI 10.1104/pp.122.4.1355; Ichimura K, 1998, BIOCHEM BIOPH RES CO, V253, P532, DOI 10.1006/bbrc.1998.9796; Jelitto-Van Dooren EPWM, 1999, PLANT CELL, V11, P1935, DOI 10.2307/3871088; Jirage D, 1999, P NATL ACAD SCI USA, V96, P13583, DOI 10.1073/pnas.96.23.13583; Johansen B, 1997, ANN BOT-LONDON, V80, P697, DOI 10.1006/anbo.1997.0502; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kumar D, 2000, MOL PLANT MICROBE IN, V13, P347, DOI 10.1094/MPMI.2000.13.3.347; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lebel E, 1998, PLANT J, V16, P223, DOI 10.1046/j.1365-313x.1998.00288.x; Li X, 1999, CELL, V98, P329, DOI 10.1016/S0092-8674(00)81962-5; Ligterink W, 1997, SCIENCE, V276, P2054, DOI 10.1126/science.276.5321.2054; Liu YH, 2000, MOL PLANT MICROBE IN, V13, P118, DOI 10.1094/MPMI.2000.13.1.118; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; Merkouropoulos G, 1999, PLANTA, V208, P212, DOI 10.1007/s004250050552; Mikolajczyk M, 2000, PLANT CELL, V12, P165, DOI 10.1105/tpc.12.1.165; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; Mizoguchi T, 1997, TRENDS BIOTECHNOL, V15, P15, DOI 10.1016/S0167-7799(96)10074-3; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; Molina A, 1999, PLANT J, V17, P667, DOI 10.1046/j.1365-313X.1999.00420.x; Molina A, 1997, PLANT J, V12, P669, DOI 10.1046/j.1365-313X.1997.00669.x; Morris PC, 1997, PLANT MOL BIOL, V35, P1057, DOI 10.1023/A:1005963222768; Nawrath C, 1999, PLANT CELL, V11, P1393, DOI 10.1105/tpc.11.8.1393; Parker JE, 1996, PLANT CELL, V8, P2033, DOI 10.1105/tpc.8.11.2033; Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; Pieterse CMJ, 1999, TRENDS PLANT SCI, V4, P52, DOI 10.1016/S1360-1385(98)01364-8; Rate DN, 1999, PLANT CELL, V11, P1695, DOI 10.1105/tpc.11.9.1695; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Ruan Y, 1998, PLANT J, V15, P821, DOI 10.1046/j.1365-313X.1998.00254.x; Seo S, 1999, PLANT CELL, V11, P289, DOI 10.1105/tpc.11.2.289; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; Shah J, 1999, PLANT CELL, V11, P191, DOI 10.1105/tpc.11.2.191; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Taipalensuu J, 1997, EUR J BIOCHEM, V247, P963, DOI 10.1111/j.1432-1033.1997.00963.x; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; Weymann K, 1995, PLANT CELL, V7, P2013, DOI 10.1105/tpc.7.12.2013; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523; ZHANG ZG, 1995, PLANT J, V8, P139, DOI 10.1046/j.1365-313X.1995.08010139.x; Zhou N, 1998, PLANT CELL, V10, P1021, DOI 10.1105/tpc.10.6.1021	65	710	784	5	102	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1111	1120		10.1016/S0092-8674(00)00213-0	http://dx.doi.org/10.1016/S0092-8674(00)00213-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163186	Bronze			2022-12-28	WOS:000166040600013
J	Kober, L; Thomsen, PEB; Moller, M; Torp-Pedersen, C; Carlsen, J; Sandoe, E; Egstrup, K; Agner, E; Videbaek, J; Marchant, B; Camm, AJ				Kober, L; Thomsen, PEB; Moller, M; Torp-Pedersen, C; Carlsen, J; Sandoe, E; Egstrup, K; Agner, E; Videbaek, J; Marchant, B; Camm, AJ		Danish Investigat Arrhythmia	Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial	LANCET			English	Article							HEART-FAILURE; MORTALITY; SURVIVAL; AMIODARONE; RISK; ARRHYTHMIAS; SUPPRESSION; MORBIDITY; UK-68,798	Background Arrhythmias cause much morbidity and mortality after myocardial infarction, but in previous trials, antiarrhythmic drug therapy has not been convincingly effective. Dofetilide, a new class III agent, was investigated for effects on all-cause mortality and morbidity in patients with left-ventricular dysfunction after myocardial infarction. Methods In 37 Danish coronary-care units, 1510 patients with severe left-ventricular dysfunction (wall motion index less than or equal to1.2, corresponding to ejection fraction less than or equal to0.35) were enrolled in a randomised, double-blind study comparing dofetilide (n=749) with placebo (n=761). The primary endpoint was all-cause mortality. Secondary endpoints included cardiac end arrhythmic mortality and total arrhythmic deaths. Analyses were by intention to treat. Findings No significant differences were found between the dofetilide and placebo groups in all-cause mortality (230 [31%] vs 243 [32%]), cardiac mortality (191 [26%] vs 212 [28%]), or total arrhythmic deaths (129 [17%] vs 140 [18%]). Atrial fibrillation or flutter was present in 8% of the patients at study entry. In these patients, dofetilide was significantly better than placebo at restoring sinus rhythm (25 of 59 vs seven of 56; p=0.002). There were seven cases of torsade de pointes ventricular tachycardia, all in the dofetilide group. Interpretation In patients with severe left-ventricular dysfunction and recent myocardial infarction, treatment with dofetilide did not affect ail-cause mortality, cardiac mortality, or total arrhythmic deaths. Dofetilide was effective in treating atrial fibrillation or flutter in this population.	Gentofte Univ Hosp, Dept Cardiol, DK-2900 Hellerup, Denmark; Odense Univ Hosp, DK-5000 Odense, Denmark; Medicon Contract Res Org, Birkerod, Denmark; Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark; Bispebjerg Hosp, Dept Cardiol, Copenhagen, Denmark; Haderslev Hosp, Dept Cardiol, Haderslev, Denmark; Elsinore Hosp, Dept Cardiol, Elsinore, Denmark; Pfizer Ltd, Sandwich CT13 9NJ, Kent, England; St George Hosp, Dept Cardiol, London, England	University of Copenhagen; Herlev & Gentofte Hospital; University of Southern Denmark; Odense University Hospital; Rigshospitalet; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; Pfizer; St Georges University London	Kober, L (corresponding author), Gentofte Univ Hosp, Dept Cardiol, DK-2900 Hellerup, Denmark.	lk@heart.dk	Torp-Pedersen, Christian/E-5931-2013	Kober, Lars/0000-0002-6635-1466				[Anonymous], 1984, J Am Coll Cardiol, V4, P1148; BERNING J, 1990, AM J CARDIOL, V65, P567, DOI 10.1016/0002-9149(90)91032-2; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Camm AJ, 1997, CLIN CARDIOL, V20, P704; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Connolly SJ, 1997, LANCET, V350, P1417; DALY PA, 1990, CIRCULATION, V82, P35; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Goldstein S, 1997, AM J CARDIOL, V80, pJ50, DOI 10.1016/S0002-9149(97)00840-0; Green MS, 1997, CIRCULATION, V96, P2536; Greenbaum R., 1998, European Heart Journal, V19, P661; GREENE HL, 1989, AM J CARDIOL, V63, P1, DOI 10.1016/0002-9149(89)91065-5; GWILT M, 1991, J PHARMACOL EXP THER, V256, P318; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; Hjalmarson A, 1997, AM J CARDIOL, V80, pJ35, DOI 10.1016/S0002-9149(97)00837-0; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KOBER L, 1994, EUR HEART J, V15, P1616; MARCUS FI, 1988, AM J CARDIOL, V61, P8, DOI 10.1016/0002-9149(88)91295-7; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOSTOW ND, 1986, CIRCULATION, V73, P1231, DOI 10.1161/01.CIR.73.6.1231; Nademanee K, 1998, PACE, V21, P1442, DOI 10.1111/j.1540-8159.1998.tb00216.x; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PODRID PJ, 1990, CIRCULATION, V82, P103; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SEDGWICK ML, 1992, AM J CARDIOL, V69, P513, DOI 10.1016/0002-9149(92)90996-C; SINGH BN, 1983, AM HEART J, V106, P788, DOI 10.1016/0002-8703(83)90002-9; Singh SN, 1998, J AM COLL CARDIOL, V31, p369A, DOI 10.1016/S0735-1097(97)85314-4; SINGH SN, 1997, CIRCULATION S1, V96, P383; STADIUS ML, 1986, CIRCULATION, V74, P703, DOI 10.1161/01.CIR.74.4.703; Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201; Vorperian VR, 1997, J AM COLL CARDIOL, V30, P791, DOI 10.1016/S0735-1097(97)00220-9; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44	37	218	221	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	2000	356	9247					2052	2058		10.1016/S0140-6736(00)03402-4	http://dx.doi.org/10.1016/S0140-6736(00)03402-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145491				2022-12-28	WOS:000165994300011
J	Jiang, P; Bertone, JF; Colvin, VL				Jiang, P; Bertone, JF; Colvin, VL			A lost-wax approach to monodisperse colloids and their crystals	SCIENCE			English	Article							ELLIPSOIDAL POLYSTYRENE PARTICLES; POLYMER; CRYSTALLIZATION; SILICA	We report a nanoscale "lost-wax" method for forming colloids with size distributions around 5% and their corresponding colloidal crystals. Macroporous polymer templates are first prepared from a silica colloidal crystal. We then use the uniform and interconnected voids of the porous polymer:to generate a wide variety of highly monodisperse inorganic, polymeric, and metallic solid and core-shell colloids, as well as hollow colloids with controllable shell thickness, as colloidal crystals. We can also uniformly deform the polymer template to alter colloidal shape and demonstrate the formation of elliptical particles with precisely controlled aspect ratios.	Rice Univ, Ctr Nanoscale Sci & Technol, Dept Chem, Houston, TX 77005 USA	Rice University	Colvin, VL (corresponding author), Rice Univ, Ctr Nanoscale Sci & Technol, Dept Chem, Houston, TX 77005 USA.							BRINKER CJ, 1990, SOL GEL SCI PHYSICS; BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801; Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111; COLVIN VL, 1994, NATURE, V370, P354, DOI 10.1038/370354a0; Ding JF, 1998, CHEM MATER, V10, P537, DOI 10.1021/cm970546t; GARBASSI F, 1998, POLYM SURFACES PHYSI; Ho CC, 1997, LANGMUIR, V13, P1925, DOI 10.1021/la960954w; HO CC, 1993, COLLOID POLYM SCI, V271, P469, DOI 10.1007/BF00657391; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; Hoyer P, 1996, J MATER SCI LETT, V15, P1228, DOI 10.1007/BF00274383; Imhof A, 1997, NATURE, V389, P948, DOI 10.1038/40105; Jiang P, 1999, CHEM MATER, V11, P2132, DOI 10.1021/cm990080+; Jiang P, 1999, J AM CHEM SOC, V121, P11630, DOI 10.1021/ja9903476; Johnson SA, 1999, SCIENCE, V283, P963, DOI 10.1126/science.283.5404.963; KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0; Kleiner FS, 2000, GARDNERS ART AGES; Li ZY, 2000, PHYSICA B, V279, P159, DOI 10.1016/S0921-4526(99)00708-5; MARK JE, 1996, PHYSICAL PROPERTIES; MATIJEVIC E, 1994, LANGMUIR, V10, P8, DOI 10.1021/la00013a003; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; NAGY M, 1989, POLYM COMMUN, V30, P130; Oldenburg SJ, 1999, J CHEM PHYS, V111, P4729, DOI 10.1063/1.479235; Pernaut JM, 2000, J PHYS CHEM B, V104, P4080, DOI 10.1021/jp994274o; PIERANSKI P, 1983, CONTEMP PHYS, V24, P25, DOI 10.1080/00107518308227471; Rengarajan R, 2000, APPL PHYS LETT, V77, P3517, DOI 10.1063/1.1320863; SUGIMOTO T, 1987, ADV COLLOID INTERFAC, V28, P65, DOI 10.1016/0001-8686(87)80009-X; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; Woodcock LV, 1997, NATURE, V385, P141, DOI 10.1038/385141a0; Xia YN, 2000, ADV MATER, V12, P693, DOI 10.1002/(SICI)1521-4095(200005)12:10<693::AID-ADMA693>3.0.CO;2-J; Yan HW, 1999, ADV MATER, V11, P1003, DOI 10.1002/(SICI)1521-4095(199908)11:12<1003::AID-ADMA1003>3.0.CO;2-K; Zhong ZY, 2000, ADV MATER, V12, P206, DOI 10.1002/(SICI)1521-4095(200002)12:3<206::AID-ADMA206>3.0.CO;2-5	33	807	844	9	283	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					453	457		10.1126/science.291.5503.453	http://dx.doi.org/10.1126/science.291.5503.453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161193				2022-12-28	WOS:000166487500032
J	Drew, S; Davies, E				Drew, S; Davies, E			Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine whether Ginkgo biloba is effective in treating tinnitus. Design Double blind, placebo controlled trial using postal questionnaires. Participants 1121 healthy people aged between 18 and 70 years with tinnitus that was comparatively stable; 978 participants were matched (489 pairs). Intervention 12 weeks' treatment with either 50 mg Ginkgo biloba extract LI 1370 three times daily or placebo. Main outcome measures Participants' assessment of tinnitus before, during, and after treatment Questionnaires included items assessing perception of how loud and how troublesome tinnitus was. Changes in loudness were rated on a six point scale. Changes in how troublesome were rated on a five point scale. Results There were no significant differences in primary or secondary outcome measures between the groups. 34 of 360 participants receiving active treatment reported that their tinnitus was less troublesome after 12 weeks of treatment compared with 35 of 360 participants who took placebo. Conclusions 50 mg Ginkgo biloba extract LI 1370 given 3 times daily for 12 weeks is no more effective than placebo in treating tinnitus.	Univ Birmingham, Dept Pharmacol, Div Neurosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Drew, S (corresponding author), Univ Birmingham, Dept Pharmacol, Div Neurosci, Birmingham B15 2TT, W Midlands, England.							AXELSSON A, 1993, J AUDIOLOGICAL MED, V2, P141; Blumenthal M., 1998, COMPLETE GERMAN COMM; Davis A., 2000, TINNITUS HDB; DUCKERT LG, 1984, OTOLARYNG HEAD NECK, V92, P697, DOI 10.1177/019459988409200618; Ernst E, 1999, CLIN OTOLARYNGOL, V24, P164, DOI 10.1046/j.1365-2273.1999.00243.x; GARDNER MJ, 1989, STAT CONFIDENCE CONF; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; Soholm B, 1998, ADV THER, V15, P54; Winslow LC, 1998, ARCH INTERN MED, V158, P2192, DOI 10.1001/archinte.158.20.2192	9	60	65	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					73	75		10.1136/bmj.322.7278.73	http://dx.doi.org/10.1136/bmj.322.7278.73			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154618	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000166496100022
J	Longhurst, HJ; Pinching, AJ				Longhurst, HJ; Pinching, AJ			Drug points - Pancreatitis associated with hydroxyurea in combination with didanosine	BRITISH MEDICAL JOURNAL			English	Letter									St Bartholomews Hosp, London EC1A 7BE, England	University of London; Queen Mary University London	Longhurst, HJ (corresponding author), St Bartholomews Hosp, London EC1A 7BE, England.							*BRIT MY SQUIBB, 1998, HLTH CAR PROV LETT; Carbon C, 1996, AIDS, V10, P867, DOI 10.1097/00002030-199607000-00010; Lori F, 1997, AIDS RES HUM RETROV, V13, P1403, DOI 10.1089/aid.1997.13.1403	3	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					81	81		10.1136/bmj.322.7278.81	http://dx.doi.org/10.1136/bmj.322.7278.81			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154621	Green Published			2022-12-28	WOS:000166496100026
J	Peyser, LA; Vinson, AE; Bartko, AP; Dickson, RM				Peyser, LA; Vinson, AE; Bartko, AP; Dickson, RM			Photoactivated fluorescence from individual silver nanoclusters	SCIENCE			English	Article							RARE-GAS MATRICES; SINGLE MOLECULES; RESONANCE-ABSORPTION; ROOM-TEMPERATURE; SPECTROSCOPY; CLUSTERS; FILMS; OXIDE; AGGLOMERATION; DEPOSITION	Fluorescence microscopy of nanoscale silver oxide (Ag2O) reveals strong photoactivated emission for excitation wavelengths shorter than 520 nanometers. Although blinking and characteristic emission patterns demonstrate single-nanoparticle observation, Large-scale dynamic color changes were also observed. even from the same nanoparticle. Identical behavior was observed in oxidized thin silver films that enable Ag2O particles to grow at high density from silver islands. Data were readily written to these films with blue excitation; stored data could be nondestructively read with the strong red fluorescence resulting from green (wavelengths longer than 520 nanometers) excitation. The individual Luminescent species are thought to be silver nanoclusters that are photochemically generated from the oxide.	Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Dickson, RM (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.							Bartko AP, 1999, J PHYS CHEM B, V103, P11237, DOI 10.1021/jp993364q; BECHTHOLD PS, 1986, Z PHYS D ATOM MOL CL, V3, P263, DOI 10.1007/BF01384815; BRANDT ES, 1993, APPL SPECTROSC, V47, P85, DOI 10.1366/0003702934048532; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Empedocles S, 1999, ACCOUNTS CHEM RES, V32, P389, DOI 10.1021/ar9501939; FEDRIGO S, 1993, J CHEM PHYS, V99, P5712, DOI 10.1063/1.465920; Felix C, 1999, CHEM PHYS LETT, V313, P105, DOI 10.1016/S0009-2614(99)01034-9; HARBICH W, 1990, J CHEM PHYS, V93, P8535, DOI 10.1063/1.459291; Konig L, 1996, SCIENCE, V274, P1353, DOI 10.1126/science.274.5291.1353; KOTZ R, 1980, J ELECTROANAL CHEM, V111, P105, DOI 10.1016/S0022-0728(80)80080-5; Libardi H, 1998, THIN SOLID FILMS, V333, P82, DOI 10.1016/S0040-6090(98)00820-7; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255; Marchetti AP, 1998, J PHYS CHEM B, V102, P5287, DOI 10.1021/jp980729i; Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670; Nirmal M, 1999, ACCOUNTS CHEM RES, V32, P407, DOI 10.1021/ar9700320; OHTANI B, 1993, J PHOTOCH PHOTOBIO A, V71, P195, DOI 10.1016/1010-6030(93)85073-H; Rabin I, 1998, J CHEM PHYS, V108, P5137, DOI 10.1063/1.475919; Rabin I, 2000, CHEM PHYS LETT, V320, P59, DOI 10.1016/S0009-2614(00)00211-6; TANI T, 1994, J IMAGING SCI TECHN, V98, P1; VandenBout DA, 1997, SCIENCE, V277, P1074, DOI 10.1126/science.277.5329.1074; VARKEY AJ, 1993, SOL ENERG MAT SOL C, V29, P253, DOI 10.1016/0927-0248(93)90040-A; Wang X, 1997, SPECTROCHIM ACTA A, V53, P2495, DOI 10.1016/S1386-1425(97)00191-1; WATANABE T, 1983, CHEM PHYS LETT, V102, P565, DOI 10.1016/0009-2614(83)87467-3; Xie XS, 1996, ACCOUNTS CHEM RES, V29, P598, DOI 10.1021/ar950246m; YAMAGUCHI T, 1974, J OPT SOC AM, V64, P1563, DOI 10.1364/JOSA.64.001563	26	655	671	6	360	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					103	106		10.1126/science.291.5501.103	http://dx.doi.org/10.1126/science.291.5501.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141556				2022-12-28	WOS:000166259100042
J	Goldberg, AB; Greenberg, MB; Darney, PD				Goldberg, AB; Greenberg, MB; Darney, PD			Drug therapy: Misoprostol and pregnancy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; PLACEBO-CONTROLLED TRIAL; PROSTAGLANDIN E(2) GEL; VAGINAL MISOPROSTOL; INTRAVAGINAL MISOPROSTOL; LABOR INDUCTION; ORAL MISOPROSTOL; EARLY ABORTION; 2ND-TRIMESTER ABORTION; MEDICAL ABORTION		Univ Calif San Francisco, San Francisco Gen Hosp, Dept Obstet Gynecol & Reprod Sci, Ctr Reprod Hlth Res & Policy, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Goldberg, AB (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Obstet Gynecol & Reprod Sci, Ctr Reprod Hlth Res & Policy, 1001 Potrero Ave,Ward 6D-11, San Francisco, CA 94110 USA.							Ashok PW, 1998, LANCET, V352, P542, DOI 10.1016/S0140-6736(05)79250-3; Ashok PW, 1998, HUM REPROD, V13, P2962, DOI 10.1093/humrep/13.10.2962; BAIRD DT, 1995, HUM REPROD, V10, P1521, DOI 10.1093/HUMREP/10.6.1521; Bamigboye AA, 1998, AM J OBSTET GYNECOL, V179, P1043, DOI 10.1016/S0002-9378(98)70212-1; Bawle EV, 1998, TERATOLOGY, V57, P51, DOI 10.1002/(SICI)1096-9926(199802)57:2<51::AID-TERA2>3.0.CO;2-9; Bennett BB, 1997, OBSTET GYNECOL, V89, P832, DOI 10.1016/S0029-7844(97)00036-7; BOND GR, 1994, AM J OBSTET GYNECOL, V171, P561, DOI 10.1016/0002-9378(94)90302-6; BUGALHO A, 1994, AM J OBSTET GYNECOL, V171, P538, DOI 10.1016/0002-9378(94)90295-X; BUGALHO A, 1994, OBSTET GYNECOL, V83, P729; BUGALHO A, 1993, STUD FAMILY PLANN, V24, P319, DOI 10.2307/2939225; BUGALHO A, 1995, ACTA OBSTET GYN SCAN, V74, P194, DOI 10.3109/00016349509008937; Buser D, 1997, OBSTET GYNECOL, V89, P581, DOI 10.1016/S0029-7844(97)00015-X; Carbonell JLL, 1998, CONTRACEPTION, V57, P83, DOI 10.1016/S0010-7824(98)00004-3; Carbonell JLL, 1997, CONTRACEPTION, V55, P165, DOI 10.1016/S0010-7824(97)00020-6; Chen M, 1999, OBSTET GYNECOL, V94, P840, DOI 10.1016/S0029-7844(99)00335-X; CREININ MD, 1993, CONTRACEPTION, V48, P339, DOI 10.1016/0010-7824(93)90079-M; Creinin MD, 1997, OBSTET GYNECOL, V89, P768, DOI 10.1016/S0029-7844(97)81438-X; CREININ MD, 1994, JAMA-J AM MED ASSOC, V272, P1190, DOI 10.1001/jama.272.15.1190; Creinin MD, 1997, OBSTET GYNECOL, V90, P611, DOI 10.1016/S0029-7844(97)00266-4; CREININ MD, 1995, AM J OBSTET GYNECOL, V173, P354, DOI 10.1016/0002-9378(95)90241-4; Creinin MD, 1999, CONTRACEPTION, V59, P11, DOI 10.1016/S0010-7824(98)00142-5; Creinin MD, 1996, CONTRACEPTION, V54, P15, DOI 10.1016/0010-7824(96)00113-8; Creinin MD, 1996, CONTRACEPTION, V53, P321, DOI 10.1016/0010-7824(96)00080-7; Danielsson KG, 1999, OBSTET GYNECOL, V93, P275, DOI 10.1016/S0029-7844(98)00436-0; DEJONGE ETM, 1995, BRIT MED J, V311, P662, DOI 10.1136/bmj.311.7006.662; ELREFAEY H, 1994, LANCET, V343, P1207, DOI 10.1016/S0140-6736(94)92406-6; ElRefaey H, 1997, BRIT J OBSTET GYNAEC, V104, P336, DOI 10.1111/j.1471-0528.1997.tb11464.x; ELREFAEY H, 1994, LANCET, V343, P1650; ELREFAEY H, 1995, NEW ENGL J MED, V332, P983, DOI 10.1056/NEJM199504133321502; ELREFAEY H, 1995, HUM REPROD, V10, P475, DOI 10.1093/oxfordjournals.humrep.a135965; Esteve JLC, 1999, GYNECOL OBSTET INVES, V47, P182, DOI 10.1159/000010090; FLETCHER HM, 1993, BRIT J OBSTET GYNAEC, V100, P641, DOI 10.1111/j.1471-0528.1993.tb14230.x; FOOTE EF, 1995, J CLIN PHARMACOL, V35, P384, DOI 10.1002/j.1552-4604.1995.tb04078.x; Gonzalez CH, 1998, LANCET, V351, P1624, DOI 10.1016/S0140-6736(97)12363-7; Gottschall DS, 1997, AM J OBSTET GYNECOL, V177, P1067, DOI 10.1016/S0002-9378(97)70016-4; Gouk EV, 1999, BRIT J OBSTET GYNAEC, V106, P535, DOI 10.1111/j.1471-0528.1999.tb08320.x; GRIMES DA, 1984, JAMA-J AM MED ASSOC, V251, P2108, DOI 10.1001/jama.251.16.2108; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; HENSHAW RC, 1993, BRIT MED J, V306, P1303; HENSHAW RC, 1993, BMJ-BRIT MED J, V306, P894, DOI 10.1136/bmj.306.6882.894; Herabutya Y, 1997, INT J GYNECOL OBSTET, V56, P263, DOI 10.1016/S0020-7292(96)02815-9; Herabutya Y, 1998, INT J GYNECOL OBSTET, V60, P161, DOI 10.1016/S0020-7292(97)00244-0; Ho PC, 1996, CONTRACEPTION, V53, P281; Hofmeyr GJ, 1999, BRIT J OBSTET GYNAEC, V106, P798, DOI 10.1111/j.1471-0528.1999.tb08400.x; Hofmeyr GJ, 1998, BRIT J OBSTET GYNAEC, V105, P971; HOFMEYR GJ, 2000, COCHRANE LIB DATABAS; *HOUS COMM GOV REF, 1996, OFF LAB DRUG US FDA, P53; Jain JA, 1999, AM J OBSTET GYNECOL, V181, P1386, DOI 10.1016/S0002-9378(99)70380-7; Jain JK, 1999, OBSTET GYNECOL, V93, P571, DOI 10.1016/S0029-7844(98)00485-2; JAIN JK, 1994, NEW ENGL J MED, V331, P290, DOI 10.1056/NEJM199408043310502; Jain JK, 1996, AM J OBSTET GYNECOL, V175, P173, DOI 10.1016/S0002-9378(96)70270-3; Kolderup L, 1999, AM J OBSTET GYNECOL, V180, P1543, DOI 10.1016/S0002-9378(99)70050-5; Kramer RL, 1997, OBSTET GYNECOL, V89, P387, DOI 10.1016/S0029-7844(97)00363-3; LEWIS JH, 1985, AM J GASTROENTEROL, V80, P743; MacIsaac L, 1999, OBSTET GYNECOL, V93, P766, DOI 10.1016/S0029-7844(98)00493-1; MCKINLEY C, 1993, HUM REPROD, V8, P1502, DOI 10.1093/oxfordjournals.humrep.a138287; Ngai SW, 1996, OBSTET GYNECOL, V87, P923; Ngai SW, 2000, HUM REPROD, V15, P1159, DOI 10.1093/humrep/15.5.1159; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; Nuutila M, 1997, OBSTET GYNECOL, V90, P896, DOI 10.1016/S0029-7844(97)00491-2; O'Brien P, 1998, OBSTET GYNECOL, V92, P212, DOI 10.1016/S0029-7844(98)00161-6; Orioli IM, 2000, BRIT J OBSTET GYNAEC, V107, P519, DOI 10.1111/j.1471-0528.2000.tb13272.x; Pastuszak AL, 1998, NEW ENGL J MED, V338, P1881, DOI 10.1056/NEJM199806253382604; PEYRON R, 1993, NEW ENGL J MED, V328, P1509, DOI 10.1056/NEJM199305273282101; Phillips K, 1996, EUR J OBSTET GYN R B, V65, P175, DOI 10.1016/0301-2115(95)02365-8; Plaut MM, 1999, AM J OBSTET GYNECOL, V180, P1535, DOI 10.1016/S0002-9378(99)70049-9; PONS JC, 1991, LANCET, V338, P763, DOI 10.1016/0140-6736(91)91490-L; RAYBURN WF, 1993, OBSTET GYNECOL, V81, P1052; Sanchez-Ramos L, 1998, OBSTET GYNECOL, V91, P401, DOI 10.1016/S0029-7844(97)00673-X; SanchezRamos L, 1997, OBSTET GYNECOL, V89, P909, DOI 10.1016/S0029-7844(97)00113-0; SanchezRamos L, 1997, OBSTET GYNECOL, V89, P633, DOI 10.1016/S0029-7844(96)00374-2; Schaff EA, 1999, CONTRACEPTION, V59, P1, DOI 10.1016/S0010-7824(98)00150-4; Schaff EA, 1997, J FAM PRACTICE, V44, P353; Schaff EA, 2000, JAMA-J AM MED ASSOC, V284, P1948, DOI 10.1001/jama.284.15.1948; SCHULZ KF, 1983, LANCET, V1, P1182; SCOTT JR, 1998, READING MED LIT APPL, P1; Singh K, 1999, OBSTET GYNECOL, V94, P431, DOI 10.1016/S0029-7844(99)00272-0; Singh K, 1998, OBSTET GYNECOL, V92, P795, DOI 10.1016/S0029-7844(98)00281-6; Spitz IM, 1998, NEW ENGL J MED, V338, P1241, DOI 10.1056/NEJM199804303381801; Surbek DV, 1997, AM J OBSTET GYNECOL, V177, P1018, DOI 10.1016/S0002-9378(97)70006-1; Surbek DV, 1999, OBSTET GYNECOL, V94, P255, DOI 10.1016/S0029-7844(99)00271-9; Toppozada MK, 1997, INT J GYNECOL OBSTET, V56, P135, DOI 10.1016/S0020-7292(96)02805-6; ULMANN A, 1994, HUM REPROD, V9, P126, DOI 10.1093/humrep/9.suppl_1.126; VARAKLIS K, 1995, OBSTET GYNECOL, V86, P541, DOI 10.1016/S0029-7844(95)80012-3; Webster D, 1996, BRIT J OBSTET GYNAEC, V103, P706, DOI 10.1111/j.1471-0528.1996.tb09842.x; Wiebe ER, 1997, CONTRACEPTION, V55, P159, DOI 10.1016/S0010-7824(97)00021-8; Wing, 1997, AM J OBSTET GYNECOL, V176, P1423; Wing DA, 1998, AM J OBSTET GYNECOL, V179, P94, DOI 10.1016/S0002-9378(98)70256-X; WING DA, 1995, AM J OBSTET GYNECOL, V172, P1811, DOI 10.1016/0002-9378(95)91416-1; Wing DA, 1997, AM J OBSTET GYNECOL, V177, P612, DOI 10.1016/S0002-9378(97)70154-6; Wing DA, 1996, AM J OBSTET GYNECOL, V175, P158, DOI 10.1016/S0002-9378(96)70267-3; WING DA, 1995, AM J OBSTET GYNECOL, V172, P1804, DOI 10.1016/0002-9378(95)91415-3; Wing DA, 1998, OBSTET GYNECOL, V91, P828, DOI 10.1016/S0029-7844(97)00553-X; Winikoff B, 1997, AM J OBSTET GYNECOL, V176, P431, DOI 10.1016/S0002-9378(97)70511-8; Wong KS, 1998, CONTRACEPTION, V58, P207, DOI 10.1016/S0010-7824(98)00099-7; Wu YM, 2000, BRIT J OBSTET GYNAEC, V107, P524; Zalanyi S, 1998, BRIT J OBSTET GYNAEC, V105, P1026, DOI 10.1111/j.1471-0528.1998.tb10269.x; Zieman M, 1997, OBSTET GYNECOL, V90, P88, DOI 10.1016/S0029-7844(97)00111-7	98	265	278	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2001	344	1					38	47		10.1056/NEJM200101043440107	http://dx.doi.org/10.1056/NEJM200101043440107			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388CT	11136959				2022-12-28	WOS:000166160400007
J	Welsh, J				Welsh, J			Children and torture	LANCET			English	Editorial Material									Amnesty Int, Program Med, London WC1X 0DW, England		Welsh, J (corresponding author), Amnesty Int, Program Med, London WC1X 0DW, England.							*AM INT, 2000, 344400 AMR; MAN N, 2000, CHILDREN TORTURE POW; Summerfield D, 1998, BRIT MED J, V317, P1249, DOI 10.1136/bmj.317.7167.1249	3	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2093	2093		10.1016/S0140-6736(00)03414-0	http://dx.doi.org/10.1016/S0140-6736(00)03414-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145508				2022-12-28	WOS:000165994300037
J	Hayden, MR; Ling, V				Hayden, MR; Ling, V			Michael Smith (1932-2000) - Obituary	NATURE			English	Biographical-Item									Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; British Columbia Cancer Agency; University of British Columbia	Hayden, MR (corresponding author), Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada.		Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419					0	2	2	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					786	786		10.1038/35048663	http://dx.doi.org/10.1038/35048663			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11147530	Bronze			2022-12-28	WOS:000165831300029
J	Hughes, SL; Weaver, FM; Giobbie-Hurder, A; Manheim, L; Henderson, W; Kubal, JD; Ulasevich, A; Cummings, J				Hughes, SL; Weaver, FM; Giobbie-Hurder, A; Manheim, L; Henderson, W; Kubal, JD; Ulasevich, A; Cummings, J			Effectiveness of team-managed home-based primary care - A randomized multicenter trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; CLINICAL-TRIAL; HEALTH; INTERVENTION; VETERANS; LESSONS	Context Although home-based health care has grown over the past decade, its effectiveness remains controversial. A prior trial of Veterans Affairs (VA) Team-Managed Home-Based Primary Care (TM/HBPC) found favorable outcomes, but the replicability of the model and generalizability of the findings are unknown. Objectives To assess the impact of TM/HBPC on functional status, health-related quality of life (HR-QoL), satisfaction with care, and cost of care. Design and Setting Multisite randomized controlled trial conducted from October 1994 to September 1998 in 16 VA medical centers with HBPC programs. Participants A total of 1966 patients with a mean age of 70 years who had 2 or more activities of daily living impairments or a terminal illness, congestive heart failure (CHF), or chronic obstructive pulmonary disease (COPD). Intervention Home-based primary care (n=981), including a primary care manager, 24-hour contact for patients, prior approval of hospital readmissions, and HBPC team participation in discharge planning, vs customary VA and private sector care (n=985). Main Outcome Measures Patient functional status, patient and caregiver HR-QoL and satisfaction, caregiver burden, hospital readmissions, and costs over 12 months. Results Functional status as assessed by the Barthel Index did not differ for terminal (P=.40) or nonterminal (those with severe disability or who had CHF or COPD) (P=.17) patients by treatment group. Significant improvements were seen in terminal TM/HBPC patients in HR-QoL scales of emotional role function, social function, bodily pain, mental health, vitality, and general health. Team-Managed HBPC nonterminal patients had significant increases of 5 to 10 points in 5 of 6 satisfaction with care scales. The caregivers of terminal patients in the TM/HBPC group improved significantly in HR-QoL measures except for vitality and general health. Caregivers of nonterminal patients improved significantly in QoL measures and reported reduced caregiver burden (P=.008). Team-Managed HBPC patients with severe disability experienced a 22% relative decrease (0.7 readmissions/patient for TM/HBPC group vs 0.9 readmissions/patient for control group) in hospital readmissions (P=.03) at 6 months that was not sustained at 12 months. Total mean per person costs were 6.8% higher in the TM/HBPC group at 6 months ($19 190 vs $17 971) and 12.1% higher at 12 months ($31 401 vs $28 008). Conclusions The TM/HBPC intervention improved most HR-QoL measures among terminally ill patients and satisfaction among non-terminally ill patients. It improved caregiver HR-QoL, satisfaction with care, and caregiver burden and reduced hospital readmissions at 6 months, but it did not substitute for other forms of care. The higher costs of TM/HBPC should be weighed against these benefits.	US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL 60141 USA; Univ Illinois, Sch Publ Hlth, Ctr Hlth & Aging, Chicago, IL 60607 USA; US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Midwest Ctr Hlth Serv & Policy Res, Hines, IL 60141 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL USA; Vet Integrated Serv Network 12, Hines, IL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Northwestern University	Hughes, SL (corresponding author), Univ Illinois, Sch Publ Hlth, Hlth Res Ctr, MC 275,850 W Jackson Blvd,Suite 400, Chicago, IL 60607 USA.		Weaver, Frances/S-1540-2019; Giobbie-Hurder, Anita/AAU-6193-2021					Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; BISHOP C, 1993, HEALTH AFFAIR, V12, P95, DOI 10.1377/hlthaff.12.3.95; Chapko MK, 1999, MED CARE, V37, pAS37, DOI 10.1097/00005650-199904002-00006; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; *DUK U CTR STUD AG, 1978, MULT FUNCT ASS; FORTINSKY RH, 1981, MED CARE, V19, P489, DOI 10.1097/00005650-198105000-00002; GAGE B, 1998, PUBLIC POLICY AGING, V9, P12; Hughes SL, 1999, GERONTOLOGIST, V39, P534, DOI 10.1093/geront/39.5.534; HUGHES SL, 1990, MED CARE, V28, P135, DOI 10.1097/00005650-199002000-00004; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; HUGHES SL, CONTINUUM LONG TERM; HUGHES SL, 2000, HOME CARE ADV ESSENT, P191; Hynes D, 1999, MED CARE, V37, pAS27, DOI 10.1097/00005650-199904002-00005; MONTGOMERY RJV, 1985, FAM RELAT, V34, P19, DOI 10.2307/583753; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; SHORTELL SM, 1993, HOSP HEALTH SERV ADM, V38, P447; Stewart S, 1998, J AM GERIATR SOC, V46, P174, DOI 10.1111/j.1532-5415.1998.tb02535.x; Swindle RW, 1996, MED CARE, V34, pMS83; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1994, SF36 PHYSICAL MENTAL; WEINBERGER M, 1988, MED CARE, V26, P1092, DOI 10.1097/00005650-198811000-00007; Weissert WG, 1997, MED CARE RES REV, V54, P439, DOI 10.1177/107755879705400403; WEISSERT WG, 1994, J AM GERIATR SOC, V42, P348, DOI 10.1111/j.1532-5415.1994.tb01763.x; WEISSERT WG, 1985, HEALTH SERV RES, V20, P461; Welch HG, 1996, NEW ENGL J MED, V335, P324, DOI 10.1056/NEJM199608013350506	28	225	225	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2877	2885		10.1001/jama.284.22.2877	http://dx.doi.org/10.1001/jama.284.22.2877			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	380RJ	11147984	Bronze			2022-12-28	WOS:000165717000027
J	Barolo, S; Walker, RG; Polyanovsky, AD; Freschi, G; Keil, T; Posakony, JW				Barolo, S; Walker, RG; Polyanovsky, AD; Freschi, G; Keil, T; Posakony, JW			A notch-independent activity of suppressor of hairless is required for normal mechanoreceptor physiology	CELL			English	Article							SENSORY ORGAN DEVELOPMENT; ALTERNATIVE CELL FATES; SPLIT COMPLEX GENES; DROSOPHILA-MELANOGASTER; BRISTLE DEVELOPMENT; PAX2 HOMOLOG; PROTEIN; PATHWAY; EXPRESSION; VIRUS	Suppressor of Hairless [Su(H)]/Lag-1/RBP-J kappa /CBF1 is the only known transducing transcription factor for Notch receptor signaling. Here, we show that Su(H) has three distinct functions in the development of external mechanosensory organs in Drosophila: Notch-dependent transcriptional activation and a novel autorepression function, both of which direct cell fate decisions, and a novel auto-activation function required for normal socket cell differentiation. This third phase of activity, the first known Notch-independent activation function for Su(H) in development, depends on a cell type-specific autoregulatory enhancer that is active throughout adult life and is required for proper mechanoreception. These results establish a direct link between a broadly deployed cell signaling pathway and an essential physiological function of the nervous system.	Univ Calif San Diego, CDB, Div Biol, La Jolla, CA 92093 USA; Russian Acad Sci, IM Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia; Max Planck Inst Verhaltensphysiol, D-82305 Seewiesen, Germany	University of California System; University of California San Diego; North-Western State Medical University named after I.I. Mechnikov; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry; Max Planck Society	Posakony, JW (corresponding author), Univ Calif San Diego, CDB, Div Biol, La Jolla, CA 92093 USA.	jposakony@ucsd.edu		Polyanovsky, Andrey/0000-0002-8116-022X	NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020123] Funding Source: NIH RePORTER; NCI NIH HHS [5POCA23100-16] Funding Source: Medline; NIGMS NIH HHS [GM20123, GM46993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BAILEY AM, 1996, THESIS U CALIFORNIA; BANG AG, 1991, DEVELOPMENT, V111, P89; BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BROU C, 1994, GENE DEV, V8, P2491, DOI 10.1101/gad.8.20.2491; Fu WM, 1997, GENE DEV, V11, P2066, DOI 10.1101/gad.11.16.2066; Gho M, 1996, DEVELOPMENT, V122, P1673; Gho M, 1999, DEVELOPMENT, V126, P3573; Go MJ, 1998, DEVELOPMENT, V125, P2031; GRIMWADE BG, 1985, DEV BIOL, V107, P503, DOI 10.1016/0012-1606(85)90331-8; Halder G, 1998, GENE DEV, V12, P3900, DOI 10.1101/gad.12.24.3900; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Jacobsen TL, 1998, DEVELOPMENT, V125, P4531; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kavaler J, 1999, DEVELOPMENT, V126, P2261; Keil TA, 1997, MICROSC RES TECHNIQ, V39, P506, DOI 10.1002/(SICI)1097-0029(19971215)39:6<506::AID-JEMT5>3.0.CO;2-B; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Lees AD, 1942, PROC R SOC SER B-BIO, V131, P87, DOI 10.1098/rspb.1942.0019; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Morel V, 2000, GENE DEV, V14, P377; Nellesen DT, 1999, DEV BIOL, V213, P33, DOI 10.1006/dbio.1999.9324; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; PARKS AL, 1993, DEV BIOL, V157, P484, DOI 10.1006/dbio.1993.1151; Parks AL, 1997, MECH DEVELOP, V63, P61, DOI 10.1016/S0925-4773(97)00675-8; PARODY TR, 1993, GENETICS, V135, P527; POSAKONY JW, 1994, CELL, V76, P415, DOI 10.1016/0092-8674(94)90105-8; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; SCHWEISGUTH F, 1994, DEVELOPMENT, V120, P1433; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Shawber C, 1996, DEVELOPMENT, V122, P3765; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; Thurm U., 1980, P735; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; Van De Bor V, 2000, DEVELOPMENT, V127, P3735; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Wang SW, 1997, DEVELOPMENT, V124, P4435	50	113	114	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 8	2000	103	6					957	969		10.1016/S0092-8674(00)00198-7	http://dx.doi.org/10.1016/S0092-8674(00)00198-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136980	Bronze			2022-12-28	WOS:000165801300014
J	Runnels, LW; Yue, LX; Capham, DE				Runnels, LW; Yue, LX; Capham, DE			TRP-PLIK, a bifunctional protein with kinase and ion channel activities	SCIENCE			English	Article							CATALYTIC DOMAIN; PHOTOTRANSDUCTION; DROSOPHILA	We cloned and characterized a protein kinase and ion channel, TRP-PLIK. As part of the Long transient receptor potential channel subfamily implicated in control of cell division, it is a protein that is both an ion channel and a protein kinase. TRP-PLIK phosphorylated itself, displayed a wide tissue distribution, and, when expressed in CHO-K1 cells, constituted a nonselective, calcium-permeant, 105-picosiemen, steeply outwardly rectifying conductance. The zinc finger containing alpha -kinase domain was functional, Inactivation of the kinase activity by site-directed mutagenesis and the channel's dependence on intracellular adenosine triphosphate (ATP) demonstrated that the channel's kinase activity is essential for channel function.	Harvard Univ, Childresn Hosp,Sch Med, Howard Hughes Med Inst, Dept Cardiol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp,Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Capham, DE (corresponding author), Harvard Univ, Childresn Hosp,Sch Med, Howard Hughes Med Inst, Dept Cardiol, 1309 Enders Bldg,320 Longwood Ave, Boston, MA 02115 USA.		Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428; Runnels, Loren/0000-0002-2537-7360				BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448	12	577	599	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	2001	291	5506					1043	1047		10.1126/science.1058519	http://dx.doi.org/10.1126/science.1058519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161216				2022-12-28	WOS:000166860100045
J	Radermacher, J; Chavan, A; Bleck, J; Vitzthum, A; Stoess, B; Gebel, MJ; Galanski, M; Koch, KM; Haller, H				Radermacher, J; Chavan, A; Bleck, J; Vitzthum, A; Stoess, B; Gebel, MJ; Galanski, M; Koch, KM; Haller, H			Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RENOVASCULAR HYPERTENSION; CAPTOPRIL RENOGRAPHY; BLOOD-PRESSURE; DIAGNOSIS; REVASCULARIZATION; SCINTIGRAPHY; DILATATION	Background: Prospectively identifying patients whose renal function or blood pressure will improve after the correction of renal-artery stenosis has not been possible. We evaluated whether a high level of resistance to flow in the segmental arteries of both kidneys (indicated by resistance-index values of at least 80) can be used prospectively to select appropriate patients for treatment. Methods: We evaluated 5950 patients with hypertension for renal-artery stenosis using color Doppler ultrasonography, and we measured the resistance index as follows: [1-(end-diastolic velocity (divided by) maximal systolic veocity)] x 100. Among 138 patients who had unilateral or bilateral renal-artery stenosis of more than 50 percent of the luminal diameter and who underwent renal angioplasty or surgery, the procedure was technically successful in 131 (95 percent). Creatinine clearance and 24-hour ambulatory blood pressure were measured before renal-artery stenosis was corrected; 3, 6, and 12 months after the procedure; and yearly thereafter. The mean (+/-SD) duration of follow-up was 32+/-21 months. Results: Among the 35 patients (27 percent) who had resistance-index values of at least 80 before revascularization, the mean arterial pressure did not decrease by 10 mm Hg or more after revascularization in 34 (97 percent). Renal function declined (defined by a decrease in the creatinine clearance of at least 10 percent) in 28 (80 percent); 16 (46 percent) became dependent on dialysis; and 10 (29 percent) died during follow-up. Among the 96 patients (73 percent) with a resistance-index value of less than 80, the mean arterial pressure decreased by at least 10 percent in all but 6 patients (6 percent) after revascularization; renal function worsened in only 3 (3 percent), all of whom became dependent on dialysis; and 3 (3 percent) died (P<0.001 for the comparison with patients with a resistance-index value of at least 80). Conclusions: A renal resistance-index value of at least 80 reliably identifies patients with renal-artery stenosis in whom angioplasty or surgery will not improve renal function, blood pressure, or kidney survival. (N Engl J Med 2001;344:410-7.) Copyright (C) 2001 Massachusetts Medical Society.	Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Gastroenterol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Radiol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Radermacher, J (corresponding author), Hannover Med Sch, Dept Nephrol, POB 61 01 80, D-30625 Hannover, Germany.	radermacher.joerg@mh-hannover.de						[Anonymous], 1987, ARCH INTERN MED, V147, P820; AZAR S, 1977, KIDNEY INT, V12, P28, DOI 10.1038/ki.1977.76; Bergman SM, 1996, SEMIN NEPHROL, V16, P134; BLACK H R, 1986, Journal of Clinical Hypertension, V2, P322; CHAVAN A, 1993, ACTA RADIOL, V34, P486; EIBENBERGER K, 1995, J ULTRAS MED, V14, P451; Erdoes LS, 1996, AM J KIDNEY DIS, V27, P496, DOI 10.1016/S0272-6386(96)90159-6; Fernandez P, 1999, J NUCL MED, V40, P412; FOMMEI E, 1993, EUR J NUCL MED, V20, P617; GEYSKES GG, 1991, AM J HYPERTENS, V4, pS685, DOI 10.1093/ajh/4.12.685S; GEYSKES GG, 1983, BRIT MED J, V287, P333, DOI 10.1136/bmj.287.6388.333; GRIM CE, 1981, ANN INTERN MED, V95, P439, DOI 10.7326/0003-4819-95-4-439; HARWARD TRS, 1995, AM J SURG, V170, P183, DOI 10.1016/S0002-9610(99)80282-7; Keller F, 1987, Nephrol Dial Transplant, V2, P382; LIBERTINO JA, 1992, J UROLOGY, V147, P1485, DOI 10.1016/S0022-5347(17)37603-6; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; MANN SJ, 1991, AM J MED, V90, P30, DOI 10.1016/0002-9343(91)90503-P; PATTISON JM, 1992, Q J MED, V85, P883; PRIGENT A, 1993, EUR J NUCL MED, V20, P625; Radermacher J, 2000, CLIN NEPHROL, V53, P333; Radermacher J., 1996, Journal of the American Society of Nephrology, V7, P1554; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; RUILOPE LM, 1994, HYPERTENSION, V23, P3, DOI 10.1161/01.HYP.23.1.3; SCHWARTZ GL, 1987, MED CLIN N AM, V71, P843, DOI 10.1016/S0025-7125(16)30812-4; SETARO JF, 1991, AM J HYPERTENS, V4, pS698, DOI 10.1093/ajh/4.12.698S; SOS TA, 1991, CIRCULATION, V83, P162; SVETKEY LP, 1991, HYPERTENSION, V17, P678, DOI 10.1161/01.HYP.17.5.678; Tullis MJ, 1998, ANN VASC SURG, V12, P122, DOI 10.1007/s100169900127; Ubara Y, 1997, CLIN NEPHROL, V48, P220; van Jaarsveld BC, 2000, NEW ENGL J MED, V342, P1007, DOI 10.1056/NEJM200004063421403; VANDAMME H, 1995, ACTA CHIR BELG, V95, P1; WORKMAN RJ, 1979, J LAB CLIN MED, V93, P847	32	484	501	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 8	2001	344	6					410	417		10.1056/NEJM200102083440603	http://dx.doi.org/10.1056/NEJM200102083440603			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399FH	11172177				2022-12-28	WOS:000166800600003
J	Kawaguchi, K; Ishiwata, S				Kawaguchi, K; Ishiwata, S			Nucleotide-dependent single- to double-headed binding of kinesin	SCIENCE			English	Article							DIMERIC KINESIN; OPTICAL TWEEZERS; ATP HYDROLYSIS; MICROTUBULES; MOLECULES; MECHANISM; MOVEMENT; MOTILITY; FORCE; SITE	The motility of kinesin motors is explained by a "hand-over-hand" model in which two heads of kinesin alternately repeat single-headed and double-headed binding with a microtubule. To investigate the binding mode of kinesin at the key nucleotide states during adenosine 5'-triphosphate (ATP) hydrolysis, we measured the mechanical properties of a single kinesin-microtubule complex by applying an external Load with optical tweezers. Both the unbinding force and the elastic modulus in solutions containing AMP-PNP tan ATP analog) were twice the value of those in nucleotide-free solution or in the presence of both AMP-PNP and adenosine 5'-diphosphate, Thus, kinesin binds through two heads in the former and one head in the latter two states, which supports a major prediction of the hand-over-hand model.	Waseda Univ, Sch Sci & Engn, Dept Phys, Shinjuku Ku, Tokyo 1698585, Japan; Waseda Univ, Adv Res Inst Sci & Engn, Shinjuku Ku, Tokyo 1698585, Japan; Waseda Univ, Mat Res Lab Biosci & Photon, Shinjuku Ku, Tokyo 1698585, Japan; CREST, Genet Programming Team 13, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan	Waseda University; Waseda University; Waseda University; Japan Science & Technology Agency (JST)	Ishiwata, S (corresponding author), Waseda Univ, Sch Sci & Engn, Dept Phys, Shinjuku Ku, 3-4-1 Okubo, Tokyo 1698585, Japan.	ishiwata@mn.waseda.ac.jp		Kawaguchi, Kenji/0000-0002-0791-0870				Arnal I, 1998, STRUCTURE, V6, P33, DOI 10.1016/S0969-2126(98)00005-7; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirose K, 1999, MOL BIOL CELL, V10, P2063, DOI 10.1091/mbc.10.6.2063; Hoenger A, 2000, J MOL BIOL, V297, P1087, DOI 10.1006/jmbi.2000.3627; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HYMAN AA, 1991, J CELL SCI, P125; Kawaguchi K, 2000, BIOCHEM BIOPH RES CO, V272, P895, DOI 10.1006/bbrc.2000.2856; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Mandelkow E, 1998, TRENDS BIOCHEM SCI, V23, P429, DOI 10.1016/S0968-0004(98)01278-X; NISHIZAKA T, 1995, NATURE, V377, P251, DOI 10.1038/377251a0; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Thormahlen' M, 1998, J MOL BIOL, V275, P795, DOI 10.1006/jmbi.1997.1503; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; VALE RD, 1999, GUIDEBOOK CYTOSKELET, P398; Vugmeyster Y, 1998, BIOCHEMISTRY-US, V37, P747, DOI 10.1021/bi971534o	26	106	109	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2001	291	5504					667	669		10.1126/science.291.5504.667	http://dx.doi.org/10.1126/science.291.5504.667			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158681				2022-12-28	WOS:000166616000048
J	Ullian, EM; Sapperstein, SK; Christopherson, KS; Barres, BA				Ullian, EM; Sapperstein, SK; Christopherson, KS; Barres, BA			Control of synapse number by glia	SCIENCE			English	Article							TRANSMITTER RELEASE; SUPERIOR COLLICULUS; RAT; SYNAPTOGENESIS; HIPPOCAMPUS; EXOCYTOSIS	Although astrocytes constitute nearly half of the cells in our brain, their function is a Long-standing neurobiological mystery. Here we show by quantal analyses, FM1-43 imaging, immunostaining, and electron microscopy that few synapses form in the absence of glial cells and that the few synapses that do form are functionally immature. Astrocytes increase the number of mature, functional synapses on central nervous system (CNS) neurons by sevenfold and are required for synaptic maintenance in vitro, We also show that most synapses are generated concurrently with the development of glia in vivo. These data demonstrate a previously unknown function for glia in inducing and stabilizing CNS synapses, show that CNS synapse number can be profoundly regulated by nonneuronal signals, and raise the possibility that glia may actively participate in synaptic plasticity.	Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA	Stanford University	Ullian, EM (corresponding author), Stanford Univ, Dept Neurobiol, Sch Med, Fairchild Sci Bldg, Stanford, CA 94305 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X	NINDS NIH HHS [NS10784] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Bergles DE, 1998, J NEUROSCI, V18, P7709; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; CHRISTOPHERSON K, UNPUB; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAYDON PG, 1995, TRENDS NEUROSCI, V18, P196, DOI 10.1016/0166-2236(95)93901-9; KATZ B, 1979, PROC R SOC SER B-BIO, V205, P369, DOI 10.1098/rspb.1979.0070; Lonart G, 1998, NEURON, V21, P1141, DOI 10.1016/S0896-6273(00)80631-5; LUND RD, 1972, BRAIN RES, V42, P1, DOI 10.1016/0006-8993(72)90038-8; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Schikorski T, 1997, J NEUROSCI, V17, P5858; Stevens CF, 1998, NEURON, V21, P415, DOI 10.1016/S0896-6273(00)80550-4; ULLIAN E, UNPUB; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; WARTON SS, 1989, SYNAPSE, V3, P136, DOI 10.1002/syn.890030205; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	24	973	1056	5	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					657	661		10.1126/science.291.5504.657	http://dx.doi.org/10.1126/science.291.5504.657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158678				2022-12-28	WOS:000166616000045
J	Khaw, KT; Wareham, N; Luben, R; Bingham, S; Oakes, S; Welch, A; Day, N				Khaw, KT; Wareham, N; Luben, R; Bingham, S; Oakes, S; Welch, A; Day, N			Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; RISK-FACTOR; CARDIOVASCULAR-DISEASE; GLYCOSYLATED HEMOGLOBIN; PLASMA-GLUCOSE; BLOOD-GLUCOSE; EPIC-NORFOLK; ALL-CAUSE; MELLITUS	Objective To examine the value of glycated haemoglobin (HbA(1c)) concentration, a marker of blood glucose concentration, as a predictor of death from cardiovascular and all causes in men. Design Prospective population study. Setting Norfolk cohort of European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk). Subjects 4662 men aged 45-79 years who had had glycated haemoglobin measured at the baseline survey in-1995-7 who were followed up to December 1999. Main outcome measures Mortality from all causes, cardiovascular disease, ischaemic heart disease, and other causes. Results Men with known diabetes had increased mortality: from all causes, cardiovascular disease, and ischaemic disease (relative risks 2.2, 3.3, and 4.2, respectively, P < 0.001 independent of age and other risk factors) compared with men without known diabetes. The increased risk of death among men with diabetes was largely explained by HbA(1c) concentration. HbA(1c) was continuously related to subsequent all cause, cardiovascular, and ischaemic heart disease mortality through the whole population distribution, with lowest rates in those with HbA(1c) concentrations below 5%. An increase of 1% in HbA(1c) was associated with a 28% (P < 0.002) increase in risk of death independent of age, blood pressure, serum cholesterol, body mass index, and cigarette smoking habit; this effect remained (relative risk 1.46, P = 0.05 adjusted for age and risk factors) after men with known diabetes, a HbA(1c) concentration greater than or equal to 7%, or history of myocardial infarction or stroke were excluded. 18% of the population excess mortality risk associated with a HbA(1c) concentration greater than or equal to5% occurred in men with diabetes, but 82% occurred in men with concentrations of 5%-6.9% (the majority of the population). Conclusions Glycated haemoglobin concentration seems to explain most of the excess mortality risk of diabetes in men and to be a continuous risk factor through the whole population distribution. Preventive efforts need to consider not just chose with established diabetes but whether it is possible to reduce the population distribution of HbA(1c) through behavioural means.	Univ Cambridge, Sch Clin Med, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Khaw, KT (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Clin Gerontol Unit, Box 251, Cambridge CB2 2QQ, England.	kk101@medschl.cam.ac.uk	Welch, Ailsa Ann/A-4850-2008; Luben, Robert N/H-5519-2015; Khaw, Kay-Tee/AAZ-3209-2021	Welch, Ailsa Ann/0000-0002-6702-3704; Luben, Robert N/0000-0002-5088-6343; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I; [Anonymous], 1996, DIABETES, V45, P1289; [Anonymous], 1995, DIABETES, V44, P968; [Anonymous], 2000, DIABETES CARE S1, V23, pS20; Barzilay JI, 1999, LANCET, V354, P622, DOI 10.1016/S0140-6736(98)12030-5; Borch-Johnsen K, 1999, LANCET, V354, P617; *BRIT CARD SOC, 1998, HEART, V2, pS1; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; BUTLER WJ, 1985, AM J EPIDEMIOL, V121, P541; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; COX DR, 1972, J R STAT SOC B, V34, P187; Day N, 1999, BRIT J CANCER, V80, P95; de Vegt F, 1999, DIABETOLOGIA, V42, P926, DOI 10.1007/s001250051249; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gerstein HC, 1997, DIABETIC MED, V14, pS25, DOI 10.1002/(SICI)1096-9136(199708)14:3+<S25::AID-DIA441>3.3.CO;2-T; Gregory J., 1990, DIETARY NUTR SURVEY; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; HAMMAN RF, 1992, DIABETES METAB REV, V8, P287, DOI 10.1002/dmr.5610080402; HARRIS M, 1979, DIABETES, V28, P1039; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marshall SM, 2000, DIABETIC MED, V17, P5, DOI 10.1046/j.1464-5491.2000.00228.x; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; OHLSON LO, 1986, DIABETIC MED, V3, P33, DOI 10.1111/j.1464-5491.1986.tb00702.x; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Park S, 1996, DIABETES CARE, V19, P450, DOI 10.2337/diacare.19.5.450; PYORALA K, 1985, ACTA MED SCAND, P38; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; Sargeant LA, 2000, DIABETES CARE, V23, P726, DOI 10.2337/diacare.23.6.726; SCHEIDTNAVE C, 1991, AM J EPIDEMIOL, V133, P565, DOI 10.1093/oxfordjournals.aje.a115928; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shaw JE, 1999, DIABETOLOGIA, V42, P1050, DOI 10.1007/s001250051269; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vitelli LL, 1997, DIABETES CARE, V20, P1454, DOI 10.2337/diacare.20.9.1454; Wareham NJ, 2000, AM J EPIDEMIOL, V152, P132, DOI 10.1093/aje/152.2.132; *WHO STUD GROUP, 1985, WHO TECH REP SER, V727, P9; Williams DEM, 1999, J CLIN EPIDEMIOL, V52, P329, DOI 10.1016/S0895-4356(99)00006-2; Wingard DL., 1995, DIABETES AM, P429; Wood D, 1998, EUR HEART J, V19, P1434	51	671	705	0	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 6	2001	322	7277					15	18B		10.1136/bmj.322.7277.15	http://dx.doi.org/10.1136/bmj.322.7277.15			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141143	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000166341400016
J	Horsewill, AJ; Jones, NH; Caciuffo, R				Horsewill, AJ; Jones, NH; Caciuffo, R			RETRACTED: Evidence for coherent proton tunneling in a hydrogen bond network (Retracted article. See vol 298, pg 1171, 2002)	SCIENCE			English	Article; Retracted Publication							SOLID-STATE; DYNAMICS; PYRAZOLES; RESONANCE; NMR	We observed coherent proton tunneling in the cyclic network of four hydrogen bonds in calix[4]arene. The tunneling frequency of 35 megahertz was revealed by a peak in the magnetic field dependence of the proton spin-lattice relaxation rate measured with field-cycling nuclear magnetic resonance in the solid state at temperatures below 80 kelvin. The amplitude of the coherent tunneling peak grows with temperature according to a Boltzmann law with energy D/k(B) = (125 +/- 10) kelvin (where k(B) is Boltzmann's constant). The tunneling peak can be interpreted in the context of Level crossings in the region where the tunneling frequency matches the proton Larmor frequency. The tunneling spectrum reveals fine structure that we attribute to coupling between the hydrogen bonds in the network The characteristics of the tunneling peak are interpreted in the context of the potential energy surface experienced by the hydrogen atoms in the network.	Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England; Univ Ancona, Dipartimento Sci Mat & Terra, Ist Nazl Fis Mat, I-60131 Ancona, Italy	University of Nottingham; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Marche Polytechnic University	Horsewill, AJ (corresponding author), Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England.		Caciuffo, Roberto G. M./B-9677-2019; Horsewill, Anthony/B-6933-2016	Caciuffo, Roberto G. M./0000-0002-8708-6219; Horsewill, Anthony/0000-0002-8086-1374				AGUILARPARRILLA F, 1992, J AM CHEM SOC, V114, P9657, DOI 10.1021/ja00050a055; BAUGHCUM SL, 1981, J AM CHEM SOC, V103, P6296, DOI 10.1021/ja00411a005; BERNHARD T, 1990, J CHEM PHYS, V92, P2178, DOI 10.1063/1.458009; BLOEMBERGEN N, 1948, PHYS REV, V73, P679, DOI 10.1103/PhysRev.73.679; Brougham DF, 1997, CHEM PHYS LETT, V272, P69, DOI 10.1016/S0009-2614(97)00493-4; Brougham DF, 1999, NATURE, V397, P241, DOI 10.1038/16672; CHENG CP, 1979, J AM CHEM SOC, V101, P2327, DOI 10.1021/ja00503a015; dePaz JLG, 1997, J CHEM SOC PERK T 2, P101, DOI 10.1039/a603035a; Diamond D, 1996, CHEM SOC REV, V25, P15, DOI 10.1039/cs9962500015; HAUPT J, 1971, Z NATURFORSCH PT A, VA 26, P1578; Horsewill AJ, 1999, PROG NUCL MAG RES SP, V35, P359, DOI 10.1016/S0079-6565(99)00016-3; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; KUBO R, 1954, J PHYS SOC JPN, V9, P888, DOI 10.1143/JPSJ.9.888; OPPENLANDER A, 1989, PHYS REV LETT, V63, P1432, DOI 10.1103/PhysRevLett.63.1432; SAENGER W, 1982, NATURE, V296, P581, DOI 10.1038/296581a0; Scrutton NS, 1999, EUR J BIOCHEM, V264, P666, DOI 10.1046/j.1432-1327.1999.00645.x; Torkar M, 2000, J MAGN RESON, V144, P13, DOI 10.1006/jmre.2000.2051	17	37	38	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					100	103		10.1126/science.291.5501.100	http://dx.doi.org/10.1126/science.291.5501.100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141555				2022-12-28	WOS:000166259100041
J	Gaine, S				Gaine, S			Pulmonary hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTINUOUS INTRAVENOUS EPOPROSTENOL; ORAL-CONTRACEPTIVES; NITRIC-OXIDE; PROSTACYCLIN; RECEPTOR; EXPRESSION; MUTATIONS; AMINOREX; THERAPY; LUNGS	A clinically useful, treatment-based classification of pulmonary hypertension divides the disease into 5 distinct categories: (1) pulmonary hypertension associated with disorders of the respiratory system and/or hypoxemia; (2) pulmonary venous hypertension; (3) chronic thromboembolic disease; (4) pulmonary arterial hypertension; and (5) pulmonary hypertension due to disorders directly affecting the pulmonary vasculature, Pulmonary arterial hypertension includes individuals with primary pulmonary hypertension, congenital heart disease, connective tissue disease, and liver disease. These heterogeneous diseases have similar characteristic pathological changes, including in situ thrombosis, smooth muscle hypertrophy, and intimal proliferation. Right heart catheterization is essential to confirm diagnosis, determine prognosis, and assign therapy. A minority of patients have a favorable response to an acute vasodilator trial and long-term benefit with calcium channel blocker therapy. Continuous intravenous epoprostenol improves symptoms and survival in patients with advanced primary pulmonary hypertension and has potential benefit in other forms of pulmonary arterial hypertension. Lung transplantation remains an important option for individuals in whom maximal medical therapy fails. The recent discovery of the gene for familial primary pulmonary hypertension and the increase in new drugs undergoing clinical trials are encouraging developments.	Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA	Johns Hopkins University	Gaine, S (corresponding author), Mater Misericordiae Univ Hosp, Dept Resp Med, Pulm Hypertens Unit, Eccles St, Dublin 7, Ireland.	Spgaine@jhmi.edu		Gaine, Sean/0000-0002-5941-684X				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Badesch DB, 2000, ANN INTERN MED, V132, P425, DOI 10.7326/0003-4819-132-6-200003210-00002; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Conte JV, 1998, J HEART LUNG TRANSPL, V17, P679; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Fishman AP, 1998, NEW ENGL J MED, V338, P321, DOI 10.1056/NEJM199801293380609; FOLLATH F, 1971, BMJ-BRIT MED J, V1, P265, DOI 10.1136/bmj.1.5743.265; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GAHL K, 1970, Z KREISLAUFFORSCH, V59, P868; GAINE S, 1998, LANCET, V352, P9124; Gaine SP, 1999, AM J RESP CRIT CARE, V159, pA161; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; GURTNER HP, 1985, COR VASA, V27, P160; Hatano S., 1975, WHO TECH REPORT SER, V1973, P1; Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; Hosenpud JD, 1997, J HEART LUNG TRANSPL, V16, P691; Kaneko T, 1998, LANCET, V352, P1224, DOI 10.1016/S0140-6736(05)60565-X; KAY JM, 1971, THORAX, V26, P262, DOI 10.1136/thx.26.3.262; KERSTEIN D, 1995, CIRCULATION, V91, P2028, DOI 10.1161/01.CIR.91.7.2028; KLEIGER RE, 1976, CHEST, V69, P143, DOI 10.1378/chest.69.2.143; Kuo PC, 1997, CHEST, V112, P980, DOI 10.1378/chest.112.4.980; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; LOOGEN F, 1985, COR VASA, V27, P111; Loyd JE, 1997, CHEST, V111, pS82, DOI 10.1378/chest.111.6_Supplement.82S; MARTOS A, 1993, AM HEART J, V125, P1819, DOI 10.1016/0002-8703(93)90811-M; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; MOSER KM, 1987, ANN INTERN MED, V107, P560, DOI 10.7326/0003-4819-107-4-560; OAKLEY C, 1968, LANCET, V1, P890; REEVES JT, 1984, PULMONARY HYPERTENSI; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1984, AM J MED, V76, P573, DOI 10.1016/0002-9343(84)90279-1; Rich S, 1998, CHEST, V114, P787, DOI 10.1378/chest.114.3.787; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 2000, EX SUMM WORLD S PPH; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; Saji T, 1996, AM J CARDIOL, V78, P244, DOI 10.1016/S0002-9149(96)90408-7; Sapira JD, 1990, ART SCI BEDSIDE DIAG; Sharma S, 1990, Indian Heart J, V42, P375; SITBON O, 1995, AM J RESP CRIT CARE, V151, P384, DOI 10.1164/ajrccm.151.2.7842196; SPEICH R, 1991, CHEST, V100, P1268, DOI 10.1378/chest.100.5.1268; Voelkel NF, 1997, AM J RESP CRIT CARE, V155, P786, DOI 10.1164/ajrccm.155.3.9117009; Wagenvoort CA, 1977, PATHOLOGY PULMONARY; WEED HG, 1991, CHEST, V100, P1138, DOI 10.1378/chest.100.4.1138; WEITZENBLUM E, 1988, AM REV RESPIR DIS, V138, P345, DOI 10.1164/ajrccm/138.2.345; Williamson DJ, 2000, CIRCULATION, V102, P411; Yuan XJ, 1998, LANCET, V351, P726, DOI 10.1016/S0140-6736(05)78495-6	49	107	112	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3160	3168		10.1001/jama.284.24.3160	http://dx.doi.org/10.1001/jama.284.24.3160			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135781				2022-12-28	WOS:000165994100035
J	Aderem, A; Hume, DA				Aderem, A; Hume, DA			How do you see CG?	CELL			English	Review							BACTERIAL CPG-DNA; INNATE IMMUNITY; ACTIVATION; KINASE; PKCS		Inst Syst Biol, Seattle, WA USA; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia	Institute for Systems Biology (ISB); University of Queensland	Aderem, A (corresponding author), Inst Syst Biol, Seattle, WA USA.	aderem@systemsbiology.org	Hume, David A/C-7695-2013	Hume, David/0000-0002-2615-1478				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Beamish HJ, 2000, NUCLEIC ACIDS RES, V28, P1506, DOI 10.1093/nar/28.7.1506; Chace JH, 1997, CLIN IMMUNOL IMMUNOP, V84, P185, DOI 10.1006/clin.1997.4380; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Janeway CA, 1998, SEMIN IMMUNOL, V10, P349, DOI 10.1006/smim.1998.0142; Krieg AM, 2000, IMMUNOL TODAY, V21, P521, DOI 10.1016/S0167-5699(00)01719-9; Murray NE, 2000, MICROBIOL MOL BIOL R, V64, P412, DOI 10.1128/MMBR.64.2.412-434.2000; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Schnare M, 2000, CURR BIOL, V10, P1139, DOI 10.1016/S0960-9822(00)00700-4; Sester DP, 1999, J LEUKOCYTE BIOL, V66, P542, DOI 10.1002/jlb.66.4.542; Sester DP, 2000, J IMMUNOL, V165, P4165, DOI 10.4049/jimmunol.165.8.4165; Sun SQ, 1997, J IMMUNOL, V159, P3119; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Yi AK, 1998, J IMMUNOL, V160, P1240	20	33	34	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					993	996		10.1016/S0092-8674(00)00201-4	http://dx.doi.org/10.1016/S0092-8674(00)00201-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163174	Bronze			2022-12-28	WOS:000166040600001
J	Majeti, R; Xu, Z; Parslow, TG; Olson, JL; Daikh, DI; Killeen, N; Weiss, A				Majeti, R; Xu, Z; Parslow, TG; Olson, JL; Daikh, DI; Killeen, N; Weiss, A			An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; LYMPHOCYTE-ACTIVATION; THYMOCYTE DEVELOPMENT; CRYSTAL-STRUCTURE; STEM-CELLS; EXPRESSION; DIMERIZATION	A model has been proposed for the regulation of CD45, and by homology other RPTPs, in which dimerization inhibits phosphatase activity through symmetrical interactions between an inhibitory structural wedge and the catalytic site. Here, we report the phenotype of mice with a single point mutation, glutamate 613 to arginine, that inactivates the inhibitory wedge of CD45. The CD45 E613R mutation causes polyclonal lymphocyte activation leading to lymphoproliferation and severe autoimmune nephritis with autoantibody production, resulting in death. Both homozygotes and heterozygotes develop pathology, indicating genetic dominance of CD45 E613R. The dramatic phenotype of CD45 E613R mice demonstrates the in vivo importance of negative regulation of CD45 by dimerization, supporting the model for regulation of CD45, and RPTPs in general.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	aweiss@medicine.ucsf.edu			NIGMS NIH HHS [R01-GM39553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Cale CM, 1997, ARCH DIS CHILD, V76, P163, DOI 10.1136/adc.76.2.163; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Gaffney PM, 1998, P NATL ACAD SCI USA, V95, P14875, DOI 10.1073/pnas.95.25.14875; Garrity PA, 1999, NEURON, V22, P707, DOI 10.1016/S0896-6273(00)80730-8; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Harley JB, 1998, CURR OPIN IMMUNOL, V10, P690, DOI 10.1016/S0952-7915(98)80090-3; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Hogan B, 1994, MANIPULATING MOUSE E; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Kung C, 2000, NAT MED, V6, P343; Lewandoski M, 1997, NAT GENET, V17, P223, DOI 10.1038/ng1097-223; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCALL MN, 1992, IMMUNOLOGY, V76, P310; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Moser KL, 1998, P NATL ACAD SCI USA, V95, P14869, DOI 10.1073/pnas.95.25.14869; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROTHGEB CL, 1984, BEHAV SOC SCI LIBR, V3, P1, DOI 10.1300/J103v03n04_01; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; Seavitt JR, 1999, MOL CELL BIOL, V19, P4200; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; STEINBERG AD, 1984, ANN INTERN MED, V100, P714, DOI 10.7326/0003-4819-100-5-714; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Tsao BP, 1997, J CLIN INVEST, V99, P725, DOI 10.1172/JCI119217; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WOFSY D, 1985, J EXP MED, V161, P378, DOI 10.1084/jem.161.2.378	49	202	208	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1059	1070		10.1016/S0092-8674(00)00209-9	http://dx.doi.org/10.1016/S0092-8674(00)00209-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163182	Bronze			2022-12-28	WOS:000166040600009
J	Bina, CR; Navrotsky, A				Bina, CR; Navrotsky, A			Possible presence of high-pressure ice in cold subducting slabs	NATURE			English	Article							DEEP EARTHQUAKES; DENSE H2O; VII; MANTLE; PHASE; WATER; ZONES; ARC; TRANSPORT; MINERALS	During the subduction of oceanic lithosphere, water is liberated from minerals by progressive dehydration reactions(1,2) and is thought to be critical to several geologically important processes such as island-arc volcanism(3), intermediate-depth seismicity(4) and chemical exchange between the subducting lithosphere and mantle(5). Although dehydration reactions would yield supercritical fluid water in most slabs, we report here that the stable phase of H2O should be solid ice VII in portions of the coldest slabs. The formation of ice VII as a dehydration product would affect the generation, storage, transport and release of water in cold subduction zones and equilibrium conditions of dehydration would shift, potentially affecting the depths of seismogenesis and magmagenesis. Large amounts of pure ice VII might accumulate during subduction and, as a sinking slab warms, eventual melting of the ice would release large amounts of water in a small region over a short period of time, with a significant positive volume change. Moreover, the decreasing availability of fluid water, owing to the accumulation of ice VII and its subsequent reaction products in a cooling planetary interior (for example, in Mars or the future Earth), might eventually lead to a decline in tectonic activity or its complete cessation.	Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; Univ Calif Davis, Dept Chem Engn & Mat Sci, Thermochem Facil, Davis, CA 95616 USA	Northwestern University; University of California System; University of California Davis	Bina, CR (corresponding author), Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA.			Bina, Craig/0000-0001-5946-3737				Baer BJ, 1998, J CHEM PHYS, V108, P4540, DOI 10.1063/1.475882; BELONOSHKO A, 1991, GEOCHIM COSMOCHIM AC, V55, P381, DOI 10.1016/0016-7037(91)90425-5; BEVIS M, 1995, NATURE, V374, P249, DOI 10.1038/374249a0; Bose K, 1998, J GEOPHYS RES-SOL EA, V103, P9713, DOI 10.1029/98JB00506; Datchi F, 2000, PHYS REV B, V61, P6535, DOI 10.1103/PhysRevB.61.6535; DAVIES JH, 1992, J GEOPHYS RES-SOL EA, V97, P2037, DOI 10.1029/91JB02571; FEI YW, 1993, J CHEM PHYS, V99, P5369, DOI 10.1063/1.465980; Goncharov AF, 1999, PHYS REV LETT, V83, P1998, DOI 10.1103/PhysRevLett.83.1998; Gottschalk M, 1997, EUR J MINERAL, V9, P175; GREEN HW, 1995, ANNU REV EARTH PL SC, V23, P169, DOI 10.1146/annurev.ea.23.050195.001125; HELFFRICH G, 1996, GEOPHYS MONOGR SER, V96, P215; Hirschmann MM, 1999, J PETROL, V40, P831, DOI 10.1093/petrology/40.5.831; Iwamori H, 1998, EARTH PLANET SC LETT, V160, P65, DOI 10.1016/S0012-821X(98)00080-6; Kincaid C, 1997, J GEOPHYS RES-SOL EA, V102, P12295, DOI 10.1029/96JB03553; Kirby SH, 1996, REV GEOPHYS, V34, P261, DOI 10.1029/96RG01050; Klotz S, 1999, NATURE, V398, P681, DOI 10.1038/19480; Loubeyre P, 1999, NATURE, V397, P503, DOI 10.1038/17300; Ono S, 1998, J GEOPHYS RES-SOL EA, V103, P18253, DOI 10.1029/98JB01351; Pawley AR, 1996, CONTRIB MINERAL PETR, V124, P90, DOI 10.1007/s004100050176; PEACOCK SM, 1993, GEOL SOC AM BULL, V105, P684, DOI 10.1130/0016-7606(1993)105<0684:TIOBED>2.3.CO;2; Regelous M, 1997, EARTH PLANET SC LETT, V150, P291, DOI 10.1016/S0012-821X(97)00107-6; Robie R. A., 1979, USGS BULL, V1452, DOI DOI 10.3133/B2131; Schmidt MW, 1998, EARTH PLANET SC LETT, V163, P361, DOI 10.1016/S0012-821X(98)00142-3; Shimizu H, 1996, PHYS REV B, V53, P6107, DOI 10.1103/PhysRevB.53.6107; SLEEP NH, 1994, J GEOPHYS RES-PLANET, V99, P5639, DOI 10.1029/94JE00216; SMYTH JR, 1994, AM MINERAL, V79, P1021; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; STEIN CA, 1992, NATURE, V359, P123, DOI 10.1038/359123a0; TOKSOZ MN, 1973, GEOPHYS J ROY ASTR S, V35, P285, DOI 10.1111/j.1365-246X.1973.tb02429.x; Wolanin E, 1997, PHYS REV B, V56, P5781, DOI 10.1103/PhysRevB.56.5781; Wood BJ, 1996, PHILOS T R SOC A, V354, P1495, DOI 10.1098/rsta.1996.0060; Zhao DP, 1997, SCIENCE, V278, P254, DOI 10.1126/science.278.5336.254	32	77	81	1	29	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					844	847		10.1038/35048555	http://dx.doi.org/10.1038/35048555			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130720				2022-12-28	WOS:000165831300046
J	Ebell, MH; Smith, MA; Barry, HC; Ives, K; Carey, M				Ebell, MH; Smith, MA; Barry, HC; Ives, K; Carey, M			Does this patient have strep throat?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STREPTOCOCCAL PHARYNGITIS; SORE THROAT; SCORING SYSTEM; RHEUMATIC-FEVER; DIAGNOSIS; ADULTS; MANAGEMENT; PREVENTION; PREVALENCE; PREDICTION	Context Sore throat is a common complaint, and identifying patients with group A P-hemolytic streptococcal pharyngitis (strep throat) is an important task for clinicians. Previous reviews have not systematically reviewed and synthesized the evidence. Objective To review the precision and accuracy of the clinical examination in diagnosing strep throat. Data Source MEDLINE search for articles about diagnosis of strep throat using history-taking and physical examination. Study Selection Large blinded, prospective studies (having greater than or equal to 300 patients with sore throat) reporting history and physical examination data and using throat culture as the reference standard were included. Of 917 articles identified by the search, 9 met ail inclusion criteria. Data Extraction Pairs of authors independently reviewed each article and used consensus to resolve discrepancies. Data Synthesis The most useful findings for evaluating the likelihood of strep throat are presence of tonsillar exudate, pharyngeal exudate, or exposure to strep throat infection in the previous 2 weeks (positive likelihood ratios, 3.4, 2.1, and 1.9, respectively) and the absence of tender anterior cervical nodes, tonsillar enlargement, or exudate (negative likelihood ratios, 0.60, 0.63, and 0.74, respectively). No individual element of history-taking or physical examination is accurate enough by itself to rule in or rule out strep throat. Three validated clinical prediction rules are described for adult and pediatric populations. Conclusions While no single element of history-taking or physical examination is sufficiently accurate to exclude or diagnose strep throat, a well-validated clinical prediction rule can be useful and can help physicians make more informed use of rapid antigen tests and throat cultures.	Michigan State Univ, Dept Family Practice, Clin Ctr B101, E Lansing, MI 48824 USA; First Consulting Grp, Okemos, MI USA	Michigan State University	Ebell, MH (corresponding author), Michigan State Univ, Dept Family Practice, Clin Ctr B101, E Lansing, MI 48824 USA.		Barry, Henry C/A-9057-2009	Barry, Henry C/0000-0001-6135-9349				BISNO AL, 1995, PRINCIPLES PRACTICE; BREESE BB, 1977, AM J DIS CHILD, V131, P514, DOI 10.1001/archpedi.1977.02120180028003; BREESE BB, 1961, J PEDIATR, P670; *CDCP, 1998, MMWR-MORBID MORTAL W, V46, P1; Centor R M, 1981, Med Decis Making, V1, P239, DOI 10.1177/0272989X8100100304; CENTOR RM, 1986, ANN INTERN MED, V105, P892, DOI 10.7326/0003-4819-105-6-892; CLANCY CM, 1988, J GEN INTERN MED, V3, P213, DOI 10.1007/BF02596334; CRAWFORD G, 1979, ANN INTERN MED, V90, P293, DOI 10.7326/0003-4819-90-3-293; DAJANI A, 1995, PEDIATRICS, V96, P758; DENNY FW, 1985, PEDIATR INFECT DIS J, V4, P352, DOI 10.1097/00006454-198507000-00003; Dobbs F, 1996, BRIT J GEN PRACT, V46, P461; FOONG BB, 1992, SINGAPORE MED J, V33, P597; FUNAMURA JL, 1983, CLIN PEDIATR, V22, P622, DOI 10.1177/000992288302200906; Gunnarsson RK, 1997, SCAND J PRIM HEALTH, V15, P149, DOI 10.3109/02813439709018506; Hoffmann Steen, 1992, Scandinavian Journal of Primary Health Care, V10, P295, DOI 10.3109/02813439209014077; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; KAHAN E, 1995, PUBLIC HEALTH, V109, P347, DOI 10.1016/S0033-3506(95)80006-9; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; KARDAUN JWPF, 1990, METHOD INFORM MED, V29, P12; KLJAKOVIC M, 1993, NEW ZEAL MED J, V106, P381; KOMAROFF AL, 1986, J GEN INTERN MED, V1, P1, DOI 10.1007/BF02596317; KOMAROFF AL, 1983, SCIENCE, V222, P927, DOI 10.1126/science.6415813; Kreher NE, 1998, J FAM PRACTICE, V46, P159; McIsaac WJ, 2000, CAN MED ASSOC J, V163, P811; McIsaac WJ, 1998, MED DECIS MAKING, V18, P220, DOI 10.1177/0272989X9801800211; McIsaac WJ, 1998, CAN MED ASSOC J, V158, P75; MELAND E, 1993, SCAND J INFECT DIS, V25, P177, DOI 10.3109/00365549309008482; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; *NAT CTR HLTH STAT, 1995, CEDROM SER, V13; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; Pichichero M, 1999, ARCH PEDIAT ADOL MED, V153, P672, DOI 10.1001/archpedi.153.7.672; PICHICHERO ME, 1992, PEDIATR ANN, V21, P789; POSES RM, 1986, ANN INTERN MED, V105, P586, DOI 10.7326/0003-4819-105-4-586; REED BD, 1990, ARCH INTERN MED, V150, P1727, DOI 10.1001/archinte.150.8.1727; SEPPALA H, 1993, ARCH OTOLARYNGOL, V119, P288; SNELLMAN L, 1993, PEDIATRICS, V96, P758; Steinhoff MC, 1997, LANCET, V350, P918, DOI 10.1016/S0140-6736(97)03317-5; STILLERMAN M, 1961, AM J DIS CHILD, V101, P476, DOI 10.1001/archpedi.1961.04020050066011; TOMPKINS RK, 1977, ANN INTERN MED, V86, P481, DOI 10.7326/0003-4819-86-4-481; WALSH BT, 1975, ARCH INTERN MED, V135, P1493, DOI 10.1001/archinte.135.11.1493; Webb KH, 2000, J FAM PRACTICE, V49, P34; WIGTON RS, 1986, ARCH INTERN MED, V146, P81, DOI 10.1001/archinte.146.1.81	42	201	221	1	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2912	2918		10.1001/jama.284.22.2912	http://dx.doi.org/10.1001/jama.284.22.2912			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11147989				2022-12-28	WOS:000165717000032
J	Talbot, EA; Moore, M; McCray, E; Binkin, NJ				Talbot, EA; Moore, M; McCray, E; Binkin, NJ			Tuberculosis among foreign-born persons in the United States, 1993-1998	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMIGRANTS; EPIDEMIOLOGY; REFUGEES; CHILDREN; COUNTY	Context Immigration is a major force sustaining the incidence of tuberculosis (TB) in the United States. Objective To describe trends and characteristics of foreign-born persons with TB and the implications for TB program planning and policy development. Design, setting, and subjects Descriptive analysis of US TB surveillance data from case reports submitted from 1993 to 1998. Main Outcome Measure Demographic and clinical characteristics of foreign-born persons with TB, Results The number of TB cases among foreign-born persons increased 2.6%, from 7402 in 1993 to 7591 in 1998, and the proportion of US cases that were foreign-born increased from 29.8% to 41.6%. During 1993-1998, the TB case rate was 32.9 per 100 000 population in foreign-born persons compared with 5.8 per 100 000 in US-born persons. Six states reported 73.4% of foreign-born cases (California, New York, Texas, Florida, New Jersey, and illinois). Approximately two thirds of these cases were originally from Mexico, the Philippines, Vietnam, India, China, Haiti, and South Korea. Among those for whom date of US entry was known, 51.5% arrived 5 years or less prior to the diagnosis of TB. Most were male and aged 25 to 44 years. During 1993-1996, the proportion receiving some portion of treatment under directly observed therapy increased from 27.3% to 59.1% and approximately 70% completed therapy in 12 months. The rate of primary resistance to isoniazid was 11.6% and to both isoniazid and rifampin was 1.7%. Conclusions As the United States moves toward the goal of TB elimination, success will depend increasingly on reducing the impact of TB in foreign-born persons. Continued efforts to tailor local TB control strategies to the foreign-born community and commitment to the global TB battle are essential.	Ctr Dis Control & Prevent, Surveillance & Epidemiol Branch, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Moore, M (corresponding author), Ctr Dis Control & Prevent, Surveillance & Epidemiol Branch, Div TB Eliminat, Natl Ctr HIV STD & TB Prevent, Mail Stop E-10, Atlanta, GA 30333 USA.	MMoore@cdc.gov						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Binkin NJ, 1996, CLIN INFECT DIS, V23, P1226, DOI 10.1093/clinids/23.6.1226; CDC, 1999, MMWR-MORBID MORTAL W, V48, P1; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P40; *CDCP, 2000, REP TUB US 1998; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P656; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P628; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P732; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P1032; Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; Chin DP, 1998, AM J RESP CRIT CARE, V158, P1797, DOI 10.1164/ajrccm.158.6.9804029; *DIV TB EL CDCP, 1998, TUB INF MAN SYST TIM; DRIVER CR, 1995, PEDIATR INFECT DIS J, V14, P112, DOI 10.1097/00006454-199502000-00006; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; HALL CB, 1994, PEDIATRICS, V93, P131; Jasmer RM, 1997, INT J TUBERC LUNG D, V1, P536; KENYON TA, 1995, TUBERC LUNG DIS S, V76, P52; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; McKenna MT, 1998, AM J PUBLIC HEALTH, V88, P1059, DOI 10.2105/AJPH.88.7.1059; Moore M, 1997, JAMA-J AM MED ASSOC, V278, P833, DOI 10.1001/jama.278.10.833; ORR PH, 1990, CAN MED ASSOC J, V142, P453; PICKERING LK, 2000, 2000 RED BOOK REPORT, P593; Sciortino S, 1999, INT J TUBERC LUNG D, V3, P778; STEHRGREEN JK, 1992, NEW ZEAL MED J, V105, P301; TOMIEPORTH NG, 1997, INT J TUBERC LUNG D, V1, P528; *US BUR CENS, 2000, NAT POP EST NAT; Ussery XT, 1996, PEDIATR INFECT DIS J, V15, P697, DOI 10.1097/00006454-199608000-00013; Wells CD, 1997, AM J RESP CRIT CARE, V156, P573, DOI 10.1164/ajrccm.156.2.9611101; Zuber PLF, 1997, JAMA-J AM MED ASSOC, V278, P304, DOI 10.1001/jama.278.4.304; Zuber PLF, 1996, TUBERCLE LUNG DIS, V77, P524, DOI 10.1016/S0962-8479(96)90050-7; Zuber PLF, 1996, AM J RESP CRIT CARE, V154, P151, DOI 10.1164/ajrccm.154.1.8680671	33	125	129	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	2000	284	22					2894	2900		10.1001/jama.284.22.2894	http://dx.doi.org/10.1001/jama.284.22.2894			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380RJ	11147986	Bronze			2022-12-28	WOS:000165717000029
J	Bonneux, L				Bonneux, L			Cholesterol-lowering therapy for smokers and non-smokers: a life-table analysis	LANCET			English	Editorial Material							CORONARY HEART-DISEASE; PRIMARY PREVENTION; TASK-FORCE; RISK; MORTALITY; SMOKING; MEN; WOMEN		Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Bonneux, L (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.							ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; Califf RM, 1996, J AM COLL CARDIOL, V27, P1007, DOI 10.1016/0735-1097(96)87733-3; *CENTR GOV BOD INT, 1998, TREATM PREV COR HEAR; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443; Prescott E, 1998, INT J EPIDEMIOL, V27, P27, DOI 10.1093/ije/27.1.27; PYORALA K, 1994, EUR HEART J, V15, P1300; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; ROGERS RG, 1991, SOC SCI MED, V32, P1151, DOI 10.1016/0277-9536(91)90092-Q; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smith R, 1999, BRIT MED J, V319, P936, DOI 10.1136/bmj.319.7215.936; *STAND MED ADV COM, 1997, US STAT; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194	18	7	7	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					2004	2006		10.1016/S0140-6736(00)03319-5	http://dx.doi.org/10.1016/S0140-6736(00)03319-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130539				2022-12-28	WOS:000165867600041
J	Casey, BM; McIntire, DD; Leveno, KJ				Casey, BM; McIntire, DD; Leveno, KJ			The continuing value of the apgar score for the assessment of newborn infants.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACIDEMIA; COMPLICATIONS; TERM	Background: The 10-point Apgar score has been used to assess the condition and prognosis of newborn infants throughout the world for almost 50 years. Some investigators have proposed that measurement of pH in umbilical-artery blood is a more objective method of assessing newborn infants. Methods: We carried out a retrospective cohort analysis of 151,891 live-born singleton infants without malformations who were delivered at 26 weeks of gestation or later at an inner-city public hospital between January 1988 and December 1998. Paired Apgar scores and umbilical-artery blood pH values were determined for 145,627 infants to assess which test best predicted neonatal death during the first 28 days after birth. Results: For 13,399 infants born before term (at 26 to 36 weeks of gestation), the neonatal mortality rate was 315 per 1000 for infants with five-minute Apgar scores of 0 to 3, as compared with 5 per 1000 for infants with five-minute Apgar scores of 7 to 10. For 132,228 infants born at term (37 weeks of gestation or later), the mortality rate was 244 per 1000 for infants with five-minute Apgar scores of 0 to 3, as compared with 0.2 per 1000 for infants with five-minute Apgar scores of 7 to 10. The risk of neonatal death in term infants with five-minute Apgar scores of 0 to 3 (relative risk, 1460; 95 percent confidence interval, 835 to 2555) was eight times the risk in term infants with umbilical-artery blood pH values of 7.0 or less (relative risk, 180; 95 percent confidence interval, 97 to 334). Conclusions: The Apgar scoring system remains as relevant for the prediction of neonatal survival today as it was almost 50 years ago. (N Engl J Med 2001;344:467-71.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Casey, BM (corresponding author), Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							*ACOG COMM OBST PR, 1996, COMP SEL PUBL, V174; *AM AC PED, 1997, GUID PER CAR, P4; APGAR V, 1962, AM J DIS CHILD, V104, P419, DOI 10.1001/archpedi.1962.02080030421015; APGAR V, 1958, JAMA-J AM MED ASSOC, V168, P1985, DOI 10.1001/jama.1958.03000150027007; APGAR V, 1953, ANESTH ANALG CLEVE, V32, P260, DOI DOI 10.1213/00000539-195301000-00041; CUNNINGHAM FG, 1989, WILLIAMS OBSTET, P748; DRAGE JS, 1964, OBSTET GYNECOL, V24, P222; GILSTRAP LC, 1987, OBSTET GYNECOL, V70, P191; GILSTRAP LC, 1989, AM J OBSTET GYNECOL, V161, P825, DOI 10.1016/0002-9378(89)90410-9; GOODWIN TM, 1992, AM J OBSTET GYNECOL, V167, P1506, DOI 10.1016/0002-9378(92)91728-S; NELSON KB, 1981, PEDIATRICS, V68, P36; Oh W, 1996, PEDIATRICS, V98, P141; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V277, P1762; WINKLER CL, 1991, AM J OBSTET GYNECOL, V164, P637, DOI 10.1016/S0002-9378(11)80038-4	14	494	518	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 15	2001	344	7					467	471		10.1056/NEJM200102153440701	http://dx.doi.org/10.1056/NEJM200102153440701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401HL	11172187				2022-12-28	WOS:000166922100001
J	Li, YC; Cheng, TH; Gartenberg, MR				Li, YC; Cheng, TH; Gartenberg, MR			Establishment of transcriptional silencing in the absence of DNA replication	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; HETEROCHROMATIN; SIR1; LOCI; MAINTENANCE; REPRESSION; TELOMERES; PROTEINS; DYNAMICS; REQUIRES	Transcriptional repression of the silent mating-type Loci in Saccharomyces cerevisiae requires a cell cycle-dependent establishment step that is commonly assumed to involve DNA replication. Using site-specific recombination, we created a nonreplicating DNA ring in vivo to test directly the role of replication in establishment of silencing. Sir1 was tethered to the ring following excision from the chromosome to activate a dormant silencer. We show here that silencing can be established in DNA that does not replicate. The silenced ring adopted structural features characteristic of bona fide silent chromatin, including an altered Level of DNA supercoiling and reduced histone acetylation. In addition, the process required silencing factors Sir2, Sir3, and Sir4 and progression between early S and M phases of the cell cycle. The results indicate that passage of a replication fork is not the cell-cycle event required for establishment of silencing in yeast.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Gartenberg, MR (corresponding author), Canc Inst New Jersey, New Brunswick, NJ 08901 USA.	gartenbe@umdnj.edu		Gartenberg, Marc/0000-0003-0713-7993	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051402, R01GM051402] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51402] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ansari A, 1997, MOL CELL BIOL, V17, P7061, DOI 10.1128/MCB.17.12.7061; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; Bi X, 1997, MOL CELL BIOL, V17, P7077, DOI 10.1128/MCB.17.12.7077; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Cheng TH, 2000, GENE DEV, V14, P452; Cheng TH, 1998, P NATL ACAD SCI USA, V95, P5521, DOI 10.1073/pnas.95.10.5521; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Dillin A, 1997, GENETICS, V147, P1053; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; Ehrenhofer-Murray AE, 1999, GENETICS, V153, P1171; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; Guarente L, 2000, GENE DEV, V14, P1021; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; Laroche T, 2000, J STRUCT BIOL, V129, P159, DOI 10.1006/jsbi.2000.4240; LI Y, UNPUB; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; Marheineke K, 1998, J BIOL CHEM, V273, P15279, DOI 10.1074/jbc.273.24.15279; Meluh PB, 1999, METHOD ENZYMOL, V304, P414; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0	28	114	115	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2001	291	5504					650	653		10.1126/science.291.5504.650	http://dx.doi.org/10.1126/science.291.5504.650			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158677				2022-12-28	WOS:000166616000043
J	Smith, JS; Boeke, JD				Smith, JS; Boeke, JD			Transcription - Is S phase important for transcriptional silencing?	SCIENCE			English	Editorial Material							ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; STRAND BREAKS; CHROMATIN; YEAST; LOCI; TELOMERES; PROTEINS; SIR1		Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	University of Virginia; Johns Hopkins University	Smith, JS (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.							Bi X, 1997, MOL CELL BIOL, V17, P7077, DOI 10.1128/MCB.17.12.7077; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Cheng TH, 1998, P NATL ACAD SCI USA, V95, P5521, DOI 10.1073/pnas.95.10.5521; Dillin A, 1997, GENETICS, V147, P1053; Ehrenhofer-Murray AE, 1999, GENETICS, V153, P1171; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; LOO S, 1995, ANNU REV CELL DEV BI, V11, pS19; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	17	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					608	609		10.1126/science.291.5504.608	http://dx.doi.org/10.1126/science.291.5504.608			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158666				2022-12-28	WOS:000166616000032
J	Hogenauer, C; Meyer, RL; Netto, GJ; Bell, D; Little, KH; Ferries, L; Santa Ana, CA; Porter, JL; Fordtran, JS				Hogenauer, C; Meyer, RL; Netto, GJ; Bell, D; Little, KH; Ferries, L; Santa Ana, CA; Porter, JL; Fordtran, JS			Malabsorption due to cholecystokinin deficiency in a patient with autoimmune polyglandular syndrome type I	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC CHRONIC DIARRHEA		Baylor Univ, Med Ctr, Dept Internal Med, Dallas, TX 75246 USA; Baylor Univ, Med Ctr, Dept Pathol, Dallas, TX 75246 USA; Deaconess Billings Clin, Billings, MT USA	Baylor University; Baylor University Medical Center; Baylor University; Baylor University Medical Center	Fordtran, JS (corresponding author), Baylor Univ, Med Ctr, Dept Internal Med, 3500 Gaston Ave, Dallas, TX 75246 USA.			Hogenauer, Christoph/0000-0003-4566-0806; Netto, George/0000-0003-3915-9134	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-RO1-DK37172-14] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; AFZALPURKAR RG, 1992, NEW ENGL J MED, V327, P1849, DOI 10.1056/NEJM199212243272605; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; ARRAMBIDE KA, 1989, DIGEST DIS SCI, V34, P193, DOI 10.1007/BF01536050; Betterle C, 1998, J CLIN ENDOCR METAB, V83, P1049, DOI 10.1210/jc.83.4.1049; BROSNAN P, 1996, PEDIAT ENDOCRINOLOGY, P509; Eisenbarth GS, 1998, WILLIAMS TXB ENDOCRI, P1651; FACER P, 1989, GASTROENTEROLOGY, V97, P48, DOI 10.1016/0016-5085(89)91414-5; FELDMAN JM, 1986, AM J MED, V81, P41, DOI 10.1016/0002-9343(86)90583-8; GASKIN KJ, 1982, J CLIN INVEST, V69, P427, DOI 10.1172/JCI110466; Gruy-Kapral C, 1999, GASTROENTEROLOGY, V116, P15, DOI 10.1016/S0016-5085(99)70223-4; HAYAKAWA T, 1980, Gastroenterologia Japonica, V15, P135; Hofmann A.F., 1993, GASTROINTESTINAL DIS, V1, P127; JACKSON WPU, 1957, LANCET, V1, P1086; KRONENBERG HM, 1996, CECIL TXB MED, V2, P1345; PANDOL SJ, 1998, SLEISENGER FORDTRANS, P771; POLAK JM, 1989, HDB PHYSL 6, V2, P79; REDFERN J, 1995, ENDOCRINOL METAB, P1675; Rehfeld JF., 1989, HDB PHYSL, VII; Schiller LR, 1987, GASTROENTEROLOGY, V92, P151, DOI 10.1016/0016-5085(87)90852-3; SCHILLER LR, 1990, GASTROENTEROLOGY, V98, P1036, DOI 10.1016/0016-5085(90)90031-U; SHIODA Y, 1984, HISTOCHEM J, V16, P843, DOI 10.1007/BF01002790; STEVENSON GW, 1964, CLIN CHEM, V10, P95; Su A Y, 1995, Semin Gastrointest Dis, V6, P217; TAYLOR IL, 1989, HDB PHYSL 6, V2, P475; TEXTER EC, 1964, DIFFERENTIAL DIAGNOS, P206; WILLIAMS E, 1959, ARCH DIS CHILD, V34, P302, DOI 10.1136/adc.34.176.302	27	55	55	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2001	344	4					270	274		10.1056/NEJM200101253440405	http://dx.doi.org/10.1056/NEJM200101253440405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	394WA	11172154				2022-12-28	WOS:000166545200005
J	Christopoulos, KA				Christopoulos, KA			The sick role in literature and society	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Christopoulos, KA (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.							BOCCACIO, 1921, DECAMERON, P5; EDSON M, 1993, WIT; Foucault M, 1994, BIRTH CLIN; GROOPMAN J, 2000, NEW YORKER      1113, V13, P78; KEATS J, 1959, SELECTED POEMS LETT, P289; PARSONS T, 1981, CONCEPTS HLTH DIS, P70; SONTAG S, 1989, ILLNESS NARRATIVE AI, P65; TWADDLE AC, 1979, SICKNESS BEHAV SICK, P18; WILSON E, 1997, WOUND BOW, P242	9	3	3	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					93	93		10.1001/jama.285.1.93	http://dx.doi.org/10.1001/jama.285.1.93			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150121	hybrid			2022-12-28	WOS:000166114500035
J	Dumitru, CD; Ceci, JD; Tsatsanis, C; Kontoyiannis, D; Stamatakis, K; Lin, JH; Patriotis, C; Jenkins, NA; Copeland, NG; Kollias, G; Tsichlis, PN				Dumitru, CD; Ceci, JD; Tsatsanis, C; Kontoyiannis, D; Stamatakis, K; Lin, JH; Patriotis, C; Jenkins, NA; Copeland, NG; Kollias, G; Tsichlis, PN			TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway	CELL			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; T-CELL LINES; TRANSLATION INITIATION; SIGNALS ACTIVATION; ENDOTOXIC-SHOCK; INNATE IMMUNITY; MICE DEFICIENT; TPL-2	Tpl2 knockout mice produce tow levels of TNF-alpha when exposed to lipopolysaccharide (LPS) and they are resistant to LPS/D-Galactosamine-induced pathology. LPS stimulation of peritoneal macrophages from these mice did not activate MEK1, ERK1, and ERK2 but did activate JNK, p38 MAPK, and NF-kappaB. The block in ERK1 and ERK2 activation was causally linked to the defect in TNF-alpha induction by experiments showing that normal murine macrophages treated with the MEK inhibitor PD98059 exhibit a similar defect. Deletion of the AU-rich motif in the TNF-alpha mRNA minimized the effect of Tpl2 inactivation on the induction of TNF-alpha. Subcellular fractionation of LPS-stimulated macrophages revealed that LPS signals transduced by Tpl2 specifically promote the transport of TNF-alpha mRNA from the nucleus to the cytoplasm.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; NCI, Mouse Canc Genet Program, FCRDC, Frederick, MD 21702 USA; Hellenic Pasteur Inst, Genet Mol Lab, Athens 11521, Greece	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Tsichlis, PN (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	p_tsichlis@lac.jci.tju.edu	Tsatsanis, Christos/AAM-9362-2020; Kollias, George/A-7079-2012; Stamatakis, Konstantinos/A-6596-2017	Tsatsanis, Christos/0000-0003-1214-4151; Kollias, George/0000-0003-1867-3150; Stamatakis, Konstantinos/0000-0001-9934-3502; Kontoyiannis, Dimitris/0000-0003-4682-9490	NATIONAL CANCER INSTITUTE [R01CA038047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA38047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Erny KM, 1996, ONCOGENE, V13, P2015; FINK MP, 1990, J SURG RES, V49, P186, DOI 10.1016/0022-4804(90)90260-9; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GEPPERT TD, 1994, MOL MED, V1, P93; KABOORD B, 2000, PREVEIWS PIERCE CHEM, V3, P4; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; LEIST M, 1994, J IMMUNOL, V153, P1778; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; UCHIDA N, 1980, J BIOL CHEM, V255, P8638; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; WARREN MK, 1985, J IMMUNOL, V134, P982	45	675	715	0	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1071	1083		10.1016/S0092-8674(00)00210-5	http://dx.doi.org/10.1016/S0092-8674(00)00210-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163183	Bronze			2022-12-28	WOS:000166040600010
J	Yean, SL; Wuenschell, G; Termini, J; Lin, RJ				Yean, SL; Wuenschell, G; Termini, J; Lin, RJ			Metal-ion coordination by U6 small nuclear RNA contributes to catalysis in the spliceosome	NATURE			English	Article							PRE-MESSENGER-RNA; TERTIARY INTERACTION; PHOSPHOROTHIOATE INTERFERENCE; HAMMERHEAD RIBOZYME; SITE; SNRNA; STEREOCHEMISTRY; POLYMERASE; LINKS	Introns are removed from nuclear messenger RNA precursors through two sequential phospho-transesterification reactions in a dynamic RNA-protein complex called the spliceosome(1,2). But whether splicing is catalysed by small nuclear RNAs3,4 in the spliceosome is unresolved. As the spliceosome is a metalloenzyme(5-7), it is important to determine whether snRNAs coordinate catalytic metals. Here we show that yeast U6 snRNA coordinates a metal ion that is required for the catalytic activity of the spliceosome. With Mg2+, U6 snRNA with a sulphur substitution for the pro-R-P or pro-S-P non-bridging phosphoryl oxygen of nucleotide U-80 reconstitutes a fully assembled yet catalytically inactive spliceosome. Adding a thiophilic ion such as Mn2+ allows the first transesterification reaction to occur in the U6/sU(80)(S-P)- but not the U6/sU80 (R-P)-reconstituted spliceosome. Mg2+ competitively inhibits the Mn2+-rescued reaction, indicating that the metal-binding site at U6/U-80 exists in the wild-type spliceosome and that the site changes its metal requirement for activity in the S-P spliceosome. Thus, U6 snRNA contributes to pre-messenger RNA splicing through metal-ion coordination, which is consistent with RNA catalysis by the spliceosome.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Lin, RJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA.	rlin@coh.org	Lin, Ren-Jang/G-2052-2014	Lin, Ren-Jang/0000-0002-2738-2438	NIGMS NIH HHS [R01 GM040639, R01 GM040639-10] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040639] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basu S, 1999, RNA, V5, P1399, DOI 10.1017/S135583829999115X; Boudvillain M, 2000, NATURE, V406, P315, DOI 10.1038/35018589; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; CHANFREAU G, 1994, SCIENCE, V266, P1383, DOI 10.1126/science.7973729; Christian EL, 2000, RNA, V6, P511, DOI 10.1017/S1355838200000042; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; Collins CA, 2000, NAT STRUCT BIOL, V7, P850; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; Gordon PM, 2000, RNA, V6, P199, DOI 10.1017/S1355838200992069; Guthrie C, 1994, Harvey Lect, V90, P59; Kim CH, 1996, RNA, V2, P995; Kim SH, 1996, MOL CELL BIOL, V16, P6810; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Murray JB, 2000, J MOL BIOL, V296, P33, DOI 10.1006/jmbi.1999.3428; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Sigel RKO, 1997, J AM CHEM SOC, V119, P744, DOI 10.1021/ja962970l; Smith JS, 2000, BIOCHEMISTRY-US, V39, P5642, DOI 10.1021/bi992712b; Sontheimer EJ, 1997, NATURE, V388, P801, DOI 10.1038/42068; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Valadkhan S, 2000, RNA, V6, P206, DOI 10.1017/S1355838200992197; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; YU YT, 1995, RNA, V1, P46	30	194	199	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					881	884		10.1038/35048617	http://dx.doi.org/10.1038/35048617			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130730	Green Accepted			2022-12-28	WOS:000165831300056
J	Leung, D; Venkatesan, P				Leung, D; Venkatesan, P			Clinical picture: atypical mycobacterial infection of a finger	LANCET			English	Article									City Hosp Nottingham, Nottingham NG5 1PB, England; New Cross Hosp, Wolverhampton, W Midlands, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; New Cross Hospital	Leung, D (corresponding author), New Cross Hosp, Wolverhampton, W Midlands, England.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1974	1974		10.1016/S0140-6736(00)03309-2	http://dx.doi.org/10.1016/S0140-6736(00)03309-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130526				2022-12-28	WOS:000165867600012
J	Pollock, AM; Price, D				Pollock, AM; Price, D			Rewriting the regulations: how the World Trade Organisation could accelerate privatisation in health-care systems	LANCET			English	Article								The World Trade Organisation (WTO) is drawing up regulatory proposals which could force governments to open up their public services to foreign investors and markets. As part of the General Agreement on Trade in Services (GATS) negotiations, the WTO working party on reform of domestic regulation is developing a regulatory reform agenda which could mark a new era of compulsion in international trade law. Article V1.4 of the GATS is being strengthened with the aim of requiring member states to show that they are employing least trade-restrictive policies. The legal tests under consideration would outlaw the use of non-market mechanisms such as cross-subsidisation, universal risk pooling, solidarity, and public accountability in the design, funding, and delivery of public services as being anti-competitive and restrictive to trade. The domestic policies of national governments will be subject to WTO rules, and if declared illegal, could lead to trade sanctions under the WTO disputes panel process. The USA and European Union, with the backing of their own multinational corporations, believe that these new powers will advantage their own economies. Health-care professionals and public-health activists must ensure that this secretive regulatory reform process is opened up for public debate.	UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England	University of London; University College London	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England.	allyson.pollock@ucl.ac.uk		pollock, allyson/0000-0002-7388-3110				BRAITHWAITE J, 2000, GLOBAL BUSINESS REGU, P27; EVANS R, 1999, HLTH REFORM PUBLIC S, P25; *FRONT FREE EUR, 1999, EUR UN WORLD TRAD, V2; *HM GOV, 1999, GATS 2000 HLTH ED SE; *INT AM DEV BANK, 1996, SUPP REF DEL SOC SER; Price D, 1999, LANCET, V354, P1889, DOI 10.1016/S0140-6736(99)11060-2; *PUBL SERV INT, 1999, WTO GEN AGR TRAD SER, P20; Sinclair S., 2000, GATS WORLD TRADE ORG; *UNCTAD WHO, 1998, INT TRAD HLTH SERV D; WESSELIUS E, 2000, BRIDGES WEEKLY  1010; *WHO, 1998, SCW56 WTO; WILSON JS, 1999, POST SEATTLE AGENDA; World Trade Organization (WTO), 2000, WTDS135R WTO; WTO, 1999, SCW96 WTO; *WTO, 1998, SCM30 WTO; *WTO, 1998, SCW74 WTO; *WTO SECR, 1998, SCW50 WTO	17	74	76	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1995	2000		10.1016/S0140-6736(00)03317-1	http://dx.doi.org/10.1016/S0140-6736(00)03317-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130537				2022-12-28	WOS:000165867600039
J	Dalva, MB; Takasu, MA; Lin, MZ; Shamah, SM; Hu, L; Gale, NW; Greenberg, ME				Dalva, MB; Takasu, MA; Lin, MZ; Shamah, SM; Hu, L; Gale, NW; Greenberg, ME			EphB receptors interact with NMDA receptors and regulate excitatory synapse formation	CELL			English	Article							PROTEIN-KINASE-II; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; AGRIN-DEFICIENT MICE; D-ASPARTATE RECEPTOR; HIPPOCAMPAL-NEURONS; TYROSINE KINASES; NEUROMUSCULAR-JUNCTION; TRANSMEMBRANE LIGANDS; GLUTAMATE RECEPTORS	EphB receptor tyrosine kinases are enriched at synapses, suggesting that these receptors play a role in synapse formation or function. We find that EphrinB binding to EphB induces a direct interaction of EphB with NMDA-type glutamate receptors. This interaction occurs at the cell surface and is mediated by the extracellular regions of the two receptors, but does not require the kinase activity of EphB. The kinase activity of EphB may be important for subsequent steps in synapse formation, as perturbation of EphB tyrosine kinase activity affects the number of synaptic specializations that form in cultured neurons. These findings indicate that EphrinB activation of EphB promotes an association of EphB with NMDA receptors that may be critical for synapse development or function.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Regeneron	Greenberg, ME (corresponding author), Childrens Hosp, Div Neurosci, 300 Longwood Ave, Boston, MA 02115 USA.			Dalva, Matthew/0000-0002-7737-8787; Lin, Michael/0000-0002-0492-1961	NCI NIH HHS [CA43855] Funding Source: Medline; NICHD NIH HHS [HD18655] Funding Source: Medline; NINDS NIH HHS [R01 NS045500] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045500] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Birgbauer E, 2000, DEVELOPMENT, V127, P1231; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; CRAIG AM, 1993, NEURON, V10, P1055, DOI 10.1016/0896-6273(93)90054-U; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Friedman HV, 2000, NEURON, V27, P57, DOI 10.1016/S0896-6273(00)00009-X; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kavalali ET, 1999, P NATL ACAD SCI USA, V96, P12893, DOI 10.1073/pnas.96.22.12893; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Li Z, 1999, J NEUROBIOL, V39, P547, DOI 10.1002/(SICI)1097-4695(19990615)39:4<547::AID-NEU8>3.0.CO;2-C; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; OBrien RJ, 1997, J NEUROSCI, V17, P7339; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Rao A, 1998, J NEUROSCI, V18, P1217; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Serpinskaya AS, 1999, DEV BIOL, V205, P65, DOI 10.1006/dbio.1998.9112; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697	45	529	554	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					945	956		10.1016/S0092-8674(00)00197-5	http://dx.doi.org/10.1016/S0092-8674(00)00197-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136979	Bronze			2022-12-28	WOS:000165801300013
J	McWatters, HG; Bastow, RM; Hall, A; Millar, AJ				McWatters, HG; Bastow, RM; Hall, A; Millar, AJ			The ELF3 zeitnehmer regulates light signalling to the circadian clock	NATURE			English	Article							ARABIDOPSIS-THALIANA; DYSFUNCTION; EXPRESSION; MUTANTS	The circadian system regulates 24-hour biological rhythms' and seasonal rhythms, such as flowering(2). Long-day flowering plants like Arabidopsis thaliana, measure day length with a rhythm that is not reset at lights-off(3), whereas short-day plants measure night length on the basis of circadian rhythm of light sensitivity that is set from dusk(2). early flowering 3 (elf3) mutants of Arabinopsis are aphotoperiodic(4) and exhibit light-conditional arrhythmia(5,6). Here we show that the elf3-7 mutant retains oscillator function in the light but blunts circadian gating of CAB gene activation, indicating that deregulated phototransduction may mask rhythmicity. Furthermore, elf3 mutations confer the resetting pattern of short-day photoperiodism, indicating that gating of phototransduction may control resetting. Temperature entrainment can bypass the requirement for normal ELF3 function for the oscillator and partially restore rhythmic CAB expression. Therefore, ELF3 specifically affects light input to the oscillator, similar to its function in gating CAB activation, allowing oscillator progression past a light-sensitive phase in the subjective evening. ELF3 provides experimental demonstration of the zeitnehmer ('time-taker') Concept(7,8).	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Millar, AJ (corresponding author), Univ Warwick, Dept Biol Sci, Gibbet Hill Rd, Coventry CV4 7AL, W Midlands, England.		Hall, Anthony/D-2844-2009; Millar, Andrew J/G-2423-2012	Hall, Anthony/0000-0002-1806-020X; Millar, Andrew J/0000-0003-1756-3654				Bognar LK, 1999, P NATL ACAD SCI USA, V96, P14652, DOI 10.1073/pnas.96.25.14652; Carre IA, 1995, PLANT CELL, V7, P2039, DOI 10.2307/3870149; Dowson-Day MJ, 1999, PLANT J, V17, P63, DOI 10.1046/j.1365-313X.1999.00353.x; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; Lakin-Thomas PL, 2000, TRENDS GENET, V16, P135, DOI 10.1016/S0168-9525(99)01945-9; LUMSDEN PJ, 1998, BIOL RHYTHMS PHOTOPE, P167; Merrow M, 1999, NATURE, V399, P584, DOI 10.1038/21190; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Millar AJ, 1996, P NATL ACAD SCI USA, V93, P15491, DOI 10.1073/pnas.93.26.15491; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; Reed JW, 2000, PLANT PHYSIOL, V122, P1149, DOI 10.1104/pp.122.4.1149; Roenneberg T, 1999, J BIOL RHYTHM, V14, P449, DOI 10.1177/074873099129001019; Roenneberg T, 1998, J BIOL RHYTHM, V13, P167, DOI 10.1177/074873098129000011; Samach A, 2000, BIOESSAYS, V22, P38, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;38::AID-BIES8&gt;3.0.CO;2-L; SOMERS DE, 1995, PLANT PHYSIOL, V107, P523, DOI 10.1104/pp.107.2.523; ZAGOTTA MT, 1992, AUST J PLANT PHYSIOL, V19, P411, DOI 10.1071/PP9920411	17	262	278	1	35	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					716	720		10.1038/35047079	http://dx.doi.org/10.1038/35047079			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130072				2022-12-28	WOS:000165815200048
J	Bundred, P; Kitchiner, D; Buchan, I				Bundred, P; Kitchiner, D; Buchan, I			Prevalence of overweight and obese children between 1989 and 1998: population based series of cross sectional studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX; REFERENCE CURVES; CHILDHOOD; UK	Objective To determine trends in weight, height, and body mass index in children between 1989 and 1998. Design Retrospective series of cross sectional studies of routinely collected data. Setting Primary care in the Wirral Health Authority Participants 35 662 infants aged 1-3 months (representing 88% of live births) and 28 768 children aged 2.9-4.0 years. 21 582 infants and children (25.1%) were excluded because of missing or inaccurate data. Main outcome measures Weight, height sex, and age routinely recorded by health visitors, Height, weight, and body mass index standardised for age and sex, SD score > 1.04 for body mass index (>85th centile) was defined as overweight and > 1.64 (> 95th centile) as obese, Body mass index was not calculated in infants as it is difficult to interpret. Results From 1989 to 1998 there was a highly significant increasing trend in die proportion of overweight children (14.7% to 23.6%; P < 0.001) and obese children (5.4% to 9.2%; P < 0.001). There was also a highly significant increasing trend in the mean SD score for weight (0.05 to 0.29; P< 0.001) and body mass index (- 0.15 to 0.31 ; P < 0.001) but not height Infants showed a small but significantly increasing trend in mean SD score for weight (- 0.17 to - 0.05; P = 0.005). Conclusions From 1989 to 1998 there was a highly significant increase in weight and body mass index in children under 4 years of age, Routinely collected data are valuable in identifying anthropometric trends in populations.	Univ Liverpool, Liverpool L69 3GB, Merseyside, England; Royal Liverpool Childrens NHS Trust, Liverpool L12 2AP, Merseyside, England; W Hertfordshire Hlth Author, St Albans AL1 3ER, Herts, England	University of Liverpool; Alder Hey Children's NHS Foundation Trust	Bundred, P (corresponding author), Univ Liverpool, Liverpool L69 3GB, Merseyside, England.	peterb@liv.ac.uk	Buchan, Iain E/H-5767-2013	Buchan, Iain E/0000-0003-3392-1650				Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; Bellizzi MC, 1999, AM J CLIN NUTR, V70, p173S; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; *CHILD GROWTH F, 1996, UK CROSS SECT REF DA; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Dietz WH, 1998, J NUTR, V128, p411S, DOI 10.1093/jn/128.2.411S; Fredriks AM, 2000, ARCH DIS CHILD, V82, P107, DOI 10.1136/adc.82.2.107; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; Fruhbeck G, 2000, BRIT MED J, V320, P328, DOI 10.1136/bmj.320.7231.328; Kotani K, 1997, INT J OBESITY, V21, P912, DOI 10.1038/sj.ijo.0800492; Luepker RV, 1996, JAMA-J AM MED ASSOC, V275, P768, DOI 10.1001/jama.275.10.768; Must A, 1999, INT J OBESITY, V23, pS2, DOI 10.1038/sj.ijo.0800852; NHS Executive, 2000, NAT SERV FRAM COR HE; Pietrobelli A, 1998, J PEDIATR-US, V132, P204, DOI 10.1016/S0022-3476(98)70433-0; Power C, 1997, AM J CLIN NUTR, V66, P1094, DOI 10.1093/ajcn/66.5.1094; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; Reilly JJ, 1999, BRIT MED J, V319, P1039, DOI 10.1136/bmj.319.7216.1039	20	204	213	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2001	322	7282					326	328		10.1136/bmj.322.7282.326	http://dx.doi.org/10.1136/bmj.322.7282.326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159654	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000167050000025
J	Cui, Y; Lieber, CM				Cui, Y; Lieber, CM			Functional nanoscale electronic devices assembled using silicon nanowire building blocks	SCIENCE			English	Article							CARBON NANOTUBES; QUANTUM WIRES; SINGLE-WALL; ORGANIZATION; DNA	Because semiconductor nanowires can transport electrons and holes, they could function as building blocks for nanoscale electronics assembled without the need for complex and costly fabrication facilities. Boron- and phosphorous-doped silicon nanowires were used as building blocks to assemble three types of semiconductor nanodevices. Passive diode structures consisting of crossed p- and n-type nanowires exhibit rectifying transport similar to planar p-n junctions. Active bipolar transistors, consisting of heavily and lightly n-doped nanowires crossing a common p-type wire base, exhibit common base and emitter current gains as Large as 0.94 and 16, respectively. In addition, p- and n-type nanowires have been used to assemble complementary inverter-like structures. The facile assembly of key electronic device elements from well-defined nanoscale building blocks may represent a step toward a "bottom-up" paradigm for electronics manufacturing.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.		Cui, Yi/L-5804-2013; Dee, Chang Fu/G-4842-2010; Chu, Yung-Ming/C-6318-2009	Cui, Yi/0000-0002-6103-6352; Dee, Chang Fu/0000-0003-1015-9181; 				Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; CARD HC, 1971, J PHYS D APPL PHYS, V4, P1602, DOI 10.1088/0022-3727/4/10/320; Cui Y, 2000, J PHYS CHEM B, V104, P5213, DOI 10.1021/jp0009305; CUI Y, UNPUB; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Fuhrer MS, 2000, SCIENCE, V288, P494, DOI 10.1126/science.288.5465.494; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; Hu JT, 1999, NATURE, V399, P48, DOI 10.1038/19941; Hu JT, 1999, ACCOUNTS CHEM RES, V32, P435, DOI 10.1021/ar9700365; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; Mirkin CA, 2000, INORG CHEM, V39, P2258, DOI 10.1021/ic991123r; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Peercy PS, 2000, NATURE, V406, P1023, DOI 10.1038/35023223; SZE SM, 1981, PHYSICS SEMICONDUCTO; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Timp G., 1999, NANOTECHNOLOGY, P161; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	21	2982	3125	16	1095	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 2	2001	291	5505					851	853		10.1126/science.291.5505.851	http://dx.doi.org/10.1126/science.291.5505.851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157160				2022-12-28	WOS:000166771700037
J	Fisher, RJ; Pevsner, J; Burgoyne, RD				Fisher, RJ; Pevsner, J; Burgoyne, RD			Control of fusion pore dynamics during exocytosis by Munc18	SCIENCE			English	Article							ADRENAL-MEDULLARY CELLS; PROTEIN-KINASE-C; KISS-AND-RUN; VESICLE FUSION; SECRETORY PRODUCTS; NSEC-1 MUNC-18; PC12 CELLS; SYNTAXIN; COMPLEX; CHROMAFFIN	Intracellular membrane fusion is mediated by the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins. All vesicle transport steps also have an essential requirement for a member of the Sec1 protein family, including the neuronal Munc18-1 (also known as nSec1) in regulated exocytosis. Here, in adrenal chromaffin cells, we expressed a Munc18 mutant with reduced affinity for syntaxin, which specifically modified the kinetics of single-granule exocytotic release events, consistent with an acceleration of fusion pore expansion, Thus, Munc18 functions in a late stage in the fusion process, where its dissociation from syntaxin determines the kinetics of postfusion events.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England; Kennedy Krieger Inst, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	University of Liverpool; Kennedy Krieger Institute; Johns Hopkins University	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.		Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036670] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS36670-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; CORCORAN JJ, 1984, J BIOL CHEM, V259, P6208; Cousin MA, 2000, J NEUROCHEM, V75, P1645, DOI 10.1046/j.1471-4159.2000.0751645.x; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 1997, J NEUROCHEM, V69, P2369; Grote E, 2000, J CELL BIOL, V151, P439, DOI 10.1083/jcb.151.2.439; HARTMANN J, 1995, FEBS LETT, V363, P217, DOI 10.1016/0014-5793(95)00318-4; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; WICK PF, 1993, J BIOL CHEM, V268, P10983; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	30	166	171	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 2	2001	291	5505					875	878		10.1126/science.291.5505.875	http://dx.doi.org/10.1126/science.291.5505.875			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157167				2022-12-28	WOS:000166771700045
J	Berger, A				Berger, A			Science commentary: HLA typing	BRITISH MEDICAL JOURNAL			English	Editorial Material																		*IMM MECH HLTH DIS, 1996, OXF TXB MED, P139	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					218	218		10.1136/bmj.322.7280.218	http://dx.doi.org/10.1136/bmj.322.7280.218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	398BF	11159622	Green Published			2022-12-28	WOS:000166733700031
J	Duncan, B; Hart, G; Scoular, A; Bigrigg, A				Duncan, B; Hart, G; Scoular, A; Bigrigg, A			Qualitative analysis of psychosocial impact of diagnosis of Chlamydia trachomatis: implications for screening	BRITISH MEDICAL JOURNAL			English	Article							INFECTION	Objectives To investigate the psychosocial impact for women of a diagnosis of Chlamydia trachomatis and discuss the implications for the proposed UK chlamydia screening programme. Design Qualitative study with semistructured intel views. Interview transcripts analysed to identify recurrent themes. Participants Seventeen women with a current or recent diagnosis of chlamydia Setting A family planning clinic and a genitourinary medicine clinic in Glasgow. Results Three themes were identified: perceptions of stigma associated with sexually transmitted infection, uncertainty about reproductive health after diagnosis, and anxieties regarding partner's reaction to diagnosis, Most women had not previously perceived sexually transmitted infections as personally relevant; this was a function of stereotypical beliefs about who was "at risk" of sexually transmitted infection. These beliefs were pervasive ans negatively affected reactions to diagnosis and produced anxiety about disclosure of the condition to others (particularly) sexual partners) and future reproductive morbidity. This anxiety, given the uncertain natural history of chlamydia, may prove difficult to dispel. Conclusions There are three primary areas of concern for women after a diagnosis of chlamydia which need to be examined in the proposed screening programme. Information provided should normalise and destigmatise chlamydial infection and positively promote genitourinary medicine services. Support services should be available because notification of partner can cause anxiety. Uncertainty about future reproductive morbidity may be inevitable; staff providing screening will require guidance in providing advice under such conditions.	Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; Sandyford Initiat, Dept Genitourinary Med, Glasgow G3 7NB, Lanark, Scotland; Sandyford Initiat, Family Planning & Reprod Hlth Directorate, Glasgow G3 7NB, Lanark, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow	Duncan, B (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.		Hart, Graham J/C-1591-2008	Hart, Graham/0000-0001-9676-6577				Ainslie DC, 1999, HASTINGS CENT REP, V29, P26, DOI 10.2307/3527734; BLACK N, 1994, J EPIDEMIOL COMMUN H, V48, P425, DOI 10.1136/jech.48.5.425-a; Buston K, 1998, BRIT J PSYCHIAT, V172, P197, DOI 10.1192/bjp.172.3.197; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; *CDC, 1997, JAMA-J AM MED ASSOC, V277, P952; Chief Medical Officer's Expert Advisory Group, 1998, MAIN REP CMOS EXP AD; Flowers P, 1997, BRIT J HEALTH PSYCH, V2, P73, DOI 10.1111/j.2044-8287.1997.tb00524.x; Holgate HS, 1998, J ROY SOC HEALTH, V118, P94, DOI 10.1177/146642409811800210; Kellock DJ, 1999, SEX TRANSM INFECT, V75, P36, DOI 10.1136/sti.75.1.36; Redfern N, 1994, Health Care Women Int, V15, P423; SANTER M, 2000, SCREENING WOMEN CHLA; SCHOLES D, 1996, NEW ENGL J MED, V334, P1352; *SIGN, 2000, MAN GEN CHLAM TRACH; Smith JA, 1996, PSYCHOL HEALTH, V11, P261, DOI 10.1080/08870449608400256	14	148	148	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 27	2001	322	7280					195	199		10.1136/bmj.322.7280.195	http://dx.doi.org/10.1136/bmj.322.7280.195			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	398BF	11159612	Green Published, Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000166733700023
J	Isacsson, G; Rich, CL				Isacsson, G; Rich, CL			Regular review - Management of patients who deliberately harm themselves	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MENTAL-DISORDERS; LITHIUM MAINTENANCE; SUICIDAL-BEHAVIOR; MAJOR DEPRESSION; SELF-HARM; SWEDEN; PEOPLE		Karolinska Inst, Huddinge Univ Hosp, Div Psychiat, S-14186 Huddinge, Sweden; Univ S Alabama, Dept Psychiat, Mobile, AL 36617 USA	Karolinska Institutet; University of South Alabama	Isacsson, G (corresponding author), Karolinska Inst, Huddinge Univ Hosp, Div Psychiat, S-14186 Huddinge, Sweden.	Goran.Isacsson@neurotec.ki.se						Akiskal HS, 1999, PSYCHIAT CLIN N AM, V22, P517, DOI 10.1016/S0193-953X(05)70093-9; ALSEN M, 1994, ACTA PSYCHIAT SCAND, V89, P255, DOI 10.1111/j.1600-0447.1994.tb01510.x; [Anonymous], EFF HLTH CARE B; ASBERG M, 1997, SUICIDAL PATIENTS CL; Coppen A, 1998, J AFFECT DISORDERS, V50, P261, DOI 10.1016/S0165-0327(98)00067-6; de Castro EF, 1998, ACTA PSYCHIAT SCAND, V97, P25; Ettlinger R, 1975, Acta Psychiatr Scand Suppl, V260, P1; Foster T, 1997, BRIT J PSYCHIAT, V170, P447, DOI 10.1192/bjp.170.5.447; Hawton K, 1998, BRIT MED J, V317, P441; Isacsson G, 1995, Ann Clin Psychiatry, V7, P113, DOI 10.3109/10401239509149037; Isacsson G, 2000, ACTA PSYCHIAT SCAND, V102, P113, DOI 10.1034/j.1600-0447.2000.102002113.x; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; ISACSSON G, 1992, ACTA PSYCHIAT SCAND, V85, P444, DOI 10.1111/j.1600-0447.1992.tb03209.x; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; MORGAN HG, 1975, BRIT J PSYCHIAT, V127, P564, DOI 10.1192/bjp.127.6.564; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; RUNESON B S, 1992, International Review of Psychiatry, V4, P197, DOI 10.3109/09540269209066317; Suominen K, 1996, ACTA PSYCHIAT SCAND, V94, P234, DOI 10.1111/j.1600-0447.1996.tb09855.x; Suominen KH, 1998, AM J PSYCHIAT, V155, P1778, DOI 10.1176/ajp.155.12.1778; Tondo L, 1997, ANN NY ACAD SCI, V836, P339, DOI 10.1111/j.1749-6632.1997.tb52369.x; Verkes RJ, 1998, AM J PSYCHIAT, V155, P543, DOI 10.1176/ajp.155.4.543; Weiss M., 1999, ADHD ADULTHOOD GUIDE	23	56	58	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2001	322	7280					213	215		10.1136/bmj.322.7280.213	http://dx.doi.org/10.1136/bmj.322.7280.213			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	398BF	11159620	Green Published			2022-12-28	WOS:000166733700029
J	Huang, Y; Duan, XF; Wei, QQ; Lieber, CM				Huang, Y; Duan, XF; Wei, QQ; Lieber, CM			Directed assembly of one-dimensional nanostructures into functional networks	SCIENCE			English	Article							CARBON NANOTUBES; NANOPARTICLES; ORIENTATION; NANOWIRES; CRYSTALS; FIBER; FLOW	One-dimensional nanostructures, such as nanowires and nanotubes, represent the smallest dimension for efficient transport of electrons and excitons and thus are ideal building blocks for hierarchical assembly of functional nanoscale electronic and photonic structures. We report an approach for the hierarchical assembly of one-dimensional nanostructures into well-defined functional networks. We show that nanowires can be assembled into parallel arrays with control of the average separation and, by combining fluidic alignment with surface-patterning techniques, that it is also possible to control periodicity. In addition, complex crossed nanowire arrays can be prepared with layer-by-layer assembly with different flow directions for sequential steps. Transport studies show that the crossed nanowire arrays form electrically conducting networks, with individually addressable device function at each cross point.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	cml@cmliris.harvard.edu	Dee, Chang Fu/G-4842-2010; Huang, Yu/AAZ-9747-2020; Duan, Xiangfeng/E-7522-2011; Duan, Xiangfeng/AAQ-9674-2020	Dee, Chang Fu/0000-0003-1015-9181; Huang, Yu/0000-0003-1793-0741; Duan, Xiangfeng/0000-0002-4321-6288; Duan, Xiangfeng/0000-0002-4321-6288				Boal AK, 2000, NATURE, V404, P746, DOI 10.1038/35008037; Burghard M, 1998, ADV MATER, V10, P584, DOI 10.1002/(SICI)1521-4095(199805)10:8<584::AID-ADMA584>3.0.CO;2-9; Collier CP, 1998, ANNU REV PHYS CHEM, V49, P371, DOI 10.1146/annurev.physchem.49.1.371; Cui Y, 2000, J PHYS CHEM B, V104, P5213, DOI 10.1021/jp0009305; De Rosa C, 2000, MACROMOLECULES, V33, P4871, DOI 10.1021/ma992132m; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Duan XF, 2000, ADV MATER, V12, P298, DOI 10.1002/(SICI)1521-4095(200002)12:4<298::AID-ADMA298>3.0.CO;2-Y; Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; FUHER MS, 2000, SCIENCE, V288, P494; Gleiche M, 2000, NATURE, V403, P173, DOI 10.1038/35003149; GUDIKSEN MS, UNPUB; Hayward RC, 2000, NATURE, V404, P56, DOI 10.1038/35003530; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; Hu JT, 1999, ACCOUNTS CHEM RES, V32, P435, DOI 10.1021/ar9700365; HUANG YN, UNPUB; KOCH DL, 1990, PHYS FLUIDS A-FLUID, V2, P2093, DOI 10.1063/1.857795; Li M, 1999, NATURE, V402, P393, DOI 10.1038/46509; Liu J, 1999, CHEM PHYS LETT, V303, P125, DOI 10.1016/S0009-2614(99)00209-2; Mirkin CA, 2000, INORG CHEM, V39, P2258, DOI 10.1021/ic991123r; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Noda S, 2000, SCIENCE, V289, P604, DOI 10.1126/science.289.5479.604; Rueckes T, 2000, SCIENCE, V289, P94, DOI 10.1126/science.289.5476.94; Smith PA, 2000, APPL PHYS LETT, V77, P1399, DOI 10.1063/1.1290272; STOVER CA, 1992, J FLUID MECH, V238, P277, DOI 10.1017/S002211209200171X; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954	26	1915	2093	6	886	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2001	291	5504					630	633		10.1126/science.291.5504.630	http://dx.doi.org/10.1126/science.291.5504.630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158671				2022-12-28	WOS:000166616000037
J	Ruland, J; Duncan, GS; Elia, A; Barrantes, ID; Nguyen, L; Plyte, S; Millar, DG; Bouchard, D; Wakeham, A; Ohashi, PS; Mak, TW				Ruland, J; Duncan, GS; Elia, A; Barrantes, ID; Nguyen, L; Plyte, S; Millar, DG; Bouchard, D; Wakeham, A; Ohashi, PS; Mak, TW			Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappa B and neural tube closure	CELL			English	Article							CASPASE RECRUITMENT DOMAIN; T-CELL; LYMPHOCYTE-PROLIFERATION; DEFICIENT LYMPHOCYTES; TRANSCRIPTION FACTOR; CONTAINING PROTEIN; DEATH RECEPTORS; MICE LACKING; IN-VIVO; APOPTOSIS	Bcl10, a CARD-containing protein identified from the t(1;14)(p22;q32) breakpoint in MALT lymphomas, has been shown to induce apoptosis and activate NF-kappaB in vitro. We show that one-third of bcl10(-/-) embryos developed exencephaly, leading to embryonic lethality. Surprisingly, bcl10(-/-) cells retained susceptibility to various apoptotic stimuli in vivo and in vitro. However, surviving bcl10(-/-) mice were severely immunodeficient and bcl10(-/-) lymphocytes are defective in antigen receptor or PMA/lonomycin-induced activation. Early tyrosine phosphorylation, MAPK and AP-1 activation, and Ca2+ signaling were normal in mutant lymphocytes, but antigen receptor-induced NF-kappaB activation was absent. Thus, Bcl10 functions as a positive regulator of lymphocyte proliferation that specifically connects antigen receptor signaling in B and T cells to NF-kappaB activation.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Mak, TW (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Duncan, Gordon/AIE-7011-2022; Ruland, Jurgen/Q-6680-2018	Ruland, Jurgen/0000-0002-8381-3597; Millar, Douglas/0000-0002-8640-7148; Ohashi, Pamela S./0000-0003-2915-9317				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Dienz O, 2000, J BIOL CHEM, V275, P24547, DOI 10.1074/jbc.C000177200; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Du MQ, 2000, BLOOD, V95, P3885; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; GRATZNER HG, 1981, CYTOMETRY, V1, P385, DOI 10.1002/cyto.990010606; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Juriloff DM, 2000, HUM MOL GENET, V9, P993, DOI 10.1093/hmg/9.6.993; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 1997, P NATL ACAD SCI USA, V94, P3914, DOI 10.1073/pnas.94.8.3914; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li QT, 2000, GENE DEV, V14, P1729; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Oxenius A, 1998, IMMUNITY, V9, P449, DOI 10.1016/S1074-7613(00)80628-7; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; ROOST HP, 1990, EUR J IMMUNOL, V20, P2547, DOI 10.1002/eji.1830201204; Rudolph D, 2000, GENE DEV, V14, P854; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SMITH BH, 1989, J INSECT BEHAV, V2, P397, DOI 10.1007/BF01068064; Spencer J, 1999, GUT, V44, P778, DOI 10.1136/gut.44.6.778; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zucca E, 2000, BLOOD, V96, P410	39	453	474	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2001	104	1					33	42		10.1016/S0092-8674(01)00189-1	http://dx.doi.org/10.1016/S0092-8674(01)00189-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163238	Bronze			2022-12-28	WOS:000166882300005
J	Beckingham, IJ; Ryder, SD				Beckingham, IJ; Ryder, SD			ABC of diseases of liver, pancreas, and biliary system - Investigation of liver and biliary disease	BRITISH MEDICAL JOURNAL			English	Review									Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England	University of Nottingham	Beckingham, IJ (corresponding author), Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England.			Ryder, Stephen David/0000-0001-9649-4444					0	19	21	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					33	36		10.1136/bmj.322.7277.33	http://dx.doi.org/10.1136/bmj.322.7277.33			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141153	Green Published, Green Submitted			2022-12-28	WOS:000166341400024
J	Harrington, J; Palethorpe, S; Watson, CI				Harrington, J; Palethorpe, S; Watson, CI			Does the Queen speak the Queen's English? Elizabeth II's traditional pronunciation has been influenced by modern trends.	NATURE			English	Article									Macquarie Univ, Macquarie Ctr Cognit Sci, Sydney, NSW 2109, Australia; Macquarie Univ, Speech Hearing & Language Res Ctr, Sydney, NSW 2109, Australia	Macquarie University; Macquarie University	Harrington, J (corresponding author), Macquarie Univ, Macquarie Ctr Cognit Sci, Sydney, NSW 2109, Australia.	jmh@shlrc.mq.edu.au		Palethorpe, Sallyanne/0000-0002-2351-5539; Watson, Catherine/0000-0001-9010-5188				Abercrombie David, 1963, PROBLEMS PRINCIPLES; Aitchison Jean, 1991, LANGUAGE CHANGE PROG, V2nd; Cannadine D., 1998, CLASS BRITAIN; Detering H, 1997, SKANDINAVISTIK, V27, P55; Gimson Alfred Charles, 1994, GIMSONS PRONUNCIATIO; Honey J., 1997, LANGUAGE IS POWER; Johnson K., 1997, ACOUSTIC AUDITORY PH; Labov W., 1994, LANGUAGE; Ladefoged P., 1967, 3 AREAS EXPT PHONETI; ROACH P, 1994, J INT PHONET ASS, V23, P47; Wells JC, 1982, ACCENTS OF ENGLISH; Wells John., 1994, NONSTANDARD VARIETIE, P198	12	102	102	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					927	928		10.1038/35050160	http://dx.doi.org/10.1038/35050160			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140668				2022-12-28	WOS:000165951100034
J	Rubenstein, L; Amato, Z				Rubenstein, L; Amato, Z			The Turkish government's crackdown on freedom of expression	LANCET			English	Editorial Material									Dokuz Eylul Med Fac, Publ Hlth Div, TR-35340 Izmir, Turkey	Dokuz Eylul University	Rubenstein, L (corresponding author), Dokuz Eylul Med Fac, Publ Hlth Div, TR-35340 Izmir, Turkey.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2094	2094		10.1016/S0140-6736(00)03416-4	http://dx.doi.org/10.1016/S0140-6736(00)03416-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	385GB	11145510				2022-12-28	WOS:000165994300038
J	Gee, JS; Cande, SC; Hildebrand, JA; Donnelly, K; Parker, RL				Gee, JS; Cande, SC; Hildebrand, JA; Donnelly, K; Parker, RL			Geomagnetic intensity variations over the past 780 kyr obtained from near-seafloor magnetic anomalies	NATURE			English	Article							EAST PACIFIC RISE; SUBMARINE BASALTIC GLASS; CRUSTAL EMPLACEMENT PROCESSES; LAYER 2A THICKNESS; LASCHAMP EXCURSION; MIDOCEAN RIDGE; FIELD; PALEOINTENSITY; CONSTRAINTS; LAVAS	Knowledge of past variations in the intensity of the Earth's magnetic field provides an important constraint on models of the geodynamo. A record of absolute palaeointensity for the past 50 kyr has been compiled from archaeomagnetic and volcanic materials, and relative palaeointensities over the past 800 kyr have been obtained from sedimentary sequences. But a long-term record of geomagnetic intensity should also be carried by the thermoremanence of the oceanic crust. Here we show that near-seafloor magnetic anomalies recorded over the southern East Pacific Rise are well correlated with independent estimates of geomagnetic intensity during the past 780 kyr. Moreover, the pattern of absolute palaeointensity of seafloor glass samples from the same area agrees with the well-documented dipole intensity pattern for the past 50 kyr. A comparison of palaeointensities derived from seafloor glass samples with global intensity variations thus allows us to estimate the ages of surficial lava flows in this region. The record of geomagnetic intensity preserved in the oceanic crust should provide a higher-time-resolution record of crustal accretion processes at mid-ocean ridges than has previously been obtainable.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Lamont Doherty Earth Observ, Palisades, NY 10964 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Columbia University	Gee, JS (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.			Hildebrand, John/0000-0002-5418-9799; Gee, Jeffrey/0000-0002-9543-7744				BLAKELY RJ, 1974, J GEOPHYS RES, V79, P2979, DOI 10.1029/JB079i020p02979; BLOXHAM J, 1992, J GEOPHYS RES-SOL EA, V97, P19537, DOI 10.1029/92JB01591; CANDE SC, 1992, J GEOPHYS RES-SOL EA, V97, P13917, DOI 10.1029/92JB01202; CANDE SC, 1992, J GEOPHYS RES-SOL EA, V97, P15075, DOI 10.1029/92JB01090; CANDE SC, 1995, EOS, V76, pF169; Carbotte SM, 1997, J GEOPHYS RES-SOL EA, V102, P10165, DOI 10.1029/96JB03910; CHAUVIN A, 1989, GEOPHYS RES LETT, V16, P1189, DOI 10.1029/GL016i010p01189; CHRISTESON GL, 1994, J GEOPHYS RES-SOL EA, V99, P17957, DOI 10.1029/94JB01252; COE RS, 1978, J GEOPHYS RES, V83, P1740, DOI 10.1029/JB083iB04p01740; GEE J, 1994, GEOPHYS RES LETT, V21, P297, DOI 10.1029/93GL03422; Gee J, 1997, J GEOPHYS RES-SOL EA, V102, P24873, DOI 10.1029/97JB02544; Gee J, 1996, EARTH PLANET SC LETT, V144, P327, DOI 10.1016/S0012-821X(96)00184-7; Guyodo Y, 1999, NATURE, V399, P249, DOI 10.1038/20420; HARDING AJ, 1993, J GEOPHYS RES-SOL EA, V98, P13925, DOI 10.1029/93JB00886; Hooft EEE, 1996, EARTH PLANET SC LETT, V142, P289, DOI 10.1016/0012-821X(96)00101-X; Hooft EEE, 1997, J GEOPHYS RES-SOL EA, V102, P27319, DOI 10.1029/97JB02349; Juarez MT, 1998, NATURE, V394, P878, DOI 10.1038/29746; Kent DV, 1996, GEOLOGY, V24, P703, DOI 10.1130/0091-7613(1996)024<0703:MAOZAO>2.3.CO;2; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; KLITGORD KD, 1976, EARTH PLANET SC LETT, V29, P201, DOI 10.1016/0012-821X(76)90040-6; Laj C, 1997, PHYS EARTH PLANET IN, V99, P161, DOI 10.1016/S0031-9201(96)03221-9; LEVI S, 1990, EARTH PLANET SC LETT, V96, P443, DOI 10.1016/0012-821X(90)90019-T; Lonsdale P., 1977, Marine Geophysical Researches, V3, P251, DOI 10.1007/BF00285656; LUYENDYK BP, 1969, J GEOPHYS RES, V74, P4869, DOI 10.1029/JB074i020p04869; Mejia V, 1996, GEOPHYS RES LETT, V23, P475, DOI 10.1029/96GL00018; MERRILL RT, 1995, J GEOPHYS RES-SOL EA, V100, P317, DOI 10.1029/94JB02361; MERRILL RT, 1996, MAGNETIC FIELD EARTH, P128; Perfit MR, 1998, GEOPH MONOG SERIES, V106, P59; PERFIT MR, 1994, GEOLOGY, V22, P375, DOI 10.1130/0091-7613(1994)022<0375:SSSATV>2.3.CO;2; PICK T, 1993, NATURE, V366, P238, DOI 10.1038/366238a0; PICK T, 1994, GEOPHYS J INT, V119, P116, DOI 10.1111/j.1365-246X.1994.tb00917.x; SCHOUTEN H, 1976, GEOPHYS J ROY ASTR S, V44, P567, DOI 10.1111/j.1365-246X.1976.tb00293.x; Schouten H, 1999, EARTH PLANET SC LETT, V169, P37, DOI 10.1016/S0012-821X(99)00063-1; TAUXE L, 1993, REV GEOPHYS, V31, P319, DOI 10.1029/93RG01771; TRIC E, 1994, PHYS EARTH PLANET IN, V85, P113, DOI 10.1016/0031-9201(94)90011-6; White SM, 1998, J GEOPHYS RES-SOL EA, V103, P30371, DOI 10.1029/98JB02791; Zhou WM, 1999, GEOLOGY, V27, P1043, DOI 10.1130/0091-7613(1999)027<1043:POPTIO>2.3.CO;2; Zhou WM, 2000, EARTH PLANET SC LETT, V179, P9, DOI 10.1016/S0012-821X(00)00100-X	38	79	81	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					827	832		10.1038/35048513	http://dx.doi.org/10.1038/35048513			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130715				2022-12-28	WOS:000165831300041
J	He, J; Whelton, PK				He, J; Whelton, PK			Selection of initial antihypertensive drug therapy	LANCET			English	Editorial Material							HYPERTENSION		Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Tulane University; Tulane University	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA 70118 USA.							Alderman M, 1997, J HYPERTENS, V15, P105; Black HR, 1997, ARCH INTERN MED, V157, P2413; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Whelton PK, 1999, CLIN TRIALS CARDIOVA; Yusuf S, 2000, NEW ENGL J MED, V342, P145	7	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1942	1943		10.1016/S0140-6736(00)03300-6	http://dx.doi.org/10.1016/S0140-6736(00)03300-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130516				2022-12-28	WOS:000165867600002
J	Kashyap, AS; Kumar, V				Kashyap, AS; Kumar, V			Shout stature and rickets	LANCET			English	Article									Armed Forces Med Coll, Dept Med, Pune 411040, Maharashtra, India	Armed Forces Medical College	Kashyap, AS (corresponding author), Armed Forces Med Coll, Dept Med, Pune 411040, Maharashtra, India.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1894	1894		10.1016/S0140-6736(00)03261-X	http://dx.doi.org/10.1016/S0140-6736(00)03261-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130386				2022-12-28	WOS:000165665400013
J	Koster, R; Vieluf, D; Kiehn, M; Sommerauer, M; Kahler, J; Baldus, S; Meinertz, T; Hamm, CW				Koster, R; Vieluf, D; Kiehn, M; Sommerauer, M; Kahler, J; Baldus, S; Meinertz, T; Hamm, CW			Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis	LANCET			English	Article							METALS	Background Coronary in-stent restenosis might be triggered by contact allergy to nickel, chromate, or molybdenum ions released from stainless-steel stents. We investigated the association between allergic reactions to stent components and the occurrence of in-stent restenosis. Methods Patients with coronary stainless-steel stents who underwent angiography for suspected restenosis were consecutively included in this study. Quantitative coronary angiography for analysis of percentage diameter stenosis was done on 131 patients (mean age 62 years [SD 9]) with 171 stents 6.1 months (2.7) after stent implantation. All patients underwent epicutaneous patch tests (Finn chamber method) for nickel, chromate, molybdenum, manganese, and small 316L stainless-steel plates. Patch tests were assessed by independent dermatologists after 48 h, 72 h, and when necessary 96 h of contact with the potential allergen. Findings In-stent restenosis (greater than or equal to 50% diameter stenosis) occurred in 89 patients. All ten patients with positive patch-test results had restenoses (p=0.03). Four male patients had positive reactions to molybdenum, and seven patients (four male, three female) had reactions to nickel. No patient with an allergic reaction to the standard test substances had a positive reaction to the stainless-steel plates. All patients with positive results had recurrent angina pectoris and needed target-vessel revascularisation. Interpretation Patients with allergic patch-test reactions to nickel and molybdenum had a higher frequency of in-stent restenoses than patients without hypersensitivity. Allergic reactions to nickel and molybdenum released from stents may be one of the triggering mechanisms for in-stent restenosis.	Univ Hamburg, Hosp Eppendorf, Med Clin, Dept Cardiol, D-20249 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Med Clin, Dept Dermatol, D-20249 Hamburg, Germany	University of Hamburg; University of Hamburg	Koster, R (corresponding author), Univ Hamburg, Hosp Eppendorf, Med Clin, Dept Cardiol, Martinistr 52, D-20249 Hamburg, Germany.		Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161				Beythien C., 1998, EUR HEART J SUPPL, V19, P1947; Farb A, 1999, CIRCULATION, V99, P44, DOI 10.1161/01.CIR.99.1.44; Fregert S., 1981, MANUAL CONTACT DERMA, V2nd ed.; Gotman I, 1997, J ENDOUROL, V11, P383, DOI 10.1089/end.1997.11.383; KANERVA L, 1994, CONTACT DERMATITIS, V31, P299, DOI 10.1111/j.1600-0536.1994.tb02023.x; Kornowski R, 1998, J AM COLL CARDIOL, V31, P224, DOI 10.1016/S0735-1097(97)00450-6; Koster R, 1997, AM J CARDIOL, V80, P1424, DOI 10.1016/S0002-9149(97)00703-0; LYELL A, 1978, LANCET, V2, P657; Mintz GS, 1998, AM J CARDIOL, V81, p7E, DOI 10.1016/S0002-9149(98)00190-8; PELTONEN L, 1979, CONTACT DERMATITIS, V5, P27, DOI 10.1111/j.1600-0536.1979.tb05531.x; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; San Martin M., 1997, Allergy (Copenhagen), V52, P690, DOI 10.1111/j.1398-9995.1997.tb01064.x; SCHUBERT H, 1988, CONTACT DERMATITIS, V18, P237, DOI 10.1111/j.1600-0536.1988.tb02811.x; WILLIAMS DF, 1987, J MATER SCI, V22, P3421, DOI 10.1007/BF01161439; WILLIAMS DF, 1981, FUNDAMENTAL ASPECTS, V1, P127	15	374	399	2	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1895	1897		10.1016/S0140-6736(00)03262-1	http://dx.doi.org/10.1016/S0140-6736(00)03262-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130387				2022-12-28	WOS:000165665400014
J	Kubba, A; Guillebaud, J; Anderson, RA; MacGregor, EA				Kubba, A; Guillebaud, J; Anderson, RA; MacGregor, EA			Contraception	LANCET			English	Review							ORAL-CONTRACEPTIVES; MYOCARDIAL-INFARCTION; ETHINYL ESTRADIOL; BONE-DENSITY; MEDROXYPROGESTERONE ACETATE; INTRAUTERINE SYSTEM; MU-G; LEVONORGESTREL; WOMEN; RISK	The supremacy of combined oral contraceptives (OCs) is being challenged. For too long combined OCs have been seen as synonymous with contraception, helping to maintain ignorance of alternative methods. Further, the efficacy of these OCs and condoms is often compromised by incorrect or inconsistent use. We particularly welcome developments in male systemic methods, that allow men to share not only in conception but also in contraception, and methods that are completely forgettable once instituted, especially if usable by adolescents.	UCL, Margaret Pyke Ctr, Dept Obstet & Gynaecol, London W1P 1LB, England; Guys St Thomas Hosp, Dept Obstet & Gynaecol, GKT Sch Med, London, England; Univ Edinburgh, Ctr Reprod Biol, MRC, Reprod Biol Unit, Edinburgh EH3 9EW, Midlothian, Scotland; Margaret Pyke Mem Trust, London, England	University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Edinburgh	Guillebaud, J (corresponding author), UCL, Margaret Pyke Ctr, Dept Obstet & Gynaecol, London W1P 1LB, England.	j.guillebaud@lineone.net		MacGregor, E Anne/0000-0002-4116-9828				Adachi JD, 1997, BRIT J OBSTET GYNAEC, V104, P64, DOI 10.1111/j.1471-0528.1997.tb10651.x; Anderson RA, 1999, J CLIN ENDOCR METAB, V84, P3556, DOI 10.1210/jc.84.10.3556; ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0; Aribarg A, 1996, FERTIL STERIL, V65, P821; Backman T, 2000, BRIT J OBSTET GYNAEC, V107, P335, DOI 10.1111/j.1471-0528.2000.tb13228.x; BAGSHAW SN, 1988, AUST NZ J OBSTET GYN, V28, P137, DOI 10.1111/j.1479-828X.1988.tb01643.x; BAIRD DT, 1993, CLIN APPL MIFEPRISTO, P148; Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96; BOUNDS W, 1993, EUR J OBSTET GYN R B, V48, P123, DOI 10.1016/0028-2243(93)90252-8; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; *COLL STUD CARD DI, 1998, CONTRACEPTION, V57, P315; CUNDY T, 1991, BRIT MED J, V303, P13, DOI 10.1136/bmj.303.6793.13; DIAZ S, 1999, INT PLANNED PARENTHO, V33, P3; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; EDWARDS J, 1999, BR J FARM PLANN, V24, pS1; GARDNER R, 1999, POPULATION REPORTS H, P1; Gbolade B, 1998, BRIT J OBSTET GYNAEC, V105, P790, DOI 10.1111/j.1471-0528.1998.tb10211.x; Glasier AF, 2000, HUM REPROD, V15, P646, DOI 10.1093/humrep/15.3.646; Grimes D, 1998, LANCET, V352, P428; GUILLEBAUD J, 1995, BRIT MED J, V311, P1111, DOI 10.1136/bmj.311.7013.1111; Heinemann L A, 1999, Eur J Contracept Reprod Health Care, V4, P67, DOI 10.3109/13625189909064007; Jernstrom H, 1999, LANCET, V354, P1846, DOI 10.1016/S0140-6736(99)04336-6; JUNGHOFFMANN C, 1990, AM J OBSTET GYNECOL, V163, P2183, DOI 10.1016/0002-9378(90)90560-T; Kasprzak L, 1999, BMJ-BRIT MED J, V318, P786, DOI 10.1136/bmj.318.7186.786; KAUPPINENMAKELIN R, 1992, CLIN ENDOCRINOL, V36, P203, DOI 10.1111/j.1365-2265.1992.tb00959.x; KINNIBURGH D, 2000, INT J OBSTET GYNAECO, V70; Lahteenmaki P, 1998, BMJ-BRIT MED J, V316, P1122, DOI 10.1136/bmj.316.7138.1122; LANDE R, 1995, POP REP SER K, P1; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Martin CW, 2000, HUM REPROD, V15, P637, DOI 10.1093/humrep/15.3.637; Meriggiola MC, 1997, J ANDROL, V18, P240; Michaelsson K, 1999, LANCET, V353, P1481, DOI 10.1016/S0140-6736(98)09044-8; MUHN P, 1995, CONTRACEPTION, V51, P99, DOI 10.1016/0010-7824(94)00015-O; MULLER N, 1998, INT PLANNED PARENTHO, V32, P1; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; NIESCHLAG E, 1998, TESTOSTERONE ACTION, P513; O'Brien P, 1999, BRIT MED J, V319, P1199, DOI 10.1136/bmj.319.7218.1199; Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0; Petitti DB, 2000, OBSTET GYNECOL, V95, P736, DOI 10.1016/S0029-7844(00)00782-1; Piaggio G, 1999, LANCET, V353, P721, DOI 10.1016/S0140-6736(98)05718-3; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; Rice CF, 1999, HUM REPROD, V14, P982, DOI 10.1093/humrep/14.4.982; Rowe PJ, 1997, CONTRACEPTION, V56, P341; Royal College of Obstetricians and Gynaecologists, 1999, MAL FEM STER EV BAS, V4; SCHWARTZ JL, 1999, CONTRACEPTION OFFICE, P113; Sturridge F, 1997, BRIT J OBSTET GYNAEC, V104, P285, DOI 10.1111/j.1471-0528.1997.tb11455.x; Sullivan H, 1999, FERTIL STERIL, V72, P115, DOI 10.1016/S0015-0282(99)00205-8; Thomas SL, 2000, LANCET, V355, P922, DOI 10.1016/S0140-6736(99)11159-0; Trussell J, 1999, CONTRACEPTION, V59, P147, DOI 10.1016/S0010-7824(99)00018-9; TRUSSELL J, 1998, CONTRACEPTIVE TECHNO, P779; UN International Conference on Population and Development, 1994, PROGR ACT; Van Look PFA, 1999, FERTIL STERIL, V72, P431; Walker AM, 1998, CONTRACEPTION, V57, P169, DOI 10.1016/S0010-7824(98)00014-6; Wildemeersch D, 1999, BRIT J FAM PLAN, V24, P149; YUZPE AA, 1982, FERTIL STERIL, V37, P508; Zimmermann T, 1999, EUR J CONTRACEP REPR, V4, P155, DOI 10.3109/13625189909040810	56	19	24	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	2000	356	9245					1913	1919		10.1016/S0140-6736(00)03269-4	http://dx.doi.org/10.1016/S0140-6736(00)03269-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130398				2022-12-28	WOS:000165665400037
J	Hammel, P; Couvelard, A; O'Toole, D; Ratouis, A; Sauvanet, A; Flejou, JF; Degott, C; Belghiti, J; Bernades, P; Valla, D; Ruszniewski, P; Levy, P				Hammel, P; Couvelard, A; O'Toole, D; Ratouis, A; Sauvanet, A; Flejou, JF; Degott, C; Belghiti, J; Bernades, P; Valla, D; Ruszniewski, P; Levy, P			Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC-ALCOHOLIC PANCREATITIS; MEDICAL-SURGICAL SERIES; CIRRHOSIS; RAT; PROGRESSION; MODEL	Background: Chronic obstruction of the common bile duct may cause hepatic fibrosis and secondary biliary cirrhosis. Methods: We studied liver-biopsy specimens from 11 patients with chronic stenosis of the common bile duct due to chronic pancreatitis; all the patients had undergone liver biopsy before or at the time of surgical biliary decompression and underwent a subsequent liver biopsy for various clinical reasons. The patients were followed as part of a prospective study of 501 patients who had been treated for chronic pancreatitis. Two pathologists, who were unaware of the sequence of specimens, graded fibrosis on a scale of 0 (none) to 3 (cirrhosis). Results: The 11 patients were all men. Chronic pancreatitis was due to alcohol abuse in 10 of the men; 1 had idiopathic disease. The median age at diagnosis was 38 years. The median interval between the first and second liver biopsies was 2.5 years (range, 0.3 to 9.0). The two patients who had restenosis of the biliary anastomosis were excluded from the analysis of fibrosis. In the group of nine patients without restenosis, the second specimen showed significant improvement in fibrosis (P = 0.01). The fibrosis improved by two grades in two patients and by one grade in four patients; in three patients, the grade did not change. The pathologists agreed on the grading of specimens from 10 of the 11 patients. Conclusions: In patients with chronic pancreatitis and stenosis of the common bile duct, liver fibrosis may regress after biliary drainage. (N Engl J Med 2001;344:418-23.) Copyright (C) 2001 Massachusetts Medical Society.	Hop Beaujon, AP HP, Serv Gastroenterol, F-92118 Clichy, France; Hop Beaujon, Serv Anat Pathol, F-92118 Clichy, France; Hop Beaujon, Serv Chirurg Digest, F-92118 Clichy, France; Hop Beaujon, Serv Hepatol, F-92118 Clichy, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Ruszniewski, P (corresponding author), Hop Beaujon, AP HP, Serv Gastroenterol, F-92118 Clichy, France.			Anne, Couvelard/0000-0002-6316-1210; Valla, Dominique/0000-0002-4460-7643; SAUVANET, alain/0000-0002-7436-5999; Hammel, Pascal/0000-0002-4630-4996; O'Toole, Dermot/0000-0001-6404-991X				ADSON MA, 1968, ARCH SURG-CHICAGO, V96, P604; AFROUDAKIS A, 1981, HEPATOLOGY, V1, P65, DOI 10.1002/hep.1840010111; AXON ATR, 1984, GUT, V25, P1107, DOI 10.1136/gut.25.10.1107; BARTHET M, 1994, ENDOSCOPY, V26, P569, DOI 10.1055/s-2007-1009041; BERNADES P, 1983, GASTROEN CLIN BIOL, V7, P8; BUNTON GL, 1963, ANN NY ACAD SCI, V111, P412, DOI 10.1111/j.1749-6632.1963.tb36981.x; Degott C, 1999, HEPATOLOGY, V29, P1007, DOI 10.1002/hep.510290444; DEVIERE J, 1994, GUT, V35, P122, DOI 10.1136/gut.35.1.122; FRANCO D, 1979, ARCH SURG-CHICAGO, V114, P1064; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GROSS JB, 1987, HEPATOLOGY, V7, P457, DOI 10.1002/hep.1840070308; Hollander M., 1973, NONPARAMETRIC STAT M; Kaplan MM, 1997, ANN INTERN MED, V126, P682, DOI 10.7326/0003-4819-126-9-199705010-00002; KONTOURAS J, 1984, BR J EXP PATHOL, V65, P305; LESUR G, 1993, HEPATOLOGY, V18, P1078; LEVY P, 1989, GASTROENTEROLOGY, V96, P1165, DOI 10.1016/0016-5085(89)91637-5; LEVY P, 1993, PANCREAS, V8, P563, DOI 10.1097/00006676-199309000-00006; Lieber CS, 1999, ALCOHOL CLIN EXP RES, V23, P944, DOI 10.1111/j.1530-0277.1999.tb04209.x; POSNER MC, 1990, J SURG RES, V48, P204, DOI 10.1016/0022-4804(90)90214-M; POUPON RE, 1991, NEW ENGL J MED, V324, P1548, DOI 10.1056/NEJM199105303242204; SCOBIE BA, 1965, AM J DIG DIS, V10, P135, DOI 10.1007/BF02236664; Sobesky R, 1999, GASTROENTEROLOGY, V116, P378, DOI 10.1016/S0016-5085(99)70135-6; WAY LW, 1981, SURG CLIN N AM, V61, P963; ZIMMERMANN H, 1992, GASTROENTEROLOGY, V103, P579, DOI 10.1016/0016-5085(92)90850-X	24	308	321	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	2001	344	6					418	423		10.1056/NEJM200102083440604	http://dx.doi.org/10.1056/NEJM200102083440604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399FH	11172178	Bronze			2022-12-28	WOS:000166800600004
J	Ryder, SD; Beckingham, IJ				Ryder, SD; Beckingham, IJ			ABC of disease of liver, pancreas, and biliary system - Other causes of parenchymal liver disease	BRITISH MEDICAL JOURNAL			English	Article									Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England	University of Nottingham	Ryder, SD (corresponding author), Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England.			Ryder, Stephen David/0000-0001-9649-4444					0	19	20	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	2001	322	7281					290	292		10.1136/bmj.322.7281.290	http://dx.doi.org/10.1136/bmj.322.7281.290			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157536	Green Published			2022-12-28	WOS:000166917600038
J	Prigozy, TI; Naidenko, O; Qasba, P; Elewaut, D; Brossay, L; Khurana, A; Natori, T; Koezuka, Y; Kulkarni, A; Kronenberg, M				Prigozy, TI; Naidenko, O; Qasba, P; Elewaut, D; Brossay, L; Khurana, A; Natori, T; Koezuka, Y; Kulkarni, A; Kronenberg, M			Glycolipid antigen processing for presentation by CD1d molecules	SCIENCE			English	Article							ALPHA-GALACTOSIDASE; T-CELLS; MOUSE; GLYCOSIDASES; RECOGNITION; SPECIFICITY; DEGRADATION; REACTIVITY	The requirement for processing glycolipid antigens in T cell recognition was examined with mouse CD1d-mediated responses to glycosphingolipids (GSLs). Although some disaccharide GSL antigens can be recognized without processing, the responses to three other antigens, including the disaccharide GSL Gal(alpha1-->2)GalCer (Gal, galactose; GalCer, galactosylceramide), required removal of the terminal sugars to permit interaction with the T cell receptor. A Lysosomal enzyme, alpha -galactosidase A, was responsible for the processing of Gal(alpha1-->2)GalCer to generate the antigenic monosaccharide epitope. These data demonstrate a carbohydrate antigen processing system analogous to that used for peptides and an ability of T cells to recognize processed fragments of complex glycolipids.	La Jolla Inst Allergy & Immunol, Div Dev Immunol, San Diego, CA 92121 USA; NINCDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma 37012, Japan; Natl Inst Dent & Craniofacial Res, Funct Genom Unit, Bethesda, MD 20892 USA	La Jolla Institute for Immunology; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Kirin Brewery Company Limited; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Kronenberg, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Dev Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	mitch@liai.org	Elewaut, Dirk/K-6831-2014	Brossay, Laurent/0000-0002-7497-8488	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040617] Funding Source: NIH RePORTER; NCI NIH HHS [CA52511] Funding Source: Medline; NIAID NIH HHS [AI40617] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASANO N, 1994, J MED CHEM, V37, P3701, DOI 10.1021/jm00048a006; Asano N, 1997, EUR J BIOCHEM, V248, P296, DOI 10.1111/j.1432-1033.1997.00296.x; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; Briken V, 2000, J EXP MED, V192, P281, DOI 10.1084/jem.192.2.281; Brossay L, 1998, J IMMUNOL, V160, P3681; Burdin N, 1998, J IMMUNOL, V161, P3271; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Harada M, 1997, LIVER, V17, P244; Jackman RM, 1998, IMMUNITY, V8, P341, DOI 10.1016/S1074-7613(00)80539-7; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; LUSIS AJ, 1976, BIOCHIM BIOPHYS ACTA, V437, P487, DOI 10.1016/0304-4165(76)90017-9; Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069; NATORI T, 1994, TETRAHEDRON, V50, P2771, DOI 10.1016/S0040-4020(01)86991-X; Ohshima T, 1997, P NATL ACAD SCI USA, V94, P2540, DOI 10.1073/pnas.94.6.2540; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Shamshiev A, 2000, IMMUNITY, V13, P255, DOI 10.1016/S1074-7613(00)00025-X; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Villadangos JA, 2000, IMMUNITY, V12, P233, DOI 10.1016/S1074-7613(00)80176-4; YAGI F, 1990, ARCH BIOCHEM BIOPHYS, V280, P61, DOI 10.1016/0003-9861(90)90518-4	23	253	266	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2001	291	5504					664	667		10.1126/science.291.5504.664	http://dx.doi.org/10.1126/science.291.5504.664			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158680				2022-12-28	WOS:000166616000047
J	Kakkis, ED; Muenzer, J; Tiller, GE; Waber, L; Belmont, J; Passage, M; Izykowski, B; Phillips, J; Doroshow, R; Walot, I; Hoft, R; Yu, KT; Okazaki, S; Lewis, D; Lachman, R; Thompson, JN				Kakkis, ED; Muenzer, J; Tiller, GE; Waber, L; Belmont, J; Passage, M; Izykowski, B; Phillips, J; Doroshow, R; Walot, I; Hoft, R; Yu, KT; Okazaki, S; Lewis, D; Lachman, R; Thompson, JN			Enzyme-replacement therapy in mucopolysaccharidosis I.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-L-IDURONIDASE; BONE-MARROW-TRANSPLANTATION; HURLER-SYNDROME; LYSOSOMAL-ENZYME; CANINE MODEL; LONG-TERM; RECOGNITION; DEFICIENCY	Background: Mucopolysaccharidosis I is a lysosomal storage disease caused by a deficiency of the enzyme (alpha)-L-iduronidase. We evaluated the effect of enzyme-replacement therapy with recombinant human (alpha)-L-iduronidase in patients with this disorder. Methods: We treated 10 patients with mucopolysaccharidosis I (age, 5 to 22 years) with recombinant human (alpha)-L-iduronidase at a dose of 125,000 U per kilogram of body weight given intravenously once weekly for 52 weeks. The patients were evaluated at base line and at 6, 12, 26, and 52 weeks by detailed clinical examinations, magnetic resonance imaging of the abdomen and brain, echocardiography, range-of-motion measurements, polysomnography, clinical laboratory evaluations, measurements of leukocyte (alpha)-L-iduronidase activity, and urinary glycosaminoglycan excretion. Results: Hepatosplenomegaly decreased significantly in all patients, and the size of the liver was normal for body weight and age in eight patients by 26 weeks. The rate of growth in height and weight had increased by a mean of 85 and 131 percent, respectively, at 52 weeks in the six prepubertal patients. The mean maximal range of motion of shoulder flexion and elbow extension increased significantly. The number of episodes of apnea and hypopnea during sleep decreased 61 percent. New York Heart Association functional class improved by one or two classes in all patients. Urinary glycosaminoglycan excretion decreased after three to four weeks of treatment; the mean reduction at 52 weeks was 63 percent of base-line values. Five patients had transient urticaria during infusions. Serum antibodies to (alpha)-L-iduronidase were detected in four patients. Conclusions: In patients with mucopolysaccharidosis I, treatment with recombinant human (alpha)-L-iduronidase reduces lysosomal storage in the liver and ameliorates some clinical manifestations of the disease. (N Engl J Med 2001;344:182-8.) Copyright (C) 2001 Massachusetts Medical Society.	BioMarin Pharmaceut Inc, Novato, CA 94949 USA; Harbor UCLA Med Ctr, Dept Pediat, Div Med Genet, Torrance, CA 90509 USA; Univ N Carolina, Chapel Hill, NC USA; Vanderbilt Univ, Med Ctr, Nashville, TN USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90024 USA; Univ Alabama Birmingham, Birmingham, AL USA	BioMarin Pharmaceutical Inc.; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Alabama System; University of Alabama Birmingham	Kakkis, ED (corresponding author), BioMarin Pharmaceut Inc, 371 Bel Marin Keys Blvd,Suite 210, Novato, CA 94949 USA.	ekakkis@biomarinpharm.com	Belmont, John/AAH-6084-2021; Belmont, John W/AAI-2494-2019	Belmont, John W/0000-0001-7409-3578	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00425, RR00046] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BJORNSSON S, 1993, ANAL BIOCHEM, V210, P282, DOI 10.1006/abio.1993.1197; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; Guffon N, 1998, J PEDIATR-US, V133, P119, DOI 10.1016/S0022-3476(98)70201-X; HERS HG, 1965, GASTROENTEROLOGY, V48, P625; Kakkis ED, 1996, BIOCHEM MOL MED, V58, P156, DOI 10.1006/bmme.1996.0044; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; Kikuchi T, 1998, J CLIN INVEST, V101, P827, DOI 10.1172/JCI1722; MCKUSICK VA, 1972, HERITABLE DISORDERS, P521; NEUFELD EF, 1995, METABOLIC MOL BASES, V2, P2465; Peters C, 1998, BLOOD, V91, P2601, DOI 10.1182/blood.V91.7.2601.2601_2601_2608; Rosenberg M, 1999, BLOOD, V93, P2081, DOI 10.1182/blood.V93.6.2081.406k07_2081_2088; ROUBICEK M, 1985, AM J MED GENET, V20, P471, DOI 10.1002/ajmg.1320200308; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; Schiffmann R, 2000, P NATL ACAD SCI USA, V97, P365, DOI 10.1073/pnas.97.1.365; SCOTT HS, 1991, P NATL ACAD SCI USA, V88, P9695, DOI 10.1073/pnas.88.21.9695; SCOTT HS, 1995, HUM MUTAT, V6, P288, DOI 10.1002/humu.1380060403; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; Stocker JT, 1992, PEDIAT PATHOLOGY; STOLTZFUS LJ, 1992, J BIOL CHEM, V267, P6570; VANDERPLOEG AT, 2000, LANCET, V356, P397; Vellodi A, 1997, ARCH DIS CHILD, V76, P92, DOI 10.1136/adc.76.2.92; WHITLEY CB, 1993, AM J MED GENET, V46, P209, DOI 10.1002/ajmg.1320460222	24	498	552	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 18	2001	344	3					182	188		10.1056/NEJM200101183440304	http://dx.doi.org/10.1056/NEJM200101183440304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	392GF	11172140				2022-12-28	WOS:000166402800004
J	Zvosec, DL; Smith, SW; McCutcheon, JR; Spillane, J; Hall, BJ; Peacock, EA				Zvosec, DL; Smith, SW; McCutcheon, JR; Spillane, J; Hall, BJ; Peacock, EA			Adverse events, including death, associated with the use of 1,4-butanediol.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GAMMA-HYDROXYBUTYRIC ACID; 1,4 BUTANEDIOL; ETHANOL; INTOXICATION; INVITRO; URINE; TALE	Background: 1,4-Butanediol is an industrial solvent that, when ingested, is converted to gamma -hydroxybutyrate, a drug of abuse with depressant effects, primarily on the central nervous system. After reports of toxic effects of gamma -hydroxybutyrate and its resultant regulation by the federal government, 1,4-butanediol and gamma- butyrolactone, another precursor of gamma- hydroxybutyrate and an industrial solvent, began to be marketed as dietary supplements. We investigated reports of toxic effects due to the ingestion of 1,4-butanediol and reviewed the related health risks. Methods: From June 1999 through December 1999, we identified cases of toxic effects of 1,4-butanediol involving patients who presented to our emergency departments with a clinical syndrome suggesting toxic effects of gamma- hydroxybutyrate and a history of ingesting 1,4-butanediol and patients identified through public health officials and family members. We used gas chromatography-mass spectrometry to measure 1,4-butanediol or its metabolite, gamma -hydroxybutyrate, in urine, serum, or blood. Results: We identified nine episodes of toxic effects in eight patients who had ingested 1,4-butanediol recreationally, to enhance bodybuilding, or to treat depression or insomnia. One patient presented twice with toxic effects and had withdrawal symptoms after her second presentation. Clinical findings and adverse events included vomiting, urinary and fecal incontinence, agitation, combativeness, a labile level of consciousness, respiratory depression, and death. No additional intoxicants were identified in six patients, including the two who died. The doses of 1,4-butanediol ingested ranged from 5.4 to 20 g in the patients who died and ranged from 1 to 14 g in the nonfatal cases. In some cases there was evidence of addiction and withdrawal. Conclusions: The health risks of 1,4-butanediol are similar to those of its counterparts, gamma -hydroxybutyrate and gamma -butyrolactone. These include acute toxic effects, which may be fatal, and addiction and withdrawal. (N Engl J Med 2001;344:87-94.) Copyright (C) 2001 Massachusetts Medical Society.	Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; Off Travis Cty Med Examiner, Austin, TX USA; Nova SE Univ, Broward Gen Med Ctr, Ft Lauderdale, FL 33314 USA	Hennepin County Medical Center; Nova Southeastern University	Smith, SW (corresponding author), Hennepin Cty Med Ctr, Dept Emergency Med, 701 Pk Ave, Minneapolis, MN 55415 USA.	dzvosec@hotmail.com						Addolorato G, 1999, CLIN NEUROPHARMACOL, V22, P60, DOI 10.1097/00002826-199901000-00011; ANDERSO DT, 1997, 1997 CAT NWAFS SWAFS; ARENA C, 1980, J PHARM SCI, V69, P356, DOI 10.1002/jps.2600690331; CHIN A, 1991, J LIGHTWAVE TECHNOL, V9, P321, DOI 10.1109/50.70007; Cisek J., 1999, Journal of Toxicology Clinical Toxicology, V37, P650; COUPER FJ, IN PRESS J FORENSIC; Craig K, 2000, J EMERG MED, V18, P65, DOI 10.1016/S0736-4679(99)00163-8; Dyer J. E., 1997, Journal of Toxicology Clinical Toxicology, V35, P554; DYER JE, IN PRESS ANN EMERG M; DYER JE, 2000, J TOXICOL-CLIN TOXIC, V38, P184; Eckstein M, 1999, Prehosp Emerg Care, V3, P357, DOI 10.1080/10903129908958969; ElSohly MA, 1999, J ANAL TOXICOL, V23, P141, DOI 10.1093/jat/23.3.141; FERRARA SD, 1993, J PHARMACEUT BIOMED, V11, P483, DOI 10.1016/0731-7085(93)80161-S; Fieler EL, 1998, CLIN CHEM, V44, P692; FISHBEIN WN, 1966, J BIOL CHEM, V241, P4842; *FOOD DRUG ADM, 1999, T9921 FDA; *FOOD DRUG ADM, 1999, T995 FDA; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; *GHB, 2000, 05578 NAPS GHB; GREENBLATT JC, 1997, GAMMA HYDROXYBUTYRAT; Hardy C. J., 1999, Journal of Toxicology Clinical Toxicology, V37, P649; Higgins Thomas F. Jr., 1996, Journal of Emergency Medicine, V14, P435, DOI 10.1016/0736-4679(96)00080-7; HINRICHS A, 1948, Pharmazie, V3, P110; LeBeau M, 1999, J FORENSIC SCI, V44, P227; LETTIERI J, 1978, RES COMMUN CHEM PATH, V22, P107; Li J, 1998, ANN EMERG MED, V31, P729, DOI 10.1016/S0196-0644(98)70232-X; Li J, 1998, ANN EMERG MED, V31, P723, DOI 10.1016/S0196-0644(98)70231-8; LoVecchio F, 1998, NEW ENGL J MED, V339, P847; MAMELAK M, 1989, NEUROSCI BIOBEHAV R, V13, P187, DOI 10.1016/S0149-7634(89)80053-3; MARKER E, 1995, P AM AC FOR SCI ANN; Mullins ME, 1999, ACAD EMERG MED, V6, P966, DOI 10.1111/j.1553-2712.1999.tb01251.x; *NAPS, 05578 NAPS; *OFF DIV CONTR, 2000, 000801 DEAODE; PALATINI P, 1993, EUR J CLIN PHARMACOL, V45, P353; PAN M, 1999, ANN M AM AC FOR SCI, P271; POLDRUGO F, 1984, NEUROPHARMACOLOGY, V23, P109, DOI 10.1016/0028-3908(84)90226-0; POLDRUGO F, 1985, ALCOHOL CLIN EXP RES, V9, P493, DOI 10.1111/j.1530-0277.1985.tb05589.x; POLDRUGO F, 1986, ALCOHOL, V3, P367, DOI 10.1016/0741-8329(86)90055-8; *RAD CORP NTP CHEM, 1991, 110634 CAS NTP CHEM; RambourgSchepens MO, 1997, VET HUM TOXICOL, V39, P234; ROTH R. H., 1966, INT J NEUROPHARMACOL, V5, P421; Schneidereit T., 2000, INT J MED TOXICOL, V3, P1; SPILLANE J, 1998, NIH PUBL; SPRINCE HERBERT, 1966, LIFE SCI, V5, P2041, DOI 10.1016/0024-3205(66)90245-1; STEPHENS BG, 1994, J ANAL TOXICOL, V18, P357, DOI 10.1093/jat/18.6.357; Tunnicliff G, 1997, J TOXICOL-CLIN TOXIC, V35, P581, DOI 10.3109/15563659709001236; VAYER P, 1987, LIFE SCI, V41, P1547, DOI 10.1016/0024-3205(87)90721-1; VAYER P, 1985, J NEUROCHEM, V45, P810, DOI 10.1111/j.1471-4159.1985.tb04065.x; 1999, MMWR MORB MORTAL WKL, V48, P137; 1990, MMWR MORB MORTAL WKL, V39, P861; 1997, MMWR MORB MORTAL WKL, V46, P281	51	149	153	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					87	94		10.1056/NEJM200101113440202	http://dx.doi.org/10.1056/NEJM200101113440202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150358				2022-12-28	WOS:000166281100002
J	de Bock, GH; van Asperen, CJ; de Vries, JM; Hageman, GCHA; Springer, MP; Kievit, J				de Bock, GH; van Asperen, CJ; de Vries, JM; Hageman, GCHA; Springer, MP; Kievit, J			How women with a family history of breast cancer and their general practitioners act on genetic advice in general practice: prospective longitudinal study	BRITISH MEDICAL JOURNAL			English	Article									Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Practice, NL-2300 RC Leiden, Netherlands; Wantveld Hlth Care Ctr, Noordwijk, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Bock, GH (corresponding author), Leiden Univ, Med Ctr, Dept Med Decis Making, POB 9600, NL-2300 RC Leiden, Netherlands.		de Bock, Geertruida Hendrika/F-6529-2014; Kievit, Job/A-3924-2008	de Bock, Geertruida Hendrika/0000-0003-3104-4471; 				deBock GH, 1997, FAM PRACT, V14, P40, DOI 10.1093/fampra/14.1.40; Duijm LEM, 1997, FAM PRACT, V14, P450, DOI 10.1093/fampra/14.6.450; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; Moss SM, 1999, LANCET, V353, P1909, DOI 10.1016/S0140-6736(98)07412-1	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 6	2001	322	7277					26	27		10.1136/bmj.322.7277.26	http://dx.doi.org/10.1136/bmj.322.7277.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391EP	11141149	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000166341400021
J	Wang, K; Stiefel, EI				Wang, K; Stiefel, EI			Toward separation and purification of olefins using dithiolene complexes: An electrochemical approach	SCIENCE			English	Article							METAL	The complex Ni[S2C2(CF3)(2)](2) reacts with tight olefins, including ethylene and propylene, selectively and reversibly. The reaction is not poisoned by hydrogen gas, carbon monoxide, acetylene, or hydrogen sulfide, which are commonly present in olefin streams, presumably because olefin binding occurs through the sulfur Ligand rather than the metal center. The reversible reaction of olefins with Ni[S2C2(CN)(2)](2)(n) (n = 0, -1, -2) can be controlled electrochemically, where the oxidation state-dependent binding and release of olefins are fast on the electrochemical time scale. The observed tolerance to poisons and controllable electrochemical reactivity present an alternative approach to the separation of olefins from complex streams.	ExxonMobil Res & Engn Co, Annandale, NJ 08801 USA	Exxon Mobil Corporation	Wang, K (corresponding author), ExxonMobil Res & Engn Co, Route 22 E,Clinton Township, Annandale, NJ 08801 USA.							BAKER JR, 1971, J AM CHEM SOC, V93, P6486, DOI 10.1021/ja00753a025; Blytas GC, 1992, SEPARATION PURIFICAT, P19; Bodke AS, 1999, SCIENCE, V285, P712, DOI 10.1126/science.285.5428.712; CASSOUX P, 1991, COORDIN CHEM REV, V110, P115, DOI 10.1016/0010-8545(91)80024-8; DAVISON A, 1963, INORG CHEM, V2, P1227, DOI 10.1021/ic50010a031; Goodman JT, 1999, J AM CHEM SOC, V121, P5017, DOI 10.1021/ja9843775; Grantom R. L., 1987, ULLMANNS ENCY IND CH, P45; HERMAN A, 1973, J ORGANOMET CHEM, V63, P441, DOI 10.1016/S0022-328X(73)80057-9; Konobeev B.I., 1967, KHIM PROM ST, V43, P114; Ladwig P. K., 1997, HDB PETROLEUM REFINI; McCleverty J. A., 1968, PROG INORG CHEM, V10, P49, DOI DOI 10.1002/9780470166116.CH2; MCKENNA M, 1983, J AM CHEM SOC, V105, P5329, DOI 10.1021/ja00354a024; MOORE JW, 1981, KINETICS MECHANISM, P304; National Research Council, 1987, SEP PUR CRIT NEEDS O; OLSON DC, 1966, J AM CHEM SOC, V88, P4876, DOI 10.1021/ja00973a022; Pilato R. S., 1999, BIOINORGANIC CATALYS, P81; SCHRAUZER GN, 1965, J AM CHEM SOC, V87, P1483, DOI 10.1021/ja01085a014; Shreehan M. M., 1995, KIRKOTHMER ENCY CHEM, P877; Suzuki T, 1997, INORG CHEM, V36, P136, DOI 10.1021/ic9608509; WATERS JA, 1970, J CHEM ENG DATA, V15, P174, DOI 10.1021/je60044a046; WING RM, 1970, J AM CHEM SOC, V92, P1935, DOI 10.1021/ja00710a025; ZULETA JA, 1990, COORDIN CHEM REV, V97, P47, DOI 10.1016/0010-8545(90)80079-9; 1999, CHEM ENG NEWS, V77, P32	23	212	216	2	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					106	109		10.1126/science.291.5501.106	http://dx.doi.org/10.1126/science.291.5501.106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141557				2022-12-28	WOS:000166259100043
J	Guyatt, GH; Naylor, D; Richardson, WS; Green, L; Haynes, RB; Wilson, MC; Cook, DJ; Jaeschke, RZ				Guyatt, GH; Naylor, D; Richardson, WS; Green, L; Haynes, RB; Wilson, MC; Cook, DJ; Jaeschke, RZ			What is the best evidence for making clinical decisions? Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CORONARY-HEART-DISEASE; RISK; SUPPLEMENTATION											Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	6	22	23	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3127	3128						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135774				2022-12-28	WOS:000165994100026
J	Toth, A; Rabitsch, KP; Galova, M; Schleiffer, A; Buonomo, SBC; Nasmyth, K				Toth, A; Rabitsch, KP; Galova, M; Schleiffer, A; Buonomo, SBC; Nasmyth, K			Functional genomics identifies Monopolin: A kinetochore protein required for segregation of homologs during meiosis I	CELL			English	Article							SISTER-CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; DNA-REPLICATION; MEIOTIC DIVISION; CELL-CYCLE; YEAST; SEPARATION; RECOMBINATION; TRANSITION	The orderly reduction in chromosome number that occurs during meiosis depends on two aspects of chromosome behavior specific to the first meiotic division. These are the retention of cohesion between sister centromeres and their attachment to microtubules that extend to the same pole (monopolar attachment). By deleting genes that are upregulated during meiosis, we identified in Saccharomyces cerevisiae a kinetochore associated protein, Mam1 (Monopolin), which is essential for monopolar attachment. We also show that the meiosis-specific cohesin, Rec8, is essential for maintaining cohesion between sister centromeres but not for monopolar attachment. We conclude that monopolar attachment during meiosis I requires at least one meiosis-specific protein and is independent of the process that protects sister centromere cohesion.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Toth, Attila/C-9624-2013	Toth, Attila/0000-0001-5744-3847; Buonomo, Sara/0000-0002-0177-2884; Schleiffer, Alexander/0000-0001-6251-2747; Nasmyth, Kim/0000-0001-7030-4403				Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDSTEIN LSB, 1981, CELL, V25, P591, DOI 10.1016/0092-8674(81)90167-7; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Kamieniecki RJ, 2000, CURR BIOL, V10, P1182, DOI 10.1016/S0960-9822(00)00723-5; KLAPHOLZ S, 1980, GENETICS, V96, P567; KLAPHOLZ S, 1980, GENETICS, V96, P589; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; LOIDL J, 1988, NUCL STRUCTURE FUNCT; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Mendel JG., 1865, VERHANDLUNGEN NATURF, V4, P3, DOI DOI 10.1093/OXFORDJOURNALS.JHERED.A106151; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; OSTERGREN G, 1951, HEREDITAS, V37, P85; Paliulis LV, 2000, J CELL BIOL, V150, P1223, DOI 10.1083/jcb.150.6.1223; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Sambrook J, 1989, MOL CLONING, V3; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; SUJA JA, 1991, GENOME, V34, P19, DOI 10.1139/g91-004; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Zeng XM, 2000, GENETICS, V155, P577; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619	44	231	238	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 22	2000	103	7					1155	1168		10.1016/S0092-8674(00)00217-8	http://dx.doi.org/10.1016/S0092-8674(00)00217-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163190	Bronze			2022-12-28	WOS:000166040600017
J	Ohno, H; Chiba, D; Matsukura, F; Omiya, T; Abe, E; Dietl, T; Ohno, Y; Ohtani, K				Ohno, H; Chiba, D; Matsukura, F; Omiya, T; Abe, E; Dietl, T; Ohno, Y; Ohtani, K			Electric-field control of ferromagnetism	NATURE			English	Article							III-V SEMICONDUCTORS; DILUTED MAGNETIC SEMICONDUCTORS; MAGNETOELECTRONICS; HETEROSTRUCTURES; INJECTION	It is often assumed that it is not possible to alter the properties of magnetic materials once they have been prepared and put into use. For example, although magnetic materials are used in information technology to store trillions of bits (in the form of magnetization directions established by applying external magnetic fields), the properties of the magnetic medium itself remain unchanged on magnetization reversal. The ability to externally control the properties of magnetic materials would be highly desirable from fundamental and technological viewpoints, particularly in view of recent developments in magnetoelectronics and spintronics(1,2). In semiconductors, the conductivity can be varied by applying an electric field, but the electrical manipulation of magnetism has proved elusive. Here we demonstrate electric-field control of ferromagnetism in a thin-film semiconducting alloy, using an insulating-gate field-effect transistor structure. By applying electric fields, we are able to vary isothermally and reversibly the transition temperature of hole-induced ferromagnetism.	Tohoku Univ, Elect Commun Res Inst, Lab Elect Intelligent Syst, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Ohno, H (corresponding author), Tohoku Univ, Elect Commun Res Inst, Lab Elect Intelligent Syst, Aoba Ku, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.		Ohno, Hideo/E-6453-2010; Dietl, Tomasz/C-9537-2013; Chiba, Daichi/D-3438-2015	Ohno, Hideo/0000-0001-9688-8259; Dietl, Tomasz/0000-0003-1090-4380; Chiba, Daichi/0000-0002-6631-5131; Ohno, Yuzo/0000-0002-7092-9793; Ohno, Yuzo/0000-0002-4364-3386				ARROTT A, 1957, PHYS REV, V108, P1394, DOI 10.1103/PhysRev.108.1394; Chien C.L., 1980, HALL EFFECT ITS APPL, P43; de Boeck J, 1999, PHYS WORLD, V12, P27; Dietl T, 2000, SCIENCE, V287, P1019, DOI 10.1126/science.287.5455.1019; Dietl T, 1997, PHYS REV B, V55, pR3347, DOI 10.1103/PhysRevB.55.R3347; Fiederling R, 1999, NATURE, V402, P787, DOI 10.1038/45502; Koshihara S, 1997, PHYS REV LETT, V78, P4617, DOI 10.1103/PhysRevLett.78.4617; Lee B, 2000, PHYS REV B, V61, P15606, DOI 10.1103/PhysRevB.61.15606; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; MUNEKATA H, 1989, PHYS REV LETT, V63, P1849, DOI 10.1103/PhysRevLett.63.1849; MUNEKATA H, 1993, APPL PHYS LETT, V63, P2929, DOI 10.1063/1.110276; Ohno H, 1999, J MAGN MAGN MATER, V200, P110, DOI 10.1016/S0304-8853(99)00444-8; Ohno H, 1998, SCIENCE, V281, P951, DOI 10.1126/science.281.5379.951; OHNO H, 1992, PHYS REV LETT, V68, P2664, DOI 10.1103/PhysRevLett.68.2664; Ohno Y, 1999, NATURE, V402, P790, DOI 10.1038/45509; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; Shen A, 1997, APPL SURF SCI, V113, P183, DOI 10.1016/S0169-4332(96)00865-3; Soo YL, 1996, PHYS REV B, V53, P4905, DOI 10.1103/PhysRevB.53.4905; VONMOLNAR S, 1991, J MAGN MAGN MATER, V93, P356, DOI 10.1016/0304-8853(91)90361-D; Vrijen R, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.012306	20	1788	1835	9	598	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					944	946		10.1038/35050040	http://dx.doi.org/10.1038/35050040			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140674				2022-12-28	WOS:000165951100040
J	Lowenthal, RM; Taylor, BV; Tan, BS				Lowenthal, RM; Taylor, BV; Tan, BS			Cold sweats	LANCET			English	Article							SPONTANEOUS PERIODIC HYPOTHERMIA		Royal Hobart Hosp, Dept Clin Haematol & Med Oncol, Hobart, Tas, Australia; Royal Hobart Hosp, Dept Neurol, Hobart, Tas, Australia; Royal Hobart Hosp, Dept Med Imaging, Hobart, Tas, Australia	Royal Hobart Hospital; Royal Hobart Hospital; Royal Hobart Hospital	Lowenthal, RM (corresponding author), Royal Hobart Hosp, Dept Haematol Oncol, GPO Box 1061L, Hobart, Tas 7001, Australia.							Bernard S, 1996, ANAESTH INTENS CARE, V24, P382, DOI 10.1177/0310057X9602400315; FOX RH, 1973, BRIT MED J, V2, P693, DOI 10.1136/bmj.2.5868.693; KLOOS RT, 1995, MEDICINE, V74, P268, DOI 10.1097/00005792-199509000-00004; SHAPIRO WR, 1969, BRAIN, V92, P423, DOI 10.1093/brain/92.2.423; SHETH RD, 1994, PEDIATR NEUROL, V10, P58, DOI 10.1016/0887-8994(94)90069-8	5	2	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2064	2064		10.1016/S0140-6736(00)03404-8	http://dx.doi.org/10.1016/S0140-6736(00)03404-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145493				2022-12-28	WOS:000165994300013
J	Morisset, S; Rouleau, A; Ligneau, X; Gbahou, F; Tardivel-Lacombe, J; Stark, H; Schunack, W; Ganellin, CR; Schwartz, JC; Arrang, JM				Morisset, S; Rouleau, A; Ligneau, X; Gbahou, F; Tardivel-Lacombe, J; Stark, H; Schunack, W; Ganellin, CR; Schwartz, JC; Arrang, JM			High constitutive activity of native H(3) receptors regulates histamine neurons in brain	NATURE			English	Article							INVERSE AGONISTS; CEREBRAL-CORTEX; EXPRESSION; LIGANDS; BINDING; POTENT; H-3-RECEPTORS; ANTAGONISTS; ISOFORMS; RELEASE	Some G-protein-coupled receptors display 'constitutive activity', that is, spontaneous activity in the absence of agonist(1-4). This means that a proportion of the receptor population spontaneously undergoes an allosteric transition, leading to a conformation that can bind G proteins(3). The process has been shown to occur with recombinant receptors expressed at high density, and/or mutated, but also non-mutated recombinant receptors expressed at physiological concentrations(5-7). Transgenic mice that express a constitutively active mutant of the beta (2)-adrenergic receptor display cardiac anomalies(8); and spontaneous receptor mutations leading to constitutive activity are at the origin of some human diseases(9,10). Nevertheless, this process has not previously been found to occur in animals expressing normal levels of receptor(3,4). Here we show that two isoforms of the recombinant rat H(3) receptor(11,12) display high constitutive activity. Using drugs that abrogate this activity ('inverse agonists') and a drug that opposes both agonists and inverse agonists ('neutral antagonist'), we show that constitutive activity of native H(3) receptors is present in rodent brain and that it controls histaminergic neuron activity in vivo. Inverse agonists may therefore rnd therapeutic applications, even in the case of diseases involving non-mutated receptors expressed at normal levels.	Ctr Paul Broca, INSERM, U109, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France; Lab Bioprojet, F-75002 Paris, France; Free Univ Berlin, Inst Pharm, D-14195 Berlin, Germany; UCL, Christopher Ingold Labs, Dept Chem, London WC1H 0AJ, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Free University of Berlin; University of London; University College London	Arrang, JM (corresponding author), Ctr Paul Broca, INSERM, U109, Unite Neurobiol & Pharmacol Mol, 2ter Rue Alesia, F-75014 Paris, France.	arrang@broca.inserm.fr	Stark, Holger/A-4235-2009; Gbahou, Florence/L-4664-2017; MORISSET, Séverine/S-7450-2017; QUEMENER, Agnès/R-9489-2019	Stark, Holger/0000-0003-3336-1710; MORISSET, Séverine/0000-0002-9930-7824; QUEMENER, Agnès/0000-0002-4026-8496; Ligneau, Xavier/0000-0003-3097-4482				ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; ARRANG JM, 1985, NEUROSCIENCE, V15, P553, DOI 10.1016/0306-4522(85)90233-7; ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; Berg KA, 1999, MOL PHARMACOL, V55, P863; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Claeysen S, 1999, MOL PHARMACOL, V55, P910; Clark EA, 1996, EUR J PHARMACOL, V296, P223, DOI 10.1016/0014-2999(95)00800-4; CLARK EA, 1995, BRIT J PHARMACOL, V114, P357, DOI 10.1111/j.1476-5381.1995.tb13234.x; COSTA T, 1992, MOL PHARMACOL, V41, P549; GARBARG M, 1992, J PHARMACOL EXP THER, V263, P304; GARBARG M, 1989, EUR J PHARMACOL, V164, P1, DOI 10.1016/0014-2999(89)90225-2; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; Harper EA, 1999, BRIT J PHARMACOL, V128, P751, DOI 10.1038/sj.bjp.0702861; Hill SJ, 1997, PHARMACOL REV, V49, P253; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIGNEAU X, 1994, J PHARMACOL EXP THER, V271, P452; Ligneau X, 1998, J PHARMACOL EXP THER, V287, P658; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sasse A, 1999, J MED CHEM, V42, P4269, DOI 10.1021/jm991068w; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; Smith GP, 1996, MOL DIVERS, V2, P2, DOI 10.1007/BF01718693; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Tardivel-Lacombe J, 2000, NEUROREPORT, V11, P755, DOI 10.1097/00001756-200003200-00020; WEST RE, 1990, MOL PHARMACOL, V38, P610; Yates SL, 1999, BIOCHEM PHARMACOL, V57, P1059, DOI 10.1016/S0006-2952(98)00378-5	30	392	434	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					860	864		10.1038/35048583	http://dx.doi.org/10.1038/35048583			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130725				2022-12-28	WOS:000165831300051
J	Gerich, JE				Gerich, JE			Hypoglycaemia and counterregulation in type 2 diabetes	LANCET			English	Editorial Material							GLYCEMIC CONTROL; GLUCOSE COUNTERREGULATION; INSULIN; RESPONSES; COMPLICATIONS; SYMPTOMS; MELLITUS		Univ Rochester, Sch Med, Gen Clin Res Ctr, Rochester, NY 14642 USA	University of Rochester	Gerich, JE (corresponding author), Univ Rochester, Sch Med, Gen Clin Res Ctr, Rochester, NY 14642 USA.							ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; BOLLI GB, 1984, J CLIN INVEST, V73, P1532, DOI 10.1172/JCI111359; BOYLE PJ, 1988, NEW ENGL J MED, V318, P1487, DOI 10.1056/NEJM198806093182302; CRYER PE, 1994, DIABETES, V43, P1378, DOI 10.2337/diabetes.43.11.1378; Frische A, 1998, DIABETES CARE, V21, P1505, DOI 10.2337/diacare.21.9.1505; GERICH JE, 1991, ENDOCR REV, V12, P356, DOI 10.1210/edrv-12-4-356; GERICH JE, 1993, HYPOGLYCAEMIA DIABET, P253; HEPBURN DA, 1993, DIABETIC MED, V10, P231, DOI 10.1111/j.1464-5491.1993.tb00050.x; Korzon-Burakowska A, 1998, DIABETES CARE, V21, P283, DOI 10.2337/diacare.21.2.283; Levy CJ, 1998, DIABETES CARE, V21, P1330, DOI 10.2337/diacare.21.8.1330; MENEILLY GS, 1994, DIABETES, V43, P403, DOI 10.2337/diabetes.43.3.403; MITRAKOU A, 1991, AM J PHYSIOL, V260, pE67, DOI 10.1152/ajpendo.1991.260.1.E67; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; REICHARD P, 1994, DIABETES, V43, P313, DOI 10.2337/diabetes.43.2.313; Reichard P, 1996, DIABETOLOGIA, V39, P1483, DOI 10.1007/s001250050602; Saudek CD, 1996, JAMA-J AM MED ASSOC, V276, P1322, DOI 10.1001/jama.276.16.1322; SHAMOON H, 1994, J CLIN INVEST, V93, P2562, DOI 10.1172/JCI117267; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; vanStaa T, 1997, J CLIN EPIDEMIOL, V50, P735, DOI 10.1016/S0895-4356(97)00024-3; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233; WHITE NH, 1983, NEW ENGL J MED, V308, P485, DOI 10.1056/NEJM198303033080903	22	20	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 9	2000	356	9246					1946	1947		10.1016/S0140-6736(00)03303-1	http://dx.doi.org/10.1016/S0140-6736(00)03303-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130519				2022-12-28	WOS:000165867600005
J	McNamee, D				McNamee, D			Pies flying low in a blue sky	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		McNamee, D (corresponding author), Lancet, London WC1X 8RR, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1948	1948		10.1016/S0140-6736(00)03305-5	http://dx.doi.org/10.1016/S0140-6736(00)03305-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130521				2022-12-28	WOS:000165867600007
J	Murakami, T; Ogura, EW; Tanaka, Y; Yamamoto, M				Murakami, T; Ogura, EW; Tanaka, Y; Yamamoto, M			High blood pressure lowered by pregnancy	LANCET			English	Article									Natl Def Med Coll, Dept Internal Med 3, Tokorozawa, Saitama, Japan	National Defense Medical College - Japan	Yamamoto, M (corresponding author), Natl Def Med Coll, Dept Internal Med 3, 3-2 Namiki, Tokorozawa, Saitama, Japan.							AOI W, 1978, JPN HEART J, V19, P946; AUGUST P, 1990, AM J OBSTET GYNECOL, V163, P1612, DOI 10.1016/0002-9378(90)90639-O; BIGLIERI EG, 1967, J CLIN ENDOCR METAB, V27, P1628, DOI 10.1210/jcem-27-11-1628; GORDON RD, 1982, CLIN EXP HYPERTENS A, V4, P1685, DOI 10.3109/10641968209061634; WILSON M, 1980, AM J MED, V68, P104	5	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1980	1980		10.1016/S0140-6736(00)03311-0	http://dx.doi.org/10.1016/S0140-6736(00)03311-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130528				2022-12-28	WOS:000165867600014
J	Teleman, AA; Cohen, SM				Teleman, AA; Cohen, SM			Dpp gradient formation in the Drosophila wing imaginal disc	CELL			English	Article							LONG-RANGE ACTION; MORPHOGEN GRADIENT; PHOSPHOINOSITIDE 3-KINASE; CELL-SIZE; EXPRESSION; GROWTH; RECEPTOR; BRINKER; AXIS; LEG	The secreted signaling protein Dpp acts as a morphogen to pattern the anterior-posterior axis of the Drosophila wing. Dpp activity is required in all cells of the developing wing imaginal disc, but the ligand gradient that supports this activity has not been characterized. Here we make use of a biologically active form of Dpp tagged with GFP to examine the ligand gradient. Dpp-GFP forms an unstable extracellular gradient that spreads rapidly in the wing disc. The activity gradient visualized by MAD phosphorylation differs in shape from the ligand gradient. The pMAD gradient adjusted to compartment size when this was experimentally altered. These observations suggest that the Dpp activity gradient may be shaped at the level of receptor activation.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Cohen, SM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Teleman, Aurelio A/E-6864-2013; Cohen, Stephen M/G-9930-2011; Teleman, Aurelio/V-8470-2019	Teleman, Aurelio A/0000-0002-4237-9368; Cohen, Stephen M/0000-0003-2858-9163; Teleman, Aurelio/0000-0002-4237-9368				Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Bretscher MS, 1996, J CELL SCI, V109, P3113; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gonzalez-Gaitan M, 1999, MECH DEVELOP, V87, P143, DOI 10.1016/S0925-4773(99)00156-2; GONZALEZGAITAN M, 1994, MECH DEVELOP, V46, P183, DOI 10.1016/0925-4773(94)90070-1; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Massague J, 2000, GENE DEV, V14, P627; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1997, DEVELOPMENT, V124, P871; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; Strigini M, 1997, DEVELOPMENT, V124, P4697; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weigmann K, 1999, DEVELOPMENT, V126, P3823; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Wu J, 1999, DEVELOPMENT, V126, P109; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	37	356	368	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					971	980		10.1016/S0092-8674(00)00199-9	http://dx.doi.org/10.1016/S0092-8674(00)00199-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136981	Bronze			2022-12-28	WOS:000165801300015
J	Gray, JE; Holroyd, GH; van der Lee, FM; Bahrami, AR; Sijmons, PC; Woodward, FI; Schuch, W; Heterington, AM				Gray, JE; Holroyd, GH; van der Lee, FM; Bahrami, AR; Sijmons, PC; Woodward, FI; Schuch, W; Heterington, AM			The HIC signalling pathway links CO2 perception to stomatal development	NATURE			English	Article							ARABIDOPSIS-THALIANA; FEEDING STRUCTURES; TRANSGENIC PLANTS; GENE-EXPRESSION; FOSSIL PLANTS; DENSITY; FIDDLEHEAD; GENOME; MUTANT; INDEX	Stomatal pores on the leaf surface control both the uptake of CO2 for photosynthesis and the loss of water during transpiration. Since the industrial revolution, decreases in stomatal numbers in parallel with increases in atmospheric CO2 concentration have provided evidence of plant responses to changes in CO2 levels caused by human activity(1,2). This inverse correlation between stomatal density and CO2 concentration also holds for fossil material from the past 400 million years(3) and has provided dues to the causes of global extinction events(4). Here we report the identification of the Arabidopsis gene HIC (for high carbon dioxide), which encodes a negative regulator of stomatal development that responds to CO2 concentration. This gene encodes a putative 3-keto acyl coenzyme A synthase-an enzyme involved in the synthesis of very-long-chain fatty acids(5). Mutant hic plants exhibit up to a 42% increase in stomatal density in response to a doubling of CO2. Our results identify a gene involved in the signal transduction pathway responsible for controlling stomatal numbers at elevated CO2.	Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Zeneca Mogen, NL-2300 AP Leiden, Netherlands; Cellscreen, NL-6700 AC Wageningen, Netherlands; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Zeneca Wheat Improvement Ctr, Norwich NR4 7UH, Norfolk, England	Lancaster University; University of Sheffield; University of Sheffield	Heterington, AM (corresponding author), Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England.		Gray, Julie E/B-4271-2014; Woodward, Ian F/B-7762-2008; Bahrami, Ahmad Reza/AAA-4090-2020; Woodward, Frank Ian/P-4530-2019	Gray, Julie E/0000-0001-9972-5156; Bahrami, Ahmad Reza/0000-0001-9122-7216; Hetherington, Alistair/0000-0001-6060-9203				Barthels N, 1997, PLANT CELL, V9, P2119, DOI 10.1105/tpc.9.12.2119; BECKMAN AA, 1994, PLANT MOL BIOL REP, V12, P37; Berger D, 2000, GENE DEV, V14, P1119; BUNNING E, 1948, Z NATURFORSCH B, V3, P203; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; GODDIJN OJM, 1993, PLANT J, V4, P863, DOI 10.1046/j.1365-313X.1993.04050863.x; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; JENKS MA, 1995, PLANT PHYSIOL, V108, P369, DOI 10.1104/pp.108.1.369; KORN RW, 1993, INT J PLANT SCI, V154, P367, DOI 10.1086/297118; Larkin JC, 1997, PLANT CELL, V9, P1109, DOI 10.1105/tpc.9.7.1109; Lassner MW, 1996, PLANT CELL, V8, P281, DOI 10.1105/tpc.8.2.281; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LOLLE SJ, 1992, DEV BIOL, V152, P383, DOI 10.1016/0012-1606(92)90145-7; Lolle SJ, 1997, DEV BIOL, V189, P311, DOI 10.1006/dbio.1997.8671; MCELWAIN JC, 1995, ANN BOT-LONDON, V76, P389, DOI 10.1006/anbo.1995.1112; McElwain JC, 1999, SCIENCE, V285, P1386, DOI 10.1126/science.285.5432.1386; NEIGHBOUR EA, 1990, ENVIRON POLLUT, V64, P155, DOI 10.1016/0269-7491(90)90112-P; Poole I, 1996, PLANT CELL ENVIRON, V19, P705, DOI 10.1111/j.1365-3040.1996.tb00405.x; Post-Beittenmiller D, 1998, PLANT PHYSIOL BIOCH, V36, P157, DOI 10.1016/S0981-9428(98)80100-9; PostBeittenmiller D, 1996, ANNU REV PLANT PHYS, V47, P405, DOI 10.1146/annurev.arplant.47.1.405; SALISBURY EJ, 1927, PHIL T R SOC       B, V216, P1, DOI DOI 10.1098/RSTB.1928.0001; Todd J, 1999, PLANT J, V17, P119, DOI 10.1046/j.1365-313X.1999.00352.x; TOPPING JF, 1991, DEVELOPMENT, V112, P1009; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEYERS JDB, 1985, NEW PHYTOL, V101, P109, DOI 10.1111/j.1469-8137.1985.tb02820.x; WOODWARD FI, 1995, NEW PHYTOL, V131, P311, DOI 10.1111/j.1469-8137.1995.tb03067.x; WOODWARD FI, 1987, NATURE, V327, P617, DOI 10.1038/327617a0; Yang M, 1995, PLANT CELL, V7, P2227, DOI 10.1105/tpc.7.12.2227; Yephremov A, 1999, PLANT CELL, V11, P2187, DOI 10.1105/tpc.11.11.2187; ZEIGER E, 1972, AM J BOT, V59, P143, DOI 10.2307/2441393	30	287	326	2	122	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					713	716		10.1038/35047071	http://dx.doi.org/10.1038/35047071			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130071				2022-12-28	WOS:000165815200047
J	Veizer, J; Godderis, Y; Francois, LM				Veizer, J; Godderis, Y; Francois, LM			Evidence for decoupling of atmospheric CO2 and global climate during the Phanerozoic eon	NATURE			English	Article							LAST GLACIAL MAXIMUM; SURFACE-TEMPERATURE; CARBON-CYCLE; SEAWATER; RECORDS; TIME	Atmospheric carbon dioxide concentrations are believed to drive climate changes from glacial to interglacial modes', although geological(1-3) and astronomical(4-6) mechanisms have been invoked as ultimate causes. Additionally, it is unclear(7,8) whether the changes between cold and warm modes should be regarded as a global phenomenon, affecting tropical and high-latitude temperatures alike(9-13), or if they are better described as an expansion and contraction of the latitudinal climate zones, keeping equatorial temperatures approximately constant(14-16). Here we present a reconstruction of tropical sea surface temperatures throughout the phanerozoic eon (the past similar to 550 Myr) from our database(17) of oxygen isotopes in calcite and aragonite shells. The data indicate large oscillations of tropical sea surface temperatures in phase with the cold-warm cycles, thus favouring the idea of climate variability as a global phenomenon. But our data conflict with a temperature reconstruction using an energy balance model that is forced by reconstructed atmospheric carbon dioxide concentrations(18). The results can be reconciled if atmospheric carbon dioxide concentrations were not the principal driver of climate variability on geological timescales for at least one-third of the Phanerozoic eon, or if the reconstructed carbon dioxide concentrations are not reliable.	Ruhr Univ Bochum, Inst Geol Mineral & Geophys, D-44780 Bochum, Germany; Univ Ottawa, Ottawa Carleton Geosci Ctr, Ottawa, ON K1N 6N5, Canada; Univ Liege, Lab Phys Atmospher & Planetaire, B-4000 Liege, Belgium	Ruhr University Bochum; University of Ottawa; University of Liege	Veizer, J (corresponding author), Ruhr Univ Bochum, Inst Geol Mineral & Geophys, D-44780 Bochum, Germany.		Veizer, Jan/ABG-3321-2020; François, Louis/K-9172-2019	François, Louis/0000-0001-8292-8360				[Anonymous], 1962, AAPG B; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Beck JW, 1997, NATURE, V385, P705, DOI 10.1038/385705a0; Berner RA, 1998, PHILOS T ROY SOC B, V353, P75, DOI 10.1098/rstb.1998.0192; BERNER RA, 1994, AM J SCI, V294, P56, DOI 10.2475/ajs.294.1.56; Broecker W, 1996, SCIENCE, V272, P1902, DOI 10.1126/science.272.5270.1902; Bush ABG, 1998, SCIENCE, V279, P1341, DOI 10.1126/science.279.5355.1341; CROWLEY TJ, 1994, NATURE, V371, P664, DOI 10.1038/371664a0; Crowley TJ, 2000, CLIM DYNAM, V16, P241, DOI 10.1007/s003820050325; ENDAL AS, 1981, ASTROPHYS J, V243, P625, DOI 10.1086/158628; Fischer A.G., 1982, CLIMATE EARTH HIST, P97, DOI DOI 10.17226/11798; Frakes L. A, 1992, CLIMATE MODES PHANER; FRAKES LA, 1988, NATURE, V333, P547, DOI 10.1038/333547a0; FRANCOIS LM, 1992, AM J SCI, V292, P81, DOI 10.2475/ajs.292.2.81; Gibbs M.T., 2000, WARM CLIMATES EARTH, P386; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; HARLAND WB, 1990, GEOLOGIC TIMESCALE; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; HAYS PD, 1991, GEOLOGY, V19, P441, DOI 10.1130/0091-7613(1991)019<0441:OIIMCC>2.3.CO;2; KNAUTH LP, 1976, GEOCHIM COSMOCHIM AC, V40, P1095, DOI 10.1016/0016-7037(76)90051-X; RAILSBACK LB, 1990, GEOCHIM COSMOCHIM AC, V54, P1501, DOI 10.1016/0016-7037(90)90175-K; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; SAVIN SM, 1977, ANNU REV EARTH PL SC, V5, P319, DOI 10.1146/annurev.ea.05.050177.001535; STEINER J, 1973, GEOL SOC AM BULL, V84, P1003, DOI 10.1130/0016-7606(1973)84<1003:PGCFPA>2.0.CO;2; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; Veizer J, 1999, CHEM GEOL, V161, P59, DOI 10.1016/S0009-2541(99)00081-9; WILLIAMS GE, 1975, EARTH PLANET SC LETT, V26, P361, DOI 10.1016/0012-821X(75)90012-6; Worsley TR, 1986, PALEOCEANOGRAPHY, V1, P233, DOI 10.1029/PA001i003p00233	29	289	308	3	95	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					698	701		10.1038/35047044	http://dx.doi.org/10.1038/35047044			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130067				2022-12-28	WOS:000165815200043
J	Fahey, DW; Gao, RS; Carslaw, KS; Kettleborough, J; Popp, PJ; Northway, MJ; Holecek, JC; Ciciora, SC; McLaughlin, RJ; Thompson, TL; Winkler, RH; Baumgardner, DG; Gandrud, B; Wennberg, PO; Dhaniyala, S; McKinney, K; Peter, T; Salawitch, RJ; Bui, TP; Elkins, JW; Webster, CR; Atlas, EL; Jost, H; Wilson, JC; Herman, RL; Kleinbohl, A; von Konig, M				Fahey, DW; Gao, RS; Carslaw, KS; Kettleborough, J; Popp, PJ; Northway, MJ; Holecek, JC; Ciciora, SC; McLaughlin, RJ; Thompson, TL; Winkler, RH; Baumgardner, DG; Gandrud, B; Wennberg, PO; Dhaniyala, S; McKinney, K; Peter, T; Salawitch, RJ; Bui, TP; Elkins, JW; Webster, CR; Atlas, EL; Jost, H; Wilson, JC; Herman, RL; Kleinbohl, A; von Konig, M			The detection of large HNO3-containing particles in the winter arctic stratosphere	SCIENCE			English	Article							IN-SITU MEASUREMENTS; WATER-VAPOR; OZONE DEPLETION; POLAR VORTEX; NITRIC-ACID; DENITRIFICATION; CLOUD; AEROSOL; HNO3; CONDENSATION	Large particles containing nitric acid (HNO3) were observed in the 1999/2000 Arctic winter stratosphere. These in situ observations were made over a Large altitude range (16 to 21 kilometers) and horizontal extent (1800 kilometers) on several airborne sampling flights during a period of several weeks. With diameters of 10 to 20 micrometers, these sedimenting particles have significant potential to denitrify the Lower stratosphere. A microphysical model of nitric acid trihydrate particles is able to simulate the growth and sedimentation of these Large sites in the Lower stratosphere, but the nucleation process is not yet known. Accurate modeling of the formation of these Large particles is essential for understanding Arctic denitrification and predicting future Arctic ozone abundances.	NOAA, Aeron Lab, Boulder, CO 80305 USA; NOAA, Climate Monitoring & Diagnost Lab, Boulder, CO 80305 USA; Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; Univ Leeds, Sch Environm, Leeds LS2 9JT, W Yorkshire, England; Rutherford Appleton Lab, Didcot OX11 0QX, Oxon, England; Univ Nacl Autonoma Mexico, Ctr Ciencias Atmosfera, Mexico City 04510, DF, Mexico; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; Swiss Fed Inst Technol, Lab Atmospharenphys, CH-8093 Zurich, Switzerland; NASA, Jet Prop Lab, Pasadena, CA 91109 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Bay Area Environm Res Inst, San Francisco, CA 94122 USA; Univ Denver, Dept Engn, Denver, CO 80208 USA; Univ Bremen, Inst Environm Phys, D-28334 Bremen, Germany	National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; University of Colorado System; University of Colorado Boulder; University of Leeds; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; Universidad Nacional Autonoma de Mexico; National Center Atmospheric Research (NCAR) - USA; California Institute of Technology; Swiss Federal Institutes of Technology Domain; ETH Zurich; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Denver; University of Bremen	Fahey, DW (corresponding author), NOAA, Aeron Lab, Boulder, CO 80305 USA.	fahey@al.noaa.gov	Webster, Chris/M-9315-2019; Atlas, Elliot/J-8171-2015; Sinnhuber, Miriam/A-7252-2013; Herman, Robert/H-9389-2012; Ciciora, Steven/I-4916-2013; Wennberg, Paul O/A-5460-2012; Carslaw, Ken S/C-8514-2009; Herman, Robert L./AAK-1986-2020; McLaughlin, Richard/I-4386-2013; Fahey, David W/G-4499-2013; Atlas, Elliot/AAE-4605-2021; Gao, Ru-Shan/H-7455-2013; Salawitch, Ross/B-4605-2009; Peter, Thomas/B-2529-2018	Sinnhuber, Miriam/0000-0002-3527-9051; Herman, Robert/0000-0001-7063-6424; Wennberg, Paul O/0000-0002-6126-3854; Carslaw, Ken S/0000-0002-6800-154X; Herman, Robert L./0000-0001-7063-6424; Fahey, David W/0000-0003-1720-0634; Gao, Ru-Shan/0000-0001-6985-1637; Salawitch, Ross/0000-0001-8597-5832; Peter, Thomas/0000-0002-7218-7156; Wilson, James/0000-0003-4699-5827; Atlas, Elliot/0000-0003-3847-5346				[Anonymous], 1999, 44 WORLD MET ORG; Baumgardner D, 1996, GEOPHYS RES LETT, V23, P749, DOI 10.1029/96GL00707; Biermann UM, 1996, GEOPHYS RES LETT, V23, P1693, DOI 10.1029/96GL01577; BROWELL EV, 1990, GEOPHYS RES LETT, V17, P385, DOI 10.1029/GL017i004p00385; Deshler T, 1998, J ATMOS CHEM, V30, P11, DOI 10.1023/A:1006023729315; FAHEY DW, 1989, J GEOPHYS RES-ATMOS, V94, P11299, DOI 10.1029/JD094iD09p11299; FAHEY DW, 1990, NATURE, V344, P321, DOI 10.1038/344321a0; HANSON D, 1988, GEOPHYS RES LETT, V15, P855, DOI 10.1029/GL015i008p00855; HOFMANN DJ, 1990, GEOPHYS RES LETT, V17, P369, DOI 10.1029/GL017i004p00369; KELLY KK, 1993, J GEOPHYS RES-ATMOS, V98, P8713, DOI 10.1029/92JD02526; Kondo Y, 2000, GEOPHYS RES LETT, V27, P337, DOI 10.1029/1999GL011081; KOOP T, 1995, GEOPHYS RES LETT, V22, P917, DOI 10.1029/95GL00814; KULLMAN H, 2000, 73 EUR COMM, P699; Manney GL, 2000, GEOPHYS RES LETT, V27, P2589, DOI 10.1029/2000GL011703; MULLER R, 1992, BER BUNSEN PHYS CHEM, V96, P353, DOI 10.1002/bbpc.19920960323; Murphy DM, 1998, SCIENCE, V282, P1664, DOI 10.1126/science.282.5394.1664; OLTMANS SJ, 1995, NATURE, V374, P146, DOI 10.1038/374146a0; Peter T, 1997, ANNU REV PHYS CHEM, V48, P785, DOI 10.1146/annurev.physchem.48.1.785; Portmann RW, 1996, J GEOPHYS RES-ATMOS, V101, P22991, DOI 10.1029/96JD02608; Rinsland CP, 1999, J GEOPHYS RES-ATMOS, V104, P1847, DOI 10.1029/1998JD100034; Rosenlof KH, 1997, J GEOPHYS RES-ATMOS, V102, P13213, DOI 10.1029/97JD00873; SALAWITCH RJ, 1989, NATURE, V339, P525, DOI 10.1038/339525a0; SALAWITCH RJ, 1993, SCIENCE, V261, P1146, DOI 10.1126/science.261.5125.1146; Santee ML, 2000, GEOPHYS RES LETT, V27, P3213, DOI 10.1029/2000GL011738; SANTEE ML, 1995, SCIENCE, V267, P849, DOI 10.1126/science.267.5199.849; Santee ML, 1999, J GEOPHYS RES-ATMOS, V104, P8225, DOI 10.1029/1998JD100089; Shindell DT, 1998, NATURE, V392, P589, DOI 10.1038/33385; Sinnhuber BM, 2000, GEOPHYS RES LETT, V27, P3473, DOI 10.1029/2000GL011772; Solomon S, 1999, REV GEOPHYS, V37, P275, DOI 10.1029/1999RG900008; Tabazadeh A, 2000, SCIENCE, V288, P1407, DOI 10.1126/science.288.5470.1407; TOON OB, 1986, GEOPHYS RES LETT, V13, P1284, DOI 10.1029/GL013i012p01284; TOON OB, 1990, GEOPHYS RES LETT, V17, P445, DOI 10.1029/GL017i004p00445; Waibel AE, 1999, SCIENCE, V283, P2064, DOI 10.1126/science.283.5410.2064; WILSON JC, 1990, GEOPHYS RES LETT, V17, P361, DOI 10.1029/GL017i004p00361; WOFSY SC, 1990, GEOPHYS RES LETT, V17, P449, DOI 10.1029/GL017i004p00449; WORSNOP DR, 1993, SCIENCE, V259, P71, DOI 10.1126/science.259.5091.71	36	237	240	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	2001	291	5506					1026	1031		10.1126/science.1057265	http://dx.doi.org/10.1126/science.1057265			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161213				2022-12-28	WOS:000166860100041
J	Lindner, A; Zierz, S				Lindner, A; Zierz, S			Retroperitoneal hemorrhage	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Halle Wittenberg, D-06097 Halle, Germany	Martin Luther University Halle Wittenberg	Lindner, A (corresponding author), Univ Halle Wittenberg, D-06097 Halle, Germany.								0	9	10	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					348	348		10.1056/NEJM200102013440505	http://dx.doi.org/10.1056/NEJM200102013440505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172166				2022-12-28	WOS:000166675800005
J	Johansson, S; Letokhov, V				Johansson, S; Letokhov, V			Resonance-enhanced two-photon ionization of ions by Lyman alpha radiation in gaseous nebulae	SCIENCE			English	Article								One of the mysteries of nebulae in the vicinity of bright stars is the appearance of bright emission spectral Lines of ions, which imply fairly high excitation temperatures. We suggest that an ion formation mechanism, based on resonance-enhanced two-photon ionization (RETPI) by intense H Lyman alpha radiation (wavelength of 1215 angstroms) trapped inside optically thick nebulae, can produce these spectral Lines. The rate of such an ionization process is high enough for rarefied gaseous media where the recombination rate of the ions formed can be 10(-6) to 10(-8) per second for an electron density of 10(3) to 10(5) per cubic centimeter in the nebula. Under such conditions, the photo-ions formed may subsequently undergo further RETPI, catalyzed by intense He I and He Ii radiation, which also gets enhanced in optically thick nebulae that contain enough helium.	Univ Lund, Inst Phys, S-22100 Lund, Sweden; Russian Acad Sci, Inst Spect, Troitsk 142190, Moscow Region, Russia	Lund University; Russian Academy of Sciences; Institute of Spectroscopy	Johansson, S (corresponding author), Univ Lund, Inst Phys, S-22100 Lund, Sweden.							Aller L. H., 1956, GASEOUS NEBULAE; BASHKIN S, 1975, ATOMIC ENERGY LEVELS, V1; Bloembergen N, 1992, NONLINEAR OPTICS; Bowen IS, 1935, ASTROPHYS J, V81, P1, DOI 10.1086/143613; FRANKEN PA, 1961, PHYS REV LETT, V7, P118, DOI 10.1103/PhysRevLett.7.118; Goppert-Mayer M, 1931, ANN PHYS-BERLIN, V9, P273; Johansson S, 2000, ASTRON ASTROPHYS, V361, P977; KAISER W, 1961, PHYS REV LETT, V7, P229, DOI 10.1103/PhysRevLett.7.229; Letokhov V.S, 1987, LASER PHOTOIONIZATIO; Middlehurst B.M., 1968, NEBULAE INTERSTELLAR; Osterbrock D. E., 2006, ASTROPHYSICS GASEOUS; Shen Y. R., 1984, PRINCIPLES NONLINEAR	12	10	10	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 26	2001	291	5504					625	627		10.1126/science.291.5504.625	http://dx.doi.org/10.1126/science.291.5504.625			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396BG	11158669				2022-12-28	WOS:000166616000035
J	Samuelsson, A; Towers, TL; Ravetch, JV				Samuelsson, A; Towers, TL; Ravetch, JV			Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor	SCIENCE			English	Article							IMMUNE THROMBOCYTOPENIC PURPURA; INTRAVENOUS GAMMA-GLOBULIN; RANDOMIZED TRIAL; IMMUNOGLOBULIN; AUTOIMMUNE; MICE; AUTOANTIBODIES; CHILDHOOD; RESPONSES; THERAPY	The molecular basis for the anti-inflammatory property of intravenous gamma globulin (IVIG) was investigated in a murine model of immune thrombocytopenia. Administration of clinically protective doses of intact antibody or monomeric Fe fragments to wild-type or Fc gamma receptor-humanized mice prevented platelet consumption triggered by a pathogenic autoantibody. The inhibitory Pc receptor, Fc gamma RIIB, was required for protection, because disruption either by genetic deletion or with a blocking monoclonal antibody reversed the therapeutic effect of IVIG. Protection was associated with the ability of IVIG administration to induce surface expression of Fc gamma RIIB on splenic macrophages. Modulation of inhibitory signaling is thus a potent therapeutic strategy for attenuating autoantibody-triggered inflammatory diseases.	Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10021 USA	Rockefeller University	Ravetch, JV (corresponding author), Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				Ballow M, 1997, J ALLERGY CLIN IMMUN, V100, P151, DOI 10.1016/S0091-6749(97)70217-3; BLANCHETTE V, 1994, LANCET, V344, P703, DOI 10.1016/S0140-6736(94)92205-5; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; CLYNES R, 1995, IMMUNITY, V3, P21, DOI 10.1016/1074-7613(95)90155-8; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; DWYER JM, 1992, NEW ENGL J MED, V326, P107; GAJDOS P, 1984, LANCET, V1, P406; IMBACH P, 1981, LANCET, V1, P1228; JAYNE DRW, 1991, LANCET, V337, P1137, DOI 10.1016/0140-6736(91)92797-6; LeHoang P, 2000, OCUL IMMUNOL INFLAMM, V8, P49, DOI 10.1076/0927-3948(200003)8:1;1-S;FT049; Li M, 1996, J EXP MED, V183, P1259, DOI 10.1084/jem.183.3.1259; MIZUTANI H, 1993, BLOOD, V82, P837; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; SALAMA A, 1984, BLUT, V49, P29, DOI 10.1007/BF00320381; Schiller C, 2000, EUR J IMMUNOL, V30, P481; SOUBRANE C, 1993, BLOOD, V81, P15; SULTAN Y, 1984, LANCET, V2, P765; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490	26	798	884	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					484	486		10.1126/science.291.5503.484	http://dx.doi.org/10.1126/science.291.5503.484			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161202				2022-12-28	WOS:000166487500041
J	Summerfield, D				Summerfield, D			The invention of post-traumatic stress disorder and the social usefulness of a psychiatric category	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England	St Georges University London	Summerfield, D (corresponding author), St George Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England.							ANDREASEN NC, 1995, AM J PSYCHIAT, V152, P963; BOWMAN M, 1994, CAN J PSYCHIAT, V44, P21; Bracken Patrick., 1998, RETHINKING TRAUMA WA; de Jong K, 2000, LANCET, V355, P2067, DOI 10.1016/S0140-6736(00)02364-3; Firth-Cozens J, 1999, BRIT MED J, V319, P1609, DOI 10.1136/bmj.319.7225.1609; Merridale C, 2000, J CONTEMP HIST, V35, P39, DOI 10.1177/002200940003500105; Middleton H, 2000, BRIT MED J, V320, P1420, DOI 10.1136/bmj.320.7247.1420; SCOTT WJ, 1990, SOC PROBL, V37, P294, DOI 10.1525/sp.1990.37.3.03a00020; Summerfield D, 1999, SOC SCI MED, V48, P1449, DOI 10.1016/S0277-9536(98)00450-X; Young A., 1995, HARMONY ILLUSIONS	10	369	384	1	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					95	98		10.1136/bmj.322.7278.95	http://dx.doi.org/10.1136/bmj.322.7278.95			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154627	Green Published			2022-12-28	WOS:000166496100037
J	Hanly, PJ; Pierratos, A				Hanly, PJ; Pierratos, A			Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE; TRANSPLANTATION; EXPERIENCE; KIDNEY	Background: Sleep apnea is common in patients with chronic renal failure and is not improved by either conventional hemodialysis or peritoneal dialysis. With nocturnal hemodialysis, patients undergo hemodialysis seven nights per week at home, while sleeping. We hypothesized that nocturnal hemodialysis would correct sleep apnea in patients with chronic renal failure because of its greater effectiveness. Methods: Fourteen patients who were undergoing conventional hemodialysis for four hours on each of three days per week underwent overnight polysomnography. The patients were then switched to nocturnal hemodialysis for eight hours during each of six or seven nights a week. They underwent polysomnography again 6 to 15 months later on one night when they were undergoing nocturnal hemodialysis and on another night when they were not. Results: The mean (+/-SD) serum creatinine concentration was significantly lower during the period when the patients were undergoing nocturnal hemodialysis than during the period when they were undergoing conventional hemodialysis (3.9+/-1.1 vs. 12.8+/-3.2 mg per deciliter [342+/-101 vs. 1131+/-287 micromol per liter], P<0.001). The conversion from conventional hemodialysis to nocturnal hemodialysis was associated with a reduction in the frequency of apnea and hypopnea from 25+/-25 to 8+/-8 episodes per hour of sleep (P=0.03). This reduction occurred predominantly in seven patients with sleep apnea, in whom the frequency of episodes fell from 46+/-19 to 9+/-9 per hour (P=0.006), accompanied by increases in the minimal oxygen saturation (from 89.2+/-1.8 to 94.1+/-1.6 percent, P=0.005), transcutaneous partial pressure of carbon dioxide (from 38.5+/-4.3 to 48.3+/-4.9 mm Hg, P=0.006), and serum bicarbonate concentration (from 23.2+/-1.8 to 27.8+/-0.8 mmol per liter, P<0.001). During the period when these seven patients were undergoing nocturnal hemodialysis, the apnea-hypopnea index measured on nights when they were not undergoing nocturnal hemodialysis was greater than that on nights when they were undergoing nocturnal hemodialysis, but it still remained lower than it had been during the period when they were undergoing conventional hemodialysis (P=0.05). Conclusions: Nocturnal hemodialysis corrects sleep apnea associated with chronic renal failure. (N Engl J Med 2001;344:102-7.) Copyright (C) 2001 Massachusetts Medical Society.	St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, Humber River Reg Hosp, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Pierratos, A (corresponding author), St Michaels Hosp, Dept Med, Rm 3049,Bond Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.		Pierratos, Andreas/AAZ-1834-2020	Pierratos, Andreas/0000-0003-2810-0698				*AM SLEEP DIS ASS, 1990, DIAGN CLASS COMM INT, P65; Auckley DH, 1999, AM J KIDNEY DIS, V34, P739, DOI 10.1016/S0272-6386(99)70401-4; Brissenden J. E., 1998, Journal of the American Society of Nephrology, V9, p168A; FLETCHER EC, 1993, J AM SOC NEPHROL, V4, P1111; HAMILTON RW, 1976, J APPL PHYSIOL, V41, P216, DOI 10.1152/jappl.1976.41.2.216; HUDGEL DW, 1987, AM REV RESPIR DIS, V135, P899, DOI 10.1164/arrd.1987.135.4.899; KIMMEL PL, 1989, J NEPHROL, V1, P59; Kraus MA, 1997, ADV PERIT D, V13, P88; LANGEVIN B, 1993, CHEST, V103, P1330, DOI 10.1378/chest.103.5.1330; MENDELSON WB, 1990, CLIN NEPHROL, V33, P247; MILLMAN RP, 1985, NEPHRON, V40, P407, DOI 10.1159/000183509; Mucsi I, 1998, KIDNEY INT, V53, P1399, DOI 10.1046/j.1523-1755.1998.00875.x; O'Sullivan DA, 1998, MAYO CLIN PROC, V73, P1035, DOI 10.4065/73.11.1035; ONAL E, 1986, J APPL PHYSIOL, V61, P1438, DOI 10.1152/jappl.1986.61.4.1438; Onal E., 1993, KIDNEY, V2, P309; Pierratos A, 1999, NEPHROL DIAL TRANSPL, V14, P2835, DOI 10.1093/ndt/14.12.2835; Pierratos A, 1998, J AM SOC NEPHROL, V9, P859; Raj DSC, 2000, NEPHROL DIAL TRANSPL, V15, P58, DOI 10.1093/ndt/15.1.58; RECHTSCHAFFEN A, 1968, MANUAL STANDARDIZED, P1; SOREIDE E, 1991, KIDNEY INT, V40, P539, DOI 10.1038/ki.1991.243; STEPANSKI E, 1995, J AM SOC NEPHROL, V6, P192; Wilcox I, 1998, EUR RESPIR J, V11, P7, DOI 10.1183/09031936.98.11010007	22	387	395	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2001	344	2					102	107		10.1056/NEJM200101113440204	http://dx.doi.org/10.1056/NEJM200101113440204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390DU	11150360	Bronze			2022-12-28	WOS:000166281100004
J	Nowak, MA; Komarova, NL; Niyogi, P				Nowak, MA; Komarova, NL; Niyogi, P			Evolution of universal grammar	SCIENCE			English	Article							LANGUAGE	Universal grammar specifies the mechanism of Language acquisition. It determines the range of grammatical hypothesis that children entertain during language Learning and the procedure they use for evaluating input sentences. How universal grammar arose is a major challenge for evolutionary biology. We present a mathematical framework for the evolutionary dynamics of grammar learning. The central result is a coherence threshold, which specifies the condition for a universal grammar to induce coherent communication within a population. We study selection of grammars within the same universal grammar and competition between different universal grammars. We calculate the condition under which natural selection favors the emergence of rule-based generative grammars that underlie complex Language.	Inst Adv Study, Princeton, NJ 08540 USA; Univ Leeds, Dept Math, Leeds LS2 9JT, W Yorkshire, England; Univ Chicago, Dept Comp Sci, Chicago, IL 60637 USA	Institute for Advanced Study - USA; University of Leeds; University of Chicago	Nowak, MA (corresponding author), Inst Adv Study, Einstein Dr, Princeton, NJ 08540 USA.		Nowak, Martin A/A-6977-2008					Batali J., 1998, APPROACHES EVOLUTION; BRANDON R N, 1986, Biology and Philosophy, V1, P169; Chomsky N, 1980, RULES REPRESENTATION; Chomsky Noam, 1993, VIEW BUILDING, P1; Eigen M, 1979, THE HYPERCYCLE, P60; GIBSON E, 1994, LINGUIST INQ, V25, P407; GOLD EM, 1967, INFORM CONTROL, V10, P447, DOI 10.1016/S0019-9958(67)91165-5; Gopnik M, 1999, LANGUAGE, LOGIC, AND CONCEPTS, P263; Hashimoto T, 1996, BIOSYSTEMS, V38, P1, DOI 10.1016/0303-2647(95)01563-9; Hauser, 1996, EVOL COMMUN; Hornstein N., 1981, EXPLANATION LINGUIST; Hyams N., 1986, LANG ACQUIS; Jackendoff R, 1997, ARCHITECTURE LANGUAG; LIGHTFOOT DW, 1999, DEV LANGUAGE ACQUIST; MANZINI MR, 1987, LINGUIST INQ, V18, P413; Miller G.A., 1996, SCI WORDS; NIYOGI P, 1998, INFORMATIONAL COMPLE; Nowak MA, 2000, NATURE, V404, P495, DOI 10.1038/35006635; Nowak MA, 1999, P NATL ACAD SCI USA, V96, P8028, DOI 10.1073/pnas.96.14.8028; OSHERSON DN, 1986, SYSTEMS LEARN; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; Pinker S., 1999, WORDS RULES; Pinker Steven, 1994, LANGUAGE INSTINCT; PRINCE A, 1993, TR2 RUCCS, P234; Radford A., 1990, SYNTACTIC THEORY ACQ; Szathmary E, 1995, MAJOR TRANSITIONS EV; Tesar BB, 1998, LINGUA, V106, P161, DOI 10.1016/S0024-3841(98)00033-3; VALIANT LG, 1984, COMMUN ACM, V27, P436; VONHUMBOLDT W, 1972, UNGUISTIC VARIABILIT; WEXLER K, 1980, FORMAL PRINCIPLES LA	31	240	244	9	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 5	2001	291	5501					114	118		10.1126/science.291.5501.114	http://dx.doi.org/10.1126/science.291.5501.114			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	389VJ	11141560				2022-12-28	WOS:000166259100046
J	Simpson, JH; Bland, KS; Fetter, RD; Goodman, CS				Simpson, JH; Bland, KS; Fetter, RD; Goodman, CS			Short-range and long-range guidance by slit and its Robo receptors: A combinatorial code of Robo receptors controls lateral position	CELL			English	Article							NEURONAL GROWTH CONES; CELL-ADHESION MOLECULE; GRASSHOPPER EMBRYOS; AXON GUIDANCE; FASCICLIN-II; CNS MIDLINE; RETINOTECTAL PROJECTION; SELECTIVE FASCICULATION; GENETIC-ANALYSIS; DROSOPHILA	Slit is secreted by midline glia in Drosophila and functions as a short-range repellent to control midline crossing. Although most Slit stays near the midline, some diffuses laterally, functioning as a long-range chemorepellent. Here we show that a combinatorial code of Robe receptors controls lateral position in the CNS by responding to this presumptive Slit gradient. Medial axons express only Robe, intermediate axons express Robo3 and Robe, while lateral axons express Robo2, Robo3, and Robe. Removal of robo2 or robo3 causes lateral axons to extend medially; ectopic expression of Robo2 or Robo3 on medial axons drives them laterally. Precise topography of longitudinal pathways appears to be controlled by a combination of long-range guidance (the Robe code determining region) and short-range guidance (discrete local cues determining specific location within a region).	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Goodman, CS (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Div Neurobiol, 519 LSA, Berkeley, CA 94720 USA.	goodman@uclink4.berkeley.edu		Bland, Kimberly/0000-0003-4863-6772; Simpson, Julie/0000-0002-6793-7100	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18366] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1984, J NEUROSCI, V4, P2311; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GIERER A, 1987, DEVELOPMENT, V101, P479; Gierer Alfred, 1995, Current Opinion in Neurobiology, V5, P91, DOI 10.1016/0959-4388(95)80092-1; Goodman C.S., 1985, P295; Goodman C. S., 1993, DEV DROSOPHILA MELAN; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; Hidalgo A, 1997, DEVELOPMENT, V124, P3253; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; O'Keefe DD, 1998, DEVELOPMENT, V125, P3915; O'Leary DDM, 1999, CELL, V96, P255, DOI 10.1016/S0092-8674(00)80565-6; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Rajagopalan S, 2000, CELL, V103, P1033, DOI 10.1016/S0092-8674(00)00207-5; Rajagopalan S, 2000, NEURON, V28, P767, DOI 10.1016/S0896-6273(00)00152-5; RAPER JA, 1983, J NEUROSCI, V3, P20; RAPER JA, 1983, COLD SPRING HARB SYM, V48, P587, DOI 10.1101/SQB.1983.048.01.063; RAPER JA, 1984, J NEUROSCI, V4, P2329; RAPER JA, 1983, J NEUROSCI, V3, P31; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Simpson JH, 2000, NEURON, V28, P753, DOI 10.1016/S0896-6273(00)00151-3; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Wong JTW, 1997, DEVELOPMENT, V124, P3597; Yu HH, 1998, NEURON, V20, P207, DOI 10.1016/S0896-6273(00)80450-X; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0; Zoo YM, 2000, CELL, V102, P363, DOI 10.1016/S0092-8674(00)00041-6	45	224	225	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1019	1032		10.1016/S0092-8674(00)00206-3	http://dx.doi.org/10.1016/S0092-8674(00)00206-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163179	Bronze			2022-12-28	WOS:000166040600006
J	Chen, L; Chetkovich, DM; Petralia, RS; Sweeney, NT; Kawasaki, Y; Wenthold, RJ; Bredt, DS; Nicoll, RA				Chen, L; Chetkovich, DM; Petralia, RS; Sweeney, NT; Kawasaki, Y; Wenthold, RJ; Bredt, DS; Nicoll, RA			Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms	NATURE			English	Article							MUTANT MOUSE; GLUTAMATE RECEPTORS; SYNAPSES; FAMILY; ORGANIZATION; EXPRESSION; PROTEINS; SUBUNITS; REVEALS; WAGGLER	Stargazer, an ataxic and epileptic mutant mouse, lacks functional AMPA (alpha -amino-3-hydroxyl-5-methyl-4-isoxazolepropionate) receptors on cerebellar granule cells. Stargazin, the mutated protein, interacts with both AMPA receptor subunits and synaptic PDZ proteins, such as PSD-95. The interaction of stargazin with AMPA receptor subunits is essential for delivering functional receptors to the surface membrane of granule cells, whereas its binding with PSD-95 and related PDZ proteins through a carboxy-terminal PDZ-binding domain is required for targeting the AMPA receptor to synapses. Expression of a mutant stargazin lacking the PDZ-binding domain in hippocampal pyramidal cells disrupts synaptic AMPA receptors, indicating that stargazin-like mechanisms for targeting AMPA receptors may be widespread in the central nervous system.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; NIDCD, Neurochem Lab, NIH, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	nicoll@phy.ucsf.edu	Chetkovich, Dane/AAV-5457-2021	Chen, Lu/0000-0002-8097-2699				Bao SW, 1998, LEARN MEMORY, V5, P355; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; Chen L, 1999, P NATL ACAD SCI USA, V96, P12132, DOI 10.1073/pnas.96.21.12132; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; LESTER RAJ, 1989, MOL PHARMACOL, V35, P565; LESTER RAJ, 1992, J NEUROSCI, V12, P635; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Liu SQJ, 2000, NATURE, V405, P454, DOI 10.1038/35013064; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Luthi A, 1999, NEURON, V24, P389, DOI 10.1016/S0896-6273(00)80852-1; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Matsubara A, 1996, J NEUROSCI, V16, P4457; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Palay S. L., 1974, CEREBELLAR CORTEX CY; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; Petralia RS, 1998, NEUROPHARMACOLOGY, V37, P1321, DOI 10.1016/S0028-3908(98)00118-X; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; PETRALIA RS, 1994, J NEUROSCI, V14, P667; RANDALL A, 1995, J NEUROSCI, V15, P2995; Sheng M, 1999, ANN NY ACAD SCI, V868, P483, DOI 10.1111/j.1749-6632.1999.tb11317.x; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Wang YX, 1998, J NEUROSCI, V18, P1148; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Zhao HM, 1998, J NEUROSCI, V18, P5517, DOI 10.1523/JNEUROSCI.18-14-05517.1998	37	841	865	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					936	943		10.1038/35050030	http://dx.doi.org/10.1038/35050030			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140673				2022-12-28	WOS:000165951100039
J	Lindvall, O; Bjorklund, A				Lindvall, O; Bjorklund, A			First step towards cell therapy for Huntington's disease	LANCET			English	Editorial Material							STRIATAL ALLOGRAFTS; PRIMATE MODEL		Univ Lund, Wallenberg Neurosci Ctr, SE-22362 Lund, Sweden	Lund University	Lindvall, O (corresponding author), Univ Lund, Wallenberg Neurosci Ctr, SE-22362 Lund, Sweden.		Björklund, Anders/ABA-1326-2020	Bjorklund, Anders/0000-0002-5676-6203				Dunnett S B, 2000, Prog Brain Res, V127, P345; Freeman TB, 2000, P NATL ACAD SCI USA, V97, P13877, DOI 10.1073/pnas.97.25.13877; Kendall AL, 1998, NAT MED, V4, P727, DOI 10.1038/nm0698-727; Palfi S, 1998, NAT MED, V4, P963, DOI 10.1038/nm0898-963; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060	5	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1945	1946		10.1016/S0140-6736(00)03302-X	http://dx.doi.org/10.1016/S0140-6736(00)03302-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130518				2022-12-28	WOS:000165867600004
J	De Camilli, P; Carew, TJ				De Camilli, P; Carew, TJ			Nobel celebrates the neurosciences: Modulatory signaling in the brain	CELL			English	Article									Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA	Howard Hughes Medical Institute; Yale University; Yale University; University of California System; University of California Irvine	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.								0	4	4	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					829	833		10.1016/S0092-8674(00)00185-9	http://dx.doi.org/10.1016/S0092-8674(00)00185-9			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136967	Bronze			2022-12-28	WOS:000165801300001
J	Graham, CS; Koziel, MJ				Graham, CS; Koziel, MJ			Why should hepatitis C affect immune reconstitution in HIV-1-infected patients?	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRESSION; INFECTIONS; CELLS; AIDS		Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Koziel, MJ (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.							Alter MJ, 1998, INFECT DIS CLIN N AM, V12, P13, DOI 10.1016/S0891-5520(05)70405-0; Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409; Donahoe RM, 1998, J NEUROIMMUNOL, V83, P77, DOI 10.1016/S0165-5728(97)00224-5; Gougeon ML, 1999, ANN NY ACAD SCI, V887, P199, DOI 10.1111/j.1749-6632.1999.tb07934.x; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Jenny-Avital ER, 2000, CLIN INFECT DIS, V30, P409, DOI 10.1086/313676; Lai MMC, 2000, HEPATOLOGY, V32, P427, DOI 10.1053/jhep.2000.9856; Laskus T, 2000, J INFECT DIS, V181, P442, DOI 10.1086/315283; Lerat H, 1996, J CLIN INVEST, V97, P845, DOI 10.1172/JCI118485; Pezzotti P, 1999, J ACQ IMMUN DEF SYND, V20, P275, DOI 10.1097/00042560-199903010-00010; Staples CT, 1999, CLIN INFECT DIS, V29, P150, DOI 10.1086/520144; Taya N, 2000, BRIT J HAEMATOL, V110, P89, DOI 10.1046/j.1365-2141.2000.01945.x; VOGT MW, 1987, SCIENCE, V235, P1376, DOI 10.1126/science.2435003; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Zylberberg H, 1996, CLIN INFECT DIS, V23, P1117, DOI 10.1093/clinids/23.5.1117	16	14	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1865	1866		10.1016/S0140-6736(00)03251-7	http://dx.doi.org/10.1016/S0140-6736(00)03251-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130376				2022-12-28	WOS:000165665400003
J	Rickman, J				Rickman, J			A patient's perspective	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	2001	322	7281					293	294		10.1136/bmj.322.7281.293	http://dx.doi.org/10.1136/bmj.322.7281.293			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157537	Green Published			2022-12-28	WOS:000166917600039
J	Knapp, AK; Smith, MD				Knapp, AK; Smith, MD			Variation among biomes in temporal dynamics of aboveground primary production	SCIENCE			English	Article							CLIMATE; ECOSYSTEMS; VARIABILITY	Interannual variability in aboveground net primary production (ANPP) was assessed with Long-term (mean = 12 years) data from 11 Long Term Ecological Research sites across North America. The greatest interannual variability in ANPP occurred in grasslands and old fields, with forests the Least variable, At a continental scale, ANPP was strongly correlated with annual precipitation. However, interannual variability in ANPP was not related to variability in precipitation. Instead, maximum variability in ANPP occurred in biomes where high potential growth rates of herbaceous vegetation were combined with moderate variability in precipitation. In the most dynamic biomes, ANPP responded more strongly to wet than to dry years. Recognition of the fourfold range in ANPP dynamics across biomes and of the factors that constrain this variability is critical for detecting the biotic impacts of global change phenomena.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University	Knapp, AK (corresponding author), Kansas State Univ, Div Biol, Manhattan, KS 66506 USA.		Noojipady, Praveen/B-2511-2010; Knapp, Alan K/A-2931-2008; Smith, Melinda D/J-8987-2014					CALLAHAN JT, 1984, BIOSCIENCE, V34, P363, DOI 10.2307/1309727; Easterling DR, 2000, SCIENCE, V289, P2068, DOI 10.1126/science.289.5487.2068; FRANK DA, 1994, J BIOGEOGR, V21, P401, DOI 10.2307/2845758; Goward SN, 1995, J BIOGEOGR, V22, P549, DOI 10.2307/2845953; KARL TR, 1991, SCIENCE, V251, P1058, DOI 10.1126/science.251.4997.1058; KARL TR, 1995, NATURE, V377, P217, DOI 10.1038/377217a0; KITTEL TGF, 1997, P 10 C APPL CLIM AM; LAUENROTH WK, 1992, ECOL APPL, V2, P397, DOI 10.2307/1941874; LEHOUEROU HN, 1998, J ARID ENVIRON, V15, P1; LIETH H, 1973, HUM ECOL, V1, P303, DOI 10.1007/BF01536729; MELILLO JM, 1993, NATURE, V363, P234, DOI 10.1038/363234a0; Paruelo JM, 1999, ECOSYSTEMS, V2, P64, DOI 10.1007/s100219900058; ROSENZWEIG ML, 1968, AM NAT, V102, P67, DOI 10.1086/282523; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; Schimel DS, 1997, P NATL ACAD SCI USA, V94, P8280, DOI 10.1073/pnas.94.16.8280; Schimel DS, 1997, ECOL MONOGR, V67, P251, DOI 10.1890/0012-9615(1997)067[0251:CSVIEP]2.0.CO;2; SEASTEDT TR, 1993, AM NAT, V141, P621, DOI 10.1086/285494; THORNTHWAITE C. W., 1955, PUBLICATIONS CLIMATO, VVIII, DOI DOI 10.1017/CBO9781107339200.011; Waide RB, 1999, ANNU REV ECOL SYST, V30, P257, DOI 10.1146/annurev.ecolsys.30.1.257; WEBB WL, 1983, ECOLOGY, V64, P134, DOI 10.2307/1937336; Woodward F.I., 1987, CLIMATE PLANT DISTRI; Wright H.E., 1993, GLOBAL CLIMATES LAST	23	991	1117	16	518	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2001	291	5503					481	484		10.1126/science.291.5503.481	http://dx.doi.org/10.1126/science.291.5503.481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161201				2022-12-28	WOS:000166487500040
J	Meyer, CH; Muller, MF; Meyer, HJ				Meyer, CH; Muller, MF; Meyer, HJ			Can we trust elderly donor grafts for corneal transplantation?	BRITISH MEDICAL JOURNAL			English	Letter									Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA; Med Univ Lubeck, Dept Ophthalmol, D-23538 Lubeck, Germany; Marienhosp Osnabruck, Dept Ophthalmol, D-49074 Osnabruck, Germany	Duke University; University of Lubeck; St. Marien Hospital	Meyer, CH (corresponding author), Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.							BOURNE WM, 1994, AM J OPHTHALMOL, V118, P185, DOI 10.1016/S0002-9394(14)72898-3; Davis RM, 1999, BRIT MED J, V319, P1382, DOI 10.1136/bmj.319.7222.1382; Duncker G. I. W., 1995, Ophthalmologe, V92, P366; MATTERN RM, 1995, CORNEA, V14, P562; MEYER CH, 1999, AM ACAD OPHTHALMOL	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 13	2001	322	7278					108	109		10.1136/bmj.322.7278.108	http://dx.doi.org/10.1136/bmj.322.7278.108			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	393XZ	11154643				2022-12-28	WOS:000166496100061
J	Wilcox, ER; Burton, QL; Naz, S; Riazuddin, S; Smith, TN; Ploplis, B; Belyantseva, I; Ben-Yosef, T; Liburd, NA; Morell, RJ; Kachar, B; Wu, DK; Griffith, AJ; Riazuddin, S; Friedman, TB				Wilcox, ER; Burton, QL; Naz, S; Riazuddin, S; Smith, TN; Ploplis, B; Belyantseva, I; Ben-Yosef, T; Liburd, NA; Morell, RJ; Kachar, B; Wu, DK; Griffith, AJ; Riazuddin, S; Friedman, TB			Mutations in the gene encoding tight junction claudin-14 cause autosomal recessive deafness DFNB29	CELL			English	Article							STRIA VASCULARIS; INNER-EAR; INTERCELLULAR-JUNCTIONS; STRANDS; PROTEINS; SEQUENCE; ORGAN; OCCLUDIN; LOCALIZATION; MATURATION	Tight junctions in the cochlear duct are thought to compartmentalize endolymph and provide structural support for the auditory neuroepithelium. The claudin family of genes is known to express protein components of tight junctions in other tissues. The essential function of one of these claudins in the inner ear was established by identifying mutations in CLDN14 that cause nonsyndromic recessive deafness DFNB29 in two large consanguineous Pakistani families. In situ hybridization and immunofluorescence studies demonstrated mouse claudin-14 expression in the sensory epithelium of the organ of Corti.	NIDCD, Mol Genet Lab, NIH, Rockville, MD 20850 USA; Univ Punjab, Ctr Excellence Mol Biol, Lahore, Pakistan; NIDCD, Sect Sensory Cell Regenerat & Dev, NIH, Rockville, MD 20850 USA; NIDCD, Sect Struct Cell biol, NIH, Rockville, MD 20850 USA; NIDCD, Neurootol Branch, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Punjab; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Wilcox, ER (corresponding author), NIDCD, Mol Genet Lab, NIH, 5 Res Court, Rockville, MD 20850 USA.	wilcoxe@nidcd.nih.gov	Naz, Sadaf/C-3911-2019; Morell, Robert James/Q-2042-2019	Naz, Sadaf/0000-0002-1912-0235; Morell, Robert/0000-0003-1537-7356	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000021, ZIADC000002, ZIADC000060, Z01DC000002, Z01DC000060, ZIADC000064, Z01DC000048, Z01DC000021, ZIADC000048, ZIADC000039, Z01DC000039, Z01DC000064] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANNIKO M, 1984, SCAN ELECTRON MICROS, P2067; ANNIKO M, 1982, AM J OTOLARYNG, V3, P242, DOI 10.1016/S0196-0709(82)80062-8; BAGGERSJOBACK D, 1988, ACTA OTO-LARYNGOL, V106, P19, DOI 10.3109/00016488809107366; Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Berry A, 2000, GENOMICS, V68, P22, DOI 10.1006/geno.2000.6253; BonneTamir B, 1996, AM J HUM GENET, V58, P1254; Bork JM, 2001, AM J HUM GENET, V68, P26, DOI 10.1086/316954; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; BUCHANAN LH, 1990, SCAND AUDIOL, V19, P103, DOI 10.3109/01050399009070760; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLAUDE P, 1973, J CELL BIOL, V58, P390, DOI 10.1083/jcb.58.2.390; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Ferrary E, 1998, KIDNEY INT, pS98; Friedman T, 2000, CURR OPIN NEUROBIOL, V10, P487, DOI 10.1016/S0959-4388(00)00120-3; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gow A, 1999, CELL, V99, P649, DOI 10.1016/S0092-8674(00)81553-6; Gratton MA, 1997, HEARING RES, V108, P9, DOI 10.1016/S0378-5955(97)00034-8; GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390; GULLEY RL, 1976, J NEUROCYTOL, V5, P479, DOI 10.1007/BF01181652; Harris NL, 1997, GENOME RES, V7, P754, DOI 10.1101/gr.7.7.754; Hassmann E, 1998, INT J PEDIATR OTORHI, V45, P199, DOI 10.1016/S0165-5876(98)00106-2; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jahnke K, 1975, Acta Otolaryngol Suppl, V336, P1; JOHNSTONE BM, 1972, Q REV BIOPHYS, V5, P1, DOI 10.1017/S0033583500000032; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liu XZ, 2000, HUM MOL GENET, V9, P63, DOI 10.1093/hmg/9.1.63; LUCIANO L, 1995, HEARING RES, V85, P199, DOI 10.1016/0378-5955(95)00047-8; Marcus DC, 1999, HEARING RES, V134, P48, DOI 10.1016/S0378-5955(99)00074-X; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Milhaud PG, 1999, PFLUG ARCH EUR J PHY, V437, P823, DOI 10.1007/s004240050851; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Morell RJ, 1998, NEW ENGL J MED, V339, P1500, DOI 10.1056/NEJM199811193392103; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morsli H, 1998, J NEUROSCI, V18, P3327; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; NADOL JB, 1978, ANN OTO RHINOL LARYN, V87, P70, DOI 10.1177/000348947808700113; Riazuddin S, 2000, NAT GENET, V26, P431, DOI 10.1038/82558; RYAN AF, 1979, OTOLARYNG HEAD NECK, V87, P659, DOI 10.1177/019459987908700522; RYAN AF, 1983, SCAN ELECTRON MICROS, P201; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SCHNAPP B, 1978, PHYSL PATHOBIOLOGY A, P83; SCOTT HS, 2001, IN PRESS NAT GENET; Shapiro BL, 1997, HUM GENET, V99, P421, DOI 10.1007/s004390050383; Shapiro BL, 1999, J NEURAL TRANSM-SUPP, P41; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Slepecky N. B., 1996, COCHLEA, V8, P44; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; Souter M, 1998, HEARING RES, V119, P81, DOI 10.1016/S0378-5955(98)00042-2; Stankovic KM, 1997, HEARING RES, V114, P21, DOI 10.1016/S0378-5955(97)00072-5; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Ulfendahl M, 2000, NEUROIMAGE, V12, P307, DOI 10.1006/nimg.2000.0617; Wong V, 1999, SCIENCE, V285, P62, DOI 10.1126/science.285.5424.62; Xia JH, 1998, NAT GENET, V20, P370, DOI 10.1038/3845; Yu ASL, 2000, CURR OPIN NEPHROL HY, V9, P513, DOI 10.1097/00041552-200009000-00009	65	333	353	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 12	2001	104	1					165	172		10.1016/S0092-8674(01)00200-8	http://dx.doi.org/10.1016/S0092-8674(01)00200-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163249	Bronze			2022-12-28	WOS:000166882300016
J	Feikin, DR; Lezotte, DC; Hamman, RF; Salmon, DA; Chen, RT; Hoffman, RE				Feikin, DR; Lezotte, DC; Hamman, RF; Salmon, DA; Chen, RT; Hoffman, RE			Individual and community risks of measles and pertussis associated with personal exemptions to immunization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN; VACCINATION; OUTBREAK; HEALTH; LAWS	Context The risk of vaccine-preventable diseases among children who have philosophical and religious exemptions from immunization has been understudied, Objectives To evaluate whether personal exemption from immunization is associated with risk of measles and pertussis at individual and community levels. Design, Setting, and Participants Population-based, retrospective cohort study using data collected on standardized forms regarding all reported measles and pertussis cases among children aged 3 to 18 years in Colorado during 1987-1998, Main Outcome Measures Relative risk of measles and pertussis among exemptors and vaccinated children; association between incidence rates among vaccinated children and frequency of exemptors in Colorado counties; association between school outbreaks and frequency of exemptors in schools; and risk associated with exposure to an exemptor in measles outbreaks. Results Exemptors were 22.2 times (95% confidence interval [CI], 15.9-31.1) more likely to acquire measles and 5.9 times (95% CI, 4.2-8.2) more likely to acquire pertussis than Vaccinated children. After adjusting for confounders, the frequency of exemptors in a county was associated with the incidence rate of measles (relative risk [RR], 1.6, 95% CI, 1.0-2.4) and pertussis (RR, 1.9; 95 % CI, 1.7-2.1) in vaccinated children. Schools with pertussis outbreaks had more exemptors (mean, 4.3% of students) than schools without outbreaks (1.5% of students; P=.001), At least 11% of vaccinated children in measles outbreaks acquired infection through contact with an exemptor, Conclusions The risk of measles and pertussis is elevated in personal exemptors. Public health personnel should recognize the potential effect of exemptors in outbreaks in their communities, and parents should be made aware of the risks involved in not vaccinating their children.	Ctr Dis Control & Prevent, Resp Dis Branch, Epidemiol Program Off, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Colorado Dept Publ Hlth & Environm, Denver, CO USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Colorado Department of Public Health & Environment; Johns Hopkins University	Feikin, DR (corresponding author), Ctr Dis Control & Prevent, Resp Dis Branch, Epidemiol Program Off, 1600 Clifton Rd,MS-C23, Atlanta, GA 30333 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367; salmon, daniel/0000-0002-1035-4422				Advisory Committee on Immunization Practices, 1997, MMWR-MORBID MORTAL W, V46, P1; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control and Prevention (CDC, 1994, MMWR-MORBID MORTAL W, V43, P463; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; *COL DIV LOC GOVT, 1987, POP PROJ AG; Deeks S, 1999, CLIN INFECT DIS, V28, P840, DOI 10.1086/515203; EDWARDS KM, 1999, VACCINES, P293; ETKIND P, 1992, AM J DIS CHILD, V146, P173, DOI 10.1001/archpedi.1992.02160140039017; FINE PEM, 1986, AM J EPIDEMIOL, V124, P1012, DOI 10.1093/oxfordjournals.aje.a114471; Freed GL, 1996, JAMA-J AM MED ASSOC, V276, P1869, DOI 10.1001/jama.276.23.1869; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; Guris D, 1999, CLIN INFECT DIS, V28, P1230, DOI 10.1086/514776; Howson CP, 1991, ADVERSE EFFECTS PERT; KITCH EW, 1999, VACCINES, P1165; Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8; National Toxicology Program, 1998, M NTP BOARD SCI COUN, P1; ORENSTEIN WA, 1978, J INFECT DIS, V137, P847, DOI 10.1093/infdis/137.6.847; Paunio M, 2000, JAMA-J AM MED ASSOC, V283, P343, DOI 10.1001/jama.283.3.343; Redd SC, 1999, VACCINES-BASEL, V3rd, P222; ROBBINS KB, 1981, AM J PUBLIC HEALTH, V71, P270, DOI 10.2105/AJPH.71.3.270; RODGERS DV, 1993, PEDIATR INFECT DIS J, V12, P288, DOI 10.1097/00006454-199304000-00006; Salmon DA, 1999, JAMA-J AM MED ASSOC, V282, P47, DOI 10.1001/jama.282.1.47; Vitek CR, 1999, PEDIATR INFECT DIS J, V18, P620, DOI 10.1097/00006454-199907000-00010	26	283	286	0	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3145	3150		10.1001/jama.284.24.3145	http://dx.doi.org/10.1001/jama.284.24.3145			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135778	Bronze			2022-12-28	WOS:000165994100032
J	Wu, G; Chai, JJ; Suber, TL; Wu, JW; Du, CY; Wang, XD; Shi, YG				Wu, G; Chai, JJ; Suber, TL; Wu, JW; Du, CY; Wang, XD; Shi, YG			Structural basis of IAP recognition by Smac/DIABLO	NATURE			English	Article							PROGRAMMED CELL-DEATH; SURVIVIN REVEALS; NMR STRUCTURE; BIR DOMAIN; PROTEIN; APOPTOSIS; INHIBITOR; MUTAGENESIS; ACTIVATION; REAPER	Apoptosis is an essential process in the development and homeostasis of all metazoans(1-4). The inhibitor-of-apoptosis (IAP) proteins suppress cell death by inhibiting the activity of caspases; this inhibition is performed by the zinc-binding BIR domains(5,6) of the IAP proteins. The mitochondrial protein Smac/DIABLO promotes apoptosis by eliminating the inhibitory effect of IAPs through physical interactions(7-9). Amino-terminal sequences in Smac/DIABLO are required for this function, as mutation of the very first amino acid leads to loss of interaction with IAPs and concomitant loss of Smac/DIABLO function(9). Here we report the high-resolution crystal structure of Smac/DIABLO complexed with the third BIR domain (BIR3) of XIAP. Our results show that the N-terminal four residues (Ala-Val-Pro-Ile) in Smac/DIABLO recognize a surface groove on BIR3, with the first residue Ala binding a hydrophobic pocket and making five hydrogen bonds to neighbouring residues on BIR3. These observations provide a structural explanation for the roles of the Smac N terminus as well as the conserved N-terminal sequences in the Drosophila proteins Hid/Grim/Reaper. In conjunction with other observations, our results reveal how Smac may relieve IAP inhibition of caspase-9 activity. In addition to explaining a number of biological observations, our structural analysis identifies potential targets for drug screening.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Univ N Carolina, Chapel Hill, NC 27514 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Princeton University; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Washington Rd, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu		Chai, Jijie/0000-0001-7591-3873; Wang, Xiaodong/0000-0001-9885-356X; Shi, Yigong/0000-0003-2030-168X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL137248] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL137248] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Horvitz HR, 1999, CANCER RES, V59, p1701S; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Lisi S, 2000, GENETICS, V154, P669; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Shi YG, 2000, NAT STRUCT BIOL, V7, P620, DOI 10.1038/77904; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1	27	674	751	4	158	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 21	2000	408	6815					1008	1012		10.1038/35050012	http://dx.doi.org/10.1038/35050012			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140638				2022-12-28	WOS:000165951100059
J	Yuan, X; Sobolev, SV; Kind, R; Oncken, O; Bock, G; Asch, G; Schurr, B; Graeber, F; Rudloff, A; Hanka, W; Wylegalla, K; TIbi, R; Haberland, C; Rietbrock, A; Giese, P; Wigger, P; Rower, P; Zandt, G; Beck, S; Wallace, T; Pardo, M; Comte, D				Yuan, X; Sobolev, SV; Kind, R; Oncken, O; Bock, G; Asch, G; Schurr, B; Graeber, F; Rudloff, A; Hanka, W; Wylegalla, K; TIbi, R; Haberland, C; Rietbrock, A; Giese, P; Wigger, P; Rower, P; Zandt, G; Beck, S; Wallace, T; Pardo, M; Comte, D			Subduction and collision processes in the Central Andes constrained by converted seismic phases	NATURE			English	Article							UPPER-MANTLE STRUCTURE; SOUTHERN TIBET; CRUSTAL-THICKNESS; EARTHQUAKE DATA; ALTIPLANO-PUNA; PLATEAU; BENEATH; ARGENTINA; BOLIVIA; UPLIFT	The Central Andes are the Earth's highest mountain belt formed by ocean-continent collision(1,2). Most of this uplift is thought to have occurred in the past 20 Myr, owing mainly to thickening of the continental crust(2-6), dominated by tectonic shortening(7-10). Here we use P-to-S (compressional-to-shear) converted teleseismic waves observed on several temporary networks in the Central Andes to image the deep structure associated with these tectonic processes. We rnd that the Moho (the Mohorovicic discontinuity-generally thought to separate crust from mantle) ranges from a depth of 75 km under the Altiplano plateau to 50 km beneath the 4-km-high Puna plateau. This relatively thin crust below such a high-elevation region indicates that thinning of the lithospheric mantle may have contributed to the uplift of the Puna plateau. We have also imaged the subducted crust of the Nazca oceanic plate down to 120 km depth, where it becomes invisible to converted teleseismic waves, probably owing to completion of the gabbro-eclogite transformation; this is direct evidence for the presence of kinetically delayed metamorphic reactions in subducting plates. Most of the intermediate-depth seismicity in the subducting plate stops at 120 km depth as well, suggesting a relation with this transformation. We see an intracrustal low-velocity zone, 10-20 km thick, below the entire Altiplano and Puna plateaux, which we interpret as a zone of continuing metamorphism and partial melting that decouples upper-crustal imbrication from lower-crustal thickening.	Geoforschungszentrum Potsdam, Telegrafenberg, D-14473 Potsdam, Germany; Free Univ Berlin, Facrichtung Geophys, D-12249 Berlin, Germany; Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Univ Chile, Dept Geofis, Santiago, Chile	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Free University of Berlin; University of Arizona; Universidad de Chile	Kind, R (corresponding author), Geoforschungszentrum Potsdam, Telegrafenberg, D-14473 Potsdam, Germany.		Yuan, Xiaohui/G-5149-2010; COMTE, DIANA/H-2593-2013; Sobolev, Stephan V/G-3813-2011; Rudloff, Alexander/C-4939-2015; Oncken, Onno/AAU-2907-2020; Pardo, Mario/H-3774-2013; Rudloff, Alexander/AAM-3304-2020	Yuan, Xiaohui/0000-0002-2891-1354; Sobolev, Stephan V/0000-0002-3382-4028; Oncken, Onno/0000-0002-2894-480X; Pardo, Mario/0000-0001-5110-7674; Rudloff, Alexander/0000-0001-8793-5455; Haberland, Christian/0000-0002-2981-7087				Allmendinger RW, 1996, TECTONOPHYSICS, V259, P1, DOI 10.1016/0040-1951(96)00024-8; Allmendinger RW, 1997, ANNU REV EARTH PL SC, V25, P139, DOI 10.1146/annurev.earth.25.1.139; Beck SL, 1996, GEOLOGY, V24, P407, DOI 10.1130/0091-7613(1996)024<0407:CTVITC>2.3.CO;2; CAHILL T, 1992, J GEOPHYS RES-SOL EA, V97, P17503, DOI 10.1029/92JB00493; CASSIDY JF, 1992, B SEISMOL SOC AM, V82, P1453; Chmielowski J, 1999, GEOPHYS RES LETT, V26, P783, DOI 10.1029/1999GL900078; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; Engdahl ER, 1998, B SEISMOL SOC AM, V88, P722; Giese P, 1999, J S AM EARTH SCI, V12, P201, DOI 10.1016/S0895-9811(99)00014-0; Graeber FM, 1999, J GEOPHYS RES-SOL EA, V104, P20237, DOI 10.1029/1999JB900037; Hacker BR, 2000, SCIENCE, V287, P2463, DOI 10.1126/science.287.5462.2463; ISACKS BL, 1988, J GEOPHYS RES-SOLID, V93, P3211, DOI 10.1029/JB093iB04p03211; JAMES DE, 1971, J GEOPHYS RES, V76, P3246, DOI 10.1029/JB076i014p03246; Jones CH, 1998, J GEOPHYS RES-SOL EA, V103, P10065, DOI 10.1029/97JB03540; KAY RW, 1993, TECTONOPHYSICS, V219, P177, DOI 10.1016/0040-1951(93)90295-U; Kind R, 1996, SCIENCE, V274, P1692, DOI 10.1126/science.274.5293.1692; KIRBY S, 1996, SUBDUCTION TOP BOTTO, P195, DOI DOI 10.1029/GM096P0195; Kley J, 1998, GEOLOGY, V26, P723, DOI 10.1130/0091-7613(1998)026<0723:TSACTI>2.3.CO;2; Kosarev G, 1999, SCIENCE, V283, P1306, DOI 10.1126/science.283.5406.1306; Lamb S, 1997, GEOL SOC SPEC PUBL, V121, P237, DOI 10.1144/GSL.SP.1997.121.01.10; Lucassen F, 1999, CONTRIB MINERAL PETR, V134, P325, DOI 10.1007/s004100050488; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; Oncken O, 1999, NATURE, V397, P341, DOI 10.1038/16909; OWENS TJ, 1984, J GEOPHYS RES, V89, P7783, DOI 10.1029/JB089iB09p07783; PEACOCK SM, 1993, GEOL SOC AM BULL, V105, P684, DOI 10.1130/0016-7606(1993)105<0684:TIOBED>2.3.CO;2; SOBOLEV SV, 1994, SURV GEOPHYS, V15, P515, DOI 10.1007/BF00690173; Wigger P.J., 1994, TECTONICS SO CENTRAL, P23, DOI DOI 10.1007/978-3-642-77353-2_2; Yuan XH, 1997, J GEOPHYS RES-SOL EA, V102, P27491, DOI 10.1029/97JB02379; ZANDT G, 1994, GEOLOGY, V22, P1003, DOI 10.1130/0091-7613(1994)022<1003:CATOTS>2.3.CO;2	29	310	320	0	71	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					958	961		10.1038/35050073	http://dx.doi.org/10.1038/35050073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140679				2022-12-28	WOS:000165951100045
J	Mason, SA; Allmark, PJ				Mason, SA; Allmark, PJ		Euricon Study Grp	Obtaining informed consent to neonatal randomised controlled trials: interviews with parents and clinicians in the Euricon study	LANCET			English	Article								Background Questions have been asked about whether the process of obtaining informed consent from parents to clinical trials on neonates leads to valid consent, We undertook a study in nine European countries to assess this issue and to seek any practical improvements. Methods Semi-structured interviews were conducted with parents of 200 babies who had been asked for consent to neonatal trials and 107 neonatologists seeking consent. Analysis assessed the validity of the consent process against four components: parental competence; information given; parental understanding; and voluntariness of consent. Findings 59 of the 200 parents had given valid consent or refusal but the remainder bad problems in one or more of the component areas (42 for competence, 43 for information, 44 for understanding, and 21 for voluntariness), The proportions with impaired consent were greatest for research in an emergency situation and for that associated with risk or discomfort greater than standard treatment. Information sheets were little used by parents in deciding whether to consent. Parents highly valued their involvement in the informed consent process, and clinicians generally agreed on the value of the process. Interpretation Current standards of informed consent to neonatal research projects could be improved. Research personnel should receive guidance on legal and ethical constraints governing the process. Oral and written information should be given at the same time. Parents could be made aware that research projects have been examined by research ethics committees. Little support was found for the argument that informed consent should be relinquished for the parents' own good. Further study is needed to identify which elements of the process are valued by parents and clinicians in a process that has some unavoidable limitations.	No & Yorkshire Clin Trials & Res Unit, Leeds LS2 9NG, W Yorkshire, England; Univ Sheffield, Fac Med, Sheffield S10 2TN, S Yorkshire, England	University of Leeds; University of Sheffield	Mason, SA (corresponding author), No & Yorkshire Clin Trials & Res Unit, 17 Springfield Mt, Leeds LS2 9NG, W Yorkshire, England.		Allmark, Peter/D-2519-2010	Allmark, Peter/0000-0002-3314-8947				BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P142; Culbert A, 1999, PEDIATR RES, V45, p34A, DOI 10.1203/00006450-199904020-00205; Davis DJ, 1999, PEDIATR RES, V45, p34A, DOI 10.1203/00006450-199904020-00206; Edwards SJ., 1998, HEALTH TECHNOL ASSES, V2, P1; Edwards SJL, 1998, BRIT MED J, V317, P1209, DOI 10.1136/bmj.317.7167.1209; KENNEDY I, 1994, MED LAW TEXT MAT, P1052; LEVENE M, 1996, LANCET, V347, P474; MASON SA, IN PRESS INFORMED CO; McLean S, 1997, BRIT MED J, V314, P1076, DOI 10.1136/bmj.314.7087.1076; Modi N, 1998, LANCET, V351, P530, DOI 10.1016/S0140-6736(05)78731-6; MORLEY C, 1997, BRIT MED J, V314, P1477; MOSER C, 1971, SURVFEY METHODS SOCI; Neuberger J, 1992, ETHICS HLTH CARE ROL; Singhal N, 1999, PEDIATR RES, V45, p35A; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; SUGANO S, 1998, SPRINGER SERIES MATE, V20, P1; Tobias JS, 1997, BRIT MED J, V314, P1111, DOI 10.1136/bmj.314.7087.1111; TOBIAS JS, 1993, BRIT MED J, V307, P119; Truog RD, 1999, NEW ENGL J MED, V340, P804, DOI 10.1056/NEJM199903113401013; Williams C, 1992, INTRO NEW TREATMENTS, P49; WILLIAMS CJ, 1994, EUR J CANCER, V30A, P907, DOI 10.1016/0959-8049(94)90111-2; WILTSHIRE C, 1997, BRIT MED J, V314, P1477; ZUPANCIC J, 1997, PEDIATRICS, V99, P117; 1995, LANCET, V345, P805	24	129	131	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 16	2000	356	9247					2045	2051		10.1016/S0140-6736(00)03401-2	http://dx.doi.org/10.1016/S0140-6736(00)03401-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385GB	11145490				2022-12-28	WOS:000165994300010
J	Sparano, JA; Wolff, AC; Brown, D				Sparano, JA; Wolff, AC; Brown, D			Troponins for predicting cardiotoxicity from cancer therapy	LANCET			English	Editorial Material							CARDIOMYOPATHY; DOXORUBICIN		Montefiore Med Ctr, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Johns Hopkins Oncol Ctr, Baltimore, MD USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Medicine	Sparano, JA (corresponding author), Montefiore Med Ctr, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA.		Wolff, Antonio C./T-8796-2019	Wolff, Antonio C./0000-0003-3734-1063				BILLINGHAM ME, 1978, CANCER TREAT REP, V62, P865; Cardinale D, 2000, J AM COLL CARDIOL, V36, P517, DOI 10.1016/S0735-1097(00)00748-8; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Herman EH, 1999, J CLIN ONCOL, V17, P2237, DOI 10.1200/JCO.1999.17.7.2237; HUDIS C, 1998, BREAST CANC RES TREA; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; LIPSHULZ S, 1999, P AM SOC CLIN ONCOL, V8, pA568; Myers C, 1998, SEMIN ONCOL, V25, P10; Norton L, 1999, P AN M AM SOC CLIN, V18, p127a; Sparano JA, 1998, SEMIN ONCOL, V25, P66	10	14	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 9	2000	356	9246					1947	1948		10.1016/S0140-6736(00)03304-3	http://dx.doi.org/10.1016/S0140-6736(00)03304-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383DJ	11130520				2022-12-28	WOS:000165867600006
J	Dock-Bregeon, AC; Sankaranarayanan, R; Romby, P; Caillet, J; Springer, M; Rees, B; Francklyn, CS; Ehresmann, C; Moras, D				Dock-Bregeon, AC; Sankaranarayanan, R; Romby, P; Caillet, J; Springer, M; Rees, B; Francklyn, CS; Ehresmann, C; Moras, D			Transfer RNA-mediated editing in threonyl-tRNA synthetase: The class II solution to the double discrimination problem	CELL			English	Article							RIBONUCLEIC-ACID SYNTHETASE; ESCHERICHIA-COLI; AMINO-ACIDS; ZINC ION; ERRORS; AMINOACYLATION; SELECTION; SIEVE; DEACYLATION; ISOLEUCINE	Threonyl-tRNA synthetase, a class II synthetase, uses a unique zinc ion to discriminate against the isosteric valine at the activation step. The crystal structure of the enzyme with an analog of seryl adenylate shows that the noncognate serine cannot be fully discriminated at that step. We show that hydrolysis of the incorrectly formed ser-tRNA(Thr) is performed at a specific site in the N-terminal domain of the enzyme. The present study suggests that both classes of synthetases use effectively the ability of the CCA end of tRNA to switch between a hairpin and a helical conformation for aminoacylation and editing. As a consequence, the editing mechanism of both classes of synthetases can be described as mirror images, as already seen for tRNA binding and amino acid activation.	ULP, INSERM, CNRS, IGBMC,UPR Biol Struct 9004, F-67404 Illkirch Graffenstaden, France; Inst Biol Mol & Cellulaire, CNRS, UPR 9002, F-67084 Strasbourg, France; Inst Biol Phys Chim, CNRS, UPR 9073, F-75005 Paris, France; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); University of Vermont	Moras, D (corresponding author), ULP, INSERM, CNRS, IGBMC,UPR Biol Struct 9004, BP163, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	ROMBY, Pascale/AGP-3328-2022; Sankaranarayanan, Rajan/AAI-9295-2020	Dock-Bregeon, Anne-Catherine/0000-0002-6913-4061; Rajan, Sankaranarayanan/0000-0003-4524-9953	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054899] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BRUNEL C, 1993, BIOCHIMIE, V75, P1167, DOI 10.1016/0300-9084(93)90016-L; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GIEGE R, 1971, FEBS LETT, V15, P281, DOI 10.1016/0014-5793(71)80638-5; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1972, BIOCHEM J, V128, P1353, DOI 10.1042/bj1281353; Musier-Forsyth K, 2000, NAT STRUCT BIOL, V7, P435, DOI 10.1038/75816; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pauling L., 1957, FESTSCHRIFT ARTHUR S, P597; RAUNIO R, 1970, ACTA CHEM SCAND, V24, P2737, DOI 10.3891/acta.chem.scand.24-2737; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; Sankaranarayanan R, 2000, NAT STRUCT BIOL, V7, P461; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627	36	153	160	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 8	2000	103	6					877	884		10.1016/S0092-8674(00)00191-4	http://dx.doi.org/10.1016/S0092-8674(00)00191-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136973	Bronze			2022-12-28	WOS:000165801300007
J	Ford, MGJ; Pearse, BMF; Higgins, MK; Vallis, Y; Owen, DJ; Gibson, A; Hopkins, CR; Evans, PR; McMahon, HT				Ford, MGJ; Pearse, BMF; Higgins, MK; Vallis, Y; Owen, DJ; Gibson, A; Hopkins, CR; Evans, PR; McMahon, HT			Simultaneous binding of PtdIns(4,5)P-2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes	SCIENCE			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; ASSEMBLY PROTEIN; COATED PITS; DOMAIN; ALPHA; AP-3; LOCALIZATION; INHIBITION; APPENDAGE; VESICLES	Adaptor protein 180 (AP180) and its homolog, clathrin assembly Lymphoid myeloid Leukemia protein (CALM), are closely related proteins that play important roles in clathrin-mediated endocytosis. Here, we present the structure of the NH2-terminal domain of CALM bound to phosphatidylinositol-4,5-bisphosphate [Ptdlns(4,5)P-2] via a lysine-rich motif. This motif is found in other proteins predicted to have domains of similar structure (for example, Huntingtin interacting protein 1). The structure is in part similar to the epsin NH2-terminal (ENTH) domain, but epsin Lacks the Ptdlns(4,5) P-2-binding site. Because AP180 could bind to Ptdins(4,5)P-2 and clathrin simultaneously, it may serve to tether clathrin to the membrane. This was shown by using purified components and a budding assay on preformed Lipid monolayers. In the presence of AP180, clathrin lattices formed on the monolayer. When AP2 was also present, coated pits were formed.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Evans, PR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Higgins, Matthew/0000-0002-2870-1955				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kornberg RD, 1991, CURR OPIN STRUC BIOL, V1, P642, DOI 10.1016/S0959-440X(05)80090-9; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Levy D, 1999, J STRUCT BIOL, V127, P44, DOI 10.1006/jsbi.1999.4155; LINDNER R, 1992, J BIOL CHEM, V267, P16567; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; McMahon HT, 1999, CURR BIOL, V9, pR332, DOI 10.1016/S0960-9822(99)80206-1; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9; Zhao XH, 2001, J CELL SCI, V114, P353	36	583	594	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	2001	291	5506					1051	1055		10.1126/science.291.5506.1051	http://dx.doi.org/10.1126/science.291.5506.1051			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	400EW	11161218	Green Submitted			2022-12-28	WOS:000166860100047
J	Safian, RD; Textor, SC				Safian, RD; Textor, SC			Medical progress - Renal-artery stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ATHEROSCLEROTIC RENOVASCULAR DISEASE; ISCHEMIC NEPHROPATHY; VASCULAR-DISEASE; STENT PLACEMENT; BALLOON ANGIOPLASTY; BLOOD-PRESSURE; SURGICAL REVASCULARIZATION; PERCUTANEOUS ANGIOPLASTY; FIBROMUSCULAR DYSPLASIA; AORTIC RECONSTRUCTION		William Beaumont Hosp, Div Cardiol, Dept Med, Royal Oak, MI 48073 USA; Mayo Clin, Dept Med, Sect Hypertens & Nephrol, Rochester, MN USA	Beaumont Health; Mayo Clinic	Safian, RD (corresponding author), William Beaumont Hosp, Div Cardiol, Dept Med, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.							ALLEN BT, 1993, AM J SURG, V166, P726, DOI 10.1016/S0002-9610(05)80688-9; ASCER E, 1993, J VASC SURG, V18, P1012, DOI 10.1016/0741-5214(93)90556-2; BERAUD JJ, 1989, J HYPERTENS, V7, P909, DOI 10.1097/00004872-198911000-00010; Beregi JP, 1996, AM J ROENTGENOL, V167, P495, DOI 10.2214/ajr.167.2.8686635; Blaufox MD, 1996, J NUCL MED, V37, P1883; Blum U, 1997, NEW ENGL J MED, V336, P459, DOI 10.1056/NEJM199702133360702; Boisclair C, 1997, AM J ROENTGENOL, V168, P245, DOI 10.2214/ajr.168.1.8976953; BONELLI FS, 1995, MAYO CLIN PROC, V70, P1041, DOI 10.4065/70.11.1041; Border WA, 1998, HYPERTENSION, V31, P181, DOI 10.1161/01.HYP.31.1.181; Branchereau A, 1992, Ann Vasc Surg, V6, P232, DOI 10.1007/BF02000268; BREDENBERG CE, 1992, J VASC SURG, V15, P1018, DOI 10.1016/0741-5214(92)90458-K; CAMBRIA RP, 1994, J VASC SURG, V20, P76, DOI 10.1016/0741-5214(94)90178-3; Cambria RP, 1998, J INVASIVE CARDIOL, V10, P55; CANZANELLO VJ, 1989, HYPERTENSION, V13, P163, DOI 10.1161/01.HYP.13.2.163; Caps MT, 1998, KIDNEY INT, V53, P735, DOI 10.1046/j.1523-1755.1998.00805.x; Caps MT, 1998, CIRCULATION, V98, P2866, DOI 10.1161/01.CIR.98.25.2866; CHAIKOF EL, 1994, J VASC SURG, V19, P135, DOI 10.1016/S0741-5214(94)70128-8; CLAIR DG, 1995, J VASC SURG, V21, P926, DOI 10.1016/S0741-5214(95)70220-2; Conlon PJ, 1998, J AM SOC NEPHROL, V9, P252; Crowley JJ, 1998, AM HEART J, V136, P913, DOI 10.1016/S0002-8703(98)70138-3; DEAN RH, 1981, ARCH SURG-CHICAGO, V116, P1408; DEAN RH, 1991, ANN SURG, V213, P446, DOI 10.1097/00000658-199105000-00010; DEAN RH, 1984, ANN SURG, V200, P336, DOI 10.1097/00000658-198409000-00011; DEAN RH, 1985, ANN SURG, V202, P367, DOI 10.1097/00000658-198509000-00015; DIEHL JT, 1983, ANN SURG, V197, P49, DOI 10.1097/00000658-198301001-00008; DORROS G, 1993, CATHETER CARDIO DIAG, V29, P191, DOI 10.1002/ccd.1810290304; Dorros G, 1998, CIRCULATION, V98, P642, DOI 10.1161/01.CIR.98.7.642; DORROS G, 1995, AM J CARDIOL, V75, P1051, DOI 10.1016/S0002-9149(99)80723-1; Fiala LA, 1998, ANN VASC SURG, V12, P128, DOI 10.1007/s100169900128; GEDROYC WMW, 1995, CLIN RADIOL, V50, P436, DOI 10.1016/S0009-9260(05)83158-7; GUZMAN RP, 1994, HYPERTENSION, V23, P346, DOI 10.1161/01.HYP.23.3.346; HANSEN KJ, 1992, J VASC SURG, V16, P319, DOI 10.1016/0741-5214(92)90364-E; HANSEN KJ, 1990, J VASC SURG, V12, P227, DOI 10.1067/mva.1990.22791; HANSEN KJ, 1989, J VASC SURG, V10, P266; Harden PN, 1997, LANCET, V349, P1133, DOI 10.1016/S0140-6736(96)10093-3; Hollenberg NK, 1983, CARDIOVASC REV REP, V4, P852; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; Iannone LA, 1996, CATHETER CARDIO DIAG, V37, P243, DOI 10.1002/(SICI)1097-0304(199603)37:3<243::AID-CCD3>3.0.CO;2-C; JACKSON B, 1990, J LAB CLIN MED, V115, P21; JACOBSON HR, 1988, KIDNEY INT, V34, P729, DOI 10.1038/ki.1988.240; Kaufman JA, 1996, RADIOLOGY, V198, P579, DOI 10.1148/radiology.198.2.8596869; Kidney D D, 1996, Semin Vasc Surg, V9, P188; KLINGE J, 1989, RADIOLOGY, V171, P501, DOI 10.1148/radiology.171.2.2523080; LAWRIE GM, 1989, AM J CARDIOL, V63, P1085, DOI 10.1016/0002-9149(89)90083-0; LIBERTINO JA, 1992, J UROLOGY, V147, P1485, DOI 10.1016/S0022-5347(17)37603-6; LIBERTINO JA, 1994, UROL CLIN N AM, V21, P235; MAILLOUX LU, 1994, AM J KIDNEY DIS, V24, P622, DOI 10.1016/S0272-6386(12)80223-X; MAILLOUX LU, 1988, AM J MED, V84, P855, DOI 10.1016/0002-9343(88)90063-0; MARTIN LG, 1994, VASCULAR DIS SURG IN, P721; MESSINA LM, 1992, J VASC SURG, V15, P73, DOI 10.1016/0741-5214(92)70015-D; Mikhail A, 1997, LANCET, V349, P926, DOI 10.1016/S0140-6736(05)62702-X; NOVICK AC, 1984, UROL CLIN N AM, V11, P477; NOVICK AC, 1987, JAMA-J AM MED ASSOC, V257, P498, DOI 10.1001/jama.257.4.498; Oei H Y, 1987, Contrib Nephrol, V56, P95; ONEIL EA, 1992, AM SURGEON, V58, P485; PERONA PG, 1989, J VASC SURG, V9, P817, DOI 10.1067/mva.1989.vs0090817; Plouin PF, 1998, HYPERTENSION, V31, P823, DOI 10.1161/01.HYP.31.3.823; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; REILLY JM, 1994, SURGERY, V116, P784; ROCHE Z, 1993, AM J KIDNEY DIS, V22, P662, DOI 10.1016/S0272-6386(12)80428-8; Rundback JH, 1998, J VASC INTERV RADIOL, V9, P413, DOI 10.1016/S1051-0443(98)70292-1; SANG CN, 1989, HYPERTENSION, V14, P472, DOI 10.1161/01.HYP.14.5.472; SAWICKI PT, 1991, J INTERN MED, V229, P489, DOI 10.1111/j.1365-2796.1991.tb00382.x; SCOBLE JE, 1990, BMJ-BRIT MED J, V300, P1670, DOI 10.1136/bmj.300.6741.1670; SCOBLE JE, 1989, CLIN NEPHROL, V31, P119; SETARO JF, 1991, AM J HYPERTENS, V4, pS698, DOI 10.1093/ajh/4.12.698S; Shanley PF, 1996, SEMIN NEPHROL, V16, P21; SIGMON DH, 1993, HYPERTENSION, V22, P237, DOI 10.1161/01.HYP.22.2.237; SIMON N, 1972, J AMER MED ASSOC, V220, P1209, DOI 10.1001/jama.220.9.1209; SOS TA, 1984, UROL CLIN N AM, V11, P503; Steinbach F, 1997, J UROLOGY, V158, P38, DOI 10.1097/00005392-199707000-00011; TARAZI RY, 1987, J VASC SURG, V5, P707, DOI 10.1067/mva.1987.avs0050707; Taylor A, 1997, CLIN RADIOL, V52, P451, DOI 10.1016/S0009-9260(97)80007-4; TEGTMEYER CJ, 1982, RADIOLOGY, V143, P631, DOI 10.1148/radiology.143.3.6210930; TEXTOR SC, 1994, AM J KIDNEY DIS, V24, P642, DOI 10.1016/S0272-6386(12)80226-5; TEXTOR SC, 1985, ANN INTERN MED, V102, P308, DOI 10.7326/0003-4819-102-3-308; Textor SC, 1998, KIDNEY INT, V53, P799, DOI 10.1038/ki.1998.37; TEXTOR SC, 1990, CARDIOVASC DRUG THER, V4, P229, DOI 10.1007/BF01857637; TOLLEFSON DFJ, 1991, J VASC SURG, V14, P327; TOTO RD, 1991, ANN INTERN MED, V115, P513, DOI 10.7326/0003-4819-115-7-513; van Jaarsveld BC, 2000, NEW ENGL J MED, V342, P1007, DOI 10.1056/NEJM200004063421403; Webster J, 1998, J HUM HYPERTENS, V12, P329, DOI 10.1038/sj.jhh.1000599; WEIBULL H, 1993, J VASC SURG, V18, P841, DOI 10.1016/0741-5214(93)90340-R; WEIBULL H, 1991, BRIT J SURG, V78, P620, DOI 10.1002/bjs.1800780531; White CJ, 1997, J AM COLL CARDIOL, V30, P1445, DOI 10.1016/S0735-1097(97)00348-3; *WORK GROUP RISK H, 1985, HYPERTENSION, V7, P641; XUE F, 1998, J VASC INTERV RADI S, V9, P215; YING CY, 1984, NEW ENGL J MED, V311, P1070, DOI 10.1056/NEJM198410253111702; ZIERLER RE, 1994, J VASC SURG, V19, P250, DOI 10.1016/S0741-5214(94)70100-8	89	686	786	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 8	2001	344	6					431	442		10.1056/NEJM200102083440607	http://dx.doi.org/10.1056/NEJM200102083440607			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399FH	11172181				2022-12-28	WOS:000166800600007
J	Crowther, RE; Marshall, M; Bond, GR; Huxley, P				Crowther, RE; Marshall, M; Bond, GR; Huxley, P			Helping people with severe mental illness to obtain work: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SUPPORTED EMPLOYMENT; PSYCHIATRIC REHABILITATION; OUTCOMES	Objective To determine the most effective way of helping people with severe mental illness to obtain competitive employment-that is, a job paid at the market rate, and for which any one can apply. Design Systematic review: Participants Eligible studies were randomised controlled trials comparing prevocational training or supported employment (for people with severe mental illness) with each other or with standard community care. Outcome measures The primary outcome was number of subjects in competitive employment outcomes, clinical outcomes, and costs. Results Eleven trials met the inclusion criteria. Five (1204 subjects) compared prevocational training with standard community care, one (256 subjects) compared supported employment with standard community care, and five (484 subjects) compared supported employment wit prevocational training. Subjects in supported employment were more likely to be in competitive employment than those who received prevocational training at 4, 6, 9, 12, 15, and 18 months (for example, 34% v 12% at 12 months; number needed to treat 4.45, 95% confidence interval 3.37 to 6.59). This effect was still present, although at a reduced level, after a sensitivity analysis that retained only the highest quality trials (31% v 12%; 5.3, 3.6 to 10.4). People in supported employment earned more and worked more hours per month than those who had had prevocational training. Conclusion Supported employment is more effective than prevocational training at helping people with severe mental illness obtain competitive employment.	Univ Manchester, Sch Psychiat & Behav Sci, Manchester PR2 9HT, Lancs, England; Indiana Univ Purdue Univ, Dept Psychol, Indianapolis, IN 46202 USA; Kings Coll London, Inst Psychiat, Hlth Serv Res, London SE5 8AF, England	University of Manchester; Indiana University System; Indiana University-Purdue University Indianapolis; University of London; King's College London	Marshall, M (corresponding author), Royal Preston Hosp, Acad Unit, Preston PR2 9HT, Lancs, England.	mmarshall@man.ac.uk	Crowther, Ruth/K-8461-2014; Young, Alexander/A-1523-2009; Huxley, Peter/AAE-7007-2019	Crowther, Ruth/0000-0002-7628-5618; Young, Alexander/0000-0002-9367-9213; 				BEARD JH, 1963, AM J ORTHOPSYCHIAT, V33, P701, DOI 10.1111/j.1939-0025.1963.tb01018.x; BECKER DR, 1994, COMMUNITY MENT HLT J, V30, P193, DOI 10.1007/BF02188630; Bond G.R., 1992, HDB PSYCHIAT REHABIL, P244; BOND GR, 1995, REHABIL PSYCHOL, V40, P75; Bond GR, 1997, PSYCHIATR SERV, V48, P335; Bond GR, 1999, J DISABIL POLICY STU, V10, P18, DOI [10.1177/104420739901000104, DOI 10.1177/104420739901000104]; Chandler D, 1996, PSYCHIATR SERV, V47, P1337; CLARK M, 1999, COCHR COLL REV HDB V; Cook JA, 2000, SCHIZOPHRENIA BULL, V26, P87, DOI 10.1093/oxfordjournals.schbul.a033448; Department of Health, 1998, MOD MENT HLTH SERV; DINCIN J, 1982, HOSP COMMUNITY PSYCH, V33, P645; Drake RE, 1999, ARCH GEN PSYCHIAT, V56, P627, DOI 10.1001/archpsyc.56.7.627; Drake RE, 1996, J CONSULT CLIN PSYCH, V64, P391, DOI 10.1037/0022-006X.64.2.391; *EUR EC INT GROUP, 1998, ERMIS DAT DORK; GERVEY R, 1994, PSYCHOL ASSESSMENT T; GRIFFITHS RD, 1974, PSYCHOL MED, V4, P316, DOI 10.1017/S0033291700043002; HATFIELD B, 1992, BRIT J SOC WORK, V22, P61; Lehman AF, 1995, SCHIZOPHRENIA BULL, V21, P645, DOI 10.1093/schbul/21.4.645; Marshall M, 2000, BRIT J PSYCHIAT, V176, P249, DOI 10.1192/bjp.176.3.249; MCCREADIE RG, 1992, SOC PSYCH PSYCH EPID, V27, P40, DOI 10.1007/BF00788955; McFarlane WR, 2000, AM J ORTHOPSYCHIAT, V70, P203, DOI 10.1037/h0087819; MELTZER H, 1995, 2 OFF POP CENS SURV; Okpaku SO, 1997, PSYCHIATR REHABIL J, V20, P34, DOI 10.1037/h0095366; RIDGEWAY P, 1998, ACTIVE INGREDIENTS A; Shepherd G., 1994, RELATIVE VALUES DIFF; WEHMAN P, 1997, SUPPORTED EMPLOYMENT, P1; WOLKON GH, 1971, COMMUNITY MENT HLT J, V7, P312, DOI 10.1007/BF01434441	27	301	315	1	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2001	322	7280					204	208		10.1136/bmj.322.7280.204	http://dx.doi.org/10.1136/bmj.322.7280.204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	398BF	11159616	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000166733700026
J	Heikkinen, T; Salmi, AA; Ruuskanen, O				Heikkinen, T; Salmi, AA; Ruuskanen, O			Comparative study of nasopharyngeal aspirate and nasal swab specimens for detection of influenza	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Turku Univ Hosp, Dept Paediat, FIN-20520 Turku, Finland; Univ Turku, Dept Virol, SF-20500 Turku, Finland	University of Turku; University of Turku	Heikkinen, T (corresponding author), Turku Univ Hosp, Dept Paediat, FIN-20520 Turku, Finland.	terho.heikkinen@utu.fi		Heikkinen, Terho/0000-0001-6504-0116				Carrat F, 1999, CLIN INFECT DIS, V28, P283, DOI 10.1086/515117; Covalciuc KA, 1999, J CLIN MICROBIOL, V37, P3971, DOI 10.1128/JCM.37.12.3971-3974.1999; NIKKARI S, 1989, J VIROL METHODS, V23, P29, DOI 10.1016/0166-0934(89)90086-4; Schmid ML, 1998, BRIT MED J, V316, P275, DOI 10.1136/bmj.316.7127.275; Zambon M., 1998, TXB INFLUENZA, P291	5	49	49	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 20	2001	322	7279					138	138		10.1136/bmj.322.7279.138	http://dx.doi.org/10.1136/bmj.322.7279.138			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	396AZ	11159569	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000166615300024
J	Slanger, TG; Cosby, PC; Huestis, DL; Bida, TA				Slanger, TG; Cosby, PC; Huestis, DL; Bida, TA			Discovery of the atomic oxygen green line in the Venus night airglow	SCIENCE			English	Article							MOLECULAR-OXYGEN; SPECTROSCOPY; EXCITATION; EMISSIONS; ATMOSPHERES; SYSTEM; BANDS; MARS	Green line emission at 557.7 nanometers arising from the O(S-1 - D-1) transition of atomic oxygen has been observed on the nightside of Venus with HIRES, the echelle spectrograph on the W. M. Keck I 10-meter telescope. We also observe optical emissions of molecular oxygen, consistent with the spectra from the Venera orbiters, but our green Line intensity is so high that we cannot explain how it could be inconspicuous in the Venera spectra. An upper Limit for the intensity of the O(D-1 - P-3) oxygen red Line at 630 nanometers has also been obtained. The Large green/red ratio indicates that the source is not associated with the Venus ionosphere. An important conclusion is that observation of the green line in a planetary atmosphere is not an indicator of an atmosphere rich in molecular oxygen.	SRI Int, Mol Phys Lab, Aeron Grp, Menlo Park, CA 94025 USA; Lowell Observ, Flagstaff, AZ 86001 USA	SRI International	Slanger, TG (corresponding author), SRI Int, Mol Phys Lab, Aeron Grp, 333 Ravenswood Ave, Menlo Park, CA 94025 USA.			Cosby, Philip/0000-0002-5139-018X				AKASOFU S, 1999, EOS T AGU, V80, P397; BARTH CA, 1961, SCIENCE, V134, P1426; BATES DR, 1989, PLANET SPACE SCI, V37, P881, DOI 10.1016/0032-0633(89)90139-6; BATES DR, 1988, PLANET SPACE SCI, V36, P883, DOI 10.1016/0032-0633(88)90094-3; BOUGHER SW, 1994, J GEOPHYS RES-PLANET, V99, P3759, DOI 10.1029/93JE03431; Chapman S, 1931, P R SOC LOND A-CONTA, V132, P353, DOI 10.1098/rspa.1931.0105; CONNES P, 1979, ASTROPHYS J, V233, pL29, DOI 10.1086/183070; Crisp D, 1996, J GEOPHYS RES-PLANET, V101, P4577, DOI 10.1029/95JE03136; FELDMAN PD, 1979, NATURE, V279, P221, DOI 10.1038/279221a0; FOX JL, 1986, CAN J PHYS, V64, P1631, DOI 10.1139/p86-288; FOX JL, 1990, ADV SPACE RES-SERIES, V10, P31, DOI 10.1016/0273-1177(90)90162-S; FOX JL, GEOPHYS MONOGR AM GE, V66; HUESTIS DL, 1993, J GEOPHYS RES-PLANET, V98, P10839, DOI 10.1029/93JE00997; KRASNOPOLSKY VA, 1981, PLANET SPACE SCI, V29, P925, DOI 10.1016/0032-0633(81)90053-2; KRASNOPOLSKY VA, 1986, PLANET SPACE SCI, V34, P511, DOI 10.1016/0032-0633(86)90089-9; KRASNOPOLSKY VA, 1976, KOSM ISSLED, V14, P789; LAWRENCE GM, 1977, SCIENCE, V195, P573, DOI 10.1126/science.195.4278.573; LUHMANN JG, 1992, GEOPHYS MONOGR, V66, P191; LUHMANN JG, 1996, ATOMIC MOL OPTICAL P, P940; RAMSAY DA, 1986, CAN J PHYS, V64, P717, DOI 10.1139/p86-130; Rowland GA, 2000, GEOPHYS RES LETT, V27, P3301, DOI 10.1029/2000GL011793; SLANGER TG, 1981, J GEOPHYS RES-SPACE, V86, P3551, DOI 10.1029/JA086iA05p03551; SLANGER TG, 1988, J PHYS CHEM-US, V92, P267, DOI 10.1021/j100313a008; SLANGER TG, 1978, GEOPHYS RES LETT, V5, P947, DOI 10.1029/GL005i011p00947; STEGMAN J, 1991, PLANET SPACE SCI, V39, P595, DOI 10.1016/0032-0633(91)90054-E; STEWART AI, 1979, SCIENCE, V203, P777, DOI 10.1126/science.203.4382.777; STEWART AI, 1979, SCIENCE, V205, P59, DOI 10.1126/science.205.4401.59; TRAUGER JT, 1983, ICARUS, V55, P272, DOI 10.1016/0019-1035(83)90082-9; Zhang SPP, 1999, GEOPHYS RES LETT, V26, P529, DOI 10.1029/1999GL900033	29	60	60	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 19	2001	291	5503					463	465		10.1126/science.291.5503.463	http://dx.doi.org/10.1126/science.291.5503.463			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161195				2022-12-28	WOS:000166487500034
J	Stokkan, KA; Yamazaki, S; Tei, H; Sakaki, Y; Menaker, M				Stokkan, KA; Yamazaki, S; Tei, H; Sakaki, Y; Menaker, M			Entrainment of the circadian clock in the liver by feeding	SCIENCE			English	Article							SUPRACHIASMATIC NUCLEUS; ANTICIPATORY ACTIVITY; PERIPHERAL-TISSUES; FOOD; RHYTHMS; CORTICOSTERONE; OSCILLATORS; TEMPERATURE; PERSISTENCE; PACEMAKER	Circadian rhythms of behavior are driven by oscillators in the brain that are coupled to the environmental light cycle. Circadian rhythms of gene expression occur widely in peripheral organs, It is unclear how these multiple rhythms are coupled together to form a coherent system. To study such coupling, we investigated the effects of cycles of food availability (which exert powerful entraining effects on behavior) on the rhythms of gene expression in the Liver, Lung, and suprachiasmatic nucleus (SCN). We used a transgenic rat model whose tissues express Luciferase in vitro. Although rhythmicity in the SCN remained phase-locked to the light-dark cycle, restricted feeding rapidly entrained the Liver, shifting its rhythm by 10 hours within 2 days. Our results demonstrate that feeding cycles can entrain the Liver independently of the SCN and the light cycle, and they suggest the need to reexamine the mammalian circadian hierarchy. They also raise the possibility that peripheral circadian oscillators Like those in the liver may be coupled to the SCN primarily through rhythmic behavior, such as feeding.	Univ Virginia, Natl Sci Fdn Ctr Biol Timing, Charlottesville, VA 22904 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA; Univ Tromso, Dept Arctic Biol, N-9037 Tromso, Norway; Univ Tromso, Inst Med Biol, N-9037 Tromso, Norway; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 108639, Japan	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; University of Virginia; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University of Tokyo	Menaker, M (corresponding author), Univ Virginia, Natl Sci Fdn Ctr Biol Timing, POB 400328, Charlottesville, VA 22904 USA.	mm7e@virginia.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Yamazaki, Shin/0000-0002-6691-1531	NIMH NIH HHS [MH 56647] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; COMPERATORE C A, 1987, Journal of Biological Rhythms, V2, P227, DOI 10.1177/074873048700200306; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; HONMA KI, 1983, AM J PHYSIOL, V245, pR339, DOI 10.1152/ajpregu.1983.245.3.R339; Honma S, 1996, AM J PHYSIOL-REG I, V271, pR1514, DOI 10.1152/ajpregu.1996.271.6.R1514; INOUYE SIT, 1982, BRAIN RES, V232, P194, DOI 10.1016/0006-8993(82)90625-4; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KRIEGER DT, 1974, ENDOCRINOLOGY, V95, P1195, DOI 10.1210/endo-95-5-1195; Meerlo P, 1997, J BIOL RHYTHM, V12, P80, DOI 10.1177/074873049701200109; MISTLBERGER RE, 1994, NEUROSCI BIOBEHAV R, V18, P171, DOI 10.1016/0149-7634(94)90023-X; MOORE RY, 1974, BRAIN RES, V71, P17, DOI 10.1016/0006-8993(74)90188-7; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Richter CP, 1922, COMP PSYCHOL MONOGR, V1, P56; SAITO M, 1976, BIOCHIM BIOPHYS ACTA, V421, P177, DOI 10.1016/0304-4165(76)90181-1; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; STEPHAN FK, 1989, PHYSIOL BEHAV, V46, P731, DOI 10.1016/0031-9384(89)90359-4; STEPHAN FK, 1979, BEHAV NEURAL BIOL, V25, P346, DOI 10.1016/S0163-1047(79)90415-1; STOKKAN KA, UNPUB; Whitmore D, 2000, NATURE, V404, P87, DOI 10.1038/35003589; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yamazaki S, 1998, J NEUROSCI, V18, P10709	23	1244	1281	2	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 19	2001	291	5503					490	493		10.1126/science.291.5503.490	http://dx.doi.org/10.1126/science.291.5503.490			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	393UF	11161204				2022-12-28	WOS:000166487500043
J	Adams, RH; Diella, F; Hennig, S; Helmbacher, F; Deutsch, U; Klein, R				Adams, RH; Diella, F; Hennig, S; Helmbacher, F; Deutsch, U; Klein, R			The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration	CELL			English	Article							RECEPTOR TYROSINE KINASES; EPH RECEPTORS; CARDIOVASCULAR DEVELOPMENT; SPROUTING ANGIOGENESIS; COMMISSURAL AXONS; HINDBRAIN; GENE; ANGIOPOIETIN-1; SEGMENTATION; EXPRESSION	The transmembrane ligand ephrinB2 and its cognate Eph receptor tyrosine kinases are important regulators of vascular morphogenesis. EphrinB2 may have an active signaling role, resulting in bi-directional signal transduction downstream of both ephrinB2 and Eph receptors. To separate the ligand and receptorlike functions of ephrinB2 in mice, we replaced the endogenous gene by cDNAs encoding either carboxyterminally truncated (ephrinB2(DeltaC)) or, as a control, full-length ligand (ephrinB2(WT)). While homozygous ephrinB2(WT/WT) animals were viable and fertile, loss of the ephrinB2 cytoplasmic domain resulted in midgestation lethality similar to ephrinB2 null mutants (ephrinB2(KO)). The truncated ligand was sufficient to restore guidance of migrating cranial neural crest cells, but ephrinB2(DeltaC/DeltaC) embryos showed defects in vasculogenesis and angiogenesis very similar to those observed in ephrinB2(KO/KO) animals. Our results indicate distinct requirements of functions mediated by the ephrinB carboxyterminus for developmental processes in the vertebrate embryo.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, D-6350 Bad Nauheim, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society	Klein, R (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Helmbacher, Francoise/AAM-2318-2021; Klein, Ruediger/C-6147-2008; Adams, Ralf H/AAE-9274-2019	Helmbacher, Francoise/0000-0001-6822-1246; Klein, Ruediger/0000-0002-3109-0163; Deutsch, Urban/0000-0003-4265-6262				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Helbling PM, 2000, DEVELOPMENT, V127, P269; Helmbacher F, 2000, DEVELOPMENT, V127, P3313; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holder N, 1999, DEVELOPMENT, V126, P2033; Kanzler B, 2000, DEVELOPMENT, V127, P1095; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontges G, 1996, DEVELOPMENT, V122, P3229; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; KULLANDER K, 2001, IN PRESS NEURON; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; Studer M, 1998, DEVELOPMENT, V125, P1025; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wang YJ, 1998, WORLD J GASTROENTERO, V4, P74; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452	30	219	224	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 12	2001	104	1					57	69		10.1016/S0092-8674(01)00191-X	http://dx.doi.org/10.1016/S0092-8674(01)00191-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	400QD	11163240	Bronze			2022-12-28	WOS:000166882300007
J	Nurminsky, D; De Aguiar, D; Bustamante, CD; Hartl, DL				Nurminsky, D; De Aguiar, D; Bustamante, CD; Hartl, DL			Chromosomal effects of rapid gene evolution in Drosophila melanogaster	SCIENCE			English	Article							BACKGROUND SELECTION; SEGREGATING SITES; DNA; POLYMORPHISM; PATTERNS; NUMBER; RATES	Rapid adaptive fixation of a new favorable mutation is expected to affect neighboring genes along the chromosome. Evolutionary theory predicts that the chromosomal region would show a reduced level of genetic variation and an excess of rare alleles, We have confirmed these predictions in a region of the X chromosome of Drosophila melanogaster that contains a newly evolved gene far a component of the sperm axoneme. In D, simulans, where the novel gene does not exist, the pattern of genetic variation is consistent with selection against recurrent deleterious mutations. These findings imply that the pattern of genetic variation along a chromosome may be useful for inferring its evolutionary history and for revealing regions in which recent adaptive fixations have taken place.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02137 USA; ARS, USDA, Ctr Med Agr & Vet Entomol, Gainesville, FL 32604 USA; Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA	Harvard University; United States Department of Agriculture (USDA); Tufts University	Hartl, DL (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02137 USA.	dhartl@oeb.harvard.edu		Bustamante, Carlos D./0000-0002-4187-7920	NIGMS NIH HHS [GM 60035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aquadro CF, 1997, CURR OPIN GENET DEV, V7, P835, DOI 10.1016/S0959-437X(97)80048-2; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; CACCONE A, 1988, GENETICS, V118, P671; Charlesworth B, 1999, NATURE, V400, P519, DOI 10.1038/22922; CHARLESWORTH B, 1993, GENETICS, V134, P1289; CHARLESWORTH D, 1995, GENETICS, V141, P1619; HUDSON RR, 1995, GENETICS, V141, P1605; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; Moriyama EN, 1996, MOL BIOL EVOL, V13, P261, DOI 10.1093/oxfordjournals.molbev.a025563; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; Perlitz M, 1997, J MATH BIOL, V36, P1, DOI 10.1007/s002850050087; STEPHAN W, 1992, THEOR POPUL BIOL, V41, P237, DOI 10.1016/0040-5809(92)90045-U; TAJIMA F, 1989, GENETICS, V123, P585; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9	15	31	32	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					128	130		10.1126/science.291.5501.128	http://dx.doi.org/10.1126/science.291.5501.128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141564				2022-12-28	WOS:000166259100050
J	Sigl, G				Sigl, G			Ultrahigh-energy cosmic rays: Physics and astrophysics at extreme energies	SCIENCE			English	Review							COMPACT RADIO QUASARS; SCALE QUANTUM-GRAVITY; GAMMA-RAY; NEUTRINOS; ORIGIN; DIMENSIONS; SPECTRUM; LIMITS; CONSTRAINTS; PROPAGATION	The origin of cosmic rays is one of the major unresolved questions in astrophysics. In particular, the highest energy cosmic rays observed have macroscopic energies up to several 10(20) electron volts and thus provide a probe of physics and astrophysics at energies unattained in Laboratory experiments. Theoretical explanations range from astrophysical acceleration of charged particles, to particle physics beyond the established standard model, and processes taking place at the earliest moments of our universe. Distinguishing between these scenarios requires detectors with effective areas in the 1000-square-kilometer range, which are now under construction or in the planning stage. Close connections with gamma -ray and neutrino astrophysics add to the interdisciplinary character of this field.	Inst Astrophys, CNRS, 98bis Blvd Arago, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Sigl, G (corresponding author), Inst Astrophys, CNRS, 98bis Blvd Arago, F-75014 Paris, France.	sigl@iap.fr		Sigl, Guenter/0000-0002-4396-645X				Afanasiev B.N., 1996, P INT S EXTR HIGH EN, P32; Alavi-Harati A, 1999, PHYS REV LETT, V83, P2128, DOI 10.1103/PhysRevLett.83.2128; Albuquerque IF, 1997, PHYS REV LETT, V78, P3252, DOI 10.1103/PhysRevLett.78.3257; Aloisio R, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.053010; Arkani-Hamed N, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.086004; Auger P, 1938, CR HEBD ACAD SCI, V207, P228; Auger P, 1938, CR HEBD ACAD SCI, V206, P1721; Ave M, 2000, PHYS REV LETT, V85, P2244, DOI 10.1103/PhysRevLett.85.2244; BALTRUSAITIS RM, 1985, PHYS REV D, V31, P2192, DOI 10.1103/PhysRevD.31.2192; Barger V, 1999, PHYS LETT B, V461, P34, DOI 10.1016/S0370-2693(99)00795-9; BENSON R, 1982, SW REG C ASTR ASTR, V7, P161; Berezinsky V, 1997, PHYS REV LETT, V79, P4302, DOI 10.1103/PhysRevLett.79.4302; Berezinsky V.S., 1990, ASTROPHYSICS COSMIC; Bertou X, 2000, INT J MOD PHYS A, V15, P2181, DOI 10.1142/S0217751X00000902; Bhattacharjee P, 2000, PHYS REP, V327, P109, DOI 10.1016/S0370-1573(99)00101-5; BIERMAN PL, 1909, J PHYS G, V23, P1; BIERMANN PL, 1987, ASTROPHYS J, V322, P643, DOI 10.1086/165759; BIRD DJ, 1995, ASTROPHYS J, V441, P144, DOI 10.1086/175344; Blanco-Pillado JJ, 2000, PHYS REV D, V61, DOI 10.1103/PhysRevD.61.123003; BlancoPillado JJ, 1997, PHYS REV LETT, V78, P3614, DOI 10.1103/PhysRevLett.78.3614; Blasi P, 2000, ASTROPHYS J, V533, pL123, DOI 10.1086/312626; Blasi P, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.023001; Blasi P, 1999, ASTROPHYS J, V514, pL79, DOI 10.1086/311958; Bonazzola S, 1997, ASTROPART PHYS, V7, P161, DOI 10.1016/S0927-6505(97)00015-7; Capelle KS, 1998, ASTROPART PHYS, V8, P321, DOI 10.1016/S0927-6505(97)00059-5; CELNIKIER LM, 1996, P 31 RENC MOR, P453; Chung DJH, 1998, PHYS REV D, V57, P4606, DOI 10.1103/PhysRevD.57.4606; CLINE DB, OWL AIRWATCH SCI WHI; COLEMAN S, 2000, NUCL PHYS B, V574, P130; CORBATO SC, 1992, NUCL PHYS B        S, V28, P36; Cronin J., 1992, NUCL PHYS B-PROC SUP, V28, P213, DOI [10.1016/0920-5632(92)90134-E, DOI 10.1016/0920-5632(92)90134-E]; Cronin JW, 1999, REV MOD PHYS, V71, pS165, DOI 10.1103/RevModPhys.71.S165; CRONIN JW, 1997, PLERRE AUGER OBSERVA; Cullen S, 1999, PHYS REV LETT, V83, P268, DOI 10.1103/PhysRevLett.83.268; Cullen S, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.055012; Dar A, 1999, ASTRON ASTROPHYS, V349, P259; Domokos G, 1999, PHYS REV LETT, V82, P1366, DOI 10.1103/PhysRevLett.82.1366; ELBERT JW, 1995, ASTROPHYS J, V441, P151, DOI 10.1086/175345; Farrar GR, 1998, PHYS REV LETT, V81, P3579, DOI 10.1103/PhysRevLett.81.3579; Farrar GR, 2000, PHYS REV LETT, V84, P3527, DOI 10.1103/PhysRevLett.84.3527; Farrar GR, 1996, PHYS REV LETT, V76, P4111, DOI 10.1103/PhysRevLett.76.4111; Farrar GR, 1999, PHYS REV LETT, V83, P2472, DOI 10.1103/PhysRevLett.83.2472; GAISSER TK, 1998, COSMIC RAYS PARTICLE; Goldberg H, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.113005; GONZALEZMESTRES L, 1996, NUCL PHYS B, V48, P31; GRASSO D, IN PRESS PHYS REP; GREISEN K, 1966, PHYS REV LETT, V16, P748, DOI 10.1103/PhysRevLett.16.748; HALZEN F, 1995, ASTROPART PHYS, V3, P151, DOI 10.1016/0927-6505(94)00038-5; Halzen F., 1998, New Astronomy Reviews, V42, P289, DOI 10.1016/S1387-6473(98)00015-3; HALZEN F, 1998, AM ASTR SOC M, V192, P62; Harari D, 2000, J HIGH ENERGY PHYS; Harari D, 2000, J HIGH ENERGY PHYS; HAYASHIDA N, 1994, PHYS REV LETT, V73, P3491, DOI 10.1103/PhysRevLett.73.3491; Hayashida N, 1996, PHYS REV LETT, V77, P1000, DOI 10.1103/PhysRevLett.77.1000; Hess VF, 1912, PHYS Z, V13, P1084; HILLAS AM, 1984, ANNU REV ASTRON ASTR, V22, P425, DOI 10.1146/annurev.aa.22.090184.002233; Hoffman CM, 1999, PHYS REV LETT, V83, P2471, DOI 10.1103/PhysRevLett.83.2471; Jain P, 2000, PHYS LETT B, V484, P267, DOI 10.1016/S0370-2693(00)00647-X; Kachelriess M, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.103006; Kang H, 1997, MON NOT R ASTRON SOC, V286, P257, DOI 10.1093/mnras/286.2.257; KIBBLE TWB, 1976, J PHYS A-MATH GEN, V9, P1387, DOI 10.1088/0305-4470/9/8/029; KIM KT, 1989, NATURE, V341, P720, DOI 10.1038/341720a0; KOLB EW, 1990, EARLY UNIVERSE; Kuzmin VA, 1998, PHYS ATOM NUCL+, V61, P1028; Kuzmin VA, 1999, PHYS REP, V320, P199, DOI 10.1016/S0370-1573(99)00064-2; LAWRENCE MA, 1991, J PHYS G NUCL PARTIC, V17, P733, DOI 10.1088/0954-3899/17/5/019; LINSLEY J, 1963, PHYS REV LETT, V10, P146, DOI 10.1103/PhysRevLett.10.146; Nagano M, 2000, REV MOD PHYS, V72, P689, DOI 10.1103/RevModPhys.72.689; NORMAN CA, 1995, ASTROPHYS J, V454, P60, DOI 10.1086/176465; Nussinov S, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.105002; Olinto AV, 2000, PHYS REP, V333, P329, DOI 10.1016/S0370-1573(00)00028-4; Protheroe RJ, 1996, ASTROPART PHYS, V4, P253, DOI 10.1016/0927-6505(95)00039-9; Protheroe RJ, 1996, ASTROPART PHYS, V5, P215, DOI 10.1016/0927-6505(96)00042-4; Rhode W, 1996, ASTROPART PHYS, V4, P217, DOI 10.1016/0927-6505(95)00038-0; Sigl G, 1999, ASTROPART PHYS, V10, P141, DOI 10.1016/S0927-6505(98)00048-6; Sigl G, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.043504; Sigl G, 1997, P NATL ACAD SCI USA, V94, P10501, DOI 10.1073/pnas.94.20.10501; Sigl G, 1994, ASTROPART PHYS, V2, P401, DOI 10.1016/0927-6505(94)90029-9; Sigl G, 1998, ASTROPART PHYS, V9, P65, DOI 10.1016/S0927-6505(98)00006-1; Sreekumar P, 1998, ASTROPHYS J, V494, P523, DOI 10.1086/305222; Stanev T, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.093005; Stecker FW, 2000, ASTROPART PHYS, V14, P207, DOI 10.1016/S0927-6505(00)00122-5; Takeda M, 1999, ASTROPHYS J, V522, P225, DOI 10.1086/307646; Takeda M, 1998, PHYS REV LETT, V81, P1163, DOI 10.1103/PhysRevLett.81.1163; Tanco GAM, 1998, ASTROPHYS J, V505, pL79, DOI 10.1086/311615; TESHIMA M, 1992, NUCL PHYS B        S, V28, P169; TYLER C, IN PRESS PHYS REV D; Vachaspati T, 1998, CONTEMP PHYS, V39, P225, DOI 10.1080/001075198181928; Vallee J. P., 1997, FUNDAM COSMIC PHYS, V19, P1; VILENKIN A, 1985, PHYS REP, V121, P263, DOI 10.1016/0370-1573(85)90033-X; Waxman E, 2000, PHYS SCRIPTA, VT85, P117, DOI 10.1238/Physica.Topical.085a00117; Waxman E, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.023002; WEILER T, 1982, PHYS REV LETT, V49, P234, DOI 10.1103/PhysRevLett.49.234; Weiler TJ, 1999, ASTROPART PHYS, V11, P303, DOI 10.1016/S0927-6505(98)00068-1; Weinberg S., 2013, QUANTUM THEORY FIELD, V2; Yoshida S, 1998, J PHYS G NUCL PARTIC, V24, P905, DOI 10.1088/0954-3899/24/5/002; YOSHIDA S, 1995, ASTROPART PHYS, V3, P105, DOI 10.1016/0927-6505(94)00036-3; Yoshida S, 1998, PHYS REV LETT, V81, P5505, DOI 10.1103/PhysRevLett.81.5505; ZATSEPIN GT, 1966, JETP LETT-USSR, V4, P78; Zurek WH, 1996, PHYS REP, V276, P177, DOI 10.1016/S0370-1573(96)00009-9	100	42	49	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2001	291	5501					73	79		10.1126/science.291.5501.73	http://dx.doi.org/10.1126/science.291.5501.73			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	389VJ	11141550				2022-12-28	WOS:000166259100036
J	Henney, JE				Henney, JE			New combination drug for HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Henney, JE (corresponding author), US FDA, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					34	34		10.1001/jama.285.1.34	http://dx.doi.org/10.1001/jama.285.1.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150092				2022-12-28	WOS:000166114500005
J	Rowe, PC; Calkins, H; DeBusk, K; McKenzie, R; Anand, R; Sharma, G; Cuccherini, BA; Soto, N; Hohman, P; Snader, S; Lucas, KE; Wolff, M; Straus, SE				Rowe, PC; Calkins, H; DeBusk, K; McKenzie, R; Anand, R; Sharma, G; Cuccherini, BA; Soto, N; Hohman, P; Snader, S; Lucas, KE; Wolff, M; Straus, SE			Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORTHOSTATIC TACHYCARDIA SYNDROME; PLACEBO-CONTROLLED TRIAL; HEAD-UP TILT; ADOLESCENT CHRONIC-FATIGUE; AUTONOMIC NERVOUS-SYSTEM; LOW-DOSE HYDROCORTISONE; VASOVAGAL SYNCOPE; DOUBLE-BLIND; NEUROCARDIOGENIC SYNCOPE; CROSSOVER TRIAL	Context Patients with chronic fatigue syndrome (CFS) are more likely than healthy persons to develop neurally mediated hypotension (NMH) in response to prolonged orthostatic stress. Objective To examine the efficacy of fludrocortisone acetate as monotherapy for adults with both CFS and NMH. Design Randomized, double-blind, placebo-controlled trial conducted between March 1996 and February 1999. Setting Two tertiary referral centers in the United States. Patients One hundred individuals aged 18 to 50 years who satisfied Centers for Disease Control and Prevention criteria for CFS and had NMH provoked during a 2-stage tilt-table test. Eighty-three subjects had adequate outcome data to assess efficacy. Intervention Subjects were randomly assigned to receive fludrocortisone acetate, titrated to 0.1 mg/d (n=50) or matching placebo (n=50) for 9 weeks, followed by 2 weeks of observation after discontinuation of therapy. Main Outcome Measure Proportion of subjects in each group with at least a 15-point improvement on a 100-point global wellness scale. Results Baseline demographic and illness characteristics between the groups were similar; CFS had been present for at least 3 years in 71%, Using an intention-to-treat analysis, 7 subjects (14%) treated with fludrocortisone experienced at least a 15-point improvement in their wellness scores compared with 5 (10%) among placebo recipients (P=.76). No differences were observed in several other symptom scores or in the proportion with normal follow-up tilt test results at the end of the treatment period. Conclusions In our study of adults with CFS, fludrocortisone as monotherapy for NMH was no more efficacious than placebo for amelioration of symptoms, Failure to identify symptomatic improvement with fludrocortisone does not disprove the hypothesis that NMH could be contributing to some of the symptoms of CFS. Further studies are needed to determine whether other medications or combination therapy are more effective in treating orthostatic intolerance in patients with CFS.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; EMMES Corp, Potomac, MD USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emmes Corporation	Rowe, PC (corresponding author), Johns Hopkins Hosp, Brady 212,600 N Wolfe St, Baltimore, MD 21287 USA.				NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI 39500] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039500] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atiga WL, 1999, J CARDIOVASC ELECTR, V10, P874, DOI 10.1111/j.1540-8167.1999.tb00270.x; BALAJI S, 1994, J AM COLL CARDIOL, V23, P779, DOI 10.1016/0735-1097(94)90768-4; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BENTALL RP, 1993, BRIT J CLIN PSYCHOL, V32, P375, DOI 10.1111/j.2044-8260.1993.tb01070.x; Bloomfield DM, 1999, AM J CARDIOL, V84, p33Q; BOUHOLAIGAH I, 1995, JAMA-J AM MED ASSOC, V274, P961, DOI 10.1001/jama.274.12.961; Buchwald D, 1996, AM J MED, V101, P364, DOI 10.1016/S0002-9343(96)00234-3; CHOBANIAN AV, 1979, NEW ENGL J MED, V301, P68, DOI 10.1056/NEJM197907123010202; Cleare AJ, 1999, LANCET, V353, P455, DOI 10.1016/S0140-6736(98)04074-4; DeLorenzo F, 1997, CLIN AUTON RES, V7, P185, DOI 10.1007/BF02267980; Di Girolamo E, 1999, J AM COLL CARDIOL, V33, P1227, DOI 10.1016/S0735-1097(98)00694-9; Freeman R, 1997, AM J MED, V102, P357, DOI 10.1016/S0002-9343(97)00087-9; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Furlan R, 1998, CIRCULATION, V98, P2154, DOI 10.1161/01.CIR.98.20.2154; Grubb BP, 1999, PACE, V22, P798, DOI 10.1111/j.1540-8159.1999.tb00546.x; GRUBB BP, 1992, PACE, V15, P742, DOI 10.1111/j.1540-8159.1992.tb06840.x; Grubb BP, 1997, PACE, V20, P2205, DOI 10.1111/j.1540-8159.1997.tb04238.x; HICKLER RB, 1959, NEW ENGL J MED, V261, P788, DOI 10.1056/NEJM195910152611604; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Jason LA, 1999, ARCH INTERN MED, V159, P2129, DOI 10.1001/archinte.159.18.2129; LaManca JJ, 1999, CLIN PHYSIOL, V19, P111; LOW PA, 1995, MAYO CLIN PROC, V70, P617, DOI 10.4065/70.7.617; MacLean AR, 1940, J AMER MED ASSOC, V115, P2162, DOI 10.1001/jama.1940.02810510038010; MAHANONDA N, 1995, AM HEART J, V130, P1250, DOI 10.1016/0002-8703(95)90150-7; McKenzie R, 1998, JAMA-J AM MED ASSOC, V280, P1061, DOI 10.1001/jama.280.12.1061; McNair DM, 1981, PROFILE MOOD STATES; Peterson PK, 1998, ARCH INTERN MED, V158, P908, DOI 10.1001/archinte.158.8.908; ROWE PC, 1995, LANCET, V345, P623, DOI 10.1016/S0140-6736(95)90525-1; Sandroni P, 1996, CLIN AUTON RES, V6, P225, DOI 10.1007/BF02291138; SCHONDORF R, 1993, NEUROLOGY, V43, P132, DOI 10.1212/WNL.43.1_Part_1.132; Schondorf R, 1999, J AUTONOM NERV SYST, V75, P192, DOI 10.1016/S0165-1838(98)00177-5; SCOTT WA, 1995, AM J CARDIOL, V76, P400, DOI 10.1016/S0002-9149(99)80110-6; SHELDON R, 1992, J AM COLL CARDIOL, V19, P773, DOI 10.1016/0735-1097(92)90517-Q; Stewart J, 1998, CLIN AUTON RES, V8, P221, DOI 10.1007/BF02267785; Stewart JM, 1999, J PEDIATR-US, V135, P218, DOI 10.1016/S0022-3476(99)70025-9; Stewart JM, 1999, PEDIATRICS, V103, P116, DOI 10.1542/peds.103.1.116; STRAUS SE, 1988, NEW ENGL J MED, V319, P1692, DOI 10.1056/NEJM198812293192602; STRAUS SE, 1994, CHRONIC FATIGUE SYND; Streeten DHP, 2000, AM J MED SCI, V320, P1, DOI 10.1097/00000441-200007000-00001; STREETEN DHP, 1992, ARCH INTERN MED, V152, P1066, DOI 10.1001/archinte.152.5.1066; Tanaka H, 1999, PEDIATR RES, V46, P691, DOI 10.1203/00006450-199912000-00009; Vercoulen JHMM, 1996, J NEUROL NEUROSUR PS, V60, P489, DOI 10.1136/jnnp.60.5.489; Ward CR, 1998, HEART, V79, P45, DOI 10.1136/hrt.79.1.45; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WIELING W, 1993, CLIN AUTON RES, V3, P57; Zeng CY, 1998, AM HEART J, V136, P852, DOI 10.1016/S0002-8703(98)70131-0	46	97	98	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 3	2001	285	1					52	59		10.1001/jama.285.1.52	http://dx.doi.org/10.1001/jama.285.1.52			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	387GH	11150109	Bronze			2022-12-28	WOS:000166114500024
J	Whitney, CG; Farley, MM; Hadler, J; Harrison, LH; Lexau, C; Reingold, A; Lefkowitz, L; Cieslak, PR; Cetron, M; Zell, ER; Jorgensen, JH; Schuchat, A				Whitney, CG; Farley, MM; Hadler, J; Harrison, LH; Lexau, C; Reingold, A; Lefkowitz, L; Cieslak, PR; Cetron, M; Zell, ER; Jorgensen, JH; Schuchat, A		Active Bacterial Core Surveillance	Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE OTITIS-MEDIA; COMMUNITY-ACQUIRED PNEUMONIA; PENICILLIN-RESISTANT; NASOPHARYNGEAL CARRIAGE; PNEUMOCOCCAL BACTEREMIA; MENINGITIS; SUSCEPTIBILITY; SURVEILLANCE; MANAGEMENT; INFECTIONS	Background: The emergence of drug-resistant strains of bacteria has complicated treatment decisions and may lead to treatment failures. Methods: We examined data on invasive pneumococcal disease in patients identified from 1995 to 1998 in the Active Bacterial Core Surveillance program of the Centers for Disease Control and Prevention. Pneumococci that had a high level of resistance or had intermediate resistance according to the definitions of the National Committee for Clinical Laboratory Standards were defined as "resistant'' for this analysis. Results: During 1998, 4013 cases of invasive Streptococcus pneumoniae disease were reported (23 cases per 100,000 population); isolates were available for 3475 (87 percent). Overall, 24 percent of isolates from 1998 were resistant to penicillin. The proportion of isolates that were resistant to penicillin was highest in Georgia (33 percent) and Tennessee (35 percent), in children under five years of age (32 percent, vs. 21 percent for persons five or more years of age), and in whites (26 percent, vs. 22 percent for blacks). Penicillin-resistant isolates were more likely than susceptible isolates to have a high level of resistance to other antimicrobial agents. Serotypes included in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78 percent and 88 percent of penicillin-resistant strains, respectively. Between 1995 and 1998 (during which period 12,045 isolates were collected), the proportion of isolates that were resistant to three or more classes of drugs increased from 9 percent to 14 percent; there also were increases in the proportions of isolates that were resistant to penicillin (from 21 percent to 25 percent), cefotaxime (from 10 percent to 14 percent), meropenem (from 10 percent to 16 percent), erythromycin (from 11 percent to 15 percent), and trimethoprim-sulfamethoxazole (from 25 percent to 29 percent). The increases in the frequency of resistance to other antimicrobial agents occurred exclusively among penicillin-resistant isolates. Conclusions: Multidrug-resistant pneumococci are common and are increasing. Because a limited number of serotypes account for most infections with drug-resistant strains, the new conjugate vaccines offer protection against most drug-resistant strains of S. pneumoniae. (N Engl J Med 2000;343:1917-24.) (C) 2000, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Atlanta, GA USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA; Connecticut Dept Publ Hlth, Hartford, CT USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA; Minnesota Dept Hlth, Minneapolis, MN USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Vanderbilt Univ Sch Med, Dept Prevent Med, Nashville, TN USA; Oregon Dept Human Serv, Hlth Div, Portland, OR USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA	Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Johns Hopkins University; Minnesota Department of Health (MHD); University of California System; University of California Berkeley; Vanderbilt University; University of Texas System; University of Texas Health San Antonio	Whitney, CG (corresponding author), Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Mailstop C-23,1600 Clifton Rd NE, Atlanta, GA 30333 USA.							[Anonymous], 1997, MMWR MORB MORT WKLY, V46, P1; [Anonymous], 1997, M7A4 NCCLS; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BARNETT ED, 1995, PEDIATR CLIN N AM, V42, P509; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; Buckingham SC, 1998, J PEDIATR-US, V132, P174, DOI 10.1016/S0022-3476(98)70510-4; CATALAN MJ, 1994, CLIN INFECT DIS, V18, P766, DOI 10.1093/clinids/18.5.766; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; Chen FM, 1998, AM J EPIDEMIOL, V148, P1212, DOI 10.1093/oxfordjournals.aje.a009611; Choi EH, 1998, CLIN INFECT DIS, V26, P1346, DOI 10.1086/516340; Dagan R, 1997, J INFECT DIS, V176, P1253, DOI 10.1086/514120; Dagan R, 1997, PEDIATR INFECT DIS J, V16, P1060, DOI 10.1097/00006454-199711000-00011; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; DEAN A, 1995, EPI INFO VERSION 6 W; Deeks SL, 1999, PEDIATRICS, V103, P409, DOI 10.1542/peds.103.2.409; del Castillo F, 1998, PEDIATR INFECT DIS J, V17, P94, DOI 10.1097/00006454-199802000-00003; Doern GV, 1999, EMERG INFECT DIS, V5, P757, DOI 10.3201/eid0506.990603; Dowell SF, 1999, CLIN INFECT DIS, V29, P462, DOI 10.1086/588389; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; Feikin DR, 2000, AM J PUBLIC HEALTH, V90, P223, DOI 10.2105/AJPH.90.2.223; Heffelfinger JD, 2000, ARCH INTERN MED, V160, P1399, DOI 10.1001/archinte.160.10.1399; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; Jacobs MR, 1996, PEDIATR INFECT DIS J, V15, P940, DOI 10.1097/00006454-199610000-00031; Jones RN, 1998, DIAGN MICR INFEC DIS, V32, P119, DOI 10.1016/S0732-8893(98)00072-8; Jorgensen JH, 1996, J CLIN MICROBIOL, V34, P2679, DOI 10.1128/JCM.34.11.2679-2684.1996; Jorgensen JH, 1999, ANTIMICROB AGENTS CH, V43, P329, DOI 10.1128/AAC.43.2.329; KRAMER MR, 1987, ISRAEL J MED SCI, V23, P174; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCCAIG LF, 1998, JAMA-J AM MED ASSOC, V279, P434; MELNICK SL, 1992, ANN PHARMACOTHER, V26, P1292, DOI 10.1177/106002809202601020; National Committee for Clinical Laboratory Standars, 1999, M100S9 NCCLS; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; Poole Michael D., 1995, Pediatric Infectious Disease Journal, V14, pS23, DOI 10.1097/00006454-199504001-00005; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; Thornsberry C, 1998, CLIN THER, V20, P1179, DOI 10.1016/S0149-2918(98)80113-6; Turett GS, 1999, CLIN INFECT DIS, V29, P321, DOI 10.1086/520209; 1999, MMWR MORB MORTAL WKL, V48, P656	41	685	732	0	52	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2000	343	26					1917	1924		10.1056/NEJM200012283432603	http://dx.doi.org/10.1056/NEJM200012283432603			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386VR	11136262	Bronze			2022-12-28	WOS:000166082700003
J	Janus, C; Pearson, J; McLaurin, J; Mathews, PM; Jiang, Y; Schmidt, SD; Chishti, MA; Horne, P; Heslin, D; French, J; Mount, HTJ; Nixon, RA; Mercken, M; Bergeron, C; Fraser, PE; St George-Hyslop, P; Westaway, D				Janus, C; Pearson, J; McLaurin, J; Mathews, PM; Jiang, Y; Schmidt, SD; Chishti, MA; Horne, P; Heslin, D; French, J; Mount, HTJ; Nixon, RA; Mercken, M; Bergeron, C; Fraser, PE; St George-Hyslop, P; Westaway, D			A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease	NATURE			English	Article							WATER-MAZE; TRANSGENIC MICE; PROTEIN; MEMORY; NEUROTOXICITY; DEFICITS; TASKS; MOUSE; TRIAL	Much evidence indicates that abnormal processing and extracellular deposition of amyloid-beta peptide (A beta), a proteolytic derivative of the beta -amyloid precursor protein (beta APP), is central to the pathogenesis of Alzheimer's disease (reviewed in ref. 1). In the PDAPP transgenic mouse model of Alzheimer's disease, immunization with Ab causes a marked reduction in burden of the brain amyloid(2,3). Evidence that A beta immunization also reduces cognitive dysfunction in murine models of Alzheimer's disease would support the hypothesis that abnormal A beta processing is essential to the pathogenesis of Alzheimer's disease, and would encourage the development of other strategies directed at the 'amyloid cascade'. Here we show that A beta immunization reduces both deposition of cerebral fibrillar A beta and cognitive dysfunction in the TgCRND8 murine model of Alzheimer's disease without, however, altering total levels of A beta in the brain. This implies that either a similar to 50% reduction in dense-cored A beta plaques is sufficient to affect cognition, or that vaccination may modulate the activity/abundance of a small subpopulation of especially toxic A beta species.	Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Nathan S Kline Inst Ctr Dementia Res, Orangeburg, NY 10962 USA; NYU, Sch Med, Orangeburg, NY 10962 USA; Univ Hlth Network, Toronto Western Hosp, Dept Med, Div Neurol, Toronto, ON M5S 1A8, Canada; Janssen Res Fdn, B-2340 Beerse, Belgium	University of Toronto; University of Toronto; University of Toronto; Nathan Kline Institute for Psychiatric Research; New York University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Johnson & Johnson	St George-Hyslop, P (corresponding author), Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.		Mount, Howard/B-4097-2013; Schmidt, Stephen/B-5398-2012; Schmidt, Stephen/AAC-6967-2019	Mathews, Paul/0000-0003-1742-7687				Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Cain DP, 1997, PSYCHOBIOLOGY, V25, P286; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Dudchenko PA, 1997, J EXP PSYCHOL-ANIM B, V23, P194, DOI 10.1037/0097-7403.23.2.194; Gass P, 1998, LEARN MEMORY, V5, P274; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Janus C, 2000, NEUROBIOL AGING, V21, P541, DOI 10.1016/S0197-4580(00)00107-X; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; MARKOWSKA AL, 1993, BEHAV NEUROSCI, V107, P627; Martin P, 1996, MEASURING BEHAV; McLaurin J, 1998, J MOL BIOL, V278, P183, DOI 10.1006/jmbi.1998.1677; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Solomon B, 1996, P NATL ACAD SCI USA, V93, P452, DOI 10.1073/pnas.93.1.452; St George-Hyslop PH, 1999, NATURE, V400, P116; Steiner H, 1999, EUR ARCH PSY CLIN N, V249, P266, DOI 10.1007/s004060050098; SUSUKI N, 1994, SCIENCE, V264, P1336; TERRY R, 1999, ALZHEIMER DIS; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; Whitehouse PJ, 1998, ALZ DIS ASSOC DIS, V12, P281, DOI 10.1097/00002093-199812000-00007; WISNIEWSKI HM, 1989, ACTA NEUROPATHOL, V78, P22, DOI 10.1007/BF00687398	30	1241	1387	4	109	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					979	982		10.1038/35050110	http://dx.doi.org/10.1038/35050110			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140685				2022-12-28	WOS:000165951100051
J	Waites, R; Simon, R				Waites, R; Simon, R			Signaling cell fate in plant meristems: Three clubs on one tousle	CELL			English	Review							RECEPTOR-LIKE KINASE; GENE ENCODES; ARABIDOPSIS; SHOOT; PROTEIN; CLAVATA3; WUSCHEL		Univ Cologne, Inst Entwicklungsbiol, D-50923 Cologne, Germany	University of Cologne	Simon, R (corresponding author), Univ Cologne, Inst Entwicklungsbiol, Gyrhofstr 17, D-50923 Cologne, Germany.		Waites, Richard/B-4877-2008; Simon, Rudiger/T-6755-2018	Waites, Richard/0000-0003-4783-0338; Simon, Rudiger/0000-0002-1317-7716				Brand U, 2000, SCIENCE, V289, P617, DOI 10.1126/science.289.5479.617; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Jeong S, 1999, PLANT CELL, V11, P1925, DOI 10.1105/tpc.11.10.1925; Laufs P, 1998, PLANT CELL, V10, P1375, DOI 10.1105/tpc.10.8.1375; Laux T, 1996, DEVELOPMENT, V122, P87; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; McCarty DR, 2000, CELL, V103, P201, DOI 10.1016/S0092-8674(00)00113-6; Schoof H, 2000, CELL, V100, P635, DOI 10.1016/S0092-8674(00)80700-X; Sessions A, 2000, SCIENCE, V289, P779, DOI 10.1126/science.289.5480.779; Stone JM, 1998, PLANT PHYSIOL, V117, P1217, DOI 10.1104/pp.117.4.1217; Trotochaud AE, 2000, SCIENCE, V289, P613, DOI 10.1126/science.289.5479.613; Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393; Valster AH, 2000, TRENDS CELL BIOL, V10, P141, DOI 10.1016/S0962-8924(00)01728-1; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; Yu LP, 2000, DEVELOPMENT, V127, P1661	16	21	25	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 8	2000	103	6					835	838		10.1016/S0092-8674(00)00186-0	http://dx.doi.org/10.1016/S0092-8674(00)00186-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	382CR	11136968	Bronze			2022-12-28	WOS:000165801300002
J	Burgio, GR; Locatelli, F				Burgio, GR; Locatelli, F			Ethics of creating programmed stem-cell donors	LANCET			English	Editorial Material									Univ Pavia, IRCCS, Policlin San Matteo, Dipartimento Sci Pediat, I-27100 Pavia, Italy	IRCCS Fondazione San Matteo; University of Pavia	Burgio, GR (corresponding author), Univ Pavia, IRCCS, Policlin San Matteo, Dipartimento Sci Pediat, I-27100 Pavia, Italy.							BURGIO GR, 1988, LANCET, V1, P945; BURGIO GR, 1987, LANCET, V1, P1484; BURGIO GR, 1997, BONE MARROW TRANSPL, V19, P163; BURGIO GR, 1997, LANCET, V379, P1482; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Jecker N S, 1990, J Clin Ethics, V1, P99; WEISS R, 2000, WASHINGTON POST 1003	7	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1868	1869		10.1016/S0140-6736(00)03254-2	http://dx.doi.org/10.1016/S0140-6736(00)03254-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130379				2022-12-28	WOS:000165665400006
J	Tonkin, AM; Colquhoun, D; Emberson, J; Hague, W; Keech, A; Lane, G; MacMahon, S; Shaw, J; Simes, RJ; Thompson, PL; White, HD; Hunt, D				Tonkin, AM; Colquhoun, D; Emberson, J; Hague, W; Keech, A; Lane, G; MacMahon, S; Shaw, J; Simes, RJ; Thompson, PL; White, HD; Hunt, D		LIPID Study Grp	Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study	LANCET			English	Article							ACUTE CORONARY SYNDROMES; DENSITY-LIPOPROTEIN-CHOLESTEROL; MYOCARDIAL-INFARCTION; LOWERING-THERAPY; REDUCTION; ENDOTHELIUM; ISCHEMIA; DISEASE	Background The LIPID study is a major trial of secondary prevention of coronary-heart-disease events that includes hospital admission,with unstable angina (as well as myocardial infarction) as a qualifying event. In this substudy of LIPID, we compared subsequent cardiovascular risks and the effects of pravastatin in patients with previous unstable angina or previous myocardial infarction. Methods 3260 patients diagnosed with unstable angina and 5754 with acute myocardial infarction 3-36 months previously were randomly assigned 40 mg pravastatin daily or placebo over a mean of 6.0 years. The risk reduction of a range of cardiovascular events was estimated by means of the hazard ratio in Cox's proportional hazards model. Findings Among patients assigned placebo, survival in the two diagnosis groups was similar. The relative risk reduction for mortality with pravastatin was 20.6% in the myocardial infarction group and 26.3% in the unstable angina group (p=0.55). Pravastatin significantly reduced the rates of all prespecified coronary endpoints in the myocardial infarction group. In patients with previous unstable angina, coronary heart disease mortality, total mortality, myocardial infarction, a need for coronary revascularisation, the number of admissions to hospital, and the number of days in hospital were significantly lower with pravastatin. Overall, hospital admission for unstable angina was the most common endpoint (24.6% of the placebo group; 22.3% of the pravastatin group). Interpretation Patients who have survived acute myocardial infarction or unstable angina have a similar long-term prognosis, a high occurrence of subsequent unstable angina, and benefit similarly from therapy with pravastatin.	Natl Heart Fdn Australia, W Melbourne, Vic 3003, Australia; Wesley Med Ctr, Brisbane, Qld, Australia; Natl Hlth & Med Res Council, Clin Trials Ctr, Perth, WA, Australia; Fremantle Hosp, Perth, WA, Australia; Inst Int Hlth Res & Dev, Sydney, NSW, Australia; Sir Charles Gairdner Hosp, Perth, WA, Australia; Green Lane Hosp, Auckland 3, New Zealand; Royal Melbourne Hosp, Melbourne, Vic, Australia	Wesley Hospital; University of Western Australia; Royal Melbourne Hospital	Tonkin, AM (corresponding author), Natl Heart Fdn Australia, W Melbourne, Vic 3003, Australia.	Andrew.Tonkin@heartfoundation.com.au	Colquhoun, David M/F-9078-2013; Thompson, Peter L/P-1071-2014; Simes, Robert John/P-1497-2014	MacMahon, Stephen/0000-0003-2064-7699; Emberson, Jonathan/0000-0001-7792-9422				[Anonymous], 1997, Eur Heart J, V18, P1569; Arntz HR, 1999, ATHEROSCLEROSIS, V147, pS17, DOI 10.1016/S0021-9150(99)00251-8; Aronow HD, 2000, J AM COLL CARDIOL, V35, p411A; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; Bybee KA, 2000, J AM COLL CARDIOL, V35, p314A; Collinson J, 2000, EUR HEART J, V21, P1450, DOI 10.1053/euhj.1999.1995; Dupuis J, 1999, CIRCULATION, V99, P3227, DOI 10.1161/01.CIR.99.25.3227; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Grundy SM, 1997, CIRCULATION, V95, P1683; JACKSON R, 1987, BRIT MED J, V294, P1588, DOI 10.1136/bmj.294.6587.1588; Kayikcioglu M, 1999, CIRCULATION, V100, P303; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Mathers C, 1999, HLTH SYSTEM COSTS CA; Pearson TA, 2000, ARCH INTERN MED, V160, P459, DOI 10.1001/archinte.160.4.459; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 1998, AM J CARDIOL, V81, P578, DOI 10.1016/S0002-9149(97)00963-6; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; TONKIN A, 1995, AM J CARDIOL, V76, P474; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0	22	63	65	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	2000	356	9245					1871	1875		10.1016/S0140-6736(00)03257-8	http://dx.doi.org/10.1016/S0140-6736(00)03257-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379WD	11130382				2022-12-28	WOS:000165665400009
J	Taylor, FC; Cohen, H; Ebrahim, S				Taylor, FC; Cohen, H; Ebrahim, S			Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STROKE PREVENTION; WARFARIN; THROMBOEMBOLISM; METAANALYSIS; ASPIRIN; TRIAL	Objective To examine the benefits and risks of long term anticoagulation (warfarin) compared with antiplatelet treatment (aspirin/indoprofen) in patients with non-rheumatic atrial fibrillation. Methods Meta-analysis of randomised controlled trials from Cochrane library, Medline, Embase, Cinhal, and Sigle fr am 1966 to December 1999. Odds ratios (95% confidence intervals) calculated to estimate treatment effects. Outcome measures Fatal and non-fatal cardiovascular events, reductions of which were classified as benefits. Fatal and major non-fatal bleeding events classified as risks. Results No trials were found from before 1989. There were five randomised controlled trials published between 1989-99. There were no significant differences in mortality between the two treatment options (fixed effects model: odd ratio 0.14 (95% confidence interval 0.39 to 1.40) for stroke deaths; 0.86 (0.63 to 1.17) for vascular deaths). There was a borderline significant difference in non-fatal stroke in favour of anticoagulation (0.68 (0.46 to 0.99)); and 0.15 (0.50 to 1.13) after exclusion of one trial with weak methodological design. A random effects model showed no significant difference in combined fatal and non-fatal events (odds ratio 0.79 (0.61 to 1.02)), There were more major bleeding events among patients on anticoagulation than on antiplatelet treatment (odds ratio 1.45 (0.93 to 2.27)). One trial was stopped prematurely after a significant difference in favour of anticoagulation was observed, The only trial to show a significant difference in effect (favouring anticoagulation) was methodologically weaker in design than the others. Conclusions The heterogeneity between the trials and the limited data result in considerable uncertainty about the value of long term anticoagulation compared with antiplatelet treatment The risks of bleeding and the higher cost of anticoagulation make it an even less convincing treatment option.	Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; UCL Hosp, Dept Haematol, London WC1E 6DB, England; Dept Social Med, Bristol BS8 2HU, Avon, England	Bristol Royal Infirmary; University of Bristol; University College London Hospitals NHS Foundation Trust; University of London; University College London	Taylor, FC (corresponding author), Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.	f.c.taylor@bristol.ac.uk						ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1997, Arch Intern Med, V157, P1237; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; *BRIT COMM STAND H, 1998, BRIT J HAEMATOL, V101, P374; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; Cleland JGF, 1996, EUR HEART J, V17, P674; *COCHR COLL, 1998, REV MAN 3 1; *COCHR COLL, 1997, COCHR HDB SEC 4 PREP; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Feinberg WM, 1998, NEUROLOGY, V51, pS20, DOI 10.1212/WNL.51.3_Suppl_3.S20; Fitzmaurice DA, 1998, BRIT J HAEMATOL, V102, P907; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; JUNI P, 2000, SYSTEMATIC REV HLTH; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Li-Saw-Hee FL, 1999, INT J CLIN PRACT, V53, P110; MCBRIDE R, 1994, LANCET, V343, P687; Morocutti C, 1997, STROKE, V28, P1015, DOI 10.1161/01.STR.28.5.1015; *N THAM REG LIBR I, 1997, US MEDL SEARCH EV; *NHS CTR REV DISS, 1996, 4 NHS CTR REV DISS C; PETERSEN P, 1989, LANCET, V1, P175; Poller L, 1998, LANCET, V352, P1505, DOI 10.1016/S0140-6736(98)04147-6; Protheroe J, 2000, BRIT MED J, V320, P1380, DOI 10.1136/bmj.320.7246.1380; *STAT, 1998, INT STAT 6 0 WIND; Taylor FC, 1997, J CLIN PATHOL, V50, P823, DOI 10.1136/jcp.50.10.823; Taylor FC, 1997, CLIN LAB HAEMATOL, V19, P267, DOI 10.1046/j.1365-2257.1997.00082.x; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509	32	90	94	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	2001	322	7282					321	326		10.1136/bmj.322.7282.321	http://dx.doi.org/10.1136/bmj.322.7282.321			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	403NU	11159653	Green Published, Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000167050000024
J	Sherwood, P; Lyburn, I; Brown, S; Ryder, S				Sherwood, P; Lyburn, I; Brown, S; Ryder, S			How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-C; ALCOHOL-CONSUMPTION; ANTIBODIES; DISEASE; ENZYMES	Objective To determine whether abnormal results for liver function tests are investigated in primary care and findings on full investigation. Design Retrospective audit and prospective clinical investigation. Setting University hospital and surrounding general practices serving a round 330 000 people. Subjects Adults with abnormal results for liver function based on tests requested by their doctor between 1 January and 30 June 1995. Interventions All patients with gamma -glutamyltransferase, alanine aminotransferase, or alkaline phosphatase concentrations at least twice the upper limit of the reference range were studied. A median of 15 months later (range 12-21) records of hospital attendances and further investigations were examined. Where investigations were incomplete the records from the general practiced were examined, and suitable patients were invited to attend the liver clinic. Main outcome measures Investigations requested by the doctor and final diagnoses reached. Results 933 patients with abnormal liver function tests were identified follow up data were obtained in 873 (94%). 531 patients were already under hospital review. Of the remaining 342 patients, 157 were suitable for investigation; the others had died, moved away, were elderly, or had repeat liver function tests with normal results. No further tests were requested for 91 (58%) of these patients. 66 had been partially investigated by their doctor, and in seven patients results suggesting a treatable chronic liver disease had not been followed up. On investigation, 97 (62%) had an identifiable diagnosis requiring hospital intervention for follow up, or both. Conclusions Abnormal results for liver function are often not adequately investigated, missing an important change of identifying treatable chronic liver disease.	Queens Med Ctr, Div Gastroenterol, Nottingham NG7 2UH, England; Queens Med Ctr, Dept Clin Chem, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Ryder, S (corresponding author), Queens Med Ctr, Div Gastroenterol, Nottingham NG7 2UH, England.							Guterman S J, 1998, J Emerg Med, V16, P215, DOI 10.1016/S0736-4679(97)00288-6; HULTCRANTZ R, 1986, SCAND J GASTROENTERO, V21, P109, DOI 10.3109/00365528609034632; Johnston DE, 1999, AM FAM PHYSICIAN, V59, P2223; LEVIN DM, 1979, AM J MED, V66, P429, DOI 10.1016/0002-9343(79)91064-7; MENDENHALL CL, 1993, AM J GASTROENTEROL, V88, P1022; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; NALPAS B, 1992, J HEPATOL, V14, P381, DOI 10.1016/0168-8278(92)90187-T; ROSALKI SB, 1999, OXFORD TXB HEPATOLOG, P506; Steffensen FH, 1997, INT J EPIDEMIOL, V26, P92, DOI 10.1093/ije/26.1.92; Sucov A, 1999, J EMERG MED, V17, P391, DOI 10.1016/S0736-4679(99)00017-7; VANNESS MM, 1989, ANN INTERN MED, V111, P473, DOI 10.7326/0003-4819-111-6-473; Wisdom K, 1997, DIABETES CARE, V20, P971, DOI 10.2337/diacare.20.6.971	12	60	63	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	2001	322	7281					276	278		10.1136/bmj.322.7281.276	http://dx.doi.org/10.1136/bmj.322.7281.276			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	401FM	11157530	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000166917600029
J	Crawley, MJ; Harral, JE				Crawley, MJ; Harral, JE			Scale dependence in plant biodiversity	SCIENCE			English	Article							SPECIES-AREA; ABUNDANCE; DIVERSITY	The relationship between the number of species and the area sampled is one of the oldest and best-documented patterns in community ecology. Several theoretical models and field data from a wide range of plant and animal taxa suggest that the slope, z, of a graph of the Logarithm of species richness against the Logarithm of area is roughly constant, with z approximate to 0.25. We collected replicated and randomized plant data at 11 spatial scales from 0.01 to 10(8) square meters in Great Britain which show that the slope of the Log-Log plot is not constant, but varies systematically with spatial scale, and from habitat to habitat at the same spatial scale. Values of z were Low (0.1 to 0.2) at small scales (<100 square meters), high (0.4 to 0.5) at intermediate scales (1 hectare to 10 square kilometers), and Low again (0.1 to 0.2) for the Largest scale transitions (e.g,, East Perks to all of Berkshire). Instead of one process determining changes in species richness across a wide range of scales, different processes might determine plant biodiversity at different spatial scales.	Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Dept Biol, Ascot SL5 7PY, Berks, England	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Crawley, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Dept Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.	m.crawley@ic.ac.uk						Bell G, 2000, AM NAT, V155, P606, DOI 10.1086/303345; Bolker BM, 1999, AM NAT, V153, P575, DOI 10.1086/303199; Condit R, 1996, J ECOL, V84, P549, DOI 10.2307/2261477; CONNOR EF, 1979, AM NAT, V113, P791, DOI 10.1086/283438; Crawley Michael J., 1997, P595; DRUCE GC, 1897, FLORA BERKSHIRE; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; GOODALL DW, 1952, BIOL REV, V27, P194, DOI 10.1111/j.1469-185X.1952.tb01393.x; Hanski I, 1997, SCIENCE, V275, P397, DOI 10.1126/science.275.5298.397; Harte J, 1999, OIKOS, V86, P45, DOI 10.2307/3546568; Harte J, 1999, SCIENCE, V284, P334, DOI 10.1126/science.284.5412.334; HOPKINS B, 1955, J ECOL, V43, P409, DOI 10.2307/2257004; KILBURN PD, 1966, ECOLOGY, V47, P831, DOI 10.2307/1934269; Kunin WE, 1998, SCIENCE, V281, P1513, DOI 10.1126/science.281.5382.1513; May R.M., 1975, P81; Pacala Stephen W., 1997, P532; PALMER MW, 1994, AM NAT, V144, P717, DOI 10.1086/285704; PIELOU E C, 1969, P286; Plotkin JB, 2000, P NATL ACAD SCI USA, V97, P10850, DOI 10.1073/pnas.97.20.10850; Plotkin JB, 2000, J THEOR BIOL, V207, P81, DOI 10.1006/jtbi.2000.2158; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; Rodwell J.S., 1991, WOODLANDS SCRUB, VI; Rodwell J.S., 1991, BRIT PLANT COMMUNITI, V4; Rodwell J.S., 1991, BRIT PLANT COMMUNITI, V5; Rodwell J.S., 1991, BRIT PLANT COMMUNITI, V2; RODWELL JS, 1991, BRIT PLANT COMMUNITI, V3; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SHMIDA A, 1984, ISRAEL J BOT, V33, P41; SKELLAM JG, 1952, BIOMETRIKA, V39, P346, DOI 10.2307/2334030; Stace C., 1997, NEW FLORA BRIT ISLES; SUGIHARA G, 1981, AM NAT, V117, P790, DOI 10.1086/283762; SUGIHARA G, 1980, AM NAT, V116, P770, DOI 10.1086/283669; [No title captured]	33	350	392	3	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	2001	291	5505					864	868		10.1126/science.291.5505.864	http://dx.doi.org/10.1126/science.291.5505.864			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	398TD	11157164				2022-12-28	WOS:000166771700042
J	Busse, WW; Lemanske, RF				Busse, WW; Lemanske, RF			Advances in immunology - Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; ATOPIC ASTHMA; AIRWAY INFLAMMATION; INTERFERON-GAMMA; BRONCHIAL BIOPSIES; MESSENGER-RNA; T-CELLS; INHALED CORTICOSTEROIDS; EOSINOPHIL ADHESION; ENDOTHELIAL-CELLS		Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Dept Pediat, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin Hosp, K4-910 CSC-9988,600 Highland Ave, Madison, WI 53792 USA.				NHLBI NIH HHS [HL-61879, HL-56396] Funding Source: Medline; NIAID NIH HHS [AI-34891] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061879, P50HL056396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034891, U01AI034891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889-8529(05)70348-0; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Bacharier LB, 1998, INT ARCH ALLERGY IMM, V115, P257, DOI 10.1159/000069456; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barnes PJ, 1996, AM J RESP CRIT CARE, V154, pS21, DOI 10.1164/ajrccm/154.2_Pt_2.S21; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Bochner BS, 1997, J ALLERGY CLIN IMMUN, V100, P581, DOI 10.1016/S0091-6749(97)70158-1; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Brandenburg AH, 2000, J CLIN MICROBIOL, V38, P3849, DOI 10.1128/JCM.38.10.3849-3852.2000; Broide D, 1999, INT ARCH ALLERGY IMM, V118, P453, DOI 10.1159/000024162; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CALHOUN W J, 1992, American Review of Respiratory Disease, V145, pA638; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Galli SJ, 1997, J EXP MED, V186, P343, DOI 10.1084/jem.186.3.343; GODFREY RWA, 1995, EUR RESPIR J, V8, P922; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Halonen M, 1997, CLIN EXP ALLERGY, V27, P1234; Halonen M, 1999, AM J RESP CRIT CARE, V160, P564, DOI 10.1164/ajrccm.160.2.9809038; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316, DOI 10.1165/ajrcmb.14.4.8600934; HOSSAIN S, 1973, AM REV RESPIR DIS, V107, P99; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Lane SJ, 1996, J ALLERGY CLIN IMMUN, V98, pS67, DOI 10.1016/S0091-6749(96)80131-X; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lemanske RF, 1997, AM J RESP CRIT CARE, V156, P685, DOI 10.1164/ajrccm.156.3.ed-13; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Mattes J, 1999, CLIN EXP ALLERGY, V29, P729; Metzger WJ, 1999, J ALLERGY CLIN IMMUN, V104, P260, DOI 10.1016/S0091-6749(99)70361-1; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; MURPHY S, 1997, NIH PUBLICATION; NAGATA M, 1995, J IMMUNOL, V155, P2194; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; Noah TL, 2000, CLIN IMMUNOL, V97, P43, DOI 10.1006/clim.2000.4914; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; Pauwels RA, 1998, NEW ENGL J MED, V338, P139; PETERS SP, 1998, ALLERGY PRINCIPLES P, V1, P342; Prescott SL, 1998, J IMMUNOL, V160, P4730; Randolph DA, 1999, J IMMUNOL, V162, P2375; Redington AE, 1997, THORAX, V52, P310, DOI 10.1136/thx.52.4.310; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Schleimer RP, 1998, CLIN EXP ALLERGY, V28, P15; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Siraganian RP, 1998, ALLERGY PRINCIPLES P, V1, P204; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; VARNER AE, 2000, ASTHMA RHINITIS, P1172; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; Warner JA, 1998, CLIN EXP ALLERGY, V28, P35; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yamamoto H, 1998, J IMMUNOL, V161, P971; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	97	1502	1580	5	166	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					350	362		10.1056/NEJM200102013440507	http://dx.doi.org/10.1056/NEJM200102013440507			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172168				2022-12-28	WOS:000166675800007
J	Deyo, RA; Weinstein, JN				Deyo, RA; Weinstein, JN			Primary care - Low back pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CLINICAL-TRIAL; LUMBAR SPINAL STENOSIS; NERVE ROOT COMPRESSION; PHYSICAL-EXAMINATION; DISK HERNIATION; BED REST; CORTICOSTEROID INJECTIONS; NONSURGICAL MANAGEMENT; CONSERVATIVE TREATMENT; GENERAL-PRACTICE		Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Dartmouth Med Sch, Dept Surg, Hanover, NH USA; Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Dartmouth College; Dartmouth College	Deyo, RA (corresponding author), Univ Washington, Ctr Cost & Outcomes Res, Box 358853, Seattle, WA 98195 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U01AR045444] Funding Source: NIH RePORTER; AHRQ HHS [HS09804] Funding Source: Medline; NIAMS NIH HHS [AR45444-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andersson GBJ, 1999, NEW ENGL J MED, V341, P1426, DOI 10.1056/NEJM199911043411903; Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Andersson Gunnar B. J., 1997, P93; Atkinson JH, 1999, PAIN, V83, P137, DOI 10.1016/S0304-3959(99)00082-2; Atkinson JH, 1998, PAIN, V76, P287, DOI 10.1016/S0304-3959(98)00064-5; Atlas SJ, 1996, SPINE, V21, P1777, DOI 10.1097/00007632-199608010-00011; Atlas SJ, 1996, SPINE, V21, P1787, DOI 10.1097/00007632-199608010-00012; Atlas SJ, 2000, SPINE, V25, P556, DOI 10.1097/00007632-200003010-00005; Atlas SJ, 2000, J BONE JOINT SURG AM, V82A, P4, DOI 10.2106/00004623-200001000-00002; Beurskens AJ, 1997, SPINE, V22, P2756, DOI 10.1097/00007632-199712010-00011; Bigos S, 1994, AHCPR PUBLICATION; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; BOZZAO A, 1992, RADIOLOGY, V185, P135, DOI 10.1148/radiology.185.1.1523297; Carette S, 1997, NEW ENGL J MED, V336, P1634, DOI 10.1056/NEJM199706053362303; CARETTE S, 1991, NEW ENGL J MED, V325, P1002, DOI 10.1056/NEJM199110033251405; Carey TS, 1996, ANN INTERN MED, V125, P807, DOI 10.7326/0003-4819-125-10-199611150-00004; Carey TS, 1999, MED CARE, V37, P157, DOI 10.1097/00005650-199902000-00006; CHERKIN DC, 1994, SPINE, V19, P1201, DOI 10.1097/00007632-199405310-00001; Cherkin DC, 1996, SPINE, V21, P2900, DOI 10.1097/00007632-199612150-00023; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; CHERKIN DC, 1994, ARTHRITIS RHEUM, V37, P15, DOI 10.1002/art.1780370104; CHERKIN DC, 2000, 4 INT FOR PRIM CAR R; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; Croft PR, 1998, BRIT MED J, V316, P1356, DOI 10.1136/bmj.316.7141.1356; Daltroy LH, 1997, NEW ENGL J MED, V337, P322, DOI 10.1056/NEJM199707313370507; DELAUCHECAVALLIER MC, 1992, SPINE, V17, P927, DOI 10.1097/00007632-199208000-00010; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1993, SPINE, V18, P1463; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; DEYO RA, 1986, J GEN INTERN MED, V1, P20, DOI 10.1007/BF02596320; DEYO RA, 1988, J GEN INTERN MED, V3, P230, DOI 10.1007/BF02596337; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1999, J PAIN SYMPTOM MANAG, V17, P65, DOI 10.1016/S0885-3924(98)00129-8; FAAS A, 1993, SPINE, V18, P1388; FORDYCE WE, 1986, J BEHAV MED, V9, P127, DOI 10.1007/BF00848473; Frost H, 1998, PAIN, V75, P273, DOI 10.1016/S0304-3959(98)00005-0; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; Gibson JNA, 1999, SPINE, V24, P1820, DOI 10.1097/00007632-199909010-00012; GRAN JT, 1985, CLIN RHEUMATOL, V4, P161, DOI 10.1007/BF02032287; Hadler NM, 1998, ANN RHEUM DIS, V57, P1, DOI 10.1136/ard.57.1.1; HALL S, 1985, ANN INTERN MED, V103, P271, DOI 10.7326/0003-4819-103-2-271; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; HERKOWITZ HN, 1991, J BONE JOINT SURG AM, V73A, P802, DOI 10.2106/00004623-199173060-00002; Hermantin FU, 1999, J BONE JOINT SURG AM, V81A, P958, DOI 10.2106/00004623-199907000-00008; Hilibrand A S, 1999, J Am Acad Orthop Surg, V7, P239; Jamison RN, 1998, SPINE, V23, P2591, DOI 10.1097/00007632-199812010-00014; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; JOHNSSON KE, 1992, CLIN ORTHOP RELAT R, P82; KATZ JN, 1995, ARTHRITIS RHEUM, V38, P1236, DOI 10.1002/art.1780380910; Keller RB, 1999, J BONE JOINT SURG AM, V81A, P752, DOI 10.2106/00004623-199906000-00002; LAHAD A, 1994, JAMA-J AM MED ASSOC, V272, P1286, DOI 10.1001/jama.272.16.1286; Loisel P, 1997, SPINE, V22, P2911, DOI 10.1097/00007632-199712150-00014; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; MANNICHE C, 1988, LANCET, V2, P1473; OSTERWEIS M, 1997, PAIN DISABILITY CLIN; Stadnik TW, 1998, RADIOLOGY, V206, P49, DOI 10.1148/radiology.206.1.9423651; SuarezAlmazor ME, 1997, JAMA-J AM MED ASSOC, V277, P1782, DOI 10.1001/jama.277.22.1782; SWEDLOW A, 1992, NEW ENGL J MED, V327, P1502, DOI 10.1056/NEJM199211193272107; THORNBURY JR, 1993, RADIOLOGY, V187, P880; THORNBURY JR, 1993, RADIOLOGY, V186, P731, DOI 10.1148/radiology.186.3.8267688; TURNER JA, 1993, J FAM PRACTICE, V37, P545; van Poppel MNM, 1998, JAMA-J AM MED ASSOC, V279, P1789, DOI 10.1001/jama.279.22.1789; van Tulder MW, 1999, SPINE, V24, P1113, DOI 10.1097/00007632-199906010-00011; VANDENHOOGEN HMM, 1995, SPINE, V20, P318, DOI 10.1097/00007632-199502000-00010; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; Vroomen PCAJ, 1999, J NEUROL, V246, P899, DOI 10.1007/s004150050480; Vroomen PCAJ, 1999, NEW ENGL J MED, V340, P418, DOI 10.1056/NEJM199902113400602; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; Waddell G, 1997, BRIT J GEN PRACT, V47, P647; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; Weishaupt D, 1998, RADIOLOGY, V209, P661, DOI 10.1148/radiology.209.3.9844656; WHITE AA, 1982, SPINE, V7, P141, DOI 10.1097/00007632-198203000-00009	75	1249	1348	3	86	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2001	344	5					363	370		10.1056/NEJM200102013440508	http://dx.doi.org/10.1056/NEJM200102013440508			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397CM	11172169				2022-12-28	WOS:000166675800008
J	Dohner, H; Stilgenbauer, S; Benner, A; Leupolt, E; Krober, A; Bullinger, L; Dohner, K; Bentz, M; Lichter, P				Dohner, H; Stilgenbauer, S; Benner, A; Leupolt, E; Krober, A; Bullinger, L; Dohner, K; Bentz, M; Lichter, P			Genomic aberrations and survival in chronic lymphocytic leukemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-CELL LEUKEMIAS; INSITU HYBRIDIZATION; CHROMOSOME 13Q14; ATM MUTATIONS; GENE MUTATION; ABNORMALITIES; DELETIONS; REGION; EXPRESSION; TRISOMY-12	Background: Fluorescence in situ hybridization has improved the detection of genomic aberrations in chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities in patients with chronic lymphocytic leukemia and assessed their prognostic implications. Methods: Mononuclear cells from the blood of 325 patients with chronic lymphocytic leukemia were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 6q21, 11q22-23, 13q14, and 17p13; trisomy of bands 3q26, 8q24, and 12q13; and translocations involving band 14q32. Molecular cytogenetic data were correlated with clinical findings. Results: Chromosomal aberrations were detected in 268 of 325 cases (82 percent). The most frequent changes were a deletion in 13q (55 percent), a deletion in 11q (18 percent), trisomy of 12q (16 percent), a deletion in 17p (7 percent), and a deletion in 6q (6 percent). Five categories were defined with a statistical model: 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality; the median survival times for patients in these groups were 32, 79, 114, 111, and 133 months, respectively. Patients in the 17p- and 11q-deletion groups had more advanced disease than those in the other three groups. Patients with 17p deletions had the shortest median treatment-free interval (9 months), and those with 13q deletions had the longest (92 months). In multivariate analysis, the presence or absence of a 17p deletion, the presence or absence of an 11q deletion, age, Binet stage, the serum lactate dehydrogenase level, and the white-cell count gave significant prognostic information. Conclusions: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival. These findings have implications for the design of risk-adapted treatment strategies. (N Engl J Med 2000;343:1910-6.) (C) 2000, Massachusetts Medical Society.	Univ Ulm, Dept Internal Med 3, D-89081 Ulm, Germany; Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany	Ulm University; Helmholtz Association; German Cancer Research Center (DKFZ)	Dohner, K (corresponding author), Univ Ulm, Dept Internal Med 3, Robert Koch Str 8, D-89081 Ulm, Germany.		Norin, Stefan/C-6658-2008; Döhner, Hartmut/C-8933-2016; Stilgenbauer, Stephan/ABE-6609-2020; Bullinger, Lars/AAL-7965-2020; Jones, Jeffrey A/E-9827-2013	Döhner, Hartmut/0000-0003-2116-5536; Bullinger, Lars/0000-0002-5890-5510				BENTZ M, 1995, BLOOD, V85, P3610, DOI 10.1182/blood.V85.12.3610.bloodjournal85123610; Bentz M, 2000, GENE CHROMOSOME CANC, V27, P285, DOI 10.1002/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.3.CO;2-D; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; Bullrich F, 1999, CANCER RES, V59, P24; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; COX DR, 1972, J R STAT SOC B, V34, P187; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Dohner H, 1999, J MOL MED-JMM, V77, P266, DOI 10.1007/s001090050350; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; ELROUBY S, 1993, BLOOD, V82, P3452; ESCUDIER SM, 1993, BLOOD, V81, P2702; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; HARRELL FE, 1998, PREDICTING OUTCOME A; Juliusson G, 1998, SEMIN ONCOL, V25, P19; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; KORN EL, 1986, STAT MED, V5, P255, DOI 10.1002/sim.4780050306; LENGAUER C, 1992, GENOMICS, V13, P826, DOI 10.1016/0888-7543(92)90160-T; Liu Y, 1997, ONCOGENE, V15, P2463, DOI 10.1038/sj.onc.1201643; Neilson JR, 1997, LEUKEMIA, V11, P1929, DOI 10.1038/sj.leu.2400819; OSCIER DG, 1990, BRIT J HAEMATOL, V76, P352, DOI 10.1111/j.1365-2141.1990.tb06367.x; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; ROZMAN C, 1995, NEW ENGL J MED, V333, P1515; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stilgenbauer S, 1999, LEUKEMIA, V13, P1331, DOI 10.1038/sj.leu.2401499; Stilgenbauer S, 1998, ONCOGENE, V16, P1891, DOI 10.1038/sj.onc.1201764; Zwiebel JA, 1998, SEMIN ONCOL, V25, P42	31	2400	2526	1	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2000	343	26					1910	1916		10.1056/NEJM200012283432602	http://dx.doi.org/10.1056/NEJM200012283432602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386VR	11136261	Bronze			2022-12-28	WOS:000166082700002
J	Lykke-Andersen, J; Shu, MD; Steitz, JA				Lykke-Andersen, J; Shu, MD; Steitz, JA			Human Upf proteins target an mRNA for nonsense-mediated decay when bound downstream of a termination codon	CELL			English	Article							HUMAN TRIOSEPHOSPHATE ISOMERASE; BETA-GLOBIN GENE; SACCHAROMYCES-CEREVISIAE; TRANSLATION TERMINATION; CAENORHABDITIS-ELEGANS; REGULATORY MECHANISM; CIS EFFECTORS; HUMAN HOMOLOG; IN-VIVO; SURVEILLANCE	Nonsense-mediated decay (NMD) rids eukaryotic cells of aberrant mRNAs containing premature termination codons. These are discriminated from true termination codons by downstream cis-elements, such as exon-exon junctions. We describe three novel human proteins involved in NMD, hUpf2, hUpf3a, and hUpf3b. While in HeLa cell extracts these proteins are complexed with hUpf1, in intact cells hUpf3a and hUpf3b are nucleocytoplasmic shuttling proteins, hUpf2 is perinuclear, and hUpf1 cytoplasmic. hUpf3a and hUpf3b associate selectively with spliced beta -globin mRNA in vivo, and tethering of any hUpf protein to the 3'UTR of beta -globin mRNA elicits NMD. These data suggest that assembly of a dynamic hUpf complex initiates in the nucleus at mRNA exon-exon junctions and triggers NMD in the cytoplasm when recognized downstream of a translation termination site.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, Howard Hughes Med Inst, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Steitz, JA (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06536 USA.	joan.steitz@yale.edu		Lykke-Andersen, Jens/0000-0003-1821-0754	NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; Atkin AL, 1997, J BIOL CHEM, V272, P22163, DOI 10.1074/jbc.272.35.22163; ATKIN AL, 1995, MOL BIOL CELL, V6, P611; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BELGRADER P, 1994, MOL CELL BIOL, V14, P6326, DOI 10.1128/MCB.14.9.6326; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; Cali BM, 1999, GENETICS, V151, P605; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; CHENG J, 1994, MOL CELL BIOL, V14, P6317, DOI 10.1128/MCB.14.9.6317; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; CZAPLINSKI K, 1995, RNA, V1, P610; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gonzalez CI, 2000, MOL CELL, V5, P489, DOI 10.1016/S1097-2765(00)80443-8; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HALL GW, 1994, BLOOD, V83, P2031; He F, 1996, RNA, V2, P153; He F, 1997, MOL CELL BIOL, V17, P1580, DOI 10.1128/MCB.17.3.1580; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jensen TH, 1997, FEBS LETT, V414, P50, DOI 10.1016/S0014-5793(97)00988-5; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kessler O, 1996, MOL CELL BIOL, V16, P4426; Le Hir H, 2000, GENE DEV, V14, P1098; LECUYER KA, 1995, BIOCHEMISTRY-US, V34, P10600, DOI 10.1021/bi00033a035; LEE BS, 1995, P NATL ACAD SCI USA, V92, P10354, DOI 10.1073/pnas.92.22.10354; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; Maderazo AB, 2000, MOL CELL BIOL, V20, P4591, DOI 10.1128/MCB.20.13.4591-4603.2000; MAQUAT LE, 1995, RNA, V1, P453; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Mendell JT, 2000, MOL CELL BIOL, V20, P8944, DOI 10.1128/MCB.20.23.8944-8957.2000; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Page MF, 1999, MOL CELL BIOL, V19, P5943; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Perlick HA, 1996, P NATL ACAD SCI USA, V93, P10928, DOI 10.1073/pnas.93.20.10928; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Ponting CP, 2000, TRENDS BIOCHEM SCI, V25, P423, DOI 10.1016/S0968-0004(00)01628-5; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Shirley RL, 1998, J CELL SCI, V111, P3129; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; THEIN SL, 1990, P NATL ACAD SCI USA, V87, P3924, DOI 10.1073/pnas.87.10.3924; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Weng YM, 1998, RNA, V4, P205; Weng YM, 1996, MOL CELL BIOL, V16, P5491, DOI 10.1128/mcb.16.10.5491; Weng YM, 1996, MOL CELL BIOL, V16, P5477; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272; Zhang J, 1996, RNA, V2, P235; Zhang J, 1998, RNA, V4, P801, DOI 10.1017/S1355838298971849; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231	67	438	453	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 22	2000	103	7					1121	1131		10.1016/S0092-8674(00)00214-2	http://dx.doi.org/10.1016/S0092-8674(00)00214-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	386BQ	11163187	Bronze			2022-12-28	WOS:000166040600014
J	Chen, GQ; Chen, KS; Knox, J; Inglis, J; Bernard, A; Martin, SJ; Justice, A; McConlogue, L; Games, D; Freedman, SB; Morris, RGM				Chen, GQ; Chen, KS; Knox, J; Inglis, J; Bernard, A; Martin, SJ; Justice, A; McConlogue, L; Games, D; Freedman, SB; Morris, RGM			A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease	NATURE			English	Article							PRECURSOR PROTEIN; TRANSGENIC MICE; MEMORY; PATHOLOGY; RATS	;Mice that overexpress the human mutant amyloid precursor protein (hAPP) show learning deficits, but the apparent lack of a relationship between these deficits and the progressive beta -amyloid plaque formation that the hAPP mice display is puzzling. In the water maze(1), hAPP mice are impaired before and after amyloid plaque deposition(2-7). Here we show, using a new water-maze training protocol, that PDAPP mice(8) also exhibit a separate age-related deficit in learning a series of spatial locations. This impairment correlates with b-amyloid plaque burden and is shown in both cross-sectional and longitudinal experimental designs. Cued navigation and object-recognition memory are normal. These findings indicate that Ab overexpression and/or Ab plaques are associated with disturbed cognitive function and, importantly, suggest that some but not all forms of learning and memory are suitable behavioural assays of the progressive cognitive deficits associated with Alzheimer's-disease-type pathologies.	Univ Edinburgh, Dept Neurosci, Edinburgh EH8 9JZ, Midlothian, Scotland; Elan Pharmaceut, S San Francisco, CA 94080 USA	University of Edinburgh	Morris, RGM (corresponding author), Univ Edinburgh, Dept Neurosci, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.		Morris, Richard G M/C-9982-2013	Martin, Stephen/0000-0003-0805-8541				Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen KS, 1998, PROG BRAIN RES, V117, P327; Clayton NS, 1998, NATURE, V395, P272, DOI 10.1038/26216; DHooge R, 1996, NEUROREPORT, V7, P2807, DOI 10.1097/00001756-199611040-00080; Dodart JC, 2000, NEUROBIOL DIS, V7, P71, DOI 10.1006/nbdi.1999.0278; Dodart JC, 1999, BEHAV NEUROSCI, V113, P982, DOI 10.1037/0735-7044.113.5.982; Dodart JC, 1999, NEUROSCI LETT, V277, P49, DOI 10.1016/S0304-3940(99)00847-2; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Johnson D, 1997, EDN, V42, P94; Justice A., 1997, Society for Neuroscience Abstracts, V23, P1637; Larson J, 1999, BRAIN RES, V840, P23, DOI 10.1016/S0006-8993(99)01698-4; Masliah E, 1996, J NEUROSCI, V16, P5795; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; RAWLINS JNP, 1985, BEHAV BRAIN SCI, V8, P479, DOI 10.1017/S0140525X00001291; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Whishaw IQ, 1997, HIPPOCAMPUS, V7, P361, DOI 10.1002/(SICI)1098-1063(1997)7:4<361::AID-HIPO2>3.0.CO;2-M; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605; YAMAGUCHI F, 1991, NEUROREPORT, V2, P781, DOI 10.1097/00001756-199112000-00013	28	616	656	1	44	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 21	2000	408	6815					975	979		10.1038/35050103	http://dx.doi.org/10.1038/35050103			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	384NE	11140684				2022-12-28	WOS:000165951100050
J	Dennis, C; Surridge, C				Dennis, C; Surridge, C			A. thaliana genome	NATURE			English	Editorial Material														Surridge, Christopher/0000-0003-4264-5176					0	32	33	3	44	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 14	2000	408	6814					791	791						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130708				2022-12-28	WOS:000165831300034
J	Salanoubat, M; Lemcke, K; Rieger, M; Ansorge, W; Unseld, M; Fartmann, B; Valle, G; Blocker, H; Perez-Alonso, M; Obermaier, B; Delseny, M; Boutry, M; Grivell, LA; Mache, R; Puigdomenech, P; De Simone, V; Choisne, N; Artiguenave, F; Robert, C; Brottier, P; Wincker, P; Cattolico, L; Weissenbach, J; Saurin, W; Quetier, F; Schafer, M; Muller-Auer, S; Gabel, C; Fuchs, M; Benes, V; Wurmbach, E; Drzonek, H; Erfle, H; Jordan, N; Bangert, S; Wiedelmann, R; Kranz, H; Voss, H; Holland, R; Brandt, P; Nyakatura, G; Vezzi, A; D'Angelo, M; Pallavicini, A; Toppo, S; Simionati, B; Conrad, A; Hornischer, K; Kauer, G; Lohnert, TH; Nordsiek, G; Reichelt, J; Scharfe, M; Schon, O; Bargues, M; Terol, J; Climent, J; Navarro, P; Collado, C; Perez-Perez, A; Ottenwalder, B; Duchemin, D; Cooke, R; Laudie, M; Berger-Llauro, C; Purnelle, B; Masuy, D; de Haan, M; Maarse, AC; Alcaraz, JP; Cottet, A; Casacuberta, E; Monfort, A; Argiriou, A; Flores, M; Liguori, R; Vitale, D; Mannhaupt, G; Haase, D; Schoof, H; Rudd, S; Zaccaria, P; Mewes, HW; Mayer, KFX; Kaul, S; Town, CD; Koo, HL; Tallon, LJ; Jenkins, J; Rooney, T; Rizzo, M; Walts, A; Utterback, T; Fujii, CY; Shea, TP; Creasy, TH; Haas, B; Maiti, R; Wu, DY; Peterson, J; Van Aken, S; Pai, G; Militscher, J; Sellers, P; Gill, JE; Feldblyum, TV; Preuss, D; Lin, XY; Nierman, WC; Salzberg, SL; White, O; Venter, JC; Fraser, CM; Kaneko, T; Nakamura, Y; Sato, S; Kato, T; Asamizu, E; Sasamoto, S; Kimura, T; Idesawa, K; Kawashima, K; Kishida, Y; Kiyokawa, C; Kohara, M; Matsumoto, M; Matsuno, A; Muraki, A; Nakayama, S; Nakazaki, N; Shinpo, S; Takeuchi, C; Wada, T; Watanabe, A; Yamada, M; Yasuda, M; Tabata, S				Salanoubat, M; Lemcke, K; Rieger, M; Ansorge, W; Unseld, M; Fartmann, B; Valle, G; Blocker, H; Perez-Alonso, M; Obermaier, B; Delseny, M; Boutry, M; Grivell, LA; Mache, R; Puigdomenech, P; De Simone, V; Choisne, N; Artiguenave, F; Robert, C; Brottier, P; Wincker, P; Cattolico, L; Weissenbach, J; Saurin, W; Quetier, F; Schafer, M; Muller-Auer, S; Gabel, C; Fuchs, M; Benes, V; Wurmbach, E; Drzonek, H; Erfle, H; Jordan, N; Bangert, S; Wiedelmann, R; Kranz, H; Voss, H; Holland, R; Brandt, P; Nyakatura, G; Vezzi, A; D'Angelo, M; Pallavicini, A; Toppo, S; Simionati, B; Conrad, A; Hornischer, K; Kauer, G; Lohnert, TH; Nordsiek, G; Reichelt, J; Scharfe, M; Schon, O; Bargues, M; Terol, J; Climent, J; Navarro, P; Collado, C; Perez-Perez, A; Ottenwalder, B; Duchemin, D; Cooke, R; Laudie, M; Berger-Llauro, C; Purnelle, B; Masuy, D; de Haan, M; Maarse, AC; Alcaraz, JP; Cottet, A; Casacuberta, E; Monfort, A; Argiriou, A; Flores, M; Liguori, R; Vitale, D; Mannhaupt, G; Haase, D; Schoof, H; Rudd, S; Zaccaria, P; Mewes, HW; Mayer, KFX; Kaul, S; Town, CD; Koo, HL; Tallon, LJ; Jenkins, J; Rooney, T; Rizzo, M; Walts, A; Utterback, T; Fujii, CY; Shea, TP; Creasy, TH; Haas, B; Maiti, R; Wu, DY; Peterson, J; Van Aken, S; Pai, G; Militscher, J; Sellers, P; Gill, JE; Feldblyum, TV; Preuss, D; Lin, XY; Nierman, WC; Salzberg, SL; White, O; Venter, JC; Fraser, CM; Kaneko, T; Nakamura, Y; Sato, S; Kato, T; Asamizu, E; Sasamoto, S; Kimura, T; Idesawa, K; Kawashima, K; Kishida, Y; Kiyokawa, C; Kohara, M; Matsumoto, M; Matsuno, A; Muraki, A; Nakayama, S; Nakazaki, N; Shinpo, S; Takeuchi, C; Wada, T; Watanabe, A; Yamada, M; Yasuda, M; Tabata, S		European Union Chromosome 3 Arabid; Inst Genomic Res; Kazusa DNA Res Inst	Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana	NATURE			English	Article							LIBRARY; GENOME; CONSTRUCTION; REGIONS; GENES; MAP; P1	Arabidopsis thaliana is an important model system for plant biologists(1). In 1996 an international collaboration (the Arabidopsis Genome Initiative) was formed to sequence the whole genome of Arabidopsis(2) and in 1999 the sequence of the first two chromosomes was reported(3,4). The sequence of the last three chromosomes and an analysis of the whole genome are reported in this issue(5-7). Here we present the sequence of chromosome 3, organized into four sequence segments (contigs). The two largest (13.5 and 9.2 Mb) correspond to the top (long) and the bottom (short) arms of chromosome 3, and the two small contigs are located in the genetically defined centromere(8). This chromosome encodes 5,220 of the roughly 25,500 predicted protein-coding genes in the genome. About 20% of the predicted proteins have significant homology to proteins in eukaryotic genomes for which the complete sequence is available, pointing to important conserved cellular functions among eukaryotes.	Genoscope, F-91057 Evry, France; CNRS, F-91057 Evry, France; GSF, Natl Res Ctr Environm & Hlth, Munich Informat Ctr Prot Sequences, Max Planck Inst Biochem, D-82152 Martinsried, Germany; Genotype GmbH, D-69259 Wilhelmshaven, Germany; European Mol Biol Lab, Biochem Instrumentat Program, D-69117 Heidelberg, Germany; LION Biosci AG, D-69120 Heidelberg, Germany; MWG Biotech AG, D-85560 Ebersberg, Germany; Univ Padua, CRIBI, I-35131 Padua, Italy; GBF, German Res Ctr Biotechnol, Dept Genome Anal, D-38124 Braunschweig, Germany; Univ Valencia, Dept Genet, E-46100 Burjassot, Spain; Sistemas Genom SL, Paterna 46980, Spain; MediGenomix GmbH, D-82152 Planegg Martinsried, Germany; Univ Perpignan, CNRS, UMR 5096, Lab Genome & Dev Plantes, F-66860 Perpignan 13, France; Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium; Univ Amsterdam, Swammerdam Inst Life Sci, Mol Biol Sect, NL-1098 SM Amsterdam, Netherlands; Univ Grenoble 1, CNRS, Lab Plastes & Differenciat Cellulaire, F-38041 Grenoble 9, France; CSIC, Cid, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; Univ Naples Federico II, CEINGE, I-80131 Naples, Italy; Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy; Inst Genom Res, Rockville, MD 20850 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Celera Genom Corp, Rockville, MD 20850 USA; Kazusa DNA Res Inst, Chiba 2920812, Japan	Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; European Molecular Biology Laboratory (EMBL); University of Padua; Helmholtz Association; Helmholtz-Center for Infection Research; University of Valencia; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite Perpignan Via Domitia; University of Amsterdam; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Naples Federico II; J. Craig Venter Institute; University of Chicago; Kazusa DNA Research Institute	Salanoubat, M (corresponding author), Genoscope, 2 Rue G Cremieux, F-91057 Evry, France.	salanou@genoscope.cns.fr	Rudd, Stephen A/A-6434-2013; Pérez-Alonso, Manuel/M-3333-2014; Pallavicini, Alberto/H-9281-2019; Sato, Shusei/A-3616-2015; D'Angelo, Maria Grazia/K-4685-2016; Toppo, Stefano/Z-5479-2019; Pallavicini, Alberto/J-4158-2012; Ansorge, Wilhelm/AAN-8780-2020; ALCARAZ, jean-pierre/M-6821-2014; Nakamura, Yasukazu/T-9038-2019; Climent, Joan/O-5877-2017; Monfort, Amparo/K-1356-2015; Mayer, Klaus FX/M-7941-2015; Terol, Javier/H-6401-2013; Salzberg, Steven L/F-6162-2011; Schoof, Heiko/Y-7073-2018; Salzberg, Steven/Q-6514-2019; Mewes, Hans-Werner/A-8204-2019; Quetier, Francis/J-7923-2017	Rudd, Stephen A/0000-0002-0344-7487; Pérez-Alonso, Manuel/0000-0002-3266-0340; Pallavicini, Alberto/0000-0001-7174-4603; Sato, Shusei/0000-0002-0293-5366; D'Angelo, Maria Grazia/0000-0003-1241-4350; Toppo, Stefano/0000-0002-0246-3119; Pallavicini, Alberto/0000-0001-7174-4603; ALCARAZ, jean-pierre/0000-0002-5924-9519; Climent, Joan/0000-0002-8927-6614; Monfort, Amparo/0000-0001-7106-7745; Mayer, Klaus FX/0000-0001-6484-1077; Terol, Javier/0000-0003-3345-0078; Salzberg, Steven L/0000-0002-8859-7432; Schoof, Heiko/0000-0002-1527-3752; Salzberg, Steven/0000-0002-8859-7432; simionati, barbara/0000-0002-0522-0737; Mewes, Hans-Werner/0000-0002-9713-6398; Benes, Vladimir/0000-0002-0352-2547; Fraser, Claire/0000-0003-1462-2428; VALLE, GIORGIO/0000-0003-4377-5685; Nakamura, Yasukazu/0000-0002-6782-5715; Cooke, Richard/0000-0001-6335-1092; Quetier, Francis/0000-0003-4388-9287; Casacuberta, Elena/0000-0002-8203-8357; Boutry, Marc/0000-0002-2315-6900; Argiriou, Anagnostis/0000-0002-9164-632X				Alexiadis V, 2000, GENE DEV, V14, P1308; Asamizu E, 2000, DNA RES, V7, P175, DOI 10.1093/dnares/7.3.175; Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; Camilleri C, 1998, PLANT J, V14, P633, DOI 10.1046/j.1365-313X.1998.00159.x; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; DANGEL AW, 1995, NUCLEIC ACIDS RES, V23, P2120, DOI 10.1093/nar/23.12.2120; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; Glemet E, 1997, COMPUT APPL BIOSCI, V13, P137; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lazar G, 2000, PLANT MOL BIOL, V42, P571, DOI 10.1023/A:1006394207479; Lin XY, 1999, NATURE, V402, P761, DOI 10.1038/45471; LIU YG, 1995, PLANT J, V7, P351, DOI 10.1046/j.1365-313X.1995.7020351.x; Liu YG, 1999, P NATL ACAD SCI USA, V96, P6535, DOI 10.1073/pnas.96.11.6535; Lopato S, 1999, GENE DEV, V13, P987, DOI 10.1101/gad.13.8.987; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; Mayer K, 1999, NATURE, V402, P769, DOI 10.1038/47134; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; Sablowski RWM, 1998, PLANT CELL, V10, P1453, DOI 10.1105/tpc.10.9.1453; Sato S, 2000, DNA RES, V7, P131, DOI 10.1093/dnares/7.2.131; Sato S, 1998, DNA Res, V5, P163, DOI 10.1093/dnares/5.3.163; Schouten J, 2000, MOL GEN GENET, V263, P309, DOI 10.1007/PL00008682; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Tabata S, 2000, NATURE, V408, P823, DOI 10.1038/35048507; Theologis A, 2000, NATURE, V408, P816, DOI 10.1038/35048500	29	131	2156	6	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	2000	408	6814					820	822						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382PK	11130713				2022-12-28	WOS:000165831300039
J	Gerton, JM; Strekalov, D; Prodan, I; Hulet, RG				Gerton, JM; Strekalov, D; Prodan, I; Hulet, RG			Direct observation of growth and collapse of a Bose-Einstein condensate with attractive interactions	NATURE			English	Article							NEGATIVE SCATTERING LENGTH; LITHIUM; GAS; ATOMS	Quantum theory predicts that Bose-Einstein condensation of a spatially homogeneous gas with attractive interactions is precluded by a conventional phase transition into either a liquid or solid(1). When confined to a trap, however, such a condensate can form(2), provided that its occupation number does not exceed a limiting value(3,4). The stability limit is determined by a balance between the self-attractive fortes and a repulsion that arises from position-momentum uncertainty under conditions of spatial confinement. Near the stability limit, self-attraction can overwhelm the repulsion, causing the condensate to collapse(5-8). Growth of the condensate is therefore punctuated by intermittent collapses(9,10) that are triggered by either macroscopic quantum tunnelling or thermal fluctuation. Previous observations of growth and collapse dynamics have been hampered by the stochastic nature of these mechanisms. Here we report direct observations of the growth and subsequent collapse of a Li-7 condensate with attractive interactions, using phase-contrast imaging. The success of the measurement lies in our ability to reduce the stochasticity in the dynamics by controlling the initial number of condensate atoms using a two-photon transition to a diatomic molecular state.	Rice Univ, Dept Phys & Astron, Houston, TX 77251 USA; Rice Univ, Rice Quantum Inst, Houston, TX 77251 USA	Rice University; Rice University	Hulet, RG (corresponding author), Rice Univ, Dept Phys & Astron, MS 61, Houston, TX 77251 USA.			Strekalov, Dmitry/0000-0001-6058-7390; Hulet, Randall/0000-0001-7045-8947				ABRAHAM ERI, 1995, PHYS REV LETT, V74, P1315, DOI 10.1103/PhysRevLett.74.1315; Andrews MR, 1996, SCIENCE, V273, P84, DOI 10.1126/science.273.5271.84; Bradley CC, 1997, PHYS REV LETT, V78, P985, DOI 10.1103/PhysRevLett.78.985; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; Chandrasekhar S., 1957, INTRO STUDY STELLAR; Cornish SL, 2000, PHYS REV LETT, V85, P1795, DOI 10.1103/PhysRevLett.85.1795; Houbiers M, 1996, PHYS REV A, V54, P5055, DOI 10.1103/PhysRevA.54.5055; Kagan Y, 1998, PHYS REV LETT, V81, P933, DOI 10.1103/PhysRevLett.81.933; Kagan Y, 1996, PHYS REV LETT, V76, P2670, DOI 10.1103/PhysRevLett.76.2670; Miesner HJ, 1998, SCIENCE, V279, P1005, DOI 10.1126/science.279.5353.1005; RUPRECHT PA, 1995, PHYS REV A, V51, P4704, DOI 10.1103/PhysRevA.51.4704; Sackett CA, 1997, APPL PHYS B-LASERS O, V65, P433, DOI 10.1007/s003400050293; Sackett CA, 1999, PHYS REV LETT, V82, P876, DOI 10.1103/PhysRevLett.82.876; Sackett CA, 1998, PHYS REV LETT, V80, P2031, DOI 10.1103/PhysRevLett.80.2031; Shuryak EV, 1996, PHYS REV A, V54, P3151, DOI 10.1103/PhysRevA.54.3151; STOOF HTC, 1994, PHYS REV A, V49, P3824, DOI 10.1103/PhysRevA.49.3824; Stoof HTC, 1997, J STAT PHYS, V87, P1353, DOI 10.1007/BF02181289; Ueda M, 1998, PHYS REV LETT, V80, P1576, DOI 10.1103/PhysRevLett.80.1576; Wynar R, 2000, SCIENCE, V287, P1016, DOI 10.1126/science.287.5455.1016	19	243	246	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 7	2000	408	6813					692	695		10.1038/35047030	http://dx.doi.org/10.1038/35047030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382GU	11130065	Green Submitted			2022-12-28	WOS:000165815200041
J	Ehrlich, GD; Hu, FZ; Preston, R; Post, JC				Ehrlich, GD; Hu, FZ; Preston, R; Post, JC			The spectrum of pediatric gastroesophageal reflux - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Allegheny Gen Hosp, Ctr Genome Sci, Pittsburgh, PA 15212 USA; Allegheny Gen Hosp, Dept Human Genet, Pittsburgh, PA 15212 USA; MCP Hahnemann Univ, Pittsburgh, PA USA	Allegheny General Hospital; Allegheny General Hospital; Drexel University	Ehrlich, GD (corresponding author), Allegheny Gen Hosp, Ctr Genome Sci, Pittsburgh, PA 15212 USA.			Ehrlich, Garth/0000-0003-1140-6594; Nurko, Samuel/0000-0003-0936-4807					0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3125	3125		10.1001/jama.284.24.3125	http://dx.doi.org/10.1001/jama.284.24.3125			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135768				2022-12-28	WOS:000165994100021
J	Bhatt, DL; Topol, EJ				Bhatt, DL; Topol, EJ			Glycoprotein inhibitors and fibrinolysis in myocardial infarction - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Bhatt, DL (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA.			Topol, Eric/0000-0002-1478-4729				Herrmann HC, 1999, CIRCULATION, V100, P188; L'Allier PL, 1999, CIRCULATION, V100, P359; Miller JM, 1999, AM J CARDIOL, V84, P779, DOI 10.1016/S0002-9149(99)00437-3	3	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3124	3125		10.1001/jama.284.24.3124	http://dx.doi.org/10.1001/jama.284.24.3124			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135766				2022-12-28	WOS:000165994100019
J	Ring, BL				Ring, BL			Glycoprotein inhibitors and fibrinolysis in myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Caritas Good Samaritan Med Practice, Stoughton, MA 02072 USA		Ring, BL (corresponding author), Caritas Good Samaritan Med Practice, Stoughton, MA 02072 USA.			Topol, Eric/0000-0002-1478-4729				Bhatt DL, 2000, JAMA-J AM MED ASSOC, V284, P1549, DOI 10.1001/jama.284.12.1549	1	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3124	3124		10.1001/jama.284.24.3124	http://dx.doi.org/10.1001/jama.284.24.3124			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135766				2022-12-28	WOS:000165994100018
J	Furuta, GT; Nurko, S; Bousvaros, A; Antonioli, D; Badizadegan, K				Furuta, GT; Nurko, S; Bousvaros, A; Antonioli, D; Badizadegan, K			The spectrum of pediatric gastroesophageal reflux	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							EOSINOPHILIC ESOPHAGITIS; CHILDREN		Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Combined Program Pediat GI Nutr, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Furuta, GT (corresponding author), Childrens Hosp, Dept Pathol, Boston, MA 02115 USA.			Ehrlich, Garth/0000-0003-1140-6594; Nurko, Samuel/0000-0003-0936-4807				Hu FZ, 2000, JAMA-J AM MED ASSOC, V284, P325, DOI 10.1001/jama.284.3.325; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Nickel R, 1999, CLIN EXP ALLERGY, V29, P23; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 27	2000	284	24					3125	3125		10.1001/jama.284.24.3125	http://dx.doi.org/10.1001/jama.284.24.3125			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385FZ	11135768				2022-12-28	WOS:000165994100020
